0001145443-14-000738.txt : 20140509 0001145443-14-000738.hdr.sgml : 20140509 20140509151600 ACCESSION NUMBER: 0001145443-14-000738 CONFORMED SUBMISSION TYPE: 10-Q CONFIRMING COPY: PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20140331 FILED AS OF DATE: 20140509 DATE AS OF CHANGE: 20140509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOHEART, INC. CENTRAL INDEX KEY: 0001388319 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 650945967 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33718 BUSINESS ADDRESS: STREET 1: 13794 NW 4TH STREET STREET 2: SUITE 212 CITY: SUNRISE STATE: FL ZIP: 33325 BUSINESS PHONE: 954-835-1500 MAIL ADDRESS: STREET 1: 13794 NW 4TH STREET STREET 2: SUITE 212 CITY: SUNRISE STATE: FL ZIP: 33325 10-Q 1 d31366.htm 10-Q UNITED STATES

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________________________

FORM 10-Q

 

x  

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2014

OR


o  

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number: 001-33718

________________________

BIOHEART, INC.
(Exact name of registrant as specified in its charter)

________________________

 

 

 

Florida

 

65-0945967

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer Identification No.)

13794 NW 4th Street, Suite 212, Sunrise, Florida 33325
(Address of principal executive offices) (Zip Code)

(954) 835-1500
(Registrant’s telephone number, including area code)

______________
 
Securities registered under Section 12(b) of the Exchange Act:

None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, $0.001 par value per share

(Title of Class)

_____________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.045 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer ¨

Smaller reporting company x

(Do not check if a smaller reporting company)

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No  x.


As of May 6, 2014, there were 466,396,016 outstanding shares of the Registrant’s common stock, par value $0.001 per share.


Transitional Small Business Disclosure Format Yes  o    No  x

 


 

BIOHEART, INC.

INDEX TO FORM 10-Q FILING

MARCH 31, 2014

 

TABLE OF CONTENTS


 

 

 

 

 

 

 

 

PART I

Financial Information

Page
Number

 

 

 

 

Item 1.

Financial Information

3

 

 

 

 

 

 

Condensed Balance Sheets – March 31, 2014 (Unaudited) and December 31, 2013

4

 

 

 

 

 

 

Unaudited Condensed Statements of Operations (Unaudited) – Three Months Ended March 31, 2014, March 31, 2013 and the period from August 12, 1999 (date of inception) to March 31, 2014

5

 

 

 

 

 

 

Unaudited Condensed Statements of Stockholders Deficit (Unaudited) –Three Months Ended March 31, 2014

6

 

 

 

 

 

 

Unaudited Condensed Statements of Cash Flows (Unaudited) – Three Months Ended March 31, 2014, March 31, 2013 and the period from August 12, 1999 (date of inception) to March 31, 2014

7

 

 

 

 

 

 

Notes to Unaudited Condensed Financial Statements

9

 

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

25

 

 

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

32

 

 

 

 

 

Item 4.

Controls and Procedures

32

 

 

 

 

PART II

Other Information

 

 

 

 

 

 

Item 1.

Legal Proceedings

32

 

 

 

 

 

Item 1A.

Risk Factors 

33

 

 

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

33

 

 

 

 

 

Item 3.

Defaults Upon Senior Securities

33

 

 

 

 

 

Item 4.

Mine Safety Disclosures

33

 

 

 

 

 

Item 5.

Other Information

33

 

 

 

 

 

Item 6.

Exhibits

33

 

 

 

 

SIGNATURES

 

34

 

 

 

EX-31.1

 Management Certification

 

 

 

 

EX-32.1

 Sarbanes-Oxley Act

 


2

 


 

PART I – FINANCIAL INFORMATION

 

Item 1.


Interim Financial Statements and Notes to Interim Financial Statements

 

General

 

The accompanying reviewed interim financial unaudited statements have been prepared in accordance with the instructions to Form 10-Q. Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' equity in conformity with generally accepted accounting principles. Except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements included in the Company's annual report on Form 10-K for the year ended December 31, 2013. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that can be expected for the year ending December 31, 2014.




















3

 


 

BIOHEART, INC.
(a development stage company)
CONDENSED BALANCE SHEETS
 
  

March 31,

  

December 31,

 
   2014   2013 
  

(unaudited)

      
ASSETS          
Current assets:          
Cash and cash equivalents  $218,984   $46,227 
Accounts receivable, net   48,754    19,913 
Prepaid and other   1,674    784 
  Total current assets   269,412    66,924 
           
Property and equipment, net   8,192    9,055 
           
Other assets   10,012    10,160 
           
  Total assets  $287,616   $86,139 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
Current liabilities:          
Accounts payable  $2,513,125   $2,382,267 
Accrued expenses   2,368,377    4,480,335 
Advances, related party   403,957    416,198 
Deposits   478,286    478,286 
Subordinated debt, related party   1,500,000    1,500,000 
Notes payable, related party   2,179,737    2,241,477 
Notes payable, net of debt discount   1,966,946    1,930,841 
  Total current liabilities   11,410,428    13,429,404 
           
Long term debt:          
Derivative liability   1,051,196    403,811 
           
Stockholders' deficit:          
Preferred stock, par value $0.001; 20,000,000 shares authorized, 20,000,000 issued and outstanding   20,000    20,000 
Common stock, par value $0.001; 950,000,000 shares authorized, 420,920,157 and 379,787,745 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively   420,920    379,788 
Additional paid in capital   104,678,615    103,819,119 
Common stock subscription   210,000    215,000 
Deficit accumulated during development stage   (117,503,543)   (118,180,983)
  Total stockholders' deficit   (12,174,008)   (13,747,076)
           
Total liabilities and stockholders' deficit  $287,616   $86,139 
           
See the accompanying notes to these financial statements






4

 


 

BIOHEART, INC.
(a development stage company)
STATEMENTS OF OPERATIONS
(unaudited)
             
         From August 12,
         1999 (date of
   Three months ended March 31,   Inception) to
   2014   2013   March 31 2014
Revenue  $322,572   $4,192   $1,688,297 
                
Cost and operating expenses:               
Cost of sales   94,446        677,181 
Research and development   9,857    163,974    65,329,892 
Marketing, general and administrative   838,329    370,533    39,943,996 
Impairment of investment           58,695 
Depreciation and amortization   863    769    900,967 
  Total operating expenses   943,495    535,276    106,910,731 
                
Net loss from operations   (620,923)   (531,084)   (105,222,434)
                
Other income (expenses):               
Development revenues           117,500 
Gain on settlement of debt   2,093,632    1,004,224    3,117,071 
Loss on change of fair value of derivative liability   (489,371)   (640,589)   (365,423)
Interest income           762,277 
Other income        939    344,821 
Interest expense   (305,898)   (352,383)   (16,257,355)
  Total other income (expenses)   1,298,363    12,191    (12,281,109)
                
Net income (loss) before income taxes   677,440    (518,893)   (117,503,543)
                
Income taxes (benefit)            
                
NET INCOME (LOSS)  $677,440   $(518,893)  $(117,503,543)
                
Net income (loss) per common share, basic  $0.002   $(0.003)     
                
Net income (loss) per common share, diluted  $0.001   $(0.003)     
                
Weighted average number of common shares outstanding, basic   401,553,577    185,421,093      
                
Weighted average number of common shares outstanding, diluted   498,696,292    185,421,093      
                
See the accompanying notes to these financial statements




5

 


 

BIOHEART, INC.
(a development stage company)
CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT
THREE MONTHS ENDED MARCH 31, 2014
(unaudited)
 
                     Deficit     
                     Accumulated      
               Additional      During    
    

Preferred stock

    

Common stock

  

Paid in

  

Subscription

  

Development

      
    

Shares

  

Amount

    

Shares

  

Amount

  

Capital

  

Receivable

  

Stage

  

Total

 
Balance, December 31, 2013   20,000,000   $20,000    379,787,745   $379,788   $103,819,119   $215,000   $(118,180,983)  $(13,747,076)
Common stock issued in settlement of accounts payable           6,750,781    6,751    100,723            107,474 
Common stock issued in connection with settlement of other debt           7,166,214    7,166    186,878            194,044 
Proceeds from issuance of common stock           27,215,417    27,215    348,785    (5,000)       371,000 
Proceeds from exercise of warrants                   6,000            6,000 
Fair value of vesting warrants issued in connection with joint venture                   22,546            22,546 
Stock based compensation                   194,564            194,564 
Net income                           677,440    677,440 
  Balance, March 31, 2014   20,000,000   $20,000    420,920,157   $420,920   $104,678,615   $210,000   $(117,503,543)  $(12,174,008)
                                         
See the accompanying notes to these financial statements













6

 


 

BIOHEART, INC.
(a development stage company)
CONDENSED STATEMENTS OF CASH FLOWS
(unaudited)
 
      From August 12,
1999 (date of
 
   Three months ended March 31,   Inception) to 
   2014   2013   March 31, 2014 
CASH FLOWS FROM OPERATING ACTIVITIES:               
Net income (loss)  $677,440   $(518,893)  $(117,503,543)
Adjustments to reconcile net loss to net cash used in operating activities:               
Depreciation and amortization   863    769    900,967 
Bad debt expense   10,000        176,266 
Discount on convertible debt   93,604    124,838    2,073,854 
Loss on change in fair value of derivative liability   489,371    640,589    365,423 
Gain on settlement of debt   (2,093,632)   (1,004,224)   (3,117,071)
Non cash payment of interest   164,757    123,578    664,524 
Amortization of warrants issued in exchange for licenses and intellectual property           5,413,156 
Amortization of warrants issued in connection with notes payable           5,437,604 
Amortization of loan costs           1,228,717 
Related party notes payable issued for services rendered           500,000 
Warrants issued in exchange for services           285,659 
Warrants issued in exchange for forbearance agreement           430,213 
Warrants issued in connection with joint venture agreement   22,546        22,546 
Equity instruments issued in connection with R&D agreement           360,032 
Equity instruments issued in connection with settlement agreement           3,381,629 
Common stock issued in connection with accounts payable           759,316 
Common stock issued in exchange for services           1,567,673 
Common stock issued in connection with amounts due to guarantors of Bank of America loan           69,159 
Common stock issued in exchange for distribution rights and intellectual property           99,997 
Preferred stock issued in settlement of forbearance agreement           274,050 
Warrants issued in connection with accounts payable            7,758 
Stock based compensation   194,564    19,632    10,271,081 
(Increase) decrease in:               
Receivables   (38,841)   (362)   (60,019)
Inventory       62,953     
Prepaid and other current assets   (742)   (37,827)   33,006 
Other assets       1    (28,854)
Increase (decrease) in:               
Accounts payable   172,786    (12,509)   3,373,406 
Accrued expenses   49,522    55,077    7,412,998 
Deferred revenue           465,287 
  Net cash used in operating activities   (257,762)   (546,378)   (75,135,166)





7

 


 

BIOHEART, INC.
(a development stage company)
CONDENSED STATEMENTS OF CASH FLOWS
(unaudited)
         
        From August 12, 
        1999 (date of 
  Three months ended March 31,   Inception) to 
  2014   2013   March 31, 2014 
CASH FLOWS FROM INVESTING ACTIVITIES:              
Acquisitions of property and equipment          (909,158)
  Net cash used by investing activities          (909,158)
               
CASH FLOWS FROM FINANCING ACTIVITIES:              
Bank overdraft      (89)    
Proceeds from issuance of common stock, net  371,000    400,000    65,679,689 
Proceeds from (payments for) initial public offering of common stock, net          1,447,829 
Proceeds from subordinated related party note          3,000,000 
Payment of note payable          (3,000,000)
Proceeds from notes payable, related party          505,000 
(Repayments (proceeds) from related party advances  (10,241)   180,500    1,072,751 
Proceeds from exercise of stock options and warrants  6,000        299,749 
Proceeds from notes payable  127,500    205,000    12,163,750 
Repayments of notes payable  (63,740)       (3,686,192)
Payment of loan costs          (1,219,268)
  Net cash provided in financing activities  430,519    785,411    76,263,308 
               
  Net increase in cash and cash equivalents  172,757    239,033    218,984 
               
Cash and cash equivalents, beginning of period  46,227         
Cash and cash equivalents, end of period $218,984   $239,033   $218,984 
               
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION         
Interest paid $84,986   $103,969   $2,790,810 
Income taxes paid $   $   $ 
               
Non cash financing activities:              
Common stock issued in settlement of notes payable $194,044   $19,500   $5,240,138 
Common stock issued in settlement of accounts payable $107,475   $146,740   $278,691 
Common stock issued in settlement of related party notes payable $   $   $397,750 
Common stock issued in settlement of interest and penalties in connection with convertible debt $   $   $150,815 
Preferred stock issued in settlement of notes payable $   $   $70,000 
Reclassification from notes payable to related party advances $   $   $544,267 
               
See the accompanying notes to these financial statements





8

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014



NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES

 

A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed financial statements follows:

 

General

 

The accompanying unaudited condensed financial statements of Bioheart, Inc., (the “Company”), have been prepared in accordance with the rules and regulations (S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

 

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three month period ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ended December 31, 2014. The unaudited condensed financial statements should be read in conjunction with the December 31, 2013 financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K.

 

Basis and business presentation

 

Bioheart, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through March 31, 2014, the Company has accumulated a deficit through its development stage of $117,503,543.

 

Revenue Recognition


The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.


At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.


Revenues for test kits and equipment sold are not recorded until test kits are delivered. Revenues from trainings are not recorded until the completion of the training. Any cash received as a deposit for trainings are recorded by the company as a liability.


Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets.

9

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014



Comprehensive Income

 

The Company does not have any items of comprehensive income in any of the periods presented.

 

Net Income (loss) per Common Share, basic and diluted

 

The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options, warrants and shares issuable upon conversion of notes payable have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation for the three months ended March 31, 2013. Fully diluted shares outstanding were 498,696,292 and 222,688,816 for the three months ended March 31, 2014 and 2013, respectively.


Stock Based Compensation

 

The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10).

 

As of March 31, 2014, there were outstanding stock options to purchase 43,650,856 shares of common stock, 16,650,856 shares of which were vested.


Concentrations of Credit Risk

 

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. The financial stability of these institutions is periodically reviewed by senior management.

 

As of March 31, 2014, two customers represented 26% and 25% (total of 51%) of the Company’s accounts receivable.


As of December 31, 2013, three customers represented 20%, 20% and 36% (total 76%) of the Company’s accounts receivable.

 

For the three months ended March 31, 2014, the Company’s revenues earned from the sale of products and services were $322,572, of which two customers represented 17% and 10% of the Company’s revenues.


Research and Development

 

The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $9,857 and $163,974 for the three months ended March 31, 2014 and 2013, respectively; and $65,329,892 from August 12, 1999 (date of inception) to March 31, 2014.





10

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014




Fair Value

 

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.


The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.

 

Reliance on Key Personnel and Consultants

 

The Company has 4 full-time employees and 1 part-time employee. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.


Derivative Instrument Liability


The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2014 and December 31, 2013, the Company did not have any derivative instruments that were designated as hedges.


Recent Accounting Pronouncements

 

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed financial position, results of operations or cash flows.


NOTE 2 – GOING CONCERN MATTERS

 

The accompanying unaudited condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed financial statements, during three months ended March 31, 2014, the Company incurred an operating loss of $620,923 and used $257,762 in cash for operating activities. As of March 31, 2014, the Company had a working capital deficit (current liabilities in excess of current assets) of approximately $11.1 million. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.

 

11

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014



The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.


NOTE 3 — PROPERTY AND EQUIPMENT


Property and equipment as of March 31, 2014 and December 31, 2013 is summarized as follows:


 

 

 March 31,

2014

 

December 31,

2013

Laboratory and medical equipment

 

$

352,358

 

 

$

352,358

 

Furniture, fixtures and equipment

 

 

125,634

 

 

 

125,634

 

Computer equipment

 

 

39,525

 

 

 

39,525

 

Leasehold improvements

 

 

362,046

 

 

 

362,046

 

 

 

 

879,563

 

 

 

879,563

 

Less accumulated depreciation and amortization

 

 

(871,371

)

 

 

(870,508

)

 

 

$

8,192

 

 

$

9,055

 


Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives.


Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment in accordance with the guidance for impairment of long lived assets.


NOTE 4 — ACCRUED EXPENSES


Accrued expenses consisted of the following as of March 31, 2014 and December 31, 2013:


 

March 31,

2014

 

December 31,

2013

License and royalty fees

$

 

 

$

2,122,130

 

Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest

 

1,356,013

 

 

 

1,373,775

 

Interest payable on notes payable

 

757,669

 

 

 

714,180

 

Vendor accruals and other

 

127,189

 

 

 

120,692

 

Employee commissions, compensation, etc.

 

127,506

 

 

 

149,558

 

 

$

2,368,377

 

 

$

4,480,335

 






12

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014



In June 2000, the Company had entered into an agreement with William Beaumont Hospital, or WBH, pursuant to which WBH granted the Company a worldwide, exclusive, non-sublicenseable license to two U.S. method patents covering the inducement of human adult myocardial cell proliferation in vitro, or the WBH IP. The term of the agreement was for the life of the patents, which expire in 2015. The Company did not use this license in any of thier technologies or made any payments to WBH other than the initial payment to acquire the license. On April 2, 2014, the Company received confirmation that it has no obligation under the patent license agreement, WBH agreed to terminate the patent license agreement pursuant to a termination letter dated March 3, 2014, and WBH agreed to terminate the patent license agreement.


Accordingly, the Company recognized approximately $2,122,130 in settlement of debt which represents the accumulative accrual and related interest from past years under the 2000 patent license agreement.

 

During the three months ended March 31, 2014, the Company issued an aggregate of 6,750,781 shares of its common stock in settlement of outstanding accounts payable. In connection with the issuance, the Company incurred $65,548 loss in settlement of debt.


NOTE 5 – STANDBY EQUITY DISTRIBUTION AGREEMENT

 

On November 2, 2011, the Company and Greystone Capital Partners (“Greystone”) had entered into a Standby Equity Distribution Agreement (the “Agreement”).  Pursuant to the Agreement, Greystone had agreed to provide the Company with up to $1.0 million of funding for the 24-month period following the date a registration statement of the Company’s common stock is declared effective by the SEC (the “Equity Line”).  The registration statement went effective on February 10, 2012. The Agreement automatically terminated on the first of April, 2014 (the first day of the month next following the second (2nd) anniversary of the Effective Date).


NOTE 6 – NOTES PAYABLE

 

Notes payable were comprised of the following as of March 31, 2014 and December 31, 2013:


 

March 31,

2014

 

December 31,

2013

Seaside Bank note payable.

$

980,000

 

 

$

980,000

 

August 2008 Unsecured Promissory Note

 

500,000

 

 

 

500,000

 

Hunton & Williams notes payable

 

384,972

 

 

 

384,972

 

Asher notes payable

 

183,000

 

 

 

143,000

 

Daniel James Management note payable

 

35,000

 

 

 

 

 

Fourth Man, LLC note payable

 

35,000

 

 

 

35,000

 

Total notes payable

 

2,117,972

 

 

 

2,042,972

 

Less unamortized debt discount

 

(151,027

)

 

 

(112,131

)

Total notes payable net of unamortized debt discount

$

1,966,946

 

 

$

1,930,841

 



Seaside Bank

 

On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2014 to extend the maturity date to December 23, 2015.



13

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014




August 2008 Unsecured Promissory Note


On August 20, 2008, the Company borrowed $1.0 million from a third party pursuant to the terms of an unsecured Promissory Note and Agreement. Outstanding principal and interest on the loan, which accrues at the rate of 13.5% per annum, is payable in one balloon payment upon the Company’s repayment of the BlueCrest Loan, which is scheduled to mature in May 2010, however the Company is not obligated to make payments until BlueCrest Loan is paid off. In the event the Company completes a private placement of its common stock and/or securities exercisable for or convertible into its common stock which generates at least $19.0 million of gross proceeds, the Company may prepay, without penalty, all outstanding principal and interest due under the loan using the same type of securities issued in the subject private placement. Because repayment of the loan could occur within 12 months from the date of the balance sheet, the Company has classified this loan as short term.


Subject to certain conditions, at the end of each calendar quarter during the time the loan is outstanding, the Company may, but is not required to, pay all or any portion of the interest accrued but unpaid as of such date with shares of its common stock. In April 2009, as consideration for the authorization to amend certain documents related to the Note, the Company issued to the Note holder a warrant to purchase 451,053 shares of common stock at an exercise price of $0.5321 per share.


The warrant, which became exercisable immediately upon issuance, has a ten year term. This warrant had a fair value of $195,694, which was accounted for as additional paid in capital and reflected as a component of debt discount and has been fully amortized as interest expense ratably over the term of the loan.


In 2013, 1,000,000 shares of common stock were issued to the debt holder, in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note resulting in a gain of $1,078,625. A gain of $1,078,625 was included in the net gain on settlement of debt and trade payables on the statement of operations. As of March 31, 2014 the principle of this note was $500,000.


Hunton & Williams Notes


At March 31, 2014 and December 31, 2013, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822 are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.


Asher Notes (During this year)


During the three months ended March 31, 2014, the Company entered into a Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”) or affiliates, for the sale of 8% convertible notes in aggregate principal amount of $97,500 (the “Asher Notes”).


The Asher Notes bear interest at the rate of 8% per annum. As of the quarter ended March 31, 2014 all interest and principal must be repaid nine months from the issuance date, the last note due December 26, 2014. The Notes are convertible into common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes.





14

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014


 

These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date which at March 31, 2014 was $153,564. At the inception of the Asher Notes, the Company determined the aggregate fair value of $214,346 of the embedded derivatives.


Daniel James Management


On February 19, 2014, the Company entered into a Securities Purchase Agreements with Daniel James Management (“Daniel”) for the sale of 8% convertible note in principal amount of $35,000 (the “Daniel Note”).


The Daniel Note bear interest at the rate of 8% per annum with all interest and principal due February 28, 2015. The Daniel Note is convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Daniel Note. These embedded derivatives included certain conversion features and reset provision.


The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Daniel Note and to fair value as of each subsequent reporting date which at March 31, 2014 was $63,343. At the inception of the Daniel Note, the Company determined the aggregate fair value of $63,343 of the embedded derivatives.


The fair value of the embedded derivatives of the Asher Notes and Daniel Note, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 158.19% to 181.73%, (3) weighted average risk-free interest rate of 0.03% to 0.15%, (4) expected lives of 0.03 to 1.00 years, and (5) estimated fair value of the Company’s common stock from $0.001 to $0.0447 per share. The initial fair value of the embedded debt derivative of $292,257 was allocated as a debt discount up to the proceeds of the note ($127,500) with the remainder ($164,757) charged to current period operations as interest expense. For the three months ended March 31, 2014 and 2013, the Company amortized an aggregate of $93,604 and $124,838 of debt discounts to current period operations as interest expense, respectively.


NOTE 7 — RELATED PARTY TRANSACTIONS


Advances


As of March 31, 2014 and December 31, 2013, the Company officers and directors have provided advances in the aggregate of $403,957 and $416,198 respectively, for working capital purposes. The advances are unsecured, due on demand and non-interest bearing.


Notes payable-related party


Northstar Biotechnology Group, LLC


On February 29, 2012, a note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267.



15

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014



On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. As of September 30, 2012, the Company was in default, however, subsequent to September 30, 2012, the Company renegotiated the terms of the Note, Northstar has agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.


On September 21, 2012, the Company issued 5,000,000 common stock purchase warrants to Northstar that was treated as Additional interest expense upon issuance.


On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.


In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.


Effective October 1, 2012, the effective interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum.


In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued. In addition, the Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock. The Company is required to issue additional shares of its common stock (as amended), in lieu of cash, each six month anniversary of the effective date for any accrued and unpaid interest.


As of March 31, 2014 and December 31, 2013, the principle of this note was $362,000.


Officer and Director Notes


At March 31, 2014 and December 31, 2013, the Company has outstanding notes payable to officers and directors with interest at 8% per annum due at maturity. The three subordinated notes, $125,000, $100,000 and $140,000 were previously due on October 22, 2012, November 30, 2012 and June 4, 2011 respectively, and are unsecured. The Company is not obligated to make payment until Northstar loan is paid off.


On October 9, 2012, the Company issued an aggregate of $1,278,324 of promissory notes due October 9, 2013 to officers and directors in settlement of outstanding advances and accrued compensation (currently in default). The promissory notes bear interest of 5% per annum and due at maturity.


16

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014



On September 30, 2013, the Company issued an aggregate of 15,350,876 shares of its common stock in settlement of $175,000 of related party notes payable.

 

On August 1, 2013, the Company issued an aggregate of $500,000 promissory notes due on demand to officers and employee in settlement of accrued compensation. The promissory notes bear interest of 5% per annum and due at various maturity dates. During the three months ended March 31, 2014, the Company paid off $63,740 of the outstanding promissory notes. The principle outstanding balance of these notes as of March 31, 2014 is $349,413.


Subordinated debt, related party


As of March 31, 2014 and December 31, 2013, the Company officers and directors have provided notes in aggregate of $1,500,000. The notes are at from 4.75% to 8% per annum and are due upon payoff of the Northstar note payable described above.


NOTE 8 — DERIVATIVE LIABILITIES


Reset warrants


On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 7 above, the Company issued an aggregate of 15,000,000 common stock purchase warrants to purchase the Company’s common stock with an exercise price of $0.014 per share for ten years with anti-dilutive (reset) provisions.


The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date.


At March 31, 2014, the fair value of the reset provision of $666,485 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 173.72%; risk free rate: 2.73%; and expected life: 8.50 years. The Company recorded a loss on change in derivative liabilities of $519,630 during the three months ended March 31, 2014.


Convertible notes


In 2013 and the three months ended March 31, 2014, the Company issued convertible notes (see Note 6 above).


These notes are convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these notes relating to certain anti-dilutive (reset) provisions. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Note and to fair value as of each subsequent reporting date.


The fair value of the embedded derivatives at March 31, 2014, in the amount of $384,711, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 173.72%, (3) weighted average risk-free interest rate of 0.03 to 0.13%, (4) expected lives of 0.03 to 0.74 years, and (5) estimated fair value of the Company’s common stock of $0.0447 per share. The Company recorded a gain on change in derivative liabilities of $30,259 during the three months ended March 31, 2014.




17

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014


Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.


At March 31, 2014, the aggregate derivative liabilities was valued at $1,051,196, the Company believes an event under the contract that would create an obligation to settle in cash or other current assets is remote and has classified the obligation as a long term liability.


NOTE 9 – STOCKHOLDERS’ EQUITY


Preferred stock


On August 17, 2012, the board of directors designated 5,000,000 shares of preferred stock as Series A Convertible Preferred Stock which was increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. Each share of preferred stock is convertible into equal number of common shares at the option of the holder; entitled to 20 votes on all matters presented to be voted by the holders of common stock; upon event of liquidation, entitled to amount equal to stated value plus any accrued and unpaid dividends or other fees before distribution to junior securities. In lieu of the initial two payments due to Northstar, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders (see Note 7 above).


Common stock


During the three months ended March 31, 2014, the Company issued an aggregate of 6,750,781 shares of its common stock in settlement of outstanding accounts payable. In connection with the issuance, the Company incurred a loss on settlement of debt of $65,548.


During the three months ended March 31, 2014, the Company issued an aggregate of 7,166,214 shares of its common stock for the conversion of $57,500 of convertible notes payable and related accrued interest of $2,300.


NOTE 10 — STOCK OPTIONS AND WARRANTS


Stock Options


In December 1999, the Board of Directors and shareholders adopted the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011.


In April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty million shares of common stock for issuance.






18

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014


A summary of options at March 31, 2014 and activity during the three months then ended is presented below:


 

 

Shares

 

Weighted-
Average
Exercise Price

 

Weighted-
Average
Remaining
Contractual
Term (in years)

 

 

 

 

 

Options outstanding at January 1, 2013

 

 

7,853,376

 

 

$

0.67

 

 

8.2

 

Granted

 

 

17,400,000

 

 

$

0.016

 

 

9.9

 

Exercised

 

 

 

 

$

 

 

 

 

 

Forfeited/Expired

 

 

(1,340,433

)

 

$

1.08

 

 

 

 

Options outstanding at December 31, 2013

 

 

23,912,943

 

 

$

0.15

 

 

9.0

 

Granted

 

 

19,800,000 

 

 

$

0.019

 

 

9.1

 

Exercised

 

 

 

 

 

 

 

 

 

 

Forfeited/Expired

 

 

(62,087

)

 

$

1.08

 

 

 

 

Options outstanding at March 31, 2014

 

 

43,650,856

 

 

$

0.08

 

 

9.3

 

Options exercisable at March 31, 2014

 

 

16,650,856

 

 

$

0.18

 

 

8.9

 

Available for grant at March 31, 2014

 

 

12,800,000

 

 

 

 

 

 

 

 

 


The following information applies to options outstanding and exercisable at March 31, 2014:


 

 

Options Outstanding

 

Options Exercisable

 

 

 

Shares

 

Weighted-
Average
Remaining
Contractual
Term

 

Weighted-
Average
Exercise
Price

Shares

 

Weighted-
Average
Exercise
Price

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$0.00 – $0.70

 

    

43,090,000

 

 

    

9.4

 

 

$

0.03

 

 

 

16,090,000

 

 

$

0.04

 

$0.71 – $1.28

 

    

162,286

 

 

    

4.2

 

 

$

0.80

 

 

 

162,286

 

 

$

0.80

 

$5.25 – $5.67

 

    

373,858

 

 

    

2.1

 

 

$

5.55

 

 

    

373,858

 

 

$

5.55

 

$7.69

 

    

24,712

 

 

    

2.3

 

 

$

7.69

 

 

    

24,712

 

 

$

7.69

 

  

 

    

43,650,856

 

 

    

9.3

 

 

$

0.08

 

 

    

16,650,856

 

 

$

0.18

 


On February 24, 2014, the Company issued an aggregate 15,000,000 options to purchase the Company’s common stock at $0.019 per share to officers, vesting at 25% immediately and the remainder over approximately 42 months, exercisable over 10 years. The aggregate fair value of $282,597, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 163.63% and Risk free rate: 2.75%.


On February 24, 2014, the Company issued an aggregate 4,800,000 options to purchase the Company’s common stock at $0.019 per share to officers, vesting immediately and exercisable over 10 years. The aggregate fair value of $90,431, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 163.63% and Risk free rate: 2.75%.


The fair value of all options vesting during the three months ended March 31, 2014 and 2013 of $194,565 and $19,632, respectively, was charged to current period operations.


19

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014


Warrants


A summary of common stock purchase warrants at March 31, 2014 and activity during the three months then ended is presented below:


 

 

Shares

 

Weighted-
Average
Exercise
Price

 

Weighted-
Average
Remaining
Contractual
Term (in
years)

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at January 1, 2013

 

    

74,073,322

 

 

$

0.37

 

 

    

4.5

 

   Issued

 

    

50,350,536

 

 

$

0.16

 

 

    

9.2

 

   Exercised

 

    

— 

 

 

$

0.00

 

 

    

 

 

   Forfeited

 

    

(6,345,002)

  

 

$

0.38

 

 

    

 

 

Outstanding at December 31, 2013

 

    

118,078,856

 

 

$

0.22

 

 

    

6.3

 

   Issued

 

    

32,292,783

 

 

$

0.017

 

 

    

8.4

 

   Exercised

 

    

 

 

$

 

 

 

 

 

   Expired

 

    

(2,314,575

)  

 

$

0.18

 

 

    

 

 

Outstanding at March 31, 2014

 

    

148,057,064

 

 

$

0.17

 

 

    

6.7

 

Exercisable at March 31, 2014

 

    

102,401,650

 

 

$

0.13

 

 

    

5.7

 


The following information applies to common stock purchase warrants outstanding and exercisable at March 31, 2014:


 

 

Warrants Outstanding

 

Warrants Exercisable

 

 

 

Shares

 

Weighted-
Average
Remaining
Contractual
Term

 

Weighted-
Average
Exercise
Price

 

Shares

Weighted-
Average
Exercise
Price

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$0.01 – $0.50

 

    

141,807,931

 

 

    

6.7

 

 

$

0.02

 

 

    

97,696,967

 

 

$

0.02

 

$0.52 – $0.68

 

    

2,699,675

 

 

    

5.1

 

 

$

0.58

 

 

    

2,699,675

 

 

$

0.58

 

$0.70 – $1.62

 

    

848,176

 

 

    

5.8

 

 

$

0.71

 

 

    

848,176

 

 

$

0.71

 

$5.67 – $7.69

 

    

2,701,282

 

 

    

8.6

 

 

$

7.55

 

 

    

1,156,832

 

 

$

7.35

 

 

 

    

148,057,064

 

 

    

6.7

 

 

$

0.17

 

 

    

102,401,650

 

 

$

0.13

 


In conjunction with the authorized issuance of common stock, the Company granted 24,292,783 common stock purchase warrants during the three months ended March 31, 2014.


During the three months ended March 31, 2014, the Company issued an aggregate of 8,000,000 warrants in connection with a joint venture agreement dated March 10, 2014. The warrants are exercisable at $0.0217 for four years vesting from June 8, 2014 through March 10, 2015. During the three months ended March 31, 2014, the Company charged $22,546 to current period operations for the vesting portion.


20

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014


NOTE 11 — COMMITMENTS AND CONTINGENCIES


Joint Venture Agreement


On March 10, 2014, the Company entered a joint-venture or profits sharing agreement (the Agreement) with Global Stem Cells, Group, LLC and its subsidiaries whereby both parties will participate in marketing for obtaining patients and provide physician training for stem cell treatments under the names of “Regenestem” and “Stem Cell Training”, respectively. In addition, each party will be responsible for selling equipment and kit to existing and previous customers. Profits are divided on a fifty/fifty basis with distribution within 10 days of the accounting for patients and physician training and 30 day with sales of equipment and kits.


In consideration of Global Stem Cell Group, LLC’s participation, the Company issued an aggregate of 8,000,000 warrants to purchase the Company’s common stock for four years at $0.0217 per share with 2,000,000 warrants vesting 90 days from the effective date, 2,000,000 vesting on each anniversary date for three years. During the three months ended March 31, 2014, the Company charged $22,546 to current period operations for the vesting portion.


William Beaumont Hospital


In June 2000, the Company entered into an agreement with William Beaumont Hospital, or WBH, pursuant to which WBH granted to the Company worldwide, exclusive, non-sublicenseable license to two U.S. method patents covering the inducement of human adult myocardial cell proliferation in vitro, or the WBH IP. The term of the agreement is for the life of the patents, which expire in 2015. The Company did not use this license in any of our technologies. The Company had not made any payments to WBH other than the initial payment to acquire the license. The Company has received confirmation that it has no obligation under the patent license agreement and WBH agreed to terminate the patent license agreement. (See Note 4)

 

Accordingly, the Company will recognize approximately $2,122,000 in settlement of debt which represents the accumulative accrual and related interest from past years under the 2000 patent license agreement.


Contingency for Registration of the Company’s common stock

 

The Company believes that it may have issued options to purchase common stock to certain of its employees, directors and consultants in California in violation of the registration or qualification provisions of applicable California securities laws. As a result, the Company intends to make a rescission offer to these persons. The Company will make this offer to all persons who have a continuing right to rescission, which it believes to include two persons. In the rescission offer, in accordance with California law, the Company will offer to repurchase all unexercised options issued to these persons at 77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted. Based upon the number of options that were subject to rescission as of December 31, 2009, assuming that all such options are tendered in the rescission offer, the Company estimated that its total rescission liability would be up to approximately $371,000. However, as the Company believes there is only a remote likelihood the rescission offer will be accepted by any of these persons in an amount that would result in a material expenditure by the Company, no liability was recorded as of March 31, 2014 or December 31, 2013.


Litigation

 

The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of March 31, 2014, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company’s business, financial position, results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.


21

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014


Consulting agreements


On November 20, 2013, the Company entered into an investment banking agreement with Cassel Salpeter & Co. (“CSC”), who will act as exclusive third party financial advisor in connection with investment banking matters. The term of the Investment Banking Agreement shall be for a period of twenty four months unless terminated or extended in accordance with its terms. For these services, CSC will receive a one-time $25,000 fee, $5,000 monthly fees and 5,207,630 ten year common stock purchase warrants, exercisable at $.0113 and applicable consideration in the event the closing of a Mezzanine Financing consisting of non-convertible subordinated debt and/or sale of equity securities. The Company will also reimburse CSC for its reasonable out-of-pocket expenses associated with the services provided pursuant to the Investment Banking Agreement. As of March 31, 2014 and December 31, 2013, the Company accrued $46,317 and $32,424 under the agreement, respectively.


NOTE 12 — FAIR VALUE MEASUREMENT


The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:


Level 1 – Quoted prices in active markets for identical assets or liabilities.


Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.


Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.


All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.


To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.


Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.


The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.


As of March 31, 2014 or December 31, 2013, the Company did not have any items that would be classified as level 1 or 2 disclosures.


22

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014



The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in notes 7 and 9. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Notes 7 and 9 are that of volatility and market price of the underlying common stock of the Company.


As of March 31, 2013 and December 31, 2013, the Company did not have any derivative instruments that were designated as hedges.


The derivative liability as of March 31, 2014, in the amount of $1,051,196 has a level 3 classification.


The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of March 31, 2014:


          
   Excess Share
Derivative
  Warrant
Liability
  Debt
Derivative
Balance, December 31, 2012  $390,048    221,179   $—   
Total (gains) losses               
Initial fair value of debt derivative at note issuance        —      673,219 
Initial fair value of derivative relating to reset warrants   —      —      —   
Mark-to-market at December 31, 2013:   84.906    (74,324)   (39,761)
Transfers out of Level 3 upon increase in authorized shares   (474,954)   —      —   
Transfers out of Level 3 upon conversion and settlement of notes             (376,502)
Balance, December 31, 2013  $—     $146,855   $256,956 
Total (gains) losses               
Initial fair value of debt derivative at note issuance   —      —      292,257 
Mark-to-market at March 31, 2014:   —      519,630    (30,259)
Transfers out of Level 3 upon conversion of notes payable   —      —      (134,243)
Balance, March 31, 2014  $—     $666,485   $384,711 
Net (Loss) Gain for the period included in earnings relating to the liabilities held at March 31, 2014  $—     $(519,630)  $30,259 


 

Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. The Company’s stock price increased approximately 447% from December 31, 2013 to March 31, 2014. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments. The simulated fair value of these liabilities is sensitive to changes in the Company’s expected volatility. Increases in expected volatility would generally result in a higher fair value measurement.


NOTE 13 — SUBSEQUENT EVENTS


In April 2014, the Company issued an aggregate of 3,839,832 shares of its common stock for services rendered valued at $43,250.


23

 


 

BIOHEART, INC.
(a development stage company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2014



In April 2014, the Company issued 5,263,315 shares of its common stock in settlement of related party advances of $100,000.


In April, 2014, the Company issued 1,002,808 shares of its common stock in settlement of common stock subscriptions of $50,000


In April 2014, the Company issued 274,681 shares of its common stock as settlement of six months accrued interest on the Northstar note obligation.


In April 2014, the Company issued 18,383,774 shares of its common stock for service rendered valued at $180,511.


In April 2014, the Company issued an aggregate of 4,793,268 shares of its common stock in settlement of $67,500 convertible notes payable and $2,700 accrued interest.


In April 2014, the Company issued 11,918,181 shares of its common stock in connection with the exercise of warrants. Proceeds received was $136,000, of which $6,000 during the three months ended March 31, 2014.












24

 


 

Item 2.  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

        

Unless otherwise indicated, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our” are to the Company, unless the context requires otherwise. The following discussion and analysis by our management of our financial condition and results of operations should be read in conjunction with our unaudited condensed interim financial statements and the accompanying related notes included in this quarterly report and our audited financial statements and related notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission.

 

Cautionary Statement Regarding Forward-Looking Statements

          

This report may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we intend that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Any such forward-looking statements would be contained principally in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors.” Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities and the effects of regulation. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions.

 

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss many of these risks in greater detail in “Risk Factors.” Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this report. You should read this report and the documents that we reference in this report and have filed as exhibits to the report completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

          

Additional information concerning these and other risks and uncertainties is contained in our filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2013.

 

In this Quarterly Report on Form 10-Q, “Company,” “our company,” “us,” and “our” refer to Bioheart, Inc., unless the context requires otherwise.


Our Ability to Continue as a Going Concern

      

Our independent registered public accounting firm has issued its report dated March 24, 2014, in connection with the audit of our financial statements as of December 31, 2013, that included an explanatory paragraph describing the existence of conditions that raise substantial doubt about our ability to continue as a going concern and Note 2 to the unaudited financial statements for the period ended March 31, 2014 also describes the existence of conditions that raise substantial doubt about our ability to continue as a going concern.





25

 


 

Overview


We are a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Our lead product candidate is MyoCell, an innovative clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients.


Biotechnology Product Candidates


We are focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. In our pipeline, we have multiple product candidates for the treatment of heart damage, including MyoCell, Myocell SDF-1 and AdipoCell. MyoCell and MyoCell SDF-1 are clinical muscle-derived cell therapies designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.


MyoCell SDF-1 is intended to be an improvement to MyoCell. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector so that they will release extra quantities of the SDF-1 protein, which expresses angiogenic factors. AdipoCell is a patient-derived cell therapy proposed for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. We hope to demonstrate that these product candidates are safe and effective complements to existing therapies for chronic and acute heart damage.


Our most recent completed clinical trials of MyoCell are the SEISMIC Trial, a 40-patient, randomized, multicenter, controlled, Phase II-a study conducted in Europe and the MYOHEART Trial, a 20-patient, multicenter, Phase I dose-escalation trial conducted in the United States. We were approved by the FDA, to proceed with a 330-patient, multicenter Phase II/III trial of MyoCell in North America and Europe, or the MARVEL Trial. We completed the MyoCell implantation procedure on the first patient in the MARVEL Trial on October 24, 2007. Thus far, 20 patients, including 6 control patients, have been treated. Initial results for the 20 patients were released at the Heart Failure Society of American meeting in September, 2009, showing a significant (35%) improvement in the 6 minute walk for those patients who were treated, and no improvement for those who received a placebo. On the basis of these results, we have applied for and received approval from the FDA to reduce the number of additional patients in the trial to 134, for a total of 154 patients. The SEISMIC, MYOHEART and MARVEL Trials have been designed to test the safety and efficacy of MyoCell in treating patients with severe, chronic damage to the heart. Upon regulatory approval of MyoCell, we intend to generate revenue in the United States from the sale of MyoCell cell-culturing services for treatment of patients by qualified physicians.


We received approval from the FDA in July of 2009 to conduct a Phase I safety study on 15 patients of a combined therapy (Myocell with SDF-1), which we believe was the first approval of a study combining gene and cell therapies. We initially commenced work on this study, called the REGEN Trial, during the first quarter of 2010. We suspended activity on the trial in 2010 while seeking additional funding necessary to conduct the trial.


We are seeking to secure sufficient funds to reinitiate enrollment in the MARVEL and REGEN trials. If we successfully secure such funds, we intend to re-engage a contract research organization, or CRO, investigators and certain suppliers to advance such trials.


We have completed the Phase 1 Angel Trial for AdipoCell (adipose derived stem cells). Five patients were enrolled and treated in the second quarter of 2013.



26

 


 

We have also initialed several Institutional Review Board studies using adipose derived stem cells for various indications including dry macular degeneration, degenerative disc disease, erectile dysfunction and chronic obstructive pulmonary disease.

 

MyoCath Product Candidate


The MyoCath is a deflecting tip needle injection catheter that has a larger (25 gauge) needle to allow for better flow rates and less leakage than systems that are 27 gauge. This larger needle allows for thicker compositions to be injected, which helps with cell retention in the heart. Also, the MyoCath needle has more fluoroscopic brightness than the normally used nitinol needle, enabling superior visualization during the procedure. Seeing the needle well during injections enables the physician who is operating the catheter to pinpoint targeted areas more precisely. The MyoCath is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. Investigators in our MARVEL Trial may use either our MyoCath catheters or Biosense Webster’s (a Johnson & Johnson company) NOGA® Cardiac Navigation System along with the MyoStar™ injection catheter for the delivery of MyoCell to patients enrolled in the trial. We are currently producing Myocath catheters with a contract manufacturer on an as needed basis.


We conduct operations in one business segment. We may organize our business into more discrete business units when and if we generate significant revenue from the sale of our product candidates. Our revenue since inception has been generated inside and outside the United States, and the majority of our long-lived assets are located in the United States.


Results of Operations Overview


Three Months Ended March 31, 2014 as compared to the Three Months Ended March 31, 2014


Revenues


We have not generated any material revenues from our MyoCell product candidate. The revenues we have recognized to date are related to (i) sales of MyoCath, (iii) revenues generated from patient paid studies, (iv) revenues from the sale of our AdipoCell system and related supplies and (v) revenues generated for providing cell culturing and banking services. We did not generate significant revenue in 2013. Our revenue may vary substantially from quarter to quarter and from year to year. We expect to have steady growth of revenue as the above programs grow and expand.


We recognized revenues of $322,572 for the three months ended March 31, 2014 compared to revenues of $4,192 for the three months ended March 31, 2013. Our revenue in the first quarter of 2014 was generated from the sale of MyoCath catheters, AdipoCell, physician training, patient studies and laboratory services. Our revenues for 2013 were generated from the sale of MyoCath Catheters and laboratory services.


Cost of Sales


Cost of sales consists of the costs associated with the production of MyoCath, laboratory supplies necessary for laboratory services, production of AdipoCell systems and materials, physician course materials and clinic supplies required for patient studies.


Cost of sales was $94,446 in the three-month period ended March 31, 2014 compared to $-0- in the three -months ended March 31, 2013.


27

 


 

Research and Development


Our research and development expenses consist of costs incurred in identifying, developing and testing our product candidates. These expenses consist primarily of costs related to our clinical trials, the acquisition of intellectual property licenses and preclinical studies. We expense research and development costs as incurred.


Clinical trial expenses include costs related to the culture and preparation of cells in connection with our clinical trials, costs of contract research, costs of clinical trial facilities, costs of delivery systems, salaries and related expenses for clinical personnel and insurance costs. Preclinical study expenses include costs of contract research, salaries and related expenses for personnel, costs of development biopsies, costs of delivery systems and costs of lab supplies.


We are focused on the development of a number of autologous cell-based therapies, and related devices, for the treatment of heart damage. Accordingly, many of our costs are not attributable to a specifically identified product candidate. We use our employee and infrastructure resources across several projects, and we do not account for internal research and development costs on a product candidate by product candidate basis. From inception through March 31, 2014, we incurred aggregate research and development costs of approximately $65.3 million (unaudited) related to our product candidates We estimate that at least $48.4 million (unaudited) of these expenses relate to our preclinical and clinical development of MyoCell and at least $5.2 million of these expenses relate to our preclinical and clinical development of MyoCath.


During the third quarter 2009, we received notification that approximately $630,000 in pending projects (Indiana University, University of Florida, Northwestern University, and other sites) was completed. As of March 31, 2014 and December 31, 2013, of the $630,000, we still have an accrual of $219,000 for the completed contracts.


Clinical trials and preclinical studies are time-consuming and expensive. Our expenditures on current and future preclinical and clinical development programs are subject to many uncertainties. We generally test our products in several preclinical studies and then conduct clinical trials for those product candidates that we determine to be the most promising. As we obtain results from clinical trials, we may elect to discontinue or delay trials for some product candidates in order to focus our resources on more promising product candidates. Completion of clinical trials may take several years or more, but the length of time generally varies substantially according to the type, size of trial and intended use of the product candidate.


Due to the risks inherent in the clinical trial process, development completion dates and costs vary significantly for each product candidate, are difficult to estimate and are likely to change as clinical trials progress.


The cost of clinical trials may vary significantly over the life of a project as a result of a variety of factors, including the number of patients who participate in the clinical trials, the number of sites included in the clinical trials, the length of time required to enroll trial participants, the efficacy and safety profile of our product candidates and the costs and timing of and our ability to secure regulatory approvals.


Marketing, General and Administrative


Our marketing, general and administrative expenses primarily consist of the costs associated with our general management and clinical marketing and trade programs, including, but not limited to, salaries and related expenses for executive, administrative and marketing personnel, rent, insurance, legal and accounting fees, consulting fees, travel and entertainment expenses, conference costs and other clinical marketing and trade program expenses.


28

 


 

Stock-Based Compensation


Stock-based compensation reflects our recognition as an expense of the value of stock options and other equity instruments issued to our employees and non-employees over the vesting period of the options and other equity instruments. We have granted to our employees options to purchase shares of common stock at exercise prices equal to the fair market value of the underlying shares of common stock at the time of each grant, as determined by our Board of Directors, with input from management.


The Company follows Accounting Standards Codification subtopic 718-10. Compensation (“ASC 718-10”) which requires that all share-based payments to both employee and non-employees be recognized in the income statement based on their fair values.


In valuing our common stock, our Board of Directors considered a number of factors, including, but not limited to:


·         our financial position and historical financial performance;

·         arm's length sales of our common stock;

·         the development status of our product candidates;

·         the business risks we face;

·         vesting restrictions imposed upon the equity awards; and

·         an evaluation and benchmark of our competitors; and

·         prospects of a liquidity event.



In April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty million shares of common stock for issuance.


Interest Expense


Interest expense during the three months ended March 31, 2014 and 2013 primarily consists of interest incurred on the principal amount of the Northstar loan, our former Bank of America loan, the Seaside National Bank loan, accrued fees and interest payable to the Guarantors, the amortization of debt discounts and non-cash incurred relating to our issued convertible notes payable. The debt discounts are being amortized to interest expense over the terms of the respective loans using the effective interest method.

 

Critical Accounting Policies

 

Our discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. While our critical accounting policies are described in Note 1 to our financial statements appearing elsewhere in this report, we believe the following policies are important to understanding and evaluating our reported financial results:

 





29

 


 

Revenue Recognition

 

We recognize revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.


At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.


Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets.


Research and Development Activities

 

We account for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.


Derivative financial instruments

 

Accounting Standards Codification subtopic 815-40, Derivatives and Hedging, Contracts in Entity’s own Equity (“ASC 815-40”) became effective for the Company on October 1, 2009. The Company has identified the embedded derivatives related to the issued Notes and anti-dilutive warrants.  These embedded derivatives included in our debt contain certain conversion features and reset provision.  The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date.  


Inflation

 

Our opinion is that inflation has not had, and is not expected to have, a material effect on our operations.

 

Climate Change

 

Our opinion is that neither climate change, nor governmental regulations related to climate change, have had, or are expected to have, any material effect on our operations.

 




30

 


 

Concentrations of Credit Risk

 

As of March 31, 2014 and December 31, 2013, two (2) and three (3) customers represented 51% and 76% of the Company’s accounts receivable, respectively.


Liquidity and Capital Resources

 

In the three months ended March 31, 2014, we continued to finance our considerable operational cash needs with cash generated from financing activities.

 

Operating Activities

 

Net cash used in operating activities was $257,762 in the three month period ended March 31, 2014 as compared to $546,378 of cash used in the three month period ended in March 31, 2013.


Our use of cash for operations in the three months ended March 31, 2014 reflected a net income generated during the period of $677,440, adjusted for non-cash items such as stock-based compensation of $194,564, fair value of warrants issued of $22,546, depreciation of $863, amortization of debt discounts of $93,604 and non-cash interest paid of $164,757, loss on change in fair value of derivative liabilities of $489,371, net gain on settlement of debt of $2,093,632. In addition we had a net increase in operating assets of $29,583 and an increase in accrued expenses of $49,522 and in accounts payable of $172,786.


Our use of cash for operations in the three months ended March 31, 2013 reflected a net loss generated during the period of approximately $519,000, adjusted for non-cash items such as stock-based compensation of $19,632, depreciation of $769, amortization of debt discounts of $124,838, loss on change in fair value of derivative liabilities of $640,589 and non-cash interest paid of $123,578, net with gain on settlement of debt of $1,004,224. In addition we had a net decrease in operating assets of $24,764 and an increase in accrued expenses of $55,077 and a decrease in accounts payable of $12,509.


Investing Activities

 

Net cash used in investing activities was nil for the three months ended March 31, 2014 and 2014.

 

Financing Activities

 

Net cash provided by financing activities was an aggregate of $430,519 in the three month period ended March 31, 2014 as compared to $785,411 in the three month period ended in March 31, 2013. In the three month period ended March 31, 2014 we sold, in private placements, shares of common stock and common stock purchase warrants for aggregate net cash proceeds of $371,000, received proceeds from issuance of note payable of $127,500 and proceeds from warrant exercise of $6,000, net with repayments related party advances of $10,241 and related party notes payable of $63,740.


Existing Capital Resources and Future Capital Requirements

 

Our MyoCell product candidate has not received regulatory approval or generated any material revenues. We do not expect to generate any material revenues or cash from sales of our MyoCell product candidate until commercialization of MyoCell, if ever. We have generated substantial net losses and negative cash flow from operations since inception and anticipate incurring significant net losses and negative cash flows from operations for the foreseeable future. Historically, we have relied on proceeds from the sale of our common stock and our incurrence of debt to provide the funds necessary to conduct our research and development activities and to meet our other cash needs.

    

31

 


 

At March 31, 2014, we had cash and cash equivalents totaling $218,984. However our working capital deficit as of such date was approximately $11.1 million. Our independent registered public accounting firm has issued its report dated March 24, 2014 in connection with the audit of our financial statements as of December 31, 2013 that included an explanatory paragraph describing the existence of conditions that raise substantial doubt about our ability to continue as a going concern and Note 2 of our unaudited financial statement for the quarter ended March 31, 2014 addresses the issue of our ability to continue as a going concern.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not required under Regulation S-K for “smaller reporting companies.”

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our CEO and Chief Accounting Officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Under the supervision and with the participation of our management, including our CEO and Principal Financial and Accounting Officer, an evaluation was performed on the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on that evaluation, our management, including our CEO and Principal Financial and Accounting Officer, concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report due to the Company’s limited resources and limited number of employees. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of legal and outsourced accounting professionals. As we grow, we expect to increase our number of employees, which, we believe, will enable us to implement adequate segregation of duties within the internal control framework.


Changes In Internal Control Over Financial Reporting

 

There were no changes in the Company’s internal controls over financial reporting during the most recently completed fiscal quarter that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.


PART II – OTHER INFORMATION


 Item 1. Legal Proceedings

      

Our Company is not involved in any material litigation and we are unaware of any threatened material litigation. However, the biotechnology and medical device industries have been characterized by extensive litigation regarding patents and other intellectual property rights. In addition, from time to time, we may become involved in litigation relating to claims arising from the ordinary course of our business.

 


32

 


 

Item 1A. Risk Factors

 

Not required under Regulation S-K for “smaller reporting companies.”

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

During the three months ended March 31, 2014, the Company sold an aggregate of 24,292,783 shares of the Company’s common stock and common stock purchase warrants to purchase 23,289,975 shares of the Company’s common stock for aggregate gross cash proceeds of $371,000. The warrants are (i) exercisable solely for cash at an exercise price of $0.011 to $0.0214 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time during the period commencing on the date that is six months and one day following the date of issuance and ending on the tenth year anniversary of the date of issuance.


The issuance of such shares of our common stock was effected in reliance on the exemptions for sales of securities not involving a public offering, as set forth in Rule 506 promulgated under the Securities Act of 1933, as mended (the “Securities Act”) and in Section 4(2) of the Securities Act, based on the following: (a) the debt-holder confirmed to us that they were “accredited investors,” as defined in Rule 501 of Regulation D promulgated under the Securities Act and had such background and experience in financial and business matters as to be able to evaluate the merits and risks of an investment in the securities; (b) there was no public offering or general solicitation with respect to the conversion of the debt and issuance of shares; (c) the debt-holder acknowledged that the shares being issued were “restricted securities” for purposes of the Securities Act, and agreed to transfer such securities only in a transaction registered under the Securities Act or exempt from registration under the Securities Act; and could only be transferred if subsequent registered under the Securities Act or transferred in a transaction exempt from registration under the Securities Act.


Item 3. Defaults Upon Senior Securities 


There were no defaults upon senior securities during the period ended March 31, 2014.


Item 4. Mine Safety Disclosures

 

Not applicable. 


Item 5. Other Information

 

There is no information with respect to which information is not otherwise called for by this form.


Item 6. Exhibits 


Exhibit No.

 

Exhibit Description

31.1*

 

Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*

 

Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS

XBRL Instance Document

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL     

XBRL Taxonomy Calculation Linkbase Document

101.LAB

XBRL Taxonomy Labels Linkbase Document

101.PRE

XBRL Taxonomy Presentation Linkbase Document

101.DEF

XBRL Definition Linkbase Document


33

 


 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bioheart, Inc.

 

 

 

 

 

Date: May 9, 2014

By:

/s/Mike Tomas

 

 

 

Mike Tomas

 

 

 

Chief Executive Officer &
President and Principal Financial
and Accounting Officer

 















34

 


EX-31.1 2 d31366_ex31-1.htm EX-31.1 Exhibit 31

Exhibit 31.1

Certification of Chief Executive Officer and Principal Accounting Officer

I, Mike Tomas, certify that:

 

 

1.

I have reviewed this report on Form 10-Q of Bioheart, Inc.;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

 

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

 

 

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

 

 

 

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

 

 

 

Date: May 9, 2014

 

 

 

/s/Mike Tomas

 

 

 Name:

 

Mike Tomas

 

 

 

 

President and Chief Executive Officer
Chief Financial Officer and Principal
Accounting Officer

 


EX-32.1 3 d31366_ex32-1.htm EX-32.1 Exhibit 32

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Mike Tomas, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, Bioheart, Inc.’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2014 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that



(1)           The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and


(2)           The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


 

 

 

 

 

 

 

 

 

 

Date: May 9, 2014

 

 

 

/s/Mike Tomas

 

 

 Name:

 

Mike Tomas

 

 

 

 

President and Chief Executive Officer Chief
Financial Officer and Principal Accounting
Officer






EX-101.INS 4 bhrt-20140331.xml XBRL INSTANCE FILE 0001388319 1999-08-11 0001388319 2000-06-01 2000-06-30 0001388319 bhrt:AugustTwoThousandEightUnsecuredPromissoryNoteMember 2008-08-20 0001388319 bhrt:AugustTwoThousandEightUnsecuredPromissoryNoteMember 2008-08-01 2008-08-20 0001388319 bhrt:AugustTwoThousandEightUnsecuredPromissoryNoteMember 2009-04-30 0001388319 bhrt:AugustTwoThousandEightUnsecuredPromissoryNoteMember 2009-04-01 2009-04-30 0001388319 bhrt:SeasideBankNotePayableMember 2010-10-25 0001388319 bhrt:SeasideBankNotePayableMember 2010-10-23 2010-10-25 0001388319 bhrt:OfficerAndDirectorMember 2011-06-04 0001388319 2011-11-01 2011-11-02 0001388319 bhrt:NorthstarBiotechnologyGroupLlcPromissoryNoteMember 2012-02-29 0001388319 bhrt:PromissoryNoteMember 2012-03-01 2012-03-30 0001388319 us-gaap:ConvertiblePreferredStockMember 2012-08-17 0001388319 bhrt:NorthstarBiotechnologyGroupLlcPromissoryNoteMember 2012-09-19 2012-09-21 0001388319 bhrt:NorthstarBiotechnologyGroupLlcPromissoryNoteMember 2012-10-01 0001388319 bhrt:ResetWarrantsMember 2012-10-01 0001388319 bhrt:NorthstarBiotechnologyGroupLlcPromissoryNoteMember 2012-09-28 2012-10-01 0001388319 bhrt:OfficerAndDirectorMember 2012-10-09 0001388319 bhrt:OfficerAndDirectorMember 2012-10-08 2012-10-09 0001388319 bhrt:OfficerAndDirectorMember 2012-10-22 0001388319 bhrt:ResetWarrantsMember 2012-09-01 2012-10-31 0001388319 bhrt:OfficerAndDirectorMember 2012-11-30 0001388319 bhrt:NorthstarBiotechnologyGroupLlcPromissoryNoteMember 2012-01-01 2012-12-31 0001388319 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-12-31 0001388319 2012-12-31 0001388319 bhrt:NorthstarBiotechnologyGroupLlcPromissoryNoteMember 2012-12-31 0001388319 us-gaap:EmployeeStockOptionMember 2012-12-31 0001388319 us-gaap:WarrantMember 2012-12-31 0001388319 us-gaap:CommonStockMember 2012-12-31 0001388319 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001388319 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-12-31 0001388319 us-gaap:PreferredStockMember 2012-12-31 0001388319 bhrt:SubscriptionReceivableMember 2012-12-31 0001388319 bhrt:ExcessShareDerivativeMember 2012-12-31 0001388319 us-gaap:WarrantMember 2012-12-31 0001388319 us-gaap:DerivativeMember 2012-12-31 0001388319 bhrt:NorthstarBiotechnologyGroupLlcPromissoryNoteMember 2013-02-01 2013-02-28 0001388319 2013-01-01 2013-03-31 0001388319 bhrt:AsherNotesPayableMember bhrt:DanielJamesManagementMember 2013-01-01 2013-03-31 0001388319 2013-03-31 0001388319 bhrt:OfficerAndDirectorMember 2013-08-01 0001388319 us-gaap:WarrantMember bhrt:ConsultingAgreementsMember 2013-11-01 2013-11-20 0001388319 2013-01-01 2013-12-31 0001388319 bhrt:AugustTwoThousandEightUnsecuredPromissoryNoteMember 2013-01-01 2013-12-31 0001388319 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-12-31 0001388319 us-gaap:WarrantMember 2013-01-01 2013-12-31 0001388319 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2013-01-01 2013-12-31 0001388319 us-gaap:AccountsReceivableMember bhrt:CustomerOneMember us-gaap:CustomerConcentrationRiskMember 2013-01-01 2013-12-31 0001388319 us-gaap:AccountsReceivableMember bhrt:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember 2013-01-01 2013-12-31 0001388319 us-gaap:AccountsReceivableMember bhrt:CustomerThreeMember us-gaap:CustomerConcentrationRiskMember 2013-01-01 2013-12-31 0001388319 bhrt:ExcessShareDerivativeMember 2013-01-01 2013-12-31 0001388319 us-gaap:WarrantMember 2013-01-01 2013-12-31 0001388319 us-gaap:DerivativeMember 2013-01-01 2013-12-31 0001388319 2013-12-31 0001388319 bhrt:AugustTwoThousandEightUnsecuredPromissoryNoteMember 2013-12-31 0001388319 bhrt:SeasideBankNotePayableMember 2013-12-31 0001388319 bhrt:OfficerAndDirectorMember 2013-12-31 0001388319 bhrt:NorthstarBiotechnologyGroupLlcPromissoryNoteMember 2013-12-31 0001388319 us-gaap:EmployeeStockOptionMember 2013-12-31 0001388319 us-gaap:WarrantMember 2013-12-31 0001388319 us-gaap:CommonStockMember 2013-12-31 0001388319 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001388319 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-12-31 0001388319 us-gaap:PreferredStockMember 2013-12-31 0001388319 bhrt:SubscriptionReceivableMember 2013-12-31 0001388319 bhrt:AsherNotesPayableMember 2013-12-31 0001388319 us-gaap:WarrantMember bhrt:ConsultingAgreementsMember 2013-12-31 0001388319 bhrt:ExcessShareDerivativeMember 2013-12-31 0001388319 us-gaap:WarrantMember 2013-12-31 0001388319 us-gaap:DerivativeMember 2013-12-31 0001388319 bhrt:HuntonAndWilliamsNotesPayableMember 2013-12-31 0001388319 bhrt:HuntonAndWilliamsNotesPayableMember bhrt:NotePayableOneMember 2013-12-31 0001388319 bhrt:HuntonAndWilliamsNotesPayableMember bhrt:NotePayableTwoMember 2013-12-31 0001388319 bhrt:DanielJamesManagementNotePayableMember 2013-12-31 0001388319 bhrt:FourthManLlcNotePayableMember 2013-12-31 0001388319 bhrt:AsherNotesPayableMember 2014-02-19 0001388319 bhrt:DanielNoteMember 2014-02-19 0001388319 bhrt:DanielNoteMember 2014-02-17 2014-02-19 0001388319 us-gaap:OfficerMember 2014-02-22 2014-02-24 0001388319 bhrt:OfficerOneMember 2014-02-22 2014-02-24 0001388319 2014-01-01 2014-03-31 0001388319 bhrt:OfficerAndDirectorMember 2014-01-01 2014-03-31 0001388319 bhrt:ResetWarrantsMember 2014-01-01 2014-03-31 0001388319 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-03-31 0001388319 us-gaap:WarrantMember 2014-01-01 2014-03-31 0001388319 us-gaap:CommonStockMember 2014-01-01 2014-03-31 0001388319 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-03-31 0001388319 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2014-01-01 2014-03-31 0001388319 us-gaap:PreferredStockMember 2014-01-01 2014-03-31 0001388319 bhrt:SubscriptionReceivableMember 2014-01-01 2014-03-31 0001388319 bhrt:AsherNotesPayableMember 2014-01-01 2014-03-31 0001388319 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2014-01-01 2014-03-31 0001388319 us-gaap:AccountsReceivableMember bhrt:CustomerOneMember us-gaap:CustomerConcentrationRiskMember 2014-01-01 2014-03-31 0001388319 us-gaap:AccountsReceivableMember bhrt:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember 2014-01-01 2014-03-31 0001388319 bhrt:ExcessShareDerivativeMember 2014-01-01 2014-03-31 0001388319 us-gaap:WarrantMember 2014-01-01 2014-03-31 0001388319 us-gaap:DerivativeMember 2014-01-01 2014-03-31 0001388319 bhrt:SalesRevenueGoodsAndServicesNetMember us-gaap:CustomerConcentrationRiskMember 2014-01-01 2014-03-31 0001388319 bhrt:RangeOneMember us-gaap:WarrantMember 2014-01-01 2014-03-31 0001388319 bhrt:RangeTwoMember us-gaap:WarrantMember 2014-01-01 2014-03-31 0001388319 bhrt:RangeThreeMember us-gaap:WarrantMember 2014-01-01 2014-03-31 0001388319 bhrt:RangeSixMember us-gaap:WarrantMember 2014-01-01 2014-03-31 0001388319 us-gaap:ConvertibleNotesPayableMember 2014-01-01 2014-03-31 0001388319 us-gaap:ConvertibleNotesPayableMember us-gaap:MinimumMember 2014-01-01 2014-03-31 0001388319 us-gaap:ConvertibleNotesPayableMember us-gaap:MaximumMember 2014-01-01 2014-03-31 0001388319 bhrt:RangeEightMember us-gaap:EmployeeStockOptionMember 2014-01-01 2014-03-31 0001388319 bhrt:RangeNineMember us-gaap:EmployeeStockOptionMember 2014-01-01 2014-03-31 0001388319 bhrt:RangeTenMember us-gaap:EmployeeStockOptionMember 2014-01-01 2014-03-31 0001388319 bhrt:RangeElevenMember us-gaap:EmployeeStockOptionMember 2014-01-01 2014-03-31 0001388319 us-gaap:SubsequentEventMember 2014-01-01 2014-03-31 0001388319 bhrt:SalesRevenueGoodsAndServicesNetMember bhrt:CustomerOneMember us-gaap:CustomerConcentrationRiskMember 2014-01-01 2014-03-31 0001388319 bhrt:SalesRevenueGoodsAndServicesNetMember bhrt:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember 2014-01-01 2014-03-31 0001388319 us-gaap:WarrantMember 2014-01-01 2014-03-31 0001388319 bhrt:AsherNotesPayableMember bhrt:DanielJamesManagementMember 2014-01-01 2014-03-31 0001388319 bhrt:AsherNotesPayableMember bhrt:DanielJamesManagementMember us-gaap:MaximumMember 2014-01-01 2014-03-31 0001388319 bhrt:AsherNotesPayableMember bhrt:DanielJamesManagementMember us-gaap:MinimumMember 2014-01-01 2014-03-31 0001388319 2014-03-31 0001388319 bhrt:AugustTwoThousandEightUnsecuredPromissoryNoteMember 2014-03-31 0001388319 bhrt:SeasideBankNotePayableMember 2014-03-31 0001388319 bhrt:OfficerAndDirectorMember 2014-03-31 0001388319 bhrt:NorthstarBiotechnologyGroupLlcPromissoryNoteMember 2014-03-31 0001388319 bhrt:ResetWarrantsMember 2014-03-31 0001388319 us-gaap:EmployeeStockOptionMember 2014-03-31 0001388319 us-gaap:WarrantMember 2014-03-31 0001388319 us-gaap:CommonStockMember 2014-03-31 0001388319 us-gaap:AdditionalPaidInCapitalMember 2014-03-31 0001388319 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2014-03-31 0001388319 us-gaap:PreferredStockMember 2014-03-31 0001388319 bhrt:SubscriptionReceivableMember 2014-03-31 0001388319 bhrt:AsherNotesPayableMember 2014-03-31 0001388319 us-gaap:WarrantMember bhrt:ConsultingAgreementsMember 2014-03-31 0001388319 bhrt:ExcessShareDerivativeMember 2014-03-31 0001388319 us-gaap:WarrantMember 2014-03-31 0001388319 us-gaap:DerivativeMember 2014-03-31 0001388319 bhrt:HuntonAndWilliamsNotesPayableMember 2014-03-31 0001388319 bhrt:HuntonAndWilliamsNotesPayableMember bhrt:NotePayableOneMember 2014-03-31 0001388319 bhrt:HuntonAndWilliamsNotesPayableMember bhrt:NotePayableTwoMember 2014-03-31 0001388319 bhrt:DanielJamesManagementNotePayableMember 2014-03-31 0001388319 bhrt:FourthManLlcNotePayableMember 2014-03-31 0001388319 bhrt:DanielNoteMember 2014-03-31 0001388319 bhrt:RangeOneMember us-gaap:WarrantMember 2014-03-31 0001388319 bhrt:RangeTwoMember us-gaap:WarrantMember 2014-03-31 0001388319 bhrt:RangeThreeMember us-gaap:WarrantMember 2014-03-31 0001388319 bhrt:RangeSixMember us-gaap:WarrantMember 2014-03-31 0001388319 us-gaap:ConvertibleNotesPayableMember 2014-03-31 0001388319 bhrt:RangeEightMember us-gaap:EmployeeStockOptionMember 2014-03-31 0001388319 bhrt:RangeNineMember us-gaap:EmployeeStockOptionMember 2014-03-31 0001388319 bhrt:RangeTenMember us-gaap:EmployeeStockOptionMember 2014-03-31 0001388319 bhrt:RangeElevenMember us-gaap:EmployeeStockOptionMember 2014-03-31 0001388319 us-gaap:WarrantMember 2014-03-31 0001388319 bhrt:OfficerAndDirectorMember us-gaap:MinimumMember 2014-03-31 0001388319 bhrt:OfficerAndDirectorMember us-gaap:MaximumMember 2014-03-31 0001388319 bhrt:AsherNotesPayableMember bhrt:DanielJamesManagementMember 2014-03-31 0001388319 bhrt:AsherNotesPayableMember bhrt:DanielJamesManagementMember us-gaap:MaximumMember 2014-03-31 0001388319 bhrt:AsherNotesPayableMember bhrt:DanielJamesManagementMember us-gaap:MinimumMember 2014-03-31 0001388319 1999-08-12 2014-03-31 0001388319 us-gaap:SubsequentEventMember 2014-04-30 0001388319 us-gaap:SubsequentEventMember 2014-04-01 2014-04-30 0001388319 2014-05-06 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure bhrt:Customer bhrt:Employees bhrt:Notes_Payable iso4217:USDbhrt:Warrant BIOHEART, INC. 0001388319 false --12-31 10-Q 2014-03-31 2014 Q1 Smaller Reporting Company 466396016 239033 46227 218984 19913 48754 784 1674 66924 269412 9055 8192 10160 10012 86139 287616 2382267 2513125 4480335 2368377 416198 403957 478286 478286 1500000 1500000 2241477 2179737 1930841 1966946 13429404 11410428 403811 1051196 20000 20000 379788 420920 103819119 104678615 215000 210000 118180983 117503543 182063 100260094 -115037724 -13747076 379788 103819119 -118180983 20000 215000 -12174008 420920 104678615 -117503543 20000 210000 86139 287616 0.001 0.001 20000000 20000000 20000000 20000000 20000000 20000000 0.001 0.001 950000000 950000000 379787745 420920157 379787745 420920157 4192 322572 322572 1688297 94446 677181 163974 9857 65329892 370533 838329 39943996 58695 769 863 900967 535276 943495 106910731 -531084 -620923 -105222434 117500 1004224 2093632 3117071 -640589 -489371 -519630 30259 -365423 762277 939 344821 352383 305898 16257355 12191 1298363 -12281109 -518893 677440 -117503543 -518893 677440 677440 -117503543 -0.003 0.002 -0.003 0.001 185421093 401553577 185421093 498696292 182062802 379787745 20000000 420920157 20000000 107474 6751 100723 6750781 194044 7166 186878 7166214 371000 27215 348785 -5000 27215417 6000 6000 22546 22546 22546 43250 3839832 194564 194564 769 863 900967 10000 176266 124838 93604 127500 2073854 123578 164757 664524 5413156 5437604 1228717 500000 285659 430213 360032 3381629 759316 1567673 69159 99997 274050 7758 19632 194564 10271081 362 38841 60019 -62953 37827 742 -33006 -1 28854 -12509 172786 3373406 55077 49522 7412998 465287 -546378 -257762 -75135166 909158 -909158 89 400000 371000 65679689 1447829 3000000 3000000 505000 180500 -10241 1072751 6000 299749 205000 127500 12163750 63740 3686192 1219268 785411 430519 76263308 239033 172757 218984 103969 84986 2790810 19500 194044 5240138 146740 107475 278691 397750 150815 70000 544267 <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><b>NOTE 1 &#8211; SIGNIFICANT ACCOUNTING POLICIES</b></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed financial statements follows:</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><u>General</u></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">The accompanying unaudited condensed financial statements of Bioheart, Inc., (the &#8220;Company&#8221;), have been prepared in accordance with the rules and regulations (S-X) of the Securities and Exchange Commission (the &#8220;SEC&#8221;) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three month period ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ended December 31, 2014. The unaudited condensed financial statements should be read in conjunction with the December 31, 2013 financial statements and footnotes thereto included in the Company&#8217;s Annual Report on Form 10-K.</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><u>Basis and business presentation</u></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">Bioheart, Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (&#8220;ASC 915-10&#8221;) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through March 31, 2014, the Company has accumulated a deficit through its development stage of $117,503,543.</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><u>Revenue Recognition</u></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (&#8220;ASC 605-10&#8221;) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management&#8217;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">Revenues for test kits and equipment sold are not recorded until test kits are delivered. Revenues from trainings are not recorded until the completion of the training. Any cash received as a deposit for trainings are recorded by the company as a liability.</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets.</p> <p align="justify" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;"><u>Comprehensive Income</u></p> <p align="justify" style="margin: 0px;">&#160;</p> <p align="justify" style="margin: 0px;">The Company does not have any items of comprehensive income in any of the periods presented.</p> <p align="justify" style="margin: 0px;">&#160;</p> <p align="justify" style="margin: 0px;"><u>Net Income (loss) per Common Share, basic and diluted</u></p> <p align="justify" style="margin: 0px;">&#160;</p> <p align="justify" style="margin: 0px;">The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (&#8220;ASC 260-10&#8221;) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options, warrants and shares issuable upon conversion of notes payable have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation for the three months ended March 31, 2013. Fully diluted shares outstanding were 498,696,292 and 222,688,816 for the three months ended March 31, 2014 and 2013, respectively.</p> <p style="margin: 0px;"></p> <p align="justify" style="margin: 0px;"><u>Stock Based Compensation</u></p> <p align="justify" style="margin: 0px;">&#160;</p> <p align="justify" style="margin: 0px;">The Company follows Accounting Standards Codification subtopic 718-10, Compensation (&#8220;ASC 718-10&#8221;) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10).</p> <p align="justify" style="margin: 0px;">&#160;</p> <p align="justify" style="margin: 0px;">As of March 31, 2014, there were outstanding stock options to purchase 43,650,856 shares of common stock, 16,650,856 shares of which were vested.</p> <p align="justify" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;"><u>Concentrations of Credit Risk</u></p> <p align="justify" style="margin: 0px;">&#160;</p> <p align="justify" style="margin: 0px;">The Company&#8217;s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. The financial stability of these institutions is periodically reviewed by senior management.</p> <p align="justify" style="margin: 0px;">&#160;</p> <p align="justify" style="margin: 0px;">As of March 31, 2014, two customers represented 26% and 25% (total of 51%) of the Company&#8217;s accounts receivable.</p> <p align="justify" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;">As of December 31, 2013, three customers represented 20%, 20% and 36% (total 76%) of the Company&#8217;s accounts receivable.</p> <p align="justify" style="margin: 0px;">&#160;</p> <p align="justify" style="margin: 0px;">For the three months ended March 31, 2014, the Company&#8217;s revenues earned from the sale of products and services were $322,572, of which two customers represented 17% and 10% of the Company&#8217;s revenues.</p> <p align="justify" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;"><u>Research and Development</u></p> <p align="justify" style="margin: 0px;">&#160;</p> <p align="justify" style="margin: 0px;">The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $9,857 and $163,974 for the three months ended March 31, 2014 and 2013, respectively; and $65,329,892 from August 12, 1999 (date of inception) to March 31, 2014.</p> <p align="justify" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;"><u>Fair Value</u></p> <p align="justify" style="margin: 0px;">&#160;</p> <p align="justify" style="margin: 0px;">Accounting Standards Codification subtopic 825-10, Financial Instruments (&#8220;ASC 825-10&#8221;) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.</p> <p align="justify" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;">The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (&#8220;ASC 820-10&#8221;) and Accounting Standards Codification subtopic 825-10, Financial Instruments (&#8220;ASC 825-10&#8221;), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company&#8217;s financial position, results of operations nor cash flows.</p> <p align="justify" style="margin: 0px;">&#160;</p> <p align="justify" style="margin: 0px;"><u>Reliance on Key Personnel and Consultants</u></p> <p align="justify" style="margin: 0px;">&#160;</p> <p align="justify" style="margin: 0px;">The Company has 4 full-time employees and 1 part-time employee. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.</p> <p align="justify" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;"><u>Derivative Instrument Liability</u></p> <p align="justify" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;">The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2014 and December 31, 2013, the Company did not have any derivative instruments that were designated as hedges.</p> <p align="justify" style="margin: 0px;"><br /><u>Recent Accounting Pronouncements</u></p> <p align="justify" style="margin: 0px;">&#160;</p> <p align="justify" style="margin: 0px;">There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company&#8217;s unaudited condensed financial position, results of operations or cash flows.</p> <div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">NOTE 2 &#8211; GOING CONCERN MATTERS</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The accompanying unaudited condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed financial statements, during three months ended March 31, 2014, the Company incurred an operating loss of $620,923 and used $257,762 in cash for operating activities. As of March 31, 2014, the Company had a working capital deficit (current liabilities in excess of current assets) of approximately $11.1 million. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The Company&#8217;s existence is dependent upon management&#8217;s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company&#8217;s financing efforts will result in profitable operations or the resolution of the Company&#8217;s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.</font></div><div>&#160;</div> <div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">NOTE 3 &#8212; PROPERTY AND EQUIPMENT</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Property and equipment as of March 31, 2014 and December 31, 2013 is summarized as follows:</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"></font><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">March 31,</font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">2014</font></font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"></font><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">December 31,</font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">2013</font></font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Laboratory and medical equipment</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">352,358</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">352,358</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Furniture, fixtures and equipment</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">125,634</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">125,634</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Computer equipment</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">39,525</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">39,525</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Leasehold improvements</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">362,046</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">362,046</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">879,563</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">879,563</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Less accumulated depreciation and amortization</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;">(871,371</td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(870,508</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">8,192</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9,055</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment in accordance with the guidance for impairment of long lived assets.</font></div> <div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">NOTE 4 &#8212; ACCRUED EXPENSES</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Accrued expenses consisted of the following as of March 31, 2014 and December 31, 2013:</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">March 31,</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">2014</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">December 31,</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">2013</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">License and royalty fees</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2,122,130</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Amounts payable to the Guarantors of the Company&#8217;s loan agreement with Bank of America and Seaside Bank, including fees and interest</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,356,013</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,373,775</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Interest payable on notes payable</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">757,669</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">714,180</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Vendor accruals and other</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">127,189</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">120,692</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Employee commissions, compensation, etc.</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">127,506</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">149,558</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2,368,377</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">4,480,335</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"><font style="background-color: #ffffff; display: inline;">In June 2000, the Company had entered into an agreement with William Beaumont Hospital, or WBH, pursuant to which WBH granted the Company a worldwide, exclusive, non-sublicenseable license to two U.S. method patents covering the inducement of human adult myocardial cell proliferation in vitro, or the WBH IP. The term of the agreement was for the life of the patents, which expire in 2015. The Company did not use this license in any of thier technologies or made any payments to WBH other than the initial payment to acquire the license. On April 2, 2014, the Company received confirmation that it has no obligation under the patent license agreement, WBH agreed to terminate the patent license agreement pursuant to a termination letter dated March 3, 2014, and WBH agreed to terminate the patent license agreement.</font></font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"><font style="background-color: #ffffff; display: inline;">Accordingly, the Company recognized approximately $2,122,130 in settlement of debt which represents the accumulative accrual and related interest from past years under the 2000 patent license agreement.</font></font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">During the three months ended March 31, 2014, the Company issued an aggregate of 6,750,781 shares of its common stock in settlement of outstanding accounts payable. In connection with the issuance, the Company incurred $65,548 loss in settlement of debt.</font></div> <div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">NOTE 5 &#8211; STANDBY EQUITY DISTRIBUTION AGREEMENT</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On November 2, 2011, the Company and Greystone Capital Partners (&#8220;Greystone&#8221;) had entered into a Standby Equity Distribution Agreement (the &#8220;Agreement&#8221;).&#160;&#160;Pursuant to the Agreement, Greystone had agreed to provide the Company with up to $1.0 million of funding for the 24-month period following the date a registration statement of the Company&#8217;s common stock is declared effective by the SEC (the &#8220;Equity Line&#8221;).&#160;&#160;The registration statement went effective on February 10, 2012. The Agreement automatically terminated on the first of April, 2014 (the first day of the month next following the second (2<font style="display: inline; font-size: 9px; vertical-align: text-top;">nd</font>) anniversary of the Effective Date).</font></div> <div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">NOTE 6 &#8211; NOTES PAYABLE</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Notes payable were comprised of the following as of March 31, 2014 and December 31, 2013:</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">March 31,</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">2014</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">December 31,</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">2013</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Seaside Bank note payable.</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">980,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">980,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">August 2008 Unsecured Promissory Note</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">500,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">500,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Hunton &amp; Williams notes payable</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">384,972</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">384,972</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Asher notes payable</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">183,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">143,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Daniel James Management note payable</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">35,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Fourth Man, LLC note payable</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">35,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">35,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Total notes payable</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2,117,972</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2,042,972</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Less unamortized debt discount</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(151,027</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(112,131</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Total notes payable net of unamortized debt discount</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,966,946</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,930,841</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Seaside Bank</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company&#8217;s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2014 to extend the maturity date to December 23, 2015.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">August 2008 Unsecured Promissory Note</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On August 20, 2008, the Company borrowed $1.0 million from a third party pursuant to the terms of an unsecured Promissory Note and Agreement. Outstanding principal and interest on the loan, which accrues at the rate of 13.5% per annum, is payable in one balloon payment upon the Company&#8217;s repayment of the BlueCrest Loan, which is scheduled to mature in May 2010, however the Company is not obligated to make payments until BlueCrest Loan is paid off. In the event the Company completes a private placement of its common stock and/or securities exercisable for or convertible into its common stock which generates at least $19.0 million of gross proceeds, the Company may prepay, without penalty, all outstanding principal and interest due under the loan using the same type of securities issued in the subject private placement. Because repayment of the loan could occur within 12 months from the date of the balance sheet, the Company has classified this loan as short term.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Subject to certain conditions, at the end of each calendar quarter during the time the loan is outstanding, the Company may, but is not required to, pay all or any portion of the interest accrued but unpaid as of such date with shares of its common stock. In April 2009, as consideration for the authorization to amend certain documents related to the Note, the Company issued to the Note holder a warrant to purchase 451,053 shares of common stock at an exercise price of $0.5321 per share.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The warrant, which became exercisable immediately upon issuance, has a ten year term. This warrant had a fair value of $195,694, which was accounted for as additional paid in capital and reflected as a component of debt discount and has been fully amortized as interest expense ratably over the term of the loan.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">In 2013, 1,000,000 shares of common stock were issued to the debt holder, in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note resulting in a gain of $1,078,625. A gain of $1,078,625 was included in the net gain on settlement of debt and trade payables on the statement of operations. As of March 31, 2014 the principle of this note was $500,000.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Hunton &amp; Williams Notes</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">At March 31, 2014 and December 31, 2013, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822 are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Asher Notes (During this year)</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">During the three months ended March 31, 2014, the Company entered into a Securities Purchase Agreements with Asher Enterprises, Inc. (&#8220;Asher&#8221;) or affiliates, for the sale of 8% convertible notes in aggregate principal amount of $97,500 (the &#8220;Asher Notes&#8221;).</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The Asher Notes bear interest at the rate of 8% per annum. As of the quarter ended March 31, 2014 all interest and principal must be repaid nine months from the issuance date, the last note due December 26, 2014. The Notes are convertible into common stock, at Asher&#8217;s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes.</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date which at March 31, 2014 was $153,564. At the inception of the Asher Notes, the Company determined the aggregate fair value of $214,346 of the embedded derivatives.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Daniel James Management</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On February 19, 2014, the Company entered into a Securities Purchase Agreements with Daniel James Management (&#8220;Daniel&#8221;) for the sale of 8% convertible note in principal amount of $35,000 (the &#8220;Daniel Note&#8221;).</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The Daniel Note bear interest at the rate of 8% per annum with all interest and principal due February 28, 2015. The Daniel Note is convertible into common stock, at holder&#8217;s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Daniel Note. These embedded derivatives included certain conversion features and reset provision.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Daniel Note and to fair value as of each subsequent reporting date which at March 31, 2014 was $63,343. At the inception of the Daniel Note, the Company determined the aggregate fair value of $63,343 of the embedded derivatives.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The fair value of the embedded derivatives of the Asher Notes and Daniel Note, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 158.19% to 181.73%, (3) weighted average risk-free interest rate of 0.03% to 0.15%, (4) expected lives of 0.03 to 1.00 years, and (5) estimated fair value of the Company&#8217;s common stock from $0.001 to $0.0447 per share. The initial fair value of the embedded debt derivative of $292,257 was allocated as a debt discount up to the proceeds of the note ($127,500) with the remainder ($164,757) charged to current period operations as interest expense. For the three months ended March 31, 2014 and 2013, the Company amortized an aggregate of $93,604 and $124,838 of debt discounts to current period operations as interest expense, respectively.</font></div> <div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">NOTE 7 &#8212; RELATED PARTY TRANSACTIONS</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: 'times new roman'; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Advances</font></font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">As of March 31, 2014 and December 31, 2013, the Company officers and directors have provided advances in the aggregate of $403,957 and $416,198 respectively, for working capital purposes. The advances are unsecured, due on demand and non-interest bearing.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: 'times new roman'; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Notes payable-related party</font></font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: 'times new roman'; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Northstar Biotechnology Group, LLC</font></font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On February 29, 2012, a note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (&#8220;Northstar&#8221;), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. As of September 30, 2012, the Company was in default, however, subsequent to September 30, 2012, the Company renegotiated the terms of the Note, Northstar has agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On September 21, 2012, the Company issued 5,000,000 common stock purchase warrants to Northstar that was treated as Additional interest expense upon issuance.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Effective October 1, 2012, the effective interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued. In addition, the Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock. The Company is required to issue additional shares of its common stock (as amended), in lieu of cash, each six month anniversary of the effective date for any accrued and unpaid interest.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">As of March 31, 2014 and December 31, 2013, the principle of this note was $362,000.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: 'times new roman'; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Officer and Director Notes</font></font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">At March 31, 2014 and December 31, 2013, the Company has outstanding notes payable to officers and directors with interest at 8% per annum due at maturity. The three subordinated notes, $125,000, $100,000 and $140,000 were previously due on October 22, 2012, November 30, 2012 and June 4, 2011 respectively, and are unsecured. The Company is not obligated to make payment until Northstar loan is paid off.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On October 9, 2012, the Company issued an aggregate of $1,278,324 of promissory notes due October 9, 2013 to officers and directors in settlement of outstanding advances and accrued compensation (currently in default). The promissory notes bear interest of 5% per annum and due at maturity.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On September 30, 2013, the Company issued an aggregate of 15,350,876 shares of its common stock in settlement of $175,000 of related party notes payable.</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On August 1, 2013, the Company issued an aggregate of $500,000 promissory notes due on demand to officers and employee in settlement of accrued compensation. The promissory notes bear interest of 5% per annum and due at various maturity dates. During the three months ended March 31, 2014, the Company paid off $63,740 of the outstanding promissory notes. The principle outstanding balance of these notes as of March 31, 2014 is $349,413.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: 'times new roman'; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Subordinated debt, related party</font></font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">As of March 31, 2014 and December 31, 2013, the Company officers and directors have provided notes in aggregate of $1,500,000. The notes are at from 4.75% to 8% per annum and are due upon payoff of the Northstar note payable described above.</font></div> <div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">NOTE 8 &#8212; DERIVATIVE LIABILITIES</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: 'times new roman'; font-size: 10pt;">Reset warrants</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 7 above, the Company issued an aggregate of 15,000,000 common stock purchase warrants to purchase the Company&#8217;s common stock with an exercise price of $0.014 per share for ten years with anti-dilutive (reset) provisions.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">At March 31, 2014, the fair value of the reset provision of $666,485 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 173.72%; risk free rate: 2.73%; and expected life: 8.50 years. The Company recorded a loss on change in derivative liabilities of $519,630 during the three months ended March 31, 2014.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: 'times new roman'; font-size: 10pt;">Convertible notes</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">In 2013 and the three months ended March 31, 2014, the Company issued convertible notes (see Note 6 above).</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">These notes are convertible into common stock, at holders&#8217; option, at a discount to the market price of the Company&#8217;s common stock. The Company has identified the embedded derivatives related to these notes relating to certain anti-dilutive (reset) provisions. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Note and to fair value as of each subsequent reporting date.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The fair value of the embedded derivatives at March 31, 2014, in the amount of $384,711, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 173.72%, (3) weighted average risk-free interest rate of 0.03 to 0.13%, (4) expected lives of 0.03 to 0.74 years, and (5) estimated fair value of the Company&#8217;s common stock of $0.0447 per share. The Company recorded a gain on change in derivative liabilities of $30,259 during the three months ended March 31, 2014.</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">At March 31, 2014, the aggregate derivative liabilities was valued at $1,051,196, the Company believes an event under the contract that would create an obligation to settle in cash or other current assets is remote and has classified the obligation as a long term liability.</font></div> <p style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 9 &#8211; STOCKHOLDERS&#8217; EQUITY</b></p> <p style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Preferred stock</u></p> <p style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">On August 17, 2012, the board of directors designated 5,000,000 shares of preferred stock as Series A Convertible Preferred Stock which was increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. Each share of preferred stock is convertible into equal number of common shares at the option of the holder; entitled to 20 votes on all matters presented to be voted by the holders of common stock; upon event of liquidation, entitled to amount equal to stated value plus any accrued and unpaid dividends or other fees before distribution to junior securities. In lieu of the initial two payments due to Northstar, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders (see Note 7 above).</p> <p style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Common stock</u></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">During the three months ended March 31, 2014, the Company issued an aggregate of 6,750,781 shares of its common stock in settlement of outstanding accounts payable. In connection with the issuance, the Company incurred a loss on settlement of debt of $65,548.</p> <p style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">During the three months ended March 31, 2014, the Company issued an aggregate of 7,166,214 shares of its common stock for the conversion of $57,500 of convertible notes payable and related accrued interest of $2,300.</p> <p style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 10 &#8212; STOCK OPTIONS AND WARRANTS</b></p> <p style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Stock Options</u></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In December 1999, the Board of Directors and shareholders adopted the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors &amp; Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011.</p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the &#8220;2013 Omnibus Plan&#8221;. The 2013 Omnibus Plan reserves up to fifty million shares of common stock for issuance.</p> <p style="margin: 0px;"></p> <p align="justify" style="margin: 0px;">A summary of options at March 31, 2014 and activity during the three months then ended is presented below:</p> <p align="justify" style="margin: 0px;"></p> <table style="width: 100%; font-size: 10pt;" cellspacing="0"> <tr style="font-size: 0px;"> <td></td> <td width="6"></td> <td width="6"></td> <td width="81"></td> <td width="8"></td> <td width="6"></td> <td width="22"></td> <td width="81"></td> <td width="6"></td> <td width="6"></td> <td width="50"></td> <td width="31"></td> <td width="31"></td> </tr> <tr> <td style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;"><b>&#160;</b></p> </td> <td width="95" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Shares</b></p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;"><b>&#160;</b></p> </td> <td width="103" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;" colspan="2"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Exercise Price</b></p> </td> <td width="13" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;" colspan="2"> <p style="margin: 0px;"><b>&#160;</b></p> </td> <td width="113" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Remaining<br />Contractual<br />Term (in years)</b></p> </td> </tr> <tr> <td style="vertical-align: bottom;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td width="95" valign="bottom" colspan="3"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td width="229" valign="bottom" colspan="7"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">Options outstanding at January 1, 2013</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">7,853,376</p> </td> <td width="8" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">$</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.67</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;" colspan="2"> <p align="center" style="margin: 0px;">8.2</p> </td> <td width="31" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: #ffffff;"> <p style="margin: 0px;">Granted</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">17,400,000</p> </td> <td width="8" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">$</p> </td> <td width="81" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.016</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #ffffff;" colspan="2"> <p align="center" style="margin: 0px;">9.9</p> </td> <td width="31" valign="bottom" style="background-color: #ffffff;"> <p>&#160;</p> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">Exercised</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#8212;</p> </td> <td width="8" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">$</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;" colspan="2"> <p>&#160;</p> </td> <td width="31" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> </tr> <tr> <td style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">Forfeited/Expired</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">(1,340,433</p> </td> <td width="8" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">)</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">$</p> </td> <td width="81" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">1.08</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;" colspan="2"> <p align="center" style="margin: 0px;">&#160;</p> </td> <td width="31" valign="bottom" style="background-color: #ffffff;"> <p>&#160;</p> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">Options outstanding at December 31, 2013</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">23,912,943</p> </td> <td width="8" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">$</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.15</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;" colspan="2"> <p align="center" style="margin: 0px;">9.0</p> </td> <td width="31" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: #ffffff;"> <p style="margin: 0px;">Granted</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">19,800,000&#160;</p> </td> <td width="8" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">$</p> </td> <td width="81" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.019</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #ffffff;" colspan="2"> <p align="center" style="margin: 0px;">9.1</p> </td> <td width="31" valign="bottom" style="background-color: #ffffff;"> <p>&#160;</p> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">Exercised</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#8212;</p> </td> <td width="8" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;" colspan="2"> <p align="center" style="margin: 0px;">&#160;</p> </td> <td width="31" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> </tr> <tr> <td style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">Forfeited/Expired</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">(62,087</p> </td> <td width="8" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">)</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">$</p> </td> <td width="81" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">1.08</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;" colspan="2"> <p align="center" style="margin: 0px;">&#160;</p> </td> <td width="31" valign="bottom" style="background-color: #ffffff;"> <p>&#160;</p> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">Options outstanding at March 31, 2014</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">43,650,856</p> </td> <td width="8" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">$</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.08</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #cceeff;" colspan="2"> <p align="center" style="margin: 0px;">9.3</p> </td> <td width="31" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: #ffffff;"> <p style="margin: 0px;">Options exercisable at March 31, 2014</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">16,650,856</p> </td> <td width="8" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">$</p> </td> <td width="81" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.18</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="background-color: #ffffff;" colspan="2"> <p align="center" style="margin: 0px;">8.9</p> </td> <td width="31" valign="bottom" style="background-color: #ffffff;"> <p>&#160;</p> </td> </tr> <tr> <td style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid; background-color: #cceeff;"> <p style="margin: 0px;">Available for grant at March 31, 2014</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid; background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid; background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid; background-color: #cceeff;"> <p align="right" style="margin: 0px;">12,800,000</p> </td> <td width="8" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid; background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid; background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid; background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="81" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid; background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid; background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="6" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid; background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="50" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid; background-color: #cceeff;"> <p align="center" style="margin: 0px;">&#160;</p> </td> <td width="31" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> <td width="31" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> </tr> </table> <p style="margin: 0px;"></p> <p style="margin: 0px;">The following information applies to options outstanding and exercisable at March 31, 2014:</p> <p align="justify" style="margin: 0px;"></p> <table style="width: 100%; font-size: 10pt;" cellspacing="0"> <tr style="font-size: 0px;"> <td nowrap="nowrap"></td> <td width="7"></td> <td width="20"></td> <td width="84"></td> <td width="7"></td> <td width="7"></td> <td width="37"></td> <td width="45"></td> <td width="13"></td> <td width="7"></td> <td width="18"></td> <td width="53"></td> <td width="11"></td> <td width="7"></td> <td width="20"></td> <td width="84"></td> <td width="7"></td> <td width="11"></td> <td width="18"></td> <td width="53"></td> <td width="7"></td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p align="center" style="margin: 0px;"><b>&#160;</b></p> </td> <td width="306" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="11"> <p align="center" style="margin: 0px;"><b>Options Outstanding</b></p> </td> <td width="7" valign="bottom"> <p align="center" style="margin: 0px;"><b>&#160;</b></p> </td> <td width="195" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="6"> <p align="center" style="margin: 0px;"><b>Options Exercisable</b></p> </td> <td width="7" valign="bottom"> <p align="center" style="margin: 0px;"><b>&#160;</b></p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="112" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Shares</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="96" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Remaining<br />Contractual<br />Term</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="83" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Exercise<br />Price</b></p> </td> <td width="112" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Shares</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="83" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Exercise<br />Price</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="20" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="84" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="37" valign="bottom"> <p align="center" style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="45" valign="bottom"> <p align="center" style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="13" valign="bottom"> <p align="center" style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="18" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="53" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="11" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="20" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="84" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="11" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="18" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="53" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">$0.00 &#8211; $0.70</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="84" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">43,090,000</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="37" valign="bottom" style="background-color: #cceeff;"> <p align="center" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="45" valign="bottom" style="background-color: #cceeff;"> <p align="center" style="margin: 0px;">9.4</p> </td> <td width="13" valign="bottom" style="background-color: #cceeff;"> <p align="center" style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="53" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.03</p> </td> <td width="11" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;</p> </td> <td width="84" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">16,090,000</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="53" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.04</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #ffffff;"> <p style="margin: 0px;">$0.71 &#8211; $1.28</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="84" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">162,286</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="37" valign="bottom" style="background-color: #ffffff;"> <p align="center" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="45" valign="bottom" style="background-color: #ffffff;"> <p align="center" style="margin: 0px;">4.2</p> </td> <td width="13" valign="bottom" style="background-color: #ffffff;"> <p align="center" style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="18" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="53" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.80</p> </td> <td width="11" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;</p> </td> <td width="84" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">162,286</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="18" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="53" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.80</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">$5.25 &#8211; $5.67</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="84" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">373,858</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="37" valign="bottom" style="background-color: #cceeff;"> <p align="center" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="45" valign="bottom" style="background-color: #cceeff;"> <p align="center" style="margin: 0px;">2.1</p> </td> <td width="13" valign="bottom" style="background-color: #cceeff;"> <p align="center" style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="53" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">5.55</p> </td> <td width="11" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="84" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">373,858</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="53" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">5.55</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #ffffff;"> <p style="margin: 0px;">$7.69</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="84" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">24,712</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="37" valign="bottom" style="background-color: #ffffff;"> <p align="center" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="45" valign="bottom" style="background-color: #ffffff;"> <p align="center" style="margin: 0px;">2.3</p> </td> <td width="13" valign="bottom" style="background-color: #ffffff;"> <p align="center" style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="18" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="53" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">7.69</p> </td> <td width="11" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="84" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">24,712</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="18" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="53" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">7.69</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p style="margin: 0px;">&#160;&#160;</p> </td> <td width="7" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="84" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p align="right" style="margin: 0px;">43,650,856</p> </td> <td width="7" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="37" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p align="center" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="45" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p align="center" style="margin: 0px;">9.3</p> </td> <td width="13" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p align="center" style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="18" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="53" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p align="right" style="margin: 0px;">0.08</p> </td> <td width="11" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="84" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p align="right" style="margin: 0px;">16,650,856</p> </td> <td width="7" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="18" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="53" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p align="right" style="margin: 0px;">0.18</p> </td> <td width="7" valign="bottom" style="border-top-color: #000000; border-bottom-color: #000000; border-top-width: 2px; border-bottom-width: 1.33px; border-top-style: solid; border-bottom-style: solid; background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> </table> <p align="justify" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;">On February 24, 2014, the Company issued an aggregate 15,000,000 options to purchase the Company&#8217;s common stock at $0.019 per share to officers, vesting at 25% immediately and the remainder over approximately 42 months, exercisable over 10 years. The aggregate fair value of $282,597, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 163.63% and Risk free rate: 2.75%.</p> <p align="justify" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;">On February 24, 2014, the Company issued an aggregate 4,800,000 options to purchase the Company&#8217;s common stock at $0.019 per share to officers, vesting immediately and exercisable over 10 years. The aggregate fair value of $90,431, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 163.63% and Risk free rate: 2.75%.</p> <p align="justify" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;">The fair value of all options vesting during the three months ended March 31, 2014 and 2013 of $194,565 and $19,632, respectively, was charged to current period operations.</p> <p style="margin: 0px;"></p> <p style="margin: 0px;"><u>Warrants</u></p> <p style="margin: 0px;"></p> <p style="margin: 0px;">A summary of common stock purchase warrants at March 31, 2014 and activity during the three months then ended is presented below:</p> <p style="margin: 3.33px;"></p> <table style="width: 100%; font-size: 10pt;" cellspacing="0"> <tr style="font-size: 0px;"> <td nowrap="nowrap"></td> <td width="7"></td> <td width="22"></td> <td width="99"></td> <td width="18"></td> <td width="7"></td> <td width="16"></td> <td width="61"></td> <td width="10"></td> <td width="7"></td> <td width="39"></td> <td width="48"></td> <td width="13"></td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p align="center" style="margin: 0px;"><b>&#160;</b></p> </td> <td width="140" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Shares</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p align="center" style="margin: 0px;"><b>&#160;</b></p> </td> <td width="88" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Exercise<br />Price</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p align="center" style="margin: 0px;"><b>&#160;</b></p> </td> <td width="102" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Remaining<br />Contractual<br />Term (in<br />years)</b></p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="22" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="99" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="18" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="16" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="61" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="10" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="39" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="48" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="13" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;">Outstanding at January 1, 2013</td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">74,073,322</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.37</p> </td> <td width="10" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">4.5</p> </td> <td width="13" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #ffffff;"> <p style="margin: 0px; text-indent: -10px;">&#160;&#160;&#160;Issued</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">50,350,536</p> </td> <td width="18" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.16</p> </td> <td width="10" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">9.2</p> </td> <td width="13" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px; text-indent: -10px;">&#160;&#160;&#160;Exercised</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#8212;&#160;</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.00</p> </td> <td width="10" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;</p> </td> <td width="13" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px; text-indent: -10px;">&#160;&#160;&#160;Forfeited</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">(6,345,002)</p> </td> <td width="18" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">0.38</p> </td> <td width="10" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p>&#160;</p> </td> <td width="13" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">Outstanding at December 31, 2013</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">118,078,856</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.22</p> </td> <td width="10" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">6.3</p> </td> <td width="13" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #ffffff;"> <p style="margin: 0px; text-indent: -10px;">&#160;&#160;&#160;Issued</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">32,292,783</p> </td> <td width="18" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.017</p> </td> <td width="10" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">8.4</p> </td> <td width="13" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px; text-indent: -10px;">&#160;&#160;&#160;Exercised</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#8212;</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin-top: 3.2px; margin-bottom: 3.2px;">&#8212;</p> </td> <td width="10" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> <td width="13" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px; text-indent: -10px;">&#160;&#160;&#160;Expired</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">(2,314,575</p> </td> <td width="18" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">)&#160;&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">0.18</p> </td> <td width="10" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="13" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p>&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">Outstanding at March 31, 2014</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">148,057,064</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.17</p> </td> <td width="10" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">6.7</p> </td> <td width="13" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #ffffff;"> <p style="margin: 0px;">Exercisable at March 31, 2014</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">102,401,650</p> </td> <td width="18" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.13</p> </td> <td width="10" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">5.7</p> </td> <td width="13" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> </table> <p style="margin: 0px;"></p> <p align="justify" style="margin: 0px;">The following information applies to common stock purchase warrants outstanding and exercisable at March 31, 2014:</p> <p align="center" style="margin: 0px;"></p> <table style="width: 100%; font-size: 10pt;" cellspacing="0"> <tr style="font-size: 0px;"> <td nowrap="nowrap"></td> <td width="7"></td> <td width="20"></td> <td width="90"></td> <td width="7"></td> <td width="7"></td> <td width="36"></td> <td width="44"></td> <td width="12"></td> <td width="7"></td> <td width="17"></td> <td width="52"></td> <td width="11"></td> <td width="7"></td> <td width="20"></td> <td width="90"></td> <td width="7"></td> <td width="11"></td> <td width="17"></td> <td width="52"></td> <td width="7"></td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="306" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="11"> <p align="center" style="margin: 0px;"><b>Warrants Outstanding</b></p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="198" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="6"> <p align="center" style="margin: 0px;"><b>Warrants Exercisable</b></p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="117" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Shares</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="93" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Remaining<br />Contractual<br />Term</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="80" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Exercise<br />Price</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="118" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Shares</b></p> </td> <td width="80" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Exercise<br />Price</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="20" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="90" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="36" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="44" valign="bottom"> <p align="center" style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="12" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="17" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="52" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="11" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="20" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="90" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="11" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="17" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="52" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">$0.01 &#8211; $0.50</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">141,807,931</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="36" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="44" valign="bottom" style="background-color: #cceeff;"> <p align="center" style="margin: 0px;">6.7</p> </td> <td width="12" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.02</p> </td> <td width="11" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">97,696,967</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.02</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #ffffff;"> <p style="margin: 0px;">$0.52 &#8211; $0.68</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">2,699,675</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="36" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="44" valign="bottom" style="background-color: #ffffff;"> <p align="center" style="margin: 0px;">5.1</p> </td> <td width="12" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.58</p> </td> <td width="11" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">2,699,675</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.58</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">$0.70 &#8211; $1.62</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">848,176</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="36" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="44" valign="bottom" style="background-color: #cceeff;"> <p align="center" style="margin: 0px;">5.8</p> </td> <td width="12" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.71</p> </td> <td width="11" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">848,176</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.71</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">$5.67 &#8211; $7.69</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">2,701,282</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="36" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="44" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="center" style="margin: 0px;">8.6</p> </td> <td width="12" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">7.55</p> </td> <td width="11" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">1,156,832</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">7.35</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">148,057,064</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="36" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="44" valign="bottom" style="background-color: #ccecff;"> <p align="center" style="margin: 0px;">6.7</p> </td> <td width="12" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">0.17</p> </td> <td width="11" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">102,401,650</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">0.13</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> </table> <p align="center" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;">In conjunction with the authorized issuance of common stock, the Company granted 24,292,783 common stock purchase warrants during the three months ended March 31, 2014.</p> <p align="center" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;">During the three months ended March 31, 2014, the Company issued an aggregate of 8,000,000 warrants in connection with a joint venture agreement dated March 10, 2014. The warrants are exercisable at $0.0217 for four years vesting from June 8, 2014 through March 10, 2015. During the three months ended March 31, 2014, the Company charged $22,546 to current period operations for the vesting portion.</p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><b>NOTE 11 &#8212; COMMITMENTS AND CONTINGENCIES</b></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><b><br /></b></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><u>Joint Venture Agreement</u></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><u><br /></u></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">On March 10, 2014, the Company entered a joint-venture or profits sharing agreement (the Agreement) with Global Stem Cells, Group, LLC and its subsidiaries whereby both parties will participate in marketing for obtaining patients and provide physician training for stem cell treatments under the names of &#8220;Regenestem&#8221; and &#8220;Stem Cell Training&#8221;, respectively. In addition, each party will be responsible for selling equipment and kit to existing and previous customers. Profits are divided on a fifty/fifty basis with distribution within 10 days of the accounting for patients and physician training and 30 day with sales of equipment and kits.</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">In consideration of Global Stem Cell Group, LLC&#8217;s participation, the Company issued an aggregate of 8,000,000 warrants to purchase the Company&#8217;s common stock for four years at $0.0217 per share with 2,000,000 warrants vesting 90 days from the effective date, 2,000,000 vesting on each anniversary date for three years. During the three months ended March 31, 2014, the Company charged $22,546 to current period operations for the vesting portion.</p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><u>William Beaumont Hospital</u></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><u><br /></u></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><font style="background-color: #ffffff;">In June 2000, the Company entered into an agreement with William Beaumont Hospital, or WBH, pursuant to which WBH granted to the Company worldwide, exclusive, non-sublicenseable license to two U.S. method patents covering the inducement of human adult myocardial cell proliferation in vitro, or the WBH IP. The term of the agreement is for the life of the patents, which expire in 2015. The Company did not use this license in any of our technologies. The Company had not made any payments to WBH other than the initial payment to acquire the license. The Company has received confirmation that it has no obligation under the patent license agreement and WBH agreed to terminate the patent license agreement. (See Note 4)</font></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><font style="background-color: #ffffff;">&#160;</font></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><font style="background-color: #ffffff;">Accordingly, the Company will recognize approximately $2,122,000 in settlement of debt which represents the accumulative accrual and related interest from past years under the 2000 patent license agreement.</font></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><u>Contingency for Registration of the Company&#8217;s common stock</u><u><br /></u></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">The Company believes that it may have issued options to purchase common stock to certain of its employees, directors and consultants in California in violation of the registration or qualification provisions of applicable California securities laws. As a result, the Company intends to make a rescission offer to these persons. The Company will make this offer to all persons who have a continuing right to rescission, which it believes to include two persons. In the rescission offer, in accordance with California law, the Company will offer to repurchase all unexercised options issued to these persons at 77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted. Based upon the number of options that were subject to rescission as of December 31, 2009, assuming that all such options are tendered in the rescission offer, the Company estimated that its total rescission liability would be up to approximately $371,000. However, as the Company believes there is only a remote likelihood the rescission offer will be accepted by any of these persons in an amount that would result in a material expenditure by the Company, no liability was recorded as of March 31, 2014 or December 31, 2013.</p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><u>Litigation</u></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of March 31, 2014, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company&#8217;s business, financial position, results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.</p> <p style="margin: 0px;"></p> <p style="margin: 0px;"><u>Consulting agreements</u></p> <p style="margin: 0px;"></p> <p style="margin: 0px;"></p> <p align="justify" style="margin: 0px;"><font style="background-color: #ffffff;">On November 20, 2013, the Company entered into an investment banking agreement with Cassel Salpeter &amp; Co. (&#8220;CSC&#8221;), who will act as exclusive third party financial advisor in connection with investment banking matters. The term of the Investment Banking Agreement shall be for a period of twenty four months unless terminated or extended in accordance with its terms. For these services, CSC will receive a one-time $25,000 fee, $5,000 monthly</font><font style="color: #00007f; background-color: #ffffff;">&#160;</font><font style="background-color: #ffffff;">fees and 5,207,630 ten year common stock purchase warrants, exercisable at $.0113 and applicable consideration in the event the closing of a Mezzanine Financing consisting of non-convertible subordinated debt and/or sale of equity securities. The Company will also reimburse CSC for its reasonable out-of-pocket expenses associated with the services provided pursuant to the Investment Banking Agreement. As of March 31, 2014 and December 31, 2013, the Company accrued $46,317 and $32,424 under the agreement, respectively.</font></p> <p style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 12 &#8212; FAIR VALUE MEASUREMENT</b></p> <p style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (&#8220;ASC 825-10&#8221;) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:</p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Level 2 &#8211; Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.</p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Level 3 &#8211; Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.</p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.</p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.</p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.</p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The carrying value of the Company&#8217;s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.</p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <p align="justify" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">As of March 31, 2014 or December 31, 2013, the Company did not have any items that would be classified as level 1 or 2 disclosures.</p> <p style="margin: 0px;"></p> <p align="justify" style="margin: 0px;"></p> <p align="justify" style="margin: 0px;">The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in notes 7 and 9. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Notes 7 and 9 are that of volatility and market price of the underlying common stock of the Company.</p> <p style="margin: 0px;"></p> <p align="justify" style="margin: 0px;">As of March 31, 2013 and December 31, 2013, the Company did not have any derivative instruments that were designated as hedges.</p> <p style="margin: 0px;"></p> <p align="justify" style="margin: 0px;">The derivative liability as of March 31, 2014, in the amount of $1,051,196 has a level 3 classification.</p> <p style="margin: 0px;"></p> <p style="margin: 0px;">The following table provides a summary of changes in fair value of the Company&#8217;s Level 3 financial liabilities as of March 31, 2014:</p> <p style="margin: 0px;"></p> <table style="width: 1422.72px; border-collapse: collapse;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;" colspan="3">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;" colspan="3">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;" colspan="3">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 9pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold;">&#160;</td> <td nowrap="nowrap" style="text-align: center; font-size: 9pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="3">Excess Share<br />Derivative</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold;">&#160;</td> <td nowrap="nowrap" style="text-align: center; font-size: 9pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="3">Warrant<br />Liability</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold;">&#160;</td> <td nowrap="nowrap" style="text-align: center; font-size: 9pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="3">Debt<br />Derivative</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 981.81px; font-size: 9pt;">Balance, December 31, 2012</td> <td style="width: 14.54px; font-size: 9pt;">&#160;</td> <td style="width: 14.54px; text-align: left; font-size: 9pt;">$</td> <td style="width: 114.54px; text-align: right; font-size: 9pt;">390,048</td> <td style="width: 14.54px; text-align: left; font-size: 9pt;">&#160;</td> <td style="width: 14.54px; font-size: 9pt;">&#160;</td> <td style="width: 14.54px; text-align: left; font-size: 9pt;">&#160;</td> <td style="width: 100px; text-align: right; font-size: 9pt;">221,179</td> <td style="width: 13.63px; text-align: left; font-size: 9pt;">&#160;</td> <td style="width: 13.63px; font-size: 9pt;">&#160;</td> <td style="width: 13.63px; text-align: left; font-size: 9pt;">$</td> <td style="width: 99.09px; text-align: right; font-size: 9pt;">&#8212;&#160;&#160;</td> <td style="width: 13.63px; text-align: left; font-size: 9pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-size: 9pt;">Total (gains) losses</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-size: 9pt;">Initial fair value of debt derivative at note issuance</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">&#8212;&#160;&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">673,219</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-size: 9pt;">Initial fair value of derivative relating to reset warrants</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">&#8212;&#160;&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">&#8212;&#160;&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">&#8212;&#160;&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 9pt;">Mark-to-market at December 31, 2013:</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">84.906</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">(74,324</td> <td style="text-align: left; font-size: 9pt;">)</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">(39,761</td> <td style="text-align: left; font-size: 9pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-size: 9pt;">Transfers out of Level 3 upon increase in authorized shares</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">(474,954</td> <td style="text-align: left; font-size: 9pt;">)</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">&#8212;&#160;&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">&#8212;&#160;&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; padding-bottom: 1pt; font-size: 9pt;">Transfers out of Level 3 upon conversion and settlement of notes</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; font-size: 9pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(376,502</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 9pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 9pt;">Balance, December 31, 2013</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">$</td> <td style="text-align: right; font-size: 9pt;">&#8212;&#160;&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">$</td> <td style="text-align: right; font-size: 9pt;">146,855</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">$</td> <td style="text-align: right; font-size: 9pt;">256,956</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-size: 9pt;">Total (gains) losses</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-size: 9pt;">Initial fair value of debt derivative at note issuance</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">&#8212;&#160;&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">&#8212;&#160;&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">292,257</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 9pt;">Mark-to-market at March 31, 2014:</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">&#8212;&#160;&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">519,630</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="text-align: right; font-size: 9pt;">(30,259</td> <td style="text-align: left; font-size: 9pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 1pt; font-size: 9pt;">Transfers out of Level 3 upon conversion of notes payable</td> <td style="padding-bottom: 1pt; font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; font-size: 9pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#8212;&#160;&#160;</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 9pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; font-size: 9pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#8212;&#160;&#160;</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 9pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; font-size: 9pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(134,243</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 9pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 9pt;">Balance, March 31, 2014</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">$</td> <td style="text-align: right; font-size: 9pt;">&#8212;&#160;&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">$</td> <td style="text-align: right; font-size: 9pt;">666,485</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">$</td> <td style="text-align: right; font-size: 9pt;">384,711</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-size: 9pt;">Net (Loss) Gain for the period included in earnings relating to the liabilities held at March 31, 2014</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">$</td> <td style="text-align: right; font-size: 9pt;">&#8212;&#160;&#160;</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">$</td> <td style="text-align: right; font-size: 9pt;">(519,630</td> <td style="text-align: left; font-size: 9pt;">)</td> <td style="font-size: 9pt;">&#160;</td> <td style="text-align: left; font-size: 9pt;">$</td> <td style="text-align: right; font-size: 9pt;">30,259</td> <td style="text-align: left; font-size: 9pt;">&#160;</td> </tr> </table> <p style="margin: 0px;"><br />&#160;</p> <p align="justify" style="margin: 0px;">Fluctuations in the Company&#8217;s stock price are a primary driver for the changes in the derivative valuations during each reporting period. The Company&#8217;s stock price increased approximately 447% from December 31, 2013 to March 31, 2014. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company&#8217;s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company&#8217;s derivative instruments. The simulated fair value of these liabilities is sensitive to changes in the Company&#8217;s expected volatility. Increases in expected volatility would generally result in a higher fair value measurement.</p> <div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">NOTE 13 &#8212; SUBSEQUENT EVENTS</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">In April 2014, the Company issued an aggregate of 3,839,832 shares of its common stock for services rendered valued at $43,250.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">In April 2014, the Company issued 5,263,315 shares of its common stock in settlement of related party advances of $100,000.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">In April, 2014, the Company issued 1,002,808 shares of its common stock in settlement of common stock subscriptions of $50,000</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">In April 2014, the Company issued 274,681 shares of its common stock as settlement of six months accrued interest on the Northstar note obligation.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">In April 2014, the Company issued 18,383,774 shares of its common stock for service rendered valued at $180,511.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">In April 2014, the Company issued an aggregate of 4,793,268 shares of its common stock in settlement of $67,500 convertible notes payable and $2,700 accrued interest.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">In April 2014, the Company issued 11,918,181 shares of its common stock in connection with the exercise of warrants. Proceeds received was $136,000, of which $6,000 during the three months ended March 31, 2014.</font></div> <p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Basis and business presentation</u></p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Bioheart, Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (&#8220;ASC 915-10&#8221;) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through March 31, 2014, the Company has accumulated a deficit through its development stage of $117,503,543.</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><u>Revenue Recognition</u></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><u><br /></u></p> <p style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (&#8220;ASC 605-10&#8221;) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management&#8217;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">Revenues for test kits and equipment sold are not recorded until test kits are delivered. Revenues from trainings are not recorded until the completion of the training. Any cash received as a deposit for trainings are recorded by the company as a liability.</p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p> <p align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 16px; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets.</p> <p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Comprehensive Income</u></p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company does not have any items of comprehensive income in any of the periods presented.</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Net Income (loss) per Common Share, basic and diluted</u></p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (&#8220;ASC 260-10&#8221;) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options, warrants and shares issuable upon conversion of notes payable have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation for the three months ended March 31, 2013. Fully diluted shares outstanding were 498,696,292 and 222,688,816 for the three months ended March 31, 2014 and 2013, respectively.</p> <p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Stock Based Compensation</u></p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company follows Accounting Standards Codification subtopic 718-10, Compensation (&#8220;ASC 718-10&#8221;) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10).</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">As of March 31, 2014, there were outstanding stock options to purchase 43,650,856 shares of common stock, 16,650,856 shares of which were vested.</p> <p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Concentrations of Credit Risk</u></p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company&#8217;s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. The financial stability of these institutions is periodically reviewed by senior management.</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">As of March 31, 2014, two customers represented 26% and 25% (total of 51%) of the Company&#8217;s accounts receivable.</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">As of December 31, 2013, three customers represented 20%, 20% and 36% (total 76%) of the Company&#8217;s accounts receivable.</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">For the three months ended March 31, 2014, the Company&#8217;s revenues earned from the sale of products and services were $322,572, of which two customers represented 17% and 10% of the Company&#8217;s revenues.</p> <p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Research and Development</u></p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $9,857 and $163,974 for the three months ended March 31, 2014 and 2013, respectively; and $65,329,892 from August 12, 1999 (date of inception) to March 31, 2014.</p> <p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Fair Value</u></p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Accounting Standards Codification subtopic 825-10, Financial Instruments (&#8220;ASC 825-10&#8221;) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (&#8220;ASC 820-10&#8221;) and Accounting Standards Codification subtopic 825-10, Financial Instruments (&#8220;ASC 825-10&#8221;), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company&#8217;s financial position, results of operations nor cash flows.</p> <p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Reliance on Key Personnel and Consultants</u></p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company has 4 full-time employees and 1 part-time employee. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.</p> <p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Derivative Instrument Liability</u></p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2014 and December 31, 2013, the Company did not have any derivative instruments that were designated as hedges.</p> <p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Recent Accounting Pronouncements</u></p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p align="justify" style="font: 13px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company&#8217;s unaudited condensed financial position, results of operations or cash flows.</p> <div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><br class="apple-interchange-newline" /><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"></font><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">March 31,</font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">2014</font></font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"></font><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">December 31,</font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">2013</font></font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Laboratory and medical equipment</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">352,358</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">352,358</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Furniture, fixtures and equipment</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">125,634</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">125,634</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Computer equipment</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">39,525</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">39,525</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Leasehold improvements</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">362,046</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">362,046</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">879,563</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">879,563</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Less accumulated depreciation and amortization</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(871,371</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(870,508</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">8,192</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9,055</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table></div><div>&#160;</div> <div>&#160;</div><table style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 10pt; word-spacing: 0px; background-color: #ffffff; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">March 31,</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">2014</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">December 31,</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">2013</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">License and royalty fees</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2,122,130</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Amounts payable to the Guarantors of the Company&#8217;s loan agreement with Bank of America and Seaside Bank, including fees and interest</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,356,013</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,373,775</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Interest payable on notes payable</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">757,669</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">714,180</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;">&#160;</td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Vendor accruals and other</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">127,189</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">120,692</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Employee commissions, compensation, etc.</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">127,506</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">149,558</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2,368,377</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">4,480,335</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table> <div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><br class="apple-interchange-newline" /><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">March 31,</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">2014</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">December 31,</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">2013</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Seaside Bank note payable.</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">980,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">980,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">August 2008 Unsecured Promissory Note</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">500,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">500,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Hunton &amp; Williams notes payable</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">384,972</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new;">384,972</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Asher notes payable</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">183,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">143,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Daniel James Management note payable</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">35,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Fourth Man, LLC note payable</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">35,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">35,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Total notes payable</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2,117,972</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2,042,972</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Less unamortized debt discount</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(151,027</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(112,131</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Total notes payable net of unamortized debt discount</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,966,946</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,930,841</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block;">&#160;</div> <div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><br class="apple-interchange-newline" /><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">&#160;<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Shares</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Weighted-</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Average</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Exercise Price</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Weighted-</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Average</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Remaining</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Contractual</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Term (in years)</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="6"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Options outstanding at January 1, 2013</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">7,853,376</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.67</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">8.2</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Granted</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">17,400,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.016</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9.9</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Exercised</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom">&#160;</td><td width="1%" valign="bottom" style="text-align: left;">&#160;</td><td width="9%" valign="bottom" style="text-align: right;">&#160;</td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;">&#160;</td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;">&#160;</td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="64%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Forfeited/Expired</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(1,340,433</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1.08</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Options outstanding at December 31, 2013</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">23,912,943</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.15</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9.0</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Granted</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">19,800,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.019</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9.1</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Exercised</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="64%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Forfeited/Expired</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(62,087</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1.08</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Options outstanding at March 31, 2014</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">43,650,856</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.08</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9.3</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Options exercisable at March 31, 2014</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">16,650,856</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.18</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">8.9</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="64%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Available for grant at March 31, 2014</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">12,800,000</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double; text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right; padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table></div><div>&#160;</div> <div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><br class="apple-interchange-newline" /><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="11"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Options Outstanding</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Options Exercisable</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Shares</font></div></td><td width="0%" valign="bottom" style="padding-bottom: 2px;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Weighted-</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Average</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Remaining</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Contractual</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Term</font></div></td><td width="0%" valign="bottom" style="padding-bottom: 2px;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Weighted-</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Average</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Exercise</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Price</font></div></td><td width="0%" valign="bottom" style="padding-bottom: 2px;">&#160;</td><td width="0%" valign="bottom" style="padding-bottom: 2px;">&#160;</td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Shares</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="0%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Weighted-</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Average</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Exercise</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Price</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" width="40%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="40%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$0.00 &#8211; $0.70</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">43,090,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;</font></div></td><td width="9%" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9.4</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.03</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">16,090,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.04</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="40%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$0.71 &#8211; $1.28</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">162,286</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;</font></div></td><td width="9%" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">4.2</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.80</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">162,286</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.80</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="40%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$5.25 &#8211; $5.67</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">373,858</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;</font></div></td><td width="9%" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2.1</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">5.55</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">373,858</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">5.55</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="40%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$7.69</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">24,712</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;</font></div></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2.3</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">7.69</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">24,712</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">7.69</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="40%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">43,650,856</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;</font></div></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9.3</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.08</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">16,650,856</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.18</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table></div><div>&#160;</div> <p style="font: 13.63px/16px 'times new roman'; margin: 3.33px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <table style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 10pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;" cellspacing="0"> <tr style="font-size: 0px;"> <td nowrap="nowrap"></td> <td width="7"></td> <td width="22"></td> <td width="99"></td> <td width="18"></td> <td width="7"></td> <td width="16"></td> <td width="61"></td> <td width="10"></td> <td width="7"></td> <td width="39"></td> <td width="48"></td> <td width="13"></td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p align="center" style="margin: 0px;"><b>&#160;</b></p> </td> <td width="140" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Shares</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p align="center" style="margin: 0px;"><b>&#160;</b></p> </td> <td width="88" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Exercise<br />Price</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p align="center" style="margin: 0px;"><b>&#160;</b></p> </td> <td width="102" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Remaining<br />Contractual<br />Term (in<br />years)</b></p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="22" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="99" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="18" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="16" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="61" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="10" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="39" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="48" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="13" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">Outstanding at January 1, 2013</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">74,073,322</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.37</p> </td> <td width="10" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">4.5</p> </td> <td width="13" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #ffffff;"> <p style="margin: 0px; text-indent: -10px;">&#160;&#160;&#160;Issued</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">50,350,536</p> </td> <td width="18" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.16</p> </td> <td width="10" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">9.2</p> </td> <td width="13" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px; text-indent: -10px;">&#160;&#160;&#160;Exercised</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#8212;&#160;</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.00</p> </td> <td width="10" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;</p> </td> <td width="13" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px; text-indent: -10px;">&#160;&#160;&#160;Forfeited</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">(6,345,002)</p> </td> <td width="18" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">0.38</p> </td> <td width="10" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p>&#160;</p> </td> <td width="13" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">Outstanding at December 31, 2013</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">118,078,856</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.22</p> </td> <td width="10" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">6.3</p> </td> <td width="13" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #ffffff;"> <p style="margin: 0px; text-indent: -10px;">&#160;&#160;&#160;Issued</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">32,292,783</p> </td> <td width="18" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.017</p> </td> <td width="10" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">8.4</p> </td> <td width="13" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px; text-indent: -10px;">&#160;&#160;&#160;Exercised</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#8212;</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin-top: 3.2px; margin-bottom: 3.2px;">&#8212;</p> </td> <td width="10" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> <td width="13" valign="bottom" style="background-color: #cceeff;"> <p>&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px; text-indent: -10px;">&#160;&#160;&#160;Expired</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">(2,314,575</p> </td> <td width="18" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">)&#160;&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">0.18</p> </td> <td width="10" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="13" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p>&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">Outstanding at March 31, 2014</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">148,057,064</p> </td> <td width="18" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.17</p> </td> <td width="10" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">6.7</p> </td> <td width="13" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #ffffff;"> <p style="margin: 0px;">Exercisable at March 31, 2014</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="22" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="99" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">102,401,650</p> </td> <td width="18" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="16" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="61" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.13</p> </td> <td width="10" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="39" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="48" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">5.7</p> </td> <td width="13" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> </table> <p align="center" style="font: 13.63px/16px 'times new roman'; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p> <table style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 10pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;" cellspacing="0"> <tr style="font-size: 0px;"> <td nowrap="nowrap"></td> <td width="7"></td> <td width="20"></td> <td width="90"></td> <td width="7"></td> <td width="7"></td> <td width="36"></td> <td width="44"></td> <td width="12"></td> <td width="7"></td> <td width="17"></td> <td width="52"></td> <td width="11"></td> <td width="7"></td> <td width="20"></td> <td width="90"></td> <td width="7"></td> <td width="11"></td> <td width="17"></td> <td width="52"></td> <td width="7"></td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="306" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="11"> <p align="center" style="margin: 0px;"><b>Warrants Outstanding</b></p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="198" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="6"> <p align="center" style="margin: 0px;"><b>Warrants Exercisable</b></p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="117" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Shares</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="93" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Remaining<br />Contractual<br />Term</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="80" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Exercise<br />Price</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="118" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Shares</b></p> </td> <td width="80" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;" colspan="3"> <p align="center" style="margin: 0px;"><b>Weighted-<br />Average<br />Exercise<br />Price</b></p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom;"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="20" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="90" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="36" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="44" valign="bottom"> <p align="center" style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="12" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="17" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="52" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="11" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="20" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="90" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="11" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="17" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="52" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> <td width="7" valign="bottom"> <p style="margin-top: 3.2px; margin-bottom: 3.2px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">$0.01 &#8211; $0.50</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">141,807,931</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="36" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="44" valign="bottom" style="background-color: #cceeff;"> <p align="center" style="margin: 0px;">6.7</p> </td> <td width="12" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.02</p> </td> <td width="11" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">97,696,967</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.02</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #ffffff;"> <p style="margin: 0px;">$0.52 &#8211; $0.68</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">2,699,675</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="36" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="44" valign="bottom" style="background-color: #ffffff;"> <p align="center" style="margin: 0px;">5.1</p> </td> <td width="12" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.58</p> </td> <td width="11" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">2,699,675</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #ffffff;"> <p align="right" style="margin: 0px;">0.58</p> </td> <td width="7" valign="bottom" style="background-color: #ffffff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #cceeff;"> <p style="margin: 0px;">$0.70 &#8211; $1.62</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">848,176</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="36" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="44" valign="bottom" style="background-color: #cceeff;"> <p align="center" style="margin: 0px;">5.8</p> </td> <td width="12" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.71</p> </td> <td width="11" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">848,176</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #cceeff;"> <p align="right" style="margin: 0px;">0.71</p> </td> <td width="7" valign="bottom" style="background-color: #cceeff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">$5.67 &#8211; $7.69</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">2,701,282</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="36" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="44" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="center" style="margin: 0px;">8.6</p> </td> <td width="12" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">7.55</p> </td> <td width="11" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">1,156,832</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p align="right" style="margin: 0px;">7.35</p> </td> <td width="7" valign="bottom" style="border-bottom-color: #000000; border-bottom-width: 1.33px; border-bottom-style: solid;"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td nowrap="nowrap" style="vertical-align: bottom; background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">148,057,064</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="36" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="44" valign="bottom" style="background-color: #ccecff;"> <p align="center" style="margin: 0px;">6.7</p> </td> <td width="12" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">0.17</p> </td> <td width="11" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="20" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">&#160;&#160;&#160;&#160;</p> </td> <td width="90" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">102,401,650</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="11" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> <td width="17" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">$</p> </td> <td width="52" valign="bottom" style="background-color: #ccecff;"> <p align="right" style="margin: 0px;">0.13</p> </td> <td width="7" valign="bottom" style="background-color: #ccecff;"> <p style="margin: 0px;">&#160;</p> </td> </tr> </table> <div>&#160;</div><table style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 10pt; word-spacing: 0px; background-color: #ffffff; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: center;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Excess Share</font><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Derivative</font></div></td><td width="0%" valign="bottom" style="padding-bottom: 2px;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid; text-align: center;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Warrant</font><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Liability</font></div></td><td width="0%" valign="bottom" style="padding-bottom: 2px;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></td><td width="0%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"></font><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Debt</font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Derivative</font></font></div></td><td width="0%" valign="bottom" style="padding-bottom: 2px;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Balance, December 31, 2012</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">390,048</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">221,179</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Total (gains) losses</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Initial fair value of debt derivative at note issuance</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">673,219</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Initial fair value of derivative relating to reset warrants</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Mark-to-market at December 31, 2013:</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">84.906</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom">&#160;</td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(74,324</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(39,761</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></div></td></tr><tr bgcolor="white"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Transfers out of Level 3 upon increase in authorized shares</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(474,954</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="64%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Transfers out of Level 3 upon conversion and settlement of notes</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(376,502</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></div></td></tr><tr bgcolor="white"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Balance, December 31, 2013</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">146,855</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">256,956</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Total (gains) losses</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Initial fair value of debt derivative at note issuance</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">292,257</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Mark-to-market at March 31, 2014:</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">519,630</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(30,259</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></div></td></tr><tr bgcolor="white"><td align="left" width="64%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Transfers out of Level 3 upon conversion of notes payable</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(134,243</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Balance, March 31, 2014</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">666,485</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">384,711</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Net (Loss) Gain for the period included in earnings relating to the liabilities held at March 31, 2014</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#8212;&#160;&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(519,630</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">30,259</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table> 0.76 0.20 0.20 0.36 0.51 0.26 0.25 0.17 0.10 3 2 2 7853376 74073322 23912943 118078856 43650856 148057064 16650856 4 1 620923 11100000 352358 352358 125634 125634 39525 39525 362046 362046 879563 879563 870508 871371 2122130 1373775 1356013 714180 757669 120692 127189 149558 127506 1000000 6750781 4793268 2122130 2700 65548 1000000 P24M 1000000 2042972 500000 980000 143000 384972 35000 2117972 500000 980000 183000 384972 35000 35000 112131 151027 980000 0.135 0.0425 0.05 0.05 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.0475 0.08 2010-05-31 2013-10-09 19000000 within 12 months 451053 0.5321 195694 2 2 61150 323822 61150 323822 598125 67500 1078625 The Notes are convertible into common stock, at Asher's option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes. 214346 63343 384711 292257 153564 63343 544267 362000 349413 362000 1278324 500000 164757 0.00 0.00 0.00 1.7372 1.7372 1.8173 1.5819 0.0273 0.0003 0.0013 0.0015 0.0003 P8Y6M P11D P8M27D P1Y P11D 0.0447 0.001 500000 97500 124838 93604000 35000 The first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012. 5000000 15000000 5000000 5000000 10000000 210000 0.08 0.1285 0.07 140000 125000 100000 25 votes 20 votes 15350876 175000 63740 666485 1051196 519630 30259 0.014 P10Y 0.0447 5000000 20000000 6750781 7166214 57500 2300 17400000 15000000 4800000 19800000 1340433 6345002 62087 2314575 16650856 102401650 12800000 0.67 0.37 0.15 0.22 0.08 0.17 0.016 0.019 0.00 0.019 0.019 1.08 0.38 1.08 0.18 0.18 0.13 P9Y10M24D P9Y1M6D P8Y2M12D P9Y P4Y6M P9Y3M18D P8Y10M24D P5Y8M12D 0.00 0.71 5.25 0.70 1.28 5.67 7.69 43650856 148057064 141807931 2699675 848176 2701282 43090000 162286 373858 24712 P9Y3M18D P6Y8M12D P6Y8M12D P5Y1M6D P5Y9M18D P8Y7M6D P9Y4M24D P4Y2M12D P2Y1M6D P2Y3M18D 0.08 0.17 0.02 0.58 0.71 7.55 0.03 0.80 5.55 7.69 16650856 102401650 97696967 2699675 848176 1156832 16090000 162286 373858 24712 0.18 0.13 0.02 0.58 0.71 7.35 0.04 0.80 5.55 7.69 50350536 32292783 8000000 0.16 0.017 P9Y2M12D P8Y4M24D P6Y3M18D P6Y8M12D 0.25 P10Y P10Y 19632 282597 90431 194565 0.00 0.00 1.6363 1.6363 0.0275 0.0275 24292783 22546 Vesting from June 8, 2014 through March 10, 2015 0.0113 0.0217 P4Y 2,000,000 warrants vesting 90 days from the effective date, 2,000,000 vesting on each anniversary date for three years. P10Y P4Y 2000000 2015 32424 2122000 46317 77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted. 371000 CSC will receive a one-time $25,000 fee, $5,000 monthly fees. 5207630 390048 221179 146855 256956 1051196 666485 384711 673219 292257 84.906 -74324 -39761 519630 -30259 -474954 -376502 -134243 0 0 4.47 100000 5263315 1002808 50000 274681 180511 18383774 11918181 6000 136000 EX-101.CAL 5 bhrt-20140331_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 bhrt-20140331_def.xml XBRL DEFINITION FILE EX-101.LAB 7 bhrt-20140331_lab.xml XBRL LABEL FILE EX-101.PRE 8 bhrt-20140331_pre.xml XBRL PRESENTATION FILE EX-101.SCH 9 bhrt-20140331.xsd XBRL SCHEMA FILE 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Statement of Stockholders' Deficit (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Going Concern Matters link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Standby Equity Distribution Agreement link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Notes Payable link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Derivative Liabilities link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Stock Option and Warrants link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Commiments and Contingencies link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Fair Value Measurement link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Notes Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Stock Option and Warrants (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Going Concern Matters (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Accrued Expenses (Details Textual) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Standby Equity Distribution Agreement (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Notes Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Related Party Transaction (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Derivative Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Stock Option and Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Stock Option and Warrants (Details 1) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Stock Option and Warrants (Details 2) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Stock Option and Warrants (Details 3) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Stock Option and Warrants (Details Textual) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Commiments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Fair Value Measurement (Details) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Fair Value Measurement (Details Textual) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink XML 10 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Option and Warrants (Details 2) (Warrant [Member], USD $)
3 Months Ended 12 Months Ended
Mar. 31, 2014
Dec. 31, 2013
Warrant [Member]
   
Summary of warrants and activity    
Options outstanding, Beginning Balance 118,078,856 74,073,322
Options outstanding, Weighted - Average Exercise Price, Beginning Balance $ 0.22 $ 0.37
Warrants outstanding, Weighted - Average Remaining Contractual Term (in years)   4 years 6 months
Shares, issued 32,292,783 50,350,536
Warrants, Weighted-Average Exercise Price $ 0.017 $ 0.16
Warrants, Weighted Average Remaining Contractual Term (in years) 8 years 4 months 24 days 9 years 2 months 12 days
Exercised, Shares      
Exercised, Weighted - Average Exercise Price    $ 0.00
Forfeited/Expired, Shares (2,314,575) (6,345,002)
Forfeited/Expired, Weighted - Average Exercise Price $ 0.18 $ 0.38
Options outstanding, Ending Balance 148,057,064 118,078,856
Options outstanding, Weighted - Average Exercise Price, Balance $ 0.17 $ 0.22
Options outstanding, Weighted - Average Remaining Contractual Term 6 years 8 months 12 days 6 years 3 months 18 days
Options Exercisable, Shares 102,401,650  
Options exercisable, Weighted - Average Exercise Price $ 0.13  
Warrants exercisable, Weighted - Average Remaining Contractual Term (in years) 5 years 8 months 12 days  
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#.X$##`0(``!0<```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F=UJVS`8AL\'NP>CTQ$K MDKRN&W%ZL)_#K;#N`E3K2VQB2T)2N^3N)SMM&25+"0WL/8F)+7WO$Q&>`[^+ MJ^W0%_<48N=LS40Y9P79QIG.KFOVZ^;;[)(5,6EK=.\LU6Q'D5TMW[Y9W.P\ MQ2+OMK%F;4K^$^>Q:6G0L72>;'ZR.:V) M;>?CNXS!^,&$\,@;?]ORW"YM;YS;E\2$'*-UJ MU35D7',WY!,HHP^D36R)TM"7T[4<=&A.,"A.,#",>.D?TZZG>.87=?NA+R6W.I#YF4)NI\X.\/?L8QRYN[D.SL?<8@4Z M_10>:ZIQ]\SG01121T]%U:'"YRDQ-V"G!SYKG&CLV`R9`]E\ZO26?P```/__ M`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4 M"_'L)MI<3_3_MCAQ M(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+ M`P04``8`"````"$`,93SQAH"``!!&P``&@`(`7AL+U]R96QS+W=OO9CS$I!-I`])]YPC^>[^UV%?O(8Q[OJN-&ZQ-$7HZK[9==O2_'SZ=GEC MBIBJKJGV?1=*JI2;X]8.5?U<;8.5Y7)EQ_,^S/I#G\5C4YKQL7%JBJ?CD(?^?^?] M9K.KPT-?OQQ"E_XQAGWKQ^?8AI!RI]6X#:DTTZ-H3V^<+C*SL9_@Y/G@XMP@ M'%F1<62%":9'?W7F&L&PEP:NC&.+C(,B(VR1$2@R;(V!$L->*;A0CCXU<&Z$ M+;\"Y5?9-:ZPR)6M?PH%T.<@2LU9?HGTV%^Q<:X0#IL&PC@VC8,XPCXP"#PP M"/O`(/#`H&R'4&P1[#)WL,P=.UHX&"V4;:`*#=2S#=1#`Z73($5F;QRX;QQ[ M:AQ<*&$G'8%)1]A)1V#24;8$*I1`9;NY0C?W;#?WT,W]K&X>VVH,S8\TYMO6 M\[N*\\=(=&:%F>XG/K^RP,F"G)#A.CFVY#@H.8XM.0Y*CK!K7&"-*[O&%>X= M99>5PKKRLR;VE+_,A/<*/S7MZ1=&/V&;E$"3\NQ@[*?9L1\^?*U_`P``__\# M`%!+`P04``8`"````"$`ASAOH04$``#O#0``#P```'AL+W=O7&ZF>%U(^>R`@]-A?&U->!(%.UZR@^J,LF8`K2ZD* M:N"H5H$N%:.97C-FBCR(!H-14%`N_+W"A3I%0RZ7/&43F58%$V8OHEA.#:2O MU[S4_M7EDN?L<5^11\OR!RT@[VWN>SG59IIQP[*Q/X2CW+#6!ZHJ/U<\AZOG M\2#V@ZNFR`?E96Q)J]S,H;Q7=?`K2J)H9+]IK7CD;*/?@NS1VSYQD/P3Y`.G7#L)]ZE=/U.6].D*@4V0J M##<[^I"PYOU'T6VL2QRJT4&1.:9>0SS:E(&9G9.(WB M(Q0?G1I/'JABT.@FBQBIU$;W9S$SU(#=PF@BE^1GR10U2"5!*LGA7!H5*S(S M,GU>8T?`],:1X0DJ=2ZW5*_)'J@(RIEN8;`U;X*V;R3D*#`?=2/!?9(L=F<(]X?83KHWBB\J. M++E9(9TA3$B30.C0^4,:I@&E'5WDV+1ABVD'RE]V/4#BP"#8Z=)"<,,5?8,F\,/*-TP7/N>$M"X:8Z-"!\1]U>08-^^<#OCD&.708K(.! M_MHPV[PGJJ"*UE@.,<6A`^"M+`J^'R0K``A9`&'1=ZK`^(4.?W>4*_)(\XJ1 M[XSJ2M6SB0O!`(8.@;-JH=F?"J@CTQ<[U3@4PQ#R(1*V$W!AA+B.'R_Z. M]J2#"8U<0H_N-RBEZ]QCJXT;'#;_]>[@'&_MQJ'BUPZ)35LY][1$:8EMA9 MLH>'TMJ,BHI;13GT'M=I];J5D(/O<2$\EC&F&`Y]]O0]@6J38,4T?4\PQG#X M+R%8,HW0"&>4.!@?>Z"1"=(Y:R7D\'Q@`;IS<8;'*G&`/JZ#>Y;@50J'KD/= M9V0/APF&&0X@$=3&P9^"E.8I_%NQ+_;G?MV!X/6_VM5?````__\#`%!+`P04 M``8`"````"$`$A:+^Q0&``!#&```&````'AL+W=O:5RVT1AC`3T]\_>Y MQ2U3"],V3C]TM^%PZIR[U,7U].%K_?#\X\_/+VUW>?^R/G@`,.YW[K'8;AL/*^OCKPI M^W5[X6>XLV^[IAS@8W?P^DO'R]WX4'/RJ.]'7E/69Q<9-MT2CG:_KRM>M-5K MP\\#DG3\5`Z@OS_6E_[*UE1+Z)JR^_QZ655M-B; M/?UIS,`?G;/C^_+U-/S9OOW"Z\-Q@'2'X$@8V^R^%;RO(*)`LZ:A8*K:$PB` MWTY3B]*`B)1?Q[]O]6XX;ET6K\<#`Y`+BJ[OX?FZO8@58B+VND^$%?1U+?#Y'1,&D!,7.(8K$T`HUL%RK M`&]=2(P*06@NG"$$:G&"6-+RNXCB%L(0#TJ6BQ=@:!=-6119XA&2CB7#*`UC M%;0QK+D."$AJW2[TVR1*$IK&TPJ&<(C/@441R31'6S(3U^1+H`F])C MWUPW0XB4GH166G+]-HE8&EN]4.B`*&0T3;2:,I2+%P!M9[R]IPBPI5P%!(.. M$%2>L`26-JWE.H#%?LC49CT";&FWVBQ#R*V"R.]# M"H1@!,(D2M5.9H@G,..71WY$6_*MP&42$XX%GT36[=RX'<]*7=Z6->?[::2J MSA0N!M;BDB$XWO3MT:[63&+DT@$+M)B--9$;B)"%-%8E@55C((@?I<2/F2I. MTX&88LL=X,PS'*B<8M43Q*"#543]E,[";T!"1OS$[EJ3A?@AI12B,360:4), ML^4F!-K<[.T09@0Q>OVKM64>[D**FRRF`S'6ECO`(0@"IC>`6%6H3`-B=`=V MG>?D/J:0&$PG(7'HJPW:M`!+/6!!H*TFMH>6>&D'#"X-=<0B9FU3N0$AOA]` ME4PU(KM!9V'@P(_?ZP4QXK0DB%=C!EO3[4%`<#`:R;`V^DQB9$\$2)2K(L)\1`+*>2FY?3?4Q! M$(.1B"-*M<(U+8C9M]P"3DK#@LJRM(`8W8)5*SFY0L07FI3-$H"W43P+@H2J M-4SQ8O`M%X]CTA!O%7I&]%&Z8J(ZK';)+4A(X97#[@6#A43P^LU"M8$;'NA# M0WE$F_ULKYY)#(:/P(L8-+0I,+<@)%4!QFXV`"M":4*(K_)D.GAH.M/Y=+:G M4B8QZ`!>@H/`ZI/<0*Q"DD"OFQX+$S)NJ2P,%,KT\-!\IO/YG*CT8AM(C-X& MLTY>@"EN8TP34-K+VX$*M%5*UBM.)C'X-?+[B4`61+R3"`-R+Q'6A%XV'.A\ M4B?VI)88>.D4NP[]::5*8PYG$X"80^"2$EW!M MBLF.<)#"J89NR$EM(IB5NQ-C4!LK"+.&PA3*?HI5:&U8&)['J)2M(X4M: M1+4OR-*-#GK7#8)NN<$S6SR.;'AWX#D_G7JG:E_%>2R%!IBN3F?%'ZDXM[.N M9V0#IX=PW9MNP!'NI3SPW\ON4)][Y\3W0.FO8]#3X2$P?AC:RW@(^M(.<'@[ M_GN$PWH.YX_^&L#[MAVN'\0"T_'_\W\```#__P,`4$L#!!0`!@`(````(0!E M@I_Q:`4``!X:```9````>&PO=V]R:W-H965TZ16JJI>GAGB)&@"1,!,9OZ^VVR38)-NR#SD M-HO%6MO>7HZS^O:9G:P/459ID:]MYGBV)?*DV*7Y86W__=?+T]RVJCK.=_&I MR,7:_A*5_6WS\T^K2U&^54J9?I4E95,6^=H#.1:%]SPMWX0+39K5+P8$LNU6*_=I^9DON+VQWLVH*]$\J M+E7GM54=B\LO9;K[+B/G?P(+G9[5[\T(_!':>W$/GX_ MU7\6EU]%>CC6,-P!.)+&EKLO+JH$*@HTCA](IJ0X@0!XM+)43@VH2/S9/%_2 M77UA`'<>A55_9)*2MM*WJNZR/Y%$%-42.(K$GA6)"QPIGXPFS_" M,E$L\-RR/"YEJDC@N24!5;0/%VO2E)C'=;Q9E<7%@GD+KJMS++N`+8'P?DVA MF!+[+,%K&_H*RE7!1/C8A)Z_@LW: MSPSUB*'4(V*!G1&&T[DQ?)RBT,2'CXB78%U\$!H-%2&&$H\(-ITU\CW=/*>N MUY3/'E$NP:9RH]TBQ%#*$=$J9\YL,H.(OOX9I>`4H69%;B!&KXT2;%JYK0JX M_B"&LH*(UHH/5JXVY`OV_+1]Q(L.G&6&DBQ%!N^HC0FQL3JX^Y MW4?3SV#C,'XX&K3N(/06^KTC!:(L*`@V1<`6X<3L#))$=R!3K3.AY$9F`JX& M0A>SL)L+P;SG!$$HDP4X:72W6X88PBTG(;H7F8(=+P,>,#.['D)F%#)B""+T M;8`::F[L!862*&(-+!((3?80G9K>UU$S(.QYO` M\-1-F(L4HQ*V6<>VPQ!.0G0+4*X'+$CTT#Y#?CL`$#D.@Q!.LN@69#J.'P7, M4FT4/'.SP:C`5:.`$-7S7L!@==);GI,LN@69BN,M8(9V+01!SP(5M,H"0M#" M9#Z=,:.E.*-(=`#`Z)`I`'D@4V%S*^I,PT7W;]9-\X:4DZ2ZHZ,S!ZW__#O M9;?QQ292(-+98+QSDD6W`C-_?+?X$CT4&@I$6D`>`L))%MW"0]'M]Z,[",WH M5B!"WU9!VH;WG>[L@M2'D[61W3) M<-(KGJZ^D!E;-GF,___=AB;PF![/D#-1'L16G$Z5E13O\@B>06Q=/[W^//#L M-P?\UW_`Z?PY/HC?X_*0YI5U$GNXU'-F(*[$\WU\4Q?GYH3ZM:CA7+YY>83? M802+>_`<``/__`P!02P,$%``&``@````A`$@G M;/9$`P``6PH``!D```!X;"]W;W)K&ULE)9=;YLP M%(;O)^T_(-^7KP1HHI"J4'6;M$G3M(]K!TRP"AC93M/^^QUS$AI(A6@N()C7 M+X]?'VPV=R]U93TSJ;AH8N+9+K%8DXF<-_N8_/G]>'-++*5ID]-*-"PFKTR1 MN^WG3YNCD$^J9$Q;X-"HF)1:MVO'45G):JILT;(&[A1"UE3#I=P[JI6,YEVG MNG)\UPV=FO*&H,-:SO$01<$S]B"R0\T:C2:2550#ORIYJ\YN=3;'KJ;RZ=#> M9*)NP6+'*ZY?.U-BU=GZV[X1DNXJ&/>+MZ39V;N[N+*O>2:%$H6VP.O4\XFPW74!_.3NJB_^6*L7QB^3Y=]XP2!OF MRT-7QO>EAND.8$1F8.O\]8&I M#!(%&]L/C%,F*@"`HU5S4QJ0"'WISD>>ZS(FB]`.(G?A@=S:,:4?N;$D5G90 M6M3_4-2-J#?Q3R9P/IEX@;WT@^CV(RZ+DPNX':_?A0#QG#(.)V?$8_9%KTOUA=JIMA0 M@6RPRD_`11^!,^(A7."]%0W"H6:%KV00+$4)]&I]B'*41&D)\$<2K,$7TSS3$IO<#2F M1!&6HK^XAL3[4Y"XE^,N53.Y9RFK*F5EXF#V:1^*O&_MOR'N%V8G&+4G_CKI MVIW^!FSM+=VS'U3N>:.LBA5@Z=H1\$C\.,`++=IN;]P)#9MZ][>$CS@&.XUK M@[@00I\OS#[6?Q9N_P,``/__`P!02P,$%``&``@````A`%7HD/.=!```51(` M`!D```!X;"]W;W)K&ULG)C=CJ-&$(7O(^4=$/<# M-&#\(]NK`3+)2ALIBK*;:XS;-AJ@+6#&,V^?*@ICNF$QSEPP-OXXU*FN[J)9 M?_G(4NV=%V4B\HW.#$O7>!Z+?9(?-_KW?UZ>%KI65E&^CU*1\XW^R4O]R_;7 M7]874;R6)\XK#13R%53%%0QP.2U+)XBET7% MZ]OY*1;9&21V29I4G[6HKF7QZNLQ%T6T2\'W!W.C^*I=?^G)9TE7F.L)+9"I2O^2$W;<9^EC#(%(H\H\I&ATD#N2AAE-^W MGKU8F^\P,G'#^,3`L6683`1]%7?NR4QX97#0P4+K`W+<]3$\OM=P$<9P<;PQ M?I].=&.SY?L&`X0K(V$?<>?+EI&BA4J8'BW"4'>=Q'GV39<,$`,EV297B2ZX M2X1CA!0]U,GTZ!'>Z'"\1>:IT1,S%OU=(APCI.CA-MWHL>(=6%?&*P8O4L;` ML=JQI3$@9EZ7O^TLF;UT'1D)NLA\,7.<7GT3`<=;NEH-R88GVQ@/'V$U?&7V M^<10^&RYL/"OO77M,)"0N3N`A(1,B'_^2/P(J_$K,]0GIGMGM;@)]$O'XD> M837ZFRX5/S$4O>MX,VLQ4Y;NH(L,SX^PBZCS0\H^@QD[/?TUK3J8R>GU&ZB9 M`-Z@A8893G"=B'`4D3U@+YM<0HPZG]0&'"7%?@,U'NS!2=PPHQ[H7L.([`&; M7L<#KJ8N7#<^'1BU2MF+4NY^`T$^\7G",I@R8($*>(I"V`!3;&#O4VS<;PJ, M.J9LH_?80U!C@QG+WYZ4E2MH=%K$ZR%A@TRQ@HWP<2O4/F4K:IMF!+5Q6HK7 MX!X0-L`4&\#\#QMXE3+17:6+^?C\#U!;6'T;"J!67J@J="I/GAW8#1\?"^JA MTEBX:K=F!+4F6&\LQCIQLU2-(;(1;(N/&Z%F*AM1BM]G_8[K]9Z;!B&E!84# MT`V1[6"?5.Q,6+6HN\IVE$7)9_T6[+G*,AT,0KW5:TCI-LJR(6RZI;XIMC&$S-`NGK:G&2^./.!I6FJQ>,,= MN@U]H#W;OCUXMG$7IYP/\*T"GC?;'V!3?XZ._,^H."9YJ:7\`)*6,8>0"WHM M0%\J<:XWQ3M1P7:^_GB"US<<=HF6`?!!B.KZ!6_0OA#:_@<``/__`P!02P,$ M%``&``@````A`+_@?S-G!0``RQ@``!D```!X;"]W;W)K&ULG%G9;NLV$'TOT'\0]'ZMS:(7V+Y(&J2]0`L419=G1:9M(99H2$J< M_'V'&IH4J8U.'A(OAS-SS@R/)&;S_2,_.^^TK#)6;-U@YKL.+5*VSXKCUOWG M[^=O2]>IZJ38)V=6T*W[22OW^^[GGS975KY6)TIK!R(4U=8]U?5E[7E5>J)Y M4LW8A1;PS8&5>5+#V_+H59>2)OMF47[V0M\G7IYDA8L1UJ5-#'8X9"E]8NE; M3HL:@Y3TG-10?W7*+M4M6I[:A,N3\O7M\BUE^05"O&3GK/YL@KI.GJY_'`M6 M)B]GX/T1S)/T%KMYTPF?9VG)*G:H9Q#.PT*[G%?>RH-(N\T^`P9<=J>DAZW[ M$*P?YY'K[3:-0/]F]%JU7CO5B5U_+;/][UE!06WH$^_`"V.O'/ICSS^"Q5YG M]7/3@3]+9T\/R=NY_HM=?Z/9\51#NV-@Q(FM]Y]/M$I!40@S"V,>*65G*`!^ M.WG&1P,423Z:O]=L7Y^V;D1F\<*/`H`[+[2JGS,>TG72MZIF^7\("D0H#!** M(/!7!`FCV3R,%TN+*!Y6U!!\2NIDMRG9U8&I@9S5)>$S&*PA\HT9UB&Y#E$% MCCS(`X^R=6'<@44%_7G?D3C8>.^@:2HPCXB!WQ*C$!Y4(TN",MHE]8M\R\S! M/#,7G9?RB!^TTX2R$"U-I*?AS".8C/%T?-'6G;=(D%C%QPH0`XV51.?]%4`8 M>Z(<#!6VHI(XDG$Q,V(630/F$8G]94PD1",/U;53VY'GB\P2%#4L`3%M\F0^ M4`/Y2@U\D5E#+#EB#8@)_$8'?^8OY?>:!@L]_WCC.=C(&YEY$8/R!V1,?GYA M,';=].SQ148)K?8B=<1(ZL$`]96>?YPZ!YMY%U)2S(N8=MO58&BB0VE?H-ZL MFMIW`F13!/>BEO[C_`-T+GWK*6%1``%:XL^N83H"@F^N,]L%P/$L! M>JROXSL!@I0`JE&Z`(;S30C08WE$W36($4!0>P2&DANV9\D?O0T&35[/N]?\ MP-H`0\,`QQ5HT.;TF=XC0%+\A9)($S^\R_8:M)G:]!\!$JF#6:AJTU/?97UA MG_6I+85]%Z#;X(?A"/)J;Q==Q'@"R:8#B?91-Z'+#C/2&")MD;[C>Q\7I< MCW1&$$'M]JL)T9MO^)XE?;2V<>L)K?TO-/QO0@&T-)CPEN^IR1(;`$%"^Q@> M?_MO`?C=K?WH-6AS[YG6(T`R-1FX]XGNM[9%A M>W9M;U:9-:C!0N4%J#U[A"B07L:7'#!"<],'0/57E($@V858`?02#/<;G[VH MQ_4ZWB-`%ETP?,^R"SW^U_&>"$'3]`W[FZ#?8WM$"2N41U![`(;:;SB?)7\T MMW'SB:P=,#(<<$(!-#5M]HBZO@L%$"3$7\R(L@A]]N[RO:C/]SH.@""&PO=V]R:W-H965T0"$B?_?KII MV::/E'XA-W;H/#K:7K6$6M;=/[^VF\[/[[O_ M*:POTV[G<%SN'I>;:E?>=W^7A^X_#__^U]U;M?]^>"G+8X=5V!WNNR_'X^MM MKW=8O93;Y>&F>BUW['^>JOUV>60?]\^]P^N^7#Z>)MIN>H-^?]S;+M>[KJAP MN[^D1O7TM%Z51K7ZL2UW1U%D7VZ61[;\AY?UZ^&]VG9U2;GMURS->";O;,OG^Z[7[7;8C#L]A[N3AOHO^OR[7#V[\[A MI7JS]^O'8+TKV=9F^XGO@6]5]9U3]Y$WL8E[C:FMTQY(]IW'\FGY8W/,JC>G M7#^_'-GNUMD:\16[??QME(<5VZ*LS,U`YY56U88M`/O9V:YY--@66?XZ_7Y; M/QY?[KO#\8T^Z0\UQCO?RL/16O.2W<[JQ^%8;?\GD%:7$D4&=1'VNRZB#:XN M,JR+L-^?10937=/'5RS*Z'U]V!+__0II'VO$=XA8Y<'TTE7JB6U\VF7&\KA\ MN-M7;QUV'+!E.KPN^5&EW0Y8Y?:=Q/8.QU^YON^R`Y5M_P-+UL\'?3*XZ_UD M:5C59MXT1"Q:Q$@N8@C"?I[-:"@;L\WHLK':S%@V=M.,)C/9.$U#5LIM$62E MO";1)Q-Y1GZ;FH')+C#Y!:90 M&RG3[#0E95K=EW,M99DV+&B#(1K$B9;'WZ0-%FVP:8-#&US:X-$&GS8$M"&D M#1%MB&E#0AM2VI#1AOR]X>Q0'I+^NV@SGR<<:7>QZX(K=A?7]UWV\[,?F7X6 M%KV1,.PBZ<.0GF8!A0&%"84%A0V%`X4+A0>%#T4`10A%!$4,10)%"D4&10Y% MH1)2O%D,KX@WU^P,?!;=(4VW(+/39>>H/YSIY-A;2$`;:S-RX60(P'[^Z?@P MH;"@L*%PH'"A\*#PH0B@"*&(H(BA2*!(H0&%`84)A06%#X4#A0N%!X3>%/B7GM*!IR#5?"$4$10Q%`D4*109%#D6A M$E+0^>WF\SM?E]T!X%/1H-.^7!A5T*$PH#"%$-VLSCK91C]KP1HV%`X4+A0> M%#X4`10A%!$4,10)%"D4&10Y%(5*2#&?_57,^50DYC-R&I\+HXHY%(80BA"; ML(8%A0WGXL`:+A0>%#X4`10A%!$4,10)%"D4&10Y%(5*2#'7V"7*7W3GI\EH MT,GMQWF-5$G'Q*B)R+HF.FQR2)FXC(6)C8F#B8N)AXF/28!)B$F$28Q)@DF* M289)CDFA)'+X^;#'^;6,^LZO)D9)SF^VZ#,RDC*OD3+THHZ"&'45$?K!*?7R MO7T3S\?"Q,;$P<3%Q,/$QR3`),0DPB3&),$DQ23#),>D4!(Y\GQ#$E)O?VH$7F!E)&'Q-`$^8R\QAZ6 MH?T]+&.1,I.;^F+I_=?$_$+.5G8]B6+Y'4Q<3#Q,?$P"3$),(DQB3!),4DPR M3'),"B61#P(^#G7%02"&K5CV/FZ?#TEW/->$J2_0Q2T5.;P+3(R:*))H8F)A M8F/B8.)BXF'B8Q)@$F(281)CDF"28I)ADF-2*(D<>9:I:R+/.?EJV^SW!5*D M=<$?W61U%,3`Q,3$PL3&Q,'$Q<3#Q,*8(B;@HREZ06 MBEV88I)ADI-%&=U,ZCO3]:E;:YRY"S*)=)DLQY\/85W1XXL1K_,>7Y^1H9&Y MIAH6.SU3L\#$P,3$Q,+$QL3!Q,7$P\3'),`DQ"3"),8DJ:5GD>$$*)9$#SX>RK@B\&/F2`T]Z@KFF&AZK`P^)@:N8F%B8V)@X MF+B8>)CXF`0UJ4,VF$R'`]+CA+A*A$DLS:CM2C7!15),,DQR3`HED2//A[6N MB+P8!9,B/R);?*ZIALKJR$-BX"HF)A8F-B8.)BXF'B8^)D%-QN*I/$W7R5-[ M(:X181)CDF"28I)ADF-2*(F<>#["=47BQ8"8E/@9V>1S335J5B<>$@-7,3&Q M,+%;B#XC#P\Y+8@\1LKTX^%:7,7$Q,+$QL3!Q,7$ MP\3'),`DK,G[W>.AWI].R(DYPF5B3!),4DPR3'),"B61P_]W`[:#YH"M-B;; M=5XC9?A%'04Q0[(Q$N$F.28))B MDF&28U(HB1Q]=KE^S=4.Y_+5SKA/GTEC+W#@2/PUU'@X&9%;48L:*`,O:BB( MB:M8F-B8.)BXF'B8^)@$F(281)C$F"28I)ADF.28\)>&_'DD2"1>O!1$O&%B M6^Z?RT6YV1PZJ^H'?^''D-TE^&C]>!G)U].[2$C[7+N=M[4OM%OV=\G\]2,? M$[!WA[PNG\MPN7]>[PZ=3?G$9M5G0P_=SEZ\?41\.%:OI_==?*N.[*TAIW^^ ML+?$E.P/F?LW##]5U?']`Y_!QWMG'OX/``#__P,`4$L#!!0`!@`(````(0`P M,SKNP1```'J2```9````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`E M`^9KO#67Y*B9.!XG8@:LU2D->9R8"$'ELF`^OK^KI^\774]XPX;P1LUE]\GM(J; M,:&SM\+IO(UU/&_39]=(!SZ6;9MONI MUT_1QX*,-*O#&2/-\>ZII/;+^:F.'V6D6@XTY4!+#CARP$T&S#R*C5W[#-,Y MPWA9YF,-'?:-_AFF>X;IG6&"+"-VH/TSS.`,$YYAAF>8T1EFG&5$^"9GF.D9 M)CK#S,XP\S/,X@RSS#`E<3BCSIL.23(F_1$RHJI.&HRHYDG!T40.3.5`E`X9GF,499IF:]"74ZTDR-1_3Y&C$F";J+/R" M:1+KAX*:NQ%[H":*%@H'A8NBC:*#PD/AH^BBZ*$(4/11 M#%"$*(8H1BC&*"8HIB@B%#,4,=*L+GA=D.98J]./HZ16RN(D MN)&8N\,E,*MB%>55L&8",DI8MB6/)1P#9"S#Q66T4710>"A\%%T4/10! MBCZ*`8H0Q1#%",48Q03%%$6$8H9BCF*!8HFB7L\C1I35-<@+HAQK&65QR-Y( M3.T09=NR:G3$1>EHT:Q;)]4L,Q1-927%Q*^[C&W6U1_3$/N3L$/%R& M?US"BA^+'R73+++:2$S.S&BB M:*%P4+B)2&9&5E;;6**#PD/AH^BBZ*$(4/11#%"$*(8H1BC&*"8HIB@B%#,4 M,4)MJ0OV1JKS+PT>N(RSN'[5T"@OSTQ:3!PFKB96.4EU6;5Y M''9_Z9>2\TELC=I-3DK:;0P M(R^.T!L:Y48^J9-#6ES%8>(R:3/I,/&8^!FD4A9-"]T,)`Z=>DP")GTF`R8A MDR&3$9,QDPF3*9.(R8S)G,F"R9*)RGQ>E,S,J[C]F\S'#S//VRME<20MKN(P<9FTF728>)KH"X3JGGU%7-#TN4B728])P*3/9,`D9#)D M,F(R9C)A,F42,9DQF3-9,%DR48'/RY$9^+AEYG@G#^?M28>-N7.7C6U67AN. M#CJ2%E=QF+A,VDPZ3#Q-U*71^(?@BM>5DJWOEB?'[>)&@,\ENTQZ3`(F?28# M)B&3(9,1DS&3"9,IDXC)C,F5U]>B@(VEQ M%8>)RZ3-I,/$8^(SZ3+I,0G>27RH(0XL^GG?'+Q_\[<_=!`R&3(9,1DSF3"9 M,HF8S)C,F2R8+)FH=.>%QTQWW(IS0;J3SATSW6+^-.+/SJ#3="0MKN(P<9FT MF728>$Q\)ETF/28!DSZ3@2;)@4G5LN3A6DA@:("27;JUQ509H1AKH4Y'?_=# M3A,F4R81DQF3.9,%DR43E?&\"!D9MR]KHCMP<2E.7G-J:)3SMC29M#1)IECE M+OZL(//8U^$B+I,VDPX3CXG/I,NDQR1@TF7?6#P\3B:^(RTT-C7+BW&32TB2=_+5;]8EUYG;#X2HN MDS:3#A./B<^DRZ3')S)@$C(9,ADQ&3.9,)DRB9C,F,R9+)@LF:C$G]TV M9ZMS;F/?'B?>BH\-\N^W'1XG(R^2V-`H-_+Q\G_7L7^X9-?B*@X3ETF;28>) MQ\1GTF728Q(PZ3,9,`F9#)F,F(PS2*4BFK@F&4CLC:9,(B8S)G,F"R9+)BKT M>5$RS]QE`QUD/:-QKB)ZOQIV7BM/(Q\9ETF?28!$SZ M3`9,0B9#)B,F8R8339+#0=LJE^2/7$VY2&06N;/5QTN;AY0S+C)GLF"R9*)R MGB1-GSJ72N6/QBTSY6J_>[)K+ZM!2'O\,+EGERUS\4='Y^^VFTQ:3!PF+I,V MDPX3CXG/I,NDQR1@TF9,HF8S)C,F2R8 M+)FHN"=1X[C'/3;GWW*SDY8<\Y:;;)C3*%EVJ7Q7EA]2WM1"/]$N"3G24>.D?.J[)`[U'PH)#F_*U6+XG2I:0#++M\>?>:N/DO/Z_PY M$,(Q\9ETF?28!$SZ3`9,0B9#)B,F8R83)E,F MD2;ZH,%6]Y'$U)YQD3F3!9,E$Y7RO)"8!^]QJ\T%>_.D,^B*:)AYW7O MZ#-T)"VNXC!QF;29=)AX3'PF728])@&3/I,!DY#)D,F(R9C)A,F42:2)SGFU M7#L]1<>I.^?E+)@LF:B$Y])ETF/2<"DSV3`)&0R9#)B,F8R83)E$FGR_B%/\D(BQ-? MN;7NTH]$5'^+_>B2GX+Z=31G=]&5+NNB.W"Y#?BXTG_8C3M=2UZRBGY>LLS=OVRKR[\#5TJZ=\R#?/$,&QKE M1C^O"TA''XG#"W*9M)ETF'A,?"9=)CTF`9,^DP&3D,F0R8C)F,F$R91)Q&3& M9)Y!*E71@K;(1*)?:)F!1-Q4VO.28J9=!=JXI^7*C/^ES77E3*:ZZJRW4:CG$PW MF;28.$Q<)FTF'28>$Y])5Y/DRG'F+X'A(@&3/I,!DY#)D,F(R5@3?[,X_J,1KN:Z%)HE/+:?Y);=DQ:3!PF+I,V MDPX3CXG/I,NDQR1@TF)Q\1GTF728Q(PZ3,9,`F9#)F,F(R93)A,F41,9DSF3!9,EIHDO]?X\!O$ MS$V.RGE>1I*REMNT[YM9 MXRW[OI4U[MCWSF'\YOT%[+Y\_K'ZM@Y6VV_/;[NKE_57]=*+US6UA=H^?XN/ M<9+_[#<_U$\&%Z[^V.SWF]?#/[^O5T_K;0P4_KK9[-/_J!5T\VNS_?.P>K_\ M7P````#__P,`4$L#!!0`!@`(````(0"W:N59D00``"H5```9````>&PO=V]R M:W-H965T:_X!X;\#FDHN2'!UB=>9( M,])H-)=G2IP$->`(:-/^^]EFNPD&QB;GH6EZ/E;V\MYX$:^_?11GYYU7=2[* MC4MFONOP,A/[O#QNW+__>GY:N$[=I.4^/8N2;]Q/7KO?MC__M+Z*ZK4^<=XX MH%#6&_?4-)>5Y]79B1=I/1,77L+_'$15I`V\K8Y>?:EXNF\O*LX>]?W8*]*\ M=%%A54W1$(=#GG$FLK>"EPV*5/R<-E!_?WRE(GB`A(O M^3EO/EM1URFRU8]C*:KTY0R^/TB89E_:[9N!?)%GE:C%H9F!G(>%#CTOO:4' M2MOU/@<'R8C1PO>VZ7:!_DZ MV5O=B.)?A(B20A&J1.!5B1#ZL$B@1.#U+D(7$8GB!TH)E0J\WE5"<7$PQY MN#CM6K.T2;?K2EP=&&"P7U]2>3N0%2B/+RZLJF2_2[B]!-:MAHEXWT9DN?;> MH8N98I(A0W5B-T*$.L*&2$3]&^-![3<#T)GI!B2\<<'GS4`8SV^ZK5O]$XF(3WO=V>D$H20@N@9#8D+U@'2KE_M+`+N4 M^1:0%_5=Q'H%"3+H@BSC>!GVB)U.!/XB[+M``GZ.3*'6@UAW8:Y>PGKU$>U] MW=\C.2C`3H54_?Z1Z"=ON7F1,U5L)9B*TZN6CQN3-4\+ZV@_O7F1P M804!#.423'J#]'5H)I!&DU[B*Z`9EV M'0/31HE@1G:-1+2?!PHR]L*4M>V\,:.*;D5&7\>*>3O`XH2"C M!=0Q(,RHHEN0^3?=`J9EMPO#78D@A.,4+,+!$\/.2C!%C'O4#0#S@`%)][>D MWN-D(K\V`#3^X;@GV1%F1'0+,O^F]P#3TC)&IDA5%JP((R9$MR!#<+H%C$S+ M&"&DGHL6PQ*&)Z6<3(EK+)@11@Q(9H%^E!.M[1^4P]W)06I74FFG-ZFG0U@ M"I@P3+27T=.&J;U*MQ'1WE>!1$'C16`G[`@S(GHG>FEM'B:*Z6H>)@49+=A3 MVJBB6Y!Y.?E^@#.J?D*,#!-"^+TY&!LF!+H>X][1ASP-^_^800=XVH4G,)?T MR']/JV->ULZ9'^`9PI_-X0,J/.O"-XVXM"R-.TVRGG]C\```#__P,`4$L#!!0`!@`(````(0"&'U;$2@(``)H%```9 M````>&PO=V]R:W-H965T*;25O;"#1O*86_)M*M.;,)MDS=)+JS;9]84JV0+$6M;!'3XJ19.E[V2A- MUS7D/L1#RL[ MT&UMOZO]9R[*RL*T$PCDW^(19MAAKK0'U]K/Y7=%&1YB M=)$_Z?B#AX"!\7:8?S@`FN?3.S!,Z((UB44T'OM4< MWV@&S&7:))YTF*`=CE?8?2TM^5>J2]$85/,">M2+QE"NP^$*"ZM:/^FULG`H M_&,%_T`.6[`7`;A0RIX7[OAV?]7Y'P```/__`P!02P,$%``&``@````A`$^= M];::`@``2P8``!D```!X;"]W;W)K&ULE)5=;YLP M%(;O)^T_6+XO!A+(AT*J=%6W2JLT3?NX=HP!*Q@CVVG:?[]CG+AITE;9#01X M_9SW/?[(XOI)MNB1:R-45^`DBC'B'5.EZ.H"__YU=S7%R%C:E;15'2_P,S?X M>OGYTV*G],8TG%L$A,X4N+&VGQ-B6,,E-9'J>0=?*J4EM?"H:V)ZS6DY#)(M M2>,X)Y**#GO"7%_"4%4E&+]5;"MY9SU$\Y9:\&\:T9L#3;)+<)+JS;:_8DKV M@%B+5MCG`8J19//[NE.:KEO(_92,*3NPAX*/GF6=D1H"T M7)0"$KBV(\VK`J^2^4V.R7(Q].>/X#MS]!N91NV^:E%^%QV'9L,TN0E8*[5Q MTOO2O8+!Y&STW3`!/S0J>46WK?VI=M^XJ!L+LYU!()=K7C[?R<<$B.V-5;)OUZ4[%$> MDNXA<-]#DBP:I]ED>@&%>$=#P%MJZ7*AU0[!HH&:IJ=N"29S(!^2>1\AZWM1 M(:.#K!REP+#:(86!Z7E<9G&^((_04[;7W'@-7(,F"0H";H(EL'%LZ>TF'RH[ ML:OLFNZLW/@7QV72M\N,_J>,$Q=X?&0^BR>!ZRM[#4QH"#@.BE& M]7)$S>)IX/K*7C,9&I]/P-GTG=:"N>/*;K9'L!L^;K$;=.I@=N+`:V:#@S1) MTV04!\6K[/EK!Q]7=N*3RLD+UV?W&E\YS[+Q2V]\7;^I_9J77-?\"V];@YC: MN@V;@./P-IPEJW0X#L('V,L]K?D#U;7H#&IY!4/C:`*IM3\-_(-5_;"CULK" M+AY^-G!H'#G3?@;6/X#``#__P,`4$L#!!0`!@`(````(0!1 M__5-]0(``%D(```9````>&PO=V]R:W-H965TA)`\ M?GG/>T[LK*Z?VL9YI$(RWN4(NSYR:%?PDG6['/WY?7^5(4U4OW2\V11TY9(E_>T@V\J+EJBX%;L/-D+2LIA M4=MX@>\G7DM8AXS"4ERBP:N*%?2.%_N6=LJ("-H0!?YES7KYHM86E\BU1#SL M^ZN"MSU(;%G#U/,@BIRV6'[;=5R0;0-U/^&(%"_:P\V9?,L*P26OE`MRGC%Z M7O/"6WB@M%Z5#"K0L3N"5CFZP?3>D34_?!&L_,XZ"F%# MFW0#MIP_:/1;J3^"Q=[9ZONA`3^%4]**[!OUBQ^^4K:K%70[AH)T7(M5+!&S``KT[+]&1`(.1IN!Y8J>HV5*I[IB614^RE MXNT_`^%1RH@$HPA<1Q$"7YP8/+` MN.R)GF.\!.778X$\-'NCX6$)5"RAE8_KV`]7WB/D7XS,[3D3V,3F%2*:$`]\ M3>8@K\O-:3A'$7(F&@<;-C$ULWB(L;Q#6Y=XT#)-S]-P@3.TG MWQKFV%NRL)&-019#\@$.`ASZ$V&9@Q2.S>FA3^"G\W9W]2+;9.S/C3$!&B8= M'.`P3GQ\TO^-3:1AFLY-L#Q"I<<>W_:F8=M;$,VU&V^&,=[2.$W.XK,`'.%L M5K"<)1]QIN%39WCJBG%FF#&U(,79:6-MP$\6\V_&=.ISU MC4/#3`YC/[%+V%A`M(CC;`(LA_K8O'@_T;#M+/;G:3'.##/.?)AD,%#3DP<" M3@^M8H@HROPPG#6,-W,ZF'VO)SOZ@X@=ZZ33T`H2]-T4)D.8L\'<*-X/^]R6 M*]C3A[&ULG)=; M;ZLX$,??5]KO@'@OV)A;HB1'#=WN'FE76JWV\DR(DZ`"CC!MVF^_8X8`=F@. MY_0A#>'OX3<7S^#5E_>RL-YX+7-1K6WJ$-OB52;V>75?5A=1O\@3YXT%%BJYMD]-66CA64]QX8X'/*,/XGLM>15@T9J7J0-\,M3 M?I97:V4VQUR9UB^OYX=,E&*#";M7\L+8?Z3+QB.UN5FV`_LWY M18Z^6_(D+K_6^?[WO.(0;_O_DN^; MT]IFH1-$A%&06SLNF^=KSO,8<5% MHM;!I[1)-ZM:7"RH&GBF/*>J!ND2+%\]0X[>U\].6^04RS3K-%#7SV&JHKDEN%'X6]Q@7B'AN",<:>3L253HD5G4J,PMWB M#V,4KW],JT@F%'XOT4@@:/-)E!B2/XI!&"YZNPB'&JB+/D[#DQ'NGD)C\[^' M38G7-GP.SXV,#&U1:6H%IF4!L(6-5V.J1,1[8_^\F"XE6@+B$,_ M`0:+6CSG$;>K3&2CMVP[T3CO8108H9T4?<:JNOKLW%.<`5J'9$:4MIU(8S2Z M:')?HZ6?&L-D9C1Q1&BDT;!)L9>WIM?V?5(TM,!&T$=:1U0M?WX0<4!H:,RL M38HBW$(/'J-^<)MG31,R/R!D2(9.J!K_B'!F$'%.;';T3#7$TJC4Q!:.9I#-.#)T9C%-39\A4MV&FAHI1$`F=$,6#MSKK M=XT>.C%[F-']MIVH2R?Q?$+#8'@\CN].--[Y0UGHA#\T?NC$_/'-U[5.-&3< M:`)))YA!"<^H_?WM%Z%VE3%R8I.R$XTAPGAH,QC/"9$93SR^X>FFY/61 M)[PHI)6)5W4TH]`]^E_[8^.CUQ[\^AMP:CNG1_Y'6A_S2EH%/\!2XD0`5^.Y M#R\:<6[/3CO1P'FM_7J"\SF'TP5Q0'P0HKE>J)-E?^+?_`\``/__`P!02P,$ M%``&``@````A`-]N>B+A!```=!4``!D```!X;"]W;W)K&ULG%C;CJI(%'V?9/Z!\'Z$`N5BU)/NZ?3,26:2R60NSXBED@;*`-UV M__WLJEURV8"BW8D*KMKWM4IJ]?TS2XT/7I2)R->2\,L!"7J[-8U6=EI95QD>>1>5, MG'@.W^Q%D4457!8'JSP5/-JI15EJ.;;M65F4Y"9:6!93;(C]/HGYBXC?,YY7 M:*3@:51!_.4Q.947:UD\Q5P6%6_OIV^QR$Y@8IND2?6EC)I&%B]_'')11-L4 M\OYD\RB^V%87/?-9$A>B%/MJ!N8L#+2?Q^3W(.U88^R0YLA7B3T!\[>0L66[W5KZH# M?Q;&CN^C][3Z2YQ_X\GA6$&[%Y"13&RY^WKA90P5!3,S9R$MQ2*%`.#5R!(Y M&E"1Z%.]GY-==5R;KC=;^+;+`&YL>5F])M*D:<3O926R_Q#$M"DTXF@C\*Z- M..YL[BS\8((5"R-2";Y$5;19%>)LP-2`S_(4R1ED2[!\R0SCJ',=2Q5RE$:> MI)6U">,.6930GX^-%[@KZP-J&FO,,V+@M<:P&F%!-'5($$8[I.$B7SQ+L/0L MBRY#><8;;3?.L!OW'C<2O#;GK>"]8%[;1<^(@8;6"3:(3H)@9GJ"$@SSTK+J M!0OB&3&^*CR;!S:,EC?B&\)K^Y;]=H$/UXLL%]$8/!(#8MK9>WY88SKY>X_$ M(!?1&/S:/G8`,NP13OP'QBQA=?]N9V\Q;V#6FXUMN M"81OM^LO%]$8FMIB[HAI:5"[ M!J/$8U*B6E68&`8*6[<:#;5P#)1IV$0NW+-'5)?=)7X*32M`V:=!V(C0]T+X M;\+K3+_\$!K?0+J=)\(WN'( M^#M$!*>%H5;1`6Q&'*=`@VH&+ORP\]<(1Z]!P3V>.(!R$8!XP?VP(B2A.I,6`./;8Z?3%T0M'Y-$A\C@Q#)3)Z_NC,MW: M'OQ&Q+MTO$LDG2&1[-&Q+9)7N_"01CI#&MEC(X)J-HZE+W\+3Q]"A29#&-(A MU*`)#'#ODD*%OD4_#9KBG$CA=?JY^)C;G;E>Y@C2.NS;S`E&MB572M3=/PS5 M*E+^'O\TJ%T!^'TV_'#D$OV;QC^UBH9!=T<-T@/HSQ9-L3K\;#%X)&ZOEL?NCTYZMBL_@+.O$[1@?\1%8FN%% M)4[2I+$5%9QVJ8]'.-WD<'YCSP"\%Z*Z7,ASN?J\=/,_````__\#`%!+`P04 M``8`"````"$`5[^5TCT%``#O%@``&0```'AL+W=O5F81MVDY2&]D!)OS"]+-"]-IK"JIFB0XS'/<$2R]P*7 M#1.I\"5M8/SU.;_6G5J139$KTNKM_?J2D>(*$OO\DC=?K:AI%-GJ^ZDD5;J_ M0-R?:)YFG7;[921?Y%E%:G)L+)"SV4#',2_MI0U*V_4AAPBH[4:%CQOS%:T2 MM##M[;HUZ-\MD=/)^T, M_%D9!WQ,WR_-7^3V.\Y/YP:FVX.(:&"KPU>$ZPP\P)DAP(T]KILDIY*FD;W7#2G^8Q#B4DS$Y2(S&#W_ MW7U:9,Y%X+T3\:V%Y\W]13!]*$"V\<`[5W&1A>:._T0X/M>`=ZXQW1.;^=M. M5Y0VZ79=D9L!:P`+V/I>_'AJCO MH4-Z#$-_G)I=A!2F$7;=A%U#WXTKCFPW)ORYB$0,&8[57RY$)I[`)&.F'XP0 M,RR%Z3%36(A9;MC)#1%K$`-:2@&-FE#P`VB#)P^ M:9@3C%$YH24B1@3MIH`\I_T3)SL>(O/%`R)1=2-8`5O8T`JU!126+9"VEY`Q MT/]/DT%+1(Q`#O/`6L8ODM&QEDA4O0@.!,\X0&'9`2G90\:H'-`2$2/0G*4! M/?.E%-!*)"I",("6D(,339T"%)8-D,86,D9E@):(QH2/Y"28P"1CII\NP87E M,RY06';!%V-'P=W?A>G*!$`^!I3.?2?MRPGY_ M/`]"[+#2GDB!EA:C]WRI[Y!#CSMO-\N='HDX56<`LOR9/V-G0OLJV1X_R2><\1[1(Q%4ZBUPK\,;GQ10H48Y'-(.66P,SIE40B!5I0U," M1ZI>0PXI36$Z"B32J\1Z).$(.X3(EM"*;&")9HFP^DVTHE]\/#-411ZW0HM$2(O$>B3A"!RZ]#K# MM1#\DSKX0\--6?2%UFC3?6$5G>A+7]-Q7U1E'_=%BT1PWZ==,5J$WAK**@'J M:T%F!;L79!=-!:Y.>(-U_2$_TBK4U[6Q@4?86@.'+>F4;$+2_:E M(=?VFFQ/&KAH;#^>X6(9PP658P%\)*3IOM`.Z$5I>\^V_1\``/__`P!02P,$ M%``&``@````A`(Q8;G,M!0``L10``!@```!X;"]W;W)K&8\;^+%M[?JZ+P635N*>NF2F>\Z19V+;5GOE^X_ M?S\])*[3=EF]S8ZB+I;N>]&ZWU:__K(XB^:Y/11%YT"$NEVZAZX[S3VOS0]% ME;4S<2IJN+(3395U\+;9>^VI*;)M?U-U]*CO1UZ5E;6+$>;-/3'$;E?FQ:/( M7ZJB[C!(4QRS#OC;0WEJ/Z)5^3WAJJQY?CD]Y*(Z08A->2R[]SZHZU3Y_,>^ M%DVV.<*ZWPC+\H_8_9M1^*K,&]&*73>#Y!I-5B6\(*9-J=IM@M MW>]DGM+$]5:+/D'_EL6Y'?SMM`=Q_JTIMW^4=0'9ACK)"FR$>);2'UOY+[C9 M&]W]U%?@S\;9%KOLY=C])(( M`/#;J4K9&I"1[*U_/9?;[K!T@V@6QGY`0.YLBK9[*F5(U\E?VDY4_Z&(J%`8 MA*H@\*J"$#HY2*""P*L.0I.0A-'7*!XNJ\_28]9EJT4CS@ZT'H"WITPV,IE# MY.MI@7Q([7*Z0_5Y+U%8FI2*\HV$7B`=:%#=)U/YL4 M+UWF.IHMO(3M\=U@8$'.[\>28@LK MN:P6L5""6"2*;2J\'/;4\2"5!E,TA4F*+29N,:$$F6C$&:&F(!T*HHA336UP MQ5.XI-CD"GSSL6N4(%="N$TUO,S]4.\9`TK:X=UC0HHM*&)!H405T/='N3*O MDT@ORL#B4["DV,*RDK%&B:IA$D?$VJ?I4)!$)-!-8'`1\*G[\]6KS=D5Z(V$ M':\TT-F?#J^;$A-OVM3'B3V<7X'N786'&I6YD$A[-$N>$D,2))1&>MJ8>),& M/\&A;>!9SUXKC<(+HB2(];/[%:2&A+'$#P(=Q<23L_CNS4!PME0;Q MF!_P<$2'492"1(3KD6C"37(`,K:`P'KT6FG4H^.$)A9^>DMAPLG!?'_F<(P; MF=.K5GV'&H0CH2]_[+Z[)3'Q)ED"&7O"8!PHO.',IR3FL9W>5(7!%5#*"!NT MIHDWR1G(V!J8E9JUTJCL<3`E-JKMT!\(#_R$Z5ENXDWR"#(VB4%@E3W#!0@C M/J-6`Z0JCEI"P"AGOAY.)N`DMR`XZF&#Z(%KVX720(-IC=U]&.:ZQ,"CDSRC M5YMNQFS/4!J5&S\DA-OE-20P>1+R277I),OHU::C,5T5K*[27,],+TEO2LSD M698AO^8Q"'W[^PP=6P?30U]AHD;MSROS106Y)C`1Y0@?##^)R*'F7R#BX!\. M07N/KBEJD(!1GU-KHZ>&(H`QE.A]9$).L@\ZM@]FVX?2?#0ABV+XW&0E.;5$ MT(82!D#CT@]#>\BFU5`E)?)[HP6!FW# M/AXZX7'**=L7/[-F7]:MJ/3S:B@Z.B_L\#'`T6 M<+;BST"\$Z+[>",/M2Z'C:O_`0``__\#`%!+`P04``8`"````"$`&.[I3^T" M``"C"0``&````'AL+W=OBZ5>JD:=K'M4D<8C6)(]N4]M_OV*:0F)(!%R0FK]\\?H^3 MP_SVM:Z<%\(%94V*`M='#FDREM-FDZ+?OQYNIL@1$C!*P7B-)0SYQA,M)SC7D^K*"WU_ MXM68-L@XS/@E'JPH:$;N6;:M22.-"2<5EL`O2MJ*=[0;T=,V)EWC@ MM)CG%%:@8G2G>B<.Z)DNZ^%O)GVSWC=!-*:'<$:Q(+6R6O]T3D4&B8..& MD7+*6`4`\.W45&T-2`2_ZN..YK),T6CB1K$_"D#NK(F0#U19(B?;"LGJOT84 M[*V,2;@W@>/>)`BO-AGM3>!X-`FG41!-_H_BF67IE.ZQQ(LY9SL'MAZ`BQ:K MC1S,P%G%,X*0/XX' MX!T8(;8NXS";$J=HC)PCV^A@J_&71@+E.TB.-]:*U9"BAP:1==$NBT]-@I@[ M]X\L@*61P(.AP@V^W%A+6)V_WL.#&+IXP\DIL8456G"3:^"4V(*++3@C&80;E/3@XC[<9;M.3;(@ MIQ:DD9S?=>>O]_!4[^R\4X9WG1);6(F%920FNR3Z>-L-:WIXR35X2MS'F_@6 MGI$8O''H)Z$?1%;Y5UW-*$[B:1R/CP]7#P_BOR(^K;8``PMPKQDF[(G.(9HV M:QI(BS?D.^8;V@BG(@6\2WTWA@>,FR9K!I*UNE&LF83FJ$]+^#-$H(OX+H@+ MQN3[0+7QP]^KQ3\```#__P,`4$L#!!0`!@`(````(0!Q@^T(F%D``&LK`0`4 M````>&PO9".>W(RG]^F,?TYOO\HGTRSMYW=9-KL??M79V-C^ZCX= MC%XDO?%\-/ON17>[W7V1S$>#_YAG!^ZGG>V-%]]_FP^^_W;V_>&X-[_/1K,$ M.)*CT6PP>TQ.1FX!X/[VJ]GWWWZEH6YX-WDW'LWNK#]\9J7D?^Q?Y[-IVIO]S_J;7]9_\'!>9+<#O0+TI^E]5A_UY9N3LQ^/ M]B^N6LG)Z<%Z_;&?Y(#-3],AF^YG'Y,_9H_U<5]N;&RTN[N[W?9>_=$^F.L; M]HZ'Z6W]Z9Y#V6_5.63H7,Y#"=-<9^^?IUN_.ZVZ[/ M7*#RZG'2?*F]\?K?EKYQGDT'8U%Z\8K%S#%XQ_!(7I_QRR=I[%_WJRV>X-\: M^_(D.1X,LVER`$)NQ],F/2[OTZ$&7&23\72&-"4'X_M).FJ,#!0>W]^/1\GE M;-S[M95O MZN,/LU[!]=WZPT#N-,^9XNO&XS2_,]'KZ8_L/^:##^D0]FB@>[]G\IPGTZR7 M,>AZF+6243:K3W@^S2;IH&]SCF=WV;0^X&H\@^UZG@L=6/4QYU,4S11-(*4@ MH"9B\H7KG6F-9/$T;JG%SP)>AH/T>C`[&?7(.#)>4[' M,QC+P_II8R%D,KY)M$C21S%(3]?!K!(NPEM]X-LQ(C'+IOL MM\F">_RWO;5C*W5W]EH[NSNMG(@#=[ M71$^GV0](7C80.Q^OP^OCT>(H(GI8)3TTLD`D:Q3$9TFK65;3?+Y==Z;#B9Z MM3[PT%$G27M8\KGC\_Y\*KW8SX!A;,(K3^.V(4&.IVR-.K7KR[BA@6,05]O^ M2J\N5ZCGZ&+G^>#A,IX@HY#+N:*CRQ@0- M)JJC9=D;CH]6'?T9++_:AF(N:@4>+T6P#M_"X8NWLG#HD_L(5O5RAD:503&9 M.H,::*/Q2/9UE,Z1CZR_E!7:.]LK>Z`-6[QTX>4<=8$$C>8-N3D8XZ*;KG+0 M(VO!"#6TI(U%>>08]H:)^O)O__6W_ZI3X2++\0K1-%HADN'Z.-31KXC.Z+:5 MW&8CT#BT-]+^_6!DCK%T4/VE$UREP=2<5H`:C#YD^4S_JH_#*N)J#(PT;MI[ M>5M_MA_J@YURD-/`XP@9]7&GV+GA.,^3F^GX/O'C(7U]G/,J!D1+]UFR%E#[ MJH';PTC!31VI&G/]0#242)-FL]G0^"Z8VOJJ;P49(WMWZ>@VTZ@;4.4M&O_" M&CYK.4]&6%Y0"F8%?'V)>&/U9\6K?K_UYQ[)YG`U4%,?+$R'0<+XJ^0Z(ZK+ MPH^S]&.3&T\7ITI8#J[-U1LO;V[/*R.:"QMC0NZ#"# M)C>@E5RG^:#W/-#-%_N#X1P-47_UYVQP>R<7+R7BQM(EH[F99<@6+PQ]2^]B M"12?-]42N$K;5V@?,=:E'*;"Y`83OH("-":H;[YFA.J/#R)7HOXL+'1+^[-&"F)]_K8?%5+X%/)%2^\^OIF/VN2`.**D_7&HY'<2133PV!V M5X/08CPTTW5#@2^!;=7IED%);-C+LKY7X4* M(#<%_9!.E?]I*/WCBN*6C1-7A=$1O>OH^&4\(#F#T9_-IPWM;5(KU86>Z9%S M(.I<:`Y+Y5O'0\373R;+_+B`D`1N?G+\`C5CWM6!T@K'P_'#2M[5P?[EC\GQ MV[.?+Y/CB[-WR=GYT<7^U7#1M<;C99,TM3W_-^_Y>Y M\S'R9#9.\"K&HQXI'J4OG#?`K_K;(*-\3O M(LZW))5)@^QI2WDV_<"NE-0B.""14%_Q9R_>X26(4L%)F.!3WV/Q:UQLTUSI M[30SMW"%2>KHJFB+9.E,1Z30R*8-1F2K+=N>1QNJSWGQ+^G]Y)O#WVFVR)XM M!6]%2_&9QG`E@JT*PKTSQWU23"B-V[EH.!L3TR-`;]+1K_I_LO)3\@FHEK21 M+%FR3@5&$G"SZ>!Z;B9W*K?2Y3I6DKF:*Q;1.:($0/Y>'/@<4=;PZ2D0Y=DK ME)[["SYL*/'2GVO(\@EJ4SANY++8:C75_$Q6.4"2K`5(7BT"!0?2)15]0%<7 M2]F;9RU%_:6Z93LY_>GH\CG+MM]#;LD,6W("F@4]:QJX2(O7EZK"=RVQ#_Y' M:,;R.H;'J/6GZ4W#_UO5Y<+RUJ&IOKKFC1DNWW@JDH$1 M69WY-28)@8-<NR^0^#OG/$;JB`X*]!X>7LJQ?)-IBBX0\G MG]JD">H39:V#9?4O8O,B&)3HP6/CAGOPQ-LX%.+(Q>]=OC\_?WOT[NCT:O]M M4`:X_W%T65R=IP4DDB.X_CLXAW^[]EI'?%%JD8*L/D0.<`^*<-B6?[Z M@,)+7(3:AFI>8K*JYN1)VJ\T0Y7!?_M\LI:6"!,;$"FE0]7XC#EJ`2T.T).. M^:HF]4F8,7!#*I$#*EDNI6D9R,HK+CB)"H7),C&_'-R.;"9"1?(<\DDD'^=C M%"*;_+;6-/',\"*WF*23R7#@%(2&3R`U M7H)#K9]"KUE=7B_.0VH?(Q$*`9[]L25Y61*XH4A#N-H0@Q]1)1< MBI(\`8C+HP,!8..*)5P(8=D@"Z:/Z01*U/"Q;HRH MSON@:3@,8`S*#A^;_V8\GC$4Z*=2UMHCCHLO*@SI`^CULHEE5TMNGV#U>X.) MMHQ?8/F088997D351O/-R.5B M)(:.U/XT!%1U,>@WP)L2")/DMH$62I)1(++,Q=("+W71?(5/2\IZ%/77$_$3 MO#P?XO37BA0VC^@\NR-B3/!TR,8Y`Y,H?NTWZL.DVT6``,D`3`Y&?=-`\)07 MD[#:[(XDSWWZ"*]9.J,G?`MT+?D(F_I%ZA7G30?TR@*6WXWG0^BK?9(^D;4> MCWZ9CXRI7(I1*]:7Z2XD;(U[>'&:$9@%?&IV358(U%_S9'\T4M("WX5ZDA(S M@8?_V."2-Q0)G$!=S_/!"')6%$U=%U3%N1"D8G&$Z8%"/L"-IRQN?1US)1X, MQF%*DLS3Q'+U^@>IL^F@GVH?^_-;TEBMI+VWM^=0[BW6@\'-\:7[([ MA*6?#:D:FEBY,9"4@H!7;-<##1_TM`+L>I<-)UC)/CR&-Z902U393`3E M<%ST*`U710$RWHRJ(NDQIKTMI3O*V]-)A8//.RW=YI;6UT6UN;W8:<^BJY MJD)C/"/!4Y?-JU(+@'D;]F\.)R@(X"AEQ8TQ&'NX& M%->]I?.3UU1,J'1!J0/TN0>PDM/WA/=^.JI9QID:^0TJ-])_^MDK?U* MUH!Z2"X1R!1`J7D0Y#'8$IG.OJ'=L67Y-\E:1TD9$[='X[0QM!$3\JC[RFB= M(Z:R<+``4R'8-X./,*)8LX^QG5+I5V?<-_;+VJ8,H*6%75,=8BV+GN8T'%W+ MC%.M8?IU=(I_UU@'"(L]:V'-KKG$R:[8`7^5]OGO?_EKGOPR[]^*9S7_K10- M0(K-'7STS+%0T#65310ZEABS/^\9OQD*_+9,'"/T M;Z=;8M]#2"C"82WF)3>GXSA8?Y-OG_)VRD5OB."8:#XQ-66)&YM% M/%BP0P3[>G*"S%14MG7Z\KJ$*2RG)#!Y+W`BV?5.82B\^+FGB:TZN,=/U9H^ M0,%=)7I!#:-TT)]B`*`>6-RG8G)'8/7-RFD!MU@*`QZ`:P% MDH$'.`*:"W`F<+"O`%I%-\CZU$7<409H"VG%C!3]#S>P%2ER#)4%`J9.4C1; MA/'D#HU$BK=DI8`?]B4*D]JA,>L!C^W.^6$FD_QN:&QPN%?$3CJ1Q5GRJRR+ ML%3D39.<_E+3,6+!("P$BK,!%K-\!TGR2E*:JYQ9'41L@0!B=.NL[J)Y!#O1 M')&)N-M#'5XC:!H]NAP5Z]-6#0JAE\RBM00[][NR1@$G\9$AQH6*[K70'?G8 M0,C[$5W.0Z:O,(FS?>9)59F&XH,$RF13%D&.1J(9I.SE5=C27KF1B975@9MY M@!/&[EQ=T&0`81J%2(X.P#FZQJO1P([%O`N,\`2Z>^4!\$&XY,/U%>R2I0-2 MX02S3TNOT!!VR)^A/&=4QC:B/N]%Q'U?QHG#A'D=0U*A*NM:',3.KD5)XWS6 MDL*%@J>?G^, M)A95+'0D18#SESD=)BXKIP(.2;HPRB#/=LYQ*V*8!99!>50'A:^ER\)H=:75 M+Z/.*1.E)2U',<#R7],^:6=P]@D.56=[PV*/HW3JQ.L<,&S]PI]R0\R?4KOS MX.8QN`#"Q-QIVE8E7O-`YSW\:+D'W@-S;@0X(L9UJVG3N78+`L4SIK77*?#1 M,^8Z!LH1VJ%E9^@@5J"CG=;LS<-G](:MNQ:MD+%O%>EZVX0!AS>O[A=)I!D9 M1(_`R7(X;`8N@5>0&!M0IAHH-2H;8Z("IHIZ27SX0WPC"?<$KF_Y.NNEM$EH M".V)&0480@W4!2I@\-K>$3=[8QM1H\@F1`F,?%'JHDNP,1^B<@(`?K]1[UQ" M1)V][59GKV-XZ70ZK>W=W=9N>WOEQ3;=FYRQJK;.-X3U4HU%8@*0 MATB04U[H5ION@UOF62 M88K&CQF<(8TU&H]>E[]<.Y?1:U+/`EZ1$":ZGNG2Q#OJESTJQ*5KESAB8CQ2 M@J\:^-LW7XLV(DQ`.*1G7@^$-&K&Y,4=`-FA7H7ZQ)YB"F@=%@F`PLP8"*0D?)NB,`S*%?1QD#])2CQA(TI_3R-]?E6@/6'IO M_@7;Q*7?F;2S_863IZTO2(#962_VM]7^HDA!BZ\MN?U7F'#!]NJ(=FS32`>* MN&V&+.^[*+4MG8Z+8US3(PCO&3?[1VWY39;9[B66`1' M@\P7<NO$U;?VR;5$&5I^I%;LL%*CCE0],WGP*.UL M9V6ZJ[O!M/]ZHM.!GS0)0;"SU,'M!F2"I%\M8G,UH^#U6L27)_)(30IU7 M'K4LTD3CY2'#^#=S2]N4PH!E\.BW0H'8&<]+!XA+4L0L&7Y=#H2?SK3[RSVL MB#N)][*]W6WM[6S^9J_!9<)>;F^UNAVFQR\Q67?)^Z2-%"M_3PL2]E02"L0N M@4J^;5Q+GC:D]%A=Q3_I@&-=+C_!M][MN&3EL>NK@&U/HK[`D-)WH\S1*!*5 M2G-YU]GKEM+Z:R\]VEM3_(;2-D6FT)DM,R>7':OT2+BP9;$:*BW9@D*$M1 MZ]CT4'B!,SV!%NB:1(4N[]H@XY&KLY[\K&H$ M*D")1Z=:).(E5YF8EO`[O#E547!OC+I2ET59`W%-@91O'&$>K']_I)ST!ZI$ MIM7B[:-EJ/9*+R&5)3RE7BTF;`BI]%'/:4609\T$G^+^[W:R:P&O(/5`C$HE;``$?WRJJ!)==1`*IZ=V,EROGKW@$M MWY(*>$&M2",8'8/.\!QHV0P*>R7*UY-3S^9.`)@]8N,[*LA4-TABPD(AY(P] MGG)ERZA9>CM8/B8LCP`2MY"5E3(R_FV0]8)"B;5;$-=R2T=R3JBM1J*A;8/0 M0=84@6ETW\3V2/CQQ:C,(/;X\YYF)5/6/]*%DCTV/*-\("O[IJ2@54!0@ MYY:.3?LH1%,CV628M[&-:AXB/?@+Q\H MK5[RUE\"T6@QCFE76".YN_URGIBC65?#XL8<.:"[[:T@-"A$E`T%5X7@+OHQ MU0K@A%$ZX8JB98POS3^QEO9*&I03:W%G9)QE#[*U!%C=&]!7)@BHG?B5PA)O M2G+AL[HN;5`X!-[PA-2V_.MR+;C$^:85:ZN31*5P*^.BZAT^J3%5V(\YB0K" M[P83IA37^!Q$&_QT%?VUA7+6$/F4L/"\//K@),?`BXM(Y>@\@=F&9!3E M\PLD.F,ZV\,[NKC`+`8$O/F4C$>&?B?EGST$RL9;4>KHIR( M+<(YK!GRMY$>>`2^LI>+?]@860,E%\\;XC'!5D&-$J$Y'.:)"A%>9&K MNYW(!QMT.944OWR>DXJ4:^L2%E8VL$:)/D5%G5E'<83J]\0Y_B#)VD"4G8#/ M*#98$=)25L)Q)"0D.73`&U-HP8PZ`'TS)?;&)8')S]+A1&9B&CI&1`%A2HY_ M2.6G/G^.<6)&-9,O-R!/]S4]9U3$HLMMR@\<]M/M0:!W.L+YGP%-PWXL'/1$ MS^8/9VK;/S@[/3BZ.$W>[5]='5TL[M3L6*?F2N.E"$4)"_8$]--HJ5AH3)$+ M14/[(J*0)K>V=Q2+[1T9&>`S.MZ0MI'],SX2#^!V#OW)?S,]5DPQ,=%396%S M%1E]A2UV"-$+&N*+L]B@*180)@SV!?&C3'0W?L"'<$,_:YP.60G:#GUGHO)KV`A1+7@]#\P@0P_/^?*C.$2^ MCA1TG95D%BJ1BL\8@`UY5@V==U6N9(E-KBX]I6+,>)?3.#?D583^',\&K(0F%Y3V;$;".4V]Y`K^P9`^JA) M0/R]`Z^J!R))[]?:??'[XT86@_]>Q]D">,B=?,)HW96IW*`B=DHQF_,ICP#< M;AVJVZO%HYY0IN<7.H-\]:=D__0P.?JW]R?G.K51G_94?>]=M.G_3E9[H0)' MV9$`-S=D=K$WH*R^ZY@/9>]E?>N%!J@#'7L8]6=O4U(HJ75DB'4IFIMY+B"M MCW]9_^&8#BD,DO4YYJ_LSZA/^9:`,M.5%3+6]%^Y(*`Y M"D\2'5[T&"+!N!0KWB.SMKO3;G5W&A<#-JX88>`&[8B[]>67$1:9EK.L=JS2 M+59S,?16AMQU5Y;^=R%6JGOA9"C)Q::-Q?F+:P%GQA@%/LW3+/;**FI8=BUQ M.$.IQ.XUG7S63'A'_A3\F0Y0`3='+V)K]4Y&;$JC+`6RAH0=Z98[U('14DI6 MYIS7C4%(^\TRG=/"&[3D@%<&P<'"&F0?&>&D/5Y'&`@[6["E*!%?ZE-+')EN M$*H1>"P^DK M+<#UNEMNPN"&AYP#VIMI4+-AN](OH])W-B)N1Q'(+NN$ M8^A"K^)DMS\K+-KJ"#P`.;`-T^O)V2C9IR%]F%!-TRW`5?[`SKI.2F3_!@WH M4&;>)V&-,K"XU?BS`^4=028>N#.%GD;%M@KDM0R_]D]SXX5A$MI4-026PV#S MK0J+I486O:0EZ09E#CLW4AS:"EN1'`LWG[I<0X+0A:A\-)T_CU>$4W)$0KOD M!,9RA2_%:YU6FUZ#=G=##%`]X&NWW-12-\XRH0.@5K7*PQ8N3E+W&(M>[A)59XM\@`J M'&]M[CJ'H;&BB-#`QJ62Q?3R'+F2(;6A\O:0_65WRZSTTA,V^_**@.C-GRPD M(CKB#/O5Q5^#8 MVD[^QGV:YY%M$6S%B%8$FF5?1!Y3*8BASNM4MF+^Y'PB:_*2V_M#(D6:.Z0- M@D;O;+XV&0C=$:67H_6MUT`I$7==O:F@,L#PIL(CT/R-*M\K"\+A==E;U^LI M0??MYQP2+A#A&?`M44:!BBN67[+N`UB/)D3.CK-KO(GI(]V#I@T[SOX4Z$NX M.'8L?>X:V0HU7(14J'N78S;SX#2J`\\]Z9-F\MMUZ!H1E/@B;1$MH1WAH;6. MXUZX3O\YYW_R/^LJSN]>[+SXZOMO:05WUO2>+R>T]C7 MFY3\UZ/[N:,?[/QAYG[`BHRG^O$K6V#V_+[X>O?+P"5TBM7"9G.__:?_-VZ.%.F/; M=,;3XV)OU54DX&*\!!?TF6"54O$;?/_8QS8?&;ME/=8-Q>Q[?K!MNS2C''MEC9ZCF`;UZ=XJ:TP& MU]TZ!R+,HR`N-\-9'[W6WFJW-CH[S=]IH6HWOTBQ```JRS-)^\IKQI2MKXO= M.>O-QF9VMDRQU**2F@EYJXBM5%RFRL/\I^8$DORU$$X&ZVI*QG^KF2P36CX4D7.=A_`WQ@8EZFU&-4S@M)"U%\ORV!Y6VGR_ M].F-9DP_O70V:"*`RS''HJ$W*#EDB#Y+/E\FY><0%0Q##E-<`D\7! M_Z-/P[62%/1%#00O+H]*<(/Q\R( M#E'SA#LQHNECNZ^,GGOLK>0;6@WI@8?9Q-`!"F78_`DLS4U?YE8+:IV= MEP04\%M*0?=_@!PAE"8/Y@V](N*BAD./Y'V%#3?%[!J8_(59%LO+M>(_.`-L MP]W::=F&QC0N*`HG_8TV0_(P,_AHK^JUW4[5.X.K9Q=[5;E/%;")X1\LDT@D MN$#F=6L1)_S56!%'&TL81NJK2%5)&A(#U!*TE7\YJ;22=O-"0N1(*[-0SCB3_Y'**H&TB-61M M6,*)[0_>C2A0!1?:N8.(GL%]?XSXFT03A#7Z27]#8[7X((<>"86P.\E&XT+W M^J7D9CDLW*N2Q9;PR*V>6T;C8CDE:4;N/*?Q%Y?Q0-&P#U); M'$`C`^6T@*RQ3P6`-N%;/Y3E7J,KHA&*[3+^95G`0``A$Q0VVHV-5WPD,R&" MT[HIU$0(9Q7N%+\7S.33W^J\9=_$/$$3:UN!]<36#3R>6.(/$PJ=JM_-`9H* MK:SIITI_@];17]EG)4O=EPR$B)=;?CX>5/77RRU.\;4[6P(LB$&Q%==9I4H6 M;"H-^4%=1NS)+XU!L3JV+[@P.?T`5G71G2&MC1T."'9(9.XO^-6<)TRO.P_) MJY)V>8UN@H4I,%&,>AJA.H(MID(6O>JG6$ICP9W M`LB4G.U&3!2PU2#0XOA`DMFH/NQ_3F.9^$NYZTC9F>=?.A2FA@KZ(+*[7T3> MJ5V*H'NDG'_F7$--J*VAA%]NM_G\T8;Q,B>;NJW=3L=JEQZ=S_HKSN$#>]JS M5S8^>X*LXA-*AOM\K7!$S]EO\4+$#*=HZSM2)=-D#19&%=.C0>CVRMRABF/R M;>UXH`O*C"[)VF%P;E$G2GTVRLG%`+GNGY311%%$E1`J0!A@Y\R0A7)*M_`Z M?8G2@7:D%^%`*RV?I:`"]O[G'P>R-M27_Z#*T+Q$)+26<2\XN%#W0%H5KCP<8;GEX M*J\0*U8=!0THYP2@`OG`[V_0"LYQA`@#'%1'D[DWS7O%6??7@+&H.99&*0RB M\T;0S35N-]/2WN(6K>U-1`2^`:X2`L\V$0!5=R\Z5*,72UF/X&..EQUJ`)K2:E5"3:.^1`P*`O],8+8JF>UTS. M_"Y033O_;ZFF"#&F-GYW753G\BM)ERLI_E.II@@1_Q#5Q"'<+O?[+=5,T?J? MIYG<`I^DF$2+JGZ3[ENDT\*TD?XT+%6@E@J.]&B9H'E#,8B+*8?)F;M0\1P; M+>*_&W/]5/4025S(H`O4QN?N!L`^GZKI*YI_).%OB8Z-+]Q-?PH*[0#$A_&0 MR#_<&-'>VEUO[WTA@][>;:_O=+_@'F(NX6M<6H.K^.OK&SFGA;\4/"\^MMJU M&3;6VUMZG\O[BN6LFU"HT2A;AD^SN@X`/!D@7=MB=-&#V$2U-ZS-RJ1Y8>Y+ MKYI7?VUN[D19`KM--W25-">.:,@G?$KS;`J;*V5:=-M;C(@ZY39094(@GF[G MTG!?N2"1H,7%$R&S%_A@A'9/UEZV.^;T@M*R05"?2&=!/=W>I/M@AYL3RRL' M\.'MDD[O<97!I-8OL.^C?-A[XGN-#QY+E$2('7B9K3TN6]G8 MM/?8QV9KM[NKW54P0,"HZR@^`60=^PK]D\/F9647/NVDJOTCQ9'B9L)&B+M\ MY!/UQHNCM_M7]!N>[ZNQ^^IB__12GY MU+UPT\$FM^.T]W8K)*!+&Y]>-T=(XX3L%&D[:SWVKG)80E%+4>?0R1=R="'D M-B#5&5=PJ4(V)FWX>W)]BJ3"ZY!IM`I+@PQ%%/YFP%O%G<$_<./LQ(J3]3=B M+Y%K&.3CT"W"I822R#)I518:WA&T(8['V=!H&A@8\^?#='3>D`5X$J^#5TPO@B'WXS ME2#5DVCP$?F,K8,N]P4C5_T3ZRKPTD[E^!;I=^OQ`.L0%=H*_E/H[R\A+.*V MHFE$`^P:WO">7T61JG4ATB!?F0F%SG+71':(@%8/.2S$`<@]W`&L*%HK)HXG MX"6N_%5^08RB\W`"F:#4KACMD17@4))8A('6&NL1XXPH_/F06@=>A`G.]%O,K(;4\IHG7LC, MEJP=]A5ZF0ISZ/AH_"!ZAM>"/GL]UJ41;$\$@1+6&[B(]\OM=0I""9RPBM=" M%A9::!A/6%9,?/7!;&RYVZ+T/U/2PODET9=4`[#FA%&1KA8[%D$;FAL6@BH. M+M>NQ=?,U)6@F'.%`)3:01PRD/ZEMPFURSS[J.S7@'MI:(Q`B0E_DWS MFG!TZ=)L/'HKJ834BATARH)9K9"0#BD6O[HN,'RX`); MS;CZ6??OQ[EV>5;85">XA:]'&=%JP7;9#8B\(0U-%9%@P5K[XPD$5P535A<, M-:BJ#G970(A]0D48+2HA,H)9,[SH52*=C]IQ;;$TD*A2]([[%FA_0Y3JFV3Z MK4IRSR?"^3MW'UJ$6O;/WGCR^-R'[1(_`,1*N=,Y3?L4NHXD-G>2Z_^=<+M+ MK#2*7[D.F"O]00LML'R/HY7\.AH_O*8*8/[-1)E<.Z;[[I$F!$P^(^P28'`F M)BQ>QS:F:O:GE]88=B+F!4]A6JUE\!F_SP9\V%OJ,IJVF,I>46@`UXR'SHMS M?>_\!IOBX;J=-L3R!"S[TF&5;.&40DR7@N&+1G2(Q`KNBG.PU<_T]>1K-B%[ MB8XGD2\_W#7QVR[!@GA8]=+HO#6-*J$S]3UG^DP`5!-8VN(

B^%!NSA?%W!<8)!>H7R35NJ=D-L/!`_D`.N'A%F!? M&EM(/'+*@_@HO1Z7S6$P;\Q'J#@]7ZCMC3F4`F-7MH:I=9JO,IMA0A[`$!(#8ZN*J>%GP*0->B=7@@L:R%A ME%N""^_U:1)#1XJ785Z$TZRAHA8.TW6)_B+V$J\A$G1MQ;R3V"5(KCQYRT7L&!# MN^R;%U,K_>C%)9F&B>L_7-B'T-WNR,=IK''FLA)F_PY]4@)%#X-\6Z^$-ZI0 M3X`23(+<^=BKD7M89`ND>I=D13ZG.<$*[O"-G98R;]I6HU>!IA1S\/C+-Z\( M])?M3=>A:PH*B0PM*3X3$H2;HU0^\5`<60D!DZ'-@KA-&].&W\J$F(OH*FF6 M!G\"8E71Q8V4*"E%SZ5_$%K8K/](?91U(IV5_L4V<(1"T[V#3/%)J110$+$C8-01[!100WRQ"&-EB.?I*J_@>:1Q M&5A7%UCOQ!=8-Q1)`QLOVSO&C<)T)5WF6FMD)M2/M`C0[%IL&.<.]=5)]56HN(MIOIFL`L*Z?H>865L"&G=-(3BCO^DWNJW\ZB?Z&5WJ(8<'AT[+_YN3MR=6R#YON6B%@M121?YSVXUY$-:/O!\K0$I M*O,M;3[R]BULTR1ZY2J_F:3G`#81^J>KZ0MT2!K51IUF>KJ_J(%].HFJ[J;C MNFA:KT:-D"4=I1->;F]OMS9WMZS>$D4OSU?&"6XHZUM3MWWYY:=DEP]6\MMT"!.5IJJ MKNO&$]?;;?IYI246J@Z45'$@QI9)UG)09BIGVZF<<%8T'W#,2-)-"`CM MYN5-;E/?>DW":>WHY.HX.>$ZQ2S9X$?B4?)FY#[3R5W2YMNI8I>P`^F&\-DR MU4;TK5VKO5HZ4CD<=V^QR;_8;#(AVUUD5?V=SZ\)'R"/0KLX?(B5GVE0OB=: MNS%BP8I59_2EOV:E;EL7C7DBZKB\.COXXX]G;PDF+IF2>R6O M_E2?TIJ/]OQM*>5P6<3%+Q!5A$!_)V2>Q-378ZJ,\K3*EI-^YJ[4AGB+TO/D MM'RMT^7(0=5*B>+R$!RA,)24*$(\;K$-T469.?W,-=:3(TNAZC2Z]E2?!@Z( MYL*S*Q]\X%>6.,;,-=]>J*1"2Q-&BWH"Y+4@09I:A M-,GC?/-!-,32D1N,V8%@F8,?I9,E7T; MZRQN>`WW1V*!K.TF-,=S`VYQ^V$8DYS;KT)7,5EUX0,*[#3$*2?WQ'SA'9O/ MA5R5)8P@6J$R,)%%HL5#GYJB%8HR1&%%T9#JY%.$Z-I6!"AIZBOFL#_MW;1/ MG1ZU;._!$V3=AMX+$2,O])4^A"K;$MWZ(DG=:7Y0E30P-&^NNU(J]A5:I&F&; M#.B;"UQ$RBT\2Q)7H`&_W\[=XIB5CA)AP?BA<:WNI3ED=WO`AK*S_U9'=T=H8 ML,;-Y12F-[O=^E)+`"RD)9P[J+_W?ZD[]]VXDN,.O\H@D$,N0,D:W@4G`;B2 M*,M82HI(:?\(@H`BN2MZR:&B$;U>(V^1/$">Q4^6[U?5M]-]>F;(:`,'`9P5 MIT]W=7=UW2_HR/ON`/KK?]>_K2LN8+^IS]59:H@[]5SQH[)4!P>X^*.#/\6^ M;<)FBSF3*+_XHQ.>9383EPW?3(/G%?',;SR?:J"SBZ>?1;H,%8S.BG69FX%$/_*_H9.0?8^(MOO*H.L9KX896\T"!#=K] M]$GA:M+U!O%B8P+5]/!.2#1^S+(Z3)0AZ+H'N3A7)!W4IFP4"7_?C@6.%"J: MJ\S82*2KPD&0K2E#E\B#S7UZ^U(4H6.0I'[53Y-CFNI9G1'#2ZBHYP6NYOUX M-L@'=._'^Y0`B/=C=^O1+LE[VO#;U@&R\YN&/]SO(DD="R$TO]X]UA=XWTMY M(BJ*A#!N)/Y;O!.C:VK&X'8!Q"(9*.))1SSO<6EGT$/*:0AATH;4F2DECG9V M=^R/_`-G%;%-2!ZA!X(J3,L>>`8##UV3HV$.85)%(W(*8X-//1UH((<,Q)?T M_*.[MB7\OX9X$L6`FE9VI(),]P7>$FG`J?!+6:<;QNZ_1:K?_(P2U])O_R;) M##7(!5,2<$LE@0B"BL,W`*RC[%+P86=OIU[F&WU7_[%:>XAV]>"P:['&]I+K MP2MQ]R685!KJ[\[T(RZ7Y1UK*-.88F_U&.-;D6OO-%R;GW>\>1O_M=MR9W'Z MR+QW0R'C+&+"O'>5U/J?DP=[CW:?U&NC(YW=S+`'(MQCZ4SN]5@U#F-HU!W< M2)+C18;\/.8!D#:L9.J]_2TFSH,S%T_/^"X$JJ$C7]V(M)]$CP0@.@!G,XC; M/YW\D4YV%'[&:DN&2HZFMUBT\R"0AHK6%%T1DJ;Y9#(HN50063:G>Y:E8=F( M1EZ2K&)Q5Q8YZJ4[MA&A/.S?'U)8B(H>]S^/2,8?$,&Z0QD7A*8N.3($%[.GKHZ.7)^K0=6SV M+YH@GM`,\?FKI[V8KJF$W/^B6^(=/OR#W3<=4.R^#V*^5/V.D),&5U))NWQN MAIZ`/P\C_J#,8'J@AYQ*77JV4DK0\+I9:<504>#%U0U1AMBS+JXG3\F-FJO, M?,R,-D9HDY%\23_IYPOL-1_PHLD-:ADO%AIO_["FP4I"".$5L@Q) MR_+^=?K7)UP5Z2XM+`NK$BG('NA3!]]@,7#0.>/:6,J!6#3\N-0_*@20BQZ23OY):7H2EA1=HT8 MB0$%/-H(CA5O%6>K_42'$+`])WXA%6.UL`!OW@`&,+*CL&R]"3>D]^N.%D0< MK'L4B\+\\ELWPG@.K]'/@;=%?^%HT1"HJI4,=$50A^`;'G![L.)-BA@B0=I6 M4#J7S=5LJ.WDY12^R#3B\&LD*E#(XF@R7E@LCEX\K_23['YC>ALSCI#/E54W MG4!!_`JRF*,&;=N6G"`ZG6EJ)$1/POEVTJ6PRB3Z'C_A"@UUR@P>LS,*'H_( M"DK=WQAQ_;[7\*@F2ER],8^VK5*D1^8QY0EGHF,'W5W![)8TK"&AHLGX<`PZW&V/L0:_KD7$W!6A:ZZ/*DA,Z'XF.0)E'G)<> MV4#^L/OZW8L#R?X_[GR4I28:SD&3X)?RXZ?`HX(L-]&/-2DHKSB%Z5@H#DQ0 MY<@M1R`0]VA**"GX62G,2T8,49#0?@D<,1,$<>0\5:T1VT*"3DXX3OLIN<;L M979YJK.'U5X-MC/H'L.6E:YY244<'V2BAURWQOM"&)9X?#%KCFF87)W^S`,Z M0*J4]0)/X%!CD0MW=FY&8$NGLE%G'($4(>R&6`#9)X=,#*=[R:KG:$AFGUHY MW_2)K#'A`V0OO($4Z@0&3@(A^%9RB&>3,SMPA15C46FN(]\/X63!AV>IH86K M37>?/W9P+0-1DD79^[$X&LYC>`*V@00V^!Z+R&H'].,+OA49=*0=$GYF)HOF M6*2L[^W]1F*=X/+14=51/I;"=:]5M)G`.31*9%&-RS$ZX0N)P-;[5)$NR40C1&O+8&GMY6(9P:09<*N(LUBX M]0`LG.[J\B8,H;@SR)V>":JL/8A4HV]/O/ST5/7,*%%\;TP[;`/S8% M-MC/"JS":HA*8Q7.O.5LQ)!P.FJ_F$/VS/B8@^_MBH9V)05!59=?[,V>0V]"\= M)6X^H>`8L>$48IN>6(1@N"5_N#G`68]))U<>BPK.<;(RTPHK#"-#V!JD`2OQ M#,LMX.6F[@4)O81,>Q$7:UJ)JY6QWL+#T($GFRA9NC*UG64QME"@E_&BN%=U MA)X1CZH+IKR8=6YN":WU/% MOJ+^GUY1\08.]??6.NKIC1?T?GK\U.N0B>T8==?U0,52)U,VG'O;Y*LAX?:2 M4N).`B_9*.IY/;M#`679Q5"0"`Q?)/J_0!ES>:,8#(:%GW(4-"1-Z=8"5C/ M?&/"P?AY!-&6]6F[\-"Z?CSPO&\5UR$+W+-N#8RK7YPP+.G/]OG'#__X=X>' M4-S'>X=?JS=3HXB]_H949_8P.G8;PX.Q[=^0R1K4' M^0O.6N_9,\CK/U?A3I:WMC^AD+WL):!:%A*'"I8_F:NY!+/+ZP]&N(4ZPEAA MF**<*<0DD1-R]/#FAX>?".\E(\EX%\7U>6OS&_6?!V--DQ9=C&@HCJ%ZK5B9 M"N59(Q:]&Y-@V>N0']BY-CQN2%UX(Y\5L?]@>Q>?#2&J7`5=&#:V2>#/%KE$ M8"HC6\+]H@/@H;R.[Y4'P.6SS_%1"RRYAP'WSW[OGDZ/G! M\;NW_8:BE`:4"7>U+TX*`:L,/!SJ$0>Y]/(QP8(T"$(I>*I2*E'O`*V^P*O/ M)ON;.P]EPP/93$V5P*C$IX>?JT ME;%C+'+)Q6>$/1NBD"Y`_'`!"29VZSJDU\E$+*NPF>_AHL!SG:_;7!T4I%2T M5W2:NR@,:<]NZ>(+MYR$K`UA801*UNE4>T7PB]X3V(C<:<'U6BQ..P1Y*G!.;;4'&9 M8X"JC1V1SW`+P\'2;A7A+7M(QY9N)NX8"J0[F%QW?8KV0'4^NVIMA,5N*-_X^4]&ZRYGG_!O&R@*6JU'WL[:L782 MC@+"C7QY7:C=XGI%D@1UTU@_+!I.'>\%VDY(,0FH5!#0%?>*=R0Y7TSB?W]VRKYN33 M"$A8/5[^OP]@$G^9(Q?8A4H)@@/#0T?=-;QX-%2*#>* MA*@7;TL]L4Q"%+:DQP;NK')S6^82?S>"N2*?S*[8&KIU=D*AT_J.8J[G\HLF1I$#)]+JE`$R?,$"P03*I%2]PQ#=96X06*_.L/4O:@O?PE78FF"-U^XN*0:;]$/AG!T`*L M8L$&*=Y]$F:=!Z,T]X2-GY%+\XNP7NAJ_$K'$>Q%;@VG!)L= MG^602O!GJ.:#I[K$%QT=XG'%'T-I)1CU1TJ1/]3!XSJ'4/ULM^N$V-W=@"'TD M?C\)<=[;HH=+%(5SFD0!?S!4R\EK-,C(@0LW'SAQ2JC.D8F%E'->O?-7)M\L M'L7X985K$:URAPSL!'G".`,T`.MXP6KS[%MV?7;!]0=J@ZP;T*4[?9;9IRB* MX]?A.L\3":N7Z&P%BL"90JZR[5+@:*&2XH.B8+I=#[Q+MC9=G9@3Y:"SU'F3'[]MH'C$X$:DB?GA M(`HDC<2M6*6U-:^*Q.@61&8IYH0#",AABRG7DCD%]HF=N`1/+,-QI"`X,B9; M0_D*XJ77]LI>4;@V.W\[-D#,15SL&N*!FVO!WXCKM%=&%0:VBO!SP,)5'HUC MWEU?38'/Y27X,X+K<)$Z(Q-V>$(?+\XQ0C;@G'#ZQ4SQ9>C8)4@,'[?9`G(7RE-J#"?%H@S/&4C MP=^%E3-RQMT(TK7511C_HV5"&ICWUY28UFF M\>$YFN6JP`&>V(R'@2#@M1UJ4'NSQ./A-,!3$HL9X*]/KIX9>; MA^%]L7*]_:WFCM;W:`"WN5U/M;[U9&-O=UK_^23HN6`ST@I8$['$ZEC`7*V4 M`.+:I(A!Q78,%:NG6M]FY2<[S$?2A_W\F`M2LL[6W2YIP<_%= M%&F2LMIC';[C]DR]/$H-RT&T+2E(7SUYZ]` MH?7OJ'KUS>0%^&T:FLA0,.H'KS6BJV*L@L!7(J'&EK3@H]I7@6R+5UT/I;-J M:`ZO;L\H_Q]\U*TSRE-930-WGBY;P+58V;GT7$6?F.R,U6/T%:D\>6/E;!J=T\-KW8X:&8/5CG-S:S&S,, MM$"/[=21V8J]%,S)=1<3L;22IO5,;3U,_2N/G7A9=FG?<1^NA)'X+%4M_#%* M9?%V4>K;"R&"U6K4T'_V0CUJ4L]LY9:4^RJX/BH-+IL(5R%LU.JFV:I,(P3[ MM(>"N!9JCV8J#ZK4'<8/RR\7.\TMU)0C+>;UT\)P%KA]O/P1\V()8['WAOD?YV8M MS^6,:4A@,V"!.?_XW;?'%*TA,'OR_+W"L^OW^DJ=MO`-R9*_=/#+6`?A#^&6`U["4:)'FQO M49^J+86]'!Q<9VH\.-U9M#PW.F0\\9U*A4#6B^VW`#V6HVXN+8)B*&]I+9'@U!M%G>G^XXV= MZ?0>Z]>H3!$[FO)M[M[M_A[L>E63KGW"5"C"(/<(@:R/]1Y04V?O"2='1\E% M=PO*`]`@MD!D,$:9Z95&J=1B[L\N+G#$H4%?F"U:)J<'TZU=B^.VP1\O,7,\ ML#]$IJP)[UY,\[@P9Q?>P#5P6:M%>@NZU$J@I7H[OS!N!4:L&MSBS.'Q1VI[1=<'TT`VE@*V# MG9R"6^X: MFJ5H_TR58JZ0\=??'3^;/&C0&6?\DA,]Q3*ME![."\5>!4#,^_U6WM5EW]1` MI;E>(Y,N^WAR0F.7Y8.L-45O&!%?//^W6%1FV+M?$)L)1^39'$<91BI9]^-E M!.X$#Q"AULT-MR>U,7E#\0-.;Z08RZM;:Q0((8_94^(NZHHN:5F&S=;P7A]L M.X=Q_F*2T">J_Z$<@ZAVEU>W6M=-!V5]C_K+UUYJH7S'2.LI&+J4AL8_Q7:, M-;5]`'DO[JLD(S('RM=3Y<$2`2<6FG9Q_>GJYI>+UB+Q]F*.7@W[$PJM@@%50H;1%7-*2H@N1E1ND\( M'I,=)]0"JV'\OFI(J^"8L\O&+M=CN M63!YDRX*8GF)=?AD\6P^N?A",4YCWAR(V42CD@1"L33QR@K`^H)I?=Y\+>.4 M3`]#=4*S-`*N17T1?2#Y#8'L65DL,X>O+GTL*$!'RLPCPG$#FX3[Q;GQSS\K M+%QAV>8]J[?Y>"$/I9G0HPDJG%26QI2Z(N"].U'_8T4ZPPGU5+D7#N'%YXM? M8).SQMH.V5=M#Y%Q#P3Y@<]%53!S(,Q:8&.]MS4B#3VBM_[EU5`(7?JZ;G]\ MQ!'H&!XW%1".B4V+[\-UP""K=OEAJ)RKR2;OD*M!)78/A8A]@P1>]^O?P]#` M+`^]_MZ3,2U2'KJW=&5,7I^'IMGN.H<$1!/2?W0ZL[;7JVWM&1&S1#[]P?*L M:4&I;!N7(EB#]&FGJ3'2FD[O:ZN]B1`ND6_![6 M,^![:^C'^22<#UI$1X@36X:"WI)[3T"#->%U#Q,.<\E5]59]VG"T]8]/RRCP M8(`;T>RCJTH+AT[L8<(-=^8U+/>Y.8QE*HWL;**XL'K]9U!P1D0?]X:$&0SR MT&TE@]6C*8T`&X`\N3'!XLZP_>,UQ%=!;2>[P_JCUV(MF`3/DC^#36#IS_VA MQ;GKK]9"?`]*T3C)"XIQY(&KBICQLV0G,3]&O;IIEF['!]B@FX:EZK%9TBQ% MWMDB+?]U4=]HX<`H$<0[K-F7;0=H4@T/2\`0!P,JRJ*P$!.I\(444HHQ`YO8%^]/I9)LB<0HIT0N) MTAR)G"I"&46Y$+)*EAUQQC%UX0/!-'9%2>*+LJ]92H+W2)(@-2'008V'JK*# M>Y#TK;Q1`E-P2T(:>)7,JP^[(Q32@G$TTVB?C$)8TAC;I!]+(P$-L6=LMOHZ M4+<525X[0;+CQ+53V2H\EM(.S?PM,B@C?[,!/2I1)(2(L<=;(AVG$N*Z(6*Z M$;!<1*R&Z\!)G&OV84RZQGKPL%Q>_:N$VLHG4P\QTT%J(E3_FB8X(82L_G%M M:B4#VS]/5>:CI8XA6J<^<-TL)/D3N7T@<(EI]-%N\'2I"'48UZ="3S M=Q?;ZQL(IBCN^(QP?$>+^*Z:;6)O2&]U)FH`:ZFOO@;UK8(;)+Z9Y\0\Y#+? M(:$M%=E--'DD%UUX^T]305/^Z)XX@5:.KA&++]49,D0F= M,QM8740,'53K+REAPK2XE,94H.[ER_[)E:.ZGC=X*"QCQ\N/T/3(2!Z M8#DS$;M2$`.*$&WT(&1Z#7PEE+4DL@\$<6&GDWDFR#U21H].\6^SC4W[05') M!3%,$Y<3\-&IRQ,LC44;98N%")'Y`=CMO:NH%H^+@5;K)2!90^+C@S8FE&Q; MR8CMDEQ]]!@7Y?\X"+S(>>BG5.G)-LH=8?!8LC1Q:PB=RGA40J]Z.OO<7=[`K<(RTR4LQYQB/"8@X\U MI!X1-FH.DHW)>V_(_1:W?.M=7XL]LNLYWJ2S7FV:T+:[GJ9SYD/I*\H+[H'6 MCI(ZN^'FFWK:(8-.RK-]6H]]!BIYL%[9T7,YB5[L8C#"$2*=&ZHB(^F7[(_J MD:T>9#WR,126>/IQ7S'VHW%AK>U[>>#);DB/3\A+K0WW^YU#] M'!X).H+JX4'7`X,2H43P7+K8!RPY,Z*S3' MN\\]^0^L:XM5YN4`:I(E>CEWY>K;9'-O5!*SAQA,V+%!U'(T-MXXW7/J7^\^ MD=ER!]73[QH22GBB";/+^O*D<]=&!A')J\!1PU[/.`\28VP)58]_&6)8A:PE M1O3,`F.DRR)%SY)ZI*EF);ER[BHM'NH=-=&P0`W/?>:_YQRG50!+PZ/M*LK/$LP2- M1N9('3[DW,2:HCC@J\G)F,+])##AJ1-XF/&8HKV6ACU.C&![=&3KT-[>I.$5^5TL0$JOCE9B=JN.JI7_AAJQ_^G\GA/^'NK&DMB MS MM(]()9<=ZQLR*\*[RFK;N_IH$<7O.K^FS32:S`D<;'-M2_?V:K+9XF3*]B M,<(EL,*P1<+Z^-BT8N2JBQ=4GRCG7SM]_F5=-XS)$7W?)?(14Q8+E<8HC?_L M;BZ?ZTGB/^,BG[$=9E,_C_YLD:;LQ=G&Y=T54#@:PGI18.ZC<`/]=HTBT8/0 M.\'X^Z(XVA)&=R`E-.A:.B(5*]WLJSO+$OZ88:W>D\-SX\[H6$[>:_IB4^L$ MQPX^NEAJAAO:S@1YL5[+R]ZG+E\-L%+.0]40#"[*(W#OJ&OM199M_64ZY''V M.830(V"C_;$Q!H2Y]1B?):H,^ZN'5O1=D+JX0!=6$2)GGS&/?IEOM^JD6 M:0I5S'I1.UJ-8Q6WY,](.C-'['U9^@ZS=)(1UQ==6VZT\'/H=YPN_==LTE!O M-5YKOGS#N/ZPX.R'7FB7?T]]0QI^/NVZD_ MQ@-Y2_0V=8SD62L*8LIQ-E)XN_Y^[6^PVG8-HY<_P"X82ZIWW2.'JO"0\KR( M0>T5N:V76+MG65>5>FT+;PPLP>E^(A+7:QOUUT,]-93WE&PO77W0Y.UW+Z[3^VH%>]OW M%OWAY:#?L[RUO[&]IT7_+Y]7%[-^;Q^:WL9T?,]:]%^M??^[NU_^XG8?OCK6 MIV?+"GL@PMLO^L]AN+LQC/WZV7+-_:6_LSSX9.L'KAG"V^#)V.\"R]SL\237 M,4:#P97AFK;7CR7N;]T^>'YB/ M#D!]&4[,=2H[>E,0[]KKP-_[V_`2Q!G^=FNOK2+*N3$W0-+=K7=P5VZX[ZW] M@Q_Z.W MPL\@&,`\_-K=[?ZGWE?3@2-#A+?V'3_HA>!EL"\ZXIFN%7]C:3KV8V#CU[:F M:SNO\>$1'H@"(_F>:X.;\*`1:SBMGD=$D]HT0QB,36,\0FURP203#];;9/ZK MQ"9&UY2OJPU_C*[(BGJ[E.DJQD6!PS:Z,E\1/<'3XZ*_6D$-&0X&2"MU6$?* MYLL!Z#N9LJOIR2P;K\:K:Z66,;%8]!LJ'*]44LE1N'I[_>YD=*I75F5=4H9/ ME0&8<&I9M"%U:_+[>H4_IXB3$S])+7GU]W,!3V8(*$]AOQ]SC??@K,U^$H&A"*G;#W'7N#*)Z6T0`\ M&0`MKQY6RX=(+T$FBJ)"Z&JUO.Y`Z,/]?*D>Z7(>Q8*AT/S1"GX4(WT[Q1_% M0E?PWU(9ITF[F*@"F7U_/Y?#:\FLUF\\EX.)E$)#\F$6U[&^O% MPCFT,IJ*"*:`8#Z>S:]&`&0PF46J3HI@#`"NI]/9=#@?3>#_J&UVCT`UI].^ M;J\2!)J\2A!H\FHT9U-1^I),@94@S;E*$&CR*D&@R:O1V%JA5Z^U>Y4@T.15 M@D"35Z.51H5>A65AS;E*$&CR*D&@R:O*!I])!9YK]RI!H,FK!,&IO9I.JY8/ M#ZMHW:DX,E,V/DYTX2#^5+J6RX>EO*YHA@ISXD<_V,!>8;H!-L19<7SL[M:Q MMB',?@/[Z1E_A_X._GWTPQ!VUNYN-[;YY'NF`R^-](ST=\V9L/<(VXR+?OAL MK[^`,F8=*/9#K*(K#5F%G>#,97(]&5Q/IJ.K>'*H2+5K;>R#6[0NTUV:`T`C M>%CP!8B(-"<$S5-B8;S6(VDC.$+.1 MG"!H(SE#U$9(G;+D2IG<^`?8]CYV\&HU&PRB&:9TO)0+),!+(H9[3I%/[BDE MC'+/$>4T)0_J2R$W[D?X$ZV%E%C*.:-H)^>$$BLY9XC:R,9-J<79,@F6YQ(D M1WPS7V\&`Q3%)Q(\I,(GY0E7JN/M)N'H9:TMJ#FRI#,]1S5=E9Z4+:YXXD3@ M0*[[IDH@_FI=0G2DIW!Q-8N65+P$H@JKD\$'C&76EN-\PM'%W[;9@`;6(^]N M7[;DTANX'@JO3<$K>_`E+/HG+^/!2_P&=%6=-*H\J6?N=L[KQX/[:`6KZ"*I M2$5T%#<7\G?WT:@K?__6L9\\UXI65/NQF.\#/[3687015[2Q5(5G7(%GF`@2 MP=-&_Z1"/_`DS$<;_;!B5^I$X$6K?@@N8?TJXP'6NE(^P`4TJ.OPJ$0`ZS(I M`G""#@1X>5V2V!">.A#`?#=%``&:(P`X-5'1)@^&I)I!#.0J07]7*J'&I%8R M*CNTLJK\@OX:*U=,^6U%,ZFW$.@YS?"F!D`KE54E5E>)(6Z'3,LI@#<.JFJ^-$%)T`4/.")2!.D;4126IN:`S!U#/R+W"<0@)"BQ%NB$`'"T0 MB".&FOKOD&+0U(%I-&AJP10"TX-/F!/4$TR'U(0!\&C)BGR<,&0ZQ@EI(!!T M54@2#2-=)9)BT%4C,=)5(`D%7A:2>T%4B*09=-9*X0E>))!"`$2T5DGI" M5XFD&'35R-P58UTEDD#052&))\8=ETB#+IO&BZAD_70XF35:0.V];+DKJ;#9 MG"T?'/LZ/3V>/L531W!&-)DBPFFH%??Q+ MV-!>TR,_!N;NL_4"<]%X%^UE>[38&TTODR5B<8SL.FN*];3(@47^VG;F&@Z; M.7.P+=#O<6DCRL59$^2G!1:$E:P%PDNFMK-!5AE67,MIP`BK*X^7YB!P78J[ MKW'D>]48N@P!1LE$88R#Y MQ3(T/IZ+LBS$NQA2'+0*"_5PHHMH!,*TO)EQ\)1WLP:DB:(\J1-EPNAX.4%S M&"F'(^J@BC"JQW,N852/LD%82U90UU-;5^*F8G8TR3^4H$QAB M^V(G0SH%?A`LDN5QP(Z9BFXXLV0N..5,DWG,%O'SJY$ZGLL#+*\=*)-$IYVF&)!;=YDETD".W\77,L M9#8B@:6BXC9!2*.GP5!?`C2[YBKHS);P)-PKYE"*ITFRG9*O)O@H84S;/WDV M$M2R^W`@->2G*X#%L;8(V2$9+^C9(85P M##;N"NS286$V(-\6A"'3*&B9-B>A^.>,MVT,,UG6-.VY,0J"MU!!\#JY[E-< M"HW6%9`JY;Q2(IR)6JF@:=4H3#NGIRU"#.NR1:2B_[KQ6*5^J/WLVD_#\854 M_!`T;-F&#^K0L(WQ)&,+=DW[#/$QS5L-OJ:^!.V/T35)6+V+D=TPLMJF'FTC M;+0-.<'/AIMP8K8%##2FM8+%6_1N,KNL6Z65D,:,W%/C:V13T9Q)IR10CC0A MH.2"4B8$ZF7+#'9KJ&$T,G]$-`3]XC4N#[J3*E,XV5;/!`<<33_1.044@K)1 MYYCC.9E@B5'G_NS`"LS'DK$SSPJV+J=YWP)OHR$<*2;P,N\C\*8\7003@A$F MWI3JI%>.-CG]I)'SE9+9W'Z2(56>*@HOSX]&-+3,9$X4E`-E$Z-3V,AIDKKB M]#9"U#:>V&H"8,NS,RX?:3&IRR9B;R/9G$(J,YB5@"*_KB\:P0B"6\4%>>=P MT[)5BM-5D5_=D4C*5?4`I$!B!)WG'B2BR,A$HBP)>AR+05G_/F]T$*=GQEW'GFU<5SKV M8Y,D(/V'+<'%*1D[IV$'#\+-B29M@ZR@GF7B[O]PX08=S!T[1*.AJLW4!^N9 MMAD&]/G'Q*GABL8$;40DY>"P<*6OW&*3JIZPBIJ.$'_^RFGM2R92L+I1^\?L M\/S3<@)XL=VH(+<%!2XJ'SC5+.)@J"5S`,;#Q3^M$C9))L*(^J/^!TNU1\8P M:P[":*C7&^0?`:B9'U8]!"9+3R-"!(<`9$..\,'98*]H48P7*ZL4]9H@2$26 MC-XK01:C6L$XJLFB#$7(#J2ZB/N6"`'L8[XRTCSR&A8&5>II3*ED!/"EJ=BD MT!:NVLPSN4:<\GN2M66G$E"7K5+J-FXTYR"(\Y`F#HP7%=*B4,._O##.>H5, MM;)=DQHD8(1?LZEO^2'@%':X*AO(]5 M=JXR/T8WI83;4)*'^K"/],EN6MGS3!<>)S@:_+IWT7N[QC*5-80AWL3T8#OP M3-5HR19@KP][>,3>?7PPN0-DG:RLUHS0*406S#)D966A-L*;S!)9,%J0E07J MX[`=@[5$%CSO2%I6UI^B/+"TY)<+'<3P6YGY3Y$;>UB(UHL@@N M*BOW(TYA":P`>R MLG(_LG4";L4K+2OW(\O]5)#[XXK*1OQ(,.)C*;GOX!7A".>Q(AS%4G*OL5$^ M%HSR6$KN+S:^)X+Q'4O)/07RB$43^$#%!?)D@-A^PC8H(>GC9.:9GAG[P MVL.;-6?B6*=/!<7]WO\!(W.#:&<8`I(R;+!98> M?'2+C!@X.T;#QA_NDLN(@;-C,6Q1Q?&3B)CWWNZ0>8BMI=BZ141\L+TOUH:- M')9AW)T5D?31.H2!F<4?FU(C06(^XN,;,QELB8B>QG@\9OP(3VM,2<3;09/< MP3&T"/`_'4)"(YY%A.`=2$2$?+9#>&1PXDTVAQ&6D`@?;J">B3BJ*((R_FH& M'F8+D[I',5IA47X_>AC];U[R1WE&O(LAG-A\`HC;6UCPXX>?LPT4_ M?_W'Z&'<$$S)M[ZWO_IA)&+1SU]_P*><0Q;##!;*S8<]/#D;?O<.@;WH_^?A M_GK^[F$UNI@-[F<7D[$UO9A/[]]=3"?+^W?O5O/!:+#\+U#F.M[^YF4X6?2? MPW!W8QC[];/EFOM+UUX'_M[?AI=K>'BZO]W::\O8[P(H*OMGRPI=QQ@-!G-C M;KAF]-QB$'*S=^!;06)L`OY3?FS1)V]B^-&CC0$V+-*G1AA[?"+J)U1R]S\` M``#__P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O M=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF998 M4Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5 MAT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX M3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV< M%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA M7=_\TG7I@O%TS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'# M'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LO MG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH- M<$/S*EAX.(N#UO5D"53,+2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W M%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9B1)? M7B?-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#. MM!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH; M!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO14=MK M-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'M MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4OR!5 MBF'\/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U! M!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH M@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMS MX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[ MUQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[ MA28&80-1?F#R`Y+<&ULG)AM;^(X M$,??KW3?(%[4^Y7[S]]/7V>N(]JTSM.2 MUVSEOC'A?EO_]F5YYLVS.##6.N"A%BOWT+;'A>>)[,"J5$SXD=5P9\>;*FWA MLME[XMBP-%=&5>E1WY]Z55K4+GI8-#8^^&Y79.R19Z>*U2TZ:5B9ML`O#L51 M7+Q5F8V[*FV>3\>O&:^.X&);E$7[IIRZ3I4M?NQKWJ3;$L;]2L(TN_A6%P/W M59$U7/!=.P%W'H(.QSSWYAYX6B_S`D8@P^XT;+=R'\@BH<3UUDL5H'\+=A97 MGQUQX.??FR+_6=0,H@UYDAG8P/K)Y6!/QLG9[OT5+9_\?-W M5NP/+:0[@A')@2WRMT`D`\.I4A2P-B$CZJM[/1=X>5FXP MG42Q'Q"0.ULFVJ="NG2=["1:7OV'(C6BS@G53@*@U_>C24BC>&;AQ4,B-<#' MM$W7RX:?':@:>*8XIK(&R0(\WQX1#$5J'Z1XY4)5`ZR`-+RLXS!8>B\0NDQK M-JB!UTX3T5E?DPPUI%-X`-;1P9CMZ:18TLGX2]P-?G&-$H=A]R"E288:VBEZ M*!`<>Q0I7KGA51#B,.K\(AUJ(/]=H$RV,46/#1YTS2;+,_S?\KPD4QI!(5X] M/PZG!B-JQAA1$:MBF,:1#]78^>@Q@I-KQO%"D^(^6Q29A8::,394S!4;)922 MP+_--KV'38K[;'$8=WXQMZ@98QM3].(6W\,FQ1_5'6K&V,84/3;9WZX6#UEW M`2RNX[F51F;\C`5B@QJLJF`6S&?!^ZS$>8N*VZ/H,<[[C.-L4FRRS8W\M+ M]+XTX#31(L2,Z#0(B+%*)EIBPVDT"[MJ)-@`^IQ&L6VTJ`LGG?E&Q29:8L,I ME_7[XRFMS+2;2R)!D8[GK:RCP(;R1D_Y>&Z3&TTE,MK:1HN0DD+3N6H9.(6T MP@83-)\(IK0R@VE4WD9N\$"DDS[S(V*4;Z(5-IA&A[&LS1NM)C);-$'1!1-6 MRS@V(IYHC0VHT6[LMA($.P845[>7B2.S)VH1@LJMPF!)LNX[Y$;C^7C#HZR, MK`]V/%J$E&$\#^AT,-6M>P^YJ_DH=9]ON.O1(N2C\3"(UNV'?JK]**L^9!P9 M$=IHD:Y),B())@.^V1/T;N/NPP\,^*1 MJF+-GB6L+(63\9,\#Q+8>W;?=F?5!ZI.F]T-."H>TSW[(VWV12V0N'1/7Q`#\*,#CK^!,0[SAO+Q?R.-O]S+#^!0``__\# M`%!+`P04``8`"````"$`IDFY3\4"``!!!P``&0```'AL+W=O+2F';I^YJ5O*;:DRUO M8"67JJ8&AJKP=:LXS;I-=>6'03#W:RH:[!B6ZBT<,L\%XW>2[6O>&$>B>$4- MZ->E:'7/5K.WT-54/>[;*R;K%BAVHA+FI2/%J&;+AZ*1BNXJB/N91)3UW-W@ M%7TMF)):YL8#.M\)?1WSPE_XP+1>90(BL+8CQ?,4WY+E=H[]]:KSYY?@!SWZ M1KJ4AT]*9%]$P\%L2)--P$[*1PM]R.P4;/9?[;[O$O!-H8SG=%^9[_+PF8NB M-)#M&`*R<2VSESNN&1@*-%X86R8F*Q``+:J%O1E@"'WN^H/(3)GBV=R+DV!& M`(YV7)M[82DQ8GMM9/W;@>!V3 M>/Y_+;Z+J[/ICAJZ7BEY0'#U0+ENJ;W(9`G,O3\NFL&Q?QD&3EF26\N28G@S MX(6&)#^MD]EBY3]!9M@1LW$8:`<,F2*V/<(F%.0-&L&WL<;SN>NE6+"58G-I MM6W_)'6)["3'1 M!@>-M=E,SN"]7';+;@+"HMB4YNTL9A2)1T9D5>E)Q(&PO=V]R:W-H965T:_X"X;]@A1$T_E;!K1AJ-9KFFA"2H(41` MMW__'6.2X&,&I],+FC@/+_9YCU<>?WQ61^F]:-JR/JUE;:'*4G'*ZVUYVJ_E MO_\*'Y:RU';9:9L=ZU.QEK^*5O[Q].LOCQ]U\]H>BJ*30.'4KN5#UYU7BM+F MAZ+*VD5]+D[PRZYNJJR#K\U>:<]-D6W[FZJCHJNJK519>9*IPJJY1Z/>['O*[.(/%2'LONJQ>5I2I? M)?M3W60O1VCWIV9F^46[_\+)5V7>U&V]ZQ8@I]"*\FUV%5?I?90?T1-N?VM/!40;?")./!2UZ\$3;:D M"&Y6N+O#WH$_&FE;[+*W8_=G_1$7Y?[0@=T6M(@T;+7]\HLVAXB"S$*WB%)> M'Z$"<)6JDJ0&1"3[[/]_E-ONL)8->V$YJJ$!+KT4;1>61%*6\K>VJZM_*:0- M4E1$'T0,J/WPN_YM$7,0@?\7$>?;(E#GOCGV5<2`RMW9#&>X&?K&I0;+A6:J M]C="X0X:&G&2QD*'C_,U4*@IO<=^UF5/CTW](4''@;"WYXQT0VU%%"_N4B^N M?O^7W>`S47DF,FL9F@5.MI"C[T^.83PJ[Y!7^8)327@&J:0\,591P)2K,Y!5C#/3_>UB`*&) M`9?0>9>"6^ATMLT;GK!-%O%Y!(D$E(!F71U"1#A!H,=$$PA;D7B"0"+)!,** MI!/$382)/0PSWX@]H9G8XX(-+O!Q04`+QG%TC%OE^MX0WL%$/&/;+AN'^`XF MX1G'L%B==)YA`@I#+A-0,LP8,-S,)S6Y:RW#]9II29LT)(^$(BX`F< MX"%%W'X>,EQ5-9=L2D1C0#/MI852.QX#NJYI#NI#"0-8MFNA8*04@.LU+T?5 M9(R`E<0WC"`TZA,&FF4\RHR?C7K-1DCX0B(0$J&0B(1$+"02(9'.$8P5L#YC MK+AOF")WL7W#--`LZ%%FSA(AX0N)@"=&24/,G.F"`E?2`1"(N0);%O$(ZA+ MQSR!11(>02(I3XQ$&%=@&\*X,C]]$)IUPS%0/GB4F7-#2/A"(N")40MI%[D@ M9!NS-!>N:JNW/S3.1Q2F:6YIKFVH;)K'8^#!@9$!Q3QA`$/5K5L_Z.N3LH#K MV+?QGK&$[-\83^X;OOK;6'-,SIP!FG-'C/AB)!`CX8#0F#_`DM"U4$PCL4H\ M@>!,2"88]*1T`AG)L/Z0W=_W1S*-;AK':R_30#GB#="L/U1G!O'%*H$8"2>0 M44CZG(XF&!39>`+!,LD$@V32`1FRQ7!L2[U-SJP_9(/X/_RA^TK&'Q/5PM,H M-!/\C1CQQ4@P@>"HA1,,JF\T@6"9>()!,LF`#,'7#%,WT22$6`F\H=M4ML_@!0&< M:A,#Z3[NP5RZAH/JN6$1VU2M)1H9?18Q;,O440H&`S)VF/=F;F,]C&E,?2<7 M`Q-/XKK,6&5J.3"K0%+_15W#8Q?.^OH(S+RA7K@^`=P3G;%_\GC7[\M1*QV(' M55,7#KC0T+<,]$M7G_MCZI>Z@[<#_<<#O`TJX'Q870"\J^ON\H4\X/I^Z>DG M````__\#`%!+`P04``8`"````"$`:5+%%24%``"+%P``&0```'AL+W=O)YUV\V,DGZ=)22MZJF<@9_&)CF->62L+E':; M8PH1,-N-DIRVYA-:1PB;UF[3&/0K);=J\-VH+O06E>GQ1UH0>63B/(K,?ZR"1\#N"I9E=.KA#-NR8[J1H,&"!$;T;X./0C>D* MZX)F,`NZ4_6Z@8\(,<+B_/=CQA$)GQ,PP]XGB0C&!$:2D^&8D52B"6+>3T5P M!:KV?E<8++@B#^SE`9\/#"->+E?]5'B:[V#".YA(S0AAS[\2-H.%L.6!O3S@ M\P&^S#2EW`U\9!XCR8?P#B92,T*,L!`-4\MN?Q<6:'7ALY.V)EREKU#LV&*^ M/,[`L6<^BJO)Z%Y+^%HBT!*AEHA4A.`5K+M#K]0>,1B\',2/;2F7'F?@^I]Z MI"5\3N!FS7VTFX^8B4"K$6J)2$4('L$CY'Z/&"QYA.0ZXHS*(RWA.0X MB[GT9`JT"J&6B%2$X!#K2@2>T1 M!0_2PR,03D`SY*R$S^B$4#N'2$4(#JY$!]F:M=2N6>PDR4E'ZBT\SJB):2&64'O$G$(P68G$'$]`227Z& M$Y!D:*1$1+]8;SBX0>][)"+>40KKO2--PFLAI6]<1X'XK0I?\N%5E'UDU[0J MH7XND1(1/6.]Y,`S]:*&>.B4EWFNAH1'8D1;N_00D>>[KD4"/A'HD4B*B M6ZP'O=\M1HMWI#LRBS-#LR0?]H@C;=4@AQ6.6#5^BRA4`CT2"A>:+UWY#2@2 M`->9#VX3T2;6Q@YL8CZ!'0CT2*1'1-0AJZ)K&+4:+Q84=N4UE>RT`*=WB"&^Q7(PFBDLK$NBO$^J1 M2(F(5K&N5BHP_;!YJ"TR+^'J5H$7X(KAP;+R4,Q?J5=A>Y^?3 MY5[QO4R^T9:3\DSV),LJ(Z$O;)]R#FUV/]KOH3[-V4Z2-+Y':]CR&H][SMJ; MY)TU;#0`;_5"L!5ZC<_DS[@\IT5E9.0$4[!G;"DM^68J_U'3:[,=>*`U;((V M7R^PZ4U@D\V>`7RBM.Y^L`OTV^B[_P```/__`P!02P,$%``&``@````A`*M: M>)UZ`P``MPL``!@```!X;"]W;W)K>V`"58!,]MIVG^_8TR(<9(NN4GX>'G/ MX^-S;"_O7JO2>2%<4%9'+AKYKD/JE&6TWD3NKY^/-[>N(R2N,URRFD3N&Q'N MW>KCA^6.\6=1$"(=<*A%Y!92-@O/$VE!*BQ&K"$UO,D9K["$6[[Q1,,)SMJ/ MJM(+?#_T*DQK5SLL^"4>+,]I2AY8NJU(+;4))R66P"\*VHB]6Y5>8E=A_KQM M;E)6-6"QIB65;ZVIZU3IXFE3,X[7)8S[%4UPNO=N;X[L*YIR)E@N1V#G:=#C M,<^]N0=.JV5&800J[0XG>>3>HT6"QJZW6K8)^DW)3AC7CBC8[A.GV1=:$\@V MS)/$ZQ^D)*DD&O#F-?[D(_M MM'WC3D9RO"WE=[;[3.BFD!!I"FE0V5AD;P]$I#`-$&L43)5KRDJP@%^GHJJ> M((WX5=/13!:1.PY'TYD_1B!WUD3(1ZHL72?="LFJ/UJ$.BMM$G0F\+_3[X/K M3<:="?QW)@B-T,0/_P_BZ4&U^7K`$J^6G.TU0D1PKSI"%UY`I\9!L/HP;:X5)AJQ&2(XE9]!FUZ`I\1`-6?T5:\F` MS6Z%8\D9-K5O7KPX*+'%9G>!E@S8#I';TT[;_?9YPFQ>E8/WR M^/U\8'G[W#;HB0K)>)=AW_$PHEW!2]9M,_SKY\/-'".I2%>2AG/LJ94(7#H9(9KI?J%Z\JBIBV1#N]I!T\J+EJBH"FVKNP%)>70J6W< MP/-BMR6LP\9A(2[QX%7%"GK/BUU+.V5,!&V(`GY9LUZ^NK7%)78M$8^[_J;@ M;0\6&]8P]3*88M06BR_;C@NR:6#0^/,OF6%X))7R@$[UX">CSEU M4Q><5LN2P0AT[$C0*L-W_F*=8G>U'/+YS>A>OKE'LN;[3X*57UE'(6PHDR[` MAO-'+?U2ZK^@LWO6^V$HP'>!2EJ17:-^\/UGRK:U@FI',"`]KD7YKGM6JCK#8>Q$B1?Z($<;*M4#TY88%3NI>/O' MB/R#E3$)#B9P/9CXP=4FX<$$KB>38![Y4?Q_%-<,:TCIGBBR6@J^1S#S`%SV M1,]C?P'..IX00GX_'LA%][G3G8:NH)90TJ=5Y/E+]PGJ4!PT^;DF&"O6[RAF M1XD+?$=(R.TMY#2<%F=XAM$1;A:'1]]A`+G10`%/FK%B/:48L4%HE[-I,03\ MYKU!8`=G-.D0:Q@%832WT"8$(S*(X'(R+;;)[-2,)AG(8/K'X:E<0ZSK"<&( M#(*_G$R+;3+KQ;G1&+(PC8+(BNS?ST=<\35<6FQS6>_-C>;`%0?>++;`)@0C MLN0:,BT>DT6>M?ARHS%D\R2%8EID$X(1F3XGK]Y`=*1&8PAOYHD? M)M9*65L*+_).2V7$F(X9I_&PO=V]R:W-H965TKJW2UED51^AV]]N?Q(`U#Y0_[ M??MUV+=^QN=TEQSOVTJGUV[%QTVRW1V?[]O__&W_I;=;:;8^;M?[Y!C?MW_' M:?O;PY]_W+TEYQ_I2QQG+1;AF-ZW7[+L-.YVT\U+?%BGG>04']F1I^1\6&?L MS_-S-SV=X_7V4NFP[ZJ]WK![6.^.;1%A?&X2(WEZVFUB,]F\'N)C)H*_MHDAQ,+\;C;[[+?EZ#MUF$S=I^/R7G]N&?7 M_4L9K#=%[,L?I?"'W>:[ABSN\V>$W\"CTGR@U-WRXM8 MY6ZIMGUY`N&YM8V?UJ_[+$K>G'CW_)*QQZVQ*^(7-M[^-N-TP^XH"]-1-1YI MD^Q9`]B_K<..IP:[(^M?EY]ONVWVTP5`?-;\K1AY%N0G3^-YVQ7.Z/'9SG:T?[L[)6XM]EMB3 M2$]K_LE4QCQR\<#%X[FFP$<9P!X]C_*=A[EOL_KLX:8L;7\^#$;:7?5SRL*0K8O]>PP[YF!3-:X-`"MRAX/PUIV;PL!J.A MW))%V9`H7EF4HOAE0Z($0LCWFK1E69CBKH1%P8>7N"I$426Z*>BR;+FF#/MX M2BE3W3<4F<$USXPB[$04L.#79ZK*-W):5'D7PX%,S#(A0:P*08+8L"6S"D&" M.&4R&!ER:]VR(:V=5PARHD4%D4_C50@2Q*\@D MA&3CA)20O`_KLZ&O/C%Y+2DQ1<%M8@Y&([G54UK)I`46+;"KPNIRV%D#XS0P M;H71>_*YY@W,HH'Q&AB_@0D:F&4#$U89TBVN&IBHWDB)Q^867T@\7DM*/%$@ MYD!\V)M28=("BQ;8-,:,%CBTP"T*WKO9@4[&FGD#LZ@R9)3V&AB_RI"N)VA@ MEE6&S$7"*D.N?55ER'5%5>:]S5*RL)G>%Y*%UY*2113<)`L5)BVP:(%-8\QH M@4,+W*+@-EGH(-;`+*H,N?%>`^,W,$$#LVQ@PBI#KGU59(*90F%!84-A0S*!PH'"AF$.Q@,*#PHSH(DP=:D)A0F%!84-Q0P*!PI7 M"&4PNKPN]SH:Z2[F%)1>."E0R73'*P'YD^Z7CI-A,B@!.<"2'N^3%H0"U#S2 M%0VAD`XK*H%K&Z1T9._#7^@Q>2V:EN3M;2),S35,H3"AL*"PH9A!X4#A%H*O MX9!!;GY[C,R$%L6Q#\<5#PH?B@"*)10A%"LHHCHAI25;M9/2LKZ7Y%I.QR'Y M1$T$,2Z=1E]5M1%Y2--;,%`,Z@B&B.B$EI<(61Z2L;+9B1+5$SE>^%$V_ MI<`K?(I8P98FG71PSXV8A"G*2.OUM0$9VZ8YJLEILTD#^5D*)K`U7I&23GS!S5)+B%B8W)#!,'$Q>3.28+3#Q,?$P"3):8 MA)BL,(EJB9RY?"'\"YG+J]%)`IF$3A2!:O)MBHF)B86)G9/\4]0?:CU=(Y/N MF634OJ&H!ATD',F,=*W?IR_L+F[-'),%)AXF/B8!)DM,0DQ6F$2U1,Y;OB9_ MF[?UKUR*6,*7>UK2/TYR5)NO(DX-,7$4"Q,[)_F,95B=K[`Q#CZ3B\D6,9])5\YI]_K^C=-EV\R$[]AB2!,;<:[K99># MT^O!#V?F)B86)C8F,TP<3%Q,YI@L,/$P\3$),%EB$F*RPB2J)7*>\B\&/M&M MBN\1Y&Z5+"]/E.++!OX&26:WT^O!FCPMZG](+!S%QF2&B8.)B\DM3?+*MU;SF=VU]+KM^_MENS4IGRAC MMFF6;:TDY8$R9EM`R^4AWSY>43Y5Q].J^*8Z9MM)RG$L=3BCRPY778=/R89V_]]^?6%[?>/V;XG M]AUHN_64)%GQ!S_!]7\0//P/``#__P,`4$L#!!0`!@`(````(0#]*;.BO`0` M``X5```9````>&PO=V]R:W-H965TPZ2F+4M@++;=I_/Y)R7$N6:ONE:1CJ4$258T$J5F1-K!_<;U\RWAY`8CGO,B;#P)UG3+;_#A5O$Z?"^#]'L1I=L.F+P/X,L]J+OBQ M60"<)S2OM/G-3\TYYT;Q8MPO0R6 M*_!WGIEHGG+$=)WL532\_$]Z!2V61`E;%/B\H:P6RSL_"L9!/+DC(OB8-NE^ M6_.K`U4#(<4EQ1H,-@!L9@14T/<>G7OS('W@ M;^<3=!X>!.TB0[3ID=$9(^/9XE8>I*$?)C2'B>:$0>>=&_J6%EDX30H-+/S36:P15_W5V<1%MH3ODUJ*> MQUVW*87M2@WY=2AT5D-)"S6/`GLW!Q:=55AIB8%[[UC79@:HUI-;`9W54-(R M9)"HL*0=X6@R<)6*WUK49"1F*@'@3^="WFJPUC1D$V!_3SXE\M:0I4"H*4E\ M"X]9(A&THD`W@6S6UF3@,4L7L"^U=+0FC8=%ZP+LW.FG)OL<(G2=2``[U\## MT.K!"HQ?-R#>7CHA4[6ME8&OX0.MXTB[[9=M=3)R2(JG1, M$EDJ;5;W!\/V;TV&#!D$X&X\04,!"$P*D%@N'U28Z15'WFJ"6M.03Z@I`"4H M&14T6J:%D%*@)>CSOE4N@G"6%)"W%DVJ@X&0)@6DT-%HAL*A)MQ,:L5]WN(J MH5F:$`XUH349"&$G]]0&"8U7'`Z1FB3<3"H?RP`0SI($\M829).$T"`)L9\L MQE,T%`7"@K@J)2M!;-)`3PH M*0=$8X$_JM&T3`MAE`)]SI&O3_)QIF3UB?W"BD(X&7_%EZ40GELZ:_?J=1]B M.>GV>',O7\.\[A=XC;JD)_9'6I_R2C@%.P*FO\#&J>5[EOS2\`OL'9ZD>`// M4/3O&=X=&3RY^'C?'CEO;E^PD+N7S/W_````__\#`%!+`P04``8`"````"$` M6F*?_;@,``"610``&0```'AL+W=OKY;/>V?-S?]GYMC_\_;O__M^OO^\.7XN-F<>I3A^7C3?SR= M7A:#P7']N-FMCA?[E\TSC=SO#[O5B?X\/`R.+X?-ZJZ=M'L:%,/A;+!;;9_[ M-L/B\#LY]O?WV_6FVJ^_[C;/)YODL'E:G6C_CX_;EZ//MEO_3KK=ZO#EZ\L? MZ_WNA5)\WCYM3S_;I/W>;KU0#\_[P^KS$]7]8S19K7WN]@](O]NN#_OC_OYT M0>D&=D>QYOE@/J!,M]=W6ZK`R-X[;.YO^I]&"SV=]@>WUZU`_]UNOA^C?_>. MC_OOS6%[]X_M\X;4IN-DCL#G_?Z+"55W!M'D`L3-Y%>W<39J_&4K:V97L_;$*5M M)]*KFSB]&$V&K5*O[-^EFT:OYVV/3M)V>_3Z6X7-73R]GK>A$?6=;0/3@/8( MOU;:P'91VY35ZK2ZO3[LO_?H3*VVF(ZN!]_H1%B[F"7&)!&ECS"=:M)6*:A3(%+0I$"F0*5` M1V!`LG3:T,GQ$=J8-$8;7]72@T@L+E7I(_R4*@5U"D0*FA3(%*@4Z`@P(>@$ M_P@A3)J;/IWT49,4O/*EC1G3(>F")CRD[$(Z=8#40`20!H@$HH#HF#"1J*Z/ M$,FDH9.1-M,)4$S'7(*E#7I5I2ZD4PE(#40`:8!((`J(C@E3B9;PCU#)I&E5 M\M4M+1G32Z1;VCI=D)]6`:F!""`-$`E$`=$Q8:+0Y8F)DO<"?JTUT;QV2ZAV M7U8)I`)2`Q%`&B`2B`*B8\(*I0LJ*_2=5QN3ABM@27+TI_RL*;L@+U,%I`8B M@#1`)!`%1,>$B6*NR6T&/BR2B`5D!J(`-(`D4`4$!T35BBY M'%;H.X^^2<,5L"3N?T>")I4C=(D+Z\-HSCND[H*\E,*122=N`ZEE-RM*70QY M:M4%^=0Z3LUT,CXL(]2%<=6GQ^WZRW)/-=`E,M,I8S)?SI*9+%RG-O%-/Q;* MHT@ICTPJ\G'#4;**UB'`UR(\BG3R*&26'G69D^N:"@$^L_:HSI?3Z63M'UUQ_3:7(X>HDT.S3&?\B)8^:MY-K#QB$XO$X]0N MJABV`L^OAO0?SRU\2!"O\;G#YJ1'KVY.^5R_WISV(>WFN,C&$Z8BCZFU,KT7 MBVJM)!/5HH*=@=-+7G@Y%9W.M4>35L&I$1`4=(G"1;'QLT)NZ5'( MK3SZ=6[M0]K<7"YC#V.YWI#)NDDFDT/LF$ZO4IE<5&B&REA&<[Z'-QJU0Z[1 MQE>3^672B\*'Q(T&N27F5GZB[:I<;NU#,EUE_.$9,ED[2?G"*6I1TDW)>EZ. M7%286'D4CGCMD3WBHZMQIIMG<)'Q$T%>:3?6FA8 MY5'8`M*F2H6\2::P5T)%Q4W4300;YUD'2E'+BHD]=E,+.)N MZB:&;NJB(@@0[6,H=`:&S$7%/9B;B(;,1KFV',UGL_DD22YH46R/6]R6 ML#WIHHQ,84?3[2F?RUX[1_/Q\&J2K#K:QV"GTFYR65]?]]IPWJD.Q6\9$56( M:D0"48-((E*(-$.LE6@UX#6_\[UCFR<1PYI]?N]@EOI2-S%ZZU0AJA$)1`TB MB4@AT@QQ?8S;C4^U-WK"FN/X%#/+%JU+48$EH@I1C4@@:A!)1`J19HC7;'QJ M7+/IB0FM3&=^=D%+<;J4.Y3T1+*PEB'*K]L5HAJ10-0@DH@4(LT0U\<8U%B? M-WK"^EG6$Q:Q=0)050"J$0E$#2*)2"'2#/&:CXRUB?-WK"FE'6$Q:QG@!4%8!J1`)1@T@B M4H@T0[QFXQ[CFDU/S.DB>NXZX5QH\%'+PB+>$[/T76B("NM$-]&C&J,$H@:1 M1*00:8:X/L;YQ?J\T1/6*+*>L(CU!*"J`%0C$H@:1!*10J09XC4;ZQ;7_-YK MA[.`<4]8Q'OB,GF+7!9=E&^`"E&-2"!J$$E$"I%FB.EC;C(P?5[OB3:<+Y<. MQ3V!J$)4(Q*(&D02D4*D&>(UYSRF"3]SG:"2TVN'0TE/)):_#%%=3R"J$0E$ M#2*)2"'2#'%]SO.88_28#M$F?($EH@I1C4@@:A!)1`J19HC7_$$>TZ&D M)]+[*B'*2U8AJA$)1`TBB4@AT@QQ?8SWB]?1-]8):Q7C:\<8W&.)J$)4(Q*( M&D02D4*D&>(U?Y#'-$<^\9@.)3V1WD(*4:$GP';6&"40-8@D(H5(,\3U,=[O MC)ZP5I'U!+C'<@RH0E0C$H@:1!*10J09XC7G/.9[KAWH,<>=58QN*5TFMP++ M$!5ZHIOH48U1`E")2B#1#7!_C_<[H"6L564^`>RS'@"I$-2*!J$$D$2E$ MFB%><\YCFH\SSO43Z#''G7N,>R*Y65N&*-\`%:(:D4#4()*(%"+-$--GTZ%H42@158AJ1`)1@T@B4H@T0[SFG,=\AY^8H,=T*.F)]#YF MB`H]@1X3HP2B!I%$I!!IAK@^YWG,"7I,AUA/H,?$J!J10-0@DH@4(LT0KSGG M,=_QOF."'M,AWA-7Z7W,$!5ZHC.G'M48)1`UB"0BA4@SQ/29GNP)1A:A&)!`UB"0BA4@SQ&O.>4RSE)[YOF.*'M.AI"?2^Y@ARC=`A:A&)!`U MB"0BA4@SQ/4YSV-.T6,ZQ'H"/29&U8@$H@:11*00:89XS3F/^8YU8HH>TZ&D M)]+[F"$J]`1Z3(P2B!I$$I%"I!GB^ISG,:?H,1UB/6&C(E1A5(U((&H0240* MD6:(UYSSF.')W=]^]I.>EDX]ID-)3Z3W,4-4Z`F;BR9Z5&.40-0@DH@4(O.L MM]E[NT6KCWUVVSXFN]L<'C;EYNGIV%OOOYKGLFG"[76'[4/CR^F8GAIO/P2$ MD0F-M`\OP,C4/VF>CDPN%\;GD`0PY>9&2!UZ?Y<;(77H75!NA-2ABU9N M9$8CL]S(F.;8`YGN]9CFT-W;3+8Q:4WW+7,CI#7=WY/ M9J2@.?1Y:V9D3'-H*5\468'JOF" MGJC#+5>DDGF(#$?$?&$>)<.!9KYH[,"@.Q7H5S%>5@^;?ZX.#]OG8^]I&PO M=V]R:W-H965T:R-45^`D MBC'B'5.EZ.H"__ZUN;G%R%C:E;15'2_P"S?X?OGYT^*@]+-I.+<(&#I3X,;: M/B?$L(9+:B+5\PZ^5$I+:F&I:V)ZS6DY;)(M2>-X1B05'?8,N;Z&0U658'RM MV$[RSGH2S5MJ(7_3B-Z57@59(_S#%9 M+H;Z_!'\8"[>D6G4X:L6Y7?1<2@VM,DU8*O4LX,^EBX$F\F;W9NA`3\T*GE% M=ZW]J0[?N*@;"]V>@B'G*R]?UMPP*"C01.G4,3'50@+P1%*XR8""T&.!4Q`6 MI6T*/)E%TWD\20".MMS8C7"4&+&=L4K^]:!D2,IS#:FMJ:7+A58'!.T&M.FI M&YXD!^+W/@6?`)`%!0#0H@]KU MR@[LE%U57"H//G`ID[XO,QG+N*)/H'4?&W6;"IQ=F$BS>>#W&7@,5#X8S0)B M9!1HKC?JP-`+(`^T:78;B+VT!UTA#9!+Z>O,NTU#"J'8I\BX'GL@<#K:R<)B'UP;N;@[3'T<`KI2RYP4(D_`W6/X#``#__P,`4$L#!!0` M!@`(````(0#(8QY/;P<``&\?```9````>&PO=V]R:W-H965T>('%%WG[^=3Y.O1=V4U65CF-.Y,2DNNVI?7IXV MQC]?HD]K8]*T^66?GZI+L3&^%XWQ^?[WW^Y>J_JY.19%.P&%2[,QCFU[]6:S M9G7@RNX-5OT:@. MAW)7!-7NY5Q<6BY2%Z>\A?MOCN6U0;7S[BURY[Q^?KE^VE7G*T@\EJ>R_=Z) M&I/SSDN?+E6=/YY@W-],)]^A=O<'D3^7N[IJJD,[!;D9OU$Z9G?FSD#I_FY? MP@B8[9.Z.&R,!]/++,N8W=]U!OU;%J^-]/])X[K<_U%>"G`;YHG-P&-5 M/;/0=,\0-)Z1UE$W`W_5DWUQR%].[=_5:U*43\<6IGL!(V(#\_;?@Z+9@:,@ M,[463&E7G>`&X-_)N62I`8[DW[K?UW+?'C>&M9PN5G/;A/#)8]&T4IV0[C:#7[5-[3>V"4\/EU+^'U?EZYH:+*9%H;?[G/&9ZQ+@"!O\_N[ MNGJ=P%,%<])<<_:,FAZ3PZGG3O7)\*-<@"1@*@],9F/`0&":&TC@K_>6;=W- MOD+2[43,EL:8:H2/$2S#F&R@@U`'D0YB'20Z2'6026`&MO3>0"9^A#=,AGF# MH]HBD,S2C,`(;!+H(-1!I(-8!XD.4AUD$E",@*?I(XQ@,AL#'C`I26QUY%L> M8\.4]$&.&N+W(;T[A(2$1(3$A"2$I(1D,E%,@G%]A$E,!AY&Z*8WP+(U"[8\ MZ*9+?4CO$B$A(1$A,2$)(2DAF4P4EV"U_`B7F$SG$HYNRXD-/Y)O"RUU^B!L M%A`2$A(1$A.2$)(2DLE$,66IF3*^[^):RZ+5L7,"Z8##\@D)"`D)B0B)"4D( M20G)9*(,%/;(CYA])J,ZP(DV^TMM]OL@M"D@)"0D(B0F)"$D)223B6(*JZ+E M+?CV[+-H=>RETSX(I3-96O&)U6$C1DU9 M(=H>R]WSMH(QP!8YDBDV%%^B)&,JJD^=\,:0C:(H0,2DH(Z;F]KN$PX!.)8( MD>03HF%52A#URMKNGPX!J)PAZI15FUC=)C\X/)\&F[Y4UQ_9!"\#O4^\_(,= M%_O20UTH1-30,AH:H%2(24VZMS#6Q20C)Z42T$Q22TTE$H?9\Z6J+0H:M1K*) MU8VR36R=L^?#.O>V[8!7GXI[`JE)IMV8SPZ"]"3CR%[V,Q&**'O%GT9KM9AK MY5BIO$.S967MXJ M3G+$S^BZY$A28!(44113%%"44 MI11E"E*]@(DE7@RGAV\_3&,Z6N7&D?J"XVC;G6_V4;BJ!12%%$44Q10E%*44 M90I2_6$5KYPK/\D)7B`K.2%JYF&?\F'S8V9)-6U`44A11%%,44)12E&F(&7, ML.NJ8^:+-QY%OSDG.ATU)P32QK36'3V/=URURA7TTZQ8*7!\,\+7'IQVC'`3&L`^,78%FL`*.7;%A2M=):_UGK@>G![0%O`Z[;$W M9GHE8U)C%^!#XD-7EFI=;,&K<:O`J9$.MK8'!^&TXP<']$<;.!Z<"=,&VX4' MQZ(CW/6VHR/P7<\?O1"X'AS?4"4XSO#8B06]$KD>.[>@%V+7B_F%6>\3?.Z\ MYD_%GWG]5%Z:R:DX0$;R&KSF'TQ%02[.'!ZK%CYT=LJ M:O$/Z'G6?RJ__Q\``/__`P!02P,$%``&``@````A`'XLU2Y%!P``*A\``!@` M``!X;"]W;W)KC-,'XY?QZ^/S3'\JHNRM/*L,838Y2?LG);G)Y7QC_?@B]WQJANTM,V/92G?&7\R&OCZ\/O MO]V_E]5+O<_S9@0*IWIE[)OF[)IFG>WS8UJ/RW-^@CN[LCJF#?Q9/9OUN##MR61A'M/B9'`%M[I&H]SMBBSWRNSUF)\:+E+EA[2!WU_OBW.-:L?L M&KEC6KV\GK]DY?$,$D_%H6A^M*+&Z)BY\?.IK-*G`XS[NS5+,]1N_R#RQR*K MRKK<-6.0,_D/I6-V3,<$I8?[;0$C8+:/JGRW,AXM-[$MPWRX;PWZM\C?:^G_ MHWI?OH=5L?VC..7@-LP3FX&GLGQAH?&6(6ALDM9!.P-_5:-MODM?#\W?Y7N4 M%\_[!J9[#B-B`W.W/[R\SL!1D!G;U0^I4;*$"5U19C.?+R?06D:D0 M@2N*3,;6;+)@/^1"YS/1#JZBW4(:P86&(-N.':ZBH;TB)5Q% MR_EU72Y%0[C>-$98KNU/A>MM8W1$0[C>.$8+>ISRG83RV6RF*1\;KJT_2AK(5V9RB.361E@`>1C#4OM[<&V M9O?F&RR/3,2L:8RE1FPP@JT%)NOIP-=!H(-0!Y$.8ATD$C#!ELX;6#*?X0V3 M8=[@J-8()+,T(S`"FW@Z\'40Z"#40:2#6`>)!!0C8-E_AA%,9F7`7B`ER5P= M^9K'3&%*NB`MCS9=2.<.(3XA`2$A(1$A,2&)3!238%R?81*3@<4(W70&V-9" M(3TA`2$A(1$A,2"(3Q11X5BFF#%<(N->R:'7LG$`ZX+`VA'B$^(0$ MA(2$1(3$A"0R408*SU9EH+_XM&$RJ@.<:+-_I\U^%X0V>83XA`2$A(1$A,2$ M)#)13&'UOOP(OCS[+%H=.R?R[!/B$>(3$A`2$A(1$A.2R$09*!0ZRD!_2#G9#-Y":F8R9&MK#Q;F_F- M):+Z6?`0V9V_/J)9ZQR<8!=3K3H,,(2?J-DI(D34:T>(>NT8T12HV":3.I3:Z#:L+V:+ND\!#U!\P?($PP9RYK979`4;(^46D(RH= M8T.13%0ZP8B!7&)5H6R2OF"OV]=X;0G=].N5(RW%M#%O+!'5-_00+3HM']&2 M+\Z%/9EIU7>`(7**$>T(HWKM&-''V@F&#*08*Q\ON7?E=L>K4,4^@?H,VK#W M5'J>D2A?1(D\NULZL![5O2[`$#G1B':$W?6_(,:&/-&&M!,,&<@T5H'J7DTG M_:/ANDSC=:QB%4=:IFD)LK%$E)QI`O79X&.4NN*U(TN`46":]"S2GA M"#FRH:Z2G-*>AKYH.!5Y93E:0"`";#EC26<11EWL+%8[(0%I. MZ.5_']7E!$4^10%%(44113%%[/M5GYC<'_X]BK_D/^;5<[[)#X=ZE)6O[%N3 MS'>8?PM9V]R5,O[-PX64.C$_G2Q?>9PSP.Q>._P/<@ANPOH?N.'"GW<7U M/NP)?)]K/[%I=R+'A>,TU8+SI1O#>9'>25@G0S?@&^!C>P;0NEB#(^V>K',; M?M-`!^NI"V^&:<>/,]`?%)JY\)*4-EC/77A/.,`==STX@HWC;@9O>(X+[S.H M$ISO77:$IW<"QV4'>7HC=-R0WS`[/^!+Y3E]SO],J^?B5(\.^0ZRBU=8%?_6 M*Q_?P33J'@]F$50F[LFSP#^C9[+YR/_P/``#__P,`4$L# M!!0`!@`(````(0"J404/OP(``+`'```8````>&PO=V]R:W-H965T&ULE%5;;YLP&'V?M/]@^;T8R*4)"JG25=TF;=(T[?+L&`-6,4:VT[3_ M?I\QL<+2;O2%R\?Q.?XN/FQNGF2#'KDV0K4Y3J(8(]XR58BVRO'/'_=7*XR, MI6U!&]7R'#]S@V^V[]]MCDH_F)ISBX"A-3FNK>TR0@RKN:0F4AUOX4NIM*06 M7G5%3*[)+M-8DRVF[Y`OP0_FK-G9&IU_*A% M\46T'*H-?7(=V"OUX*"?"Q>"Q>1B]7W?@6\:%;RDA\9^5\=/7%2UA78O(".7 M6%8\WW'#H*)`$Z4+Q\14`QN`*Y+"C094A#[U]Z,H;)WC61*EJT6R6`(>[;FQ M]\)Q8L0.QBKYVZ.2@PRT+20X#XA1@D`S M/4$'AAX`>:!-DS@0>VD/FB`-D.G2#MQ+A^(.D5$=DE?:N'R+E`./I8;(O#]_ MY^-Q/>9U1V[V^ID[3:A;-188(N-<7ID5Y]>3#X,#CZ6&R&4NZS%O;Q\K<*%_ MGS:W:BPP1,:YS,*0C*8/_/`-R?3HL=@0ZOW,,WM_]/8AN:[X!]XT!C%U<-Z7 M@B&$:/#E7>HZ^W=\GNV\7Y/P!?RRHQ7_2G4E6H,:7@)G'%W#+&KON/[%J@[V M"::I+!AE_UC#GY&#*<01@$NE[.D%E$GXUV[_````__\#`%!+`P04``8`"``` M`"$`#U!DJ[\&```[(P``&````'AL+W=OLJZR\N(*A&VS!*,^',J\^%SG;U5Q MZ01(4YRS#IZ_/977=D"K\B5P5=:\OET_Y'5U!8B7\EQV/PC4=:I\^_5XJ9OL MY0QY?_>C+!^PZ0\%OBKSIF[K0[<"N+5X4#7GS7JS!J2GQWT)&6#9G:8X[-QG M?_OIP7/73X]4H'_+XKV=_.ZTI_K]UZ;<_UY>"J@V[!/NP$M=OZ+KUSV:8/%: M6?V%=N#/QMD7A^SMW/U5O_]6E,=3!]L=0T:8V';_XW/1YE!1@%D%,2+E]1D> M`'XZ58FM`17)ON_<``*7^^ZT<\-D%:=>Z(.[\U*TW9<2(5TG?VN[NOI/./GT M4`*+'NUSUF5/CTW][L!^@W=[S;![_"T`ZY\%'@)]G]%YYT(_0I@6"OCMR4^] MQ_4W2#KO?3X)'_AY\QD]UA!TC`S1ED=&9XR,5<%'^20,TS"!/DPHA\&BA[!U M]Q/%13LWFB:1^B.^>`+A`Y4?$XU&#RE1@%F>*#K#7@#X".NGM]1$:.&T(#2X M+`^-SA1Z++*P4"]*&24R[+*:XB(9OK=,-]%/0WT14SGD_>U#9SF4L*B9H+8N M;G]TEF&%187=V,"BLPPK+"JL#XT[?5PL?`J;=+\:M$H.T)M@Z:3+#.WK(Z,7 MUXB\63`$V+F:=*PDP.\I']Y$H#=ID!GK9PHDJ`RD&SL?":A_9BLV^R.=;\B] M";*9U#[6=SV.!XO:"[Y*>0B3ID*,PS,54LGK"Y,&V8JJOLK5WJ1!9FRE`0H3 M>Z[_5=[Z`W&G>Y`8]L"*S+[*YMZDYA,P.M_?`_*6F=6;-,A6G`T$0:=]TYLT MR(RSN`=!#%TV\_`J>0-A@J43'J3Z/0BL^$S>K%(F/@=6?"9OABSXK*D44F^Q M;N(1CDV!WJ1!MN)NH')W,,D:]&"HO16?`Y7/O4F3!^/S3`NI-`X&&H.Z2@>4 MP(JSY,UVU32"\>PXW54Z^R2S&D3+Y!"]2>[_C7X/0BL^DS<+9IK!(>/S_3T@ M;X8\T)CO06C%6?)FR";.AE:<)6^&K)O!#[>;C-1+H16/R9M%$]16^S]D/*9> M6G`Y40E-2'C$FFCIP^W"(N=CQ>=0Y7-OTN3#^$SY>//<4(D=#L2>YG.[!X8`1 M,VFXWWKDS:(-BL"/`3&C/XD.7EQF0@C23^\DA,2Z>V,8VK&5-)`WRT=(@]K= M>->9R@#F,_\9#*UB$08YF&S/QC"S8Z80,[53E8$`(+[4#!O#1(VMI(&\66HF M:8@UTK"9[P55&@B(]X)AH,96RD#>+!V3,N"YG_?"_%V`5LD1>I,D#!O#/$V8 M,&`#+@C:J\'D,RX"XC4T#+_$2A_(FV5HTH=$HP_S+4&K6(3AF##EDV'X)5;R M0-XLF.[DL#&,IH1)QGWVDC>+-D@%%]>$Z0+V0KB@>JI`$!)O!L-H2JST@;Q9 M/D(?F!H91E/"-&.F>JI6$`"FIE2/"0-5;P&5A!Q,1U,R*,2M]^#+5?U=/M6( MAK^!';Z?&"V3R]B;IJH1>(8)DC+5F`FFJ@4!Z*J8,FF@*LYJ.JUBZ0B)D+HB M\`PS*F6R,9./>IH@`&T^3!LP'Q]).1.B5X2)P*;").^/84CA$6(Z2F:"H3>K M7F^"(L(#BV]G`\\P0U*=;LP?:6D9"RND1,[1,$12*]T@;Q;,=*Y(K32"O!ER M+QMR]0S3(V6Z,;-7JEP0@*[W\#(^[0+J/?Q(Z7X(6B8GU)OD?>'S2;RJ(-X' MJ(KF6/Q2G,^MD]=O^!I"`-_PC];Q%8GG`'64VZ/M,T1$@1W_`Z\N7+-C\4?6 M',M+ZYR+`V!Z*VST1KS\(/[HZBL\.KS`4'?PT@+]>H*75`KXEM];@?.AKKOA M#PPPOO;R]#\```#__P,`4$L#!!0`!@`(````(0#-1*?:[@H``-&PO=V]R:W-H965T&ULG%M=;Z-*$GU?:?^#Y??$=#<-)DIR M-=":W2OME5:K_7CV."2Q)C:1[9G,_?=;396AJ[`;G#QD)N90U*FOTS3F_K=? MV[?9SWI_V#2[A[FZ3>:S>K=NGC:[EX?Y?_[]]68YGQV.J]W3ZJW9U0_S/^O# M_+?'O_[E_J/9?S^\UO5Q!A9VAX?YZ_'X?K=8'-:O]79UN&W>ZQT<>6[VV]41 M_MR_+`[O^WKUU)ZT?5OH),D6V]5F-T<+=_LI-IKGY\VZ=LWZQ[;>'='(OGY; M'<'_P^OF_7"RMEU/,;==[;__>+]9-]MW,/%M\[8Y_MD:G<^VZ[O?7W;-?O7M M#7C_4NEJ?;+=_C$PO]VL]\VA>3[>@KD%.CKD7"R*!5AZO'_:``,?]MF^?GZ8 M?U%W+LOFB\?[-D#_W=0?A^#_L\-K\_&W_>;I'YM=#=&&//D,?&N:[Q[Z^Y/_ M"$Y>#,[^VF;@G_O94_V\^O%V_%?S\?=Z\_)ZA'1;8.2)W3W]Z>K#&B(*9FZU M]9;6S1LX`+]GVXTO#8C(ZE?[[\?FZ?CZ,#?9K_IN+[:2$I&X-^3D7RJD06R:H/D5L?5X_V^^9A!Y8'? MA_>5KV-U!X9/T4$N7;PNA0OBY(U\\58>YM`R$(D#Y/CGHU+Z?O$3\K(F3'D& MPQ'5">&3X,TZ_`!^=V8STYVS``8=#0AP2.-\>K#W]G2=$C\(KR.'D-X(\Q6*(/35A]Q`6<=]]B<]S"%#72B4ZF/1>E`B!JJRPP@?JU&$ MBR$8"W`E9!'WWH.!9>"94L*W$C%%6SU9GJ=IP@-1\<+"&$V#8) MRZ#9VJ-5>#3/"D[1F:7L3S/6"NSZMX/U)DH+PH$0,4DBA*7/%7:Q"0)8F=BDK)P28S*:Z M+TM&0<&8G![^%LV=SZ7OA$'G;W12F,ST8QNKGF.@P%*M^QBW&,BS"J.T,;*2#B&R++4!ARY_U[H`O]](:70 M7/%>4"B/C(<6C5H2*-:IU02,(PS&PZ;**'NAGY77.T%F7(S;LWAE*2VJOB10 MG(R__,,\AG%DYT3&Y.&0X)GQ^A>0&,(0Q6J]3)7 M?8ER$G"MD,2T.>57]')0!5,$9RV!XF304`SCR`YEQ`M.7\B46LZEGRM48TR/M4T%H%((B!?892. M?3<2#P3%W*S4.,81!G,"ZYLDD%?&10MMG]8K[5ER$DN1)U"4RP2,(PQQ,4N5 MZ0O-HH7&3R1S1NN#*V!B6M-QR:@F8!QAD$QN"Q,LJWEBSNC]N$3J,WIO^C%) M7!`43\PXQM'%D`MH?9X%-S:<#%2][)CQQ8OV9XDJ,U+O"10G@X9B&$=VD$Q6 MJ$L#60NU]S4V@#(#G+) M<]O/2\Y$*'Y\.:G/*'W26Z9L(`BOK(K4REVTBLR<$(.[,<,60-/5!1GT/3P]`2U:]G,_,;"""!3M`<(@0]!H M*X:"BQMA"3!"R>,):-&2@FP"`E%X\U2$MZ+CIP3E2RV"X!C"&'B@U.VX<.>% M=(\X/Y3L@QF=/'\,BB[XV,V?@0(0!J.G[ MNSC54*C2-W`+:P:[A=Q*;D$IU:4]-K-4'N6>-8B1V5)(*B)KF=$NU;C M$!>%\'P(.9Y(Y8PL!X^E:#@A**0RV-`QXQA'&,IOD<`-Q(4&2:]2YQ8MI"T5 MP2X)%"4Q`>,(,X6$T.=I&4GQ3IO)12J'%8%",H)O-0YQ40@KKO0JM6[1,A]" M#4H"A10&1=5AO%S?#)[-=(?[%@M,<`)>7P.]F)@+5.50-U3:ST/LCA1!6!#P MA"G<=DX%J?2(L_2]97?P4B@Z`XF7&,\_L6<#%*;YN\"[?7Z56JWJ(% MB>#&G4A,4'4R%"/J"$-#"U;E_J>35IX2H>L3Z^N,OEMQ\U:F"(IY6DW`.,(@ M&PO;'1>Y?$K>4[R19EUOQ4*D)!!%5"5:KF8JAE!+[V87<>IZO!#:4`FLF8.0 M\:1\2MS3,^(N;SA+`J$3<,,LG*SH>"QICMF`96^>]MW(>-BK=+U%RQ81.E<2 MB((((1PP8`C-RP43P1#PN!16E4$K<@9"U.-+=XMBSDM)BCF!J)3@VG)Q7Q$B MF@-NQ63+3!5]T7(.5ZFY'=Y[A\^L<5`1*.9A-0'C"$.Q@%04.NMEBK/PNGNU MI%M4:YX1*>D$0B_@:9T-=I%:OA5#Y+!3H,2P7L\$598S MZ:]`>6%2[">,X%K9$*%-D1BY)<41:EDL^Q[D&8'T?X*'/TMV>3\_B`>"*".9 MEOM.E44`_.YNMX*U8&O$Q3&_K@H@,!5]`7-0*IR+$?&3RGA%QN9M0 MVE"`EVDQV+)B`)688EA3H0F=%[#CWR><^R\T?,3_,]HMO_186@2%*9`.5A,P M+HYA++*K%+Q%BYT2^5RE)%#(0E1)-0YQ40BG("1\6F]G9Z0\DU).(.Q<>(B4 MR&V(2B`&JQ7'`/!-MT0%WZOD/(2,3^1Q1L[EDJG,$$0\DAR^ML?7KA5'I-E@ MT>(8PF\'%_T$X3R\)%\M?YD_2\A&L,V'LD&@L+0(!XPB#\3`%/)B\T.29 M5U/!9?S)=WN6Y"*$NB10G`N*>0SCR`[EUL+`ZG/+\P)F)!?_>"H^N#)_EN0B MER4$BOE93<`XPB"7_/)-+;S%\QDJY^1?=J]O_1%^U=)Q.>ENJO: MEX`6W0%XK>A]]5+_L=J_;':'V5O]#":3VQQWQ_P```/__`P!02P,$%``&``@````A M`+:5&4,/!0``"Q8``!@```!X;"]W;W)KK?UC__M#S3YJT]%$6G04+=KO1#UYT6AM'FAZ+*VAD]%35\LZ-- ME77PL=D;[:DILFW?J#H:EFFZ1I65M6HO:57^3%R5-6_OIY><5B>(>"V/9??5A^I:E2]^[&O:9*]'F/ MT-]E<6Z%?VOM@9[3IMS^6M8%V(;[Q.[`*Z5O#/VQ9?\%C8V[UDE_!WYOM&VQ MR]Z/W1_T_$M1[@\=W.XYS(A-;+']BHHV!Z,0,[/Z8>3T"`.`O[6J9*4!1K+/ M_GHNM]UAI=ON;.Z9-@%<>RW:+BE9I*[E[VU'JW\X1-B@KB'6$`+7(818DT/L M(02NEQ!GYA$SL+WG1^(,(7"]A1#'="?,!GKKE,/=ID`<&L8&PHN\<%`S>9M?G. M&O5-@6ZARC_6`5D:'U"8^8"$#Q!+1C8/$%M&H@>((R/Q`V0N(\D#Q)61]`'B M71$#7%V%056+PL9%,1B$ZMI-E'^-[5V&'`EZBR_$]AS/]-#H-B(#*ZIIRAF1 M^+WM!9Z/.HE%@)BV3P)"`CDD$1F+S.]Z247@A1"?^&;@W^Z89`FF+%IZKJQ8 M(V0+#3+D"#R+5Z&H'C:<\'J?O:N[B40BTNOR/`?53*SL*%$2Z1@AV8+U:;HM MUDBV17!AA)SA,H@)M85M<4#TZ2+ED9CA>G/TH,?BUS``S[I51%_@B;J+=!21 M3,%(IYMBC;`I-(V0,Z((K$I)1)S@ML&4Z?FHEUB9D2B)=(R07,'+9KHKU@B[ M0@MWR)FAJ@+'=+`J#L!`KT_I756)&1YQT8H7BU\3W_4]M*(E]UV@0:3WA#`( M212\]Z:+8HVP*%3Z(6=$#VB0&R41<8++9J(L@C)B94:B)-(Q0G+%?BE,WB^P M1M@5FD7(&3Y/&S9Z>"W;<&!$9B1&6!Z\P^0W7"Q^;SM04PA(1.#EP1MP;`B2 MI>#_6&*-L"4TPI`S(Q(V2B+B!#?=:W+(;:_3K]FQ,B11$ND8(R*!,W?1(K89B!$+D1J)E?TDZI!T%)%-L7WJ\Z;XKE8VA?:,(>'0\/S! M]MI!/UDV`S%JBH>,(+$Z)5$CZ=AH95-LH_J\*;ZME4P1Y"$D'+K\_K.(YY@F M*KR-!#WZ`2@!CF4&%NHGE@AB.J[GN_@%F4B0Q=[!*":5"/@1"+M<>^[<]CVR M+KAU$W0Q&BWL!&V@0W:8!=!(36P&9%C-V!S@C[SB11+#?9$Y6A9C=5^)&F'' M??\]8JZ+'^?Q8YE3MB]^RYI]6;?:L=C!JFW.V(E7PP_S^(>.GOKCEU?:P2%< M_\\#'+H6<#9CS@#>4=I=/K#CPNLQ[OI?````__\#`%!+`P04``8`"````"$` MQ?MH._D"```U"```&0```'AL+W=OLI'V=HE\_'VYND2$D[DOL&0&QI2^7+"$5&5R1?ZIYQO&TA[F?'Q\7$'B_.\!TM.!.LDB;@+&WT/.;8 MBBT@K5(FN]&O/SFY*]./EOB(;M/W%:?J4]@61#F50! MMHP]*NF74BW!9NML]\-8@._<*$F%=ZW\P?:?":T;"=4.("`55U*^Y$04D%#` MF&Z@2`5KP0!\&QU5G0$)P<_C[YZ6LDF1%YI!9'L.R(TM$?*!*B0RBIV0K/NC M1*!^\-]]]T0_P"!WPD270NQ=%1CDG(L\7K%V=Z`Q@/?8L"JC9T$ MP%-V="QSOMY*%^1)0>X5)47PQ$`F!)3X:>W'T,#;UYCP41S&%`@D_#^'=Q)[=*K-Q.YV1ZX?0<=SYF=+(Y5X3^4I*? M2XZ0A5=H@NN]*G&*H#)S"OSX=GERIC70C4?-4K'YKR*_I%BX!RNG[E7#>/!0 M7LZXV@2Z4X=QO/28:4T\=D_HVK%[++6N@19<"#._I%@$`9#3("Z;5^*E><=_ MU;J9UD2C^1LWB*+P6'SM?J$(_-"+7I4Q7RBBP/$")PSG)"W\A^_QK\1+_X%M MS]S17:8U.OF.X]CJLY1LM`1,OM5E,,7506]`M'\]IO4$Z@BOR8:TK3`*ME,C MV(7\S:OSV^'>54_JJ_7,26!>P+HUWX"I/>":?,.\IKTP6E(!TC8CL,SUW-<7 MD@WCW-LR"?-Z_-O`ZYG`Q+%-$%>,R>E"'3"_\-=_`0``__\#`%!+`P04``8` M"````"$`QH'"_ZL#``#*#0``&0```'AL+W=O\F%2P$1*KI5=ROM2JO57IY-8L!J$D>V*>W?[XP= MTC@))7D!,AR?\?%X#L/J[C5+G16;+XCYT&1'/Q^(FYED!%%N6,O6F25TGBY=/^YP+LDU!]VLP(?&96S^TZ#,6 M"R[Y3HV`SC,;;6M>>`L/F-:KA($"/'9'T%WD;H+E?3AUO?5*']!?1D^R]MF1 M!W[Z*ECRG>443AOJA!780H;@%CZ:T_#B#I%1+/[$@+?""* MK%>"GQRX-9!2%@3O8+`$XFY%L`G$;A`7F'N# M@=<*$U0(#Y)6F2%;_\P(QLQX'KB5>Q.HIPF[TXR'I$%PY$YJFQ_[MQ6OR6PP M<.*5P$F%L`0"37^!"(8:`'E%._;G%;%);4`]4@.D?VH$Z]35X981^QP6U68L ME;,AJ1!LIS(1W;L6[>T06@3;M&7$4A#XW0K0I7NW`(+M5";25K"P:;5GC.%D M/VXQ7&7SEQ%;RH6>"L#:^FO1:#M9&6JK";"O:Z>DYC> M8)!+:'0CFS&*#D$-8^@KR+0_-&K5+=BT6#-;T+C[LB&J?HX?WP:-;@A"@LCM M$(1=6ZO0%>:RQ^LZRI"MXX*Y!8/Z7J,;.BYU?M!H?2S,Y/I%:WN`)FK597JA M+H-<(&C;0!GJJ$N'$803:-0K!6H[0=!I!>\_P):!AH.L0*/M`I6AMJ"PPPIZ M"-++&BDZK>#]!]<6-,@*PG)`J-WO<0W8/O?^. MVXH&>4%H&K_N/&6HHT0-+]#FUD-0VQ1PM&R;6W,6,).S&2PS*O;T"TU3Z<3\ MB%-Q"*-B%:TF]DV(=6C&)\N-&:&]ZAN8I`NRIS^(V+-<.BG=`:<_PLE9F%G< M/"A>P/6"29@K&*'UQP/\9Z(P+OHC`.\X5^<'R.Q5_\+6_P$``/__`P!02P,$ M%``&``@````A`)U"RWD4(```7[$``!D```!X;"]W;W)K&ULK)W9P:'[EKB38MB>*)%G7[ASKE6V;"O*MAR2JJK[ M[2=!()E(_#`E>JHZHFU_2"2`3*R)PW/>_L^_OWU]\]?=X]/]P_=W%]W+SL6; MN^\?'C[>?__\[F*W3?\UN7CS]'S[_>/MUX?O=^\N_G/W=/$_[__[O][^_?#X MQ].7N[OG-Z3A^].[BR_/SS^F5U=/'[[=4CX]/'Z[?:9_/GZ^ M>OKQ>'?[\9#IV]>K7J__]PFJ8/KY&Q\.G3_;W__2NW^=W=P^X%U'_X!ZK_=?WA\>'KX]'Q)ZJYL1;'-UU?75Z3I M_=N/]]0"8_8WCW>?WEW\UIWN)\.+J_=O#P;:W]_]_>3]__L\?[C_7] M]SNR-OG)>.#WAX<_C&CQT2#*?`6YTX,'EH]O/MY]NOWSZ_/ZX>_\[O[SEV=R M]Y!:9!HV_?B?^=W3![(HJ;GL':KQX>$K58#^_\VW>],UR"*W_S[\^??]Q^=$G^S>]W3\_IO=%Y\>;#GT_/#]_^UTIU3:V.6GI."_W)6D:7 MPW&G?U!R(F/?9:0_7<;>]DR3%Y5$+7ET$[ZDVLX\-IYHHHCEY/^ M=#G'E^-NY[H_)ETG\HU=/OKS=4VC(7FH(OUY5M/(8(=\]*?+USUMPR[U,NMT M\NKKZM9E#YN_G%6[+KO8_(7K-[R<#(>#T>0%$W;9VZ9'O[*B[*ZN^.MU/:3+ M#C-_<87U7]E'NNP[8_G75;3'3C!_<5E&E[W)L#L-":O[BLW5>: MM,>.-'\Y6=,K.U,<)I[Y[?/M^[>/#W^_H=F<"GWZ<6O6AN[4:.$IQ];X.`G] M;`ZB:<-H^7=!AJ/9Y8DFSK_>]WOCMU=_T63WPO+$R?>I>1Z&! M%ID=18Z>!I(`28%D0'(@!9`22`6D!M(`:8$L@"R!K("L@6R`;('L@.Q]HIQ/ M_OHGG&_4T.1/Q1P=V^]=:]?>6*&3WC^*'+T/)`&2`LF`Y$`*("60"D@-I`'2 M`ED`60)9`5D#V0#9`MD!V?M$>9\V%11)C,@)\J!M*,]PX%&6CO0 MDK$_(??['3UN9T)\BF=-<[PJ9'6/K7$'Y1`YD`2("F0#$@.I`!2`JF`U$`:("V0!9`E MD!60-9`-D"V0'9"]3Y0#Z0!SA@.-M':@(QTJ0%;3?GC,$:GCL$24($H198AR M1`6B$E&%J$;4(&H1+1`M$:T0K1%M$&T1[1#M%5*.II/]&8XVTMK1EO@C%<@< M2`(D!9(!R8$40$H@%9`:2`.D!;(`L@2R`K(&L@&R!;(#LO>)RD/FL!% M;WA)Z^VYH0NC27OWH/S=Q8A*]X9Q>+`5J>,P1I0@2A%EB')$!:(2486H1M0@ M:A$M$"T1K1"M$6T0;1'M$.T5TKW`A#O\\-7I;7#71D?HL,,>NW'('\F(YH@2 M1"FB#%&.J$!4(JH0U8@:1"VB!:(EHA6B-:(-HBVB':*]0MJO)N)QAE]M@$3Y MU:)@"/>#_;$)@-/8)RGN$'-$":(4488H1U0@*A%5B&I$#:(6T0+1$M$*T1K1 M!M$6T0[17B'M:A/@.,/5-AZB7.V'2`YQXYD)9Y!?O5$]1Y0@2A%EB')$!:(2 M486H1M0@:A$M$"T1K1"M$6T0;1'M$.T5TGXUH0O?K[]ZLV!#(%00#]$;LOSV$X4J0XXQQ1@BA%E"'*$16(2D05HAI1@ZA%M$"T1+1"M$:T0;1%M$.T M5TCW`1/]\/O`"\NS#98H5ULT$._/S/4A>=]#QGD;?`S>BB0%0RDHP5HIH1S9>RC`R"Z&WC` M=\C;+LP0S1T:CSR36ET>2E$J0UTY2A6(2D05HAI1@ZA52-O//TB_PGYXD#8/ M!=&`'=!@\)P:QL)$BITZ1Y0X-.P?X\-4@J-2L=Y3B2LT1)8Q&AY9VQX..^4]OU%(6DBDC M0Y0+DFI%/.2J94W;O1PE_PJ<6(HBKGF%J'9H/#G4_/HR7#(EG;6T2HMVBCE@ MOG[)[-GSJ+]D.A2,FO"(*E)48J[WQQ1 MXI!;7WK]ZV[O.IP)4\R7(R&_2H4M1PO2M$M4,3JP:F M+EL(I;*.5NG0#C''QS,<8D^;RB$6O;2>'*6X4O,>H(01I7A#)>BJ*4OY"PKH MRD5*=$46%)>1%Y3KR(("NBO1S:VI'3HN*+"-M5HHG;.T2HOVBCE;GN$5>Q15 M7K$H&":PH!REN%+S'J#$H9<6%,B8H:X<42'JN1(E2E6(:H=HG\49&T2MRJBM M;`YLOI5_;?6PQSYE?(M>6CV.4ES]N?G]BUY0$D9Z]0C&?,I2_GH563U`?1[/ M"*N'R_CSU0,T5Z*9FU<[I%8/F]%#K9.*K![]\!Q]>O4XB.O-KT-Z6`R#'>M, MI+CJ%:+:(5X]+ON' M3?OQ_X*EM!%Q5MHJI6I(401&#ZD7/(3G[X.&=Q=Z.1D&L^E,I+A21TV=6$UO=@Z2I%#=>[0E0[Y-:2"1Q.))VU MM$J+=HDYD/^_9[F^/=;[LYQ#(]JXRF(]#*:.F4AQ7>>($D;.4[W)H3L&!TD6 M$K=DB')$!2-9*$I&HJM"5#.21;MQR#OKM`IIVYOC*MO>'.I_\5*S;X^]ROH6 M&;][U@^/\2XC28GUCQD9)2B5(LH0Y8@*1"6B"E&-J$'4(EH@6B):(5HCVB#: M(MHAVBND^X`?'#!]X(4I$8,#?7>\EOCMC)$$S^>($D0IH@Q1CJA`5"*J$-6( M&D0MH@6B):(5HC6B#:(MHAVBO4+:K^;`CF/[S*!^WQ[[U(,D0YH@)1B:A"5"-J$+6(%@X-I-E+D?*;'1RC5R+% MS5XCVB#:(MHAVCMDZZ4[A3E[^YWBA<%NC^K*^Q9=R]7)K&^1=Y\V=^A:>;\? MF"$1*39#BBASR+NXR$7*LW(_V-L6(L7J2T05JJ]%ZH3Z1J18?8MHP>II59-Q M$%IB*5*L:X5HS4CZV\:AP-"!);8BQ>IWB/8.63_J;F."`V=T&QM+4-W&(M5M M+%+=QB+O&COI`TH190YYNG*1\@T?G!X*D6++E(@J5%^+U`GUC4BQ^A;1`M$2 MT0K1VB&OV1N1.E&OK4AQO7:(]DJ][A`FF')&A["Q%]4A+%(=PB*O-?.^1:I# M`$I1*G/(TY6+E&^9(%)1B!1;ID14H?I:I#SUPZ"_-2+%ZEM$"T1+1"M$:X>\ M9F]$ZD2]MB+%]=HAVBOUND.8.,D9'<*&552'L$AU"(N\ULS[%JD.`2A%JM4A!GXL3(Z69VX_#UITB,RA:SE:S!SR'C.9,Y)-:H(H190Q MDANDG)':S(21M$*DV&`EHHJ1J*\9R5&_0=0B6C"2-BX1K1"M&4DE-HRD$EM$ M.T1[1@==N@>88-/KIX2!C4WY4X)#_DF#D7A_CBA!E"+*$.4.C41]@:A$5*&N M&E&#J$6T0+1$M$*T1K1!M$6T0[172/O5#]B]'#`88&3.H8G:$P^#E7CFI+Q( MUMPA==/3'P7A\82E[&,Y@W[GVD3K@F`=:L\0Y:Q*U30LL!`I:O@*(SCTV-V)J,7?)\SHG.) M'.C"+I&P%(?VZ;(K.)2E+")3;H8H9T2;G)\75XB4,>7@,HAREY+.[JX82?$U M([]ID1[H;,*7",&.IF4MHGB!:,E(8MXK1C^WV9I%1/<&T9;1R7;L1,IVOZ`= M>TX_E*5[GPEXGM'[C'C0^RS2,^`H\-J,%CZ34F MJ#M#E#LT))>?ZGVN./,L\%_O>Y?!*"I%B_0^:%K-4BS**)'93CRQ$LTU9`39$.^>,OLDP[*:NY-QAW@_Z?NNIXJC-$.:,79DA7 MVK7KHSWUS.MU,/A+42I=%AI:LY3?T,B$>32'<2N:L&4U,JLM$"T9^86!55BQ]&96FFK,;PZV#S]HSG3_ M>-4/$"C>#?.L11._%?U1L&6:N8P3N4:=,SK9J1(G=@%/JL2[1FBG%7Y M,P1XMQ`I8^_K%YZ-*$5<>K&SB-2FYMKX;057-R)EBN[`$YHM"XCF!:(E([\P M:.?*23G#=J-/1JQ9E12X0;1EY!<(K=N)E&U=^&3$G@4.A>FIESI79.H]^\4= M`Z,GV"8XU*&8I[?^!OOD&>,@JW0;'"4 MDFX!*$&I%%&&*$=4("H158AJ1`VB%M$"T1+1"M$:T0;1%M$.T5XAW0=HVOE' M^H#1$TP.%@5](#AESF@?;#+Z3]@@2A"EB#)$.:("48FH0E0C:A"UB!:(EHA6 MB-:(-HBVB':(]@JI/D!/8/XC?>"@1_D65I='T(4;3':+8`#MQQDBN,>:($D0IH@Q1CJA`5"*J$-6( M&D2M0MI^)AKI;[)./]%D(EGA4+'(OWAV4MXM\UR0-]&&S_$D(L6^2!%EB')! MOOI@,2]$BM67B"I$M:`3ZAN18O6M0MKP)H)WAN%MP,_?Q`XM4H:W2!D>4.(R M>E(IH@Q1+L@W0[!:%B+%9B@158AJ02?4-R+%ZEN%M)5-[.@,*]M0D[*R1&,,Q?B!2;H414(:H%>>K# MAV,:D6+UK4+:RF&@Y`4K8SQD:)&RLD6>2>=.RD,)HA11ABAWR-L.%8A*1!7J MJ@5Y)@WCZ8U(B4G]-FJ3FN.\/SW\4MA_:(,":M:PR'_*QDG1$]U%C/O]\$T2*6K/$.6LRB\00LZ%2-F0 MW[T.[Y#^E&+<7#9 M-W-2M$B+XZPN,R.>PTY_V!F&OP5(47N&*&?D%QAQW+%:[JX@V*:7 MK$::4B&J&?F%P4U((U*FL.L77M;3LCC>MXW..V@>Q(,!:,^>P0`,+]-<1C4` M;<:7!F!,:AS<=:2H/D.4.Z1*C#CR6.+!D?H)L1+55HCJ6$D1+QY+XL[=*EUZ MQ(5'VE]:U.D9QO"DZ]`U[?5E/(V#J6#FI&A&X+K.&5$K)",\\\3J[8-!_QK1 M"VDZG6"8IZR*E@-/5="),I'B.N2,_#I$7&I;3<:U8S-\KU#):J1U%:*:D5]8 MQ*NN,-'58U(F<)&ET&7 M:Y5B/1[-V?@,S]FCM/*<12^M@%9*K8`.G5PC$O,3=SJ\T\G+-(UV+=>]\21H M7\I"LBAEB')&?H$1QQVK90KL7HZ/;V\:0J?1(^ M;MNREL@:>-XY?X3G?(>",1C8>N:DU!IH=;TT!B-2^&XT5)\ARAU2)49<^9H2 M2U1?(:H1-8A:A?1`([^K@?9K"Y_1$NQ<+`H6OF"_/1M9*;7P.71R'4@XHY(: M!YM1-@A/P\ MK2Y/?88EYJSKA97O6"_GK*`OEJBY0E3'"H/F-2)E"AM=!F6U2K'VG(D\G+'R MV4"%6ODLTBO?!`[M5DJM?`Y1KSKN(*!I"?VNS5OYNIW>H-.EA_#T3CYE*5E\ M,D0Y([_$R#`[ULMY+IC[2U8CA56(:D9^8="\1J1,84/TG&\WY3GZ+9SVG)U* MSW[VZ*!'3Z8.Z:OE2;#/GXD4SV-S1`FB%%&&*$=4("H158AJ1`VB%M$"T1+1 M"M$:T0;1%M$.T5XAW0=,G.+UHY=>?AZNFP[Y(4M&7L@248(H190ARA$5B$I$ M%:(:48.H1;1`M$2T0K1&M$&T1;1#M%=(^Y769N777]HFC8V68&1;I-SMD.]N MB_2;7<+C1N+4>[<%*:(,48ZH0%0BJA#5B!I$+:*%0_03()Z]EB+E+4B38).P M$BG.N$:T0;1%M$.T=\C62W>*,&AT>I-%EV/@?8O\RS4G1^O!YED:D6'V+:('JERBU0K1&M!%T MHEY;D>)Z[1#M'8IU"!,@.J-#V'B2ZA`6J0YAD>?$.:T"IMMXWD\0I8@RASQ= MN4AYE@D?7BE$BBU3(JI0?2U2GOKPT9M&I%A]BVB!ZI6Y'B M>NT0[1V*=0@3Z/$[Q*]M/XV68/MID?_,";T[^]`I),XT9R2/>R2(4D09(]&5 M,Z+U2H(,\&87D6*#E8@J1J*^9B2A@`91BVC!2'0M&4FS5XC6B#:,I!);1#M$ M>T:'2NA-@XE>^3W@A;VF#7:I*<'%TJ0U,WJ;L'&UM^6>(TH0I8@R1#FBPB&Z MLA._0B4JS%@C:A"UB!:(EHA6B-:(-HBVB':(]@IIOYIPTAE^M=$GY5>+@D!M ML`&>T?=4#J[VCQ46O1"H=1F/@5IS1WG=#Z*)*:K/$.6LRP_40@2N8"G[:@.( MG9:HN$)4LQ:_+`@M-B)E0XOAW7F+FA>(EJ+&F]3""/Z*I6S,^WH\NJ;_!7OH M-6K?(-JRJI.MVXE4O'5[I5GU2WK[_CG]\B"NEQ:'@C!T<)B:.2D_#,V(UB%9 M(4)C)BSE?G0_NB93!IT^91F9AS-$.:.3Y14L95]F,+SLZ)<9!.TJ65R*KA#5 MC/RBL9.*E'7C<'RR[);EI>P%HB4COVP8C"N6.F'F-1M$6T9^>=#6G4B] MJJU[EC^4K7NPB:V^?F:E;Q^$FR.'@IDU&+`S)^7=4F%F92D['4P&DRY\ MR0YU9XAR5N1/!N#)@J7LM#J\#.Y*2U1<(:I9BU\6>+$1*>O%\)'1%C4O$"U% MS8F98,52/[?C&G5O$&U9TZO?#R*65-LG_.$.6,3I97L-3@<#D\ MN83)U=;':TC%6:3XFI%?5J2K.EWVZ;4QOMR(U8CF!:(E([\P&(,K)^4,V>T. M1Y-^<(NW9DU2W@;1EI%?'C1N)U*FKXXOPQ_/[5G@4)CNJ^<%M\TD&9PM';J6 M+>>,I3K2N/F1^4T!TR5',=LINC]Y8N`H)B5D$98?VQ#5G+F,W@^4 MYH@21"FB#%&.J$!4(JH0U8@:1"VB!:(EHA6B-:(-HBVB':*]0KH/F+CU/]$' M;/Q;]0&+=!^X#IYOF9EC#^P>_S-X]VG=Q?K]J?DD4"1E,)Z:=QK%4B:4EY(%8^W_K3G^+ MZR)5L192X5%Y8_J(_&^#Z6]Q-Y(7HTXDOT?=/IKN#U\("9IV0YZ--8PNLJ4$JLS1:\I)58#BMU/ M31@>:T#W_E,3C<<4NOZ?FIO\6,J`4F*UIML_2HG5FJZ!*"56:PK\4TJL!O-Q MCU)BW8*>+Z&6QE)NJ-8W46TS2IE%4^@QC:FY`\&6TD,74W,5@BDYI9C'*&(I M`TJ)68>N7BDE9AVZ@Z.4F'7HE[Y3\SM>+(?>7#$U/^?%%'J!Q=2\BR*60IZC M]R?$4LAS-I87C`3Z<3NEQ.I&O]&FE)AUZ#?%E!*K&WTWAP9H=&JB6M]$\\PH M919-H1>-3,TOIK$]]-J0J?GA-*;0VT/(HC'KT!LO*"5F'7I+`Z5$/4?6,2\) MB)5#8RYJ'?K,T=1\:0#ST$>+IN:#`YA"WRZ:FL\0Q5)HU-/'9V(I$TJ)V8`^ M:T$IL:6#OFTP-5\N0&WT98>I^4@#IM!7H:;F6PV80A^'FIKO/,52J.]$:TW? MAJ&46*WI(R&4$JLU?19B:C[Z@.70I]4H3\QS]/4QLD$LY89J?1/51E_OFIH/ M:,3*&4W-%S(PA3[)-34?RL`4^C+7U'QD*Y9"?2=J'?HP#Z7$K$-?:*&4J'5Z MHVE#7PW'ZT[3 M7BPEIY0VFE+W>E2#V.Q?]_J4$AO;=6]`*;&Q7?>&E!+K!V67^G4OVAY*:;M1 MBW:I7W>C%NU2O^Y&+=JE?DU[WXC=>M2OHS6XH1K<1%-FE#*+ILPI)8VF9)22 M15-R2BFB+6%M&6YM32PM;@ZK@`/;U_^^/V\UUS^_CY M_OO3FZ]WG^B4T#E\%>?Q_K,)P=I_/+NW'__^\/S\\(T.$O1MUKO;CW>/1H#. M=I\>'I[Y'V3DJ[\?'O\XG$3>_Y\`````__\#`%!+`P04``8`"````"$`AMW0 M7KP(``!<)P``&0```'AL+W=OEZ-__>7]]O=>%35 MV]-^>RA/^6K\(Z_&OS_\]S_W[^7Y:_62Y_4(%$[5:OQ2UZ_V=%KM7O+CMIJ4 MK_D)_N>I/!^W-?P\/T^KUW.^W3>-CH>I/IM9T^.V.(U;!?M\BT;Y]%3LO;ZV^[\O@*$H_%H:A_-*+CT7%G MA\^G\KQ]/,"\OVOF=H?:S0\F?RQVY[(JG^H)R$W;@?(Y+Z?+*2@]W.\+F(%P M^^BR_"I, MP[U`T'C*6GM-!/XXC_;YT_;M4/]9O@=Y\?Q20[CG,",Q,7O_P\FK'7@49";Z M7"CMR@,,`/Z.CH5(#?#(]OMJK$/'Q;Y^68T-:S)?S`P-S$>/>55[A9`_VZ-FAGU(F8G`I^=",C=V!9Z:08`GUU;39]HYLSZ1/]6IP&?J#%9:+.E ML;A]#K`@FG'`YZ?GL.S:PF?7]FZBW\VU^6$+CF'VV7!HF`_B"ZK<&I!IFZ!-OCO;>OMP?R[?1[")0`I6KUNQ)6FV M$,9,;_.RS_V/4A]R7JA\$3*K,409LKJ"]?KMP5P8]]-OL,9VG!3X%`04A!1$%,04)!2D%V0!,P;6]?R%+?H5_A8SP+WIFC4`Z M7"?.1`MLXE#@4N!1X%,04!!2$%$04Y!0D%*0#8#B3%@^O\*90F8UAF27R3J[ M4[VW;FT,"*LT4DTVO4GO849<1CQ&?$8"1D)&(D9B1A)&4D:R(5&<#?[Y%6Z-;KJ[=ZD]S8C+B,>(SXC`2,A(Q$C,2,)(RDCV9`HWH8C M5?'VY4H#MUMAW3@5G;%N"7@0R881AQ&7$8\1GY&`D9"1B)&8D821E)%L2!2' M057R"8<):]5A+3':ZDT<-AM&G(Y(I[J=#HQ*9K-.LMECS7PF'3";\**TI2Z4 MB#6+F73";-*+TF3'R[IF>E,8#X^P!?%T6R),1!58OQ2[K^L2?`$;Y864-:`4 M:`L$(:(&H"7#`##B8*MF4(V0VR$8[2`"<]5-7JU%ZIVQ+1C MIIUP[?2B-AEWUBGQ&(@+2UZFR1C\5;Y^%`.H^#$(0D4-0D>4PDU?JC/>]$:X MMS@]D4'0=5*`N*V1/FO*06,YFYDDY;Q>!H5]1@)&0D57US5M008Z M96@M#%TCRR536JG>%YC$M=8BDLSD$G$CK;"APY&+2*DI MZ;+TT$J>'3Y'`46ST,3:4$THX M2A%=E<_0ZL(*$U=I?->3U=9-%:^XFT:CUJ%ALI@&V8XWV%"N$:=#AM4'TD4K M4S(/F6SI(ZD(9$ MF\N0W%8`BWOX-"8M4E>22:NLKJ&RDBXTY$4P-KR:BQY:R;SV.0HDDGYE/89H M938[LF9:=W.V3?9#QU4:8RLY@D2B*]VE:-5VI\^MY9SMD"ALZLB$B%]&PJF,-?;22ZR+@*$0DM2)$LF', M4<)1BDAJ98@:+=6EXAIRZ-(;SQB\9!VXMD7JRC!8P=Q;H1\=C2$7T4^6`6OH M8T.9EP%'(:*K\A%:2:V8HX2C%%&7XTM=GY.C-D.31EL-"*2F$I"?Y+@P)X=] MAY0<-UD@>BL9"(9<*.<:>;6J(7NSAU8R57V.`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`OOAZB\:ZS=:9HXR/5MB MP1)J8"NUH0LB%\0N2%R0NB!S0>Z"P@6E"RH7U"Y8NF#E@K4+-B[8NF#G@KT+ M#@)<48C;.%-HWR/.2HV*,T=HSL`$ON\$E26X2.B"R`6Q"Q(7I"[(7)"[H'!! MZ8+*!;4+EBY8N6#M@HT+MB[8N6#O@H,`5E!I0GR/H"HU'R]IN6L'[Z#O#MY& M9D#=JQ4:.H%N1=I(`XF`Q$`2("F0#$@.I`!2`JF`U$"60%9`UD`V0+9`=D#V M0`Z26,&G>+U'\)4:FOS)C`GL>&:'=MX(G8U^*])&'T@$)`:2`$F!9$!R(`60 M$D@%I`:R!+("L@:R`;(%L@.R!W*0Q(H^[9G>(_I*S2GZ'+5Y0P;-[EHMP@M- MFDWR:5D&$@&)-1FV2T4",JDF-+VU?6\P&-M]+VN%N(HYJ"Y`==F6.J.Z:H58 M=2U56_ZF_>-[^%NIL?W=$.EO382_-;']-++]%+5"W)A8$Q$"4)VVI:2?)K;J MK!5BU3FH+D!UV98ZH[IJA5AU+55;(:#-]WN$0*FQ0]`0&0)-1`B`1$!B382_ M02;5Q`ZEL]AFK1`[)0?5!:@NVU+2W\Y,7K5"K+J6JBU_JZ3*.QP-E!K;WPV1 M_M9$^!M(!"361/@;9%(@&9`<]!0@4VIBQ6W8M<=)U0JUSI6J+>?28=KCW(XZ M"S]_O[WY8_Y`4R+MMCR9CP&=KYI3EU)BN[8ATK6:"-=RJ5,>YZ0H0A3K%BU0JU[I6K+O3TZ8Y_U[^[AYZ_\2RD:=O!) MC>UA1L8Q"T0AH\&@7?\B#XN935JQA)$QD&HDPIHARA$5B$I$%:):(\I\D*]M MSZH3IIP6/#U4>K`YD-+^DH,V[VE$8\,L^T/WV,A2L[9@R,@B<@Z3 MZ6@PF#@;B)AES!!(6)-1GC*2M>KWG5IE+#4[V>MVQLY2F:.Q0J.AJ7;):@RJ M:IYW>S/K/P)YJ:LN.'2":H]X2("7N=/$&J720")!3@X7*Y%'!OHELR$C, M+(R&)X?U)L.N^H_=F)B%S*8S862TIXQDM3P1:JNE>D2O,XY^X-XR:YM1GC1J-9/\<#-TSN#K' MJ6B:CATR,GTM8D339QO@_L#9A<1:JB_'35L)'LTIZS+J,T:F$CGJ*EC*%"P- M$O5RQV#%4D9];:FW':].4-+Q38+SC0MMKSF'D1EN]UPC9Y`XF_(%2YF"(:-Q MJRMB9,<6YK&F$NH&P43-3=0DK,M83!G1SEH4=$9%QE+39J1VNDY_R%E`#INF M2M:PT;64PT8C4Z7:TF4'3!W!W(`-NB9@KURYFY.<%3&-;"\[$_A"73>Y(Z@M MR-&/M)1>=_J#6:\_&SHS9,Q"<@"!]I0-RFIYIK6VH)IZNIV>T]-R-%9H9"T\ MT)2*[3<+#TQI38%F$K`#I0YJ,E`O;`2:N,.LV](2C-X<\*BD:R.WK6&2UEYN!0W9*I@6/F\XC1"^M,4]!:9T!]RKJ, M^HR1J42ND=!5:&2-`JAJA;IJ2Y?=]2BHA']:6?]P=`9WS'KHF'>2O5Q40&+*1>DKBH*PJ+25J(9);BH:`$S)`NM MV1HC6DJ.$:A2S57R#`MU4)3#P@W8*Q>5YKQI#1>-J#:M&P8C9X.[H/W8*=2F MIX:,3'^.--*+RG`P'G6G(]@%-*I$#T]8E=&>,I+5\BPJ;;6:106C`\8*K=D: M3EJ-:4K%]O6BTAFT0'"]GQ5B=N7+GXC:E7OZ!#:1J]V3#KU'#BK%-S+77VHM?(<-F6$9*N=K?G:2'&K-XBVB':(]H@.&GG69'5,/]Q1RIIF;&9MLQHRT!;[I$J6F:TE2TS MVBIF\M@#KQ[4+"5:M=1,K(DKC]BZ97('/A@X_673BIGZ;EMFZKOSL#VSLVTX M:*DF?O8LHK(,LL^\L+5NDA+6=-$@JV\`"OL:F8U1I)%*/9E3D^N<&`LFC$RG M2AD9]9E?O7.2RK%@P.DVLLN$2T0K1F)/L#>'#+4J9>.T1[C6Q/ MN%4]<$%/?U!9ES?T!R7N'#,:9/4'0&%?(].:2",3BAB%$D9&*F5D5&4:V5X8 M.*FQ'`L6C(SZDI%17WG5CYR3>XT%EXA6B-:,9'\`#VY9RM1KAVBOD>T)MZH' M+NCI#RKU\X;^H#-%9?N6F:H=N*BG)[R4_7O=24.E&)R5@9$X?"(*$46(8D0)HE0CX[(, M2`ZD0$4EH@I1C6B):(5HC6B#:(MHAVB/Z&`A>]B[V<;S1P3J\!!4C6B!$N/* M66H77-`D2D-&-+N9@F,G815I*4I6JQN,X:`[4W<,SNM%K,IH3Q"E&HVHPK\V MF!DI97#6<=(>N7XNKD<*M%4RDHV#ZYG*2.GK&>=JO&8!T[`EHA4CDU]>:Z3= MUAO[W+;AU:S&S%!+1"M&TACX<:VESOAQPXJ,N2VB'2-I#MJV-U+^MAU8 MP#,AJHRL/'/]N[VXTN+LQ1DUHW+2<3\'N*!MNIY).90A([M[.TMPQ%*3IML, M)SUG`,0L889[@BC5J*?^BKG<,9<)L::;]JV7J6?.^,^UO+@R+S2B18.;6C*2 M387(5D9*F48GUBQ@-"\1K1A)8YY>JP/R2[]N6(^QMD6T8R2M0=/V1LK?M`,+ MG(S9\ZA*`D.GI2_GH#BJS[OPJ>'U'WX9-&EEF8]F)%LQ&#N[IH61XLB&C-1. M^-?=*M)B=#A2[?_%"SJLR\P2":*4D?K[:XN9$%,F9R^\2)-K>6OZU7XR]2E; MK;*Y$.Y*B"GC77@EN&8)HWN):,7HO'?76DQ[M^=]N6;#NHS%+:(=(\LB-'`O MQ)H&NJ_7'%CB9,[NT"H%"QUZ9.Y@N4>_L&%H,KE6+];)77-L7]`%E)IWJ3FF MRP**4"I&E"!*$66(Q.09L\JU.\,-B5N+/G:M#8',X7`T`A MH@A1C"A!E"+*$.6("D0EH@I1C6B):(5HC6B#:(MHAVB/Z&`A*ZY#-]U]/JXG M<2NN"XU,:C$$$@&)@21`4B`9D!Q(`:0$4@&I);$=Y,\"OWDV'&(:N$5B2#"C MO^U<)YB92>$-BTB(<='8PQ(/2P63)ISL3B;$V$3N886'E8*=,5$),391V\P. MC\JZXN;D[>'1V5N3N9D/&E@HF'>7UCA8:5@9TQ40HQ-U#:S8Z%R:.\1BR87)W>*0T8R%IH)OX%GM8XF&I8,)1;@XP$V+LJ-S#"@\K!1,FW/OQ2HBQB=IF=BQ4ZN(] M8M&D0*QQP4C&0C,K%LBB(;+8PQ(/2S43V^\,48ZH\"@K!1->=U-RE1`S7K?: M8'O=FX<1Q]977>0/,??"B+8,7(]%RTSR*?2PR,-B#TL\+-6,OCB%S6:(9D+SKT8M@@T\802`0D!I(`28%D M0'(@!9`22`6DEL1VD'NV?L%![1&:O3^GA)ZI>J&E1'8LU$A] M`,T4A$L6+:4O!^A++":#@?N]!#%J3Q"E/H.0F*X^AMY]V3N'7>G6OD#$"G!@LM11V*1V[(NLAO M9^+HE9HX&;$8U2>(4I\N#*21.HU`.S^7H]H"46ETG&E;9:38*;6ERXZ4_^!M MTLZO6K]'>.S62&TG3!PFSE2P8"GST810HS&I-`5A(&JIV?@T$'\;#X:C;M<9 MYK'1+E4YG2@Q4NROU%<'3TB;5E--3R'MN-]XDZ/F`E'I,X9C$PO6%K*CJ@[0 MKY]'U1V]DT?4R!E_SN2ST%+6^-.Z7AA_C12_,-2;=B=3_&PZJD\0I1I92ZXG M6&V]FF"YRVV.F@M$I<^8)UB6L7''Z7*UI=B.G#INOR%R?&)O)\#YJ$$OK(!: M2JZ`&KVP`K)4LP+2KF76GTR=]L6H/4&4LBJYY'H"U[2'JJ4"U^M,VD_]G_[1 MP^])05,%HM)GW1-)R_K4?3^OMA3;D50'\S=$4I_C10J`@N/9A#J^7F@I:PQJ M72^,08\4?FL7JD\0I1J]-`9?8S%']06B$E&%J+:0'1YUII7A^5=OO8STR5A& MK4'.PN?LMQ>Z(!UA>-$)-7IIX6O4VU(3YP64V*@7*]_$>4TV,5).F@M$I<^89PAJAQI7U98N.ZQN/N+\T6^$B0>-[)5OZKP1M-!2 MUJC3NEX8=8T4KWS#:9=^@V4,.\]&2JA/T&+*M9<6/<%JZZ6#Y?3%'#47B$J? M,4^P+&/CCF.KMA3;D7M;5F,$68VY1O;*-W6NPA=:BF8&[O2A1B^M?(U%??;K M=?O#;H^^L,7>R<>H/D&4^BQZ(JZD`!HD7V48`0H1 M18AB1`FB%%&&*$=4("H158AJ1$M$*T1K1!M$6T0[1'M$!PM9<1V_+;5S$K?B MNM!())^!1$!B(`F0%$@&)`=2`"F!5$!J($L@*R!K(!L@6R`[('L@!TGL@+U+ MAD?M-^WQN=!(QE$+J=MKD[MQ3X<1ZR(QGIYC#TL\+/6PS,-R#RL\K/2PRL-J M#UMJ9ARP$E+2`<[N;BW$V`$;#]MZV,[#]AYVT.Q4.;L_J-P$'GS>O%J/=8Y# M''U:).Y)-1/K;LAB]A')_;J.2(BQEV(/2YAU318X9>:81.5$&,3M8-A6,*G.\QA#1.>"UE,7,Y''A9[6**94)<*,>DY9X><"3'V M7.YA!5HHA=@9"Y408PNUARW1PLHCMO:PC8=M!3M3NYT0X]KM/>R@F:_GJ`31 M>_0J$F)LH?:P)5I8><36'K;QL*U@9VJW$V)=R#RO00BG$A`7W M3:]*B+&%VL.6:&'E$5M[V,;#MH*=J=U.B''M]AYVT,S70;3%I,O%T4-H:I)NA MK7LC]:JV'BQ#5@^>O"W1>Q*W$KUSC9R9U1FP"RTE9U;618/BUSTJTE)Z.I@. MISWXJ3[4G2!*7V4NTU)Z6AUUG"OW'!47B$J?+8AB9:2:*+IO'M>H>8EH9=2< M\>-:2YWQXP9U;Q'M?.:@;7LCY6_;P=)L=\EW265/()4]U\A.Y4V=""]8RKR( M$&JDDJWG>FIC4;^LV)]TZ?(EH9-6<#I=GNJVZ:_?S&=(+9=$;T^3/>K"Y:9M;%D%GWA4ZH+73UBW2_>/.$M=$G MK=AJXF$IL_-6LU9,_0BN;S?*`L)>X6$E,\L>1*P28LWTTG/6FYHEA,&EAZV8 M609A?[]NQ;1;_:^%;%A,6-UZV(Z9916:N1=BNIG.JR$'EF@,-EWSZNG[\?@< M7C]??_IP=WS\=EP9J\>V13\XO'X]>/E?#`)U+=84%]H2S1/ M/@^FP6=Z*02?T+=-4)G3;8Q39CZ8T9-3'LUY\GE$VJC.'FWT1+UGX'M"VNBF M&I_0Y42@COGXY',O^.RUT@L.IT\;._6:DR*O_(`:XM,_)/W>`L/@9[,J`G MOEI3LIR>^&I-R5!ZXJLUI;OHB:\&X;A'3WR=ANZ!J:6^)W.J]=RK;4%/%MXG M=%\:J.P?MI2N/@.5`\0G=`%*'O5YARZSZ(G/.W1904]\WJ%D-#WQ>8>^@R!0 MGWS$&M`W$03J*P5\3RAR3<+/Z2'T*6UZXJL;?6:8GOCJ1I]KI2>^NM&G+^F) MKVYSJMO<^V1!3]3'3+'6(3U1'R+%)_15#X'Z*"D^H2]\"-0W-_B>4'R\/J`/ MP],3GP_HH]GTQ.<#^J`P/?'Y@#[.2D]\=:-?&0G4=T%CW>BW1@+UC=#XA'Y> M)%!?#(U/Z$=&`O7]T/B$?FHD4%\3C4_HIT1H#O4]H1]L"=2W:F,9^I&60'UK M-CZAGVH)U)=GXQ/ZP99`?838^J:F(;\D)>]T@ MHI^YQQ(I/:F\3^BGCP+U:T%8AGX>*%`_V(-/Z`=T@KFW9O0[.L'"^X1^3B=0 MWWF.VN@G=`+U+>?XA'Y()U!?=HY/<@J!SP,%!<#'RU%0^?IF.0XJ7\\L)T'E MVU:4TZ#R;0/*65#Y[,;4-!]/J&$^GHZ"S%?/=!QDOGJFDR#SU3.=!IFOGNDL MR'QVYQ10'U]0.'T\'`61KY[A.(A\]0PG0>2K9S@-(E\]PUD0G>Q>M=/STZ59DX-;5)<\GI?7HXK[9]?T8^Y M-FF[[++/SO6E6&FO1:O]7/_^V_*Y;A[:4U%T$V"XM"OMU'577]?;_%1463NM MK\4%OCG4395U\+$YZNVU*;)]GU2==ZB:[ M/\.X7TPGRY&[_Z#05V7>U&U]Z*9`I]..JF->Z`L=F-;+?0DC(+)/FN*PTNY, M/S4]35\O>X'^+8OGEOM[TI[JYUU3[O\H+P6H#?-$9N"^KA](:+(G$"3K2G;4 MS\!?S61?'++'<_=W_1P7Y?'4P72[,"(R,'__NBG:'!0%FJGE$J:\/D,'X/>D M*HDU0)'LI7\^E_ONM-(L9SIW7<>;SX#FOFB[J"2"GAB^U-K M[IJN1P;QSN@7+!&>V+@QMOY.H@G33=4G\\Z$'3/?%U^G,]D;8Y-UV7K9U,\3 M6&TP5>TU(VO7]$D+:`G:D<$D;WD$S$%8[@C-2@,Q8/9;,/;3VO&\I?X$9LQ9 M3*#&F&)$B!'$>81V(P-;&8AD8"<#L0PD,I!R@`ZR#-J`0;]#&T)#M,%1!0B, M8EF2$!B!*1L9V,I`)`,[&8AE()&!E`,$(>SO$8+0K#18L8-)+%<:>4!C;)B2 M(#==$.G M*7E#=:U1R2$,/;!GB]+*Y1#59-A8QKON= MPALKO,F'O"G/*V@$A9N@T?O:D&A1&X8`_[@)N7/1#"$+XEPVI`W:4(19RIX[ MBYEDNHA%<)92>&.%-_F0-^5Y!6U(!?D%AD3M&:.1.$&+I M4XRX82%2AWY!)%JV"B(Q2+2.M(6$I!`E&]@X.O0*&8=RS1GZF;$TBS> M/`IYK)(GF$C?G9;A6`IYBC$]N>@F4HI^02A:N0(?.B`P*22Y2:I?0HP:$S<( MC5.^10@&/N[^GE1A11A%BCT\3UN6]([88=388HS0V&*"D-BB*Z[L%*/>:E&4 ME%2MO*3DTN`3VQ=)DW9[!HD>E$LN_!6HE)TL41F2W/A>0M'(H\PAK>E MTEZ,71`Z*K>7(!=UJKFPC;DC[3HIQMQP*BEX>5D_V/=H?2PXE97,XUA"N$XD MVL%1$?V\4:&M"D4JM%.A6(42%2)WFF,GJ)7H'26]BJJ*YEB$Q?G<3O+ZD=P_ M0L)Z.<#TB,^L'RX M&%%Y`MN'RP`5OW/\.^B_^D7@^'`NOH&;'E[[REUR_>`64^CZX2U\X_IP?%5; MV'@^G-I4/')].+NI^,[U=SVN#QV":^!K=BS^S)IC>6DGY^(`TP07E[!4&GJ1 M3#]T[.QU7W=P_PLS"5>*<.%?P('>6:W*X_?UKMI7K2!>?&`89:QZ0PIHDHU4G!*Z9=V?`:GF12 M57-!7 M(E%2R\RX0$?M1B\]+^F2`M-ZE0IP@&%W%,]BLO&C.W]&Z'K5!NBOX'M]\M_1 MA=Q_52+]+FH.T88\80:V4CXA]#'%)7B97KS]T&;@IW)2GK%=:7[)_3L]UPE$%&C<8(I,B2QA`_#K5`)+`R+"7MKK7J2FB$FP<.>^MPSG MP++EVCP(I"1.LM-&5O\LR#]069+@0`+7`TDXRF;74.+X#ZM79F< M)BT,PN'@S:^10G!?RJY<.L`#>72Y([A/:UHX3@OI)=N33@ MP]EUZ@!/HF#AX['S4?/BFWV1E@SJO5]U[Y2SCYT].G8M^DP-"6(RX.FJH\`_ MM'YX/`P.2_V\O&<#^W>\#=OMT)==&PO=V]R:W-H965TC8TQH$2*HDWRS."VC<88"YB9 MW;]/-7VA+][);+0OX_%QU:'K5'5UT0^?OS87ZQ5W?=U>5S::N;:%KU5[J*^G ME?W7E_33PK;ZH;P>RDM[Q2O[&^[MS^M??WEX:[OG_HSQ8`'#M5_9YV&XQ8[3 M5V?$K_')LNZ8+N(QSM\5A7 M.&FKEP9?!TK2X4LYP/K[/*?D1Q@7S;63^,`OU=X[=>^M_JS^W;OJL/O]57#&I#GD@&GMKVF9CF!P*! MLV-XIV,&_NBL`SZ6+Y?AS_8MP_7I/$"ZYQ`1"2P^?$MP7X&B0#/SYH2I:B^P M`/AK-34I#5"D_#I^OM6'X;RRO<7,6\S1/`1[ZPGW0UH33MNJ7OJA;?ZA5HAQ M41:/L<`G8_'#V3QR??0#)`$C@4^^E`\O`,IY#`,^N:\4Q3LK7S)'^&2.R)U% MR%WZ$81O.CI4OS$=23F4ZX>N?;.@QD&@_E:2'8-B!&GDB:`4(C7?RPRDA+`\ M$IJ5#6&`YCV4T^LZ"(,'YQ5*H&(V&],&J19;;D'R36@3'=CI0*H#>QW(="#7 M@4("')!%:`-E\3.T(31$&Q[5A@.36)XF!+?@+HD.['0@U8&]#F0ZD.M`(0&* M$/[/$8+0K&S8)Z)(/-]7(]]0&Q]2(HRT.MH*$Z&.@>P,)#60O8%D!I(;2"$C MBD@0U\^H%D(#FQ$>,PD0SC65J-&[*@D3H9*![`PD-9"]@60&DAM((2.*2M"= M%)7N-WS>5HCU*`8/8D,1B)PC6P-)#&1G(*F![`TD,Y#<0`H940(-M4#_9V,E M-*H"%)$5,)"$(;"?11%Y:*D6T4X8<2E3A@1"W+U!G0DOB=IS5>I<&''J0J96 M=(KNZC0CQ]APKJOG30LA0#NX4R@^'#3T^"$DJDH4D54RD(0AA.9U[;E(:S0[ M\3N/(F6())#!F@DOQJIUN%S\SED+F571ADR[YN$\:?.EO7U/&QA@N#B$116' M(?)Q[?F1FL,M,UJ*8DCNN7G:T;43;E)]^`N5.Z5&WK2+]\*-JY)]Y&DY(W)I M"I'G(5^KQ4)^EJ(NS$Z&NB&,0'*EJ4L13-INO;;8M,QI':CK;"#<> M\8XAP1@,\N>AB[3B29D)'8G)B+0WB#.#.->((S^*M!.ED(D5EA:&F=,I-I.+B1!-WQJ&).^>. MC!L%:*$MLN`F([A%]IJ#OQ0WN3GB++Y?>JMH7<@6!0EB]@.G]2!;&,.3`@G4\BN&`-_$BC.&8 M-W&X9WD9>`-LPWM[#DS"&`=/D2:(8YBH33\,8IBL3WX?Q?L0=H1#<`]W*$_Z] M[$[UM;BI'>`""/((MQMPXX?AU'3)ECFV[<"_P(,= M<8>X_A<``/__`P!02P,$%``&``@````A`,6"(6Z]"```JB\``!D```!X;"]W M;W)K&ULE)IMCYLX$,??GW3?(>)]-YAGHLU6VZMZ M5^E..IWNX35-R`8U"1&PW?;;WWC&`3PV`;^INL,PX['G][?&]57G;UOKJ\;+U__O[T+O-6;5=<]L6IOI1;[T?9>N^??O[I\:UN MOK;'LNQ6$.'2;KUCUUTWZW6[.Y;GHGVHK^4%KASJYEQT\&?SLFZO35GL\:;S M:1WX?K(^%]7%HPB;9DF,^G"H=N7'>O=Z+B\=!6G*4]'!^-MC=6UOT'. M1?/U]?IN5Y^O$.)+=:JZ'QC46YUWF\\OE[HIOIR@[N\B*G:WV/B'$?Y<[9JZ MK0_=`X1;TT#-FO-UOH9(3X_["BJ0T[YJRL/6>Q:;#\+/O?73(\[0OU7YUH[^ MOVJ/]=NO3;7_O;J4,-VP4'()OM3U5^GZ>2]-9+-B+ MVIPF+F&ELQZ6+!$LH;5&+57JDDHZZZG(8E8@175QVTMG/2Q9HA#1&C=U[A)7 M.NMQR6(.5T#'CL_KQO,6WZA<1Y\42A-\M& M>F`IR8E_H7C'&2<(E,FR")(>AT$3R#IRF=_/A\I&7C#A?<].X"Z<>$=O-F4W MO.5F,FXNN5DXU$7T0ET]SQ@`DFGDC4K5LSE1+DS,EHMLV`+TF7*B7IC8*Y-93V#A/O1GMR^\36\J9=+KF=@R`R?H MT9LEFX(^8-#C$VBU]0F<]`"]6;(;_)S(@+&.]63S MZT.$C]'$2%M/KV="8>1Q;[D.H#?6,TB7R.)^JDC?E-E]C'_*7]?!!_(7DMX"]THA^]66$R@'7*&-FR!8)$/HS.=8$) M>4@FAN)0M=X%3N"')OC*9.D")\A#$W)ELG6!$^6A2;DRF8..&.2X#B&^%9A9 M"+Q37VUE8C@.3Y3:0D1,!.YW-GICME%G^T-HZFSEM:"S9;,L%S?T9K7>#@5< M#&3U#I&)_+',8`!X(P`)^O._R"8>FB(G?4!O5L=-#(PZG-B/"'2M#C)9VCEB M\,\LO4D\!K#)2L3HENVB8D2T7(18/*?3#3!+:SL=-A+$`!L!D@"&?>#B* MG:!&;RQI''IX3B%)45XP]C[_Q&$U=@(?O=F$DA98)M0)\IB(UF:13+JDY$.I M6C?'DMO%[V'0F]5!X%OJ<.(^-KE7)ELW,_!G&LW>)2,G=A';[8.)`=F28D3^NBM1U8FRSHDC/W[ZX#>+#1I@&70#&ZY M#O)8,Y.!MNDQ#`F9V"),0)TX08W>K)XIJ!,GJ-&;1590FV^&$R>"T9N%GB(X M800O7`239`QDZ/KPID!3I,0);O1F]4S!G3"X9YK))!H#8!W\_)0XX8O>;-!3 M^*8,W\6*A#?J292)P3#Q!)TZP8W>F&W8.D4^/);1_JJ\H.'F]M>4"<#]M4)O M5BN!;TI+Z@0Y>K/(!#G;7X=2M6Y.G,KAE-P"SM&,C1E>$;45\&)_+0G?VA3D0_/9*J7 MR6M)+SN)0TI*H-4Z)0[RC?#RTQMZZ]VE3*R7AU*U61^F^?*G#GACMXL]-2>GC&TL9"PB'>R+(2Y)LWP'4W_,D]?""?T,Q-] M93)%)7,B'[U9'20&%E')&/KWB4=O%GIJ7\\8W7(AA'P[-).BQQQZAIC&2$Q4 M`G_B`31SPAJ]L:!!5`)_>"I3`[B1/CA-G%7EBX[EZ*.W/IW*9/9`[H0Y>K/( MA+DF*N-2M5[.G=!';Y9M:J//G0',G]-$;LPV=&OA#KU([*R\8QMQY+W=2!_1FM4ZI M0\[4X;XHH#>+3#K!VGDH56]G)U'("7>M,VX*P#7]YTY*Y7#!@W3U4K'6W\)U$@MQY M-71"L%7CI`'")^+U:LAF;7`G'1"^>3JXV6Q#9]BC;/O!@M?@\LM@_F1VLS'A MYH^8]$$P?75[+IN7\I?R=&I7N_I5?NP+'V,]/?9F]2ER'&R>X2T`:`N_D@JX MDEJO9)MG.!A9[LGRS3-L.Y8K>;)YEO1:+@$\\AI^#\T'`6.PWA/!'=8+`F+! M%RZ6-$&\>88?WRU70H@&/UY:KD20'WZ#@"OK?F3PH?2U>"G_*)J7ZM*N3N4! MYM;'A6WH4VOZHZNO,.?PN73=P2?2^-\C?!-?PC?%OOR<\E#7W>T/F:#_RO[I M?P```/__`P!02P,$%``&``@````A`*3XN[E1!```1Q(``!D```!X;"]W;W)K M&ULE)A;CZLV$,??*_4[(-Y/N)B]$(4<[7:U[9%: MJ:IZ>6;!2=`"CK"SV?WVG;$)P38$>(F2R?`?S^5G#)OOGU7I?-"&%ZQ.W&#E MNPZM,Y87]3YQ__G[]=NCZW"1UGE:LIHF[A?E[O?MSS]MSJQYYP=*A0,*-4_< M@Q#'M>?Q[$"KE*_8D=;PSXXU52K@9[/W^+&A:2XOJDHO]/U[KTJ+VE4*ZV:. M!MOMBHR^L.Q4T5HHD8:6J8#U\T-QY!>U*ILC5Z7-^^GX+6/5$23>BK(07U+4 M=:IL_6-?LR9]*R'OSR!*LXNV_&')5T76,,YV8@5RGEJHG7/LQ1XH;3=Y`1E@ MV9V&[A+W*5@_DT?7VVYD@?XMZ)GWOCO\P,Z_-D7^>U%3J#;T"3OPQM@[NO[( MT007>];5K[(#?S9.3G?IJ11_L?-OM-@?!+3[#C+"Q-;YUPOE&5049%;A'2IE MK(0%P*=3%3@:4)'T,W%#"%SDXI"XY'YU]^"3`-R=-\K%:X&2KI.=N?\HI MD(M26G)I+ZE(MYN&G1WH-WCS8XK3$ZQ!>'@ML`CT?4+GQ(5YA#`<"OBQ)7&P M\3X@Z:SU>58^\-GY7#T\"-I%AFCS(Z,S1L:JX%*>E:$?)NP6HH4A>A@L.H'6 MW4X4+TK*SM`+$.]D24PZ815:.*>*#'O)V^]!9#Z4L=B:XM\X> M?W36997%EHV7R**S+MM:8,9[0W#7#8'6BP"&>7X*TEL/UIKL)`)$>79QI+>A MC`*).Z!LL(\#%#["M-UN:]!"3Z[;0&N"2WN5NA^IE+$53`13?`.)'0Y(Y7`^ M!N)R9X^G\^E@OX:PT2;QPT@^B.?\_J"WT1]E&NB/`?A$I6RR@]:D3_#C2!Z+ MV`YLN%O30!Z+\`YLOEO3@+)!N-P"QV_FW0W49CU0)FA%;X+CX4J%BUB7WGK' M6Y.=3[B(=>EM*(^Q'AJLWYXEZ6TH*^H'UFSPC#V()V_MH7@@'YK6-'`]Q?9SE2$VGHQCN;U-2"&K8AR_RQTYABU`/;=1;TT![ M%F$=VEBWI@'E15B'-M:M:4!Y`.O(CU=0Y(E&VV"'-MB1?SU$:KW'$VF_][># M26\=DM9D9T06@2V]#64%MC%-UQ.IGL M1#2QB6Y-`\H#1(=(Y\3B;:2),L%G=Y.(_)&3,EE$M/0V.JX@'\AG$='$)OIB MTG>FD8,M/(IK3.!^&/G3U;-QETIX#NU7SSPDJL=V]6Q!U_\!C_#'=TS_29E_4W"GI#C3]U0,LJ5$O M`M0/P8[0"WB89P(>X.77`[RPH?#$Z^,FM&-,7'[@_:-[!;3]'P``__\#`%!+ M`P04``8`"````"$`!)-*QMX.``!_4```&0```'AL+W=OCL)SJ>3 ML\WK>O>P??U\._GO?]+?KB9GA^/J]6'UO'O=W$[^W!PFO]_]\Q\?ON_V7PY/ MF\WQC&IX/=Q.GH['MYN+B\/Z:?.R.ISOWC:O=.1QMW]9'>G/_>>+P]M^LWKH M"KT\7X33Z>+B9;5]G>@:;O;OJ6/W^+A=;^+=^NO+YO6H*]EOGE='.O_#T_;M M8&I[6;^GNI?5_LO7M]_6NY%J/`% ME$Z['OC7_NQA\[CZ^GS\]^Y[OME^?CI2=\_IBM2%W3S\&6\.:W*4JCD/YZJF M]>Z93H#^?_:R5:%!CJS^Z'Y^WSXSRZIED^;PS'=JBHG9^NO MA^/NY?]:%/15Z4K"OA+Z:2I9G,\OI[.`VGQO);.^$OII*PFBZ4+5<:+QJ"]' M/_MRE^?AU3R8_ZP@5=M=.OWL"X97[RNYZ$O2S[[DXOP=9WK9%Z.?HZZ0QFIW MHO1SW!5>]P7IY\@K#"@0=5RHB-1]_JYK##B@Z)=15QF8*%*_C+O.P,2.^F7L ME9KX"6P`G;K2"SV`NO$8KXZKNP_[W?@]O*S5E!C>J+C,2=>CRV/S1 MT*0QJ6KYJ*JYG5!7TZ@[T'SR[2Z:7GZX^$9SP+K7W*,FD(JE4:@!KZJ-?9#X M(/5!YH/)#U(?9#[(?5#XH/1!Y8/:!XT/6@<(,VF<_`HS536W$PIV)UBOI'OW6C.C M;K4B*5FRA!T&D@!)@61`"=DIENE[DPU M9MQK0@X:L@02`TF`I$`R(#F0`D@)I`)2`VF`M"X1AM$N9H1A2BT-T^12#/!@ M*N-RR2+C:@PD`9("R8#D0`H@)9`*2`VD`=*Z1'A(6[H1'BJU]%`3-^B`Q$`2 M("F0#$@.I`!2`JF`U$`:(*U+A&$J__1W2S/:?E.4CMPPJ9JDF9HL:-=K)\K` MWR&QB`,22`(D!9(!R8$40$H@%9`:2`.D=8GPERY>^'MZ%E1JZ:$F;D`"B8$D M0%(@&9`<2`&D!%(!J8$T0%J7",-4QC/"L4XN+>N1%W?^9M*J./`0)8A21!FB M'%&!J$14(:H1-8A:@:2E:BOO#O+30:A21R\*>^2&(:(848(H190ARA$5B$I$ M%:(:48.H%4CZIW;OKG\JI0SGY^/G2)52^]9JY$7KS%NV^X*DLM'*!0U*4)4B MRA#EB`I$):(*48VH0=0*)-U6^W?7[9]$J][NTW;P%-]UC^-O)",_)!DE2D8J]LM9+P3 MI0FB%%&&*$=4("H158AJ1`VB5B!IJ=JSC[!4;_&%I1J)D`04JQO&,G`31"FB M#%&.J$!4(JH0U8@:1*U`TC^U7Q_AG][>"_\T\D)R[H725&/O`G4>Z"QM"H.240)HA11ABA'5"`J$56(:D0-HE8@ M:>FXI"C$I*A'[IJ.*$:4($H198AR1`6B$E&%J$;4(&H%DO[Y2='I(1UBYM,C M+R2]QQ9+J[(AB9D/JE)$&:(<48&H1%0AJA$UB%J!I*7C,I\0,Y\>B9#$S`=5 M":(4488H1U0@*A%5B&I$#:)6(.F?2C_>O\J$.EMQ5YD>>2'I/=M96I4-2>T_RK`J.R]` M1I6@*D64(JVR$C^NU0V`L7&MLQL1UQIY7ONW[T-6 M6:\!):A*$66(JZ3F5WBMDR/A->=+[ASBWWP.666] M!I2@*D64(#T;EVAUT4;#6)H@ M2A%E6%>.J@)1B:C"NFI4-8A:@:1_X[(J-?9S"D9DFR@%6,;--U,QD$UX2U#@RTT0K MF>P%/S?3*^&Y>I7X^+1=?[G?D67D_4#.-J-W'?4;D#-,V0P2G=/+:&$VYQ:S MCJ9DIW.\^[6)(S-%TP&6,;/.Y/2RQFFEP:I)TW..?C[R%XVMS-@S"4M2XSLDL==.B#+C,R6S`=D MA9'9VLH!665DMK9Z0-88F:VME3+IK$H(_1U.&'7SU<`41;,/SU&JI+>`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`9OS,P- M5+S)RK*3ZU#*,KN^9,QLJSFSDZT6+!.M^G=W2Y;)VKSTKV*9/9&:F2SJ175C M9/T:.9N&&J61\`]0'`%*$*6(,D0YH@)1B:A" M5"-J$+4"2?]44NO&GUKYU=PT\@4(RA3`6(W4\SW>@421-S:6?4''_AA1@BA% ME"'*$16(2D05HAI1@TA]G4DYH2](>ZV_MJ2_[O*RV7_>+#?/SX>S]>ZK^I(2 M!??=!\;Z,T\TJND[3]UD!$>NZ$CWO1$X4?":,;]7(<31!P9$Y'NH<@ M<&1!1[I;(G"$SHU>J1FJCK=HJ#;R6F?I4(:\UMMB_P@5&>P=*C#8-V3SH,MD\J#'`7E,>\&ALR6/ M=5;EG1.]&G"CGD!C&7I!X$8]Z1\Z0AX/EJ%/G7T-3]0T[WJX"%.7374 MNQ^CFX\T6/&4[JD'!P<+]=]0]]%;,#?J'1>LB=YIN5%OK.`1>D.%SFKHR#U9 M=3]H"+T_Z M,A?<]_3YM[?5YTVSVG_>OA[.GC>/-*E-N]WJ7G]`3O]QW+W1RDO?;]L=Z<-O MW:]/]*&_#7U.:JK^#?+C;G[\N\"''^7!7GEI+4 MQ2EKH?_-L;PTG*W*[Z&KLOKI^?(CQ]4%*![+4]F^=:2F4>5^3/38NK_VB0S:@H"6(D\.0DWI=) M)HP$GHP$Z.[L`'2U&P4\6=O9",U.]/[E8!EU74$ MGGP0HPERI[-.S@\DG+.&\.3)QX.$'S2TP3)T!HEWV.SFW`EM^A#:$AVO!1 MK3DPB*5(%?`(WB14@8T*1"JP58%8!1(52`5`$L+Y'B$(S=*$9=^;!-FN;($U MC7%@2OJ@B1P2]"&].AJRT9!(0[8:$FM(HB&IB$@BP;B^PRV$!A8CI!D$\!Q9 M@C4-^E"E/J1724,V&A)IR%9#8@U)-"05$4DEV&&_0R5"TZG$1[>F"$C"D4!# M0H:`S7MMD3V7M=WT09PH8DAWN'?[TE:CCOM6`C4:R]1)'\2I4Y%:T@G.IALZ MC<@)U1[+_&F-80BP2FX<_P[LOW17)B2R2A015=*0D"&$YF6%QK:R_C;]>SZ* MB"&"0!IKW+=BK(JED_X]9TU%5DF;Z2?:_,*7][2!*H&+0UAD<1@BGF((J6<4 M"YKW/@MO-E-V]`T-0N-.5,=%CCN3S1&QB,'`6RU5?$^JY--4J9A*4A:&+KGN MAKL$!4FTK"!%D+3`D#+3`0MR!@7[9GSN-PR9=')!2>4YB@LC%D%+75(L;#7> M6.--/N5-15Y)&RC8OJ`-B9:U80CP#YL/4D85L"#!77VS7AN*<"O-7:2O=M9S:M8J%P MX$99?J@"PC.=#Y M-Q-"RJ&PY5Q#QIA#0\:$0W)&I;!)>=1[&66E29VK*FW#QSZK/[@I[R]&2$FK M;(D<&NP1<&@P4<@@!/N/H)1ZP+(HAYZP,WNN!$2<1G0LZ]*0+.91'R9+Y&3S ML:OL22FGN6%A4AIKPKJ#A;FR'Y^]<-6DJ2D6W5T!&+`HH=X+=6BC0Y$.;74H MUJ%$A\BM&.DJ[00U&;WEHA<155$?BJ`XG1HCQ\_D!LOV8(_N87J]%KL^E,^P MM:FXYT/IJ..IZT,!J>-P3?>`;N!KN+#5]$-W(87MUNX_OK6$`+7#V[AH>O#QXN>(?1\J-EU/')]J-QU?.OZVPZW M>JWA(O&2'8H_L_I0GAOC5.QAFNBV6].K2+8'L\K[$;=PA0@S"1=*<&5<0'D& MEURFL<>XY3\@L=5?0J_^!P``__\#`%!+`P04``8`"````"$`--K@S#L#``!A M"P``&0```'AL+W=O4G"Y/@<&P<8"AV0U)AR2:D.4YXS[YR7AA+HGC&#.Q?IZ+4![8\'$*7,_6\*V]"F9=`L169 M,&\5*7'RADEK&Q@4Z:C?:];R@"PI,ZU4D MP`&FW5$\#LC&7][["T+7JRI!?P7?ZY/?CD[E_JL2T7=1<,@VU`DKL)7R&:%/ M$89@,>VL?JPJ\%,Y$8_9+C._Y/X;%TEJH-Q3<(3&EM';`]MR^5;88*%MC<-*O##3##2(8:@#D1]KIT9*5MJ`!T@`9+HW@ M2KI);AUIYV'<[W)VC12"VU(V4MV9UNF8MVGQPLW@VKY_/G%1F[Z.M)UI0UXR/U_LD2#;#47;?FXO^+FJ"?C=+E"'>OST]($! M]>DV`K^W$RPN^+FJ%?C=7E"'>OST=(/%AWT-1IO.">CK![/CR]@V4SO0V!=^ MSE7"O_`LTTXH=SBLC.`5WD2;06HSPGMS'I\L-W;`HLT_,."4+.$_F$I$H9V, MQ\#IN5@>94$!E&DS'*__`P`` M__\#`%!+`P04``8`"````"$`+>F#,S,!``!``@``$0`(`61O8U!R;W!S+V-O M&UL(*($`2B@``$````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` MG)%=3\,@%(;O3?P/#?B)B.?HV=D.]B M#7A$R"4V$(424>`],'<#$?5()0>D^_!U!U`20PT&;`R8%A1_=R-X$_Z\T"4G M3:/CSJ69>MU3MI*'<&AO@QZ*;=L6[;C32/X4ORSN'[M1EDIT=DQY$!)6E]]C![I@\CV_OEG/$1X1.%:BW!.FET-SHY;DZXPKHZ$;K="8(5S0!^*///<0 M-.:8F;)[%"KW_^L2/$;>B.?YH2SJI_2XF[-K\I21G&F)TD?2V940IL!RZ1D; M&M2D1!EMDPZ"J,K[TP0+K)@`J]D=]QY[E+1<-^*J(N*ED'E(G#3%LVV!Y1^\ M8F\ZH.-A5CJ;K-@`0R&G?8F:E),BM`Z[FI%Q?QL/#HE9\8FBT_D#"AG)`GD8 M?::*I5A?=:8]]NA%,H\@F:?N$48 M]2;;EK]G%@M9"2C8(@^!,;P9]\&XQKYGCUP5P.Z`N\*6\J.1%!,'+P62Q`;+ MH%':JE$S)Z0/+04V#K30I[Q71)-MC>4FPY(2JM2E$XF<+E_C(8WU.25/(9N* M]<%SJ>CZ[*EHD\N'DG[&F(WQ72S())K[DQ9&G;HF0*1EA8;C4[EMD+>;:F]K MEX4E7>CV;B2"://#]J0&0_8DJOVR#2YT89M]:!4V^YQ]`EN']&FZPUB?=-G3 MADV":7;94[7W-R!%96UR>3>KW$K][![RL>GCJ[(9QNJ+R6B.@T*&8\IF_VTA MN<$YS*H0I#?G>*]G&YN/&V%T?*SFX_2D<]P^:^-4N+.6Q.L[`E^&]!\```#_ M_P,`4$L!`BT`%``&``@````A`,[@0,,!`@``%!P``!,````````````````` M`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4` M``!,`@``"P`````````````````Z!```7W)E;',O+G)E;'-02P$"+0`4``8` M"````"$`,93SQAH"``!!&P``&@````````````````!@!P``>&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`ASAOH04$``#O#0`` M#P````````````````"Z"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@` M```A`!(6B_L4!@``0Q@``!@`````````````````[`X``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``K; MB?\1"0``O$8``!D`````````````````PB@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(8?5L1*`@``F@4``!D` M````````````````RD<``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%"YB4]D!```-A```!D````````````````` M2%```'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`(Q8;G,M!0``L10``!@`````````````````;U\``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`&E2Q14E!0``BQ<``!D`````````````````/^4``'AL+W=O M&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`*:*KA;L`@``YP@``!D`````````````````2^X` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`%IBG_VX#```ED4``!D`````````````````3?X``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,U$I]KN"@``US8``!@````````````` M````!2&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)U"RWD4(```7[$` M`!D`````````````````@#X!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$I9()M0!@``AQ@``!D````````````` M````GX0!`'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`,6"(6Z]"```JB\``!D`````````````````5Y0!`'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.IK MG-+D!0``R18``!D`````````````````Z+`!`'AL+W=O&PO=V]R:W-H965TU%U.@,``$\+```0```````````` M`````-^\`0!D;V-0&UL4$L%!@`````V`#8`K`X``$_!`0`` !```` ` end XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
Notes Payable (Details Textual) (USD $)
3 Months Ended 12 Months Ended 176 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 3 Months Ended 3 Months Ended 0 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Mar. 31, 2014
Oct. 25, 2010
Seaside Bank note payable [Member]
Mar. 31, 2014
Seaside Bank note payable [Member]
Dec. 31, 2013
Seaside Bank note payable [Member]
Apr. 30, 2009
August 2008 Unsecured Promissory Note [Member]
Aug. 20, 2008
August 2008 Unsecured Promissory Note [Member]
Dec. 31, 2013
August 2008 Unsecured Promissory Note [Member]
Mar. 31, 2014
August 2008 Unsecured Promissory Note [Member]
Mar. 31, 2014
Hunton & Williams notes payable [Member]
Notes_Payable
Dec. 31, 2013
Hunton & Williams notes payable [Member]
Notes_Payable
Mar. 31, 2014
Hunton & Williams notes payable [Member]
Note payable one [Member]
Dec. 31, 2013
Hunton & Williams notes payable [Member]
Note payable one [Member]
Mar. 31, 2014
Hunton & Williams notes payable [Member]
Note payable two [Member]
Dec. 31, 2013
Hunton & Williams notes payable [Member]
Note payable two [Member]
Mar. 31, 2014
Asher notes payable [Member]
Feb. 19, 2014
Asher notes payable [Member]
Dec. 31, 2013
Asher notes payable [Member]
Mar. 31, 2014
Asher notes payable [Member]
Daniel James Management [Member]
Mar. 31, 2013
Asher notes payable [Member]
Daniel James Management [Member]
Mar. 31, 2014
Asher notes payable [Member]
Daniel James Management [Member]
Maximum [Member]
Mar. 31, 2014
Asher notes payable [Member]
Daniel James Management [Member]
Minimum [Member]
Feb. 19, 2014
Daniel Note [Member]
Mar. 31, 2014
Daniel Note [Member]
Notes Payable (Textual)                                                    
Net of unamortized debt discount $ 151,027   $ 112,131 $ 151,027                                            
Notes payable 2,117,972   2,042,972 2,117,972   980,000 980,000   1,000,000 500,000 500,000 384,972 384,972         183,000   143,000            
Common stock issued in connection with issuance of a note payable, Shares         980,000                                          
Effective interest rate         4.25%       13.50%         8.00% 8.00% 8.00% 8.00% 8.00%             8.00%  
Notes payable, net of debt discount 1,966,946   1,930,841 1,966,946                                            
Debt instrument, Maturity date                 May 31, 2010                                  
Gross proceeds from private placement                 19,000,000                                  
Occurrence period of repayment of loan                 within 12 months                                  
Warrant issued to purchase common stock               451,053                                    
Warrant exercise price               $ 0.5321                                    
Fair value of warrant issued               195,694                                    
Number of outstanding notes payable                       2 2                          
Outstanding notes payable                           61,150 61,150 323,822 323,822                  
Accrued interest     598,125                                              
Shares issued in conversion of debt 6,750,781                 1,000,000                                
Gain (loss) on settlement of note payable     1,078,625                                              
Description of note payable                                   The Notes are convertible into common stock, at Asher's option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes.                
Fair value of embedded derivatives                                     214,346   292,257         63,343
Recorded fair value of derivatives and faire value of each subsequent reporting date                                   153,564               63,343
Outstanding principal amount of debt 349,413     349,413                                            
Amortization of debt discount 93,604 124,838   2,073,854                                 127,500          
Interest expense                                         164,757          
Dividend yield                                         0.00%          
Expected volatility                                             181.73% 158.19%    
Risk free rate                                             0.15% 0.03%    
Expected Term                                             1 year 11 days    
Estimated fair value of the Company's common stock                                             $ 0.0447 $ 0.001    
Notes payable, Principle value                   500,000               97,500                
Common shares issued in conversion of debt 6,750,781                 1,000,000                                
Amortization of financing costs and discounts                                         93,604,000 124,838        
Convertible note in principal amount                                                 $ 35,000  

XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurement (Tables)
3 Months Ended
Mar. 31, 2014
Fair Value Measurement [Abstract]  
Summary of changes in fair value of the Company's Level 3 financial liabilities
 
   Excess Share
Derivative
   Warrant
Liability
   
Debt
Derivative
 
Balance, December 31, 2012
 
$
390,048
   
221,179
  
$
—  
 
Total (gains) losses
            
Initial fair value of debt derivative at note issuance
      
—  
   
673,219
 
Initial fair value of derivative relating to reset warrants
  
—  
   
—  
   
—  
 
Mark-to-market at December 31, 2013:
  
84.906
   
(74,324
)
  
(39,761
)
Transfers out of Level 3 upon increase in authorized shares
  
(474,954
)
  
—  
   
—  
 
Transfers out of Level 3 upon conversion and settlement of notes
          
(376,502
)
Balance, December 31, 2013
 
$
—  
  
$
146,855
  
$
256,956
 
Total (gains) losses
            
Initial fair value of debt derivative at note issuance
  
—  
   
—  
   
292,257
 
Mark-to-market at March 31, 2014:
  
—  
   
519,630
   
(30,259
)
Transfers out of Level 3 upon conversion of notes payable
  
—  
   
—  
   
(134,243
)
Balance, March 31, 2014
 
$
—  
  
$
666,485
  
$
384,711
 
Net (Loss) Gain for the period included in earnings relating to the liabilities held at March 31, 2014
 
$
—  
  
$
(519,630
)
 
$
30,259
 
XML 15 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commiments and Contingencies (Details Textual) (USD $)
1 Months Ended 3 Months Ended 1 Months Ended
Jun. 30, 2000
Mar. 31, 2014
Mar. 31, 2014
Warrant [Member]
Nov. 20, 2013
Warrant [Member]
Consulting Agreements [Member]
Mar. 31, 2014
Warrant [Member]
Consulting Agreements [Member]
Dec. 31, 2013
Warrant [Member]
Consulting Agreements [Member]
Commitments and Contingencies (Textual)            
Warrants issued     8,000,000      
Fair value of vested warrants     $ 22,546      
Warrants exercise price     $ 0.0217 $ 0.0113    
Warrants vesting description     2,000,000 warrants vesting 90 days from the effective date, 2,000,000 vesting on each anniversary date for three years.      
Warrant exercise period     4 years 10 years    
Warrant expected to vest in future period     2,000,000      
Patent expiration period 2015          
Accrued expenses   2,122,000     46,317 32,424
Repurchase consideration for unexercised options   77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted.        
Total rescission liability   $ 371,000        
Fess received by Cassel Salpeter & Co       CSC will receive a one-time $25,000 fee, $5,000 monthly fees.    
Common stock purchase warrants       5,207,630    
XML 16 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Option and Warrants (Details) (Stock Options [Member], USD $)
3 Months Ended 12 Months Ended
Mar. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Stock Options [Member]
     
Summary of options and activity      
Options outstanding, Beginning Balance 23,912,943 7,853,376  
Granted, shares 19,800,000 17,400,000  
Exercised, Shares        
Forfeited/Expired, Shares (62,087) (1,340,433)  
Options outstanding, Ending Balance 43,650,856 23,912,943 7,853,376
Options Exercisable, Shares 16,650,856    
Available for grant, Shares 12,800,000    
Options outstanding, Weighted - Average Exercise Price, Beginning Balance $ 0.15 $ 0.67  
Granted, Weighted - Average Exercise Price $ 0.019 $ 0.016  
Forfeited/Expired, Weighted - Average Exercise Price $ 1.08 $ 1.08  
Options outstanding, Weighted - Average Exercise Price, Balance $ 0.08 $ 0.15 $ 0.67
Options exercisable, Weighted - Average Exercise Price $ 0.18    
Options Exercised, Weighted - Average Remaining Contractual Term 9 years 1 month 6 days 9 years 10 months 24 days  
Options outstanding, Weighted - Average Remaining Contractual Term (in years) 9 years 3 months 18 days 9 years 8 years 2 months 12 days
Options exercisable, Weighted - Average Remaining Contractual Term (in years) 8 years 10 months 24 days    
XML 17 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
Property and Equipment
3 Months Ended
Mar. 31, 2014
Property and Equipment [Abstract]  
PROPERTY AND EQUIPMENT
NOTE 3 — PROPERTY AND EQUIPMENT
 
Property and equipment as of March 31, 2014 and December 31, 2013 is summarized as follows:
 
  
March 31,
2014
  
December 31,
2013
 
Laboratory and medical equipment
 $352,358  $352,358 
Furniture, fixtures and equipment
  125,634   125,634 
Computer equipment
  39,525   39,525 
Leasehold improvements
  362,046   362,046 
   879,563   879,563 
Less accumulated depreciation and amortization
  (871,371)  (870,508)
  $8,192  $9,055 
 
Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives.
 
Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment in accordance with the guidance for impairment of long lived assets.
EXCEL 18 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\S8C8V-S(R,5\Y,S'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O M#I.86UE/D%C8W)U961?17AP96YS97,\+W@Z3F%M M93X-"B`@("`\>#I7;W)K5]$:7-T#I7;W)K#I%>&-E;%=O5]4#I7;W)K#I%>&-E;%=O3PO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-T;V-K7T]P=&EO;E]A;F1?5V%R#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E!R;W!E#I%>&-E M;%=O'!E;G-E#I7 M;W)K#I. M86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D=O:6YG7T-O;F-E#I%>&-E;%=O#I%>&-E;%=O'!E;G-E#I%>&-E;%=O'!E;G-E'1U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H M965T4V]U#I%>&-E;%=O5]%<75I='E?1&ES=')I8G5T:6]N7T%G M,3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5S7U!A>6%B;&5?1&5T86EL#I%>&-E;%=O5]4#I%>&-E;%=O#I%>&-E;%=O5]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K7T]P=&EO;E]A;F1?5V%R#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D-O;6UI;65N='-?86YD7T-O;G1I;F=E;F-I97-?1#PO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D9A:7)?5F%L=65?365A#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D9A:7)?5F%L=65?365A#I7;W)K#I%>&-E M;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I% M>&-E;%=O7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!);F9O'0^)SQS M<&%N/CPO'0^)T))3TA%05)4+"!)3D,N/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S(P,30\'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@ M8VQA'!E M;G-E3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S8C8V M-S(R,5\Y,S'0O:'1M;#L@8VAA'0^)SQS<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY M-3`L,#`P+#`P,#QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\S8C8V-S(R,5\Y,S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-C,\'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO M'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XV-S'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S8C8V-S(R M,5\Y,S'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!O9B!W87)R M86YT'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPOF%T:6]N(&]F('=A'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N M8G-P.SQS<&%N/CPO2!N;W1E'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N M8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO6%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA&-H86YG92!F M;W(@'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO&-H86YG92!F;W(@ M9&ES=')I8G5T:6]N(')I9VAT'0^ M)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO M6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO2!I;G9E'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO2!N;W1E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG)FYB'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO6UE;G1S("AP&5R8VES92!O9B!S=&]C:R!O<'1I;VYS(&%N9"!W M87)R86YT'0^)R9N M8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO&5S('!A:60\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO'0^ M)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA6QE M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F M;VYT+79A'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N M;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M#L@=&5X="UT#L@;6%R9VEN.B`P<'@[)SXF(S$V,#L\+W`^#0H\<"!A;&EG;CTS M1&IU6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@;W)P:&%N#L@=&5X M="UT#L@;6%R9VEN.B`P<'@[)SY!('-U;6UA2!S='EL93TS1"=C;VQOF4Z(#$S M<'@[(&9O;G0M#L@+7=E8FMI M="UT97AT+7-T#LG/B8C,38P M.SPO<#X-"CQP(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0M#L@ M+7=E8FMI="UT97AT+7-T#LG M/CQU/D=E;F5R86P\+W4^/"]P/@T*/'`@86QI9VX],T1J=7-T:69Y('-T>6QE M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F M;VYT+79A'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N M;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R M;6%L.R!F;VYT+79A'0M:6YD96YT.B`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`P<'@[)SXF(S$V,#L\+W`^#0H\<"!A;&EG;CTS1&IU#L@=&5X="UT#L@;6%R9VEN.B`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`C,#`P M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#LG/CQU/E)E=F5N=64@4F5C;V=N:71I;VX\+W4^ M/"]P/@T*/'`@6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@;W)P:&%N'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US M<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V-O;&]R.B`C M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A2!I2!O9B!T:&]S92!A;6]U;G1S+B!0#L@=&5X="UT#L@ M;6%R9VEN.B`P<'@[)SX\+W`^#0H\<"!A;&EG;CTS1&IU#L@=&5X="UT#L@ M;6%R9VEN.B`P<'@[)SY!="!T:&4@=&EM92!O9B!E86-H('1R86YS86-T:6]N M+"!M86YA9V5M96YT(&%S&5D(&]R(&1E=&5R;6EN M86)L92!A;F0@=VAE=&AE2!S='EL M93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0M#LG/CPO<#X-"CQP(&%L:6=N/3-$:G5S=&EF>2!S='EL M93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0M#LG/E)E=F5N=65S(&9O6QE/3-$)V-O;&]R.B`C M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A6QE/3-$)V-O;&]R.B`C M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A2!B:6QL86)L92!T;R!T:&4@8W5S M=&]M97(@<'5RF5D(&%S(')E=F5N=64@87,@'!E8W1E9"!T;R!B92!C;VQL96-T960@=VET:&EN(&]N92!Y96%R(&%N9"!A M2!S='EL93TS1"=M87)G:6XZ(#!P>#LG/CPO<#X-"CQP M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=M87)G:6XZ(#!P>#LG/CQU/D-O M;7!R96AE;G-I=F4@26YC;VUE/"]U/CPO<#X-"CQP(&%L:6=N/3-$:G5S=&EF M>2!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X-"CQP(&%L:6=N M/3-$:G5S=&EF>2!S='EL93TS1"=M87)G:6XZ(#!P>#LG/E1H92!#;VUP86YY M(&1O97,@;F]T(&AA=F4@86YY(&ET96US(&]F(&-O;7!R96AE;G-I=F4@:6YC M;VUE(&EN(&%N>2!O9B!T:&4@<&5R:6]D6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA&-L=61E9"!A6QE/3-$)VUA2!F;VQL;W=S($%C8V]U M;G1I;F<@4W1A;F1A65E65EF5D M(&EN('1H92!I;F-O;64@2!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X-"CQP(&%L:6=N M/3-$:G5S=&EF>2!S='EL93TS1"=M87)G:6XZ(#!P>#LG/D%S(&]F($UA28C.#(Q-SMS(&9I;F%N8VEA;"!I;G-T'!O2!R979I97=E9"!B>2!S96YI;W(@;6%N86=E;65N M="X\+W`^#0H\<"!A;&EG;CTS1&IU6QE/3-$)VUA6QE/3-$)VUA28C.#(Q-SMS(')E=F5N=65S+CPO<#X-"CQP M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=M87)G:6XZ(#!P>#LG/CPO<#X- M"CQP(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=M87)G:6XZ(#!P>#LG/CQU M/E)E2!A8V-O=6YT3L@86YD M("0V-2PS,CDL.#DR(&9R;VT@075G=7-T(#$R+"`Q.3DY("AD871E(&]F(&EN M8V5P=&EO;BD@=&\@36%R8V@@,S$L(#(P,30N/"]P/@T*/'`@86QI9VX],T1J M=7-T:69Y('-T>6QE/3-$)VUA6QE/3-$)VUA6%B;&4@86YD(&%C8W)U960@;&EA M8FEL:71I97,L(&%N9"!S:&]R="UT97)M(&)O&EM871E(&9A:7(@ M=F%L=64@8F5C875S92!O9B!T:&4@2!O9B!T M:&5S92!I;G-T2!S='EL M93TS1"=M87)G:6XZ(#!P>#LG/CPO<#X-"CQP(&%L:6=N/3-$:G5S=&EF>2!S M='EL93TS1"=M87)G:6XZ(#!P>#LG/E1H92!C;VUP86YY(&9O;&QO=W,@06-C M;W5N=&EN9R!3=&%N9&%R9',@0V]D:69I8V%T:6]N('-U8G1O<&EC(#@R,"TQ M,"P@1F%I2!F M:6YA;F-I86P@:6YS=')U;65N=',@86YD(&-E2!H87,@ M-"!F=6QL+71I;64@96UP;&]Y965S(&%N9"`Q('!A2!D97!E;F1E;G0@;VX@=&AE(&-O M;G1I;G5E9"!A8W1I=F4@<&%R=&EC:7!A=&EO;B!O9B!T:&5S92!C=7)R96YT M(&5X96-U=&EV92!O9F9I8V5R2!O9B!T:&4@2!S='EL93TS1"=M87)G:6XZ M(#!P>#LG/CPO<#X-"CQP(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=M87)G M:6XZ(#!P>#LG/E1H92!#;VUP86YY(&%C8V]U;G1S(&9O2!I'!E8W1E9"!T;R!A M(&AA=F4@82!M871E7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-T MF4Z(#$S<'@[(&9O M;G0M'0M:6YD96YT.B`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`@("`\=&%B;&4@8VQA'0^)SQS<&%N M/CPO'0^)SQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`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`P M<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L M.R!W:61O=W,Z(&%U=&\[('=O'0M3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQF M;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^/"]F;VYT/CQD:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q-#PO9F]N=#X\+V9O;G0^/"]D:78^ M/"]T9#X\=&0@;F]W3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T M3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA M;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX] M,T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`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`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L M:6=N/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXQ,C4L-C,T/"]F M;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SY#;VUP=71E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R M:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M6QE/3-$ M)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R M/CQT#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)V1IF4Z M(#$P<'0[)SY,96%S96AO;&0@:6UP#LG/CQF;VYT('-T>6QE M/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`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`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SY,97-S(&%C8W5M=6QA=&5D M(&1E<')E8VEA=&EO;B!A;F0@86UOF%T:6]N/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&%L:6=N/3-$#LG/CQF;VYT('-T>6QE M/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[#0H@<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF M;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXI/"]F;VYT/CPO M=&0^/'1D(&%L:6=N/3-$#LG/CQF;VYT('-T>6QE M/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`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`G=&EM97,@;F5W(')O;6%N)SL@ M9F]N="US:7IE.B`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`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V1IF4Z(#$P<'0[)SY02!A;F0@ M97%U:7!M96YT(&%R92!R96-O6QE/3-$)V-O;&]R.B`C M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'0[('1E>'0M=')A M;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U M=&\[('=O'0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E M:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT M+7-T2!O2!A;F0@97%U:7!M96YT(&9O M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'!E;G-E6QE M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@ M;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-TF4Z(#$S<'@[(&9O;G0M6QE/3-$)V-O;&]R.B`C,#`P,#`P M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#L@9&ES<&QA>3H@8FQO8VL[ M(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R M;6%L.R!F;VYT+79A'0M:6YD M96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@ M;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^36%R8V@@,S$L M/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1C96YT97(@#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V)OF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q,SPO M9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)V1IF4Z(#$P<'0[)SY,:6-E;G-E(&%N9"!R;WEA;'1Y(&9E M97,\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\ M+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXF(S@R,3([/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@ M;F]W3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@] M,T0Q)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z(#$P<'0[)SXD/"]F M;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O M;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT3H@8FQO8VL[(&UA3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M6QE M/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z(#$P M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Y)2!V86QI9VX] M,T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z#0H@,3!P=#LG/B8C,38P M.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXQ M+#,W,RPW-S4\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`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`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T6QE/3-$)W1E>'0M:6YD96YT.B`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`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`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`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)V-O;&]R.B`C,#`P,#`P M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#L@9&ES<&QA>3H@8FQO8VL[ M(&UA6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@ M+7=E8FMI="UT97AT+7-T3H@:6YL:6YE M.R<^26X@2G5N92`R,#`P+"!T:&4@0V]M<&%N>2!H860@96YT97)E9"!I;G1O M(&%N(&%G6UE;G1S('1O(%="2"!O=&AE6UE;G0@=&\@86-Q=6ER92!T:&4@;&EC96YS M92X@3VX@07!R:6P@,BP@,C`Q-"P@=&AE($-O;7!A;GD@F4Z(#$S M<'@[(&9O;G0M'0M:6YD M96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@ M;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V1IF4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=B M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!D:7-P;&%Y.B!I;FQI;F4[)SY! M8V-O2P@=&AE($-O;7!A;GD@F4Z(#$S<'@[(&9O M;G0M'0M:6YD96YT.B`P M<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L M.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$ M)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^/&1I M=B!A;&EG;CTS1&QE9G0@6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT M97AT+7-T3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\S8C8V-S(R,5\Y,S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R2!$:7-TF4Z(#$S<'@[(&9O;G0MF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^3D]412`U("8C.#(Q,3L@4U1!3D1" M62!%455)5%D@1$E35%))0E5424].($%'4D5%345.5#PO9F]N=#X\+V1I=CX\ M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=C;VQOF4Z(#$S<'@[ M(&9O;G0M'0M:6YD96YT M.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R M;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE M/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$ M)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA M;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT M+79A#L@ M9&ES<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M2!$:7-T2!T:&4@4T5#("AT:&4@)B,X,C(P.T5Q=6ET M>2!,:6YE)B,X,C(Q.RDN)B,Q-C`[)B,Q-C`[5&AE(')E9VES=')A=&EO;B!S M=&%T96UE;G0@=V5N="!E9F9E8W1I=F4@;VX@1F5B2!T97)M:6YA=&5D(&]N('1H M92!F:7)S="!O9B!!<')I;"P@,C`Q-"`H=&AE(&9I2!O9B!T:&4@ M;6]N=&@@;F5X="!F;VQL;W=I;F<@=&AE('-E8V]N9"`H,CQF;VYT('-T>6QE M/3-$)V1I3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S8C8V-S(R,5\Y,S'0O:'1M M;#L@8VAA6%B;&4\8G(^/"]S=')O;F<^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]LF4Z(#$S<'@[(&9O;G0M'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US M<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^3D]412`V("8C.#(Q,3L@3D]415,@4$%904),13PO9F]N=#X\ M+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=C;VQOF4Z M(#$S<'@[(&9O;G0M'0M M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^ M/"]D:78^/&1I=B!A;&EG;CTS1&QE9G0@6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@ M+7=E8FMI="UT97AT+7-TF4Z(#$S<'@[(&9O;G0M6QE/3-$)V-O M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A M#L@=&5X="UT#LG/CQT M86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ("=T:6UE MF4Z(#$P<'0[)R!C96QL3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T M=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C M96YT97(@3H@8FQO M8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^1&5C96UB97(@,S$L/"]F;VYT/CPO9&EV/CQD:78@86QI9VX] M,T1C96YT97(@3H@ M8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#LG/CQF;VYT('-T>6QE/3-$)V1I MF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/"]T3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6%B;&4N/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L M:6=N/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE M/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N M="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF M;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXY.#`L,#`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`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`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`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T6QE/3-$)W1E>'0M:6YD M96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SY&;W5R=&@@36%N+"!,3$,@;F]T92!P87EA8FQE/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z M(#$P<'0[)SXS-2PP,#`\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXS-2PP,#`\+V9O;G0^/"]T9#X\=&0@=VED=&@] M,T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`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`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`G=&EM97,@;F5W M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE M/3-$)V1IF4Z(#$P<'0[)SXQ+#DV-BPY-#8\+V9O;G0^/"]T M9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M(&%L:6=N/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V-O;&]R.B`C M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'0[('1E>'0M=')A M;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U M=&\[('=O'0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E M:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT M+7-T6QE.B!I=&%L:6,[(&1IF4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^4V5A6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N M="US='EL93H@;F]R;6%L.R!F;VYT+79AF4Z(#$S<'@[(&9O M;G0M'0M:6YD96YT.B`P M<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L M.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$ M)V1IF4Z(#$P<'0[)SY/;B!/8W1O8F5R(#(U+"`R,#$P+"!T M:&4@0V]M<&%N>2!E;G1E2!R96YE=V5D('1H92!L;V%N('=I=&@@4V5A'1E;F0@=&AE(&UA='5R:71Y(&1A=&4@=&\@1&5C96UB M97(@,C,L(#(P,34N/"]F;VYT/CPO9&EV/CQD:78@#L@+7=E8FMI="UT97AT+7-T6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@ M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#L@9&ES<&QA>3H@8FQO8VL[(&UAF4Z(#$S<'@[(&9O;G0M'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!T.R!T97AT+71R M86YS9F]R;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N M="US='EL93H@;F]R;6%L.R!F;VYT+79A2!P=7)S=6%N="!T;R!T:&4@=&5R;7,@;V8@86X@=6YS96-U6UE;G0@;V8@=&AE($)L=65#2`R,#$P+"!H;W=E=F5R('1H92!# M;VUP86YY(&ES(&YO="!O8FQI9V%T960@=&\@;6%K92!P87EM96YT2P@=VET:&]U="!P96YA M;'1Y+"!A;&P@;W5T6UE;G0@;V8@=&AE(&QO86X@8V]U;&0@;V-C=7(@ M=VET:&EN(#$R(&UO;G1H2!H87,@8VQAF4Z(#$S<'@[(&9O;G0M'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!T.R!T97AT M+71R86YS9F]R;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@ M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#L@9&ES<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M2!IF4Z M(#$S<'@[(&9O;G0M'0M M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V1IF4Z(#$P<'0[)SY4:&4@=V%RF4Z(#$S<'@[(&9O;G0M6QE/3-$)V-O;&]R M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O M;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#L@9&ES<&QA M>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@9&ES<&QA>3H@ M8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS M1"=C;VQOF4Z(#$S<'@[(&9O;G0M#L@9&ES<&QA>3H@8FQO8VL[(&UA'0M:6YD96YT M.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R M;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-T2!H M87,@='=O(&]U='-T86YD:6YG(&YO=&5S('!A>6%B;&4@=VET:"!I;G1E6UE;G1S('5N=&EL('1H92!. M;W)T:'-T87(@*&]R('-U8V-EF4Z(#$S<'@[(&9O M;G0M'0M86QI9VXZ('-T M87)T.R!T97AT+6EN9&5N=#H@,'!T.R!T97AT+71R86YS9F]R;3H@;F]N93L@ M=VAI=&4M#L@+7=E8FMI="UT97AT+7-T6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L M.R!F;VYT+79A#L@9&ES<&QA>3H@8FQO8VL[(&UA6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@ M;F]R;6%L.R!F;VYT+79A'0M M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V-O;&]R.B`C,#`P M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[ M('=O'0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-T M2!P97)I;V0@<')I;W(@=&\@8V]N=F5RF4Z(#$S<'@[ M(&9O;G0M'0M:6YD96YT M.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R M;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE M/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^ M/&1I=B!A;&EG;CTS1&QE9G0@6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI M="UT97AT+7-TF4Z(#$S<'@[ M(&9O;G0M'0M86QI9VXZ M('-T87)T.R!T97AT+6EN9&5N=#H@,'!T.R!T97AT+71R86YS9F]R;3H@;F]N M93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R M;6%L.R!F;VYT+79A#L@+7=E8FMI="UT97AT+7-T6QE M.B!I=&%L:6,[(&1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^1&%N:65L($IA;65S($UA;F%G96UE;G0\+V9O;G0^/"]D:78^/&1I M=B!S='EL93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0M6QE/3-$)V-O;&]R M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O M;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#L@9&ES<&QA M>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M2!E;G1E6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N M;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M2!H M87,@:61E;G1I9FEE9"!T:&4@96UB961D960@9&5R:79A=&EV97,@6QE/3-$)V-O M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A M'0M:6YD96YT.B`P<'0[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O M=W,Z(&%U=&\[('=O'0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI M="UT97AT+7-T2!D971EF4Z(#$S M<'@[(&9O;G0M'0M86QI M9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!T.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@ M;F]R;6%L.R!F;VYT+79A#L@9&ES<&QA>3H@8FQO8VL[(&UA3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M2!O9B`Q-3@N,3DE('1O(#$X,2XW,R4L("@S*2!W96EG:'1E9"!A M=F5R86=E(')I2!A;6]R=&EZ960@ M86X@86=G'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!4'0^)SQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V-O;&]R.B`C M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#L@9&ES<&QA>3H@ M8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V-O;&]R.B`C,#`P M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[ M('=O'0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-T M6QE.B!I=&%L:6,[(&1IF4Z(#$P<'0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[('1E>'0M9&5C;W)A=&EO;CH@=6YD M97)L:6YE.R<^061V86YC97,\+V9O;G0^/"]F;VYT/CPO9&EV/CQD:78@#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V M,#L\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0M'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US M<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V1IF4Z(#$P<'0[)SY!F4Z(#$S<'@[(&9O;G0M6QE/3-$)V-O;&]R.B`C,#`P,#`P M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#L@9&ES<&QA>3H@8FQO8VL[ M(&UA3H@:6YL:6YE.R!T97AT+61E M8V]R871I;VXZ('5N9&5R;&EN93LG/DYO=&5S('!A>6%B;&4M3PO9F]N=#X\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0M'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!T.R!T97AT+71R M86YS9F]R;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N M="US='EL93H@;F]R;6%L.R!F;VYT+79A6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L M:6=N/3-$;&5F="!S='EL93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0M M'0M:6YD96YT.B`P<'0[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W M:61O=W,Z(&%U=&\[('=O'0M M6QE/3-$)V1I MF4Z(#$P<'0[)SY/;B!&96)R=6%R>2`R.2P@,C`Q,BP@82!N M;W1E(&ES2P@:6YC;'5D:6YG($1R+B!7:6QL:6%M(%`N($UU M2!*6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N M="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`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`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L M.R!F;VYT+79A'0M:6YD96YT M.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R M;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-T2!A;F0@3F]R=&AS=&%R(&5N=&5R960@ M:6YT;R!A(&QI;6ET960@=V%I=F5R(&%N9"!F;W)B96%R86YC92!A9W)E96UE M;G0@<')O=FED:6YG(&$@2!D871E(&5X=&5N9&5D('!E2!A9W)E960@=&\@:7-S=64@-2PP,#`L,#`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`X)2!O;B!R979E;G5E M#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV M(&%L:6=N/3-$;&5F="!S='EL93TS1"=C;VQOF4Z(#$S<'@[(&9O M;G0M'0M:6YD96YT.B`P M<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L M.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$ M)V1IF4Z(#$P<'0[)SY%9F9E8W1I=F4@3V-T;V)E6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L M:6=N/3-$;&5F="!S='EL93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0M M'0M:6YD96YT.B`P<'0[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W M:61O=W,Z(&%U=&\[('=O'0M M6QE/3-$)V1I MF4Z(#$P<'0[)SY);B!C;VYN96-T:6]N('=I=&@@=&AE(&-O M;G-I9&5R871I;VX@<&%I9"P@3F]R=&AS=&%R('=A:79E9"P@9G)O;2!T:&4@ M969F96-T:79E(&1A=&4@=&AR;W5G:"!T:&4@96%R;&EE'!I2!O9B!T:&4@969F96-T:79E(&1A=&4@*$]C=&]B97(@ M,2P@,C`Q,BDN($EN(&QI974@;V8@=&AE(&EN:71I86P@='=O('!A>6UE;G1S M(&EN('!R969E2!T:&4@=F]T:6YG(')I9VATF4Z(#$S<'@[ M(&9O;G0M'0M86QI9VXZ M('-T87)T.R!T97AT+6EN9&5N=#H@,'!T.R!T97AT+71R86YS9F]R;3H@;F]N M93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R M;6%L.R!F;VYT+79A#L@9&ES<&QA>3H@8FQO8VL[(&UA3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V-O;&]R.B`C,#`P,#`P M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O M'0M6QE M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@ M;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-T6QE.B!I=&%L:6,[(&1IF4Z(#$P<'0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[('1E>'0M9&5C;W)A=&EO;CH@=6YD97)L M:6YE.R<^3V9F:6-E6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E M:6=H=#H@;F]R;6%L.R!L971T97(M#L@9&ES<&QA M>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL M93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0MF4Z(#$P M<'0[)SY!="!-87)C:"`S,2P@,C`Q-"!A;F0@1&5C96UB97(@,S$L(#(P,3,L M('1H92!#;VUP86YY(&AA2!D=64@;VX@3V-T;V)E2!IF4Z M(#$S<'@[(&9O;G0M'0M M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!T.R!T97AT+71R86YS9F]R M;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL M93H@;F]R;6%L.R!F;VYT+79A#L@9&ES<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O M;G0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@9&ES<&QA>3H@ M8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS M1"=C;VQOF4Z(#$S<'@[(&9O;G0MF4Z(#$P<'0[ M)SY/;B!397!T96UB97(@,S`L(#(P,3,L('1H92!#;VUP86YY(&ES6QE/3-$)V-O;&]R.B`C,#`P,#`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`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@ M;F]R;6%L.R!F;VYT+79A#L@9&ES<&QA>3H@8FQO8VL[(&UA3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S8C8V-S(R M,5\Y,S'0O:'1M;#L@8VAAF4Z(#$S<'@[ M(&9O;G0M'0M:6YD96YT M.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R M;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE M/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M3D]412`X("8C.#(Q,CL@1$52259!5$E612!,24%"24Q)5$E%4SPO9F]N=#X\ M+V1I=CX\9&EV('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US M='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE.B!I=&%L:6,[ M(&1IF4Z(#$P<'0[)SY297-E="!W87)R86YT6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US M='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M2!I#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\ M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=C;VQOF4Z(#$S<'@[ M(&9O;G0M'0M:6YD96YT M.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R M;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE M/3-$)V1IF4Z(#$P<'0[)SY4:&4@0V]M<&%N>2!H87,@:61E M;G1I9FEE9"!E;6)E9&1E9"!D97)I=F%T:79E2!R96-OF4Z(#$S<'@[(&9O;G0M6QE/3-$)V-O M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A M#L@9&ES M<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@,36QE/3-$)V-O;&]R.B`C M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'0[('1E>'0M=')A M;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U M=&\[('=O'0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E M:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT M+7-T6QE.B!I=&%L:6,[(&1IF4Z(#$P<'0[)SY#;VYV M97)T:6)L92!N;W1E6QE/3-$)V-O;&]R M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O M;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'0[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z M(&%U=&\[('=O'0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT M97AT+7-T#L@ M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M28C.#(Q M-SMS(&-O;6UO;B!S=&]C:RX@5&AE($-O;7!A;GD@:&%S(&ED96YT:69I960@ M=&AE(&5M8F5D9&5D(&1E6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L M.R!F;VYT+79A'0M:6YD96YT M.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R M;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-T2!O9B`Q M-S,N-S(E+"`H,RD@=V5I9VAT960@879E2!R96-OF4Z(#$S<'@[(&9O;G0MF4Z(#$P<'0[ M)SY"87-E9"!U<&]N($%30R`X-#`M,34M,C4@*$5)5$8@27-S=64@,#`M,3DL M('!A2!E=F%L=6%T97,@:71S(&-O;G1R86-TF4Z M(#$S<'@[(&9O;G0M'0M M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V1IF4Z(#$P<'0[)SY!="!-87)C:"`S,2P@ M,C`Q-"P@=&AE(&%G9W)E9V%T92!D97)I=F%T:79E(&QI86)I;&ET:65S('=A M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3QB"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$S+C8S<'@O,39P M>"`G=&EM97,@;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@ M;&5T=&5R+7-P86-I;F#LG/CPO<#X-"CQP(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT M.B`Q,RXV,W!X+S$V<'@@)W1I;65S(&YE=R!R;VUA;B<[(&UA'0M M:6YD96YT.B`P<'@[(&QE='1E'0M M2!A8V-R=65D(&%N9"!U M;G!A:60@9&EV:61E;F1S(&]R(&]T:&5R(&9E97,@8F5F;W)E(&1I2!T:&4@=F]T:6YG(')I9VAT M"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M2!S='EL93TS1"=F;VYT M.B`Q,RXV,W!X+S$V<'@@)W1I;65S(&YE=R!R;VUA;B<[(&UA'0M M:6YD96YT.B`P<'@[(&QE='1E'0M M"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z M(#$S+C8S<'@O,39P>"`G=&EM97,@;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[ M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'0M:6YD96YT.B`P<'@[(&QE='1E'0M3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S8C8V-S(R,5\Y,S'0O:'1M;#L@8VAA M'0^)SQP('-T M>6QE/3-$)V9O;G0Z(#$S+C8S<'@O,39P>"`G=&EM97,@;F5W(')O;6%N)SL@ M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG/CQB/DY/5$4@,3`@)B,X M,C$R.R!35$]#2R!/4%1)3TY3($%.1"!705)204Y44SPO8CX\+W`^#0H\<"!S M='EL93TS1"=F;VYT.B`Q,RXV,W!X+S$V<'@@)W1I;65S(&YE=R!R;VUA;B<[ M(&UA'0M:6YD96YT.B`P<'@[(&QE='1E'0M'0M:6YD96YT.B`P<'@[(&QE='1E'0M"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$S+C8S<'@O,39P>"`G=&EM97,@ M;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P M86-I;F#LG/CPO M<#X-"CQP(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,RXV,W!X M+S$V<'@@)W1I;65S(&YE=R!R;VUA;B<[(&UA'0M:6YD96YT.B`P M<'@[(&QE='1E'0M2!R969E2!T:&4@0F]A2!S='EL93TS1"=F;VYT.B`Q,RXV,W!X M+S$V<'@@)W1I;65S(&YE=R!R;VUA;B<[(&UA'0M:6YD96YT.B`P M<'@[(&QE='1E'0M"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`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`@86QI9VX],T1C96YT97(@ M6QE/3-$)V)O M#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$ M)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/@T*/'`@6QE.B!S;VQI9#LG(&-O;'-P86X],T0S M/@T*/'`@86QI9VX],T1C96YT97(@#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\ M=&0@=VED=&@],T0V('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)VUA M6QE/3-$)W9E6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE M/3-$)VUA#LG/C`N-C<\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-B!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$ M)VUA#LG/D=R86YT960\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-B!V86QI9VX] M,T1B;W1T;VT-"B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F M.R<^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X-"CPO M=&0^#0H\=&0@=VED=&@],T0V('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^#0H\<"!S='EL93TS1"=M87)G M:6XZ(#!P>#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0X,2!V M86QI9VX],T1B;W1T;VT@#LG/C$W+#0P,"PP,#`\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$."!V86QI M9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/C`N,#$V/"]P/@T*/"]T9#X-"CQT M9"!W:61T:#TS1#8@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA&5R8VES960\+W`^#0H\+W1D/@T* M/'1D('=I9'1H/3-$-B!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)A M8VMG6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/B0\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$.#$@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)A8VMG#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0X,2!V86QI M9VX],T1B;W1T;VT@6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$ M)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$)VUA6QE.B!S;VQI9#LG/@T*/'`@ M6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE M/3-$)VUA6QE.B!S;VQI9#LG/@T*/'`@86QI9VX],T1R:6=H="!S M='EL93TS1"=M87)G:6XZ(#!P>#LG/C$N,#@\+W`^#0H\+W1D/@T*/'1D('=I M9'1H/3-$-B!V86QI9VX],T1B;W1T;VT@6QE.B!S;VQI9#LG/@T*/'`@6QE/3-$)V)O#L@8F]R9&5R+6)O M='1O;2US='EL93H@6QE/3-$)VUA#LG/D]P=&EO;G,@;W5T6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)VUA6QE M/3-$)V)A8VMG6QE/3-$ M)VUA6QE M/3-$)V)A8VMG6QE/3-$)V)A8VMG M6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG M6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0V M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`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`@6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE.B!S;VQI9#LG/@T*/'`@ M86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XZ(#!P>#LG/C$N,#@\+W`^ M#0H\+W1D/@T*/'1D('=I9'1H/3-$-B!V86QI9VX],T1B;W1T;VT@6QE.B!S;VQI9#LG M/@T*/'`@6QE.B!S;VQI9#LG/@T*/'`@ M6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA#LG/D]P=&EO;G,@ M;W5T6QE/3-$)V)A8VMG M6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/B0\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$.#$@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE M/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0V('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^ M#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X-"CPO=&0^ M#0H\=&0@=VED=&@],T0R,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED M=&@],T0V('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O M;&]R.B`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`Q,#`E.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\ M+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT^#0H\ M<"!A;&EG;CTS1&-E;G1E#LG/CQB/B8C M,38P.SPO8CX\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,S`V('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B`C,#`P,#`P M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q<'@[(&)O6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+6)O='1O M;2US='EL93H@6QE/3-$)VUA&5R8VES M86)L93PO8CX\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B M;W1T;VT^#0H\<"!A;&EG;CTS1&-E;G1E#LG/CQB/B8C,38P.SPO8CX\+W`^#0H\+W1D/@T*/"]T6QE/3-$)V)O#L@8F]R9&5R+6)O M='1O;2US='EL93H@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO M=&0^#0H\=&0@=VED=&@],T0Q,3(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$ M)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE.B!S;VQI9#LG/@T*/'`@6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@ M6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\+W1R/@T* M/'1R/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CH@8F]T=&]M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P M>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T* M/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V M,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,C`@=F%L:6=N/3-$8F]T=&]M M/@T*/'`@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^ M#0H\=&0@=VED=&@],T0W('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$ M)VUA#LG/B8C M,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0W('9A;&EG;CTS1&)O='1O M;3X-"CQP('-T>6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0S M-R!V86QI9VX],T1B;W1T;VT^#0H\<"!A;&EG;CTS1&-E;G1E#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF M(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-#4@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@86QI9VX],T1C96YT97(@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@] M,T0W('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO M=&0^#0H\=&0@=VED=&@],T0Q."!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL M93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[ M)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-3,@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@6QE/3-$)VUA#LG/B8C,38P.SPO<#X- M"CPO=&0^#0H\=&0@=VED=&@],T0W('9A;&EG;CTS1&)O='1O;3X-"CQP('-T M>6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0R,`T*('9A;&EG M;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@ M=VED=&@],T0X-"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M87)G M:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\ M+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT^#0H\ M<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@ M,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,3$@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)VUA M#LG/B8C,38P M.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0U,R!V86QI9VX],T1B;W1T;VT^ M#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O M;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P M>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T* M/"]T6QE/3-$)V)A8VMG6QE/3-$)VUA6QE M/3-$)VUA6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0W M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C M8V-E969F.R<^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO M<#X-"CPO=&0^#0H\=&0@=VED=&@],T0S-R!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@] M,T0Q."!V86QI9VX],T1B;W1T;VT@#LG/B0\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-3,@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG#LG/B8C,38P M.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0X-"!V86QI9VX],T1B;W1T;VT@ M#LG/C$V+#`Y,"PP,#`\ M+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA#LG/C`N,#0\+W`^#0H\+W1D/@T*/'1D M('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0S-R!V M86QI9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG6QE M/3-$)VUA#LG/B0\+W`^#0H\+W1D/@T*/'1D M('=I9'1H/3-$-3,@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED M=&@],T0R,"!V86QI9VX],T1B;W1T;VT@#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0X M-"!V86QI9VX],T1B;W1T;VT@#LG/C$V,BPR.#8\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI M9VX],T1B;W1T;VT@6QE/3-$ M)V)A8VMG6QE/3-$)VUA M6QE/3-$)VUA#LG/C`N.#`\ M+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT@6QE M/3-$)V)A8VMG6QE/3-$ M)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q."!V86QI9VX] M,T1B;W1T;VT@#LG/B0\ M+W`^#0H\+W1D/@T*/'1D#0H@=VED=&@],T0U,R!V86QI9VX],T1B;W1T;VT@ M#LG/C4N-34\+W`^#0H\ M+W1D/@T*/'1D('=I9'1H/3-$,3$@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)A8VMG6QE/3-$)VUA M6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@ M=VED=&@],T0Q,2!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D(&YO M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^#0H\<"!S='EL93TS1"=M M87)G:6XZ(#!P>#LG/B0W+C8Y/"]P/@T*/"]T9#X-"CQT9"!W:61T:#TS1#<@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE M/3-$)VUA#LG/C6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A M8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$ M)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED M=&@],T0Q."!V86QI9VX],T1B;W1T;VT@#LG/B0\+W`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`C,#`P,#`P.R!B M;W)D97(M8F]T=&]M+6-O;&]R.B`C,#`P,#`P.R!B;W)D97(M=&]P+7=I9'1H M.B`R<'@[(&)O#L@8F]R9&5R+71O M<"US='EL93H@#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0S-R!V M86QI9VX],T1B;W1T;VT@6QE.B!S M;VQI9#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XS,W!X.R!B;W)D97(M M=&]P+7-T>6QE.B!S;VQI9#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA#L@8F]R9&5R+71O<"US='EL93H@#L@8F]R9&5R+71O<"US M='EL93H@#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q."!V86QI M9VX],T1B;W1T;VT@6QE.B!S;VQI M9#L@8F%C:V=R;W5N9"UC;VQO#LG/B0\+W`^#0H\+W1D/@T*/'1D M('=I9'1H/3-$-3,@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2UW:61T M:#H@,2XS,W!X.R!B;W)D97(M=&]P+7-T>6QE.B!S;VQI9#L@8F]R9&5R+6)O M='1O;2US='EL93H@#LG M/C`N,#@\+W`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`R,#$T+"!T:&4@0V]M<&%N>2!I28C.#(Q-SMS M(&-O;6UO;B!S=&]C:R!A="`D,"XP,3D@<&5R('-H87)E('1O(&]F9FEC97)S M+"!V97-T:6YG(&%T(#(U)2!I;6UE9&EA=&5L>2!A;F0@=&AE(')E;6%I;F1E M&EM871E;'D@-#(@;6]N=&AS+"!E>&5R8VES86)L92!O M=F5R(#$P('EE87)S+B!4:&4@86=G2`R M-"P@,C`Q-"P@=&AE($-O;7!A;GD@:7-S=65D(&%N(&%G9W)E9V%T92`T+#@P M,"PP,#`@;W!T:6]N28C.#(Q-SMS M(&-O;6UO;B!S=&]C:R!A="`D,"XP,3D@<&5R('-H87)E('1O(&]F9FEC97)S M+"!V97-T:6YG(&EM;65D:6%T96QY(&%N9"!E>&5R8VES86)L92!O=F5R(#$P M('EE87)S+B!4:&4@86=G3H@,38S+C8S)2!A;F0@4FES M:R!F2!S M='EL93TS1"=M87)G:6XZ(#!P>#LG/CPO<#X-"CQP(&%L:6=N/3-$:G5S=&EF M>2!S='EL93TS1"=M87)G:6XZ(#!P>#LG/E1H92!F86ER('9A;'5E(&]F(&%L M;"!O<'1I;VYS('9E2P@=V%S(&-H87)G960@=&\@8W5R6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)W=I9'1H.B`Q,#`E.R!F M;VYT+7-I>F4Z(#$P<'0[)R!C96QL6QE/3-$)W9E#L@8F]R9&5R+6)O='1O;2US='EL M93H@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@ M=VED=&@],T0W('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T M=&]M+6-O;&]R.B`C,#`P,#`P.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q<'@[ M(&)O6QE.B!S;VQI9#LG/@T*/'`@86QI9VX],T1C96YT97(@ M65A#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\ M+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT^#0H\ M<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@ M,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,C(@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)VUA M#LG/B8C,38P M.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q."!V86QI9VX],T1B;W1T;VT^ M#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O M;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P M>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T* M/'1D('=I9'1H/3-$,38@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q M,"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S M+C)P>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D M/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H-"B`S+C)P>#LG M/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0S.2!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN M+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H M/3-$-#@@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D(&YO=W)A M<#TS1&YO=W)A<"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^3W5T2`Q+"`R,#$S/"]T9#X-"CQT9"!W:61T:#TS1#<@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)VUA6QE M/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE M/3-$)V)A8VMG6QE/3-$)V)A8VMG M6QE/3-$)VUA6QE/3-$)W9E6QE/3-$)VUA M6QE/3-$)V)A M8VMG6QE/3-$)V)A8VMG#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED M=&@],T0W('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O M;&]R.B`C9F9F9F9F.R<^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C M,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q-B!V86QI9VX],T1B;W1T M;VT@#LG/B0\+W`^#0H\ M+W1D/@T*/'1D('=I9'1H/3-$-C$@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)A8VMG#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0W('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^ M#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X-"CPO=&0^ M#0H\=&0@=VED=&@],T0S.2!V86QI9VX],T1B;W1T;VT@#LG/CDN,CPO<#X-"CPO M=&0^#0H\=&0@=VED=&@],T0Q,R!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`M,3!P>#LG/B8C,38P.R8C M,38P.R8C,38P.T5X97)C:7-E9#PO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0W M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C M8V-E969F.R<^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO M<#X-"CPO=&0^#0H\=&0@=VED=&@],T0R,B!V86QI9VX],T1B;W1T;VT@#LG/B8C,38P.R8C,38P.R8C M,38P.R8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Y.2!V86QI9VX] M,T1B;W1T;VT@#LG/B8C M.#(Q,CLF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,3@@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A M8VMG6QE/3-$)VUA6QE/3-$)VUA#LG/C`N,#`\+W`^ M#0H\+W1D/@T*/'1D('=I9'1H/3-$,3`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)V)A8VMG6QE/3-$ M)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@ M6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$ M)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$ M)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$)VUA6QE.B!S;VQI9#LG/@T* M/'`@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XZ(#!P>#LG/C`N,S@\ M+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,3`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$ M)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R M+6)O='1O;2US='EL93H@6QE.B!S;VQI9#LG/@T*/'`@ M#LG/B8C,38P.R8C,38P.R8C,38P M.R8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Y.2!V86QI9VX],T1B M;W1T;VT@#LG/C$Q."PP M-S@L.#4V/"]P/@T*/"]T9#X-"CQT9"!W:61T:#TS1#$X('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\ M<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\ M=&0@=VED=&@],T0W('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O M=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P M>#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q-B!V86QI9VX] M,T1B;W1T;VT@#LG/B0\ M+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-C$@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)V)A8VMG#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0W('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E M969F.R<^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X- M"CPO=&0^#0H\=&0@=VED=&@],T0S.2!V86QI9VX],T1B;W1T;VT@#LG/B8C,38P.R8C,38P.R8C,38P M.R8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0T."!V86QI9VX],T1B M;W1T;VT@#LG/C8N,SPO M<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q,R!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`M,3!P>#LG/B8C M,38P.R8C,38P.R8C,38P.TES#LG/B8C,38P.R8C,38P M.R8C,38P.R8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Y.2!V86QI M9VX],T1B;W1T;VT@#LG M/C,R+#(Y,BPW.#,\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,3@@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A M8VMG6QE/3-$)VUA6QE/3-$)VUA#LG/C`N,#$W/"]P M/@T*/"]T9#X-"CQT9"!W:61T:#TS1#$P('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^#0H\<"!S='EL93TS M1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@] M,T0W('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R M.B`C9F9F9F9F.R<^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P M.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0S.2!V86QI9VX],T1B;W1T;VT@ M#LG/B8C,38P.R8C,38P M.R8C,38P.R8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0T."!V86QI M9VX],T1B;W1T;VT@#LG M/C@N-#PO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q,R!V86QI9VX],T1B;W1T M;VT@'0M:6YD96YT.B`M,3!P M>#LG/B8C,38P.R8C,38P.R8C,38P.T5X97)C:7-E9#PO<#X-"CPO=&0^#0H\ M=&0@=VED=&@],T0W('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O M=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P M>#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0R,B!V86QI9VX] M,T1B;W1T;VT@#LG/B8C M,38P.R8C,38P.R8C,38P.R8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@] M,T0Y.2!V86QI9VX],T1B;W1T;VT@#LG/B8C.#(Q,CL\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,3@@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)VUA6QE M/3-$)V)A8VMG6QE/3-$ M)VUA6QE/3-$)VUA#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S@R,3([/"]P/@T*/"]T9#X- M"CQT9"!W:61T:#TS1#$P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K M9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\<#XF(S$V,#L\+W`^#0H\+W1D M/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)V)A8VMG6QE/3-$)W9E#L@ M8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA M'!I6QE/3-$)V)O#L@8F]R9&5R+6)O='1O M;2US='EL93H@6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE.B!S M;VQI9#LG/@T*/'`@6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@ M6QE/3-$)VUA6QE/3-$)VUA6QE.B!S M;VQI9#LG/@T*/'`@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XZ(#!P M>#LG/C`N,3@\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,3`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`S,2P@,C`Q-#H\+W`^ M#0H\<"!A;&EG;CTS1&-E;G1E#LG/CPO M<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="US:7IE.B`Q M,'!T.R<@8V5L;'-P86-I;F<],T0P/@T*/'1R('-T>6QE/3-$)V9O;G0M6QE.B!S;VQI9#LG(&-O;'-P86X],T0Q M,3X-"CQP(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)VUA6QE.B!S;VQI9#LG M(&-O;'-P86X],T0V/@T*/'`@86QI9VX],T1C96YT97(@&5R8VES86)L93PO8CX\+W`^#0H\ M+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL M93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[ M)SXF(S$V,#L\+W`^#0H\+W1D/@T*/"]T6QE.B!S;VQI9#LG/@T*/'`@6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL M93H@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@ M=VED=&@],T0Q,3<@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE.B!S;VQI9#LG/@T*/'`@6QE.B!S;VQI9#LG(&-O;'-P86X],T0S/@T*/'`@86QI M9VX],T1C96YT97(@6QE.B!S;VQI9#LG M/@T*/'`@6QE/3-$)W9E6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED M=&@],T0W('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)VUA#LG/B8C,38P.SPO<#X- M"CPO=&0^#0H\=&0@=VED=&@],T0R,"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@,RXR M<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$.3`@=F%L:6=N M/3-$8F]T=&]M/@T*/'`@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@ M=VED=&@],T0T-"!V86QI9VX],T1B;W1T;VT^#0H\<"!A;&EG;CTS1&-E;G1E M#L@;6%R9VEN+6)O='1O;3H@ M,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,3(@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0U,B!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P M>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T* M/'1D('=I9'1H/3-$,3$@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^ M#0H\=&0@=VED=&@],T0Y,"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF M(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O M='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$ M,3$@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE M/3-$)VUA#LG M/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0U,B!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN M+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H M/3-$-R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P M.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\ M+W1D/@T*/"]T6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q-R!V86QI M9VX],T1B;W1T;VT@#LG M/B0\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-3(@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)V)A8VMG#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0W M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C M8V-E969F.R<^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO M<#X-"CPO=&0^#0H\=&0@=VED=&@],T0R,"!V86QI9VX],T1B;W1T;VT@#LG/B8C,38P.R8C,38P.R8C M,38P.R8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Y,"!V86QI9VX] M,T1B;W1T;VT@#LG/CDW M+#8Y-BPY-C<\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B M;W1T;VT@6QE/3-$)V)A8VMG M6QE/3-$)VUA6QE/3-$)VUA#LG/C`N,#(\+W`^#0H\ M+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)A M8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$ M)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$ M)VUA6QE/3-$)V)A M8VMG6QE/3-$)VUA M6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG M#LG/C(L-CDY+#8W-3PO<#X-"CPO=&0^#0H\ M=&0@=VED=&@],T0W('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O M=6YD+6-O;&]R.B`C9F9F9F9F.R<^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P M>#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q,2!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)V)A M8VMG6QE/3-$)VUA M6QE/3-$ M)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE M/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE M/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/B0\+W`^ M#0H\+W1D/@T*/'1D('=I9'1H/3-$-3(@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)V)A8VMG6QE/3-$)V)A8VMG M6QE/3-$)VUA6QE/3-$)W9E#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA#LG/B8C M,38P.R8C,38P.R8C,38P.R8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@] M,T0Y,"!V86QI9VX],T1B;W1T;VT@#LG/C(L-S`Q+#(X,CPO<#X-"CPO=&0^ M#0H\=&0@=VED=&@],T0W('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D M97(M8F]T=&]M+6-O;&]R.B`C,#`P,#`P.R!B;W)D97(M8F]T=&]M+7=I9'1H M.B`Q+C,S<'@[(&)O#LG/B8C,38P.R8C,38P.R8C,38P.R8C M,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0T-"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)V)O#L@8F]R9&5R+6)O='1O M;2US='EL93H@6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL M93H@6QE/3-$)VUA6QE/3-$)VUA6QE M.B!S;VQI9#LG/@T*/'`@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XZ M(#!P>#LG/C6QE/3-$)V)O#L@8F]R9&5R+6)O='1O M;2US='EL93H@6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL M93H@6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$ M)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA#LG/B0\+W`^#0H\+W1D/@T* M/'1D('=I9'1H/3-$-3(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$ M)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$)W9E M6QE/3-$)VUA6QE/3-$ M)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG M#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0W('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E8V9F.R<^ M#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X-"CPO=&0^ M#0H\=&0@=VED=&@],T0S-B!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)V)A8VMG6QE/3-$)VUA M6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA#LG/C`N,3<\+W`^#0H\+W1D/@T*/'1D('=I9'1H M/3-$,3$@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$ M)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA#LG/C`N,3,\+W`^#0H\+W1D/@T*/'1D('=I9'1H M/3-$-R!V86QI9VX],T1B;W1T;VT@#LG/DEN(&-O;FIU;F-T:6]N M('=I=&@@=&AE(&%U=&AO2!G6QE/3-$)VUA6QE/3-$)VUA65A7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPOF4Z(#$S<'@[(&9O;G0M#L@=&5X="UT#L@;6%R9VEN.B`P<'@[)SX\8CY. M3U1%(#$Q("8C.#(Q,CL@0T]-34E4345.5%,@04Y$($-/3E1)3D=%3D-)15,\ M+V(^/"]P/@T*/'`@6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E M:6=H=#H@;F]R;6%L.R!L971T97(M#L@;W)P:&%N'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M2!S M='EL93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0M#LG/CPO<#X-"CQP('-T>6QE/3-$)V-O;&]R.B`C M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#LG/CQU/DIO:6YT(%9E;G1U6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@ M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#LG/CQU/CQBF4Z(#$S<'@[(&9O;G0M#L@=&5X="UT M#L@;6%R9VEN.B`P<'@[)SX\+W`^#0H\<"!A;&EG;CTS1&IU M6QE M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@ M;F]R;6%L.R!L971T97(M#L@;W)P:&%N#L@=&5X="UT M#L@;6%R9VEN.B`P<'@[)SY/;B!-87)C:"`Q,"P@,C`Q-"P@ M=&AE($-O;7!A;GD@96YT97)E9"!A(&IO:6YT+79E;G1U7-I8VEA;B!T2X@26X@861D:71I;VXL(&5A8V@@<&%R='D@=VEL;"!B92!R97-P;VYS:6)L M92!F;W(@&ES=&EN9R!A M;F0@<')E=FEO=7,@8W5S=&]M97)S+B!07,@;V8@=&AE(&%C8V]U;G1I;F<@9F]R('!A=&EE;G1S(&%N9"!P M:'ES:6-I86X@=')A:6YI;F<@86YD(#,P(&1A>2!W:71H('-A;&5S(&]F(&5Q M=6EP;65N="!A;F0@:VET#L@=&5X="UT#L@;6%R9VEN.B`P<'@[)SX\+W`^#0H\<"!A;&EG;CTS1&IU#L@=&5X="UT#L@;6%R9VEN.B`P<'@[)SY);B!C;VYS:61E2!D871E(&9O6QE/3-$)V-O M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A M'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T97AT M+71R86YS9F]R;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T#LG/CPO<#X-"CQP('-T>6QE/3-$ M)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA M;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT M+79A'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T M#LG/CQU/E=I;&QI86T@0F5A M=6UO;G0@2&]S<&ET86P\+W4^/"]P/@T*/'`@6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@;W)P:&%N6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L M.R!F;VYT+79A'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@ M,'!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT M97AT+7-T#LG/CPO<#X-"CQP M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=C;VQOF4Z(#$S<'@[ M(&9O;G0M#L@+7=E8FMI="UT M97AT+7-T#LG/CQF;VYT('-T M>6QE/3-$)V)A8VMG6]C87)D:6%L(&-E;&P@<')O;&EF97)A=&EO M;B!I;B!V:71R;RP@;W(@=&AE(%="2"!)4"X@5&AE('1E2!H87,@6QE/3-$)V-O;&]R.B`C,#`P M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#L@=&5X="UT#L@;6%R M9VEN.B`P<'@[)SX\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C M9F9F9F9F.R<^06-C;W)D:6YG;'DL('1H92!#;VUP86YY('=I;&P@&EM871E;'D@)#(L,3(R+#`P,"!I;B!S971T;&5M96YT(&]F M(&1E8G0@=VAI8V@@6QE M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@ M;F]R;6%L.R!L971T97(M#L@;W)P:&%N'0M M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@;W)P:&%N'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US M<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M28C.#(Q-SMS(&-O;6UO;B!S=&]C:SPO=3X\=3X\8G(@+SX\+W4^/"]P M/@T*/'`@6QE M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@ M;F]R;6%L.R!L971T97(M#L@;W)P:&%N'0M M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V-O;&]R M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O M;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A2!I;G1E;F1S('1O(&UA:V4@82!R97-C:7-S:6]N(&]F9F5R M('1O('1H97-E('!E2!W M:6QL(&]F9F5R('1O(')E<'5R8VAA2!T:&4@;G5M8F5R(&]F M(&]P=&EO;B!S:&%R97,L('!L=7,@:6YT97)E2!W;W5L9"!B92!U M<"!T;R!A<'!R;WAI;6%T96QY("0S-S$L,#`P+B!(;W=E=F5R+"!A2!B96QI979E2!A;GD@;V8@=&AE'!E;F1I='5R92!B>2!T:&4@0V]M M<&%N>2P@;F\@;&EA8FEL:71Y('=AF4Z(#$S<'@[(&9O;G0M#L@ M=&5X="UTF4Z(#$S<'@[(&9O;G0M#L@=&5X="UT6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@ M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#LG/CPO<#X-"CQP(&%L:6=N/3-$:G5S=&EF>2!S M='EL93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0M#LG/E1H92!#;VUP86YY(&ES('-U8FIE8W0@=&\@ M;W1H97(@;&5G86P@<')O8V5E9&EN9W,@=&AA="!A&-E28C.#(Q-SMS(&)U6QE/3-$)VUA#LG/CQF;VYT('-T>6QE M/3-$)V)A8VMG&-L=7-I=F4@=&AI3PO9F]N M=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$ M)V)A8VMG&5R8VES86)L92!A="`D+C`Q,3,@86YD(&%P<&QI8V%B;&4@8V]N2!S96-U2!W:6QL(&%L'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$S M+C8S<'@O,39P>"`G=&EM97,@;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[(&-O M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E M;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG/CQB/DY/5$4@,3(@)B,X,C$R.R!&04E2(%9!3%5% M($U%05-54D5-14Y4/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$S+C8S M<'@O,39P>"`G=&EM97,@;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z M(#!P>#L@;&5T=&5R+7-P86-I;F#LG/CPO<#X-"CQP(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS M1"=F;VYT.B`Q,RXV,W!X+S$V<'@@)W1I;65S(&YE=R!R;VUA;B<[(&UA'0M:6YD96YT.B`P<'@[(&QE='1E'0M2!A9&]P=&5D M('1H92!P2P@F4@=&AE M('5S92!O9B!O8G-EF4@=&AE('5S M92!O9B!U;F]B2!B92!U"\Q-G!X("=T:6UE#L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE M/3-$)V9O;G0Z(#$S+C8S<'@O,39P>"`G=&EM97,@;F5W(')O;6%N)SL@;6%R M9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG/DQE=F5L(#$@)B,X,C$Q.R!1 M=6]T960@<')I8V5S(&EN(&%C=&EV92!M87)K971S(&9O2!S='EL93TS1"=F;VYT.B`Q,RXV,W!X+S$V<'@@)W1I;65S(&YE=R!R;VUA M;B<[(&UA'0M:6YD96YT.B`P<'@[(&QE='1E'0M"\Q-G!X("=T M:6UE#L@8V]L;W(Z(",P,#`P,#`[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@=VAI=&4M M2!S='EL93TS1"=F;VYT.B`Q,RXV,W!X+S$V<'@@)W1I;65S(&YE M=R!R;VUA;B<[(&UA'0M:6YD96YT.B`P<'@[(&QE='1E'0M"\Q M-G!X("=T:6UE#L@8V]L;W(Z(",P M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X M.R!L971T97(M#L@ M=VAI=&4M2!T:&%T(&%R92!S:6=N:69I M8V%N="!T;R!T:&4@;65A6QE/3-$)V9O;G0Z(#$S+C8S<'@O,39P>"`G=&EM97,@;F5W(')O;6%N)SL@ M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG/CPO<#X-"CQP(&%L:6=N M/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,RXV,W!X+S$V<'@@)W1I;65S M(&YE=R!R;VUA;B<[(&UA6QE/3-$)V9O;G0Z M(#$S+C8S<'@O,39P>"`G=&EM97,@;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[ M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'0M:6YD96YT.B`P<'@[(&QE='1E'0M2X@26X@6QE/3-$)V9O M;G0Z(#$S+C8S<'@O,39P>"`G=&EM97,@;F5W(')O;6%N)SL@;6%R9VEN.B`P M<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F2!S='EL93TS1"=F;VYT.B`Q,RXV,W!X+S$V<'@@)W1I;65S(&YE=R!R;VUA M;B<[(&UA'0M:6YD96YT.B`P<'@[(&QE='1E'0M"\Q-G!X("=T:6UE#L@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$ M)V9O;G0Z(#$S+C8S<'@O,39P>"`G=&EM97,@;F5W(')O;6%N)SL@;6%R9VEN M.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@ M=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG/E1H92!C87)R>6EN9R!V86QU92!O M9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-A6%B;&4L('-H M;W)T+71E6%B;&4I+"!A;F0@;W1H97(@8W5R&EM871E(&9A:7(@=F%L=64@8F5C875S92!O9B!T M:&5I2!S='EL93TS1"=F;VYT.B`Q,RXV,W!X+S$V<'@@)W1I;65S(&YE=R!R M;VUA;B<[(&UA'0M:6YD96YT.B`P<'@[(&QE='1E'0M"\Q-G!X M("=T:6UE'0M:6YD96YT.B`P<'@[ M(&QE='1E'0M2!I=&5M6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA2!B96QI979EF5S('1H870@=&AE M('5S92!O9B!D:69F97)E;G0@;65T:&]D;VQO9VEE2!A6QE/3-$)VUA M6QE/3-$ M)VUA2!D:60@;F]T(&AA=F4@86YY(&1E M6QE/3-$)VUA6QE/3-$)VUA#LG/CPO M<#X-"CQP('-T>6QE/3-$)VUA#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93LG(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@6QE/3-$)V9O;G0M M6QE M/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9EF4Z(#EP=#L@9F]N="UW96EG:'0Z(&)O;&0[(&)O M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE.B!S;VQI9#LG(&-O;'-P86X],T0S M/E=AF4Z M(#EP=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/'1D(&YO M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O M;G0M6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Q-"XU-'!X.R!F;VYT+7-I>F4Z(#EP=#LG/B8C,38P M.SPO=&0^#0H\=&0@'0M86QI M9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-"XU-'!X.R!F;VYT M+7-I>F4Z(#EP=#LG/B8C,38P.SPO=&0^#0H\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M'0M M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#EP=#LG/C(R,2PQ-SD\+W1D/@T* M/'1D('-T>6QE/3-$)W=I9'1H.B`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`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`Q,R`F(S@R,3([(%-50E-% M455%3E0@159%3E13/"]F;VYT/CPO9&EV/CQD:78@#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV M(&%L:6=N/3-$;&5F="!S='EL93TS1"=C;VQOF4Z(#$S<'@[(&9O M;G0M'0M:6YD96YT.B`P M<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L M.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$ M)V1IF4Z(#$P<'0[)SY);B!!<')I;"`R,#$T+"!T:&4@0V]M M<&%N>2!I#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\ M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=C;VQOF4Z(#$S<'@[ M(&9O;G0M'0M:6YD96YT M.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R M;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE M/3-$)V1IF4Z(#$P<'0[)SY);B!!<')I;"`R,#$T+"!T:&4@ M0V]M<&%N>2!IF4Z(#$S<'@[(&9O;G0M'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!T.R!T97AT M+71R86YS9F]R;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@ M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#L@9&ES<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M2!I6QE/3-$)V-O M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A M'0M:6YD96YT.B`P<'0[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O M=W,Z(&%U=&\[('=O'0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI M="UT97AT+7-T6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E M:6=H=#H@;F]R;6%L.R!L971T97(M#L@9&ES<&QA M>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL M93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0MF4Z(#$P M<'0[)SY);B!!<')I;"`R,#$T+"!T:&4@0V]M<&%N>2!I#L@9&ES<&QA>3H@8FQO8VL[)SXF M(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0M'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V1IF4Z(#$P<'0[)SY);B!!<')I M;"`R,#$T+"!T:&4@0V]M<&%N>2!I#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V M,#L\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0M#L@9&ES<&QA>3H@ M8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$S<'@O,39P>"`G=&EM97,@;F5W(')O M;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO M<#X\<"!A;&EG;CTS1&IU"\Q-G!X M("=T:6UE#L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L M971T97(M#L@=VAI M=&4M28C.#(R M,3LI('=A2!I M2!I;F1U2!D96QI=F5R:6YG(&-E M;&P@=&AE6]C87)D:6%L(&EN M9F%R8W1I;VYS(&%N9"!O=&AE'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@=VAI=&4M M'0^)SQP('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#LG/CQU/E)E=F5N=64@4F5C;V=N:71I;VX\+W4^ M/"]P/@T*/'`@6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@;W)P:&%N'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US M<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V-O;&]R.B`C,#`P M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A#LG/CPO<#X-"CQP(&%L:6=N/3-$:G5S=&EF>2!S M='EL93TS1"=C;VQOF4Z(#$S<'@[(&9O;G0M#LG/E1H92!#;VUP86YY(')E8V]G;FEZ97,@&5D M(&%N9"!D971E2!A6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US M='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'@[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O M=W,Z(&%U=&\[('=O'0M6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US M='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'@[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O M=W,Z(&%U=&\[('=O'0M6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US M='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`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`Q,W!X+S$V<'@@)W1I;65S(&YE=R!R;VUA;B<[(&UA'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)V9O;G0Z(#$S M<'@O,39P>"`G=&EM97,@;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z M(#!P>#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X\<"!A;&EG;CTS1&IU"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$S<'@O,39P>"`G=&EM97,@;F5W(')O M;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO M<#X\6QE/3-$)V9O;G0Z(#$S<'@O,39P>"`G M=&EM97,@;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T M=&5R+7-P86-I;F#LG/CQU/DYE="!);F-O;64@*&QO"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M2!S='EL93TS1"=F;VYT.B`Q,W!X+S$V<'@@)W1I;65S(&YE M=R!R;VUA;B<[(&UA'0M:6YD96YT.B`P<'@[(&QE='1E'0M2!H87,@861O<'1E9"!!8V-O=6YT:6YG(%-T86YD87)D6EN9R!T:&4@8V]M M<'5T871I;VXL('!R97-E;G1A=&EO;B!A;F0@9&ES8VQO6%B M;&4@:&%V92!B965N(&5X8VQU9&5D(&%S(&-O;6UO;B!S=&]C:R!E<75I=F%L M96YT2X\+W`^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$"\Q-G!X("=T:6UE#L@ M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN M9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M"\Q-G!X("=T:6UE#L@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,'!X.R!L971T97(M#L@=VAI=&4M2!S='EL M93TS1"=F;VYT.B`Q,W!X+S$V<'@@)W1I;65S(&YE=R!R;VUA;B<[(&UA'0M:6YD96YT.B`P<'@[(&QE='1E'0M2!F;VQL;W=S M($%C8V]U;G1I;F<@4W1A;F1A65E65EF5D(&EN('1H92!I;F-O;64@"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M2!S='EL93TS1"=F;VYT.B`Q,W!X+S$V<'@@ M)W1I;65S(&YE=R!R;VUA;B<[(&UA'0M:6YD96YT.B`P<'@[(&QE M='1E'0M'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)V9O;G0Z(#$S<'@O M,39P>"`G=&EM97,@;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F#LG/E1H92!#;VUP86YY)B,X,C$W.W,@9FEN86YC:6%L(&EN2!O9B!T:&5S92!I;G-T:71U=&EO M;G,@:7,@<&5R:6]D:6-A;&QY(')E=FEE=V5D(&)Y('-E;FEO"\Q-G!X("=T:6UE#L@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,'!X.R!L971T97(M#L@=VAI=&4M2!S='EL M93TS1"=F;VYT.B`Q,W!X+S$V<'@@)W1I;65S(&YE=R!R;VUA;B<[(&UA'0M:6YD96YT.B`P<'@[(&QE='1E'0M2!S='EL93TS1"=F;VYT M.B`Q,W!X+S$V<'@@)W1I;65S(&YE=R!R;VUA;B<[(&UA'0M:6YD M96YT.B`P<'@[(&QE='1E'0M6QE/3-$)V9O;G0Z(#$S<'@O,39P>"`G=&EM97,@;F5W(')O;6%N)SL@ M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG/D%S(&]F($1E8V5M8F5R M(#,Q+"`R,#$S+"!T:')E92!C=7-T;VUE28C.#(Q-SMS M(&%C8V]U;G1S(')E8V5I=F%B;&4N/"]P/CQP(&%L:6=N/3-$:G5S=&EF>2!S M='EL93TS1"=F;VYT.B`Q,W!X+S$V<'@@)W1I;65S(&YE=R!R;VUA;B<[(&UA M'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)V9O;G0Z(#$S<'@O,39P>"`G=&EM97,@ M;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P M86-I;F#LG/D9O M28C.#(Q-SMS(')E=F5N=65S(&5A6QE/3-$)V9O;G0Z(#$S<'@O,39P M>"`G=&EM97,@;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@ M;&5T=&5R+7-P86-I;F#LG/CQU/E)E6QE/3-$)V9O;G0Z(#$S<'@O,39P>"`G=&EM M97,@;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R M+7-P86-I;F#LG M/B8C,38P.SPO<#X\<"!A;&EG;CTS1&IU"\Q-G!X("=T:6UE#L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M'!E M;G-E(&%S(&EN8W5R2P@:6YT97)N86P@'!E;G-E9"!A"\Q M-G!X("=T:6UE#L@8V]L;W(Z(",P M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X M.R!L971T97(M#L@ M=VAI=&4M6QE/3-$)V9O;G0Z(#$S<'@O,39P>"`G=&EM97,@;F5W(')O;6%N M)SL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X\ M<"!A;&EG;CTS1&IU"\Q-G!X("=T M:6UE#L@8V]L;W(Z(",P,#`P,#`[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@=VAI=&4M M6EN9R!V86QU92!O9B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+"!A M8V-O=6YT6QE/3-$)V9O;G0Z(#$S<'@O M,39P>"`G=&EM97,@;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X\<"!A;&EG;CTS1&IU"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M28C.#(Q-SMS(&9I;F%N8VEA M;"!P;W-I=&EO;BP@2!097)S;VYN96P@86YD($-O;G-U M;'1A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@86QI M9VX],T1J=7-T:69Y('-T>6QE/3-$)V9O;G0Z(#$S<'@O,39P>"`G=&EM97,@ M;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P M86-I;F#LG/CQU M/E)E;&EA;F-E(&]N($ME>2!097)S;VYN96P@86YD($-O;G-U;'1A;G1S/"]U M/CPO<#X\<"!A;&EG;CTS1&IU"\Q M-G!X("=T:6UE#L@8V]L;W(Z(",P M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X M.R!L971T97(M#L@ M=VAI=&4M2!S='EL93TS M1"=F;VYT.B`Q,W!X+S$V<'@@)W1I;65S(&YE=R!R;VUA;B<[(&UA'0M:6YD96YT.B`P<'@[(&QE='1E'0M2!H87,@-"!F=6QL M+71I;64@96UP;&]Y965S(&%N9"`Q('!A2!D97!E;F1E;G0@;VX@=&AE(&-O;G1I;G5E M9"!A8W1I=F4@<&%R=&EC:7!A=&EO;B!O9B!T:&5S92!C=7)R96YT(&5X96-U M=&EV92!O9F9I8V5R2!O9B!T:&4@6QE/3-$)V9O;G0Z(#$S<'@O,39P>"`G=&EM97,@;F5W(')O;6%N)SL@;6%R M9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG/CQU/D1E2!S M='EL93TS1"=F;VYT.B`Q,W!X+S$V<'@@)W1I;65S(&YE=R!R;VUA;B<[(&UA M'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)V9O;G0Z(#$S<'@O,39P>"`G=&EM97,@ M;F5W(')O;6%N)SL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P M86-I;F#LG/E1H M92!#;VUP86YY(&%C8V]U;G1S(&9O2!D97)I=F%T:79E(&EN'0^)SQP(&%L M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+S$V<'@@)W1I;65S M(&YE=R!R;VUA;B<[(&UA#L@;&5T=&5R M+7-P86-I;F#LG M/B8C,38P.SPO<#X\<"!A;&EG;CTS1&IU"\Q-G!X("=T:6UE#L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M'1087)T7S-B-C8W,C(Q7SDS-S-?-#AC95\Y-&)A7V5E.6)F,#%E,S(U-@T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S8C8V-S(R,5\Y,S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO2!O9B!P2!A;F0@97%U:7!M96YT M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG;CTS M1&QE9G0@6QE M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@ M;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-TF4Z(#$P<'0[)R!C M96QL6QE/3-$)W!A9&1I;F6QE/3-$)V)O3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA M;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^36%R8V@@,S$L M/"]F;VYT/CPO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQF;VYT M('-T>6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^/"]F;VYT/CQD:78@86QI9VX],T1C96YT97(@6QE/3-$)V1IF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q,SPO9F]N=#X\+V9O;G0^/"]D:78^ M/"]T9#X\=&0@;F]W3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M2!A;F0@;65D:6-A;"!E<75I<&UE;G0\ M+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`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`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)V1IF4Z M(#$P<'0[)SY&=7)N:71U'1U6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O M;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1I MF4Z(#$P<'0[)SXQ,C4L-C,T/"]F;VYT/CPO=&0^/'1D('=I M9'1H/3-$,24@;F]W3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O M;G0M6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SY#;VUP=71E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`G=&EM97,@ M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O M6QE/3-$)V1IF4Z(#$P<'0[ M)SXS-C(L,#0V/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O M='1O;2UW:61T:#H@-'!X.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[ M('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'!E;G-E'0M:6YD96YT.B`P<'@[(&QE='1E3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@ M86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M6QE/3-$ M)W!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)V1IF4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^1&5C96UB97(@,S$L/"]F;VYT/CPO9&EV/CQD M:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0MF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6%L='D@9F5E6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z(#$P<'0[)SXD/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^ M/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D(&%L:6=N/3-$3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXQ+#,U-BPP,3,\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q M)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$ M)V1IF4Z(#$P<'0[)SXQ+#,W,RPW-S4\+V9O;G0^/"]T9#X\ M=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`G=&EM97,@ M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T M('=I9'1H/3-$-S8E#0H@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`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`G=&EM97,@;F5W M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`@("`\=&%B;&4@8VQA M6%B;&4@6T%B M'0^)SQS<&%N/CPO2!O9B!N;W1EF4Z(#$P<'0[)R!C96QL3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T=&]M M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT M97(@3H@8FQO8VL[ M(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^1&5C96UB97(@,S$L/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1C M96YT97(@3H@8FQO M8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F M;VYT/CPO=&0^/"]T3H@ M8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6%B;&4N/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N M/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$ M)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US M:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT M('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXY.#`L,#`P/"]F;VYT M/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@F4Z M(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Y)2!V86QI M9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H M/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA M;B<[(&9O;G0M6QE/3-$ M)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z(#$P<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Y)2!V86QI9VX],T1B M;W1T;VT@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/"]T6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SY&;W5R=&@@36%N+"!,3$,@ M;F]T92!P87EA8FQE/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA M;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE M/3-$)V1IF4Z(#$P<'0[)SXS-2PP,#`\+V9O;G0^/"]T9#X\ M=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L M:6=N/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXS-2PP,#`\+V9O M;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/"]T3H@8FQO8VL[ M(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M6%B;&4\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$ M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX] M,T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@ M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T M9#X\+W1R/CQT3H@8FQO8VL[(&UA M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M6QE/3-$ M)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z(#$P M<'0[)SXH,34Q+#`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`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V1I MF4Z(#$P<'0[)SXQ+#DV-BPY-#8\+V9O;G0^/"]T9#X\=&0@ M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N M/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M6QE/3-$)V-O;&]R.B`C,#`P,#`P M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O M'0M3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S8C8V-S(R,5\Y,S'0O:'1M M;#L@8VAAF4Z(#$S<'@[(&9O;G0M'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M6QE/3-$)W!A9&1I;F3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D M97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI M9VX],T1C96YT97(@3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0MF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M6QE/3-$)V)O6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I6QE/3-$)V1IF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^079E6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)V1IF4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^4F5M86EN:6YG/"]F;VYT/CPO9&EV/CQD:78@ M86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0MF4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^5&5R;2`H:6X@>65A#LG M/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX] M,T1L969T('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@8V]L3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M2`Q+"`R,#$S/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXW+#@U,RPS-S8\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q M)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`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`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M(&%L:6=N/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z(#$P<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Y)2!V86QI9VX],T1B M;W1T;VT@6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I MF4Z(#$P<'0[)SY%>&5R8VES960\+V9O;G0^/"]D:78^/"]T M9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H M/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG M;CTS1&)O='1O;3XF(S$V,#L\+W1D/CQT9"!W:61T:#TS1#$E('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T M9#X\=&0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N M=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^/'1D('=I9'1H/3-$ M,24@;F]W3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M'!I#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z M(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI M9VX],T1B;W1T;VT@#L@8F]R9&5R+6)O='1O;2US M='EL93H@'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O6QE/3-$)V1IF4Z(#$P<'0[)SXH,2PS M-#`L-#,S/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W6QE/3-$ M)V1IF4Z(#$P<'0[)SXD/"]F;VYT/CPO=&0^/'1D('=I9'1H M/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O6QE/3-$)V1IF4Z(#$P<'0[)SXQ+C`X/"]F;VYT M/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F3H@8FQO8VL[(&UA M3H@:6YL:6YE.PT*(&9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^3W!T:6]N6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Y M)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+W1D/CQT9"!W M:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[ M)SXP+C$U/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$ M.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\+W1R/CQT3H@8FQO8VL[ M(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O M;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I6QE/3-$)V1IF4Z(#$P<'0[ M)SY%>&5R8VES960\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L M:6=N/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`G=&EM97,@;F5W(')O M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\ M+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXP+C`X/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W M3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V M,#L\+V9O;G0^/"]T9#X\+W1R/CQT3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[ M)SXX+CD\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/"]T#LG/CQD:78@86QI9VX],T1L969T('-T M>6QE/3-$)W1E>'0M:6YD96YT.B`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`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)W=I M9'1H.B`Q,#`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`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^4VAA#LG/CQF;VYT('-T>6QE/3-$)V1I MF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED M=&@],T0P)2!V86QI9VX],T1B;W1T;VT@#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I M9'1H/3-$,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O#L@8F]R M9&5R+6)O='1O;2US='EL93H@6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXD,"XP,"`F(S@R,3$[("0P+C

6QE/3-$)W1E M>'0M:6YD96YT.B`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`P<'0[(&1I6QE/3-$)V1I MF4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L M:6=N/3-$6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXP+C`S M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N M/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)V1IF4Z M(#$P<'0[)SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXP+C`T/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]F;VYT/CPO=&0^/"]T6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXD,"XW M,2`F(S@R,3$[("0Q+C(X/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$ M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M(&%L:6=N/3-$6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&1I M6QE/3-$)V1IF4Z(#$P<'0[)SXD M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I MF4Z(#$P<'0[)SXP+C@P/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O M;G0M6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXD-2XR-2`F(S@R,3$[("0U+C8W/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$6QE/3-$ M)W1E>'0M:6YD96YT.B`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`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`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#LF(S$V M,#LF(S$V,#LF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R M:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D M97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@ M,G!X.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/CQD:78@86QI9VX] M,T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^,C0L-S$R/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^ M/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#LG/CQF;VYT M('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V M,#LF(S$V,#LF(S$V,#LF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@#L@8F]R M9&5R+6)O='1O;2US='EL93H@6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&1I6QE M/3-$)V1IF4Z(#$P<'0[)SXR-"PW,3(\+V9O;G0^/"]D:78^ M/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA M;B<[(&9O;G0M6QE M/3-$)V)O6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXY+C,\ M+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T M;VT@#LG/CQF;VYT('-T>6QE M/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)V1IF4Z(#$P<'0[)SXD M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)V1IF4Z(#$P<'0[)SXP+C`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`P<'0[(&1I6QE/3-$)V1I MF4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L M:6=N/3-$6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)V1IF4Z(#$P<'0[)SXP M+C$X/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS M1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M-'!X.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M2!O9B!W87)R86YT'0M:6YD96YT.B`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`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`S+C)P>#L@;6%R9VEN+6)O='1O;3H@,RXR M<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$.3D@=F%L:6=N M/3-$8F]T=&]M/@T*/'`@6QE/3-$)VUA#LG/B8C,38P.SPO M<#X-"CPO=&0^#0H\=&0@=VED=&@],T0W('9A;&EG;CTS1&)O='1O;3X-"CQP M('-T>6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q-B!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@ M;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D M('=I9'1H/3-$-C$@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0W('9A M;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\ M=&0@=VED=&@],T0S.2!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V M,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-#@@=F%L:6=N/3-$8F]T=&]M M/@T*/'`@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^ M#0H\+W1R/@T*/'1R/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=V M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E M969F.R<^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/D]U='-T86YD:6YG M(&%T($IA;G5A#LG/B8C,38P.R8C,38P.R8C M,38P.R8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Y.2!V86QI9VX] M,T1B;W1T;VT@#LG/C6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG M6QE/3-$)VUA6QE/3-$)VUA#LG/C`N,S<\+W`^#0H\ M+W1D/@T*/'1D('=I9'1H/3-$,3`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)A8VMG6QE/3-$)VUA M6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\+W1R/@T* M/'1R/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^#0H\ M<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@=&5X="UI;F1E;G0Z("TQ,'!X.R<^ M)B,Q-C`[)B,Q-C`[)B,Q-C`[27-S=65D/"]P/@T*/"]T9#X-"CQT9"!W:61T M:#TS1#<@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)W9E6QE/3-$)VUA&5R8VES960\+W`^#0H\+W1D/@T* M/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT@#LG M/B8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED M=&@],T0Y.2!V86QI9VX],T1B;W1T;VT@#LG/B8C.#(Q,CLF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I M9'1H/3-$,3@@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE M/3-$)VUA#LG/C`N,#`\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,3`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A M8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$ M)VUA6QE/3-$)V)O#L@8F]R9&5R M+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$ M)VUA6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US M='EL93H@6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US M='EL93H@6QE/3-$)VUA6QE/3-$)VUA6QE.B!S;VQI9#LG/@T*/'`@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G M:6XZ(#!P>#LG/C`N,S@\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,3`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O#L@8F]R9&5R+6)O M='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US M='EL93H@6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@ M6QE/3-$)VUA6QE/3-$)W9E6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$ M)W9E6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG#LG/B0\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-C$@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)W9E6QE/3-$)VUA&5R8VES960\ M+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT-"B!S M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\<"!S='EL M93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED M=&@],T0R,B!V86QI9VX],T1B;W1T;VT@#LG/B8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO<#X-"CPO M=&0^#0H\=&0@=VED=&@],T0Y.2!V86QI9VX],T1B;W1T;VT@#LG/B8C.#(Q,CL\+W`^#0H\+W1D/@T* M/'1D('=I9'1H/3-$,3@@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG M6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S@R M,3([/"]P/@T*/"]T9#X-"CQT9"!W:61T:#TS1#$P('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\<#XF M(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T M;VT@6QE/3-$)V)A8VMG6QE/3-$)W9E#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA'!I6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$ M)VUA6QE/3-$)VUA6QE/3-$)VUA6QE.B!S;VQI9#LG/@T*/'`@6QE/3-$)V)O#L@8F]R9&5R M+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$ M)VUA6QE.B!S;VQI9#LG/@T*/'`@86QI9VX],T1R:6=H="!S='EL M93TS1"=M87)G:6XZ(#!P>#LG/C`N,3@\+W`^#0H\+W1D/@T*/'1D('=I9'1H M/3-$,3`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O#L@ M8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA M6QE/3-$)V)O#L@8F]R9&5R M+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$ M)VUA6QE/3-$)V)O#L@8F]R9&5R M+6)O='1O;2US='EL93H@6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG M6QE/3-$)VUA6QE/3-$)VUA#LG/C`N,3<\+W`^#0H\ M+W1D/@T*/'1D('=I9'1H/3-$,3`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)A8VMG6QE/3-$)VUA M6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\+W1R/@T* M/'1R/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^#0H\ M<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/D5X97)C:7-A8FQE(&%T($UA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE M/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA#LG/C`N,3,\+W`^#0H\+W1D/@T*/'1D M('=I9'1H/3-$,3`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X\ M"\Q-G!X("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)W=I9'1H.B`Q,#`E.R!T97AT+71R86YS9F]R M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;FF4Z(#$P<'0[('=O'0M#L@;6%R M9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I M9'1H/3-$-R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M87)G:6XM M=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^ M#0H\+W1D/@T*/'1D('=I9'1H/3-$,S`V('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B`C,#`P,#`P.R!B;W)D97(M8F]T M=&]M+7=I9'1H.B`Q<'@[(&)O#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[ M)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,3DX('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B`C,#`P,#`P M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q<'@[(&)O6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\+W1R/@T*/'1R/@T* M/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@ M8F]T=&]M.R!B;W)D97(M8F]T=&]M+6-O;&]R.B`C,#`P,#`P.R!B;W)D97(M M8F]T=&]M+7=I9'1H.B`Q<'@[(&)O6QE.B!S;VQI9#LG/@T*/'`@6QE.B!S;VQI9#LG(&-O M;'-P86X],T0S/@T*/'`@86QI9VX],T1C96YT97(@6QE/3-$)V)O#L@8F]R9&5R M+6)O='1O;2US='EL93H@6QE/3-$)VUA#LG/B8C,38P.SPO<#X- M"CPO=&0^#0H\=&0@=VED=&@],T0Y,R!V86QI9VX],T1B;W1T;VT@6QE.B!S;VQI9#LG(&-O M;'-P86X],T0S/@T*/'`@86QI9VX],T1C96YT97(@6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL M93H@6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$ M)VUA#LG/B8C M,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q,3@@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@ M6QE M/3-$)VUA6QE.B!S;VQI9#LG(&-O;'-P86X],T0S M/@T*/'`@86QI9VX],T1C96YT97(@6QE M.B!S;VQI9#LG/@T*/'`@6QE/3-$)W9E6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^ M#0H\=&0@=VED=&@],T0W('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$ M)VUA#LG/B8C M,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0R,"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O M='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$ M.3`@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO M=&0^#0H\=&0@=VED=&@],T0T-"!V86QI9VX],T1B;W1T;VT^#0H\<"!A;&EG M;CTS1&-E;G1E#L@;6%R9VEN M+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H M/3-$,3(@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED M=&@],T0U,B!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M87)G:6XM M=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^ M#0H\+W1D/@T*/'1D('=I9'1H/3-$,3$@=F%L:6=N/3-$8F]T=&]M/@T*/'`@ M6QE/3-$)VUA#LG/B8C,38P.SPO M<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Y,"!V86QI9VX],T1B;W1T;VT^#0H\ M<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@ M,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P>#L@ M;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T*/'1D M('=I9'1H/3-$,3$@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0U,B!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`S+C)P M>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V,#L\+W`^#0H\+W1D/@T* M/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=M M87)G:6XM=&]P.B`S+C)P>#L@;6%R9VEN+6)O='1O;3H@,RXR<'@[)SXF(S$V M,#L\+W`^#0H\+W1D/@T*/"]T6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA#LG/B8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO<#X-"CPO=&0^#0H\=&0@ M=VED=&@],T0T-"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE M/3-$)VUA6QE/3-$)VUA M#LG M/C`N,#(\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$,3$@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\+W1R M/@T*/'1R/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^ M#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B0P+C4R("8C.#(Q,3L@)#`N M-C@\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)V)A8VMG6QE/3-$ M)V)A8VMG6QE/3-$ M)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@] M,T0W('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R M.B`C9F9F9F9F.R<^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P M.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q-R!V86QI9VX],T1B;W1T;VT@ M#LG/B0\+W`^#0H\+W1D M/@T*/'1D('=I9'1H/3-$-3(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A M8VMG#LG/B8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO M<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Y,"!V86QI9VX],T1B;W1T;VT@#LG/C(L-CDY+#8W-3PO<#X- M"CPO=&0^#0H\=&0@=VED=&@],T0W('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^#0H\<"!S='EL93TS1"=M M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q M,2!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/B0P+C6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG M6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0Q-R!V M86QI9VX],T1B;W1T;VT@#LG/B0\+W`^#0H\+W1D/@T*/'1D('=I9'1H/3-$-3(@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V)A8VMG6QE M/3-$)V)A8VMG6QE/3-$ M)VUA6QE/3-$)W9E#L@8F]R9&5R+6)O='1O;2US='EL93H@ M6QE/3-$)VUA#L@8F]R9&5R+6)O='1O M;2US='EL93H@6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$ M)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$)VUA6QE.B!S;VQI9#LG/@T*/'`@6QE/3-$)V)O#L@8F]R9&5R+6)O='1O M;2US='EL93H@6QE M/3-$)VUA6QE.B!S;VQI9#LG/@T*/'`@6QE.B!S;VQI9#LG/@T*/'`@6QE/3-$)V)O#L@8F]R9&5R+6)O='1O M;2US='EL93H@6QE/3-$ M)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE M.B!S;VQI9#LG/@T*/'`@6QE/3-$)V)O#L@8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)VUA6QE/3-$)VUA6QE.B!S;VQI M9#LG/@T*/'`@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XZ(#!P>#LG M/C6QE M.B!S;VQI9#LG/@T*/'`@6QE/3-$)V)A8VMG6QE M/3-$)V)A8VMG#LG/B8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0W M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C M8V-E8V9F.R<^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO M<#X-"CPO=&0^#0H\=&0@=VED=&@],T0S-B!V86QI9VX],T1B;W1T;VT@#LG/B8C,38P.R8C,38P.R8C M,38P.R8C,38P.SPO<#X-"CPO=&0^#0H\=&0@=VED=&@],T0T-"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA#LG/C`N,3<\+W`^#0H\+W1D/@T* M/'1D('=I9'1H/3-$,3$@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG M6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA#LG/C`N,3,\+W`^#0H\+W1D/@T* M/'1D('=I9'1H/3-$-R!V86QI9VX],T1B;W1T;VT@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S8C8V-S(R,5\Y M,S'0O:'1M;#L@8VAA'0M M:6YD96YT.B`P<'@[(&QE='1E#L@8F%C:V=R;W5N9"UC;VQO#LG/CQF;VYT M('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O M;G0M6QE/3-$)V)OF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^1&5R:79A=&EV93PO9F]N=#X\+V1I=CX\+W1D/CQT9"!W:61T:#TS1#`E M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D M('=I9'1H/3-$,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M6QE.B!S;VQI9#LG/CQF;VYT('-T>6QE M/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,"4@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V)O3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0MF4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^1&5B=#PO9F]N=#X\+V9O;G0^/"]D:78^/&1I=B!A;&EG M;CTS1&-E;G1E6QE/3-$)V1IF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^1&5R:79A=&EV93PO9F]N=#X\+V9O M;G0^/"]D:78^/"]T9#X\=&0@=VED=&@],T0P)2!V86QI9VX],T1B;W1T;VT@ M#LG/CQD:78@86QI9VX],T1C M96YT97(@3H@8FQO M8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)V1IF4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&%L:6=N/3-$6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)V1IF4Z(#$P<'0[)SXS M.3`L,#0X/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$ M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D(&%L:6=N/3-$6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)V1IF4Z M(#$P<'0[)SXR,C$L,33H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS M1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`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`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$ M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D(&%L:6=N/3-$3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M:6YD96YT M.B`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`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D(&%L:6=N/3-$6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I6QE/3-$)V1IF4Z(#$P<'0[ M)SXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)V1IF4Z(#$P<'0[)SXV-S,L,C$Y/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/"]T6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&1I6QE M/3-$)V1IF4Z(#$P<'0[)SY-87)K+71O+6UA6QE M/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS M1&)O='1O;3X\9&EV(&%L:6=N/3-$3H@8FQO8VL[(&UA3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z#0H@,3!P=#LG M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$ M.24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^*#3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I MF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI M9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L M:6=N/3-$3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I MF4Z(#$P<'0[)SXI/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I MF4Z(#$P<'0[)SY4F5D('-H87)E3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)V1IF4Z M(#$P<'0[)SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D(&%L:6=N/3-$6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I6QE/3-$)V1IF4Z(#$P<'0[ M)SXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)V1IF4Z(#$P<'0[)SXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T#LG/CQD:78@86QI M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`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`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&%L:6=N/3-$6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I6QE/3-$)V1IF4Z(#$P M<'0[)SXQ-#8L.#4U/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O M;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T M.R<^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H M/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^,C4V+#DU-CPO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SY4;W1A M;"`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`G M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N M/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXF(S@R,3([ M)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$ M6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXR.3(L,C4W/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T3H@8FQO8VL[(&UA3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXF(S@R,3([)B,Q M-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D(&%L:6=N/3-$6QE/3-$)W1E>'0M:6YD M96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXU,3DL-C,P/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I MF4Z(#$P<'0[)SXH,S`L,C4Y/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\ M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`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`P<'0[(&1I6QE M/3-$)V1IF4Z(#$P<'0[)SXF(S@R,3([)B,Q-C`[)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X M.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#LG/CQF M;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)O3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V)O6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)V1IF4Z(#$P<'0[)SXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^ M/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M#LG/CQF;VYT M('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V)O3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V)O6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I MF4Z(#$P<'0[)SXH,3,T+#(T,SPO9F]N=#X\+V1I=CX\+W1D M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@ M#LG/CQD:78@86QI9VX],T1L M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXI/"]F;VYT/CPO9&EV M/CPO=&0^/"]T3H@8FQO M8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B<[(&9O;G0M3H@8FQO8VL[(&UA3H@:6YL:6YE.PT*(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T M.R<^-C8V+#0X-3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@ M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B<[(&9O;G0M3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA M;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\+W1R/CQT3H@ M8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M M3H@8FQO8VL[ M(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B<[(&9O;G0M3H@8FQO8VL[(&UA3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@ M=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N M/3-$6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXH-3$Y+#8S M,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q M)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[ M(&9O;G0M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I6QE/3-$)V1IF4Z(#$P<'0[ M)SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)V1IF4Z(#$P<'0[)SXS,"PR-3D\+V9O;G0^/"]D:78^/"]T M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\S8C8V-S(R,5\Y,S'0O:'1M;#L@8VAA65E65E(%-T;V-K($]P M=&EO;B!;365M8F5R73QB65E(%-T;V-K($]P=&EO;B!;365M M8F5R73QB65E(%-T;V-K($]P=&EO;B!;365M8F5R73QB'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO65E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2!A;F0@17%U:7!M96YT("A$971A:6QS M*2`H55-$("0I/&)R/CPO'1U2!A;F0@97%U:7!M96YT+"!'2!A M;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\S8C8V-S(R,5\Y,S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'!E;G-E2!O9B!A8V-R=65D(&5X<&5N'0^)SQS<&%N/CPO2!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB M2=S(&QO86X@86=R965M96YT('=I M=&@@0F%N:R!O9B!!;65R:6-A(&%N9"!396%S:61E($)A;FLL(&EN8VQU9&EN M9R!F965S(&%N9"!I;G1E7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'1U86PI/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!$ M:7-T2!% M<75I='D@1&ES=')I8G5T:6]N($%G'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO6%B;&4@;F5T(&]F('5N86UOF5D(&1E8G0@9&ES8V]U;G0\+W1D M/@T*("`@("`@("`\=&0@8VQA6%B;&4@6TUE;6)E'0^)SQS<&%N/CPO6%B;&4\+W-T'0^)SQS<&%N/CPO2!.;W1E(%M-96UB97)=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2!O9B!N;W1E'0^)SQS<&%N/CPO6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO6%B;&4@6TUE;6)E'0^)SQS<&%N/CPO6%B;&4\+W-T'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!O9B!N M;W1E'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S8C8V-S(R M,5\Y,S'0O:'1M;#L@8VAA6%B;&4@6TUE;6)E2!.;W1E(%M-96UB97)=/&)R/CPO M=&@^#0H@("`@("`@(#QT:"!C;&%S6%B;&4@6TUE;6)E6%B;&4@;VYE(%M-96UB97)=/&)R/CPO=&@^#0H@("`@ M("`@(#QT:"!C;&%S6%B;&4@6TUE;6)E6%B;&4@6TUE;6)E6%B;&4@6TUE;6)E6%B;&4@6TUE;6)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4L(&YE="!O9B!D96)T M(&1I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO2!D871E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2`S,2P-"@D),C`Q,#QS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)W=I=&AI;B`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`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!H87,@:61E;G1I9FEE9"!T:&4@96UB M961D960@9&5R:79A=&EV97,@'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N(&]F(&1E8G0@ M9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO2=S(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!'2!.;W1E(%M-96UB M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S2!'2!.;W1E(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)U1H92!F:7)S="!O9B!T:&4@9F]U6UE;G1S(')E<75I2P@,C`Q,B!A;F0@86QL('-U8G-E<75E M;G0@<&%Y;65N=',@=VEL;"!B92!D=64@;VX@82!M;VYT:&QY(&)A'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&-H86YG92!F M;W(@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S(U('9O=&5S/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`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`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6EE;&0\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!P'0^)SQS<&%N/CPO&5R8VES86)L92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6EE;&0\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M6%B;&4@ M6TUE;6)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4@6TUE;6)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H1&5T86EL'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS M<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'!I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO&5R8VES M92!0&5R8VES92!0&5R8VES86)L92P@5V5I9VAT M960@+2!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#`N,3@\'0^)SQS<&%N/CPO&5R8VES960L(%=E M:6=H=&5D("T@079E'0^)SD@>65A7,\'0^)SD@>65A'0^ M)S@@>65A7,\'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO&5R8VES92!0'0^)SQS<&%N/CPO&5R M8VES92!0&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA7,\&5R8VES86)L92P@5V5I9VAT960M079E M&5R8VES92!0'0^)SQS<&%N/CPO7,\&5R M8VES86)L92P@4VAA'0^)SQS<&%N/CPO&5R8VES92!0&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA M&5R8VES M86)L92P@4VAA'0^)SQS<&%N M/CPO&5R8VES92!0&5R8VES86)L92P@5V5I9VAT960M079E&5R8VES92!03X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\S8C8V-S(R,5\Y,S'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!O9B!W87)R M86YT'0^)SQS<&%N/CPO'0^)SD@>65A&5R8VES960L(%=E:6=H=&5D("T@079E M&5R8VES92!0'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'!I&5R8VES92!07,\'0^)SQS<&%N/CPO M&5R8VES86)L92P@5V5I9VAT960@+2!!=F5R86=E($5X97)C:7-E(%!R M:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`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`@("`@("`\ M=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`@("`@("`\=&0@8VQA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO M'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S8C8V-S(R,5\Y,S'0O:'1M;#L@ M8VAA'1U86PI M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO6%B;&4@86YD(&%C8W)U960@:6YT97)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4@ M86YD(&%C8W)U960@:6YT97)E'0^)SQS<&%N/CPO&5R8VES92!O9B!W87)R86YT'0^)SQS M<&%N/CPO XML 19 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurement (Details) (USD $)
3 Months Ended 176 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Mar. 31, 2014
Excess Share Derivative [Member]
Dec. 31, 2013
Excess Share Derivative [Member]
Mar. 31, 2014
Warrant [Member]
Dec. 31, 2013
Warrant [Member]
Mar. 31, 2014
Derivative [Member]
Dec. 31, 2013
Derivative [Member]
Summary of changes in fair value of the Company's Level 3 financial liabilities                  
Beginning Balance          $ 390,048 $ 146,855 $ 221,179 $ 256,956   
Total (gains) losses                  
Initial fair value of debt derivative at note issuance                   292,257 673,219
Initial fair value of derivative relating to reset warrants                     
Mark-to-market          84.906 519,630 (74,324) (30,259) (39,761)
Transfers out of Level 3 upon increase in authorized shares         (474,954)          
Transfers out of Level 3 upon conversion and settlement of notes                   (376,502)
Transfers out of Level 3 upon conversion of notes payable                 (134,243)  
Balance 1,051,196   1,051,196       666,485 146,855 384,711 256,956
Net (Loss) Gain for the period included in earnings relating to the liabilities held at March 31, 2014 $ (489,371) $ (640,589) $ (365,423)      $ (519,630)   $ 30,259  

XML 20 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accrued Expenses (Details) (USD $)
Mar. 31, 2014
Dec. 31, 2013
Summary of accrued expenses    
License and royalty fees    $ 2,122,130
Amounts payable to the Guarantors of the Company's loan agreement with Bank of America and Seaside Bank, including fees and interest 1,356,013 1,373,775
Interest payable on notes payable 757,669 714,180
Vendor accruals and other 127,189 120,692
Employee commissions, compensation, etc. 127,506 149,558
Accrued expenses, Total $ 2,368,377 $ 4,480,335
XML 21 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Property and Equipment (Details) (USD $)
Mar. 31, 2014
Dec. 31, 2013
Summary of property and equipment    
Laboratory and medical equipment $ 352,358 $ 352,358
Furniture, fixtures and equipment 125,634 125,634
Computer equipment 39,525 39,525
Leasehold improvements 362,046 362,046
Property and equipment, Gross 879,563 879,563
Less accumulated depreciation and amortization (871,371) (870,508)
Property and equipment, net $ 8,192 $ 9,055
XML 22 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurement (Details Textual) (USD $)
3 Months Ended
Mar. 31, 2014
Dec. 31, 2013
Fair Value Measurement (Textual)    
Derivative Instruments and Hedges, Liabilities $ 0 $ 0
Derivative liability $ 1,051,196  
Percentage of stock price increase 447.00%  
XML 23 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accrued Expenses (Details Textual) (USD $)
3 Months Ended
Mar. 31, 2014
Accrued Expenses (Textual)  
Shares issued in conversion of debt 6,750,781
Settlement of debt related to Accural Interest $ 2,122,130
Loss on settlement of debt. $ 65,548
XML 24 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
Standby Equity Distribution Agreement (Details) (USD $)
In Millions, unless otherwise specified
0 Months Ended
Nov. 02, 2011
Standby Equity Distribution Agreement (Textual)  
Funds contributed by Greystone $ 1.0
Period for which funding is provided 24 months
XML 25 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Going Concern Matters
3 Months Ended
Mar. 31, 2014
Going Concern Matters [Abstract]  
GOING CONCERN MATTERS
NOTE 2 – GOING CONCERN MATTERS
 
The accompanying unaudited condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed financial statements, during three months ended March 31, 2014, the Company incurred an operating loss of $620,923 and used $257,762 in cash for operating activities. As of March 31, 2014, the Company had a working capital deficit (current liabilities in excess of current assets) of approximately $11.1 million. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.
 
The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.
 
XML 26 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Notes Payable (Details) (USD $)
Mar. 31, 2014
Dec. 31, 2013
Aug. 20, 2008
Summary of notes payable      
Total notes payable $ 2,117,972 $ 2,042,972  
Less unamortized debt discount (151,027) (112,131)  
Total notes payable net of unamortized debt discount 1,966,946 1,930,841  
Seaside Bank note payable [Member]
     
Summary of notes payable      
Total notes payable 980,000 980,000  
August 2008 Unsecured Promissory Note [Member]
     
Summary of notes payable      
Total notes payable 500,000 500,000 1,000,000
Hunton & Williams notes payable [Member]
     
Summary of notes payable      
Total notes payable 384,972 384,972  
Asher notes payable [Member]
     
Summary of notes payable      
Total notes payable 183,000 143,000  
Fourth Man, LLC note payable [Member]
     
Summary of notes payable      
Total notes payable 35,000 35,000  
Daniel James management note payable [Member]
     
Summary of notes payable      
Total notes payable $ 35,000     
XML 27 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Option and Warrants (Details 3) (Warrant [Member], USD $)
3 Months Ended
Mar. 31, 2014
Warrants outstanding and exercisable  
Warrants Outstanding, Shares 148,057,064
Warrants Outstanding, Weighted-Average Remaining Contractual Term 6 years 8 months 12 days
Warrants Outstanding, Weighted- Average Exercise Price $ 0.17
Warrants Exercisable, Shares 102,401,650
Warrants Exercisable, Weighted-Average Exercise Price $ 0.13
0.01 - $0.50 [Member]
 
Warrants outstanding and exercisable  
Warrants Outstanding, Shares 141,807,931
Warrants Outstanding, Weighted-Average Remaining Contractual Term 6 years 8 months 12 days
Warrants Outstanding, Weighted- Average Exercise Price $ 0.02
Warrants Exercisable, Shares 97,696,967
Warrants Exercisable, Weighted-Average Exercise Price $ 0.02
0.52 - $0.68 [Member]
 
Warrants outstanding and exercisable  
Warrants Outstanding, Shares 2,699,675
Warrants Outstanding, Weighted-Average Remaining Contractual Term 5 years 1 month 6 days
Warrants Outstanding, Weighted- Average Exercise Price $ 0.58
Warrants Exercisable, Shares 2,699,675
Warrants Exercisable, Weighted-Average Exercise Price $ 0.58
0.70 - $1.62 [Member]
 
Warrants outstanding and exercisable  
Warrants Outstanding, Shares 848,176
Warrants Outstanding, Weighted-Average Remaining Contractual Term 5 years 9 months 18 days
Warrants Outstanding, Weighted- Average Exercise Price $ 0.71
Warrants Exercisable, Shares 848,176
Warrants Exercisable, Weighted-Average Exercise Price $ 0.71
5.67 - $7.69 [Member]
 
Warrants outstanding and exercisable  
Warrants Outstanding, Shares 2,701,282
Warrants Outstanding, Weighted-Average Remaining Contractual Term 8 years 7 months 6 days
Warrants Outstanding, Weighted- Average Exercise Price $ 7.55
Warrants Exercisable, Shares 1,156,832
Warrants Exercisable, Weighted-Average Exercise Price $ 7.35
XML 28 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Balance Sheets (USD $)
Mar. 31, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 218,984 $ 46,227
Accounts receivable, net 48,754 19,913
Prepaid and other 1,674 784
Total current assets 269,412 66,924
Property and equipment, net 8,192 9,055
Other assets 10,012 10,160
Total assets 287,616 86,139
Current liabilities:    
Accounts payable 2,513,125 2,382,267
Accrued expenses 2,368,377 4,480,335
Advances, related party 403,957 416,198
Deposits 478,286 478,286
Subordinated debt, related party 1,500,000 1,500,000
Notes payable, related party 2,179,737 2,241,477
Notes payable, net of debt discount 1,966,946 1,930,841
Total current liabilities 11,410,428 13,429,404
Long term debt:    
Derivative liability 1,051,196 403,811
Stockholders' deficit:    
Preferred stock, par value $0.001; 20,000,000 shares authorized, 20,000,000 issued and outstanding 20,000 20,000
Common stock, par value $0.001; 950,000,000 shares authorized, 420,920,157 and 379,787,745 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively 420,920 379,788
Additional paid in capital 104,678,615 103,819,119
Common stock subscription 210,000 215,000
Deficit accumulated during development stage (117,503,543) (118,180,983)
Total stockholders' deficit (12,174,008) (13,747,076)
Total liabilities and stockholders' deficit $ 287,616 $ 86,139
XML 29 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8
Subsequent Events (Details) (USD $)
1 Months Ended 3 Months Ended
Apr. 30, 2014
Mar. 31, 2014
Subsequent Events (Textual)    
Common stock issued for settlement of convertible note payable and accrued interest, shares   6,750,781
Accrued interest   $ 2,122,130
Subsequent Event [Member]
   
Subsequent Events (Textual)    
Common stock issued for services,Shares 3,839,832  
Common stock issued for services 43,250  
Common stock issued for related party advance 100,000  
Common stock issued for related party advance, shares 5,263,315  
Common Stock issued with connection of stock subcriptions, shares 1,002,808  
Common Stock issued with connection of stock subcriptions 50,000  
Common stock issued in settlement of accrued interest, Shares 274,681  
Common stock issued for service rendered 180,511  
Common stock issued for service rendered, shares 18,383,774  
Common stock issued for settlement of convertible note payable and accrued interest 67,500  
Common stock issued for settlement of convertible note payable and accrued interest, shares 4,793,268  
Accrued interest 2,700  
Common stock issued for exercise of warrants, shares 11,918,181  
Common stock issued for exercise of warrants $ 136,000 $ 6,000
XML 30 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Statements of Cash Flows (Unaudited) (USD $)
3 Months Ended 176 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income (loss) $ 677,440 $ (518,893) $ (117,503,543)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 863 769 900,967
Bad debt expense 10,000    176,266
Discount on convertible debt 93,604 124,838 2,073,854
Loss on change in fair value of derivative liability 489,371 640,589 365,423
Gain on settlement of debt (2,093,632) (1,004,224) (3,117,071)
Non cash payment of interest 164,757 123,578 664,524
Amortization of warrants issued in exchange for licenses and intellectual property       5,413,156
Amortization of warrants issued in connection with notes payable       5,437,604
Amortization of loan costs       1,228,717
Related party notes payable issued for services rendered       500,000
Warrants issued in exchange for services       285,659
Warrants issued in exchange for forbearance agreement       430,213
Warrants issued in connection with joint venture agreement 22,546    22,546
Equity instruments issued in connection with R&D agreement       360,032
Equity instruments issued in connection with settlement agreement       3,381,629
Common stock issued in connection with accounts payable       759,316
Common stock issued in exchange for services       1,567,673
Common stock issued in connection with amounts due to guarantors of Bank of America loan       69,159
Common stock issued in exchange for distribution rights and intellectual property       99,997
Preferred stock issued in settlement of forbearance agreement       274,050
Warrants issued in connection with accounts payable       7,758
Stock based compensation 194,564 19,632 10,271,081
(Increase) decrease in:      
Receivables (38,841) (362) (60,019)
Inventory    62,953   
Prepaid and other current assets (742) (37,827) 33,006
Other assets    1 (28,854)
Increase (decrease) in:      
Accounts payable 172,786 (12,509) 3,373,406
Accrued expenses 49,522 55,077 7,412,998
Deferred revenue       465,287
Net cash used in operating activities (257,762) (546,378) (75,135,166)
CASH FLOWS FROM INVESTING ACTIVITIES:      
Acquisitions of property and equipment       (909,158)
Net cash used by investing activities       (909,158)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Bank overdraft    (89)   
Proceeds from issuance of common stock, net 371,000 400,000 65,679,689
Proceeds from (payments for) initial public offering of common stock, net       1,447,829
Proceeds from subordinated related party note       3,000,000
Payment of note payable       (3,000,000)
Proceeds from notes payable, related party       505,000
(Repayments (proceeds) from related party advances (10,241) 180,500 1,072,751
Proceeds from exercise of stock options and warrants 6,000    299,749
Proceeds from notes payable 127,500 205,000 12,163,750
Repayments of notes payable (63,740)    (3,686,192)
Payment of loan costs       (1,219,268)
Net cash provided in financing activities 430,519 785,411 76,263,308
Net increase in cash and cash equivalents 172,757 239,033 218,984
Cash and cash equivalents, beginning of period 46,227      
Cash and cash equivalents, end of period 218,984 239,033 218,984
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION      
Interest paid 84,986 103,969 2,790,810
Income taxes paid         
Non cash financing activities:      
Common stock issued in settlement of notes payable 194,044 19,500 5,240,138
Common stock issued in settlement of accounts payable 107,475 146,740 278,691
Common stock issued in settlement of related party notes payable       397,750
Common stock issued in settlement of interest and penalties in connection with convertible debt       150,815
Preferred stock issued in settlement of notes payable       70,000
Reclassification from notes payable to related party advances       $ 544,267
XML 31 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
Derivative Liabilities (Details) (USD $)
2 Months Ended 3 Months Ended
Oct. 31, 2012
Mar. 31, 2014
Oct. 01, 2012
Reset Warrants [Member]
     
Derivative Liabilities (Textual)      
Fair value of derivative liability   $ 666,485  
Dividend yield   0.00%  
Expected volatility   173.72%  
Risk free rate   2.73%  
Expected Term   8 years 6 months  
Loss on change in derivative liabilities   519,630  
Common stock purchase warrants issued 15,000,000    
Exercise price of warrant     0.014
Warrants exercisable period     10 years
Convertible Notes Payable [Member]
     
Derivative Liabilities (Textual)      
Fair value of derivative liability   1,051,196  
Fair value of embedded derivatives   384,711  
Dividend yield   0.00%  
Expected volatility   173.72%  
Loss on change in derivative liabilities   $ 30,259  
Fair value of common stock   $ 0.0447  
Convertible Notes Payable [Member] | Minimum [Member]
     
Derivative Liabilities (Textual)      
Risk free rate   0.03%  
Expected Term   11 days  
Convertible Notes Payable [Member] | Maximum [Member]
     
Derivative Liabilities (Textual)      
Risk free rate   0.13%  
Expected Term   8 months 27 days  
XML 32 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accrued Expenses (Tables)
3 Months Ended
Mar. 31, 2014
Accrued Expenses [Abstract]  
Summary of accrued expenses
 
  
March 31,
2014
  
December 31,
2013
 
License and royalty fees
 $  $2,122,130 
Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest
  1,356,013   1,373,775 
Interest payable on notes payable
  757,669   714,180 
Vendor accruals and other
  127,189   120,692 
Employee commissions, compensation, etc.
  127,506   149,558 
  $2,368,377  $4,480,335 
XML 33 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Details) (USD $)
3 Months Ended
Mar. 31, 2014
Aug. 17, 2012
Series A Convertible Preferred Stock [Member]
Stockholders Equity (Textual)    
Preferred stock designated as Series A Convertible Preferred Stock   5,000,000
Preferred stock shares increased   20,000,000
Loss on settlement of debt. $ 65,548  
Issuance of common stock, Shares 6,750,781  
Common stock issued upon conversion of notes payable and accured interest, Share 7,166,214  
Common stock issued upon conversion of notes payable 57,500  
Common stock issued upon conversion of accrued interest. $ 2,300  
XML 34 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Option and Warrants (Tables)
3 Months Ended
Mar. 31, 2014
Stock Options and Warrants [Abstract]  
Summary of options and activity

   
Shares
  
Weighted-
Average
Exercise Price
  
Weighted-
Average
Remaining
Contractual
Term (in years)
 
       
Options outstanding at January 1, 2013
  7,853,376  $0.67   8.2 
Granted
  17,400,000  $0.016   9.9 
Exercised
        $  
Forfeited/Expired
  (1,340,433) $1.08     
Options outstanding at December 31, 2013
  23,912,943  $0.15   9.0 
Granted
  19,800,000  $0.019   9.1 
Exercised
           
Forfeited/Expired
  (62,087) $1.08     
Options outstanding at March 31, 2014
  43,650,856  $0.08   9.3 
Options exercisable at March 31, 2014
  16,650,856  $0.18   8.9 
Available for grant at March 31, 2014
  12,800,000         
 
Summary of options outstanding and exercisable for stock-based payment awards

  
Options Outstanding
 
Options Exercisable
 
    
Shares
    
Weighted-
Average
Remaining
Contractual
Term
   
Weighted-
Average
Exercise
Price
   
Shares
   
Weighted-
Average
Exercise
Price
 
                     
$0.00 – $0.70
 
    
43,090,000
  
    
9.4
  
$
0.03
   
16,090,000
  
$
0.04
 
$0.71 – $1.28
 
    
162,286
  
    
4.2
  
$
0.80
   
162,286
  
$
0.80
 
$5.25 – $5.67
 
    
373,858
  
    
2.1
  
$
5.55
  
    
373,858
  
$
5.55
 
$7.69
 
    
24,712
  
    
2.3
  
$
7.69
  
    
24,712
  
$
7.69
 
  
 
    
43,650,856
  
    
9.3
  
$
0.08
  
    
16,650,856
  
$
0.18
 
 
Summary of warrants and activity

 

 

Shares

 

Weighted-
Average
Exercise
Price

 

Weighted-
Average
Remaining
Contractual
Term (in
years)

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at January 1, 2013

 

    

74,073,322

 

 

$

0.37

 

 

    

4.5

 

   Issued

 

    

50,350,536

 

 

$

0.16

 

 

    

9.2

 

   Exercised

 

    

— 

 

 

$

0.00

 

 

    

 

 

   Forfeited

 

    

(6,345,002)

  

 

$

0.38

 

 

    

 

 

Outstanding at December 31, 2013

 

    

118,078,856

 

 

$

0.22

 

 

    

6.3

 

   Issued

 

    

32,292,783

 

 

$

0.017

 

 

    

8.4

 

   Exercised

 

    

 

 

$

 

 

 

 

 

   Expired

 

    

(2,314,575

)  

 

$

0.18

 

 

    

 

 

Outstanding at March 31, 2014

 

    

148,057,064

 

 

$

0.17

 

 

    

6.7

 

Exercisable at March 31, 2014

 

    

102,401,650

 

 

$

0.13

 

 

    

5.7

 

Summary of warrants outstanding and exercisable

 

 

Warrants Outstanding

 

Warrants Exercisable

 

 

 

Shares

 

Weighted-
Average
Remaining
Contractual
Term

 

Weighted-
Average
Exercise
Price

 

Shares

Weighted-
Average
Exercise
Price

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$0.01 – $0.50

 

    

141,807,931

 

 

    

6.7

 

 

$

0.02

 

 

    

97,696,967

 

 

$

0.02

 

$0.52 – $0.68

 

    

2,699,675

 

 

    

5.1

 

 

$

0.58

 

 

    

2,699,675

 

 

$

0.58

 

$0.70 – $1.62

 

    

848,176

 

 

    

5.8

 

 

$

0.71

 

 

    

848,176

 

 

$

0.71

 

$5.67 – $7.69

 

    

2,701,282

 

 

    

8.6

 

 

$

7.55

 

 

    

1,156,832

 

 

$

7.35

 

 

 

    

148,057,064

 

 

    

6.7

 

 

$

0.17

 

 

    

102,401,650

 

 

$

0.13

 

XML 35 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 36 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Significant Accounting Policies
3 Months Ended
Mar. 31, 2014
Significant Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES

 

A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed financial statements follows:

 

General

 

The accompanying unaudited condensed financial statements of Bioheart, Inc., (the “Company”), have been prepared in accordance with the rules and regulations (S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

 

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three month period ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ended December 31, 2014. The unaudited condensed financial statements should be read in conjunction with the December 31, 2013 financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K.

 

Basis and business presentation

 

Bioheart, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through March 31, 2014, the Company has accumulated a deficit through its development stage of $117,503,543.

 

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.

At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.

Revenues for test kits and equipment sold are not recorded until test kits are delivered. Revenues from trainings are not recorded until the completion of the training. Any cash received as a deposit for trainings are recorded by the company as a liability.

Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets.

Comprehensive Income

 

The Company does not have any items of comprehensive income in any of the periods presented.

 

Net Income (loss) per Common Share, basic and diluted

 

The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options, warrants and shares issuable upon conversion of notes payable have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation for the three months ended March 31, 2013. Fully diluted shares outstanding were 498,696,292 and 222,688,816 for the three months ended March 31, 2014 and 2013, respectively.

Stock Based Compensation

 

The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10).

 

As of March 31, 2014, there were outstanding stock options to purchase 43,650,856 shares of common stock, 16,650,856 shares of which were vested.

Concentrations of Credit Risk

 

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. The financial stability of these institutions is periodically reviewed by senior management.

 

As of March 31, 2014, two customers represented 26% and 25% (total of 51%) of the Company’s accounts receivable.

As of December 31, 2013, three customers represented 20%, 20% and 36% (total 76%) of the Company’s accounts receivable.

 

For the three months ended March 31, 2014, the Company’s revenues earned from the sale of products and services were $322,572, of which two customers represented 17% and 10% of the Company’s revenues.

Research and Development

 

The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $9,857 and $163,974 for the three months ended March 31, 2014 and 2013, respectively; and $65,329,892 from August 12, 1999 (date of inception) to March 31, 2014.

Fair Value

 

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.

 

Reliance on Key Personnel and Consultants

 

The Company has 4 full-time employees and 1 part-time employee. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.

Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2014 and December 31, 2013, the Company did not have any derivative instruments that were designated as hedges.


Recent Accounting Pronouncements

 

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed financial position, results of operations or cash flows.

XML 37 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Balance Sheets (Parenthetical) (USD $)
Mar. 31, 2014
Dec. 31, 2013
Balance Sheets [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, shares issued 20,000,000 20,000,000
Preferred stock, shares outstanding 20,000,000 20,000,000
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 950,000,000 950,000,000
Common stock, shares issued 420,920,157 379,787,745
Common stock, shares outstanding 420,920,157 379,787,745
XML 38 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commiments and Contingencies
3 Months Ended
Mar. 31, 2014
Commitments and Contingencies [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 11 — COMMITMENTS AND CONTINGENCIES


Joint Venture Agreement


On March 10, 2014, the Company entered a joint-venture or profits sharing agreement (the Agreement) with Global Stem Cells, Group, LLC and its subsidiaries whereby both parties will participate in marketing for obtaining patients and provide physician training for stem cell treatments under the names of “Regenestem” and “Stem Cell Training”, respectively. In addition, each party will be responsible for selling equipment and kit to existing and previous customers. Profits are divided on a fifty/fifty basis with distribution within 10 days of the accounting for patients and physician training and 30 day with sales of equipment and kits.

In consideration of Global Stem Cell Group, LLC’s participation, the Company issued an aggregate of 8,000,000 warrants to purchase the Company’s common stock for four years at $0.0217 per share with 2,000,000 warrants vesting 90 days from the effective date, 2,000,000 vesting on each anniversary date for three years. During the three months ended March 31, 2014, the Company charged $22,546 to current period operations for the vesting portion.

William Beaumont Hospital


In June 2000, the Company entered into an agreement with William Beaumont Hospital, or WBH, pursuant to which WBH granted to the Company worldwide, exclusive, non-sublicenseable license to two U.S. method patents covering the inducement of human adult myocardial cell proliferation in vitro, or the WBH IP. The term of the agreement is for the life of the patents, which expire in 2015. The Company did not use this license in any of our technologies. The Company had not made any payments to WBH other than the initial payment to acquire the license. The Company has received confirmation that it has no obligation under the patent license agreement and WBH agreed to terminate the patent license agreement. (See Note 4)

 

Accordingly, the Company will recognize approximately $2,122,000 in settlement of debt which represents the accumulative accrual and related interest from past years under the 2000 patent license agreement.

Contingency for Registration of the Company’s common stock

 

The Company believes that it may have issued options to purchase common stock to certain of its employees, directors and consultants in California in violation of the registration or qualification provisions of applicable California securities laws. As a result, the Company intends to make a rescission offer to these persons. The Company will make this offer to all persons who have a continuing right to rescission, which it believes to include two persons. In the rescission offer, in accordance with California law, the Company will offer to repurchase all unexercised options issued to these persons at 77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted. Based upon the number of options that were subject to rescission as of December 31, 2009, assuming that all such options are tendered in the rescission offer, the Company estimated that its total rescission liability would be up to approximately $371,000. However, as the Company believes there is only a remote likelihood the rescission offer will be accepted by any of these persons in an amount that would result in a material expenditure by the Company, no liability was recorded as of March 31, 2014 or December 31, 2013.

Litigation

 

The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of March 31, 2014, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company’s business, financial position, results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.

Consulting agreements

On November 20, 2013, the Company entered into an investment banking agreement with Cassel Salpeter & Co. (“CSC”), who will act as exclusive third party financial advisor in connection with investment banking matters. The term of the Investment Banking Agreement shall be for a period of twenty four months unless terminated or extended in accordance with its terms. For these services, CSC will receive a one-time $25,000 fee, $5,000 monthly fees and 5,207,630 ten year common stock purchase warrants, exercisable at $.0113 and applicable consideration in the event the closing of a Mezzanine Financing consisting of non-convertible subordinated debt and/or sale of equity securities. The Company will also reimburse CSC for its reasonable out-of-pocket expenses associated with the services provided pursuant to the Investment Banking Agreement. As of March 31, 2014 and December 31, 2013, the Company accrued $46,317 and $32,424 under the agreement, respectively.

XML 39 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information
3 Months Ended
Mar. 31, 2014
May 06, 2014
Document and Entity Information [Abstract]    
Entity Registrant Name BIOHEART, INC.  
Entity Central Index Key 0001388319  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Type 10-Q  
Document Period End Date Mar. 31, 2014  
Document Fiscal Year Focus 2014  
Document Fiscal Period Focus Q1  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   466,396,016
XML 40 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurement
3 Months Ended
Mar. 31, 2014
Fair Value Measurement [Abstract]  
FAIR VALUE MEASUREMENT

NOTE 12 — FAIR VALUE MEASUREMENT

The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.

The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.

As of March 31, 2014 or December 31, 2013, the Company did not have any items that would be classified as level 1 or 2 disclosures.

The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in notes 7 and 9. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Notes 7 and 9 are that of volatility and market price of the underlying common stock of the Company.

As of March 31, 2013 and December 31, 2013, the Company did not have any derivative instruments that were designated as hedges.

The derivative liability as of March 31, 2014, in the amount of $1,051,196 has a level 3 classification.

The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of March 31, 2014:

             
    Excess Share
Derivative
  Warrant
Liability
  Debt
Derivative
Balance, December 31, 2012   $ 390,048       221,179     $ —    
Total (gains) losses                        
Initial fair value of debt derivative at note issuance             —         673,219  
Initial fair value of derivative relating to reset warrants     —         —         —    
Mark-to-market at December 31, 2013:     84.906       (74,324 )     (39,761 )
Transfers out of Level 3 upon increase in authorized shares     (474,954 )     —         —    
Transfers out of Level 3 upon conversion and settlement of notes                     (376,502 )
Balance, December 31, 2013   $ —       $ 146,855     $ 256,956  
Total (gains) losses                        
Initial fair value of debt derivative at note issuance     —         —         292,257  
Mark-to-market at March 31, 2014:     —         519,630       (30,259 )
Transfers out of Level 3 upon conversion of notes payable     —         —         (134,243 )
Balance, March 31, 2014   $ —       $ 666,485     $ 384,711  
Net (Loss) Gain for the period included in earnings relating to the liabilities held at March 31, 2014   $ —       $ (519,630 )   $ 30,259  


 

Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. The Company’s stock price increased approximately 447% from December 31, 2013 to March 31, 2014. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments. The simulated fair value of these liabilities is sensitive to changes in the Company’s expected volatility. Increases in expected volatility would generally result in a higher fair value measurement.

ZIP 41 0001145443-14-000738-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001145443-14-000738-xbrl.zip M4$L#!!0````(``=ZJ41*N!F@ELD``(1D#``1`!P`8FAR="TR,#$T,#,S,2YX M;6Q55`D``WXI;5-^*6U3=7@+``$$)0X```0Y`0``[%UM"P<]8!CN2/HC#\?_?ITW=>/ M>O\X_>EOG_[>[_>^``<@TP>C7N#A%WI7?_5_/W_X.F_?TXZ%8_E8[OV7,!P( MQD`21*4GZ">R>")+O?MO_]/K]^>?.C<]_!G<)OR`="Q&S_#3]Q=DPQ/ROSW, MF^.=O$R0__EHXONSD\'@QX\?QR_0G0`3^="QCBUW&M(19%D\^NEO<1,;.M\3 M3+U-1(_Y/!]T3",0?@T M\;H'TU[&'Q<'OW_[^FA-P-3L0\?S3JTBBEMH-N M9+F!XZ./I``\8!V/W;=!_)!(6NX+8A_+FFX:((1!D]4V?DH:2^N-1P"FM\,/ M,NB-P`P!B^`PLXO&P$06#4MOP_>9[;IF+Z+/J[QO^F/@7=KDLX`>9+! M`73>@.>G-XN>931T3&AYZ>W"1Z29F-(,^#E=#?N)7TFT.W`()6HNWFANN-$'C-9%$=X*?TRQZTTH6`'V2(P/-G**,-?I+1*/#Z M8].<+=J]FMY+R%3\($-+\=.^Z?O93?%#!%\"'W@K38F$O-1VX9,LFC[*43%^ MNN(41GZJKQI&OLI/^JH<5_#[U[FK(JZ9^*T3+_1&#^"U%_JQD]B4\KW=8(;< M&8#Q$7KN.#=[_W M""R?C"[QZ!&-#U;\$&(?$+_X?.8]W[T^/V,@G`7C/F'M:-D`.#[T/Y;_AB/R MRRL$J!?V-]F].;8N;OYY="I@+RWKNBP:GP:KCOET_DOR_:#1)_SA7`1>+X[?<;X^B5PL&@%X5D6%G\W2B"XP\B_ MQ'X<_T28ZPLJMHME>_KY@NG12@-9H`G.GU:380PD20B!A"GISX\3%_E/`$TO MP8O_A/%\]@Z]9_P8B_OIA_LT<0//=$97<#SQ?W6PM`($1O?(G4+/PZ/.K>N# M;V#Z`M!N-!`+$(RGP%ET=H1)XH$06M"/>.F-('X>A7ZQ6SM)[>C1*3'4DRVZ M^VF02IG2",5D:4,BJB&&)`EU&M("!!P0S03$BB,)(5'&D:QAB+$CP0[X;(8( M;@R.FP;A)N%(\(BL)$:3&AS)'`0<$,T$Q(HC"2%1QI&L88AU1#+LWUEAP"QD MX.81F!Y6V+GI?">BNC<_S!>[`P#)ZU?=KD$4^OC_I&%MKD&2EVKE*MZ5BI/& M'BM9+FSLZZA@;.S8E433-E%\?@`V6>^ZQQQ]/"'3\.KLHG9`HW@78[QD=;1V=R"&$U6ESDCAUGV+%"](B[\;/'?'(@F7 MWXH;3]1`JF^D-/K7X(7(32IC/+?8/4T([^<0NR!KXKBV._[X@MQ@]M6VVAAU ME3:K\B*HW>`DC)2^9-1I<-],%($%A^:+OTL`YR"@L9\PG*A?+N5Q_'51GRM."8\-11JV-U+`4OZ(L$#\(#_FXFP`'VO'8K/6QM(Z4Y[ ME3A?]=&7(PJW_G9;?]KH(NEE1I<5K+$>78RM\,77DG;C9&J9.XL6RJUO80S(]44+LC#? M=.#&WS3C%VO)4;G^X^J9F/LEL/@DI#N3D')[U^`!`N'=_-B*C;@9-$-Y;+XIG].2BES\>2I=H;M8&]ZE>30F"\7L<]:[L] MZ][`PAUEUW08SRY:K;=$'SJEJ\6F]]6?`>;PPIW.7`?_TXMW]*=3UVGC'GY: M=^A]_)5^'9!.ST8C2!R/:=^;<'3C7)@SZ)MVI_2;V\=#TK5E!=,@C#,NP2OI MZV6`H#.^!&_`=F>D'?[`N"6Q5%'EE^KT`:&AU4E9^3K?4S964S3[&+QX%H)A M0/D`+`#?6G1"(E_#T4F)G/YU2LW$83E@=`X<_(=_;YO.^0?YWS//`_X%%M38 M11!$2K]ZMX#G/4Y,!"XQ_3?3AV\MT7F);L8(R.GLP0*@53.K4BKO_KRKC)X[ M;=W+1EVQZN6^0]B`3H]CM><@?XLV MFN(3/'*C=AS6I59NIT8.3[74L%.S*K6LD@3>!"`"+"]Q-/?Y*QB;]E78^<@_ MFPX$]B_F%'C?3`?/+`FZVF&/N24*TKN?8U\;R8X`/%F17DPL1X:[,>B&0',9 M*C32I!,CZ)H0V"?]QZ?.2HV:/"NG[M!)7JTW5-MY<)F4H%K\G;\(DI@L/%]# MQW0L:-HWF#<4D%;S0XI>8/O0&9^-$0B_UI8\OF)+847G3(7I9D@R!F&V/'?B MMTN>P@\;U%'X:B7CIUE>N_IHMYL\J&VGMMJ":CAB>-'+S26[46NJ\L MD_8H%S^P<&^0&>[X0._[^<]]@8]GKG0C,R%5@"@ M52LTS4Q$:(6>.VW=>RO!L__P\.?`\5WGS!G]!FT;FE.O6Z%B@>YQ)8=!Y&I- M%VI#>7$ZXW"1L)&%[,(N:8+DF-N$N<6)`XZY:I@K]M-2XI"S_ M?H(^GJB\WC@C^`9'@6G36;7M4'UJ%Y:K/(F^[$KU]/V]A50O*JDWQAM1B;+!R^3D'#@)^,&+W!R,Z`PY^DF(?)RFZ`A]^]()#@9_5.'1< M\,W2`];^!:\&W]2*G3D";E*ES$Z"FU>#;[)E\&KPW#YY-?@.VNH/8$=\"GT=V\W7.(G+BT543,!^&#^>F!T9DQ1K+-Y1.^*MW%O@3[#3^ M`J-?G1%`5$X,<2PXD+YZ!\B"'KA'6+,/IC..4\#(7\N5B!8GC]0@G7E>64)& M+&R!)[KL#>O+63W'>A;6F=E]XV`H"8;GI8O[!ATX#:8'#9+"]"G? M-_\I(3\.Q`I`--\Y$*L`D9;?H0.QIE`PO&PN-1AL[3&XF@-#2F(UAH;\T-YN M[>`69JSM(1CC&1">=SU-W,`SG5&XY_^K@[L>(#Q10^X4>IZ+/KIQM\86 MW:W#>!H&@D=@>ECZYZ;SO5.W5>7UJU-JY57_]UOUOPV*O\5V,B&C\CG$MF!- M'-=VQQ]?D!O,OMI6&QU]:4B4%T&GP,)O?.B`$CN2IM&$O(>&Z+!5Z^C[.MZU M/Z?)KU/@Z&R,0?JTMJQAL4Y(*T\V0Y#P5+U.>G8(> M+TO=,V?T&[1M:$Z];H6* M!;K'E9R:\T9E!2Q.#!TN$C:RD)W@EB9(CKE-F%L<=^&8JX:Y(N>&NH*YU%S2 M3J5M%>OA`:CZV@V0/\$R^&I;G=)P;L<.0+$1PMN3:;796CN;,L7O5\B#!;]? MX?"@RZ]+.)#K$CH(77[[P>'=P_2O(HUKV*]5V#S*HF=T26#0AIM+9:U MBP(;Q9G90T6KKH"N384+&P^ZNJL+-FRECY=W;7I10(XTP*NUMKG55#> MIGCRD%'>C5`UNAOA693Z9\&X+QJ&T=BJJG2U6<)H7]#[HD2)>-_5:(7^V8Q? M8K7+^$;IRT)M-B&(2WURW>[A@C*E;+'I)!P8F[>@8K?XT3RWN&H3P[Z@;FL3 M?^_W>[\ZT.\]@G".WNOU^_/??_K;S?^)_WW][_N?P3NX'*J:_L<#^!.>WDR^ M@[>K[Q"]_]!42U$4:S@<6D__.SF]NKHV;K[\IR:JPR\_B_H7]42\UGZY$6^N ME2M5&W[^8OSR2TP@XB0@I(GHO7`1_.@T_GT*3"]`X#0&0OAPSOW\V?S?Y!LI M7_SU\7+M<]!S%4G43O"S\E][QG*,]CL6WQW!-ZS!4^KEVV`*D.F[:$O2:^W) MCY?`<:?02?ML40$E/C%((%"%78O98@0JXD^N[#!(3[B:3R3" MCX+[!S"&GD]HWN*HOA<[J0?PFGTYQM'I^P"D$O![!MG!-[_"3X*TJ+==^:WYH3.<%='I+O7MCDN2.#5M#T0?3O1?/[- MBP`A\A/T+-/^`YCH*AKP"GZ^CX-G'`Y'!+*^-:=UZ5IA$1D2'Q3\OBCT_Q5] MG&Z\^L'[<#0JQ_DRED]^/_&M54++KEWC7[P2I))$5KZ33B;BI`RA?XEI9*CO M)"%[#6V`XNH/10'[.#5MW*KW`&9XU@Z=<8_L_9G.!XW?Q(=7S&19+S3:I+X+ M?!)'YTJJBH;JB"J":/*H4QX M7.1YFM[DS!F1_T29@.PH._\"4!A"1V/H=`T6J4%:+)EL9``157;GD?F M`E-50Z+5R8)P,?M3#464"E"^1RZ.ROVPY)*/!42L,ZR>BX'&0@*&,!S2^LBF MQHBK0N+114,JSQ4%GEO7L1@Z(QP/"$M^4NE49:28]>"87RK!2/2,A0AT592- M5;R6)E7,-G1-)?%7#JW8[<8S788.09)U25*U=0^?)%69F6*"&(JR*`U+,H/C MM-%7:+Y`&_H0L/26BJ+C."S)3SHU%BP5$Y&LZK*FE63I,@!/+I7\PUA,HBH: M^I*E;&I,>"H6MPBR,=1*\X1G:A[TY\+\8"DD39=TRL@S2%7GIIAXBG,S+X7M MHA%9:R+E[5]\.I&,R8`S%,A_/@TV4F/!4K&AIQ1+KF$7CADL)F2R8*NB#$" MJ4'>208\-5L6!#$@Q)*,U5QG5*;.:WV#@- M4:0G>.G4JC-4T!855<-3SF$IAM:6Z>D;2YC,@J4P"DI570I%9KP5#"*$+7E; MO9/I"M-',P0]$%_=1%_FE'J+$Q,0BKJH"X8NTQZX*F,[[6;!T5D;"O)0J:V; MH<8GKCT"R(N.V!7<^BE]#6%N-W5)4*D^KG.U"Y[SK]G;L-(FJ8)@*'OO0KG; MX_+ZU!>Q^Y(U3=I[IU(O02N^\U@76[DW>-7/7KY_[(NRIFB"IM:M/)FI(UB- MP?;#OELT\M_YTY MHWJBDY7]X4TD&;*WU9YR&?Z2V+HWT1T*U3H*5VON`0JGUUL)D4KBI_B5CTZ% M8T$0LU;4LEA@SG2Z:'?%]&HEHO(2SLCQ#&T_9\5RE3`S%E/DN2,6;SPOV+D$ M(Z),6&,MN6*L55J.KL1?H:7\LDRR%N+FY?.].,L"]-FR6\U-;L]N;0[2&*[I M/XS=<^S'5?%Y17-G$0Z_6<;KNIPAD4$MMG+ MU.<'BX@N@[]'TP;>`RF!&("LK-B5,S*;TLKHG-B5SU>DG!\\RY(TU.JC34J_ M6^&QM7`>!+WOYQ_GP+$F4Q-]C^9)U%>_N.XHC-D!>H,6\#"5N(9)RF>6U>7C MHYQK[Q19P63;_0T5+_*3YW5=,K1"K%RXGG_WNBJM1SS)V0J*>>>`*E'*[[&A M*(I*&U\6J0H,55"(JFFB+I;E[P%XP$06.7!#+;K$AR"J.PI1E0WZD$4N.:9\ M;="E3OO1&KFJHM"A+!DZ[6@+\_D(;!N/`5^``Y!IX]?/1E/HA(=^20X1,_7* MFC"D3\,5HUL/IQM.<<@ZEN:>.*T``MDP%/Q?M0KGRZ,9-].9"1$!S06.%\:@ MT(G<,OZW(JDU63`D54$)0UTUJ+`PA_)*CCC"7PF'=Z*F*3EI_%?XS^J6IZD4 MF',H,61H@X&I`IM;;%;;&4P23/)0HC?.UTA4 MIK\IC)&5!)JKTZ\21@JJ(0J:+)9EZ,:Q7B8/(PGXV(S9"#YY'H40-Y@MA']A'1Q4H5,F+"A%IX+P-5+0AYK"9-%=FR33 M<4+T:O6!P*`S;#*H;,M(E7%4471)+,797&SL%L6&DDQGLZX0J$A[0__)Z*PS MHUUI?T`::C)=T"6'EW4-L5N!ED2#`D0F)6;L;!"+9.@RO512`T.59GR2I(NB M8)1D<#D9O$;NE#`"G0`WB&>+Y(8;\.HB$+WW9+X##P>UR(P.[J./&Q],P[HQ MN"5RPP7.2L/":G"AXSB01F)MW#9(*!NWBQ1%Z+Q,*MG">D;Q3J6$F\>F%@>A M[".DK9Y;^>F!ZTM<)29>MW5J8$L1FKN0Q$M&+IJJ!*=AE*A#UNF;U:I M!Y"I&TE0)9UV>/O@?,-AL3GS>2>\M\R(92_2E`S:.D1:\1QOX6,&3'EG<`YU MG7$A-2MX'WS7*O.HRA_Y<)0:'H6AT7T`X=D$S+83W9SQ&_0GC\#WH_LT[EY7 MJI0R6+\1-(4D-++C:0\]9'H86M6&8K?E4:ERBT:V2SHMG4K3Q)2!K5G=V[(\ M3+,Z4;&83%YG(H_=&/^4.DAB%R5H^@8O5;(CA91,MV>3UR*2FIY%QI]5TO7Q MRW0TT415;5/O*HP-NJIK>JOZNG-/7T*/(.]:4W\__;>M4MM)$D8_NYS_!_T>MV[]CDJC"2N[>D^IVR7 M>SSKV[JJNY_YU$>@I-!82(PN569^_1L1F;J!``$"!.3L=C<%4F9D9&3<,R(M MVETX1P405,J,]*Z.-7*."?#V_,5H`7LY,O1;%Y6Y:N]$*IS`#W\`N56+5-/2 MNJO`YP`FB_CJ>T/&+`HJWOQ@_M`.X'F1/E=%$"G%YNJIJH1H;Y2]^6J(!:;? MPV0Y->\?GNV&?P!DD<^N[WW&FW%6%&S=*P!KDJ#U=E*.?AL(]@_^WFBD?DO? M(7!9Q6(2#]L*=8M__=[SX]O"JQ9234OXE54&#+T]7UBL+.0EEIRM-G&D-2]S MI/>,?B][>6&S%637?FW]*^))HL&=M^0XT3`#,V`6'C_F!KPB`0!N!W;(Q+!\ M2I#BWKU+HRQO`+FI1=ON9!O?[1GBVF%G?Q;F$3&;O5\)GQUVV%NPRZ;V4E<.WALZ-3K8[TA'` M^^MV#,/<,7^"(R1*PW5`=Q;2[E&BIM!'=F\Z-]0$G%\Z,EV;.?\P)RSX9+KF M/8F0,F)!SU\L/<#*=]%]FUVCU]YVH[AL^U_;M:I+)]=TH]W-$/;B'+M#L.YN M1:N;C?A7`L$NE6HZK7;V,G`Q/&2^Y'6,WRR0/ M2!"[`5$1`6P(Q$X;;G1)5.X$U7(A\MYV37<(1BU6+*M<1=QUKDWN'&P\URZ: MGZ[WNEIWF5S,3Y[05+8W:G9W%GP(WYAK`>>NK$#?_F8O?9ZJF7V7@Y3M6KLQ M-+D;-4E,@3Q#P%/C@YAY\8O_UC'M2>4GJO+)-[I+M//DN^BBO78G>W5_(V`2 M.EPA).'_!\ST<K+8LR0'!*;WQ>P)GER(G[;ZAQ<;E[N"M M6FF&YZ^,_56XUUM.NEVNL;R32N`80,2I/[FP;N(W7F_12B8 M0\\/OHS>F.[W+Z/K"?/MH?G1,[<+)VU_,JH$J\(#NQ-8N_@`^UJ[7_K%_W5(,HC2(F52U;$)O/&0V MNW7O9M7^0"B]\16"L(N%W&TUVVERWC8@+;475XK^O5K).\^\M8V\^I!I#-TI4JA62G0MIZ5VMF&X"LA^R# M._09//".\?]^R"1I5U`SQ^AD=FSE7)4"M<;"[/5:VD'`VD69:C:S3;YW`!*+ M1*)R95>QH5=@FK>-57!EIJL4K@W+36TX665%IQ:G!ADX-6V\+T624%3``I4F M;2)1Q4GK]O3NJGTI`\9A%K)&!+56LHPC+F.GJKE&L]G9[[KHP:0V?U5T=;62 M4Q;-N1\H=SN#I6?=*3242U*J`EE5:+CSQ3W;S95B985B5PE\ZY(9]6YOY3FI M'+Z=7-5=H[7Z6&\*+GHN,]W`=]_Q=KO972D7%B?=!Y!K`G/]MKZ2Z^\)R%TL MI9:F]_-UEG<%.N;]HH/B'DI][C[A;FRXS(2[Q'<[;;VWDMCG`)BK._G6#,:4 M/FTQZ\WL]P#-WI1?@^W[0+N(D,[7?*VBO&BK8V232G<#Z+!+6Z/]Z.UN-VL) MUGIINZAYW;9FM+5L.GYU2P41$E_<&?X[LGT6NT&Q)44(FB+&2J=5.C;W,_,F M+&3'F7>Z`]/7VKD4[[*0E"!/WK=A/TQE=4'D/4.S87GFJJ'9Y>C.;_ANX"7N M7(IG/3#?\LU1!3G&`+3?N]K.5=DNO'[DR%TKV1O_6=2G6="]O+ESL6CUE MY?"5*Y1R0/AV:E/;:Q1\P7\MTU>1IV)9K%E]& MF`.^CUCFMA.4#SR7G:`*W"Z=L;!P33:O/KL#%"[%9@D MT[]0D:\@+L)D92Y#[.VX53'Q5H6SUDU<';2[A"3Z_6ZKOR7T14)LY^N6[ MVTO%Y;*+@[M`L^XZ7?Y2?.70['353^L8W?:&T('&)[P67%!6G2E5Q3QK#I_1 MS38-6C;1UL#L=`^EU]&R/3'*`/0)36_=RVW7+*;;QRJV;8C>"[^N=`O]; M9LX2SJ3D#NR^O??=7KNE:6N]1R7A.>S*UEZ::V`[C% M2G$8D*[X'[2\'TP'29F7T)H/4E4@5HU^T\CD:&TR^SZA7A_ZSU8T.1K4N^A; M6J_?:^V^AOCN$E91J<`Z:AK]3B[I(QU]EUG75#W#ME$53+I3*GJ_V=.:98!( M>G5NC?(RW2_+#[]5<\T5P^_LG%]V;R.;RU^M=:#U4YM^@XGW!>P&31F.`>TN MGAV]!7O1VQ_PE:>Q::T.V05;3+Y'F$NTC6H?'>:=V&FOT]?VNH)E)5'V?6FO M*ABJXJ0;P;"+$=OO=MLE#](RF,JN*1:^H!!]9:[IH.(\?ZT(_GI@?FC#L%4& MGHX(7E44415X.UWR!FVJ)`?;`MP-[C'NC354/W6%MS?WR0BZV>#:1I!DBFL- M'3,([)$])`LX]DR*Y^Z\RF(_R\M[[0F"#0J,507!3M7Z6GJGFQ09VP*BK'7Q MQ;\W75%4#H`+/,>VZ`_LL!Q\&0&U!$`4_*LHL%T6!.]8TO.%%^1`70!KUL/+ M0^`$=[#"-T[I3)E?_]L)7T\5T['OW5^>805S>S1[I@3AS&&_/!MZCN?_K/P7 M#Q"_5D8PS-7(G-C.[&?E?T)[`AAVV:,""S?=_Q&_!_9_V,^*9DQ_Q%_@8#\K MKN<#'L5W#Z9OFVXX]^TC]3Y.OW3@8##_*IB:Z!3*?`^HN!J+A[4.SN3YT['I M!C\K9A1ZKQ5<[97M6@SG:.(#]$WHPS,C&`7'8S+4 MH^=;*0@T%@`Z^&[#<#AF$/K>=W8%+X5C\?O$].]ME__Q[+_OP]>(Y0%^^/SE M[D;1E/\V)]/7_]73->VU_WY3KE^^_;+[Y_O/GS^3?GZY>.' MMQ]N;O'55X-XD%=3_/3TB=RV@VP;;9/6:4K<'QSWUTH03>#;F>*-E'#,E`#P M3;S6#14SX7O*5#`^Q9Q.'9M9BNW2X],,\XR'P- M";24$7=`FPYLIV@;$0">'0<7)VE`GK\+PCU@.<(/OS&7^:9#.Q!).23/P67A M_FYKN0%"YXWMC1FH_ZKRP1TV5.4%2J%8^=.;K]_R89-OM-0^(5[3FU?\UE&N" M$%#DS%1\=J98'FQ,".\,G<@"-#I.#);MXE9RX8SCCSPO=-'TA970'2!+&\YZG!FNGDT1YUG)[\/`]A11`(,IN$5`=:QP,QKRX$BF=3FX_\!U8&]JNT+] MG21-;%0ZAV;:KDQY`8PLL.GJ%3[*P8*#")P#V^'AF?,CTPE>*O0@+]_NLB$+ M`M3/\?"9RLBT_;S2G?(QP0"LAH+<%)Z)'-2K81L5+\TZP7$0ZG#L,Z9,8(/& MRI0"^@I6:;>43Z8_'"N&IBKHNU"`,Q)[B2$!*H&9+/+&P,R"T\2SA6,S!"S, M`"*%_9BR(7*3>,H9,&DQR3L8#;O\)/-PH$MS_6#L18Z%L_C,),X-+_PK+0\;\0J%PR8;HS/V-:9$R-:]W6@7+LN[)GRC4T]/U1@ZIA3_Z_D MA9(77A+N8T.&O*ITH@;"F9KC5]+`D>?C$G&?MU'*F"C*HQF@#()U>3Y&.$`Z M@E)`HL@Q'X/$]D`YAG^\AZVR+1/%U75T#QNI*AAVX9)53*#802S.+/;`'(_7 M'@!9>,]`90G@6Y"0W"Y(PQXXAVN9OA7`.%82BE&":!""]C-4^EK[2FNJ(&_3 M,6]Q3(6:_:%=]"*SVNO;M^*5!1/()OFK#&$RVWLP@R$87+X2@"(!2H18\9"! M:A6RX=@%ZKPG=016"SJ2Q1S024B;XL^`)#>GL54VL/%Q>RBTE#%S@.PMRT<6 M!=K#/5Z+!XV&M@D5+2?R`2>.]PA(=^S)`&`;CMG$-E5E./8]%];-GTV_-X<1 M[,5DYA'\H!B`!0;J%->\$`8/08(7@H@%L#&>8L'FJ5GU`A2Z@!0N;I;AOF=] MLH'ID/E&Y5\"E9X&(HDPW$D:%S8H4VDN_"D`Q)BTH8X7!#@GAL!X/VX&$0P"^@W#RT"X.)38L%J\,,M]5J`_V$$8O%9>Z"]C78H+ M7F_(-0SXR7C)X\2@7PGW,`P%6MO(_H%2&?0.BP&4$]O%])S7],V+%CJUJ/L! M+R5(>BC>&O'PJ1DHG@$H6U8#%$CQ;AQ03M:,$\=CH9HRP*K@Z'%)?6XYS\R_ M(NN>>W=\=F^2QYP`YW#"!#!A$O3.+B91K*>^9T5#4BH(%6)YI('F%T,O>`%3 M3-X4I*$D33IPPI2PHV1T5URIZ0:N,S`$XHC"9&Q2FG M2-&`=C^(,WM.D8)3[FS"`I'\0S MGV&#/+HG!H/?T+X3/$2\5L0,*2A*H,06UCP\2^>#'SB#C*:>R-3A]X\5?"AA M<1G8&\H'M."RMB;ZM`4;-N/I+)`QYBC$941^',28&]OGL]H8*9RDV4&^,G1L MQO.*P/!#IJ9F5R*"CH*+"2MXP)`Q+T=J(K>#C,S#E\7`@`>&M\L(I90S2U@,)FY!2 M#$0L96!F.P3B#\?A#ZJJ1?8(0<_-TXS_[@*Q.VQ. MF/./9`/GA?L@HF](AT+IC)YL!4<@I0",*CI.PK!2IA%:OB[YL_&RAF]2"SZN MJX#2X\;Y3RJ8\:`3"A,N5AN2<0L<`U-@)$(?`;!B)0B#`1:FC*D$:5XKB9>% MKOFXE2D9<,Q'Q"-C$HTE<^D'T3R&\)TDOP)6-DAL4J&:PDNPA3SE@NQ(GZ4C MB@<$]DB3V21Y:_LCL]PUB2X9GXV92SX*7A%@BUAQ%3'/E2XCRV.<]"COAB)J M(>,*]3"W!)N60&3C)MGUW!Q/(N*;F-Y[65F"_L\L%$A77F"DB#Q&"K\CJ5`7 M-E4XH51%N,&CCN]TR3'W8WID,17!LSO;CD@,Y$"@_&!1+[90AWV(:"F"(P@`Q12H-+[7L M\2)[JO(8U_C#18CG,9!)W)&F&M)]V$#H1SR9:BJN>Z9I:NR'X$)FD,Q.,[&T MPDP2H^:$-K]DX,UF%*!P8+:OL-$(XY64=1+:5_0.I::Y\[M1E/P6%*6]&0WE M?809L3$`B_@!I`(DK7Y/[?0[JM[7"2^ZKJN=7D_M:9W2D[7XFS"KBGETR-0! M?*=(]]LC`^:[3;T6E6RSQ3T?<@Q9;G',Q6VA38YX5^O1$<]UL)P_W/RAM4YY M#(P325SQDQ87SB-1[(%JP,!2\&9,9!Z`-G65?I-SS\>4+L1%DI28>A4XD5/B M)YP.RAMX<]@*N;)O+Z=*$\4$/KQ%01>IJ,8=(\124581FC-."N MS5PJ;C:2`@*3(+##B*/1#H3F!(<:N3)HP39[Y+8S"%<;&&WJO:WG>7C,Q'H` M_D0!!'7B)\[_VS\I+T(O-.GV1EO[*;E<4K1514@]!N'SU2ZD6:M"Z"U9*QI8CN@/J#+)+[*DEHLYG!L,^'2C?-CTUQV`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`U?N#7U5/& MHL1MS6>5$&CUEJ250IWE4446)')%K1VSP>1>%@NRA3QXMASE])$G-N;)*^:B M6V3,NN?E">)F$=F*FP"+?4XA1IH6;ZF0QZI'90 MIM*Y@OC,Y72X/+M61?ZW(Q+HXO60O87\=6Q/84@\$"+*EI%<5/&$2KD0XO,: M+K]$6;ANSA0(O&S*9A9R.$<.$`:JI`@2RP$4)#F`X6S*%9_\SS'`S,HGP].] M//33DJBF@=$J#XN,M$*O72;2;5OY0/>2M9)_F-Q16:#$Y+NZD0:^\FI.[*#; M.;M'7WW/A<^"&=5(VL0!$,SF\2)@H5/+Y+5WACQGA:Z!6BI8TT&8>O"R/CNZ MY(I.;S@>("W2@D!QG3V!`P!7*ST1G08]2]R3C"[@FE6]_\^!G"M_X[B<3,ZNVJO)J MV0\QC3AL%)Y6LEC\Y>ITL?"PZ6)@7($.`5@:X%;$Z6-7B%T!C?C&YXO`KQ+^ M@;B(MR`9R'9QU9OM`4V4P^S`@EOBS))SS)9PBJ2+IX$+I8/M2AP4E"^G6R;U'JCB7792F M%\2V``DN,"9-4=@*G7:.D*6D3Z=.-!YS#.U@)*ZGP,]9=YIP((HK/R!0?>X- MC4U$4#.I+M>C&S^ZU2I5Q8I\GDFW24PU#7&`,2K4"U2,A)7\O*,WU;YNT$HC MG/NYWNZJW8Y.M<-(`<$"(\F+J;E#ZRI.<SI+*"/,`+:ZI$;)TO'[@I^\2!/2KSF7,;/*X),:/P`L3Y,V148;7?6G,@!VD/%A4A[ODAOU<8X6,`T1.<:(],@.B35DJPBY M9$MZ`W(-F99%!B`PQ%$DT@!!>`P9=V3Z2)M%5996U.]Z?RO7G=\K-__W^X>NGF\]W:[6* M4ZJ4"G>$!K-G_:XIA2B5,!!;;-H[^GJ&WSOY,I_>23A<%+VM:! M%X;>)-E8\=H5__IG1<_"?%A7:&C5"=QERLRN*QA@[0=?+.!*G*N!8R+KS_\F MB`27./>+.$<4#T-R\)`:8"K]P*B81T"&>PRI!FRRZD4>6!^QMVIY!YDHD:J+ M%%7"Q28Q77XBU%K*(SE_GEWOT3>GOSSC_WVV['QG%0!$\6OE]'G6Z:]`.J/V(!\Q/H)[@1IVG*<'='H M60[<4B+?(]C/RT';+POL".(4D;DG<9TO<59N'I4); M)RLA/S(S8&-LCF%/L$-8YH9TM5*R[FDDZR&O/#*HU._PE.);^T7$_CEA1U>; MK<[^6>$!PTK[$?[RS,HS*\]L#6A]?Z;]"7"A&H`J39`JX.YUP0;I%&1WG)T- M(JE;4O?Y4K>TL#>SL`.JL1=-1.,E"XMW88?@N-N3.<&">_])6^E(RUMJ\M'N^Z)X1L'\+2-7Z^A$84EU(7!Y5>51/ MY*CVU6;[`,D`]3RJ&27B%15;*+*U9941665$%A$Z6A$AGS=`]JVT9P$5K>4M M?X.PH6!?S8+BL-@N&'O0!MA6G8^M8H,1T28O/T7BBL-N?4'IA[B+P3+7G60GDIU(=K)W=G*#+2HM MF]^!XKU6I]B0A:X&F]AASN4]<:CRM:C'&?>Q<&8*K)*).M?9LRUZ["[C5)F. MIVDI46I6YZ:O>9DL=*I\ADEW6$\Z:2^'**`^?-Y(%6VB@E"TNN&A@^5A!.*7 M$^\AVQTX[:V9=@VB9D#BQ\BA,M;WU,K,YW6P1_9_)NYQ['PN$==37C35:R)O9P#IXU"-BE6 MFBUR*MJ#!%]Y9TG>,`3[2GY,ZW7+>J>2-VU1[[25JW=Z_?;MM]]OWBDW_^_K MS>?;F_4-0NJIL,_1O,"R%K6AYQW7TYX[&_*8U<8ID2?Y6^1 MZ9LN=8==U>/0,UW%O/<9C_U18.Z-Z7['=ZXGS+>')DG66V8&ML7H-U6T.$1_ M*$I:>@"#KSX+9`6NVAR4^K$I337:';50I3\[-G4\^G[Z1%+X$2F\:ZC=[@57 MXKID6_2#$(*)+/9<3$%BB7"6TK$NU%L_WM%M=]5.IW\!G$-2]P52M]92M9XT M4"]0*O[!7,OS,?_3CTR'FXN4%BNE85UHMG[\0M.[P"^D-)34?9[4W50[A[A- M?73<'ZZDPWG4D[J93!UOQO!VR&1B!P%>SU#Q#\Q-I=L:JL+"X>KK:++\C2Q_ M<\KE;U#XMYL76P]6GEEY9D_OS+;Z:OL0'0KK>68/536S%B4V9#4<60WG=*KA MZ*K1Z:E&MWL$WE07,I?']>#']>D3>6"WPT!+;?6:JF'($E;AFA)69WYY\63N M)5_R#=.3V:3]'.BY40?`9>]]+W*MF/'^UXC^EX%<3"A21I1_1"Y3="`#-9NF MJ8Q-2Z$;/%2M)?24Q4S-/VW'L?B;OA6(!KIBKLQ]")`OL!/L)F7@4@!?@]"TIK M$9\IU?314WYOW#;B0EI3,\06<\H0*VK%);>`6*(ABRN[C*,)+L6*G%"9S+RA MZ5M8XPNO]6(U&<<>B;HT6#7FP082H.7@0`C[AZ\-Y0X^`V8F<6IK!B\FKPR$ MW^)(\1,"+E4@@?V8VCX"AG?UVWS`&!&6;5'AH`A7.+:#9+E8Q`9^IQ%MK!?& MAF,7-OG>QAI"/A">Q>B)J3FC1GN((`29HIWPDND*=-@AKE@\AD^9PW]'"!`' MFZ9K*%]?KPV9!1>9RAYXYL.%V$,I@D5.P0J`>(UU,\V+=[ M_@N0)*]Q)G"1+"M!GDK`TI]4[0@Q;+OP\,JW)Q=>D"<'L)%.(ETL-@@%D_>QAEK`&?&8I>751,DTS$;)U5^+[S#P&FM3 M$S[-F.D'&=:)8KHJUB0/Q3D?BA6&GJ2#RZ&#=U&B!8=CX!,*ZNGC`#1[*]6) MM"+]S@X"K$I%6C]PF'M4C("_==1NNZEV>YH2C$V?%Z^T2>&>P-``/-8E7."* M7A2"ZN#2G:VD6J1(2F\H8(2`$NEB-4D8(JG.B!!@=<8YN-QAY*-1\KS35MNM M'J\L6PQD\&/KV(,)U7,=L699KE.>R M=+G&=EJN47NMW-Y=?W[WYI_*S?_]_N'NG\J[#[=WWSZ\^?WNPY?/RO5OWVYN M/MU\OI,,7A)2Z5H>DC0N@C1HU"^N\ME[X'5[N`M'RXM2-#Y^\]D,A+8+WYKD MNU.^@HGO,C`[7L2L2&^^3AY+OM->ORSP$2I"'BI<("I9B:@D(E%Y@6!DAD]^ MR0[?R!!R\NEKQMN#@URGWJ-T*0A7ZM@!T^T!+X]GETY*1C3%GY]KC:8R05DKLQM-;5Z0TB.(+^$$N+!N/\`% M"Z!N$FR\@V6]7*5#;JH`9DM^OP/]5);TEOQ["QVQD],1\:M;Y>OU/Z_??+R1 M`O]""48J?I(.DE$_9^_\@XSWZ3H'B.-`UA27X:X3W9*+KRF>V]43NX=Q='"W M\97(8L*RP'A5:Y8%QB5/D#Q!%AB7!<:WN<9VR47=LJ5/J9I;$C??@'!DA8\M MP3ZQ2LS]7E,%\V[_%U?J0"F2J"51GQ=1R]IM\\7%H_LH"#'MM:?\[@9L&&&$ M]"N\8P>!Y\\4='5*.5@7^JT?[V@W+X5W[).ZGSZ1]"WINY:R\9)-P[]';NBY M/!L`_XDO9`:RZG<]:;A^_,/HM=1^]Q(J04KJEM1]OM0M+<=YRS'`.^]2#M:2 M6NO'*;2><2%ZM*3N"Z3NUJ50M[02%Z\`FZ[-'.4?)C[]R73->WZ1(QM+E**Q M+@1VMT'WR=*WM!'GT/;>B_QPC#)153Y^?"LE8BW) MMGYL-UG(]O%SB]+BZ?3F`0, MS8W5QB?,MX:3MH!\I]9%*_21A\,%.&S`]-;!>#[6O&P"JQU'V^3GN^ M'Z//`*NB664Z[SHD6&GC'5[W_-\`!78CA*FHPBJL$TB&N7S@B1G""^&,UY.' MWY*"6#IO6=A>7>[GXO6NIT^DYB49:&TTK]T+EUS\B9;G69[G@RA$R5E5Z;SF M]:&!Y_L>BO]T[[(+BGP@%(84C4JX;R M)=,G;PH*Q-">BB:AB;8DVJR@)A)WDZ9FHK!8,Z2??-&J3S,:685+15TH=N&# M`H2-<@:FXW@P8MP*.IJ*X8N4+I_%CPEUZ8T3L;<$U,<,-#!+,!PS*W*X-D>J M#W,S_AS""2$+$/B"*@GK0K^$(/0T#Z*U!D:>.H"R"H:\P?V@'A#W5< M^/^AYU+'&8Y2`'AA&(Z3>]`A<5MHCQR&K5V?:_U\WZ%['QL93GUO")IJD*?" M"6!N2OA72?WTHA`V%M3.$+Z`/2>`THDRR`8,Q8.-^9'G#LF$%@CVS2RVUA$,#WP=CS0SI[4E^N`7>7TO6R MI>NM8!C`&6.[&SM[V6@S`XL3`@N-8#CVS`1..30=^-/T$WLY8TCCI"E/@5.? MX7H+_%)5!L`DA5#QV;\CVR>9HJ(\X3P3!2/P58QA7Y!&U04/%HJ_B^[!\]!N(3FQQCSG8;V!<]G_XM^AY MF2!28IQ9WC#B(C#N%2Z4#-0A"MOV9GY7N),#!-^CZ?M"0P%M90A\E"DMS%1J M&YE5Y*5@B/J+D'P,&?^06/3S9J-MZ!II%_2J9+I=RA@A7S#FJMJ8Q, MV\?(=<29@=9OJYU^*YX3?;FBRS>SN#L8OK`XVP>UE'@IB@+1<1355)^-')`4 MC)BL2?HZ[%O:RSM)+J*G$58.S(WG79?,N4)6P&X:J:!@UHLC1$IV$&MKE]1SB$%S/49&SL!^@ MW;CWW$Y_+HJDX@]YV_AYN]]3-;U-;AJA[B7L@U0M4CT]BV M.#P9.?04#&XJ]ZBM$4=4F]V>VM';#>6ZX%MBD0")$UFI=8UIE?Q16"F0E9,X M)VAY"#"0AI5<40]B7U"NW[`W%KBN@=94.%/%\ M%>%J$IZFJ>\]V!;`^`ASHC%I,<"+M5O8A\_AAV,\V\H+#,U$PR'#6-K+Q4B0 M9'C'/W"2X9TJPSMLJ@Q5:N8]RU^\B[W]<)C1!55P74\>9'F0Y4$^:`793`AN M[#,6!^Z9B]Z+O%*S,IOX-DTL^!H'H)+LEX"K,IP=W."+4]\.4$GYX`X;RHLX M%T5OI`^F`8#>EK&.">80#G@0%AH@+RUA(6@:;:0=);UCE-218X_4NZ>-T67,/UH*JWV3VDX M37C031C2O$_2KSB?=\!>`]"&CD>)8@/;XAD`":)R?OE,IH;6)%1;[LB14$`%'^J@5:NS;2<9S9Q11$A651A0%*.K,?V$(61&:_U_-@>?K/ M^/3+:VZ2#H04");PCB3JEDE($\Q(&3'*50Y$1D+`0N[+2CF52&L@/N?#TVF$ M+IY!X7?7;!.E!&`J2=RB#+2`WW;+ZL@^&P*^YU(J>%`SA=H,TORT(2-FGJ3+ M9L4=!0F][&#\3^8*'D@*"6MM0VQT00]?A M'`0"I`P`>?7?8IAJ`=O(>7FJ;<_EC^A@-QBM3CQ>T;Y)Y;H&QUHJUZ7P__1) M#1GK07UZ2WK.R#,LS_")G.$:GN#*+KR]9P,?+-R9HO4K MNQ)NNKFDK=0WQ^O4+_CF!"1TO5;ZYNI%^I+U7#;K00,J$._ M6<+5])ZHF*',3V@')9QG/(EAA?>L>U[>LPR":+S*#6?)>H]_]"7KE:RWCKZK M+'?>A^^J8ZA&RUCNNLK,OYWKBD\@/5>2_]5R2^J"_SKPOT4N5:CG+#JU>:)N MEE,@;\EPB+2.QAO;]2;(/[]P-O,5%#[\[9-GP>`AH@_FD$0 M3>AYP/@+[24@#_-G8=(93$EWXYL_O59>Z"_I3B/=DGSP\':2@R7CL-1+N]?0 M^C\A^]1Z6J-K_*0J+XR7"J\Y"5;<;#0-&J'9T-KX M?BLSG1.C!I^B:1I@?&.&'E[C!TA?M.'I`':#5,M%5!<5E,GIOQ0@?P[#-S4< M'S^U6MW,!7/2=6W7#A&]*_<2;XNF,HT"#'U=U=M=?C,5T#XTDYNF^E=MO=E\H00+[G.O8P\GT4 M6T*-3^]G%5U6;2COA4]D;:85H7TQ8SQS%S:;WT3I3(;::?+W8!TMM6?T%J[7 M!AN#K*+"CV0"R'9FRZ7=WUY%P=6]:4Y_?@<3OH/YP#`"H^$..,@;9!*_/GWR MM_B1;]Q&^8JEE>Z08YE#`J#@-;1#D`M]8Z-?GKWEG_\R/MW\]9>A70'*KA!9 MSWZ5;/Z\V?RR4,3G+W"\AQG+<@M9FH35*@NIG7NF,?N.7#*P'3+HKN`@I M3[L\[?*T'^]69%&)@A(7([W1R!YBZ6Y\UK)]T#\]^&L,ADY\_Q`T8''JXPH+ M>76XU334/A@%I`^WM(ZJ]7LY79;?(P`P0"2$Q5-@9FY2 MYU.EB(07WWRD*6!3KQ+=&4,?,*CT#=7@"$@6=*HLJ,8*Q^?L)>VK..1&I8*E M#E(S`I0,0#*`/3"`N%;!&QMXP7#L`KGZ4J#J`;G4/+!B^>#PB'3C)E@+L((O"#E:B:F@EN9=F:\ M7!/V^N".&UUDWO#`;5Q`BOC&2)1@)Q>)XZ1EVBGLB>6)DWX5/.Y.I=>3+"3> M6$TPE9$7^VH9,3\2+!E,-V`7[BF5%)1[LJC+B4"[ABL3.Y1,G!V``]+ M?\93#\S`QDPIYC-SA-(!H]S,16IX^@0?_4?DLA@U:IST]&ABJ#J+"XN-S,@) M@[@1"?4T"7B\EGY97%(XCMU7."3A*H8WOMU^RZ:A<*L5[BVO2QI/D53L4K,X M@+'7#8,]\^Z]T.9YIMEN..E>IB1$5:<3,@HB6()HBR>V+\Y42P5*L@\@"^=I M$P/\CTJF#4GL=;OR7"S?ZN:+]$N) M2OI9B#KU05[U3EJ,4N(K3_VY3@O2+Y2,SY7%EQRB!A0J.<3%\@K MI7-7&)W$-K<%0KUVJ) M$@;51`V-F:V3V.&3&(('M9E1$'W=E"B@'<:"*#XHYG3KVT!0-J*B>/M#Q=_@< M,/\!NQN)/X?>=$:D'21M]!SL4!*A]NEC2B0`(AZ@+H\SQ:5+4-3FZ1$>QO]R M)38@15[0R1!.`4#@P.1@$,%,WUWO\0H4;=H#ZO)'-\$^S;P!5H:")SQ'A)"! M")/7@9A,-77YP,*`>)%LQ+!D4"%\W,:P0X<:2V>&S4."JP*R\!R^8`]-F/F5 M2E%8`U8L1>%EB\*EK)*8(DFZ+5;Q]SXJ&(:5S6RP8^O9`-&H" M7F4ZE-+-'X^Y-3DQ?+P9%C>I0WYN6[SV]^\NB==;[$,2$"\?>J[+*&4[392/ MP1.`9#T`(->(5\\9\X"'&?8X1=;),_-[/R'\/CI#L.-MW%?5DHRI!@=#,J;+ M9DPWHQ%/G2M6U5GR<_[N$=KEFM[HM7/5.%$AQG@7:KE<(5;%?=#YB_Z8&>@! M3P"6QO(M/&EX^*V;'5ERBN-3JN04E\TIEF@(^>:X6$,WJR20]0[?)*5T4X8B MNI#X7G3/1P+3'JQ`GR(.=$M3*"T^NOAL,4$YP%G@12@CCKV]IZISYWJ5GG8;B)>T%7F,O8%3G;2H5[$++--Y-9 MN!.`_3LB#RA:S1$%6=+`R=`,QMG>>":%]T3[3L%C`5'\@K[]@\?`D,VBFR5` M%AU?SLSOU(LY^?"2%A0#D`T78JN:)-9#I:!RT(L\`R$F*/D[>W'?`X@L>\2U MR@>/[.349,Q!$PIS.^D8I+GYC($0*Q._@`W>\54:F4'61[9B]2T?*FU\H+C.9- MR,7U4LT2%E*3NCFQ)$'BY40H97H-9(J4Z9]R;.J!ZG1T64/TIK0E3S7 MIWJNLQBL67;\%WY]C_,'D<.ZK%6I//_R_,OS?WI]2Y?W+`6+8LG]W6VZF5*A M'+!Z`--HYXO6[-C<5-.Y\0V?A`G.:]^T^!]D8&<:NXM_D9+/!< MMB.-0XF<+?I"F[LW3%99]D+P@G6ULN>IR*%-71^.[&\J&6-=MJ0N^#\V8\RD M)/579"PNE.'25+W;4PV]Q5.:O8F-38QG@D^B MR5)VZI-T(-C3=72/?5,+[<6*3J>/-J/KM'-[K682H\YH??/PTBJ>/LGZVS-/Q^GL?*`@ M[HUM%CGS;?3,M_IJ2S.D:E>#LRM5NU/EG37VS-]F'6G\IH>L7B6Y0/VVI"[X M/[8&M=<*FEP;L!==6$(!XRJ2F_2F!ZV'LJ5:C6[[)Y&PG]>-\"G4C^B*+=B" MJ,TD=0%B?S=E`L31@C3CSAQX#RL,Q[3"_`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`.3O*(>O$(R]!/8 MI+TP]#?$0"E'^/KVK=)K-:^T]I7>5E[H1-^+*/G1V`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`MCW8B*H8&2/6#*5\=T545H'/$SXMLX6YP&RT\,PCJ(G)!J`"P?+VF( M@]_R-)G<%,D,N0=%PJKCQ&THE,0+$GK*&)09FR(W^"(^+Y(RZ2.OW65-;-<. M4.U)W%%+$!CK;$DA>;1M;=AED=7C#?[%H4C\-'P:D2NJF"&%KVS17=QGF#B* M?WUG,_2I!&A\.`@$<\$V\4T,#<6Y1(\N/#"VIW'>5A(PFRE!!*HE?Y\[I-)> MP4VMJ>:0%G"=`?_)[0OA\C%M8HC8`\)C\1V`3#O1.(DT7B`^FE(A[PQ28.U< MQHF\U'4#U5U/?=O)%S0N.DBBM:N*R<5X7LA?F[(F\8#IB/;98*\/'#L8QV8U M3T/TQLST0WY/Y99[#]8[@'([O)F5+3PYC6@=3(1?46YM[X@ M^U/TQJ"@\VQI&B%\X0KSUDEY(IQ3-6,CW_&'^MT*R_/.L\V_6!GK;VB9WGT/7= MH=A]I>WFNB>,M5`L>^)5Z&=W-O>JV&5R:@Q-)TZ5&GAAZ$U>*UC'%Y@=__-J MGF7F?XUIK6%0AE'^1Y%J%'B.;66):,6IS2=%3;/K68)C#%'1H>&3)F?FF*N( MG0QSRRET("Q96+]]Z)6A<`2^`/,9N54*((;(N?S5+(D62`ZH8.,%G^U.:DWC M>%NI[[25?XJ+`E?TC:^\(OG(+PUDO[J)JXOA;0:V.89J@Z"]TL$QE[G;D2Y+ M!]_8A-MCV2_?BIS#R'2R7]]A!N`+6]2;>UD2G=N+M4/)G[U,4R0-ENSMJ2U- MU_LKUM:M]R+72D[G<,C8:%2.KH1[-1\]#95_F"XY&83%M[ND MW`W**K6O`T,"ZOJ.H(B7*4MH.4OLJKVVH1K=3EFX:H.A^NP5&%][`N5YS:BE MV>AT3VY[Z@/)=MNTH_+;:^@EP3-VI:*CB:X1_:_Y%/!9@Z"=,J]CUM+Z&DHG4H?3B3;"?MITNVGTY\!^H# M2:4FTE80G(H5=+P@TGO/'S$;;*A7-S^FME^%I)(1V@.O8M4YV_\RRDG7%YIJ MM)IJRRCK2%XA7(^W-2\OBJY6R?+C+:,*/:`NIT)K-'L715+GL8K#D]:N21/[ M59Q.U3Q?$OE9:U]'T@.9"$6 M78R[JWD5[4.(+AF-J3;$X[V(1%KN?;:^V$.OL"#NVC*KG`5GW_Z)*,8Z$D>ULZ* MP7ELZ=G3[,'][?)4;J9]29*]N`6VFS5=83T\_U65)#B:T^8557PO13IS8RY_ M$FOVCSS'\1XQH&"[V!)!]&V?3AWLEAIZ24'\7.S!M58[=$ZSTKWB>H^^.?WE M&?]O"DXQ+737/:"O+??>:^T\R=H'C+5/M-KKGM",G<'0UA;Q;Z^=1%M;';\> M>[(>SBJPL02,50;S'(&O,:"72ZJKT)O^K!@-'86$^(J_%'^['5/OKBQ!7%:4 M.+O7[C::U6H,Y>/F@G:V77/L;_^2LNN-%U^;7=`J;HI0?A;"F0V'N!!R12V0M^!50S M8I3Z[/MM8'DLULB!4[56L;8@>X6Z5[A6]F0U2#RE,CM\V$^/:, M83]"?)?+\;VRRM]F*M>%L*DCR$$IZ0YO0$C>VQ#3,8A2H)M=`VUU]Z+77@AWCT9A%@#MUZZBXD,0IR.%_#IDT/[`=N- M=ME>>S7RVM:'LFO^**X>TWW0

,1W"*RTNN/&E1^'6Z"T\BH\ M%X&UW<72N2"K=H+SLA"[<3\K>7XEKSNTI^!WMD>ZL,PW-!UN%,U[/$V-,G*U(!2[>77.4,.1>T20XFC51II)X?8C?N7"G/ M;S5>7_OLWLS9(K6QK(1^$_2E2GTE&GD#\=F MP+*O)U=5NJ\#9>A-)IX+L'C#[]BJ":MJ:7UERGPEP$+1U.5I-+*'S`]4Y8$! M[-CC*53T]D^*/9DPRX;9G1FU?<))?*J_#GNH>`_P+W,Z];T?]H0_U-(5F"T< MPU#9%E'TI-949LST@X:"K:?2A8U,VT>:C>"YD?)<[^EJN]]5%8N%S)_8+B`B M"A`HG/V-`S2BW`['GL,"@0AEZMO8]0FFMI@#!R$6<_ MV!:#U6+9E@#Z3;6%K<3D_F??I'9M.429CI/L:KP'5N3' MF`K'"#8_C0HL%]#X*=>FC18('PS"NM9OJ>U.F[Z$/]2.H:MPUH,I&X;V`^RI MJCR:0!JP__-D!.[CPDI^=1`++8`(^0:"+>@*"6[@E\X8J-L0.@81:@ M-]52!@RHMJ"'WARH!I>TA>LZY;9Y^KHG^OUU3ZSOK[:^B5MGW1.=]6W>UG:; M6]^^;^U:6VO7NJQ]GVSRM*'FO+?EE8VF.!4T56M5VRIVW3(OMJG)`?>T5VU3 M]4-MZ26U-CGD"6^>9MNB??7_4E[8;O8[,D%>ED2K[!NS6WG_15(\.`R@+AX= MACI4M:\!.6B+G0D/#D.G#DT.:M!.J1IR>/IDMTY"-3B;K1J.Z$042<"]@=UMJLVNHAEZZ3.;. M51(.D;9SZ-(1*]KW'J-T1('`W`L\S891MJ9:@?R4=%,@2T^!.16(W[V`W6J4 M+IFTY-Y+L^[_)O9EDWZ7JK%::;G:NIG"& M=+.99*\-<]I,LF\/=O^`9?EK+=E+JB);2O8X#+,7X2[-]N.9[4GJEWZ,.H=G M:(E=K@5?NJV9M."E!;\#V!=HR&\1N<^GXF^69+63JO#>\T?,#JM0%8ZR[.K5 MC/TOHW8J2EV6_**C&BV\.Z&_K$"IJ04]'C>S\5CG:Y5:51=BJT(EJ\M:F@VC M=(6`:I-*CT5AYW%.5JF1!Z:M%?4G#JB$[GW1E6NGM:>V6CBRBM)*WK$AFPR8 M']_%*5NTJ3Y6H/16K2[HH/749K>W044'Z:.2/JJ,4E,^.TGZJ*2/:D.P.WOJ MR5!SYY3,,I%9)KN#;>BJWM?5;J_T&9)9)KM*]G/*,FEJ^TD@O1#"D6DF*\'N M-5I[$>TRS42FF9R.=*\FS40:[M)P+P//1G?=-B*M76W[HU#1<2SVK6;=V>#> M[G#L:E0?24G+'S8^I[OJD%JD=.]@CIY(+J2.1\QP#>9Y@`' MD=\RL6-7^;T]V%I35UM-#3MQ[45^7TB`_G(S.TJG<=/J,D+]GUR;$;]A-:T1_&RIOI<7Z`% MT5_0]T3`6J:0>/;%4^Z!LK9Q2'_WUB+K>X^L;8'2:JU[0EO;S65])Y:U3[37 M3J*M[=52CSU9#V<5V%@RA*QUOULMZV:U0:QU'MRT[X*@FBWXY0`_Q`VUE(Q/ ME=8Y*&*K]=T`K7^L/BB=:O"?L8E/!_^RBU1IM?\'H5V#K=!JT)6P M!ELA14=MMJ(.%"FYPQDY=W=+<'N.Y3V4Y**O]EJ!;TJG$]4GE[*`PYU"+F4! M4]Q3IK>F]II=M6]H)[>U]8&D0.<^!2(K4-.W`WN=PV2#C-V=+V:<(7FM"@$= MXQY!@8C>TSV"9NG:D3M?;3A#NI&R;W4?LZ[:Z7?4?JI?9-RJT1N=4C#/IKBE;#[S54[5NV29$ M]=G6^D`BPQ3K3(K2JJ$,4TA/8"JTNZ5-T?KX;>M#-U+NG:7[HY M^>KNG`#:C4XW;XIT&YW^[GMP0C5S5['S,ZN96T84U&7)NMIM:JK>J\`N/B%B M/(]5K#+0\L>HX)(?.T);._1V&$='-%/ MG^P9EHU=T0N@U$YJ50GVYGU!-G4KUH+,]@S)QF'8>A#9QF'896`?\;;8)9#7 MQL&.+'9I.O,IJ&I2Z`;*?LJ[JE1GZVM$;U?,'_O?79OAH0\T.>;3?PGQ8%-Z'=9 M!ONF\B_/=D/E`186^;`3,`*;P!^*98;)Q%I3($;!+A;)>":\,->"`HN+Z%I7 M&7D^_!/YRHR9?@##P_)A>2/?FRC_B%P&X-&(N%@ONA_G)VHWE.WQ`1OOW\,S MSW5=;;^'`,X]7S\(4,!?WL5!5?WICG] M^9T=#!TO`#1]&>%DS`UHE&_,05R]]8(PH#J9;X#RK*_F#/$8W+$?X1L'B/+7 MIT_^%@\%KT_LD'Z_=BVLHPN3,W=HLR"=)7D3=PT[S']CHU^>O>6?_S(^W?SU MEZ%=`2JN$`G/?LVQB'E7!C7=&)D3VYG]K/Q/:$]8H+CL48$-,=W_>9WKY$'N M#?X%]VJXV*O$$=\]F+YM8I_[W+>/5#`S_=)A(9R4*]$*)/.][;*KL7A8Z^!, MGC\=FV[P,[(![[6"JXL]%T%H^J'XRH:=QVGQR/!O0B##`/NHX/`N>ZT\CNV0 MT9P9H('W>H_)Z(^>;Z50T5@`^^"[#]]9[.NAWPM/^0`_?/YR=Z-H MF6(Z^FOE[9=/GS[K7']^!W]_OOOP^;>;SV\_W-P260V*.87U2O#9&GX`A(C_##/TCT_R%$_W4L^FE3(KD]Q]Z>!28E M]Z0^?$I*AOUB_(L[9WODE7RRP]#JX?;+56R_@#H_];V1#=9)`*HX-7CQ[?498\&BP:!;=DP(FS@ MXQCF'LPPKC96ID"O]*7M./R/H3U%&PRL+5C5=\8-'P#,&X2\AP8\!J^0!07# M`[P/ML64Z7@6P+M@QP'.^7/X5H"`85<]^)J9W&90(M@G;KBX)I(4V'NQ#JHW M7W]C8$LP?#'Y4GM-2A:LW(GI,@^KBL^"*1J*#\R9-10PW$W+LM':415F M#OFR9WS1`T9/@SEEHQ5(0,.XN`#V[\B>$NYQ=B``M,;8#YL;6WSU[,'VH@!L M-##=)\P/&LI7L8-H7UHV(@=L-H!`&=FC$&?(P#(=>Y"9;D=^`1<3CUP:-P&<(3(=C>6%!P7)G@>0-DAN?"<:Y MXPXXH'"F/Z-G MA:,)'5D$4(T<7%*-E.;NN2.=+*<_05FQS8GRAID1'C;E[UXPM4/>O$P:5\?? M(&GPUFI/I(IU:(SC"E=$A+.U?D`CHSB:CAI(H6D,9K''5:O8_B5]9RD75-%X M_O/-WU74M#`(2\8:K!X4$?@ZB;G"E]GI8.V.!2L#=8C]&#I1`'J/BJB[`IO9 ML8?,#1A%!\5G>O_14WYOW#:4"0O'H*^@O8R*U]`#G2G6BF!KHB$'''3"<33! MM5B1$RJ3F3FG,%Z\6G@:?X<141D- MV7#LPF[>VRS(#S`V^0`3TV+TQE3$#Q%?N`(/($(0T4PE[(`U;CKQ8_B4.03C MU&=B&33]_!P!6.I#!CMDH3X_LH&8"6,H$R"F15$'(3>VK" M)VZOIVP'!=QR!K*&]LZ#UDY,4Y1(/YS)E*8.S4B%^<;NT1F>..G*^,KRII:T MQ&JVU4M3.Z5HW3?NL\KS@#DV>V!!HBM/3-2H0;`)+[8WY1[7K*LZYY)&/RWS M,0:()Q,#7&PR=;P98V!B6*"Y#T//YR$I=+:#I1-G;;Z%C8;EN[;)K1O/R1UP M/W?H?>7?$3YO#_D7%%\,"#1X'L0Z2%$RR#*C!FP8^3;%,1WS$4R3:X`#HWH` MQ)S+'B2V:]$J)^9WQI\:`@HX/".4VF0@PNJGS`]@VKP10FH&O4IV4O**B88< M?P&VU^.H-2GUT78C-`HI#QL?36>,33/8CG1_/``2#%&PH]#.3(#XX`IDY<%5 MR40CI8CRCLE(SJ`&\%&@)R5@@\83;S:N`$QRT1$\)0A!'_-HP9A$M_M3O(G\ MZ3B?%I["+N(*:$^A#3L&[P]F/.`;308P-1J4_`V*90`%3<'V3A4J&)Q6*T(J M,$\2Q;!BLRP&\!%>BPPB(KB""S8O'Q9`,$I?P7BS9K9RK`_C>A!1)<2AQ]T/3 MR;[FV.;`=FP,5GN18V&T.IH2P>457*.KH7K;4/[N/0(=^0AN;K(,`\"U(^VZ M\"(>@`D:L([]'9X8>YY5"'D2*P=:8].0;ZAP#>3I@EP&BCG!@+5`-D'.CR/] MK"#4/MK_[,<44&93\H.@$`$P.F&RJ^?&/UY:ML06Y8-,R#GF-DTS9)Q(ZM07 MA'12+ZGZUE;UE>B7,:"SMC?L(*M><>^_P^Y-"G<,&4,7GM#%`$D\ MTD!*'3KW,.UDZ$5^0,K?(`H`$T&J`WM3VQ7V`^R(>4^^-+50*^`*EU!&X%?4 M1U'YR&H6J#&+?$&$E90Z>`;V!-12>Z20,F*C;CL$*.:L$!LL'9\T;XK^`#`J MKAUC(:11S7!(80PD6H\-.(+)A(I:Y."(UZPJ(T"'.Z18B1>(%$:N2@5X+:/MAR(["^4%=#6Q"T M61M@#>#HD%$&>`1[P;UG0;QEJ1H+VAQ=_4('#:I\E"JY7`SQ\6IF$0 M,$>Y-9TI@W=Y2BW^`V,VE!>9#-NWMV\S*;4O53)KR0I`V@6J2N*E:`K[ELBI M3>G5M,!P!Z(LN+=9`*:ZW*=HP8L`/GO//!(8S6_#Y9RDB*XNZHX*:1UAIJ&0<:P-* M`S"YYZ:MZLVNVC&::,I2,&/-S61UX0IMHZEI!@V689/Y],N8<3Q0Z!<^X951 MRC\$WJI\8O_YC^D"^U/>)"HG`9R:8MK008*-7WNAJ"LA@ M(3=?`\1=$'A`]#A_N6YH:LMO94)3"5\82Y9?DE(*KU'O-GEW^RUX?>F[?]A.A%+GTOO%V]S M2QC!1"6LT0$][!6J2$7Z6I8-*_/*7K'"M*A8+5/2"O2F0FUKC3)5=#%7SUW, M?7_]X9ORQ_7'WV^43S?7M[]_N\%+NB5NY)XADDI)WS-;=Y9?F98WY6Y#-N)P+[@PMS1SQM)ZL)7`,K MY$]G%0)47_]ANA$JZ]Q'V@.>E3P*?'B$*JPR@E./=4,B%JNBW#><<0W2%1R1 MV$-^WO@"#CH205\)Z6*4:7,O-.T'0W&?*O'',1=`>'FWCH)K<>8"%@=.`5)+%" M0$425>#HC=&1Q&;XD.3/SCK%BU#$1\"\L$?$"6Y=C(]D9Y)M4+GQ9*)I@%YF MP"?8=EC\)-XS=.[#$#2IRG,IX`$ATP%#>,Y0``(6S,."FD=@YW.OY)R-W\5G" M!"Q3AYCX3=Y^)GE3,A&.+%R:LR.,F<3==Y+Q>>EKIO3D9ZCHR\+ MW"R3F1L3GJ"RF)G_.T=[=$$6^*1C^L5T]GKNA>0F<1`;_T&$'B:\PJH\>$XT MH8O/MCM"!DXF82J_01,AJSU/[B]?<*9!DI#L@KA2M4T3`4/`K,N%XK$32@C)!"@D^XOF^!W:F*8*?F0&$X`3=P>3HB08!9C_8 M-`#I#A'>@,YF;\L3*D^H.*%&[H3^7J!Q"']!0N+BY@&FXL]B)SK+4;IX(ZO: M`N5E="=TM4@:E#3X^AHX$[PZR5@K1D#)+Y!FG?C M"*KFQ"L)ZL+6?<=9#WG61090RKB`6CBE(!-#^1UPV9_:0TA,)/+S$GK.$./< MC>0N-YEC:SU)+`@D_2&*QA7:O*!?" MM9WE3@H>UJ-9J&"!15\(C*$Z$V\)S>H]8@I>/#D@0^2G!442IGA">>@O;-V_ M(^,GOZ0X?JDG1!4IAX_\=E[F3@TO2`&O(7+B>X`#!BLFIYO/\&AB7-GT7?>E MFLVZ$)5/EOB/,TF^648[8$-3^"=A%-O/0@//8HQS)D_`3NM^^N3T5EX8,"Y* MB\X'&>++WSQ+"7.WR!K(QV>&#I`HB'Z>?>T(1Q$,KF?4ER*VNY\LFNW>S,;0 MDJNB`87XR?/#I5+N``:)-8-GDX[?_`NH*L8Q$6Z75\*//P_$]S&X M9#NY,E`+EW."!4N?VUC$#J8^YAFDL9P@3))[.$\I"..H&`S*K)CFR40Y4A4V M=2S@\GED*XT2>:G2.*_\8<%[H4NG`MG.1!2'"[<`TEGC%+(YO3V^!<*H[!.@ MF$?G[G@L;(*1QX4@%J?8C***EQRXGI&'>.VV?@1,`B`]T@XD"CQ0W M$@BGL*:0.I1HXJ'&8HAW:VFQKJM;O4`T),SGT,=OCP?.]I#(B M["//<4B%4*BK19PQA)``>1.AX_E*\R[S!V^9FA.[%],#.I)OH-@OQTS&D`DBW^]/H9E4$1,O"79TW^]Q0K=O*_,W/X M\01+F@1FG[6R@CY.V&Y.P\+$N;F.)]6_B>N%-0(U&W+^U:/,]8S<<EMX+RC.A-Z:#^4WJ@O*EKV!*B31MM%O+!B[% MW>8'RFZJPT:+))1I6;9ZQ,(AZ>X$X'KJR@2JCTGZ_T>QO@,Y,_O721I`'0O/.K(N\2L6,JQQP M=U2:X,4]6/C!2\7QP$P.]J(ZK@1GA[$6-_J(@-4#"HF>4T+/?M67QK;U6H]_L')K:GSZI/6)>=%NJH;=VANGE>=#)"Z.O=CO:'M!Q?-WA M3MP:#;#J`JH-<3R3LLQM=XAU&7B/@B@<>SZ\;8EZDF>RN2T@]GY;$OOQ99W$ M5YUT@T7PRL3#2C`5GK49Q*6Q\IT"*(]K!=+6P5"Y&V$/T;4J/29U`:\43:[8D%0%UP6BY8]0??"Z';4=G-5''P'MG]8_7:CR+]Q/&5C5BW!(O"]&O)O"` MW5-HCAW]JMY[';NKXZH#TKEU5.=6E0ROVOV2NW^)N__TB=S_`[JV-:.EZJU5 MCMYZN;8WUEL3YW9>73UI'^4E**D5H*G3Z:BMGO1LBR&,7DOM:KLG9-7:K_49 M;-,7'[T@>*G\1A5?>'NDN/^2:&!,5522VFW91&\J,Y@I13%FCK5H[)XT'4CN M4$7%6M*_5U=YB6_6SXV^5:6>]TXT##-UVI>5 MKA'MQJBD$I6^2BH^65BBW4]8SEPSPHQ;/5,0WN*=.I@Y'&>J27%NE6L%MA2& M.-O4FFN\W6K%O=8O-DYKV,;/ZO<,Y?Y5(P^F4U4Y1QA15SQ95P-*RV?M*I#)=?XE&#, MK`V45<8V3J+GU98IE4=/QI&)1MIAL49N5*$@;J2\I:XNMW3((*X*S&'E\ MTP.;2I%BUZ'Y>DI!7D!A[5OF8O_-!\+V'-4538R]X88X=HH`K/X;;S8U%%UX M0I0O2_-!/#<[&4S&?J5&?D.M7=_O[F]N;_?K_Y?*?<_`'_OB7*Q`%BT%X! MJ<2?D6K.A5"$?"[NAWUMNH.(JL(K MYOV]S^Y%'4Y#[1E]^$<75VJH;QG5\\98!B MVRSH*BI9@&0!D@74BP6T5;UCJ(;67G7D017-7XN)S13>_YM:4@[YN\^U9A-; M7\OC7P/RD\=?'G\\_NKR\Z_!8=757K.WT?G/_8JM[X:^+2IR(P]H$PN0'.#X M%"@Y@.0`JQ4`O=M2.SUMU?$W@[GC']@_%/@Y'&.3SJ$?D=,.-@Q[2`G_X6?/ MAY_A1/`\9V\`5)8IJ"[9@F0+DBW4F"UH/=7H&6JWVRKI"RAT!6B]IMK6-'GF M:T!S\LS+,[^9.["E=ON&JG=[IJN]E/I$\HJ:\`I-4_N@(VBK+0>;+BBX;$A]S:AA&>\3S/RAS?N0Q:4_&\I7 MWQLR9L5M&&$2;!_Z7#,ZZ$U0Z6%J>ON#@)@ M@*W8L-O,%$O`NB$9A[0Q4;)%T_C392"I(-?J8A;_QO;&#$2ABODR#>4%GNHX MPT!OOI[+MM&UUR^).]CN$/BXYU,T@AKP\70F\S'IR7T;"G7F/:S>MDQD2M?1 M/>!25;1^OY]+!L.LGR2M[($YWI34&I#2]]@3%G.+1KQ]]DQ)>0#.X5JF#[SK MK6/0,QIZ4WNH]#7>%?E=9LQ;'%.Y@0$HW>A%9K782)F_DENP:.(=\KZW MENT]F,$P$B!G]UCQ\8'IM`V84:2$_F`$VP=[H.$G0P` MMN&836Q3589CWW-AW?S9]'MS&,%>3&8>P4_=(D?`I[GG.&V12S(&$[8\:O^8 M%T!CZBD=)[CAOF>SR@+3H;`T8'(>*;P??<9HQ;VTI"`CP!>JN M'8QCS=BDHYDP/NJH!%(V8`WE?3Z;FK(+`6S&>VN#>/.B^_%"4\-YM(`V'<7I M;2:1ZM`.D[=Y"],YHN8Q.PU5=D-MMXS&!?*>(L:;J@7E)'Y61_C&J>\;;[Z* M.[B+>G!*!@^2PA;FSH_#*MN%&<^D=8B=4S);5Z22S&50RZTYP-;DLM+EGAQ[ M3TI=!3CQ3:@/QI=T,1=J#J6*@WCR+4K/)S-[`^6TT^3*:0'S6]!*^;-Y-9QL M:&]1&4HB&`04#H9]D9V>:]M=%.BS^">NQS9#SL(@]?*"_UEK.!R;<@;\NL'H/32+1!^"R-01O8/\GM:29-S=%"^IF]>M%Y2PV+0]>*[$3:BW`P\ M?(KW(8?A&Z#5BW=#488A63-.'(^%NN.`KI-@BW?3-3G\N0L$_XJL>]YA&[VP MOA7[-SB<,`%,F-RER"XFL7:FOF=%0]+T"!5B>606Y!=#+WA!W!.;.V`>[(`4 M70SL8&=T^H5&\-G`1"T";&E?B\,X.DD@>Y;$;P M$+.,!_,H=2;FVN*U(O&#R@$')78TS,.S=#X[$"*):@F1_#!G-`H^E`B5#.P- MY0,Z,K(N%[I;R06?&4]G@50W1R$N(_+%=LV/[8NF'I,I#QX*\>DK0\S2L,@DBL5/:;BAO1K5%`V,A$QQV(27Y_GN2Y"7I2EEK&H-]XH-,DI!0# M$3&19>.098.,.A9"0F+1:PWE M&DSFH1F,TZ@R.LIAPJD7V"$'/S=',OY@E@R.=C>]EMR3EVQ5'G*)<8GQBC'^ MNPOLQ6%S"BO_2)ZUO`([B.@;LA-0`\6@I8(CD.(K2H3$[AIE&J$_S:70)4:@ M?!/KLCA<'\="%7$1"E4)(K![A&,H5HV3<0O@& M0DCSFG>\++I=(*X3DUN(^8AX%`77`H!L<:EH'D/X3E)6`U8V2#Q=POR"E[`$ MR8R9/O=.\?(G?$3Q@,`>:>MA4%A88VU4+QL"1&>MS\98/^2!?7`1?S)1:)-$ MH1P"%8Y!F1UTJ=E!V?B'Y3'.\<8F-E+`G)V0<5_%,$< M9)WE_,@7@\[5"0]E>5>6W]V(DG]?F7^+Z:"2S95C>%0<44@4"1U MS*$E3*HBCD9!*MN)@&0E'Y1\4"1\6=X4U9P-HKUZITG1WOC$*G!D.:4M!'OY MH[E@;P!Z%B`WCDLBPXVX=U3-)?(*3]8_CPUZD'E=UW5?2Z6"$SV0RB9YEQ:/"+CP708UVUY MMBD_VO-+!M7;C`+4_9GM*VPTPLQ#RJ`.[2MZ!R6=6'QF-Y2X5N*ZS'BCH;R/ ML.I<#,`B?@"I`$FKWU,[_8ZJ]W7"BZ[K:J?74WM:I_1D+?XFS*IBE3O4V0%\ M9U:H;Z\1*?/:-H@K6ODW'C%^ZP5A(*50.2G$Z?\-':4L+J6@D8)F!J<;TSF" M381,5^N1D,D2TX)XX0^MS27")&MB2E>7%+>/W%Q6M^5(:"Q>V^&O25@KR M[GW&Q6)63@99-0+)T!;2LM0.^VFVFMW,K?ELBJ!JFB=@D?X>:")'EB0 MMU;S!EL)\9>7F.Z0H0>0WK&#[V\IB(R?I)1P#W6)AZYE+1X!BE1%EXLHJ3A M3+0X>`90.EV03_'$NM8(@1U&H@1[(+Q@V#F"ZDT_V.R1!SS!@+-!F4^3G*3$ MN[#%+Y%XCYFT7ZRG'[M/%;WS$[?JVC\I+T)J?@WOM[6?7JXJT5Y$QA>(;$EI MBST45.%&6$)NS9_P,4YS1B>AN6Y'$IPDN-6+?U_63:4N):/X8C$Y,)FXJ,LO M+CB4,)SK6I>3N`:DOH*L8WB6V`5+E?S\ M==6`X?*O72MS/_V&WY7F-H2T"9;8!#'N:*\RV)/FP*4RF:SG+!$ZZ"#WLZ22 MO8<_1%M]QSM\7:,I[O`5T^.B\\V8C^TTE-^I?D;ZJTJ^MS5PQ]?ZAF/8(6[/ MB#(+2J;T0H,60Q?:J*P"ECYPS;6#Q[D];L"C*.EP=V,;]HS7']]DD,8),A,<\@W(/((7LJ)@Z@+3#&/)\RF5;"']^!B_V=0DC0TZ.(K@2F4B>[5N'N3#OT M);C+U#N):V,L!2(NFD&5(OIJK]WE!=RTCJ'VNZV=@S_\MN7S3ELU=!B^KW.A MRDNT*)K.J[0H+RQ1QB4IB_&RH-M6<>+66OF6%8=)`Z4OH_>Q3?TAM>"E0%PI M$!%["J%/BL!+%8$;R*V>SN^>)R=-R1RU!:'%G\Y%C))842;90.C+^09O0^:' MU+>TR"W'>>+0]'U*;4A?BMUN]"$3ME=3V9ZM:AF7L\STD5-%%H'G(]+\"7:. M]KU'C&RK/`UV)')5!;O.==G#9]+F@]DEQ9D!\6WP=(()7A-?\^(('7F[+[%3>1.%BR*9),N$W<:?<\;)=_K)NRY#% MD;U[?H&1U"!1$RI-#T&)R!X(:O)5?L<],].[D?/7(860I#T<82A33SO7^5(HK MG])^DYRX,WTE"QCT0L88OG)`@:`*S\H4#UA(1=;XZ:,.GA[6NX!/HHDFQCEF M2P(UQ`Z$S!`?)*Q!S3=*(XXJ9_,:O:8$"2FH;FSJP`YS9BAI26"8*J,<6JM4THG*<]%R. M6V[+_!+&^2YI,ITRUX_Q[6#),G%O]T+O.>J' M6CM6")-JO"P)!I/92,5AJ(0-9?#%VNF*N:AV,+/NZ77DKL+.3TNXQ'KCD@$P MWFV)ZZQS\-+9A>OF4HK`RU8HRD(. MC-T!FD;'"(+$<@`%2`U-AM-#`&)$(BQS4A?D( MF=N'MI6_?+ADK93G16'?+%!B\F!1%&TB3K+>ZL_L,5.9V/=<^"A$HKQPO)GR MCK'R+)GGL2EET07+HCC;&ZM1>!$HHE.+BF'Z1#1.W!5%529>$*;I'=F$#JK' MCQF7L%;0N8=)DCA%"E.J<[!TJ"CTZ<12SOG%COF]B46V4Y'3R.CL_95Q!J(>CH M-W&9H6UXVP5T.SML*9.$F0ZP2)X9!+\\0]IE5^1IY]K"%6`.%_(LK>(=DG-; M(%\,IS6;/VV&>>I;1"TM!,R_/&OROZ>F98F_DRG]Y!/U*B0B&'AAZ$T2,A"O M7?&O?U;T[`JK;[`2YWX1IRX`%F(A.7A(#3"5?F!4S",@PVM06C`_6?7H^^.?WE&?_OLV7GF_`OFAH@BE\K MI\^S3G\%DNM*7C`W4=;](1GO_AFO(1GO$K;U*J.H^\K@GMC3+\_^:SAD;#1Z MED%%SI`C3O7+LV[GIP6<%%!KSOBK,ZW2J!_-`;8ZQ&+@:/5/&%WA3`ON;D`^ M8OT$=X(T;3G.CFCT+`=N*9'O$>SGY:#MEX.6\+]/<(VVKAKM7GD4;\M7ZD`I MDJ@E49\742\1@N3"NT@1^#[R73NDSK,C^T=(`;U5CM& M@:_C[/B&I&Y)W>=+W=(T7$#<6ZK]R7PI".M'KO5C%49?;>OMK3G%TRE@IMG:R,_,C,@(VQ)YD]P>;#F<2^:N5DW=-(UD->>610J=_A M*<6W]HN(_7/"CJXV6YW]L\(#AI7V(_SEF95G5I[9&M#Z_HS[$^!"-0!5FB!5 MP-WK@@W2*50S:L0KJN=09,[''_,CBF_3`B'KBWQD M2X+<#L?,BASV973-"V]_3,LMWR$D6Y8&60XI[>72FA6[5JW9=).*ZG0,X-#< M^U[D6O$Y^J\1_6]]"0]90:/VER*/?9?[O"[ZKB@Q<;:7FXN+/5SN-6/)$R1/ M*%\`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`+BWIFNS1SE'R8^__2T;,Y2BL2X$7#_F8;0OA'UC7'?V%UM;4IGZ`:B9[I(Z74NS5`^RZ MB+T7FH;MI;3SI6II^I4Q_>"E$#M#22$H[V25;XK3[W34?NL`!4/K0"N2K"^& MK(VFVFN=MDS4*RC:-K$+ M157(%NN)%=<=NQV;/GMC!LQZFZEF?AO""U^F^#&X'H;V@QW.9'4R69U,5B>3 ME8@VKD24@_"\BO,0]]RDX_S9E^>19T56[:WY^H'YYOWJ M>/EYK?CF!^@==L"4K[X]W"110/+#$UZ!Y(>2'TI^6+3B;VQBVBZ<[@M:,SH! M?',81J9S0:N^8_Y$>6&[RHR9?E`0:KIR6&M!IG6%J@`@)*%X4!J'IHAA2S%#YA^E&IC]3-%79L%RU MC)H>".RZA$^[:J]MJ$979@5(^CZCK(!FHW/:J9\5D$FM@3L%G!80\],G1R'G M7D->=+A`]>XWWW1#9DG]K2X46C]!IW75UL64%)8$?D$*7%.[$)M$$O'9<^E^ MHW\!M"P==`N(BQ,QI`Y7&RJM'W?@^=W/"ND[].%_$2EWB+YGP+UG-?).&LGWM,GE>;9 MO6-#-ADP7S%DIMUY\)L]PJT;:E_3U7[K`#IQ'=`O";QV'JF]@-ML:.W+H&A) MPV?/I/N-2\BCD8EV,M&NWA1:/\Z@]=6>3+23!'Y^ZEM3NX3D)*F_70*7[CCH:K-W@,(6,J=2'M;C^#Y/_(3*G,JS/9DG)O1D3F5]UB;]M64S*C^9 M_G`X8#\I3GT.IW-66?NO'-[2.5.XD@9^C,?WBI#?ZVE MH2_+BV`'+BE0OQDN]J_`ZH>[+;00\Z@+RSE']UP.[E&#E74A^")-YBS/ M[8D>LA(Q_1KNP7D=DXQ=\"I$?;=(E8T_YD<4W_[M511F`&SWGJ3*7,#$SVIMR%H]L*I>CT,[0<[G-WAG'>`JS>H]O_Z],G? M2H^&WP;743CV?%BZ]3M8$WYFBJ^.Z09O9O&-*FHA_\UT[]/9E"'@!/[XQD:_ M/'O+/_]E?+KYZR]#NP)-_PIU_&>_KK)CA&3XKR;];[.=,E!D\"^XI'`]?V(Z MXKL'T[=-M(YRW\9-<^,O'1:&('&"J3D$TLI\#W1S-9Y[V/.G8\#)SXH9A9X0 M2*D-]D-\$X*M$X#1,\$7D?HH`$!39&"$`^$])D,]@N!+@:"Q`-3!=QN&PS&# MT/>^LUA6-K.$/_"5H6,&P2_/S.G480`0+&@XQHVZ`LSA0IXIKY*C2":90+X8 M3FLV?]KBC"A#YC@"YE^>-?G?XHSBWZFYO$RDG%ANV'F`6WEF9::QK:85.2[. MH)UX',GZDJ8I;>"[D(2SCG`Z9TXW-VD$]$SI9INN\K5>T(G#+A3NY@%3[(L` MK"%,Y\5AN!:_`5-9OPG+2;ILWQ%Y5N19J>%9^9.^8=;5RN-R7FN^?F"^>;]: MZSBO%7]C$]-VUVGHY[5F=+[XYC",3.>"5GW'_(F4?%+R5033V9T/*>\N8<6Q M@_Z"EDRQB.-S_J,-*YGRZ=+NQ@;[>>L7AX-\V89(9>ERS^73)U)=DNK2N2]Y M4W7I9"5.J2"48)FM`IYY;/C+Y]Q)2'>$M""MKJ:0G@Y.ZPGI*0!73VJL->9. MAP!/&])ZDN9IXU1"*NE40GJ9D$HZKHCY+95/'.J>QJ!B6K/VV\S7GDK>!&IXN\EJ$V^TMN M79_/*3@!2#I]U)JN3^<$7H[$+"@!)D4AEI$M M*+TIA6"-CV#=0#W+TDEF4BV2?[NAM_,>JG:C MTSV_O;\HIB8]5#L@S^@::J]]UD[:$X!4>JBDARH956]HTD-UON+RZ9-C$YBT M`HJPTFZTVU(,U@%2J;-*G57JK"<"Z04<5BDO+T=>5IW55:J:SNDZU+J-3D%O MX%V)H-8EB+;H=WF0"FTGQCZ.J`');5GA?&BI76V3#)GS.M*GOHR:\*)3<[D= MU$4I=V*E\W.3VVRG>U#/A-](3:B>YJ7$]W)\7[3-R#,ER:J;Q2,Y43<52:82=Q3(D M?Y(JT0DAO-G0+DTERL0`7H4F[&/1LN./^1'%MW][%057]Z8Y_?EV.&96Y+`O M(^K\_L8,F/76FTR9&YBA[;F\'_QU%(X]'X"U?@=2\&]#V/DO4_S]JV.ZP9M9 MW+:8>OE^,]U[=@>$\P8IY->G3_XV&/OA^JEPU#]-WS?=,+@>AO:#'<[N<'W) M6,H0,`)_?&.C7YZ]Y9__,C[=_/67H5U],OTKO:FUGOV*2YW&.X-(!!P;C8XQ M_?%*ZTQ_%&T'I]F?%:-A&'AJQ.GZKR;][[5"YR`$T(*1YP,AN!YN\MSI@/<< M%H9PVH*I.02ZP>?\B>F\5A[A%*;?TJ-T+8.^8^ES5X]L\-V&J7#D(/2][RP^ MSG3XBL$4?Q1(LB&_/./_?39W8)+'Q&'OKGM`U]<]T>^O>T+K[0R&UEGW M1$=;.T9S9S",M6MMK5VK9A0_(?A8O-FK-C4FA`?FA_;0=*Z(76,7<>3+\T)N M_O`6"D>M3'R8S-AIR5P0;KS`XLQ[UGVJUBYR7Y'BHZDAF*IHY\U.7QC$]-V05O)?HG*J&\. MP\ATLE_?,7^BO+#=[''1P$?9$4#PX#J(M'AT%;Y-"7 M2`Z@5!\=!E#;CPZ#MJB#72(YXF:T:G$PPT(X$0Y4FH#G\?N][D6LE>@5/ MBETA^3)JP)=NOY]J)U+_`T&T9W>TDK MZ:9`[IX"3^?PB"B%G[.#PE MX3Z$9"\"Y00D^_9@MYNJ`?^TC)/M>M[8^1+:99-]^M_8CV;>'I]G02M/- M1I+]0NAF,\E>&^:TF63?'NQ^H[2]L9%DW\.>UL(RWU*RQP&;O0CWO6C&3Y]( MPWT#L'NZIE?B!)>VV.7:\,VFM.&E#;]_L"_0E-\BRB_R+K=*R-I)67CO^2-F MAU4H"T=9=O5>A/TOHW8J2EV6_**C&JVVVFSJ+RM0:FI!C\?-@CS6^5JE5M6% MV*I0R>JREF;#Z%6@SIT0A9W'.5FE1M:%M@ZH@NY]R97KIK6GM5HXLHI23-ZQ M(9L,F*\8,LFD-HI@E6!K6D]M=GO)I6CIH9(>JHU4FO+92=)#)3U4&X+=:905 M.&?EFI)9)C++9'>P#5W5^[K:[94^0S++9%?)?DY9)DUM/PFD%T(X,LUD)=B] M1FLOHEVFF52<9O+TB33=:VFZ9]-,I.DN3?/`J1V:3.TXP57(U(YC[MP!:X74,GNE%HZEHK2/3Z8_',:A M(NL'D=\RL6-7^;T]V%I35UM-#9O9[$5^7TB`_G(S.TJG<[S0;]EU2=[<#,?W3;/.W)=.7 M9'_)9"_-X-WZ[M6@P5B_!C#48"MJ`()1@[9[K=9*&%:QV;T)U!HTIZP!=138 MD@>'H5V#K=!JT!BR!ELA14=MMJ(.%"FYPQFY=G?+''R.=5.4Y/ZT]EJ!;TKG M:=4G2;6`PYU"DFH!4]Q3"KVF]II=M6]H)[>UQX;^ESP02M"G[7XSSEJ;Y/G-..OV8.O` M6/MJIW3]E?IL;'T@VS*2Z$O#83V_N_-K:9 MV-[EVEB[=(F;G6^RG2'=2,EWII*O1M0N>5/MZ:96H8IN,V]2:(W.J9AFTEE3 MMM!ZJZ=JW;+=G>JSK?6!1`8IUAD4I15#&:20?L!4:'=+&Z+U\=K6AVZDW#M+ MN5XW2[::/VBE$'J?2 M"F%=CE,5RF1=UM)MM$MW8CEJEPQY3J0F5_\E:ZK6[J@]X[(TN3/A#%+V'%KV M&!7$XFM/8'N/QPYKXXK>'R0;NZ(70*F=S*H2[,T;KM1G:^L#R<9AV'H0V<9A MV&5@'_&NV"60U\;!CBW):V_!CBWAV:2=SZ:AJ4N@&RG[*FY64I^MK1&]7S!W M*MNLY-ATLZ:;Q($Z0&#+B2BXNC?-Z<_O3=O_PW0B]M$V![9CAS8+/C$SB'QF M?7&_L6'D^S`<3&D'O[O>(&#^`P[VP9U&(?SLN4-XBP#=IL.$93\4H"_^%O>N MUKT8EN<#;]RF@?Z>FI:5:=N0VIN"C`7M.FP4+J5D,492*B4ME`)CX*+B!RT[ MF#HF+-YV'1MQMRE&BB@?GXDG$Z1_!K`+]M'\:3,OQL`!^ECBP]#+.##F`#PV M3/QT"9<&MS7VM#W\BT$T<@Y.;'D`6!0FQP8<^`;2PQA.:X`HR?0#A` MCI74%T+J%$^(;WP.0DHSAUKJ.^;;#\!8'Q87FF60FQ+%\B.V@M;DV95G=V>" M%EK*F1_;6(^:R5-[DJ?V4'0B,>%D)CICAG!`A6&PR%R7*51WYB.Z0Z9 MJKQC0S89,#]NZZUO0)9%V-*6(ZLNCH3UD)[LMC[??/>$IS3VWY="2MZ[6GNL M&/VFVFSU)&5+2#>!]`).AJYKJM;MRY-Q2I!*Z7169S"YGZ@O#[R?U=E'EY\8>Y%I!>PADT^FJWH\DSN/T9E([B^<1. M*C7#_$#QHA!]Q!_9`W,40XFFG@M##WUF!@P^*&84CCT?7K>4``M52$=Q+2"] M!+[7`N6CWY;*AU0^:@KI!1S"B_.D24CEB9$GYKB^YTUK1YR6\%ZM>P\]]P%^ ML^&CZ8+.S<+0H7J9^"2F!N]!`:][_:0-EW$B)83VPT`O`0D71L]GLHQSIDAY M+"^/GL]D&>=,D34XEJ=KR+PPNAVUW=Q#W:WSUN]E5&+7VF]/GRSFZIR?W7Q! M_FI97T=ZBLX<4GDVS^IL:JV.VA/-J.49/!%(Y1D\JS.HMSMJOWV&6;,R6U]6 MFCL92&7M$PGI24`J"55">A*02D*5%4#VA3999>YT(;T`DTZZ/"6D\L3($W-F M='@ZD%[`B='[NJJWN^=W,J3;L$21#_AF.,:L@:=/,&^@)6M\U`+2"^`[4E)+ M2.6)V00E;:VO=HRF/!D24GDRYG)OFZ##[K%D\\EJ?$?+KCWOI.72EQ+C6XC* MU)R9`VK[B$^Q4'MQ?.[&"=R3(D?Y#\0?('R1\D?Y#\83,;43-: MJM[:P\VX\S9U=K4@+SG>$M_03,,L%&21'KP3WE-Y^:06VM?I4?SI0"K/9DW/ MYM,GV^&ET^FHK9Z\GGE2D,I36--3N!U6C%Y+[6I[K$M_+,J6EPKFT/:9AV8X^>/.Z%ULJ> M$^IJ8*R\"BDA"_[ZVZLHN+HWS>G/[TW;_P.O`7],]>]/S`PBGUE?W&]L&/D^ M:.EOS,`.?G>]0<#\!QSE@SN-0OC91@'L#O,7 MGN'O/E,BU^:`30$5SQ2+#>V)Z02_/-.?_=IL=#LI"EO/L\7CWZ$D\5H''L<\.0)'&(4ZV\8EC\I/I M(R9;]61R;>VT4%%;)G=B)%5;)M>N)1YO38\B" MSRRL.7%JW\]?/*BGH3G'3V;1 M\^'S^V>_&G][MT#7[FG#FMO9NDC7\T9?G7]:/K6ERDQG2]1&(2FBQF1?.I"I%X' M?WT99<^I_A<-DF#@9C)UO!ECMR&8TGSHA;7S3LO9E3>?_=KMM0TC:YA6OJ`: M8NM/$V<,2V*HU>P:AJZ?-XJ,J@A*-_J:WF\9EX6NC2A*TWK-;J_7/M=3E[#^ MBDBJ973:S8M#UV8DU>HUV]UFIW4B./J#!2!20=#?_)BR(7R\\_"KFQ^@YMH! M:B*'IS32`[1.U;16=JD+JM?[R''N[`F+5Q.4TK7%AE:T[;69AJ`1BT MB?8$C#8'S,)46<(#A?"#.P3-##.'KA],VT$,WGFP-Q//I0T?>XX%BAM&'X:; M0OG[[;NYD]71FWT](\TV!"!!Y)^>_QV.TEMS:H>F\XZ-[*$=EB3OY0!>M5&< M:$W\GT!CX419%'XRAV/;9?X,:?+?D3U%BOW-A^64E'TK\66T=:/=2_&U?+9* M8"JUA]O!]#[R84BPU.&I]_8/_!14AB9-;W>,#+=>.ED5$)5"TE80"2JS_\.Y M8Q0R_]8;A<#^6'44U6_GG'AKIJP0O'+$M3UX'QG(#.06'R93WWL@:5(=B1G` MNEH90;9\MDI@*H>LK6#ZZGM3YH>SKPXH1'OA6KUN'Z@_A6OUC)7!5@IGV\-V M/1Q&DXA\FN_8U(=!27>!SPXC)<:UKB>>']K_H>^7#EP-AIN@6*6KJ`JV(ZRW MY*YI1E?;^WK]B%G?O)GI8`[&V\CW*]HN7=-US6CFX"^::W=PEF'S1V#_[-K. M+\]"&/39JX*)`$VV%Y:_9,K*@"LGJ8UV!Q:P#7`? M8$*0X^%77F>I0HQUM9;6R]!+\4P[PU(*0=UVM]/I;P++NPA4^.O1B-*2JD2+ MIC<[_8SOL'"B72$IJ=]UM5Y_`T@$5<5FV!OF@BT15GK*6OUVN[=`QTMFK`RV MLNAJ-SO;P/:.#<*W26TS_@FX_@"E^5T4P_WT:#@/T[@J%N'N!?R<[. M?5]V[UK=OJ%W>E6LO9AG@B;RV7.'U1VS!3VCQ+Q5@EG!7A0LJMO`XO!^7U[ M$)&W$[](A$JQ^9,>B<_>`T*J_=74D\]K?%WSS*DD((D;[BO=+GSO^7^.[>'X M?43^[0\!#/-@XVW#+0#^]:O>^B2<;VN&SWDRL>"EH(E5)*H#B4;W,%6SMQ'*P&EUC(.#.7?(SM@;*&/&@-Q-OQH`.=^&,Q)YPM-;9^=TWNXF76.SN@ MO,)*W"@:F%!S!N_*2:N$L)PSI:TU]>Z&$))"30%U;IZ^B_!2(=>P4[,5*P=^ M&0G+U@;TX]BKU'C=N/HR#!'FYE]Z._V\$V,K3,J)>=L."UF^4[%5^0W,FYO1 MB`VQ!VN:)7Y,BV(^N]V@[':CO6S_URQE/SBH:N?G%]O"Q8(94ZO5-OOQ:O5- MKC]\`?MYR'R00N]L'^;S_'(W&9KU6KPFR!UTU(M;?%9!/\3B>W5=_-9JUE\? MV;WIW+BA+7"3X0;)92N)EQQ>DOM2IX47K7_UG@W6*[FEI%X-UY=5B"^1&>QL M&9[%,B^6Y^T7+R?*\RKF"7]]P[1X>N23[=J3:%)68^[636_:%UK,'Z70LB]: M^62&8'^&LW?PXKJ0=6PE[L=B_!6MKZMF^VJY\R(+;`5+ZJ5F4-4F$2[&N,+U M]#==3#:&F7H"OOKV`SSXU3&';&E2XL'V:G6\L+\J++M\28F7Y\N0!\*'C'M% MOHR^L2F_2O-E]-$SW2,3ZJ,=CFU7T71E`G./`^'360MV>ON#7^;B_I\[[VOD M#\=FP#*71DIE*33[A\P$:K6U9CN^=K]^!;A8VWT`GO3S!_H/XD&\%HCK3@Q( M8+B6[<1KW?>Z@93_F@)S)B?<@DAJ&SKPI7(K2C8Z*8WV993#V#&WM\`?VV]W M^O$EL&4@+]P!R]X(/%*PE7[\2_RZ]A+_$H`K6EBE$9S*%I9>6Q1`O?%\WWND M\MEUCERPE4O,C#VW^'W\C#VW([;^2\ M_C[T\?*3R"N.U?E2Z<"K@__]GK8J^E`X[499K]<3#-$=--^U@,"Z[8V2E`70 M">^/LQN_N+R^$UJSV^O@5I2;,`'M'0N&ODVWQ]=#M%!O9S/? MUJ]W8Z;0]PKH0*(G-X4?%1N.$'R!^IT2H(*G8GL%&NA_`L4C^.@K4VFU?\+2 MO#Q>+'HSF#`0&MG>B/X,L1*CXGB/1.2.%V`;AX%M*5/4GX+XL>Q\BD6!4OI> M:RJA;Z+`4RQS%C>)@'>Q:X27Z27>4'!%>/72=&<*J*B*C?6#[9$-2AB.A.NV M,-738F2.@-DL&DO@`QQV6B1'2T-LW[)-R:7NBJ'?)2-G=*O%'[$#QD[>Z&U2 M672M961O8&X.\_Y67#;)I*26VS&,;!V:TUII)A%@\]2?KJ:=ZKJ7T/2"M"Y, M-RI#_WU=;W=WQNYWCW ML]]\+YI^=(:;YW^V6GIG:;I5?C55K'K+)(.*5XVU!>95PCVONES-@U:_E;VM M>T"X3GXWWIM#MG[%^TMO*KP7VC/TUK*%I0#OO*B]I2VM3Q@OLZ;8=,2R5FZP M/.UR-P.E,KFO=5K=K-PO`#]7:B<6(-=!$$UX):^X@-<[&R]SN=:W9?*MY)*_ ML8`E[N22\<#,)I4%\=#+*JNYGNP"JR75@Z/A#P^;*#H`Y6$)N`6'L-$ULK<2 MRH-Y^,5M2\8GMLP*B'F+Y`9"4D_K&A>)I/*),5JCW=/Z^T`2EL=^[S.6S2,Y M*"\`)J>OV_\B(`^]L)5\8.MTIV;SG)9>_M3CTK436/K1V"(AJ'UQ"#K^X4G* M\\)*JV:$OW[M_;/SJ1P;QP$/!>MVO.W7KYKV[H07DSN,L#6?]&X-E[-/#@0[ M^,^S7_%^:79=.MLA`QXE),WJ5+=FJ]5=AYRY;+?3Q,X2,;,4.X80R!LBAR=K M9:"&7]RA/75*^/V.5[)F'=05K&P/\:T^3P0I`WR\A]E"JU]&[VW7A"?=^[=> M$`;D..69#*5JW&]8ZJ8Z?Z;>ZAG9VHDEU[0O/!S%KWL%Y[-O=)JMG/=Z&U3, MA2=25>)#?"4?#&P\]A_"6?-PA5%.?:8_K.R/:#,$X)&GF1S_/NG9DBP,.,G7]' M-G`[P)#%?'H01U$>;<=1!DRQ(J8`:\07*'?*,I.I!]C.&B?RF3D*J3?)!%Y!TL('_Q&Y3-'X!''24!Z="98S2?-Q'OU< M>GT65[Q<1`:7*^FM?W7+IGPK="W]?*A`8&$AC'8S*V%V7/TAL-C,8`Y87!)< MW,;U5=RO9U\H24[]5Y^-F`\')%-XA$[^&+6A]Y[_-2;XU3'(;0*K^Z>@S9>Y M-QQEV\R=#XX2>CQURA&U+`M.6AE$X#G/7+:HVXJ+TCLSBYV#/EL$55P3Q1MK MU-,RN//>,-X'E%G7`:_A/UM91ZF7\LACK'WI?=G-EI@@);E$FW4:KBTF53,D MD#6OZ;TXZ7SIHG9;-BQ5:+(&HB#Y?-R][Y99=')9(QIX/IP*WI!CR7+CH]VZ M`NV.5_[=>WY1*Y^*,P_GMFO0]4/F2+7WL@:P,T35Y0.LH5E^'S)"Y0\/TTF_ MH4.F6#[.W2#9-ZOX56\K#VA]9WN+%T*;OY&>U1CJMZ;F_)J6`[RNDB"LP64$ MW9]V.,Y>SP^>#'P%_! M*>^VUY9HW'*!.2;'/;-K^5O9XOU&MY5E3>GH>9=6P8V&],N/MCF@;!'N'P70 M`8-@R%[?F[8;A&\]!]?E+W%OE7;IKC:."];6Z;1ZN>N+U:RB?IC9_H:/UFQK M6K]S*"3Q6XOIW_M+$RJ(3<`ZC6;12N>AVC_LVV^8T=3;_4T7\=8QT4DKD/7% M)WF6"S4E/P;BU](F^9:;0T$R\*;.15M'MY MA]E*<',ZSJH"UY_9(_VT<=OPLDV^RLU>&MZWR7WR7$ENTK1L[&U9T3JZ6J>C M9_GF;E"56%^LS5:[O`+!G:_/L!,T94V0U:-\<>@?(;B9$/+@=A>>OAA<:"-$@B&^+NAK0T/G1)+WNW->\OJ7Y%QT!8[.?5 MT]"]WDH_W]E@!WX9?7`MO(@3F4[6%"UOO\^7SY/(\XO*#"VK4]<[3_0M*'15 M'=;^H1&V2JAEP$\2Z8KUH`J9UXK65XJ0]_"BFJ(KHT( M3&OJK:;6:5>H!A;B:#[B)/'[S7&WU%M,J3F="N5`R:6>#':7'=K5D1G?2GE=C5ZM0 M[IX;=K>C5[U"G?ID,;J#;%J-W6R;&(G=*NA5JSE_#3;RR&V,U0K\$VONU&J; MZ.;5K;9.2*[`\%Z'Y/[I(SD>>6_$O!V#V,A]7ND::X;=2B-DAZ3G2T7ZD@8> M$N^[L^R2K&27<,2Z-6;&[2W]`Q+#AU&T)#WOAT?. MVV.G@N'R+O(Z.A(V0G,U2ST9[&Y)N!4&XS?`Z&[!BJS%Q^;/QC>K=KY&6KQ=0)AUN++\+AI\[Q,)@C_,'Z MF0<;>]"6S:Z7NZA:'I.]?^J?-/W=W&$^[)I.`*6;'7")S5UL@5^_MG)5924. M=V>7QB>M=SZ'?+G"L&SZXJZ>.Z"TETCQ(R[J!'$Z?]3;_^Q5*W^J0..",D'? M!M=1./9\^S_,^AV+\V7(XJMCSI5+_8;@?O0>F<\_V1.[=!^AK2%X,UN$@=_T MQ$]43E64J:P\4KLV;%`-"B]DJS[;L3.[\IWJ:G*G*MRI.^;N9:/:#7UMLD[- M-^KWZ;1&&[5/[M?=%_>;0^&%;-7>N)_6T-]F9;J/37^EWVQ)C>SLP<6V+C,DJ+(4#9]RWC')W-RI?Y\F@MOP] M#WZ_O-5KMKO-3DMB]``\Y])CEEWQT'AX3.Z1J^]+^>.W+L*O0N%VZ>WNEH-!-]" MW''+*1>GJGGH_^#K/!/4SX>S.^7"V1+=9=%]9'^&W-'3V=%RS@Y,.>')HS7# MGMS0;5TAN*5]*>5.8D_+N4HPOZXK#^DI;.@VCA142UMELB?E_AY]?[=PM&`" M=ZE;!7)[C[Z]FSMB?OVJ2P7J-#9W*T\-[J_T&:RXA_B&W=LNPO?&A.&&K#@/ M_ACEL6J"C_/:IXH*;=4$!Z>^-[7);UES-.>=V35!L]S^BC)E5F__0B2J)FB6 MVU]9ULV&MVQJ@FA)`!6E\*S.D6[/Y\K5!,UR^X]Q-W*^5$I-D"Z)X?"W+WOS MV6$UP;FDA8/?<)(RXL1(8>^WJNJ(];TGN&7J-6R8X';@GCJ5K_-D4+OI%9^R M'7@N":.U\5LMV;1^M].'_]O7K5NY9R=[+4MNV>E=RY)[5N&U+$UK=WK&OK/3 MY9;MZ5J6UCG(M2RY?R=]+4MNW^E>RY)[=\K7LDKL7E6^D,6I5OE"CI;7LU"M M_DCK/^U]J*BNO<3]:?DWCI27([?WK/-NY/:>>5Z-W.`ZY,T8^XJ)RNVM85[, M?.$^N=DG[+PY4MZ+W.N+R6N16WU)>2N[[O8")DLT!..@?@B"B%EQ!\4J>YL6 M^MC:3:/=;!N;](W?!/[#(F;+)IG%OF-=[^O=7A6-!FN(F-O0#&GHFW]'=CC# M>3T7FWQN%51N-LN$N';`5+E.>T4=2H-L=Y[\P/7H*:QURC82K'!Y]<%IU7UM M16OU;JV1NJ8E))]RCPU"Y\N=]..""8<'OT9(V[#86B\N(G+"2-N\D]X7MP+> MB'7-Q"7_XRVCADCWJ[O[9&QX7B+SUFJU#8 M;[86VKB<$P;G=8$UQ['5[E0ALC;%QC9,+QGN&G3>"9_PYL>4#6'*=T@/S+6^ MF>&Q1'\ECHRR:SQMA!:=U`O`Z1^>`\,X=C@[#IFVL)=DQ^A4X9LLO\Y31VL9 M8CTSS'ZS@^_O?<8^`/9\8.E'(U=,?5M_5:S"59XV2DN2ZFEB-:3K*K^PP)%=@V M>KM513AQIR7O[MQ;-,U+>^TVP>2O8@IEY'L3Y1\1S-%3%1Q&"<>^%]V/%1AW M.%:T)GW=WM7;5[BNP]#H;[CN8$DHA7Y\!XA;3;:"K3:UJ\_>`_,GLXV5\>=5NV2 MOE`GM0X(*=,4?#MNF1SY/?"QKZU_KN_,O2/8E=#O.Q8,?9M&WP,:=+79;.(_ MRB/_(5`>!(?O-Q7+G`6P#7:>UCQ7P MGUHNMB)=-/8=W'G($X^8[J7'Z5Y[6U2"L:\`-@#]8VK[-.R*-:=<`)3H*X3Q M+Z.9?$:H$]VY>-3L8;D>#OV(6=^\F0FGG@5O(]]'N%WKL^<.^1]K[-4D$>*0 M*NE"#F-+SUQS*+.JBK%0*GJA:[J>RQ\\(J#'W*Y6Q\@JI&6Q0#3]C4TC,!/A MD.'DML4X:;_W_-]=)K+4XNA.N7C3K]WN3XHW(DW%X^I2/)`RI7R^":YQZMC, M4@8S>LXE'PB^)=[@+$15IDX4*+9P)2EF2$_[J,G`LS!/HA.1=I-.&2B/\(IR MCTAG5D,#/#?U\'`0O?`D+O/1\X$+^U\6/(@H!D^CL0G`\F M6C!EA%&_V6QE;DCO9<$GB=%-?*N:UNU+'"[B49G'/V[%5- MUFCLZ^2=PW++'PNMU>EE+_Z=\['8#(<;<6B]W>EG*Q&?)1K+Y5,UVYK6OQ14 M7`@3VFJYY9E0I]-I]8X867E^+P0'&YV_3M?0M7YLP1\3$37> MC@4'^\4?TITP@WXP(-61`/!'=YZ^.J MVS(PUG9%(ZWCAD$]LC&7&':\['G6,P/>("(!_\_N$,?I@-RX/^M"0M"G+6ZK7Z[ MM;M!7"E^+F##-I7!9XZ.(SC[$I7T#C8B&,&2OT3AE]%']L`#E;2B6NIUVMC;[7A99B,4/+J;ZTC&_<4,;TWSNQB:LQAE&H+&SSRRDY='# M<-2).A?`H.F8/PH^UT];.LDE[WPZ3F&1FYT1S6CI+:/@C%2_U"Q&4R`S$O': MM?[.K'N6."U@SI+1TY6+S*0@EIYW'\"6BE%N"RQ/@4T*$7T942H25;"+M8A- M"U(4W/EO-5JQ?VKU7&EV-/[$RZ"]B_SDS@>G,?KZO>>3'P/SB/UP=FT]H`=J MW:6`ZZDX&T8S_7P;`?G].\(TL0?X5U)B:^[[,KD'N63H;=>P#@O\4FEMT+`T M]ZUC&.D5Q:V7DF`CDRLG"N2!%(:UN7AOQG,%/0&T\;75Z6JF#LO4R-^.LMR"-@2V#1HN9NDNNXQ^.J_8P`V<3KCH/_X8< M]9C+7\9'>D;/Z'9;&['3'=$@%-^XKFT=L*#UM9Y6\JPL6<9F)Z$,#A9O6%5& M^IT-U8F]K_5PA][8?>VP^O_OZDIY[WFA"]Q1N>6<4[FZ0L0XMOO]YY'X[2/\ MH?R@KT(`^I=GL%@\-=8S\:WO.?#M.`RG/[]Z]?CXV/@Q\)V&Y]^_TIM-XQ7^ M_`H??(9#OUH8F[[%5^R?\=_PY_\/4$L#!!0````(``=ZJ41+(A)>-PT``%C) M```5`!P`8FAR="TR,#$T,#,S,5]C86PN>&UL550)``-^*6U3?BEM4W5X"P`! M!"4.```$.0$``.U=;7/B.!+^?E7W'U+LYPR3R=[=SM3.;1$@<]QE`@>9G=U/ M4\*6@VJ,Q4DV@?WU)\DX&+!>#,:6S59-30A12]W]M*3NUMO/OZSF_M42$HIP M\+%U\^9MZPH&#G91\/RQ]>7I_OJGUM4O__SK7W[V4?!]"BB\8@0!_=B:A>'B M0[O]\O+R9C4E_AM,GMOOWKZ];2<%6W')#RN*=DJ_W"9E;]J_?7Z8.#,X!]$0@0M7U?2$ORWZZ38-?_J^N;= M]>W-FQ5U6UP'!/MP#+TKT?R'<+V`'UL4S1<^9UM\-R/0^]B:SDC(Z&]^?'L; M4__0Q0'%/G)!"-T[X'-))S,(0]JZXI5^&0]V.)\B/(.`A"APWCAXWN9EVO(Z MVIPY!_A.Y`LM/#!6=IB$JQ`&+G03-GE]IS0H#`([.VWX'`),=C6Q:4+HV0-T M*I0=T>MG`!9,Z3>W;>B'-/F&Z^SV^NW-1N<_;+[^UJ&4M=J-"(%!F#3@@RGT M1;/?).7:);/9!736"5S^H_^_""V!S]B@G;`+"%FS#O4K\".H8-^0?A_M#MF5 M$!`G:81]/(!ZU^8W)=HTFL]%;=-.1%E M3.(%9P#XK:L7B)YG(?M3JVP,.XZ#(\;L&#J0,3[UX2,,#2Q/268_8FK^-T"] MLPFH0;!DO&&R9HPJ@-DM9C\0N_QN%']KD^)'!"X`PR+.6-7/;"KR2R&1,VXC5-M:FQ[Q(&C[1Z2\A9C(N'8>/J]L`'\ M`8$I\E&(H,%@F56X;`N^`\'WX1(2EP!/.?/L%ZS49N5JWK???;9M'.>3$&,$ MUCR^,(^I]@EJ@HF,?1M'>,8KB:";JU\K:.J#D$P"&P.O7@2?\!CZ?/@?\;G! M!"4544U@4HE@'&*5B1-<8(K"1,"U`4@RBKH@).-_`\_?BH'G,*W.O_DVB::L M'11P^^C!:9@RE76&T@UH+%>[@00;Q?_=IG[QB$.8S(9[W=D'E"(/05??5W+5 M8CF01\FT@?8?9^U3:8Y87#KTN(GU$!4NC:Q3:8@L!\-$A(WN?_HS(-SMVI,0 M.]]GV&?:H3R?D3GPJ@I7D,3V(#,#5S`CUJ.&42@L.,XT3P2SF,O(FQHV*=0!J"G5UX3[(L051_67E^F'YCRLCN!F\LK MU).6W>.*6>6P(.!10K'?/Q394*N\P1XD:,D4L82O:2<6O`FV.G-)E)J#MI;8 M&H"E$<+*^0WZK,[G3S!@,OJ,\8X[ M1P&B(1%SM1XXTPKJ@:"I-#9F3K8;Q0;S!4"$VUYW!LBS>FA74=4#-*4(=N9+ M%@0Z*%8IL[$Y9M["'^)7]4J\G*H>2"E%,%Z0+S]Q89G'-@@8E_`!4R.?+5VZ M].D%^)".V5P81%"]9_J@I!T6?:CJ@RECGW$;W;(BG/T:8)'!NM[IJBX?:L>P M\H@#O*MBO=>GH*EP\6%$L(?$-OE7YLP6%C()*S5Z+2B*M8-,:6P MGR$=!OT59S1"=,9EB'>W*-`SH*T7@`8"V1A`P;!9!RDGH!)Y?#QFA2A+^' M,NIB_BR*>L$D%:/8K=U%=:?8AO2^U4')>J%RP+Y^O_>E>^#;P.:>Z9_QQQB. MF+ZW'-U!#Q,8EWL"*TB9@T!`O,F>K`=,!G$XE%$R$7T!E<%H?<96*PMP3\R- M5-7-2C`!:;"<5H*-8<(Y`M0+PEFA"N.`XE)'9N:C&PTH>^7*=RZ:.8%4YO1D MP7[HZ)Q1?!O'X5=!-N/''0R@A_06DD%1%W0S6#\MH7S"1JCAXV3X,.AUGOJ] MR1/[_W/_\6DRO.]V)O^Z?QA^G>39!Z6MZUS;H+0-ES_`\ZL`1P0O$9/F;OV% M0G<0O/I&'2=$RWC':48'5\\()U5`VIMF%(OA%R/>8]'`T#;W(3VYQ42"M)FL@PFJ!;`UH&XBQ@=0VYNDO:*7L++#G7DXS.`/WYV*WY8";K8@;K"V4 M.5>+4];_08%KD$3)*MQ`++/$+.6VF-W)XBL@!+#!8D!IQ*7JKYP9")XA\Q8> MD".VC'5B%GT?.F$$_.1*U`P("ZZ_0:@7K!GCJVW.9RA,ZH"QQ?[V%86S]%4\ MQQF&JK[+,@25)C;`O[?)C=N5YAX%('"8#OA!+>6]X4JR!D%N)O!K5N6L?3I] M\5S:LF+;8T-/JP*$I"MRIUQ?ODM%$-/G')FDTXR M(J5D&)*N#]!<^_!NC(/R5\1,1/<;'U=4TH(_30H)V01DV M"=KQW1.I)$^VTSAVM5@?4U/3D#Y&!PG.Y[TFV9"S"0Q#7S!6%-Z9-5XH[IFZ M2/`OZ+9F"?ZI2^^R>=M[L(`OV<47Y"LR;(75W#1[*$(GB5V<-WF7P6G*#TE< MS!S89U)?`+Z9OIK:0(`<\8)"U MHZ'P%B[`%H[636(O!:7CCNKS/7X7"YI&O.$Q;S-OOKZPZB_`4HY3S.OVF;.: MR>XMX0G'6Q]FZ.4)]X^MK6E&<*P>$LP+RO09YG:47HMI9D=32=,0SBE^`JQ5 MF^'$Q=AW@.F"#5I\=[9NPZ.,H$'@ZD1-@+1J[]L@<`@$_'KK^.<@V#[RK45&S@KD]6YZ M#MJ+P%OJE!>4N#LCTGMOV.8%^X#\4O`^$#R!W*JM<(>L)[/3YC[,7'@?T%X$ MV`=2OYY1LN52AIHG;*@YX$.Q`Z(I['[:;X%()=-5Y#SUM@R#-(;6EIVY?V1[#142<&1NT MAY[V)2`=8<,ASA+9QK.WNSQO]S=KCN.IR1J/[;[`Q1ZVE:WW@76\`,7WGFN6 M>+++-@@7A90%GWV5KKYN#4+R0KQT!=Z,MG%H&4FM/\]:,'CIYCONDL_+TOU4 M>KHF@Y8M<2EG6--L"&]I&+\&W%]!XB`F9>KHA0EX^CJ:#*1>^F+/FQ;OJFB. MG^I)&@2O7E@;#Y$R!SF>O6D\?1N@*2=I()IR80T.CE9RY4/"+=\JJ3L+G%FZ M@2AFRFEP*+3D^\!M2W!R)-A\Q'_PX'D)?*[$$20(N_L)9(65Y:NF@OL&+;YX ML:I^>`ST&?<7GJ0`&R\\E,@4/]1Q!FLQKKBIUF*L`!O3MG:O$#706HP54-$C M\J/Q<-0?/_W>>>SU__ME,.(S?`^&`/EY7H]7U7*F^Y)5398?@(H#'B.?!?F/A'UC<$ZPK)'A\_`F:$`DG4>(51$E?9J,UCV^[%*'!OG__N(!$A< M01"X]VC%/U$=9`J:&B*FD,;&*;@+%B@$/OHC/H<0A9!,L!>^``)UN.E):PB? M7B@;UT(J.I8$S@K(SQ&OBY MF#^DJ+3':F'(Z*[98E@ZY+;HC:K-?J M(9,1U`LJF10V!G7BJI^.YS')V.RM1TA2OEX`282P\9V8C6Q]YL/@-4P>'C0? M_:2$]4),)XWQ(^_%>HV/PZ?^9-3YO7/WT,_O,F91G\E?S&KJU(V(Z:TX+#;8 M?7Q)MO-00U3^:])&VZTLV&)EKO+#)Y\SMTQ9-,AQ*;8WDGX)0!PKLF!2;DTY M:&N&EX%$IT7);=[L%%#(?OD_4$L#!!0````(``=ZJ41CW1:JU#(```20`P`5 M`!P`8FAR="TR,#$T,#,S,5]D968N>&UL550)``-^*6U3?BEM4W5X"P`!!"4. M```$.0$``.U]67/CN)+N^XV8_]!1Y[G:+=FU=4S?"7FKZS,NR6&KNN8\(6@2 MLGB:(MU]Z#"L?H,O7[X/W MVZO=?F&<'P7AXFC9YLB+(C(5)>+W_/41__$N"Q>/$:Y_-T_QC(NQ)H"2_H$2 M_0\ZVE$':LC/.*:J\3[`,Z^(3&N%THG!-B4K^XQ^]7P`W2R1J]"[5QDH^,+IGE@"5--4&RP>_G*1UACL[.)M_'TZOQUYO)]=79U<7= M.G-^,;J?_FMZ.QG>CL^G59-Q"!64C M=23T'*?A$SF!/.$H].[#*,Q#3!:C+I7"8;JNZ<8V@?\NPOQ5GS[^&%V)FT[. M_GMR4XID-#[_,;HE,IJVV6K$`UDE[]9ZB3[?ZF!V) MO_3"]$\O*O`W[&5%6IYU]+<#T2A=%:*XIWL@&1`_X;7L='2`,T))&#W)Q2'5 MCVM"Q09]A,$X#G!04T@',WIZ+._[B;\Q:41OV$G*/%67)^J9E]V7Q^HB>__@ M>8_D>#TX/L)1GM6_H?P[?O_;8'FE_L?RU^BNIH8@Q5?DQZR>)?+N<53.C?B- MT6_O?CF"(GGJW:]5141NV1`-EJ2NI3M*-XDF%YMZN.4=1\MH,$N3A0K#EE,F M,FJ3E"C&'^](CR(CE"QW+#+=+]7%Z7>Z!1"%O(C*?F3QX`?ZP[O5WZ,DP\$? M[W)RJ@:4TT5Y6B&[UV,2T[4V>@F5M(S5#PVM2%%P\19(=24IB41Y0/@"WK>L MMB@\W[#C,&3$;(^.KG'S0>6U*M"NG38.E;4&M47$% MMF]YW9"Q<)KBH#QK?MNP.#+$Q6J.3NQ(B64$W940=TVP)<,#X,X*HH?G)%83 MQTY;]*%'LF!2OQ3$P`%)C((@K":_\<+@*C[S'L/VVBOT'TYN.G83GB+?9Q^$1/,5SN2_N@3SW@O!**)=>/75@COE\LBHC> M%\^KB^%YD9+;_CFYK4;)(_UTDF_H`U]L[09"GWL@R_;0E@(^L;&L&KMN4\_$ MZTK8"7WI@3#48"P9_\&!E=4THU<8A5?1[<9H\!ND5/0,"DSB'3H)W,V]%&>3 M(J?^)]3M122*[;9H8,>@8T,23-JM?N2I[*^RK"![8[DIWN`T3(+2''N6Q#'V MZ5P_PGQ^A_.\LA]-9F1'30IR"[OQ7CFF-7.#HX$=2XY!\1D&:^1XH2?O2O%L M"5QS=#2P9!\22]RP%-55I`U[3-R76VP)3;+.\7W>9N5OCX$&H`8,(PNF)B-T0#4D*&\:OC$ M&SGKZ_"W$K46EZLN:`!BNI#P3Y79#0P6-?HF37R,@^R2D'_Q@E,_S`@9/Y8^ M$SRFBWNA`:B905G'%5`L.?_1EK(WYKN*-X\2_TP(_C\)C"+%HX<4X^73+W<5 MZ(Z%!J`&"*VMJ!6VI?`^.7`3'@7_+K+*M6>:<,S#DWPNL8\KCH&&O;%AZ&%: M"O2S`P(5'6W&^+G\B]@)0J$_&O;'!**,9RG$+Y:-M!4MWV,RV4V12S=0>4\T M[(=!0Q')RDP((P?QH4ZU/QK"F1P4^=Q*0@UT0!:#YI$T?L)I'MY'N*WI@#L8 M&O;?AB`&5R\S)\SQ$A0XN$S2.YP^A7[K;]?..&@(ZEMAZAO&QE5+MYN-WZIT MJZW$@'@Y`Z$AL$%#5V9:LA>!MGHK;[I;5=-?Q:KV0;7>:`CJV*%Q2U=&4R]' M*T\P:G2(SS4Z8Z`AB!5%E^>M)=9`N2?[%L>-0<7(Q>F*AOTPH:A"J1=0M[>/ M_9E,2AVB&24"ZLB"X\RK?+_^+L(LS/%RNZZV\EOL)P^5B,JO0T=+2Y>IT?&; M,M!T9D6M=B[X#XUQ?A7[R0)?)YGHE+31#AWWQE"S2W?-?:Z1^V@S7LY*!)U2 M&H.]NY23:UVQ]KM M`#M]/<6Q/U]XZ5^2<#M95Q*@MJV1`ZHD6$FE,VQ$G[Y`])`YY.-_B\L(G1MRH'^=IAZY_)6>&=GI M:_,ODC.*^B"6X@"MGE;TT#DJ6^EG;K>QK/;28$IFD9R)-MK9"H:T M>N[91>"0&,I'B]/M1XL1]3%^*$V`Y,.S;G/CO=+?E8C6L.+@)O+BL;?`TB^O MC>FLA5@J'[!V)#N$R_/^B7L"QV;+%A%'?`J8 M;+[DA`]Q.`M]CWR@J[9U8L^6P(I@Q-V MWW)Y"TYS&*!`<1-":PW7H678?!4>8]8NRFD)%`=N$W/0Q#3.\3"O:3#3*S#`J6'+=!P>**S>Y2@TQ MP4CB+3,Z\P.'#W-"[>@)IX2\6NW/PZ@@O]7):ZDY$F1$NR%M:(/8I02R,N,D MSS9961:;T"KH7:SXNG,!!=0;_>1;X8F11$YN*-B?.*.K*R[K:/KDQVE"?[7, M8$5/L-;U3I4$H.!_E]11BU5&,E9)CK:7111-PP6N7T6XP6OT:T%\J+"]7FBH&C&\2$]NVWT&>4JYP=@R M>#3W/+2SG3\@8-"F4!CLS6*'=G<>A-^"WQ9T$.B.>%L>I5MB/RB348:ZXLX` MJE4N^CUTJG`(FVC1TLKGO=`RP%M\E=W^%JIY/8A[P<2OFCB6[>)PZ"V5)AZK MTG32/6B9L)-F)R/4%NO,JU7.,I&3@]Y`,-4K%<7#>]/1!>C.9_B*OC_A+%]6 MWCDKTI3N)W$P3F*_^H=`M`J]86IB=I*G(BJ'UNK%"[5,%&$V7R<-_$KX0Q-7 MC3'YQ=1[$8A1I3M,]&4G.:K"DGE)[,/X,IY,+^YN1O\:G5Y?`.7PNILG:3[% MZ8+R262?$7>`R-UUY\]Q4$1X,MN@29;!2]0-(H\7GZ&<\[R$_IZ;>S9!R?TL$.BPCVHN,3ITI+1V%KC"VA7;"481CT\-[E,UQJBX`3G,8`T#+%<&'8+-D]=6] M?UG$0:;\F>!V@,V1I,=L(0B;E84ODR+-Y]^\^#KRE5DN[`2;24F/[5(@-JO6 MGGMQB*-_>@N<$0J\ZD5#609JO8$3,.E)0P.2S0*K=\5BX:6ODUES\Y,&HXHZ MV4K#U$8*LG<9.1"';+U-&@57N68S:]F/5'SHI+QE7]UVZ'?G7DU5:OVX\SWV M%D37PO_%P7F8E5Z"DL]D*R&,#3DH MHG'TG4/;P_3PW'%X[C@\=QR>.^`E='CN>)O2.3QW')X[>O+<<1H5V*?>2LL* M@Y=A3$ML*XM`M7^?'C9T,-F\E:SHN$Z\>$16?4"/&XKR8/3IT_N%#(?5U#3X M6?ZXM]&H3X\4.X3;?)K0>2YE/ACVZ$&"1[_-MXC5:^O2;3BDMWG'AI:_TO"/FO-XH?7JMT$=F\_E"2,TEOD\-B&MWF%X]:+3!9O-E`]@=Q*%7 M$"O^((W'$2NI."P[A,`\C-CS"&D\E%C)RO$UQ:\9H0*KBT'0!3RWO@[[93B, M).*P[R`"\ZQAVD.D\9S!3YKA@.^3K23U^W1^:F2E'UBY)J_(5.>WH`MP:G)- MPY$$1\UW*]?DCG1-;@&M%IB5 M*[.0GF_>Z^!C1W%MC0&4%MN"L%C`:E%9N6;SJ"&G0C/+BSL04#)JLT(3HUL] M^.U_5RQB//C0=5/<&@0H7[.-/9&%K):6E0N_D)P[_)B7='04&&,+S8J]@$?1:):7Y>[_A3W)V5U]!*"DS69%Q8%5"\F.6:&X)^.',2T@LE27 MB9\G2NM)I2]0/N:6%RQ50+5([-@:=JD8)T^*>YQ29S3LD]U!&5$M%3O6AUTR MZ)>0-!QH2V2S(SKNDPU""4TM"2MFB#&A=Y[E7GH:$@+\>9Q$R%7G\D=-PC8T1+>+7PNMDCS#AIKSZ5%#!7F(+6Z+@?M@@9A%HH5FP.552Q M?+ULMT/'/;(=,(FOV>I"/8R[G&RJ9:F'OXLP?Z7Y?).89O"5!?:(^J%C!PK5 MMXSPD>)R*,QZBT9I+`FS/3J&+E(OYSE;5GPX[@3\F!*1,]$^AF7E8&+V'QY- M9"[_\&^T0\>@9AO^4F"+8Y=V=Y9,M\3XQZ`V&5TYL.DW_HDAQ[M?'Y*GHP"' ME1S(#]OL)[]"U_C!BR[BG&#@?/\9K="Q'6N+Q:\]#X61@)\VC*_HX'X=MIN@ M8TNV%.DWF\>Y7?[NT&MZA[''6^B/;6LF[R.&]IOW$'OE?5Y\;]MNATY`+$Y, M563PV'\H,!-3G-T`F(:4F6JB&J;0:TK/_AE<*VB]_]& M:W0"8L119:V`:)MAJX)W]=;N!C7I('8=57ZKT6\SS)5'@=0A5]H1G8!X=G1E M_2;]-B-@=9S/F9[:)R".&*H,YI)L,TY5QZ697=`)R%U:E<,RRHV$?!JJ.DT+XTDLZJLVZ*1W]VDV!B,?0X,"D%J3&JW0 M"=0-F\U+`;\;!+MCQ&O#<.AK=WO..VC%_N:]A(MB(17!1COT`=0K9%N=V:S? MI=@=M?]&F*;$]68[]`'4OT.1ZSL4[RM7KF(!5D$7],$=?XQK29YO&0R'GI_M MYIC^`)=C6B8#]@I1@^3.7M4F2?L'N(33[82R0[W-7:M\QZM*Z)X7:1@_W.`T M3()U:5V:X6\R:Y@QJ,[P-K1VHZ$/<*6F]434%:3QQSI3.V%=F_?6R_'%;(;] M/'S"!)=/_D:NJ2;[:79)R)_.PS2X\=+\]:9(Z9Z: M3Q-*5#:9<5*GC>)@])!BO&`75S<^!_H`$AW25J+&H1NQ"MOXF'WS7N#JWZ+KLK_42U9TIQ=O)`+0IAALI1]UO=(K2/ZV!<[A@8>J_D/+[TP M_=.+"K*+;J@/;]'PVJ./O3)/"&%837PX+BB2R6Q2Y%GNE1YT*GJ@@<=,&D=3IQ6R_N_)EA_0@$4<9U[%XI0ZA%#R3U_736ZJV_KHV4N# MU:EX1/:.10F`W$<>L4]4D!X%1&O2WJ3H4U],(GOBA=4\E.Z:7(6)1E]->>80Q1[HD]]L8?H`#*3'])0'@C" M@2"@&79*&W3XA!NFA=T_CK'H/J(_&/K4%[-+1XQ6DTLV*%C/G(WBX,+SYW?% M?8;_+HA>WN)'ZOD5/W#>S%J/A3[URGK3&J+5Y),"Q:JOP#R9*71%G_IBP-%" M9#7WI/P]HB2H_?M,V1U]ZHM]1AN5F1R4-FQM9P3%*UG:U754V<2VV0U]ZJ/I M18C&3*Y**Q);>UINTCV93>=X*[^-ND!U1D6?^VB.Z0+6I>R7FU@N/1]K+MYU M%_2Y+Q8<)21VTV$V+Y;E'>8R2>E!:=-Q+&LHUU6<)XWO`?627CQZ\:O2%;S; M%.AS7VPM5I"[E,&3[ZW60-W*Z+E4Z;I88'HA:+%5/, M*`C":C0UCLL[H<^],J[(L=3\=\$Q9A3\NZC\U[)ILB;]Q@N#JWB9P6HKQNM' MF,_73YR7F.[@(@]T4U.@SWVQX%A!7FN-"WX[HF>N\_`I#'`:6*K9>N"+8E%^FV8_769 M8MR,]]24+&L(]*5O5B(M9+5473`)R=P-6JY3VA5]Z9N)2`E1+3T7W'S8!(O# M*)3[HB]],03I0:H%:,5WIDDXF3+VP\>(;V65=4%?^F*;44*RBCEW8.ELVA\N MP]@CY,8/9TF6TW?LVA@AIHXO_J)XNCDC^W%]>CZ<7YS>AV^J_I[6A\-SJ;7DW& M=^[?OK(DXHC4.RU0"T]2+,R*#"FR5,TR@?;*NJ#XM[]/!>)5$E$-= M=OJZ\1=)*JI6XR$[!TPOBG;7DXXPV,NJ-41^7C$*( M9?AAF1Q@^?B: MU$G+H^TV1I8.O^IY>K7X+I?=&M8;DI$SJ7TM"MDMDZ5/DE7![+)&EQ7C+;`[18*0BT]#3(M41'=AV` MV4P%JB,6)GV@Y225&<\CW68)HK.DR$)J<4C2!4[/YEZ8+CSR[]/$2P,QIQ6Z M(M#ZD3)-//9GY() M)K-&#*GDSL1LC^P\F4)>C[@X'4JHWJ".6E#'A(SU;YK(I4CNVY!3YWKE.0%L72!ESKSC;![IP'VC#^X/N<=M)6V*]LU@#6.;:DSF_6[%+NC]NU* MU`U@+6-J7-^AV*$/[UU.OE#T7+`5B9Q)/L;"?FA@QVX&^8&6`W:HPND6C=)7 M.F9[-+!DBU/^D,MYSI85'XX[^YTI$;GRZ3"S4=.WD%2L2BQ8G$"[HP(#D9 M,ION3:OJ76690_[NUVR%AG`)-MJSFP?$KH?3ZB1>YWW<2@>YX;52UDUNH.)[ M/W4:%@WA$F-TE)\)Y#9/&8WPJ&4(UIY;'RR1=YH'G+KHV8Z$A7/:+ MSJ)M"==F;>.&OK62H$IO-(3+:V%N.+#O,SHLQGV:0[P9C(243XU;@=T#)<5HJ,XQ)AL%@N6?,GHSHACJ@AK+ZN6 M9P#64.@8+HN$W2,`%ZV1.V=Q3\8/8XJ`+ODF&-Y2$_5!QWTT,*C!,E-MV$Y]S_7&O=K-UU]996.1 M9!QTW$=S1GNH9JH=&WJ)VM).T4/45E-TW$\LV$&G%XGVD%UZ758Y"[YZ6[0AQ%L#D%KZ;)VGIOT99=*V0 M49C=`3:/\`9-ZNF"=[M!9`7F,Y2CTA+Z>Y[R=Q,4F4T6?\IJ[U8B7[:<.-+E MP7''YWJ'1&G((J<'>))>+K,59>-B4EZ#TG$FHM20F/:1^ZFJ:D`^[=02$.;D M]%+=$\29A\2]8%/E"K2><7R6([&<[RE?NG!+.,YH"IO55H_-'/(=BJ=JN%\U M+T0*\=*"?K#Y;Y5%I(S%H6 MN^NUY4XQZ%^E+W"^5U53E!X>FP*YBOT4>QF^BALOK]6-8U3D!$[XOVOK[+9$ ME#H#97_58S%#/.K@W-FEUGA7COZ3V2X37BN?27*DGLQFY!XT>B"*-H%M-";.&L)65%DB^7(A&LB387\'TPM%RW=*N MUK+3PJ[6%30CJ1A,G\^ODRR;Q.M_*YVXMSL!94(U>X9F@K*9C\'5-%!P04-= MKLDF8!M)_V#HU2WRB#K.EA`F:>G&?/&"4S_,\$T:^GCUQVSY5Z&/?HOA@%*Z MFEC5K>$:R1G!\_^E-IM3HI95'%W5`#I]73=91M^,GKTTJ"E=`J#O M8I4O*V\+,#\34"[9SKN")4Y835/1N+(W-C6>K-FM@3+.=I:7`(TT(\4^/'Y+ MT&X^G*YR?X< M2:CONZ-O72>BR1758C/;?1QS^&6)BR-C$2)W7F::U$D=2G<;PWOZBM@L/`QN MH7A#(G'%H\60;!QT=.&FH-/Q@F06.`#U"&:O#(ZDY$`<6E*=ZOJ`N@_KR81! MND,/N79*T=EYT]GC"8&'RB')F:EE9NEUQE"UN8_<5W0>&'[D8$10 M3AX@NGR00-[%I*M!]9MDR&%3(\QUGX4.:R'&7G>DSV&K; M+W/@E*]I;64M'1C2]]F6#JB!=LB#4I*YRK1JJ(T+Z2UM7C,T,-LL4=6)NDG< M-@F<=%Q(Q^FV!S0CF&4^FGOQ,9A.SOY[G<.E5>L MI0?-M5(.LJZ#0^M\>\!A4'-Y$7C[V%2EHP\].!^X'LB)>S6UC"?E`FHPQU MY1T*5*L-)!2EK M5!N^3:+H,DGI'VT<^(430B?\LWC:M<8OAUXK#(*LGM'VHX#57-"9#&WIAW5] M7+/O[>R'7\N8H:NX,CU]39/,BO6#/YLMEZNWJ8T-AJ'BSI.C?D@ MWWXP6,^CO:M3*_ZX]%#WA'O(TX7>MGP)VY@/-K]DTWV?PS\@!O.O1^].2%$264,*4Z+7"? M7,U-`9X\=#_J9(5M#J5*,LC''YBFJ,`$-$Z]![R1R6(_EUT1!4"N@'W=_G2X MZE#.J/8&5.9MRY9*FZ,"R!_26;4VS%DCJ;4<4>T:';AV:Q$"Y.S96P779ZY# M"<4ZHV_<**&U7),4(-?5WNIY&_8:29SFQKF[<3T%.GNL7AODJM4$ M;T:>+?#VFKS%5&J$F6=)7/I)%U[$R<@+0`50JN9^V33:+S5`B:Q!]V4`#M\+]-/!X,+.I\"VJ`4H#W5>?; M>Z3'7R`TL"-"*7JU7Y=(>L[P9DV'O&I)V>V\H%7"25@6P,9F3`3+FGZ8L M,]#Y0T];CB;/.%WR=A&R-',?TX)F_[:F,WLPFK+XZ/IYJB74[X^/$)JZ-2UH MCO(^:RJ+CS;-F$:)W\L'&S3)^9Y4RQ+7G$^#TA)<79BGX2&X].';U_;'IP`T M37N?=T()2UW+B[+C:-H2]BY<:P[V>Z<0*,`$;BTXPG*'WA7VRY:-+J?X(8PI MCTX],IR/];WS8<@$"E7Y"5:-`M^=SU73\>O:"'(`.C+M4@`4I_)VCDP]OV-YMOP69;8!CY$:^A&B-:AB-2AB)2%D$[! M"Y45QO0\3NI01.I01.I01.I01*KWRN2FT]6AB-0/CV+BA_DPV[D8YF.K6-0. M\+T[4RF+:WJ]_YYZ[P[EP*_*YM_5=#+9@4K MUCPPU:KZM/_RN&8S=KC5O2YK+J=->C7/`'NG`:@PU1[5$(:E3M:JVH`"G!Q: MBPB@.#KGM-0X3UUR,`(N9`H3@0?Q/6['&]?\=UH97[>0@=IV+S7/NWJ/%RD,!J9^X@)2+6NUL[2A+MRE]\]DD;G_UMT&, M>T&"3MZNVO/63*TH-PX7P&74#X]675CG7!$H,PA=+\+W4[U$[8FAA]I.MMY: M^U/;J8>/K6^XK-.Q&S%#E1WS4-:I4VR1$J9#62>[2L'9@0YEG:QM"X>R3OO3 M,ITC9&=VNNY?VG*[.)1U,J_:=CE<+`4'],(2L[,&^R^*-ZX>/EE!=J4`%%P_@G/:Q>/-6-[]#,:">**5: M@1]WO4M;PCX4^'%G6PGJA7BM#:(B!JCI2'KACO-ZB M4/KTS6P/'U,A8SA;3EPP;TX^KK@6F!74F_$4`(T/X*X"E8=^R\5<\&->SC.) MJ3O[=)X4&3F]3N=AFF,PH#/\)\?HNC*K'?/'R<)A=Q3E1:^IW2',E6<(+R"8,K M'45ARN&Y<^8`E+(KYQ3;XG;PY#*9S4(?\V.&F.U@XU1:K#*V_'8P63S3+.>2 MAI!NMX.-0^G,:BXFFY&)S73@HWB5,FE:F3NEY?V4>@.5H+!I#]-%[]`)I34[ MEDB_EB#KS*Y?TR2S8F/FSP9:*T)=Y#IOAMWYX<[9J/WQ?S.#&GR*:,T<\X#E M):QKI7E6N;8CMDGY5_[G3YSE8?QP2_%F!+Q/_DH0:[]4=YP/M':$$?VSPA'7 MW#S;;/U-D-7JDOI!&)H&M)8#V*>6QPCG72;5LY12=.MB9Y=>F/[I144+_YKN M4X)65@#;N%28XKQ/HL):6D$:95FQJ`\+C]@GL,_I11G'P:V76\GBK3HW:'D$ ML%U.BSNNN1^:!OQG0NTT49B_0BCCYNR@-1"<5$<&?_I4K$X'\FV8_7698GP5 MYS@E'X=]JB-K;M#:!DXI(Y<[;Z&P7.U]ONWR:T/U>'.!UA@`4S4A-_I4^\W) M$NR`?OEP*L7EA)$J:\#J5#D$7<6$?45IF9SD%-5$&3+I+-I\"M!Y?R MC^?DB`J[]VG2B(9]?\1PAHMFRJ=I[9`=-OO5$M;;+4W,B(8]?./8!T^8C,/$1F'B(S#Y&9A\C,0V3F(3(3 M)#+3#/,OP]@CQUHO6I_1)5\K3@]+\9JN?:<$Z!UR+9T2G-D,I_1V=X?3I]"G M24/X@"R;)5P31Z=S:%7JJ/*]]K8#W:1ZG% MLR3.R!0TY==#BJO]5!PSQ^\!6]W,]!IFF,O$T"W&,S9L6`3=6=.&I1AGISZ" MBV71#(3:Z3'`H0-`/]TFX!QQ]`2]#\>)+RX="`YN$]4+%TQ$,;R&=N?:6]@; M?\JG<<"H9[=5O@TCWT)8X#G._#0L";>AP(WA(6.;075OFP>N10!:64^-1-** M%26L/&7;H!,R2-KM3;0M,VW6HN[F&5@'#TT3>B827*&LS049/=U%V^PRQ$@H M(4=C;LB'/L[)Y&%:DBN6.;LU9#QR9ZD)(#D4,3?R_91[B2BXC\V6E'Z9W7X;.\@6TTQ0RZ-.` M'-AXC`0_<=A]B7%VBWT&'A`#(/LS'P)+*MA.[7W],UR&9+# M!\63Q*67-4\0XEZ0`82=A:$`31HILP\?[Y5IYAOVLB(MU>6\MU?WBI1Z M[R#,7E(53&*BV>3+6Y:.R\+L>YS<9SA]HGXJ5_%CD9,_DV\SZ>4MF2/U\[8Q M'83G]PK'Z>NRJM[='./\:YH4CX1^F5.W2G<(?VU;XN%X-"ERH>?.V>=4?C@X MQ3'Y(:4A2PF>)\YO&*"XX;JO*EJT9FF#=>:YD$"EU M1N+V`??4UA0#6Y9">&]6?)QEI?'M'*?A$_F^/$DRI0NZ MP/IO"U<#XT@K`>+.^FGG2P]::D=#%ESJ'?(N4%@;O*:V7*"MR8$%P*$G;H/G MZ#,O\HNJIL)M$D6724J?&_9SQ6+/#>LW"W1%L5D6BK:6Y:]!5GL(O'K:^$_==)EEW%?E0$U.GOPDOI M0WTFY%!'[D95DX>ZT>SO+2 MJ0I[29;V'#=_:LTL^0\J=4RGD2$;19Y61;N=P1 M#J9D.GR.J_];N/09I0_25]6R@KK'9X<*N[1ERFJK705N3XI\,KO&3S@ZMJ#L MPOD@778=5UXYWQPJ[;(">14_X>4YX8+6S*4N3W,OKV_H>(SSTD)>-B8+K5Q] M.ZPH(>-TEHV9'^D]S`KIA;QOQ;3$/8?+UC:CQ.2`4WZ0X]UX$NJ8Z M!)`GM`-&6RT.R8[X^_!>O"L(_+\+0AS94PF%`8SGXIJ,"TK&M4J664X7D-RQ MF[1(T\`RFH-D=!6PD*W?/,I[[M6W#8O,)TNVRN[A@K<>3T9J$FT`<<AU9UA*KGC=F127@WE3MZB5NALQV\/ZX0G7AY*,7'3" MHYY48V\A^Q(UFSF1/57K\[--O4/N,S5I2I[#ZX;@&4BW62IFO(N)0UMSWI5/ M1CL1[,/]FMQ@[\DED#YTKX(;Q=[7_!ZPOH.["LSR)!`2[X[&K[*SEU;YR:R, M<52M][#=QY++G,U+B`B*0Z[`3?*DF]-N8UO.9OK5&EA\9HN&C<*=E=-9)*Y\ M,PS)QL4;!BZCDF[(D#A-<5#2*[]G\'L!^;^)EP1G9Y.@,+V0,NS_^I`\'04X MK`1$?MB6"_D5NL8/7E2^=+QR/C.,5K:QQUAG*3Y/,N]]#1,/L;D!.4=HL%U!OU2LWF^-4S.!& M$R`G'55F;E-JTWMTZP.L6@5"T@W(V43_*509C$.FS/+4654&."_25:'<9L6` MRR2M*I=@L\;E+(!H\W.D M1$T9P4(3UJ;DS!@\4;,F-SBH]8"0*?STI6D`J]6/I=)F8D"N"B-"I@,T*UA5 ML$9N^X*Z6,MDA!4AU*'Y+(EC[--)EO8A@KO.P<^5J/Y(:`@7Q==2DBU!VLS0 MOD-2N5^8$Z/:<&@(%S5G2I8:2&TF4!?O%O&:.$KJ';EU5MZ(DQF-_\UNO%=J M2QS%P3)]]55,KJ4XX]]H[$R'AG#1=E:VZ6Z<,.)"W^;0M2]]Z3@;&L+%OMDX MKG5CA,V$\EH7AEOJC)]B?LF.-H.A(5RHF,VC.1.GS0SS>G?\EK*4C(:&<.%5 M5H_C3*!&$MB;RJUWGY--Y@FG])&F^JDL.[@JM%Q&Y`\8XM8=`@W[:`'30F)-O4U$[RW1@(#?MH_VJ!49IP?X^RKC_[R_.`9A4>A=YHV"<[F"ZP6I2` M5J]E`IZ+97F9;E_7K<'0\1NU=;%PUK*T8N=2.L!U$Z5P+'3<.UM7:YBU(+GF M+D9(\!&=_][+,/G'_P=02P,$%`````@`!WJI1!F:^R,+BP``%+H(`!4`'`!B M:')T+3(P,30P,S,Q7VQA8BYX;6Q55`D``WXI;5-^*6U3=7@+``$$)0X```0Y M`0``[;UKD^,VDBCZ_4;<_X"8W3BV(]2VVY[Q8_;LGE"]VIJI+M6I*MMGPW%B M@B5"):XE4B:IZM;\^HL'GR(!`N`C4[TW8G=<785,()/(!Q*)S/_YOS[NMN25 MQDD0A?_^I[=??OTG0L-5Y`?AR[__Z>>GFS<__(G\K__X?_^?_[D-PM^?O802 M!A`F__ZG39KN__K55Q\^?/CRXW.\_3**7[[ZYNNOO_TJ'_@G.?*O'Y.@-OK# MM_G8MU_]G_>WCZL-W7EO@C!)O7!50G$T;7!O?_SQQZ_$7]G0)/AK(N!OHY67 M"A(ZUT64(_B_WN3#WO!?O7G[S9MOWW[Y,?'_Q'D01UOZ0-=$3/_7]+BG__ZG M)-CMMWS9XG>;F*[;U["-XZ\X_%1?QVZ+?4$>M(U/Z9>G/98=05^HG4_1:FW M=5IQ!7*BM=Y1-]X6<%/QE"D[ZL;3$G+`M:;-=5HSLN0@U]3\YULV?VUE]&-* M0Y_Z^=HXI$9;"L1"RPKE'ZUJR+9?OGK[^5.O-?^&_^<16M M#CL:IO.0B7T:I,=%N([BG5#7\^(5M2)??H7ZTKSG?]PNOO_IQZ]_^.YOW[Q_;[,T M9MD8&FY8:?CFY\<__4<.1KS0)Q*05"#);SGL__V?KB/D4^_1-[5.NXVC7;Y-EZXIZ,>LK8\G*R!0D)G3U MY4OT^I5/`T;JVV_Y#USJOGWS]=O,5_D7]JM_R'D?Z$O`IPO3.V]'6\3LYN;= MUW_[Z9L?OO_NI\6//WW_]MT/?__;/]3P$TC73S\MOKG]VY^__O&'O_W][=]^ M_';Q]?M;S8H:.R[;9.4XP@=.+4#34#&%C%CND+IHV+%A"HFX9&(9>]L%LX4? M_TZ/799'`SBUI='1H-@^V4`B1A(V%-2.C$'`Y%:BU6@4UU+A[?LZLD,\M MT[%1_R>`D'K_E(;3K5+\G?`!:!1]OV6#:O;67=.ITNM0X^[KRT,<\YF" M9.5M_Y-Z\77H7[$SFHDZ5\-":'0-):<[)AM*Y%C"!S.7VB=\.+AB'XD.$/W> MM;N4*EX).*XTY,>-)X;61LG7X2!U_`D%RE,D_SL:#=]GT:#ZO6V_=*KW&M`T M^[D(%INJ=@4@A%Y7T:#<)7(@'H4^-`$@FER[DY1JO!UJFCU?VHX;]IO$19TW M4�[$VZE!NIZA>(P>@T_I#$H+`$BEUG;!1.X:>4%2FE*FE1JH068$@[T49+ MUZ;*-"Z(C$Q&"*C=4.ZP3MO1A)PBNGD3;&E\R:S52Q2WQ38[@KDGX/#1_E-Z M%&%",8SDX]"8BP%I0!#I;]U;AH'^.NPD7-@L#>[KA%T*-SD:^TE MSX+"0_+FQ?/V4LCH-DWRWYQ*6_;K?SRF3+*YT5NN;X+0"U+3J M&SN<4!;*DO+3+7OA;7FR(]NEE*8)8)['&,058"1:DP*0Y)#`*1\#;#H#RV>% M<&IQG2<)VW6FN5P:V4?I.T6B4%",RV MSJY@7,V.`@FTG5'1UK[W9R2_8D-J64S)R MLIF'/O_/]1^'X-7;LM4D\_32B^,C\RA_\;:'S@L82V10]L.4UL9>9``BBU7\ M4`&=D7E*.!KBA;T_.6WM$T MLV;6KI<6%[@'IJ>TX8AEPTDY?D881.&:X?+''(F+*\2%='B:M`8"@B)XC]-` MX,P<3QVBJ=7((GQETT;QD:W!U,VLPT!YDRA@EESL4RW="X=B*UM>%&**%-N1G=I[LM M@R(9F'!#!2`Y";J@LNS]:.4T1AP`D64?^>O-B'@ZC\[P6PBKD?TWP0<:P;6[ MEYA2N6B"WQH/$U9).*U92`)9U8*P"-R"(98-?*^BD%@#,_^QR'8\QO-=E>]0X?I<,&[!5I*FQ9%#I\1`2`+'.0@(.[^&-0)LFA)%JY3 M/F*B#.+`T^[&&;DHXL%9_LGTT>"I2;X6"5$J>A$X==W*U=";TR":VF14/,D[ MQAP[=TX!#.76J6@YW8SULT0Y%(6?9T<$&C^O+^\!CW(V6]O`!6R'A#F>N674 MP+MWQ>K;3V:HG#7E6N71!D)"AU\ON/6M[V>+=)W))>\V\)Z#;9`&-&'&761] M;Z*M3^.$&_KT:)O+:8X/RNY:4'RZYRJ@A4_(?'YD^:!]"%S,+Q:WBZ?%]2.9 MWUV1QZ?EY=]_6MY>73\\?D:NKF\6EXLG-%;/=N]J#:$Q,D`)[9F!JL,$;4.U M5&KD$'U"JA5A.2W;$@A?:FKWAC0R>!HT4XO8A1?^OF0?V8^]=:L;VJI^3J&@ M#%IC]'O)"I&H#!2EHM&8W/:MXK6LIR`0"72W7M'GHO3,X7N%`NTW5!2 MI\S#RD;BO%2W)V8R#79D=+KT$)#N4SJ.EI;$$YLO`8CKC\ M!6M"\.2M=>PIK755P9K+A:*WT./A.8K](.0R=T6?TXKX&5<_,T`$92U-:&Q4 M7ZD,)WS\K*:01S`NE7Y:XY%U%Z6T.$:/;2]='(#>W\H7WVID\27(?NNM^`4BV?*V:0(7^SF@(=GGA8R>*9LP&[[Q M7CEFCVR"%YZ-LH^#*.;7CHP>OL"C*(C$D&R#/PZ![U4Y0T5%K\^2[)Z&V[*,$ZX#ZEDZ4%4HHQ\J.[G:=7(0% ML9S/1J/4S/J`>6@.FUCKM=G@Z^W)52>[H^ERS77"59"(.*R5*]>!"=27ZZ)2 M*V$\HYDLU\*I(SD0'M_'C;9"ID(JZ@4*8^J/19Q](,2)-)GU%E8)S.D[A-Z. M^T7_S/V,T6AU]_5LR7T\[-J=O$3OT&5_R?Q$,9+[8V_8B6+7SKT:QXC/W,@6 MKX_C//'U*JX>+E_*2.UU.U-Z-/"Y4*9.$Z:+*J-;$;0W4T:KKS^4K*0S(;B; M&I8`#-F/-KX7@HNH6Z8OGY@FYJJD?'3@G-78@0WZ0JJ3VH;D%Y9*!MFN/ZZV M!_'8+$\/?.^EAUBF(6/->G0AF@BBN25&F/1HM&?-$A_UJ*:_THF#5^;1O-(B MBLZ,/G.;O.U\IS@C*>+XG8C@KGFZ:6S>D^0PU3N?'(Q(N&ECWH/1=N,%<1DM MY6ZM]'\+5#B21'M^MMQJXPFD&,M:QZ57%Y;IVS18O!OJJ),/^F*HH^2^Q5.: MZN#\H=`\3>/@^9"*@^=3Q..9B%\N.)/[&5,DZV`5(#3CYH^$7%D#4&IM39D' M(9\LB5JM%OV(3+%`&>Y.ZEJJ<4F`O%V/@)FAZ44T`&&))&SOY2;\7[_^\NNO MW_X;^>;KV==?B_\GB6Q2Y!W2313SD."L^M<@27C"I:C!AJB-D=V6UIK(#A23 M5\$O>RH92*A6@VE105M(/9V-UVZUOEKP@CH\:4I1_?$O6EG],Q/6']G_O_W+ M]T)*O_W^Q]GW/WP_^_[/?\F'M\MP%A9_S\1O0[Y]RZ7^[9_%H"NZHKMG&N>_ M_99?-B9[NN)^Y!9/5T`+D3$RU3H\D[^Z\/U`^NGW7N`OPDMO'Z1>8RLJ$]%5 MX&`O+I3T-/.1\Y&$#R6+D&2#45AC)T)$;E`0DM5(A#B\NL!(AFO;"O?-%12; M"T5ELA&I@R]"9J>H##PW%2R@RR;;8#X>GI-5'.S%C7(/KZT5&R+'K9U:(]^M M!H0@'?B^\M5+E?A^%RK4QHDTF:R5M5U`($GW1DM*WD+@100@. MX`,0@;3*MUJ?.5YCHJL_:NKC=N-!D.VKHM"LSB@*7].!&JG2MB-5.!DR&8.[.,F7EC_J<(X=S36!S\;7T^4ZS0?J`Q]9U)$_?RO8N$ MEO$OPN")0(`HL#<`Q:=7M*B\WQ'H(Y\'(?&C[=9CYP#F.LG[Y"_0N39VHFS: MF,X$):S2DJ')>9$,X);!U<2"(X.KA;I.921A2`F$(.FZ!U690#:R/E"X=Q/0 MA22M3"5G%FEE#108-,="Y`7UF@ZC(*F32G`8_3 MJ20N&(?"X=P7XR\W"5V]V@0/M1^Q%B[L5BP.#E<-#095V3M/O@4-)C?+,J$\ MDS=-1C@:EP0?9:Y9;GVHJVN4"A3>M+>1R$6:!V>H=*Q=3B1/&8:*KQFAA/9" MS>C6)Y*=2UBM%ZVH`VJ#4G8NH30+D;5-I$,31&LD]]E'T+0HH/PZ/5UZ=8,Q M<&9'SR))IK% MSF6$#'>Q$TBTH^*$N^M1I%*)!MIG5-/7?$"0C1$5)I:R##(OKHRT?)4Y97(D M*89J*`+W03KVHY$/HL(Q^6L<;TN3!_I*PP.O+6WJ=C3`H#R-YOI/=U;VQQDO ML(_"CS!>,H),;.>U@ID^Q8;66KM3F*F%\%T<)* M^"N1?T9EI4R6O1]GV>['?/=%@]O/ENUN9#.K<%.+Z#)O.7$9)2E_:7&==4K6 M>*.M^LD`$90M-:'Q=*,5,$0`R:=2&1B@5SH8?7RH+/!6$)KWR`:IK.JZIPRL M8#>6Z0-D2;ILO4(G<@ M@;+&7;0U#V)R?%9IM"R,DH$@2#SH15*UU@L=B207KV(HHA"<]L>EQLO?J%MY5O;#[J3C8D*&E9R='\\!.$KS1)1W%IG*(^5K15/H^6%+A83[=$ MZ:,\&OCIRZ_N8[H*Q!TV5UFR=W)K2^,NE:I%!>VXZ.ELUKLL1_-*J/LMY3]* MIZ4"RAOAA?LX\@^KMK+!H)Z+.\72?E?&(W)31J0*W"HV2JS[/;2B@'8%VNE2"W26%_#[-!>443I3 M.%OU80D!-^0:R3$RX&WP4TL_/@55S\+4+F4!S$DS%V@KF/ M:>I]M+7FYGBA[;H%!UKWK3QF\^U;PI,*`O&(:$8D$D1%&GK0S<$XP:L-^RWE MLKKV@KRXDI#<@A%Y=P5<]1MZT,[/]-DG%Y]_'<6B3(5\7OOJ57Y1#N%\\MZIX`[D;8ZTNQABBG2 MZ5].Y_?7\I2YX.WAV&],_4DU/)0;J:&H^:0X'YJ%2F8D'XW"8;0B1?XIBXR@ M\:2Z]I?6@5("@R0I-4,RUO<-*C307I&:OO;P6TN4$97%MZ4'3FC<]HM-L%Z! M8WI#(V77\NE%`PS.K)RN7ZF"@1*%^RY[K"<3]O?JD(ON$0SIOVQ`,]TJG1W6 MN0Z#Y@K0UBQK$$$;9AV-5E=_J,RS#559_DS[K1^B'('1:`+W0CKES,@/46.! M*1;&3^,WC`&74"0?G>RG1X MRM&B<)^G9D9NQ+9"&$?E2B__'.LF`?3[1[>%'6>(\>:'\2O8&C/'YH*&U*%> MFQ(-]%E$39_"-K.A>2R$?)Z-QG40L29)2"_Y_'DL8MS/'WA(&>`.::I]7[Y,W4+KPD6+6H0ZU=4""!=O54M)UNHWQ< MV1]Q1L181)EOIK0TS[&\66`UX#$CSVVT@3L7VIUHY%JT8X"6J*M@>TC-.P,J MP:&<#34])G*4C4;@:9C382)#?CM=8':G8]=I+9`*=FK)^94&+QLV\9SY9MX+ MO1.=%Y?K1F,6)QMEB1S:=MGRXG0/Y_`D0T#NBCZ6K3V\D9F[P3<2_IQ+`8ZL')-U*`2BL.DBP MH3\/RJ^]/FRWQYPZ@QY]8&Z,H\QKW1M;G),7N\V;8S'-RQO193?2UW\<@O3H MV@3.$"FTFV-*N[)!G-!E%):[^*/O#:"CGU MKKIGN&@4WX\LM7D[3B@%;B"LM,M5@R33>P1A4'="""_R9&X#,\P M'P/*?"MRJX%$,J"M-'0;%0G8WWCBH5]@!//VEU. M7+:K1V.JE=M>:Z:;4%.+Z]SW10*5M[WW`G\17GK[(/6V;K:Z`QFTT>ZB]72C ME>,)!WBS"$D&@M,.]J2/UR/*0-#91J-M:F0D]9C,Q>]Y$Z=92/'? M_./Q\)RLXF#/IWB@*QJ\\F"*F24T0#"U132AJ7&NKPPGY7@(0BI?`SQ()0WV17-=BMHDB_!;:JQ(+7:UF[HR6WLBGW7PY:_]LBN MD*X.<1"^5&KH/J;>BUI+Z%6C)79P*VS+C8;9*A$45W*^0%%KVBN0(#74?5F0 MDUUCA8(%^&RYDSB8&7<[U+VM?<5_KVH<"W/?@0'$WG=1I3B0"0!2,Y9X3/X0 M-#V/D+]C;_-M*9F_O,3BJ2'9>S&)8G9P%OJBJ#H:),F!_3N,PICZE.Z$?["J MA@@^C^+Z+RH#$T;%]LAKMO):KI'\[@PK_Y?`''_Q)7G:!`D)4KK+*\(F)(VI MEQSB8X%QSUBW\1*VDN>C@&9<"=+CE^0N2NE?"96EL!-18K9,N6I?M9RL)^,'R6H;L9GY:*'$$N*)Y^=LD!R24-$.D'P(TDV0D5RD1%`164?B M)!GI'[67I`<'NP"^#4(J'JX[W_I6,$"[.ZU4:?((^#!9<`67SS(@'>`>B'JG MV5W=EN"3RXIKCC*B+&231-/'3),OU1FE('%JD[5?>%O^))5\+LW1\,]?99%U MMAOC=/C%TY<@Y&]W2$;&+$OL'HF*Z]"N5HW%!U"M'"XWRRG9N$\ZL2I8R2W_ M0KA_\IQT+[[%+]QENHS"4/I!OS(WZ+'H1;)V+UW5.0BMBK?(6>$ M,NJ#_0 MCS1>!0DM-9>,*[�`;(@T"G^@BVTB8(\_0*>C27W>&BHP\PSZDFE.K&BU:>;U]!$C/;OY]N!=6ZZS:/9R_:L7QUZ8&N>U&:$"M?.=="KE MAD.0'(2KA!P(B^EW)TVHA.H=QH>Q2'.W_R-0A\P),!/!;F^@`\\@;D$%X2*L MA]7_%@5A^@O[QH>8SE]B*@X?QOZ"/6(P1\*!!VU6JZ9+"'^R>W+]*I"1#!LI MT&%P/P9@P8T7Q&5J_RM-1+?;7$0U(9#_$FQYE3/`!WX&8L>OEH03;[3]X.:R M@?(`D9OGJB'U_I\UUNG+,_S7(4G%PY>G2/%T?9MX#T' M6UX4C?%*/G0BAWT4UMY5$>^0;J(X^*=09/Q!%W_)A?"9J:WH&):/,,4Z_?,I M]<7D'?T@_F+D88N!R`HW&S*Z6J``ZX17?:KAUU M:TTP#?G66T[V<^C3^/Z0ZDYEZN.I"3K0T(X1O=IGTYF<"3C"`*$.6P/3>/UQ MM6'_IL2/O0_$CSZ$A)$L\E:ER63S(WI]T><[UN[-#^([[MEWA#LDP9")++)E MKHFZHUL&N";0G!:W8.;(H&MG=-'JJ#O'NE+J4U+#D=0NN4-T?38^L;BNUFQE MUJC(A![3J$GBU=N^D&WU-'C>TD&SQ34SH$T;UW'%^GEJ_7Z_0$>NSB9[W(8= MAIF%].>4Z;B%SPGHIFWYIYFKTF&).\MIONY$0F"B)1!JF4^]LY6-7$B$2>I8-F M(M`=99?LL$-?/%ESPT;$\\I&"&1\7"9T"?L,KCK/H+O5XA+)$O4`V8C5QB!R M@D7H]'S,%!5(\,683G5KF)K(+L*38@T01YE1R-07$@`YG`#1B23>8B>BZFB+ M(9Z)5(HRKJM+V[1!#)S\;,6#/DH'*.@[`>W=$@H6!49!/618>"@I-0UZ6&$= M](V&HA*RH4MD@`?('S*A4/]$0UG<'8,?U(L\\9"A_KAI3/)<_)\1Z4/C]Q@+ MH<[IZ4:",7-7:+)G7O.>=VJE8>+)?C5_'((D2&EV`)2'PP>ZBEY"@44$BVR# M+^.O!SI<,P''=>G%3\WTXD4EO5C,_.9"-#BHSCTCQ>QY`"B_5JLL`(7C!\AH M:7X$/J[2"H1HO**IQ7ZP9.5>BP%K$;%<7WK)YF8;?4CFSTD:>ZO.\)49#KC; M)"UERD8+HN`AAR`"A/R6`^'HY^I*EC%5@%=#W5NQXR9(@V!JP;JC*5\$ M`Y_Z%\>?$W[T6NYI[/$7A/-5&KPRP1=%']DO#NQWV1^C4">"6F4YU*S0GL=@ MW&L4;:*I%(,<-;DXDL\Y=N9;?$&*"4@YPXR4V$&5+>;*5;@LU(`2@Z1E9! M47E-`]`J"/3&)#"-4F^+ECQP5\]&4HT<.2.$4^LCH2L3-O--%%]%A^=T?=CF MW0%,W2T]#BBWJ8.REFL9.9RP\20'*-J_H/!:+$FZ\'QY14T_\L`A2`D(APUC MX`IH$4Q^TJG(K[P!OPH2L9;[F.Z"P\[Z*J@;(;0Q-Z&YX0Q78'C\4.3-Y&#D M\PQP^#:<]F_/^U!9$"3*LHS\H*C7+=$`GU!H%S\#0V?!C073[+*F$]ODMEO< M$_T]"-G_LDU.$^,`21LDF)UNHZ)AG=F@-XOP#1]&\G$X;++)\N^X,N!'_+UW MS*]/`@45<%99N9WTMK@)UCOUJRYK10FX+.$L+_#!C/]ML.*>33*7LV^W=)4> MO"WS#]B9/SU:9;8.-REHUNN`O-.J_UH9SR(UMBB^PKWH?`9QV*O.0?))4%C$ M2=E6*-KS6Y4M,7[R4YH<8$41] M"8-_2L;Q5\FK0QQSI5KM'^B\5>>JK8HLPW=H%=F=_3O8C".;AWJ=T+LHI59M M=-V1@^00]^"%@WH_+=8L,&)IC3L6*]I5]FE]A%"P`DUGKD^9&?:IV@-R8V2K MI)4P)$GA??6O.E/<&3-LT.\F"+UP%80OEU%BWC[$#!>N4%^#TBXC4@`0`8'" MX1^"-*8'MY''-5\+5&/_0'E1 M,NH;>7`.6$%<-Q?JFW7$!0XBD-2-16Y4;BJE*TB."MY!&9+ZO:"^YG2TE;)@ M5GHDZNT]$DCRD;@1SM*O]A_L44[M.)3%P<2;&79&SKV76"W;6GH0E MJ1?SQ=AU!K/&">*^V%.NW+V*H&P%S8BUZ:T]EP$)5XCMND(X MIHY72#XYC+OB*.EJ9\4686]==2WZ'RS")(W%AU<$5AY\MY89+NA!KTJ=^-%H M-R&;2E2P:*)Y#SZ<(IN&#T&%#^KX\,/_\';[?[M"V:EB$&[TB1+;[:B,D\5B MD-U3NNN<[AM)!]Q3Z="R*)*=Z]<'/8@7V(L?O71II0H;(N=P#'Z8Z=1*;3), M/N.@#)E,K;9M+B1AL_X:2.V2]L`]?!NBTUGS#/\LIL>?SJQ6L1BH3'^UZ-+D M,!VN!G`N_#)I3V,'R-S`\>3KLY-(VSGVL,;5Z);YCV'+%"A:.AG(I.0TU;BX:AZ"HR")FG M6M+HE@+`6W6F[]CG6GFWD6=_"OC^I>C<3[L_-> M;=7G$%ZL\9PC>[-709+&P?.!+^PA>-FD%N\1;4VKQ5P(_6$;3KDXS%7\1$Z` MY_$A`+.T;K=?959<,@O'D\,IN36V\]ZV+7$]-!Q1#?4[`IA/-$'/),.,KCY] M6<`2O/JT?3%,_C'MJ#1-WI=]79BQN*'O,C1-,MB(G:;.DA]C-I^:@B$-*^+. MD1\E1T)A'?U/98=@;]!EDE,X.,\'3X?6WCLX)4-W8$21"MU%M4%6;->=%_SA M93"B$=^=#D]UGZ.&PS9!$M>RY.6_:8GA.ZL$`_VE)2 MY]H3"L1UQ4N->UGFP6D!?R6FER2S7N[M*"9_]AFN8LI6<47E?ZM5Z1/FO5KW MN+!`"%79T8;FQM/.#)9\GD-_P$P("MKT0?DC_/@;\@?@;.G`$\C1^L MM["V;*0Y-GA1?:`K&KQR7\+^1;8>&;0Q[Z+54"PK0*BLNRUY8]+A;M=14-$C M"#0"'>">B9&2,'NOKL4$K_P6X2OE%^M!=[:F(1(\_DB=-D-E5P%"ZG-TD27_ M.OR5KE;%85V[F6(;=_6(?+H6<;?TXZH8X-77?4SW7N!?9>'P:QEPFX?^,MW0 M6+J:_9TZLUGP>7N&W#'4C!DVDJ$1R20"479:0^X;.C(CIYI3&PEJ\]BM-P[5 M0WJ2Z&D>Q>^P;=6;'@\706UIF$WL=E/ M@V](O5]#4B5-$"KZ'.@8U"L>@!)$'K).<=B&/-M0(5"-^8IN`^\YV';UX+8T M07KL^'SD#FY8WUQ4T`!>7TS%!+]@`M!=QJ"[LY=CI$4-+_66R5D6B/"X0=WY M.0KQ195^U8>^^=@I54.X/OW)0.0OV&0WF6-!H2]XR8B*,NOO&[3AQ.<1M%)N MKDA$F9(*,'+3;T1M3E:6T(@[Z#4(10A]%[5$.GHL+0CA]4X>6'J@KS0\]/!3 M&HCP^"E-&@W52PY(,DBD?DHW?04A<3LAB`R\8D-:&OA3+%,+VAU-+[UD!4ZX#(*V2\.['?9'Z/0VO3WG0W:*>C-K4:+:)H2 MCI'D*,GSD7S.L;*#\Q?5V&N!>49*W*1$CLJ=&(5/HI7V0;*&1`5GO`(7(N\# M!P/`G95AM(N1&]-S*B1ZEV=1)-W+M4T;'VHV*%=I,&YUZ]^+7/\NPB](,4&W M_L66DSX:RR[GCS^1F]OEKX_DYF'YGBSN?KE^?%K5,Z]P---74FNC>.XJ:ST_1?/7'(8AI7EKCGGWV=![ZO#KTWJ;FA0MF:,_. MB@N-#)$,F->GR\"+NBXS(C#,1/I(@025M]:+=@&2!%('1NNB1TQX6?J'4_@%6/1HT4+=.=SN4NQ;1$(6.VE?S86YNUCSN!`"F&=;KJTVTH*[7G`^#K M6!FM-QIMO?8EJ(P6+/XX>1'`H;D+4ZVJ5>[4U:CJPR>/VL71BE(_N6$$E;W/ M*T5UK8-UW0BAO0L3FIN/MR0,X4`DA^+E9JL5G%%Y`KW(Y!MZ9UMIXR5L3;+KHFGHI0L+5&BEDSK]5OV\A&&[ M]8NL72>*H$A?RO;YK<`ZBOD[".8Z\LKZA^=ML&*TKFG,3R8F(@H0&,%#/%AP MQ$QNM<&/#A2PFFC+7;I[+TZ/5_39_G)/BPN3J]!"J=Y+R`"(@"`AM]$%U]/,+D M.HX^<*N:'/;[*$[E_8-'/L1!FM*0W]WN@D1T(F,T$R\D$;/&+V)]"$(&PWX^ MF!""3@VH(PFM4`/TM2D5'D>O,O`(LFTS5G`(4? M,`BEPAD(!:69!,WJ[@"JUBI.M!9Z,@B%FO22)%H%@D+19H#7VZ]_:Z89:Y\; M63M&&XDVZ15B@&U0+53%//=?>63&K!5X-Q(8AZF;-IN#1@Z&P).R)XS'Y*%X9!E8:(V2[WXH[U M^B.-5\R%]>>AGS<#<79ANA&C<64,>*!7-++U0X:!%"A$-\H<"4[?I@_I0OG0 M#(@?&&3_L"AC`T]A_3`6\<-X.Q-1C]C/,15_.W^G$RMD9+;JC+G<#M7A,=P+ MG5!D*D-HWF9$G/C.X.V,J.\8W-#7@J35`Z3_+.)!& M`V@#YFH\T'>!DEYD6,6T'!G(16.I3/*YDNX..(&(C#-;`A@$O)EJ]_->SZ M>U3M'7#]`">#.SS!:9H)'-)/K7[[6>>CS__"B^?5JLS=3# MLL,)Y7I94MYX5<8%@<<0Q0\5##,B<9"64H4H7+:>A',M4"MOGE')^]CG/!$_ MT!(Y@M#/`%0[D0KF%;I(MM9=M$(X>?/YPWZ_I>+"8+.-/BS"=13OA&)U M?9=LC!;:,S2GO]$5O0(IE1F')15@K"^&>]#\\_W][?7[Z[NG^2VY6CQ>WBX? M?WZX?B3+&U(\%R:+NYOEP_OYTV)YA\ZCL=SO9CWC#7%.7PLYI6QOI?=>X)OZ M('48N`K'M94WBQG+/Q/^=Q2^@>F"]RT+!BQ-W-P?'56(*P``E;VC'7WR/O+H M:>N&[BI_7@>'MCQ->EIJ=K,11`P!V>K#K#\5ZX?:^7:;PD+KG\)"G$"YI;EC M]+,?R[HXH=]R:+X*DM4V2@XQM2T!VW\>R)-J3PZUGEXYSAG)L%9*=O%C35OD MCY2HL15['8%%#)4\W+5%N/#4=QU*?#J/?KTFZ9T167F_SA^U\Y#:(TU3Z:ZZ M)0S8XP7-A[3C0$/@*\4>B(3G?3-*##CS#(:C7";_!9+R@/V[I'R\=(3>N9#] M2#?)U;;?&,B2)1TT0W>NI`W2L76;98-")Y0@ST>LZ792:JA:&`Y*MUZE>6-W M/+1_;H+C@\,\.W$3X[H-5VSBL<9NG(3,N6\'+@NS=+;F5-.,+;.S,/0[!1]3T-OR\_.B_`R M"D.ZXMOK5^:CLW\Q_R(-V'H418JL38W3M!@=1#?^.2G=XN*#/Q@L)N/CRND( MGX]4)ARG2$80`R M+]A-&YB\^K;"VUNK/=#5UDN28!VLQ$[(WY5F$SQ%SD5P'#&#>*ZN7&B^,*SC M*5^(%S6;GJ*IRNA8>IZC\:#YM)P7KD);9&=\/BC9@,3CZZ43U$Z=&]JI\UNR M2&P0OMQ'VV#%/$O79&0=)N@L,"V5C?3;X"447XV9Y1*0Y)!8\XVM:+2C"SR# MK'N7&B63:=!,+7?+^,4+@W\*S<#.;@E;CR_^<>$E0;)<,\+R_G=$YE?7BY_OA,= MS>^7MXO+Q?4CN!\QJ51K<^'&74'O\]>[B.&]Y)R-P_=>RGUV6W^C&P]HO$A/ MX>G&%J-)-IQDX[%Y&!/0!1O=,-B5W:$,'9(QY,;8VAL@`(E"=-!DN*6PF$8G MDI;S=[UQ.[`4+H@[L)S2VU$06,<*<+`&Q&=0@*9T1`&1,*?HXWWL*F/8,ZL*$1 MT?+1B?4AW0XG8#U9&\KM=G3U91<6>S\4X0_+^^N'I_\D\[LKA@G> M`+@=5?GH/.@FQJ.VG=V;T\QJ:O``W3[E]_OYDJA_&WC/P?;DO::UZ71&#V5% MW?FAN.`IFR<5VYQ)<@4;:MLZ(#LN+Q]^OF86]O_<7]\](HH8]Y0`K:UUQ=T[ M6O68LMWV?)1M=-D,:1P\'T1X^26FU.7(:HT6-`9L17_CKD,"9ZVV216<%/#8 M;/`G0+9[AF`ONODK:#8B8/K7+U4Q[QF::R"[M;X0.)PMM1["BU6!R+(2A^8B?UB_\49W5V;+]:/#X]+"Y^YF7XR/S= MP_5UV_D=((8_P7=%$N)WD%EUQ-\&V=2G)?ZPPZC"E/8%"A@Y<@ZJJ`$AXH:J.DYW6Q\).H3OSDI=\NGZT=R M/__/^<7M-;@A,MQ:VN.Z"G;Z5F=E7OI3[(6))UX9.H?"N_%!FQX#BIO/':J/ M6JI`6"W25$2"&RK3_6O84ZP#&1;I[&'0K%!"&3D[NBUV,F9SV)/HZ]OYT_45 M,Y+\@OGI87[W.+_D!U4\X6^'W:RUH3;XIG<[X^"5'>!?Z2)DRD.8"MH:]^-3T^7-L=6NO1#;KP'VB>%IS'V>,Y`=AW-=GSG@#G^] M.*,1EPH^<7N<8525W,9F.X=FS/7#XI?YT^*7:W*[F%\L;A=/F%X>#2$@':?3 M'A-,K2YD^-;5>IY"0QO$!C7-:#UC\B;:^C1./LMC]H@M7/OG,3):)Z"3-_*J M<%HNA<=O>Q@="X10%L:&9MW.S#>FJ`^"V7+T(OAI>?GWGY:WS%P\?I9=$J(Q M$M:[5VL1S+%-[BT6:UBN+Z,=3UL5%Z?9Z5#TDG[<>#%]]A)^6)2-IIT/6SUG M@S8OO;G5*O1DN9?Q%>XZ_NK%[#">XCYV#;)IS$Y>_:9"*TX7U>7:G[_Z3@-V M!.O-G\9AH[2.T9I4<1;5M`36&1%XWXA]0G+,^"SJ\!P2=I8L[T4X4SR>^77^ M\#"_>T)T)!M&;/2GLIYS3-Y.+=KM@C0_.\H>XR\T7`T2];1$#FUW;7G15H\W M@Y>MOJL8,%M:ITU@9%CM,*/<_-9FTQ8K6)]`6^KM]COF`V5_TI?OWR^>>&:I MM'672U$`Z?H.5?4CM_VM;^UGAW)JB;[Q@O@7;WNHG'J=CY%Z7-#&JH/2TPW+ MAQ,QGKRG'A^-O32!R:7\\??WYH?8(`9A6,MJ#6".@Q3'X%<'A.Z!\'ILZN7_N$#=5XH'6] MAL+&,;P82N18S"J^Z\L9J7/V_ M?V::FUS_-H7:E,/).EB8_DM^R_@((W)M$\RO"<%VK>5RKGHC-M=GO;R-`9HIP^_YVI MD0-]H*OH)0SXQ^@68$7J<2X"AE2`,(GIF'2BL93&>[,CA[T+ M"T#@FFF_#0T3D?ZWBG9T$-MICA?:>EIPH"5L78(2"8M),J>D&YW=M-W9IK=0 M9D@G3XOUXI`9\N2>QN)2V-%R=J*!LIO=])UNTAR",!"92X%)-`7LKX?#ZP?:04A^-437N M`I?7\,8DCA.2C\Y.6NQJPVHEW?C`4E"6ZYL@],)5X&TK3TB5LJM/)M`C`T]) MZ:!5DYK";$D!6GV"C4ED1Z(=C>&TVK)FJ2M:3`.TM=\&O'_T,OP[/;)#;A*% M(>.?R)A,#MO4"YW/EN[X04MPNW&DI6R0P$*6(6%X2($H3T#.46&0RLF8$74P M`U%I[F$HKS_'\LH.O7OYT7FU[KC"G=\9=_8U[JS*Z9!5[.ZA.KI+=[L@[ZT, MVRI5Y*5_#&ZLF@6&[1""5/&VI-FHZDM1+PF?SS$!S0A*>`]'8%`2N,T1(*G> M[2*MZO+=5MBF/@G=T0^5;)HX"MF/*UIQ!'N&_^WQ0TE%Z>-AM_/B(S]5[*M=BVD.#&ZC[;>K6_M/P/<\JPWU#ULJ4EU/NJ.)K>9L MCVTP0UMB*RXTMG$&G&6)-WH,PHOLB+27(NQEI-.L42HZBVN_U1)FCA1-N MWEVA4YS;W[]H<8`]E=)3IA-1T04$7B8'(:N4OE`TTMG+1CIH[*;)!M2_G](A M@!.GLJA0-2]')"AEA=^RBK#'H6RH^XQX;&L/KND$NEH$K(IX1FJE^&9YZ>8C M`ND'X%BI*Z)*;4(O@T=LK?L*FZ45=YX.G3KBOTWFAW03Q<$_J?]SZ-.X0@<_ MA207Q^N/-%X%";V/@Q5]8%NFCX\PWDK@/8T1N>RHWL34I)R;'/CD-;4G@@A, M]_%NEMD2B%@#$8M`H`H1<;VI(J-#FO">F#R@*$(3$J'@&;_W3/B4V%0AAU91LJ` M.LB@N?P`D_77NJU3S_FD+^+.ZN+8*.([YS8V7]BR--(\J%Z::+N(U\2+@>EW M/QVO&T*J4N25VLWXC&2U*.IU:XZ;6FRE8`]_JA<"64%8?UE^$!7ASAF:Q:U MAGX.H^>$QJ]\Q8MP?TAY!91PQ:`$-YQ#R..L`3JH/!)GU:\S9K4KW7PJ(IYA M9Y,1,=N,5.:8U M0`K+6O'6(!BH``7?6Q?'"QJN-DPM_3[_&"2VMK8;'[3=-*#88"<6(.0W#H2O MUK'IAS4LO=&!#'[;YLNYBG9>T#AF&0MP`P\:-=FDT&Z;2C#$NE/Q">VTZ"F2 MJ3=FEG.>\&3\0+@2[^GNF<:V>E2-!UI_:B@\W9#Y4%*.);_)T;C<_9%H`C<" M7;O12/DKD?0/>WM;FF353M]%D<];_#PR#SQ8T>2.IDK):8GDF&&""3@;4MDX M''(XDI>[%9`BCI;#$E[6#TJ^$32*XD.1%9(]2\N!S<;S-`NB!476JI8B)J18@S6TYO]=S8L#V6,%G)GVYWAVB#A"O>W M4-&Q`[$=S-1?HJ-J?0.LMX-X>4C2:$?C96AYC%)!@V:*M5'3.,-G8P@;A.NL MA(P$]P0L*QJB$.:RVFI7F^8Z-4$'D]"G#Y'%<:T%"N1HUK9ZY59@@Q`=M_`L MW?X(9;7V]$.$Y&2AW.OJ4T039#B)8Z/Z6,4:/`J[6*=(O9GY,,2V$0<9_>VC M(1TI'X;41K;(B+F5K`)/?HW`<[N>V"R*HWRKXWX"!'4&.EU[(Q`FT@3Y`,#3 MMPD##0X]=8C)GS]V90TFJK3!_MIO%P*BIH>'3?(X:I\@V'VI25\DVOTKC0+7D^0![4^Z M96BB+8,<4]AH6A+A#8'9SC4S!AVXP`W";1#214IWQM$;'08TYJ!*E M"`#$QJ#QJ>QL00G>/R$R>`F#=;#BM7'+XM6\4#6OI$D_I@=O.W].V.2KU"KH M;X<8MIZ*'0\:)[,2O%8*/4-`/L]0?,'H[&&#%=Q> MW-.8_\)[H6^=+48-!QJ;4:?,I&]L"8$B,#0J17C,8,L.M#.$502]3>'=@?MQ MRW7NZ"69#%/_)HJ;3Q*LK*$U;E"#:,^)1HL4@8&7$BMPD`()85A(RZL6/$9Q M,`;P9_;YPF.3B"2QST8>U;E^1EC0I8BH M[LZSN\U*72E)W^#Y(?8+@(Y(C\'3UCIL+26O:Z4"GX^UTMBU4H&SLNA_9;X9 MD3.B<.ZFY&>6<%"M29=&9,_(W#"LO$KJ+J^/.CAOY./.Q]2+4^3\J17MFY$+ M^A*$H:SKM>7O1D=BS77HGQ=CKN4.4G`%_*)E-*4_3+Z6]>SG9C1_H0FS^J(. MXYZNV(]/$?]5I2JCTI:VUZ^?;#U@+2:FX_B8EE8N(RO(*Q?"S0S_]:Q:HA?* M#&/C?:Y<7P4*\,,`E/SKNT9,M9C!PAHWA^WV*=C1/(_0.%>O"PN*,&P;=>HH M!A]-^'!2C$?A>[N2Q,[T:TY2RDFBHY'4/U;:FR:DT4^E<)G'.9LH!A-]_OJ_ M2_35\9<6:-#891LU:E'GHX%%?1!2>"]J3@JPB(]("[*PHU)HNF.-3=#>HOPN M8@L!6]':)+$;P4KW4VT=9G*^7US%==IM<9+520 MP)[^AE6@*9$HR.<D0,//Z1(1J6*:B98&*Q0']6'HWS)@7N(O3>/@^9#F MM.<1<'Z4S+"`6\F>&U][K+;%V=NN_AK%OW.5XNV#U-M>T76P"NQ,J0(#J/54 M476Z\[)Q)!M(LI%XK*,M(:N,$'\D0MQ/P#TI07;NU8I-MQEO!Y_:^]U28(:7RL+NA=S'P!VP07 M'2;H3!4ME:=;LQA\*GT"`(6E=J*+S1#%?!])PG;4#U;,W(%*G/..LKB'UZ"9 MO`O@(0Z#]!#S0BPWP4?^4Z(2ME9EI$$`9>ET-#6:Z.5CQ0[,1P-)UG#4S,@Z M&XK4AG7N.ZWA4D-/_EI,NJ_!/^4E\"&E\6.T3C^PL[J3S>K&!VVY#"ANO+LJ M04@.0W(@C%;,A<:<+KS6RW2OFCWS[T(VM23>4B\1\;'%COGOK[+^F)4ITV&` MLF5:JAK^5#Z85$=C,F:.Y`25T6A,6/>&T]HP#3B:((B3">O"!FW`.JFU#(&, M(UUIQ+2KD_%RIJ_N*BH(`[=B9IO5R(9UH`+H4'C8'42OCBNZC^E*MC=F/V^I MR"P,_?DNBM/@G^+WRM6;VKOAY@,K:#P:H217WC!38A;Q4\3,%45<5 ML[JN0&&"1^39+4W$<\*"<7YE`L$*KX)Y.&[\*+D1BB9NR@P[*A<37D9$^A'_N"@F?P)[I[U$`RKGK"`;I:"GA;!%=NS&%I(*!;?QY"0VV#%Y4LHGE@,/Y)U2[(U MI)G6[;$NJ]L*"R0GS*JOF:_$[+NWO:$Z<>G2/%IL"$RCGEJ5,%4A"`S-R[*!:ME?EO>(#9"X^?)60;>P,&T8I+<07C674 M[S.M852`3BTI5P?Z%,W7:^;.LI.QHSE4((&V@BK:3O<;&\<-0C$2I\TSI>87 M&OJRE%]\\+;2!$7,M#7J#(#;'^W>,S([[1B`?,O\^=T%#>DZ2!V/8DHLP"U. M-;WIS@@*Q``2A.R`DV/CD6^?X4=Q?.M-Z&6EUL'$]/)'UF'`O9)WA\#GU6,G MIUJT+LZ(YK78$YJF6WG3P2NV2\0!#[[RR&L1B16I1)E>S^\U9AD/P1V@?II/ M>PZV1(GCOF,>^G>,?6XQ72.4T!%>,[J[KDFF5=LC$/18$UZNLDA,92(@CVNO M&"1S*A>*>TC0J+8;P?,3%83&H7002*-`MPF^J97.]4?>2^\0)!N^\Y9KKB/? M>4'(:^G<4?:+)^^CJ5MIA@O*F32DM!$PKH%QT>2`,\)!L])3LJH%^PO#@,![ M="24_YE?TB8-/00?%7'9K5I7P`A1_R:PO/C]\Y%G':?'JR"1=;IXFG*>D=*K M$ZP]=MAVL`[<:!A)B8-()*2*A11HD%=O!.`#&M/:3RP,.L5:HP9X.[FBU$]N M&*/8$:18H/A%<0MN_`;9&!U@&2E#>EN>&0I(PO<4J<'*7Y70*((9[I3>'$)& MYBJ'83XQ$^UW,3VR$WZ()U'*9X5\D M;/[7P*>^E<7MQ`5J7[LI;4B8@!"]&`4,R8#((B$Y&!Z[Z4P?#XU]$/2M,_J" MA-=L&X<^]YOZ<0A$=I%O*(_=IKX+T>2MIE8;ZA^V=+E^W$0Q\S/B'3]5J+)A MVMO5:'&`M7324];P3;/A_/@H`-ZP,^Q.')M5Z3%P_8$,/IJ^IX\.P?3=SJI+ M8+/-/P;6Y3@42*"CQ"K:FE=?M1TW(WPL.P>RT2#;SH77%C'%=@S@&^\JVGE! MP_JINW0IP.&:V*GH,=QNM/\F83#%L7J05KN/'HTT=U=\*-J0.=\F$F<0 M9--AZ9]H>'@Y).G3A^AI$QT2+_2O@Y=-^G.8T-4A%J\3>=Y^%!_YW$IET9)4 MZ8(7)A?7B0.-ZU6!A3`T),=#!")28"(E*JELH)3,R#Q@Z_@!@FJ'W&6H3P]_ MQ]=7^#5)T0Y(>ZNQGPYA*NH1_1ILMX&W2SCRQ-W',<('ZNJ847RZ5R64R$G+ MX<2&3!![/KTH_1_>;O]O):VU-]$87:'1B$7F&UD(;+>+9(*LOZ>4;&ALI%9: M%*T*%L;C45+2,&U\Y%0*PCSWQHD*1-Z6Y+TFBP@/HM.NH:6ENE/%3*GHU.RNET- M-8K>>^%M]N5B>PW=5D'!A!GHXNJ1G:.&$\8`&$0.`1_2*IFY/;V MTDST80RBT394FT4]>&\AN?+"@&[_YNUHPN;P7D2683]+:8H2U&P:T]UXE"D` MB8`D)2@.P1J;WEU)+QJ)Z[\136V5(3[0Z^M;TS(>7=`H+J]O-=4O&LDYM^HZ M'CANKAO?QOSB^G:X4AA9>>WENGK6W/=0:6JZ/AR?1J>P?@&PY&X M:`U?Q-)Y.QG?[VK13*V=PP7 M_,0[8L&+J\$&-;!E-0"(*C1EE82?PZP/#?6O@D1T5S`U>A8(H?--36AN+3=3 M+2Q3`2,Y'*)"!7C3$-IV!N(R^*N&. M?K!,@C^!`/$>3E?==,4_8,M&AU^RO2TW73,2D]RZE]5VMSZ\?Y4(LU,QQ61:]Y?BO#G01 M_LT+#UY\Y,%-"U-IBQ+$EEK3?;K5R@=!%0Q2?GA'K45(,BR$HT%DDGM37M17 MDM>5,]+!BIP/W\Y&9H6]J1]S%_B,]*"^"Y!X#&XRKW8I+/&-J[-NZ'/S66HX'58V/RP%:A%1SY#EJC`>V,3+75=@8R7\M11W2[8;:( M>VN[8GC0ZX?S9DGF79 M\X&[%@]L)J26PM:L6L*'(Y'T00F3Z<(X[B]'(@SK`W4#03/([=0@&5859+B7 MH8V5[\``8N>[J.I0`(7\,QA$UMZ)JA;IC\:DRM[F#T@6$LMO)%1JVZ\''T7D MGSY$?>U_$Q,>#Z"%2E,5P"LR(7<#C*EKRDPZ)G4#.0/]R,/L$:B$S](G:*`9 M1T4PB+Y^00T'&L^@3IFQ8N!0R+T#$\I:I&9IW_#2*WHS_Q.6'?BSO-M[H[T.SZ M;RIF#)S68;D5&LW`"^K_JT(]$F?&4?H=4SM:$$Z5CZ967XY7PC!:S/&:>1AE MAD*5CMZ9B4;#H<\FV10JM0:NU(:3WT$R.J96<>^]X]OOAO3/&@CQ.6=- MFNV5&<-!WGYW5FY9-]F2*&/U51E^/NZ8S<=7*:U=^?'/P1%3R+BC%W:*;33] MM`S'],(TV%$Z8CIN6*@O?K=]WOZ8#2,L%=JY^F-N>Z.AW7B&P/FZ99WJPMTS M4Z,>^?QY".G;OPSIG34QXG//6JAV.&PR).3M7\[*03,@/"/+7*-5QI^/CV:U M`Y0GR\H..`&2/$/&,$RUJ1H_32-+RPUV$%GG-ST2RX M4*'Q!V.M-A5C1HJ<]=X?K6PX$S>M2UOTC)^U81Y-\\W7*8V9<_B?U%-G1YB; M@39TJ-RS5GHM]JV`%T=0CN$,W#(C@J_H2DKAMV^[-9@G6,!/6L=163"<1V;Y MT1ON6)UBY)Z86J+MW;`67`-4M'^.8C\(>4723.9(02N;V]$<[,2 M?`E6NE49)%:/:AQ:OX$^_P%\7&3ND(W@FA3^-\`VAK*YBUZ[3WDM2:]FF&!R MPPVI--N".2BVP--(5'[[]=BJ91\E01J\XB$5@:LVXI9%XI]9J1Y-KKP1FC$4 M)0^_\;/`,"[9*39L_EB#6K.=)Z+3XL1T%IY8'RK_/!N9T$%=L+[?$[_SU2Z? M3I[7":K^Q8*C.-TDJ1=?!&R"U2:,MM'+\5T<'?:WVY5A`=26NJT.:&'*#KO0 MWVR"E"$A-2Q$H!'M8;&44X5@@.PDBZ8.*QH6(/%^W#6`I@ZS/ M!<;.<=*B@.Y0U4Z7.H0J>WR.)8SN7:ALZ<"B80''NVG7,4P-`VX)26TXV3 M_1VGCNR[>'!5V+J3C)1@'=)-`I@:_?(E>OW*IX'<_.R'TSW/?O6/6_KB;:_# M-$B/\X]!9UOS5I"I%6/[NIL]#=D((H>0W_@@>*VHX7BK3FP;/^Y^D!-=13LO M:)R:5#N^"0>E^5HH.-T6^8:0`_"H#17SM1JC`=3;5WKOO82>.*%9^$I-(!!? MJ67MS<<9;$@6D,$3?#%>.*)HB?&:7XK(!Y)(AVJ+J[W2!D1O,;N-TD-RA!>-EB2\(Z^R1""4#G5-_+R#,4S\<%`2[KTX#=ELQ,^N&?,\A;'O M4MT[,I@3BA%W>#=@MUN#%?M`_[@AV%EV%"K>4+=7RNQSD1 M.;O)G0EOS4B!5FR_;R)&^ZM MD!EU#3T!5;#=25:ZG(IN%`-DB!EU;5&KP78$H%Z$@J9F3@^21BW#4(*B.CB;OO=![H?Q#.!A7+1Y0&ZNG4)'+)(:3MZW5( MILY^>F#?@IKD@;0`3&T.VM9\NIW$W[`D?RB9W*ITFJ-!-H-;(EP-%#H-KDZ' M8HM@2P?1?`2C'+(JW-0;Y[WW,=@==F8.I@((2IN*B`^Y>O2*/5[XLD.5#_ZA`'XU MRS^.$('E')8=E]%N%X4D$5P))%>"D%\+AG3%`Y_D0Y!NQ%\$3Z(U\6H-&V<9 MVU`89G#>5*]3?89U-.[T*#$R%'ON#B(#D%&=2,')6.1+H4HW;(](P6IA&O^K MCG'(KJWZJ66#4B9N^*<^-/%)%R&S=6+O+4*FO6B2/G@IO5ZO^>=]I6SA*[XO M7VB7X^:(%"H"8DM[LS3M&W(E`YJ"H):3;^6B![2VQ%U$<1Q^8 M(Y/'F#LSZ5/$9TV6ZR)%KU[V:![Z\Y>8BDM?HPC0L!." MA(P&YMGI-B[1$XZ?B`G$PYXCR:<@3Q$1DW#%HZX>Y(4^*::"CTQ-QS@NBNSL MPAFW%XS;YXQ+(Y(*QC%%<2@8MR\9%^:,\T9CG'W&TIER#DG&U!A*3AUW''0V MV)/C>R]EI]ST>,4<1MN[-QTFZ(LX+96=!\)\/+D".!@-3%?01I=ACGRYOHT\X])8 MIMA`HS0FU)YNP1(FOU5D!ZD"C/^#`Z(P[D/0F%WP,)T9%S2R?VS'H-$]RC,> MD%(=A\M(.&#+KVHRZZ*V=%_GU.WJMRV(XB,C$D>DO"%N?RI@Q(& M./H5Y@S"5YJD\O`C?SX]]LC?_F,A_L,_!OK&"^)? MO.V!G25JRQM*T\N%5E"H MFX1V.AH/"/BH-_S&>IP7`2X1<[.5+TT5`5A(7+.3M/'O-CCHW.A53-E!>+Y: MQ0]22S#N6I)/V'RU)VBD:;JE^>5=H^YI7H]-Y!DB4-,]U8R!TV2,K'\+ M""\(;Z,D68:/Q4>0">1DZJE$%IXP%M+N`$4WJNE#%,S`/3/'TV?F84_# M1.R$.0^VRL*"%\=RR+U,D MI)PM+TXS-J0M;`","8TMNAVAI=&F[U\EER:K.!"HW=TI-1+8^KAJVIKGTV(H M7H?)D1Z\GM$P!"%S@KHDRJ!LL0I#;VDO']0OUU=!LN*'LZ?HDCF:O%Z((L>I M>4]M@@8D0\.(OL8CC@*(BWX.QM,F,T"8S*;AJ>.!FYPZ_F)R0]D1XP,O-;'* M"!7I3OQ_HYB/6!5'>P2I'@-37R,92?Z'N7BJ,T$,<$Q]/5/?I_X5%:]) M@E=:25=I_O&.6M]QN'EQ)5&V9AL'"D'ULXH;-.W#F'84/@U@S*CGN%% M<[K]`JP1G@:_+',7#:.;,P?T0V9\EIB3>>A?>ZO-X^$YH7\+/6(IJGX>Q$A%LFO(E6^61.5`RU<1N%+F=8_ M(Z*8#()Z_X[D5$HVRK++^YC9\V#O;;.$QNJ[&12NFB.AU5<-31IENB,:!\9& M"AW2JT\0`>N6,L6ROJ[E^FE#K_\X!.F1WZE'H44ULEY3X"@=;\N7SD<3%83L M'QE*4B;\2I2DP(DBPV58GEQGZ$;@SLB`(F51R-T./ZQZN?%6=`BWI8H'E\M2H[!3"_#1(&\P MAJ)($%!$0[F8(G9+M)3A9N!86*Z;33T2RZF/6#RX;- M\-2,L22`RF'@]M%@'VD#'FUPO0\G<]\7S]R]K=GV5E]N=V`"S1;IHK)16&OC.79/CYH`SQ@!QK"D2!FF7!AG^ M6:-1O+QAJ)23R69!4!YG1(8)RHN'.EZ:QL'S(96Y'\\TI.M@%3#NE4^3R%KB M$@FOJ_9^ZXCJ[XS(N@LM>TQ[SD-%ED?6+09^W6"33:WQ=>_$KX+7P*>A_^#0 M)\\<+W0@PX(#FD<6[14=@<,UZT5)\ MHUE+TH:OTD"W08E,Y#D/Q^$U.:G\V'\H3:\6+TA!0<,%4_')QP^#)2 M=0:ND"'1@K@U)R[&UC)Y-*I0>D(Z,77VA%J18E!*U3)>0_@_$@]&KR>CT-K7 M05-(SX$X+1$HW8#J/G0V_@()#NER:-MG@1"CD>_J;:<6.'3]^_J0>9VDP(96EF+T6:+M%(K2.MIW^#/'UK]'6*5U4):XO%4GUC=SU;3P((FO>HH: MC:2J';](,7ZL5'KK?%07:K+BBK,*.5B>$]N1\R3S.ZLTY(\#8-M\69`]TK7C#-VSW07ZS>KHHO2+UFY'2+QGR* MO3#Q1'Y*-#I=9'BX'LC&$P%`JKAFO-E%_<^_"8S_ M%YV%[;5IC,RMVPR3OWW8[:@?L$7<>+M@>WQ/91_?]U[HR5X2R[B0[.6'D,9R MA*G9=48/]H;"F1^-9PHY)B)1$3F22U")C41Q:5>)0$A^DP,;,@-B9H?CQV.0 MI#1^$X1O;KT/PB6/XATC]W+C!?'.*]Y.7D1>["N9`/>XHY^@Z!^`..+N'6B[ MC`Y)P`\#XE/D7V*Y%M]`*>GJ_'\2$W6X7@DY]8GBB4VP M7%>ZT042Z..TBK;&'1$;Q^U'M0\DWVUW4?C&J_RN>AHDOW%D^$[* MVN]I=!)NQS#Y'5(Y/P]WLT]1^1+5#V%WPK5&"_8HT9K^QIU*!8/!=KZ*=EX0 MXCG!.6X`_1,O2YR]_:BR>_'\):;B!X=SF@8+Z.E,1UTCGE!VL2X&(SR%X27) M_:35ER9DIZE.F>H^0ZE1]);X!YI01N*F6]Z;[J02%N3=" MAOV)J0\=2(Y+';*A/BVI`">_NQ2UZD02I9T9UR"`/B2UT=2P"K+&IBR:B,IH M#TX%^`%.N=/R=IS'YE==8RQ@EZ\C*GW'@G M)N3S#/H+\EN.`(>2GX!D1,>U,0A%=H2S%-SN`YTIP@%43E8%EC]VZ[1EK2!` MA[F3=3?W3E[>5HS`<&XS7G$ZRHI=CFAV2T9S+&O;T[K36&W\`&DM11WPO,G= M2>^[JGA?'>(@?*D(N67*2\^Y@--A^G*JNVEFW8A('%5;@LGL)HKOI1XW\V/<$(-X.XX\T+TR*?!D#6NR;'!N\_#<2#1QH'-"'S6I'0?<&,TU*K-&<&[Z:R'XL9]J[9"#O"D@E( MG+T^ZD'M$CIA'=)QM%-N1G8"6JT9V1C;[5MIF85,@XU'+DX=!4PO7O_,0A'U MYN$`306?TTK_:"-'J@$#U-SO=.6M[X^7<#V^7=;\2U[@@[>;&+5!N4M?NZ[5 M5SN1YXT_0[C.&09;M\LQ.`7H+7#WE'TGQO47\5+SE88'FCQ%%_2!KFCP2OUY M\A`=O6W:UJ-3K7XLL():?AOJ&SUE"UC^#"J'YB&?"TIR!&2>D`P%'@=@(*J9 M5HASJD4["?;/C&HO(?%(5+O[`9.0G:%`Y@Y82WFW1V".LK>.NEZO>:N-UUK= M49,^=5W0((Z"CII&^;U\;+U6,'S/NAZ4%)VL1JD0;.]&#$`%,J^B4U[4_H4: M=.Q`*C]&T)`KC#*;V#+4X(`?..[@PA&'J*J(0TA4I,2%QR$9GA&*8*(XL6>, M2,9C1)]8!2@GD+DM/52&24C#'OGDK_82]FV2HN8L+U*WC1*;;H)J!&`O\30T M-=[-/IWP0JH2=_77!XCF(_ M"/GML$W;7S4\^-N")D6-^\7*$#P]?5T)$&6%T=BDKHUE]J+@%'B,:[O29/'2 MA-&.&?TH/O*:QH:I"588@7(2[*@VO+NK/-A<\J*?.19RU]+($R(+81"J3Z^T M2@^0A[?V)=6M`@B2;P!`-Y+CO)-\ZW(+;-!-JYT>-Q[;3WTS#+KQ8TLW,.#( M$/IK)K&A<`F&9X65<,^2<5@Q:)K"5+R0V-`=_IT5AU,^0R?RX57A/,DR)Y1Z MS\`:-)#@<,>:M)EHL'F2)TS-"(RR&I*TFA1Z29XL!*5[IB,-J^>D$#@+9^D4 M0W^EX"6;N?_J,=(L'9\:(*Q'4Z>AL678GTG^=T3.AW[5^9^XP5RQH9AP&)7H:8.)5;4P"]1&H0O#\'+ION=1R38_.2,^('$SD:`3] MTG'2X7*/,`HE8%<('?*BO4!0P4XM\_5+P0ZQU\:+=9B@KQ2T5#:RX.HW5J#Z M8$2J7B55,8AV@/I:X+]I'$3^912&5#PW_35( M-]4X0O5M:K6CI,5Y?_`Y0<(#PW.NO1I9%D;(GMG+24@Y"^'3G,1(ZP_T:\UG MQXJ7FCLZ$S'/*&I8?Z)>Z_@*%%C^_UG5)_AS!KQ"%4T:2?NK@T]#3SB6_1.) M/O:KLHIV#3TU;*'OH?EH80QE%IVS243@Y$_#PKZZ"\6YX;\IJWK4=L?.*V2Q MW'$L@D'%^6'GG3PUE:X.L3(KM36D5@.!BAO7U]VL;2/^"O\ZS6RYU=?A72EO M8)'4EIVBC9Y6Q_=_>"FZ6P>OE&NM(&6B(SU)AYXK7:A`_;%..AOO`',`4D!D MZ0JXRKF?#W7N)KL'>:N"/,"#IKO,F!K+#CR#]&A)LZI\AOW#U'!@O5F:%+0U M`DE)/@Q93Q8\RW?KQ6*Z_KQV)I*@D&;OZ_NOG`)-G])0/'^LNL)N?5@ZD$%? M,_!-D@#:M!` MHZTTE`DBH%)G1C0VZY_E8*0"AZ)-QF0TXC!:-IM45XO,`$MO@5J$JYAZ"5V$ ME<0@Z;_.#^DFBH-_4M_J*&J($?1$:DKUZ?[+X?A3H%I^?79^*X%16+!A:`U" M<9++PZJS[#0W(]YXU+J?5X?9LW03>U.E\JP*'VP7#PW)4<4%AYL/*I8\(,<,K/"Q6D1D M1B12[OT2B99D>$F)&$4(>T0N5;#$X'W49) ML@S+?]N>YW68H`_S6BK5FF!&^'!>J:_\'0H?R(FNG):L$GD0MLEO@+!V2O<> M-3K%:]!,'DC;>FP%ZRRQ\&*%G],LK^:/QQRP@WVJLB- M$XWP%$?#35+>3"N*9<[ZC.3(B,!6&9,4@Y`\YQF&%06]^YS>+/R-QC+WV?WZ M9T`NB/MG./)SQ`4[7?CL<+&G82+.=W,^S8M((KDXED.RE\!S]DW\?"G9"GE( M4::DV&4YCC`];*;C&/QLY)UP#$2@(-5I2&4>_2I3)Z.)&!0IR M5:.DHS48('/#E^M:Z!C^+L:.B"*B40V2(DAR<*=B[X7\$JE*#Y+L![V8J*^. M%'"3I^&N-M0_;-DJQ/P71^%T/MD\3C%"!1TRT=/9L'O9:+[[Y.71\Y'(0]EO M`@9?>H#!AS0KSJK!,_GF9+I%F+_L)"16-/\8&`P\6^8:'&[5T$#1*[&`JVCG!<;]WW48H!5>*U5=&TP.Q*?I$""2<-7:>M2\GPL$8-Q*_K&][+6]26&8=[];Z*M3^/D^H]#D!Y= M,EH-L,#5INF@KO6!?09#)!#21-;!J0-7V79;LJ.\AA9%;\&Y.W#%S^M)5\W! M%4V"%]$`9)XH;8;5O5&O>4`OB/IQZ'3C2FRR\GW=X2@Q\AK3&M<$SWW/L*PI MR919HW[)$"\A)DX;HON?47:-*(RO8])*W58/V77.`'JG^]ZFSR3]^Y;7\,GT MWSPSN.W.O6E!.C"`N")=5'64>,RS_`L0>/?#G:):O+Y:W[9@1!B]'X"JA MZTPS_P.O/G]ZM:QJ5`(>3K#;VV;W8V8H44FQU*@)T^[\LKG0KJ)0CLB1-K]/ MZS<+W*5;3^ZX2'^)E\M+U:J5J%$$N`?G3EN%M\.>Y^K76%*KZD:\D+D!*UD^ M*PA3RN;..R"!6_UAI:SC7K37%$CT3EZ%SEKMN*AST\F0^AK&O+)10MDC/XPZ M:%(>N:BB?`;`W."N]PF)ZH%"WTSBOA.#^WP#\E";I=`]9YU<;%T?$^D2I-J/PP/,!!82&H)+K>_E M.J2P0PB!L[-&^\XFH8_^TYR-K"WW?&!2*<#^$&VW-U',_VAM+T=:!;CQ'(N[ M@\OMC&13LA\J-?5_X].2;%Y<%5.GX^UAM_/B(W=2(@F:A7K3X!6HP!*(,-GX M'N,LX=R4XSOQM'D1RG/2.W[X'-TST4U]=JZ*EH]CZD`Y(Z_)E,>CQ:P(VF5/ MP\ML,$DCLF.^S':Z!)R$,6(4]?/ZI(-3OH^20)3$ MPD=ZOSUQ?KY_MQ(?YS"@F1?)Y:B\RQ5_S!:;%W6R]_P=9@#WZEVX,J:URN>I M&"P$/1X'95=11:T(VTVI6Q@O@=U(]L\S.TVK'OIGJK6C/[<3`CO9K&F0 M'GCAZ]"__K@/8H&AT/M3G1<,%G*NIP<3'H^IG2OSB\!!9075`\93E"*I5PW! M\`R&^E^)\6JEY\Z1'R5'0OK"7[9\.APY6\_:6/F-ZF=WK^+`^^P@\G<"EY_/-B)P1DTL_`3?S<$.-$QA]_0EXT5;1=31FR.RGZU!I M(L'98;$UX,](8RGS22YBFK/#E>>>OWK!EJ^$66P9'#/+EAUR/IC$V4$Y-GR) MY&(:?M3)KDX0)-2.RK62YC6C^84/@U/(GS+Q#KG#XXM+YKRMJN+BU9V\I#)N MGXF+)\3%:W(/2R?D$72S)IUXP,G.[8A627#XE?*^%Y1116/OA=;:8P#F4>F7 M=>['.7/^3Y1I-2/Y.DBVD)-&.3-R05^",.1961?>EK]B_Z2.0>Y?I&"1..!ZSL[6%"EFCN:FG]:>HK!M2YN>U3L\]-"FO()L/_T%Y6-,U=>;L0&[" MT/FTU:@U/?5E'BCO,AN$+Y=1*!JI';SM$XUWXZ;<.B[IO+)R7?D^?.)NKCZR MI33M?;$:4ED.X>LYX_S>H?A_\@I!<4:;D(43ILI^$GOXW)-N>RGP$?)RW=8# MRT[^'>`BUEBL+.*/81R$16E=$3/6-#J+UJKB49>F%[P3 MKPM;0QOQVV1^2#=1'/R3^C^'/HTKE?+NV?Y,+HZU"/0#Y\\H76[ZK@;\1#HV MMUWZX>0/[4DY+SGPB;/V\7)J(N:><1M:O_LA8@%GVRIGF`T^2/^%]U11:+-Y MW]<$`LE?:%G[Z3Z76U*,(;_)49/W@'):^+]^_>777[,3-OOO]U^/MW3["W=C MIHL3*)(+:M4N5U\A-R"&D;2[(*1*06O57NVP4%9*04G[#N!#P*2NS_*YT+WE MPO?VRV]^@!.^_E\@9$-`1-!B*QM8T%;`803RB8:VAJ\"`F?VJNMN__9L!#:3 MIUOTO_[ERV_^PF7N+U]^]STZ@]?-[I2&F(Q=8U]WF+IR_$`NY9:^:D2K0S_4 MH>&-W0DU"B]3#,)J\#I(^-?OO_SN1[2FSHC_5`S":.[:A,'0X-5`!S)Y'^CV M5>V%JA1*#0K0\-57K[!]8A`Z\Z=?^K_^\.6?$5H^$WZG8A`J^]>RR;M,8!7D MK,.IMZ<]WT$BJI55?%)!U2IWIXRK\GF)F/@3CZTVMN_TX=5R"2.];G-"-3,7,EJ1LT3^PDDXF.@B( M=JAMG0;P-F,8:^=))M3:,B1RYWFGEJ/:1);LQP1K.,,G2A+-3VA$Q.YP=0PGYX'R'L!P8^:.Q&.U/.,;776+.-E>/; MO0!<02FK^]V!9P:]&QZ:BU,%HU"XOI-P4*6P$%UP3[.)/I&XTF1ZQ?22?MAI MS]K_E^VUE^M*,84!02Z$:]G*4LKR!N/W7@0^/UA] MB*)60:VVDISYTSM26+$FORXRX,RG<:[HUIC3'3$T:\%1:<>1KB8]T]:\`U@V MBCL4#(R8U`JVVCZTU7S.]`.V6\\55$X(U M?]KVOP92G%6RHTK/$GQ0:\95FP_LR^$S_W78ZMF8G9YE2R8LIV.\G['#"4#2 ML.8<.:LW^XB:L9R!#C8]P&-9\"<1>ZZ40%3'GJ=+--(M"\4I?1+^P\2B*TM! M$XM&^D$*@UJK1`P3DT;*HMPR&G`(QUEW.LTZ?=JD9DUG?59MTJ,SX3!G4^LU M?A)G4?LO,Z71:S5UJ%J?GL,7:K>"C:#GIWZJ[,_(5EMIR<=/XQ#IJ-"G.S3: M+A"NUV6-\%($Q#[AO''I MEY[J/"FN)%1WWHW0&BL[$LFI2!`BNQH;D7F%^@K$2#S'B[$W##NQMI.,+-6S MIXYQ2.ATG7%\7SUI64]2[4A57Y'N:#&L#S_HPG#[]L-^`Q=_+%$X9,E)?_-, MFR]R;3YYA&J\X\"X'R&W"=,'HT8\+TRP;]^T/'KSJON6.2%)96"M]-0L>P%7 MV"7NANS%6F;D0[YSO>P[U!_(G=MY8P0]/L`Y9,A5P<6M:FLU3+GL.I!`K`A1 MU;_QN#Y\..+$^$&^!QBH3.!TW&_:/>!&OD,5#YQZ`^OM8&$&28L9S*U@;@0; MEB\NOL2J\B78P7J'NO#@R)K;MB#A6,L!MWN58*'AFI?AP(?!<5:(^U0XTE<9 MSSY6;X1LM#U;UQF=$R?Z+#E3H[8T;J.V[>=TDOSOM-?/[60YIG48\:JKU_*& MZ=*RU#0*5/2\6$[:'U#116/9V91N.6970/,;';,E?_WEUV]E&\Z_C-B&TZV? MC&[=N/N'=F^2"$C7=8M6EX-_,GZHGDV1:R^U"BA\([4J':K631&0=NBQ=*8= MOI'"]MV(_4+[-8#3K?\\&IYV;Y[T0X3,0VJ77L/F;R7<0%J$#;%O_%8%`NS[ M5EN[0G?P,;A\"_VRA7$68O?=-]B\"_W*D;=K-=@L*1^#R<=HD!JAMN4Q@['H@(PC#YX##ZZNA454'BOHDI'^[=G M([`:9=WBA1O/E`1JT]S-_23XB-$P-[:_H5TNX7J+8=OKG="OO/^T:BUK@0W$ ME-M0:U)>3#S+JSZSQ]3.=1!B-3U:$5C>L4E$8JVMA51MQ\U1]<\18C0*+;4, M>0ZD8>00XG+D+Y=4<.2G)8A`Y$?VK? MS@A_S(G(IX#X@L#Y&C:2:I!?881NZK?!3T&ZI-OYQ\"X!8T" M&.JMKHJ6TRTIQO$Z`N5(YJ*PL2`;T(:S&CNFAP3?5K\&Z>:!;H7>23;!_BFZ M#M,@/5Y%/#?(U-XYHX>N'VG/C\:1K3*8I!&1P\EO$@"/ZNRY`XSJX]GBGGKW M+]?K8$75=T.M(G\"!*5$3]?>2)>5?P>UV2;\,U"5=8C>GGV&3I>+J'8VFL"@ M_GH++:J-,&J&HKN_:D$!5/J7:6[=LZ-KNY&JG(W:^.4@&N;\&Q\N,P= MY$'\B[<]M#8Z&,?R=*[C;#VY;@Z/H-V*7@1RVK*0YXSPJ8F8^]/P MZ.SY*SCPRO_*[VW2#:TZ>#!E,(&$:@J/KFL19^/4%6N>)\EA)ZFZ_KBG*T;7 M%;\[H*'_X*5M1]]A+9SY0L[._;/@\0A:LU2-I#(_[_(B5T#R)1"^AO/V%GMP MNN#",:#;3\!CM!7L<=Q(XU5\$@KSEXA?L&Z#]*A0F0Y]U@9>$@J/9`ZI>P-FZFQJ>CJ`1RS;CS`Z(YD MS]6=G7?9]VN,H&#EDDAE340LBJ1L53@OEG!_D_IUD[QC*KJ.GK^K.HA"&<=_ M[;26C\&JPH'^X'_*\SLO/BWVE: M_H9$?"#[(.LHWGEA=3"RMRKCJ,P1Z]6WS_OIG`;>"2]%T>E-_/'*2RFB`X+U M@C^],X/]-X,[1LBU5H\1C;X<8@CA2_[O<\3H_PF+QU3U!IG_#5@;BK_')17U442KFIXIB!GX8@82[[4<:],>8 M\]YK9W$B&5)=NIY.!EG#U">5FR!D!]#`VY8KM"D2I02'\N+5]#3"P/G(BCA@ MJQ35\76T+I(*=O)J44QE)VL:\R?VCR(VPG;[9>HR*QK8`7;_;A>D`B63QLL\0K\*J$$- M([63:8,6]'!K17]SOQ7`HMY/#1Q%>2-8PM&8/,>MWGV0LXE-'?LYQ??;Y&G<4+SU8G.1MMT MAG?L.Z>W!5_&R=T=9_'0QV1D[`"\S*VLM^4>MU@SJ2R:B%6C\//.Y7OFMQ+E MQ2Y8Y:9S4A,6$1=<*P?.0\T?R3Y%_.8@OZ@V"O:,,S%,0=]Q>#A6)FKQU/XI M$M=K3'5CJ'$W)2M+-9FQ(HV$P\QSC=:']!"K%"=`V&[2W=7R7LRK>P))9=P^ MVUTR057^;QM+]W"7MU,IGJ[`XRBS]M;^]U[*YF'8@UBLQR%71X4"-!2II*N1 MBBT&DG(DNJ066U)H20JZE)3>GP59_H=>?+I#G@KXJ0,.\]4J/E#_(3IZVS2@ MR>4ACKGZ"?T[QAGY#]/PI1DNJ/"D(:6GVS$#(P4\TO%0.?2AF^B>*?P_SXG1>XM+*H=HAANV_;\:#9 M:BP')S5XPA"0"H8\BH3'*@]'^*I&^)H1?J@0'HU$>(^6W]-2CLSBNPB]05=Q M&ZP#**Z$(4P8LMO`>Q:ES8PB-JUP(`&7=@J:6RT?18IA\!$.L[6+Y^8D+BG8 MCD:!?43"FOW%XI&$`#02H#[!MP'UEL4;2I,'NJ+!*_5_#IG@%VE)5BZ##@VH M@Z"EKY'TR0:3?#01P\M4.CRVWY*F)&%RG-'T?"277I*PU3]ZVSU-&8'_P]OM M_XVY/XA,O/U'*P@\B(\&FS'H)B:FMEJ#H[%94%(K&+$9& MN@L%B+WNI$N9Q5)`\,L*"4,$T+1U@0<@*5M\(EKL%#ZPJM0/@%4?F"(DIMY, MI-16OP-^\B=2^5O?B^.%M^7E.AXWE*;OXNBP#\*7)]ZMR39EQPPG=":-(>6M M!;8$W(Q;WPR4"%B2`Y/?!#B^=R4VG]LH>\$(X=2;^HJN@Y#Z%S1D/Z3W;%D7 M1_Z_<^8II9=>2E^B.*")S5M`*Y10T6@[NAN=-B0TR<`)AYP1`4M*8&RO"!V^ MM3;6:X-OZGW=L@ZWIX,:1-!J64=CXU:/_:ME@V)]U-?Y^8PTKAI+[^/"]<<5 M.UV*M($K&@>OS-=[I1;O[;3P(`<%/46G^TF.SO*=RO&8WMPY$213;/QB/!)7 MVF"[J?UH'?#T_D:GL&@5`XBP:)6,P=XRD`]PC=NUK>QX`'8VR^/#3-6_IUYR MB*F_#!\HOWEF/O:%EP3)SV'TS(LSX/*?LS8QR#$KKEEODTBY2V/K]H M+\XPRMQ@A3/&X:3N;%B9B>13\=*:Q61$S#8CU?F(F)#49R2_\3F)F!2/WSWF MYM27_AACXC,6[4MONSILQ8\/T79[$\4\P=,Y9C/>@J!MVA0\GT8CS$AE`>0W MO@22K0''*W9(EC\>=CLO/O*RQ:L-3X86!3_7C3;,/&W:"X^?)>26OC(^?4O6 M18V8;;E<=#[-9*K#+OXWVFK`5'-&!C^?_1JDF\;JD_KRDSJQQ9V^5:GBD28' M][L&YJ5.S5:F(A_87"WJ-#G1I[S'W:D2+N9$5`)X*G96CG;CI0G)QP2/J1>G M*)EP05^",)0[0EQLC,2!Z]#'27\[U?`'CC'TLMF)8]"9^Z=Z-4VORO*^\X+P M-DJ21;C:'GS>A.;:B_G>3IPJ2`T\,VQ"VILW3PE?(,E7")_"C^T#Y7RL!TU\SL?R$I%X*0DY'X.Q M^&A_._II,)+L1;7^@+)=2_T MQ^FX4(9=7F_3VS9?/M<#Y6&U\.4I>J`)3?,45"N?WPD_J&?OQA&5")_:E$)Z M('O#TD-Q=)]/ M7)#W5H5S_[\.B2S\^Q3-?=E[TMO>>P$[]%QZ^X`=)IG6WGI)$JR/LDQP*NKH M[+)&)^R0)/.+ENNR[?I\%QW"]"FR>^0ZW6)`SA83\KI1=Z*1"^'X$3WY!62ZE=ZC;`KJBY+_)4=7 MV2L?L0P$9P9`9N+PRZ=6EVH7?+*5]#8Q[[WX]Z?HO6A];.5&UP%!_>,3&DXW M)_\#UWMR`!Y?UF#9;]+HS6Z<9;O[G1WK+O<^^;"A3#_R8Z5,%N*D<'6:==KV M4I&_0D,_3V59!\F*Z>0C]6)DSF6;G'1[C36H<\G_J, MV59=YF=9\?195MZ0Y&LEG^>K;31^Z?W%S!^Z8_]L1?,S$AU2KESSS,##GGFL M0K=HEVXOR/N\BG6W"W&1N_QTMA&7:EYV+*BX-"H1"6AW2Y%MK@6^?, M^F$7@2:;?F#>#FY*BPEG1*7?41QNIF:LWM@QS(P(46R--Y%+:)IN)>/92'Y; MB2?_9A)IMTN&'W0%8%IS$?)Z^T+=7X>I.(L^;;PTS].G=S05#]'%8*;RA1UH MT"IHHO$ZN6L-E>@-ZQA+`#^LC,)7G=ZL3#@C^92\G5):/"2BA*'):BG(6TXV ML3Q;M#U(JNC2&8?$Y?Y.PF!C_9DK3-[=@B/'Y[Z.)^AF3ND(\X^2RMBGZZX1 M/AR9T%J*#9/Y<#?8'8=4-!Z1[0:VR#/6((.KNE$YE\Y#_R?JO]`B$8OI$E.O MPP(A7(4OZ7(OB MCO=QL*)Y4,3*>'2A@NV-U$5GHVQ7`<"3+00($3!%N!J/I>A#''/\LEJF@KA@ M+.)Z]$\:GCID%Y!F0FC064F/9_*6S@?F^_YQX,V>7KDI5I1I;6^6W0H+UN"] MG9)F58=\&!'C("NL6G#5P"*U`D+O)S:?HCJJO@NO"@UTM%I-7^=&XV,!BYZZ M\=LB:*G"@6`+*HN;&DE@!0$6Y5:ER7#C`18SM>6R@[(KH8&WFUOA1@429-I. M6<*Q:53'*G3:YT)L<&JPJ6V'VI3M&"#J4=]Y.Y6KT*H_ZC!0BOEDY:V%I?G? ML54[;^.X5N'6`*#VAWN1\BHTM%9M4*/9-9A+D#>_B''=\0IH_PN6*'ZF7LQ? MOQ8=CRQJC>O`8:HLZ.AI7"64@\N.9&#F][R(<2@+T)L:+$_H.V5&\[Y=#3NY M[TU%"XU[AI+&,?5%0,W1`]>A@K88>CH;_JL83>:D&)_%QD>3)&WF]AB478JL MB#3@>22F5(+;3(/=:N:S:_#TMJ9W49QNDM2++X(HI:N-:,!TNUU96-0N%"!6 MM9.NT[U6`)`,0C;E(@P&D7T=BJP9N;V]Q&1J!R4,B=4UDRVUY>V`'T[VTUN: MII4&HG8FU0P7Z%5S-Z7*[942"6+@H<+>6!I^S>XKRRY$_>ML)!L:6QB8VGB8 M:A6U%3>>X/*_`GE;PZX5J)!`P[68<6>X>/;]U:`.C4(DGF)/NC.&F&'7B`%&=W91U;:P$15+PR)3A MT,2&VU"MG;L0]!<4?OCEU0^I?W7@#TSEDU'Y'$#\^B:*184PZM\S%^8X]U]Y MZ,JN:&&/64#]W#[<:6Q6$5V14$1BRZL#R%SV[$\,(\E0$H&3Y$A1W`8/SI=: MM_E`\F#->!!G/-@+'G@2`:*P*O&A2`DVX`>1`AA?I0\_+/1G M7CMP<@5J>90G.&I\[?H$RX._"#J]"<<@^B^(R=R^F"'M37=.*'0BG4=*7HYU`B*M_Z M5'$AN-,7<"9-<@<27?MT>U! M.N`>7AL*?]5%)38MB#-N$*?1G1,FRE">M&!4HG5$;"16V(@]`H=Q<"[47&99 M.QNO"AQ0G+N\05?$(Y^;PW)VOI;'H@36=%'0$=@;)O2 M"L*32G!>QJ@@PS/+F([(D9V.8ZJ@@"]W)3_ARY:_G(\5I2^,`/]K2Y6]O&B4 M*-.11Q).N8[,1QY9K3J'8GLO8-Q;KR'MC7$XI_?4F`*\_?EH?WEV?L8%D)U. M-@7!46`R!I47:"AS^;UAT^5 M:,Z`\931R94^*1(Y.I+C0W\VL&:'ZH8OD:!,=XQ$^:#@6)TO?\$T8BN%ZK]5&$SVP%<%X[("%,E>'89#@:TVV0W M(%6$P\GS,+D,4*HOZZI[_9'&J\"RZJCC#!A=PDZN]-*#&3J2XT/O$EJS0Z4- M:0;"54+>WQIA,L-0;%`I1A4KSL,'-%,9?<.N*O33G(V[]:!E$`)2_5G&+0;1 M>HV#,+32&XT)-KH.K]=G2W7[4P!4BFTH">T5!-2J,]_9F_WGV$LK^ M\/\!4$L#!!0````(``=ZJ42%5.T0MTX``-RO!0`5`!P`8FAR="TR,#$T,#,S M,5]P&UL550)``-^*6U3?BEM4W5X"P`!!"4.```$.0$``.U]:W/;QI+V M][?J_0^I[.?$$24[\:D]NT5)E`_WR*26I./-)Q0$#DEL0$#!19;.K]\97$B0 MG"LP8,_`JDHYLCP]F*>[Y];3EW__SY=M\,,SBA,_"O_^X\7/O_SX`PJ]:.F' MZ[__^&5Q]]-O/_[PG__Q___?OP=^^.>CFZ`?,$&8_/W'39H^_>W=NV_?OOW\ M\A@'/T?Q^MW@EU\NWU4-?RQ:_NTE\0]:?[NLVEZ\^Y_/]W-O@[;N3WZ8I&[H M[:E(-S2ZBX\?/[[+_Q4W3?R_)3G]?>2Y:0Y!.*X?F"W(WWZJFOU$?O73Q>"G MRXN?7Y+ECX0'<12@&5K]D'_^;^GK$_K[CXF_?0K(L//?;6*T^ON/CYLXQ?07 M5[]<%M3_=AMYV1:%Z3!Q%VW>DS3MN-^_:#?$F"I,H\)=NBI;7;D"$,=\@E"8*XV/WT=7@'MP8\V.# M4M]S`QTC/>Q0X[#G*?Z3""^9KJ9/*,Z%UI2YC,XT#C>IOA"MDC3R_MQ$P1(O M$TNT\CT_;3AL0:=MAS^=S*?WX]OA8G0[7^`_/X\FB_GT[F8X_\?=_?3K7&74 MPKY:#G;NKT,?PW;Q;/:\*,/3.5P_8$9Y/E+1"GX_+0?Y*<*=80%Z*`X_NVF* M9:4P-!IURP$]Q!'6]O25+(!_9?X3T26%$5')6PX)JJ+,K.+ED.[1;'_C%?U9W3ONX]^X*=JRP*=OK6& M[=?L0C.4-.J$6,=PID\YO_&,_NK&6`!*YQ56#ZWWT>W63_/M&?>*5T"R)N-C MM9H(>;VT'."=Z\>_NT&&/B,WR6+5Q8%*WE:8V6."_LIP3Z-GI"C%8]*V0QE_ MFHSOQC?#R6)X\&G@9CR:-]FBI?IKNS/.I@^CV>*/X>1V]-]? MQ@_DO+(@BZ3*2#F=M-TE;VYF7T:WH_]Y&$WFH[GRR.CT;;>@Z0(+8/C'\/I^ MI#PB"G%;O5M,;_XY?5B,\=D32^#K<#;#*J/.*WX_'2P=RB/D=-+EW+U%J>L' MVJ9NU5W;0_84]XGO&S>CV>3S<+$8S1H,E--)!PN+^OAXO>A=6M3'QNA`[[V@ M['6!7M),R5+![Z?S.T.#.2/=I\;E6WV8-&K]`U*7-Z>3MM>=T3TQ9SP,\3Q< MX"UA/KS)]PAUWHEZTG;Y"?:7EZ7R*+G=:+P*H5S3U:AOHI9;I$^47;[Q9?"OOW:7ZI\IKIE1W^B[U^!M> M_3K>>-SR?79P:E=?#GB]:!C@,^EZN^^Z,5LE.M-FK4"YR:'!XL_H06E@M*?, M((Z++X1H34R3Y"'S(WG(O/B0#[W\];W[B!@\K;^*?CSHJR!Z]Q\_G&.$#WC[ MCI:CL-E0CZC/.F9\`H[3%J.NT9]IW(LH=8-&(ZY1GFFL$]2,MSNZ<_&4'.N: M\71/J7&LZ>DXE1FYYR!>I9YBE."E*W][OL?#.!@@7F=1N$3+:HBD@Y8.#KD; M2N0=?"8@CA]1+%JOR6\<7N?#1WQ/=;VTZB@@.//N'6E:YYWRV1C]E]<4E^(``N?_KEHG1`^3?\*Z?X]`RMR:T:'W$F[A911LQJ MZER4`ZQ+;A@?#M:-O:I+_..)V`Y=9LH6[YYRKXF?O(T?["2^BJ-M`PZ68XG$ M4*(8WYS^_B.FR1(\R/+\%YQ'"#<82NP&8ZSC+_]$KUPI'+5U!A:+@8*EE,/% MN04QQ#B6!,M=X*X9`CAHXUQ:R?@3#"7#!^=F^$T6$YAW?N*YP1]X\<;'JUN\ M83%XSVKN7%DI!AZ<4B*7YY9(A6:!NV5(H=[$>6\EYX\AE-R^@N+V[F[!47YJ M6^>#U?P_P5(*XCV4(/9S\0[_)A&(XJBU\ZO5PJ"@*<7Q`5888^J='Z#X!D_7=13S#ZD'+9V/5@J"@:04P6]`-X5HNXW"W$0] MWV#TR31+2;`#B;'@7QLXA,[%+Q9+2(BLE-A'AL3>'9L>CAFAR1S!CF=HI#/,]ND#LAIS=N'+_B)3I_ M`^2(5HH>RA@C%"%=XM*8>J$!92A1,D,>PE@?`S1!:1:[T9E`VIH1R/A\ZVG=HDMX<8/;E^Y12*UZ5IND'Q M`6LXXI2@AK)4-92R)"*VF=8FX1<`)NEE$0HU`(:NEY8+:[=\,\I'L(R=E?DSK*:PH8A/2.!?`-B@EPS',APRUC$I6F=`;212RQ&UA%; M!EHO;%^-GC$XDVI@C@VLZ>P7H.N'N>2A&FN.-G3/9:$(2"Q#E4S@#82M9(W")`_=C;A\NE7XS[P?67X_#&??)3`H)M]:93 M.`-@,UDC(?/`]&,)/PEI(@F>O-A_*C/*RTQH"J$S`#:NM9W3+$Q]L7X_HR#* M'=GFJ;M&HS!%\5/L)^BVJ&DR]+QLF^4VI=LLQFO:,07W3-^V.*#ZN/O049Z[]<8PY/XWRHR_RZ\8#B_(@B?,N3L,Y3I),6?`%$70@LWZA[W'UXVY. MP]C$OGJ:JP38OJY?]$?@^G%+KYDC&FS_$M30,='M]$`2(+0[6T=V.JEMGT,% M'2FM3?8T8/WP@SL!*=SM&1300=2:9;T'!>W2UI&O0 M%P["E,*HBG[VG"IX<&@W%@G+"8,"PE@R=P.4S$A)D@SQLQ(S6/YR'4`;(EHH@CS`?JSZ^]1)X^V3Z\=$[6_P!6V->)YB'"IH MPT0+V0M0]<,"?8OP:/'=/1<+5N]MA*^Q_RK*FK$%SJ&"MDNT$+@`53_,S#O^ M5'R1.L^,(MI`5/&*-PHB4U-'+^6-3",&3Q,G)D+4G"Z'U MX@;^R?7#A"QD*)F&HQ<"+O.33?'`0B)3>293$2UX'KDV&B"'KA\7ULIF0Y1#2%("KF#5 MF$2>X-]PW^[H)."YZ=H(G@NJ'S?RW.QPRB.1^>64`CPW71M!\S#UX[17J:[8 MRGK4$CP?7;L)?(JE]2W:7-C`4]>UD3$?E2Z/+LA+^M[N<(Y]>Z[1*HI1T6[AOJ`$GUQCM\CM%[^.\?4WKTV`*3&8(&>4Q([>V5?! M\^,I&P:Z9D8?3(,[[.7\NT8AXGO?,"C`\^TU5`\ZD'[XE.)+CI3%]Z`=>'H] M=0/@R?!U^89"SLR1&X=XQ4FJ,(9K-_$]CA"I[<%SZ"D+DPU#6ZI$P$OZ,;I; M/\A2KC<_@P(\)5YKP=:!L$MFVR/:K\A?;S"@(5[SW36:9-M'%$]7)[[KHGFL MU`]XECQE-5"'M[/;]E`[RDF@$O&AV!-X'CU=&L(%6.E(>T?J8QV!B`5)*F9% MJZ2616199!`"3*W1,,>G!#U(O$@UL`7)N"V#(&\('2TBS4_Z]#H%H^EU-(!* M,E7B*1AP$VV?HI`\\0Q??-ZEATL''5=R*B2!,%D@[);M$:K;:.OZ/*=#:GOH M$!*AC!CG9186NT5ZF+CA,R*;.T>BM.;0@2),R=`%R8+0"Z>46I2N4)8G;:'# M/Q0%21U_/[Q*&#ENA2+ETD$'=2B*5X@%.GZ#71-KEY]VACSD/Y,S`U-T0AKH M>`Q)L4GAZ(>_1SUG;'$'I*>.%4]7I8Z@XS14YZ\R.&@O$<:$KF>^J.DW?T9S MB:"#,E2FM!!(/_+Z[&X%]WZ(\I=FF;OJKC%X1(;R#?5PZ+J.36!&AW:9K:&# M+!A288F0.GY-]YER)FG8!V=@T=.2"F`9KRF M7H7H``NM[TI=%'L'BZK0K`+R^M6$0<#&L0:K41T1(QI+N0_P0`P]:PL5%O35 MO,D2TE+&]$[`@C":R4UUWE/AFCF]"012SV*ZJEU"63*F-@8/O)"?L.SQZS*+ M-/.W49%-H6%*$BI(P((G!*R7E5,-A::II%58#W'D(;3,_>Y'+RCV_`2/_ZL; MQR[>YUGRXE.!QQ_(3RT)(-IB!W3/L=I`Q^'AF>V_(C],?\<,R&(T7,CZ!D8%&# MU6$.ZW,;0QE'R`GZEO\+W[HM00\>R:!N,I6"I"NJH;LWJ`+&EQ"/\R%+A0N_ MF!(\=D%^F9<$HRM^X>Q"Y!^@9>G!HA!49-1(NC5\9EY9>0M-_>80XN^F_F.` MFIJFF)V!!QCHL5'Q\6F+03%WIRY^?1?%5?KJACOV23_.P)0J0VUW;CHT;;$G M1NI&O=I.*^5@=.0,P"UFJ@)74AP>;#.WE$-_Y6+DXU#6]"U'[0Q,J4TD8\EW MQ)86O3:?=B[[9@ALS8U*:2W/<]ED/KT?WPX7H]OY`O_Y>319S*=W-\/Y/^[NIU_G@(DD;MQDR_"JQMF\`-.#*M-AC)GJ;Z4=SBX,)#3?NCY`3K`NH@D^2JQR'3Q M.>A,&UTK7E<\ZT<.@7IM-/QS@'+I-RH8QR*'SOS1E0+0U4V6([U8_G*.)7C@ M=U%\&V6/Z2H+JL`0CM;PR*#3BYQ76T2'=+/,^A"((WT[C`6:1*E M2)3:H&E_X(ELC-$K`8_Z$>ESR(([/W0QN\M2Z](7KT,R\/PYD): MH3RQWH.+%\:Z<->.`+8SWB'.OP?X_(C0E.8;"B8C?@ M^7C.N!8U80UX*(RIB0V@ZRR?46\:\\?4Z(G"Q:]FUZ0?^6=+H>JH]P2>3^B, MBM.0.^".^^W49A]9HDM]*#V"UXHV3XU87`)WJ9>-Y3\&=)1%D?@)>%Z<-V3: MG#7U#)Z:Z8SJI8E;VKS_NU>SVL&/$_VK0`V>Y@E675@T$O!8XH'%2S)B=(Z/=KR1YP.+U<[S*X\./-F7FBAEU>$88=N`'".<5D]ACL-G1*Z0OJ("U.C`\WYU MHP#'"%O'VABJ`?B4_N3ZI+QFCF'T0O928N+,4UH7#%12#9D.P;*)=:LSTM!; MA^`8JDPYSB-.JIU.*!V`9R;K1EF84/L15L-AVKWO/OJ!;%2[6D?@&<6,.<>R MF%.M/99GQ3M%+C;`2-.")R)K(%=9!:%![46X.14J>:6M<4Q5*8[(P9.:=:L7 M-+3]B#$_A5L=TF8(G_.Y23"%M.#YT3K4"AI4Z$JQ)N3\XNA+NXZ=2V`S[AE2 M/;5EC[8,!E'J!F:I'S$[)%VFG%/\@'-I2J4''3GGFH#OQP:(3WM5XF+OK\R/ M4?5D_Q"X83H,E\3'\HGQX*W>B7,);!76J`!T#5/D12_LQ^V8VME:Y5P"6Z`[ M5S8-_.G',L9@Q"[HMJM=4_$#SJ4IA6UU[)I-P$/?$1@N/+F?).YS&;LKIFO7 M02/G"MCZK%$H%*^;4ZR]V*GJ)4)D2\!+TSI7P#;FSE1"C07]V%+J6&?H*8N] MC4MJ>PMK'O`)G2LS4S9WHR0,_-"[0!<:LD_G($@.QR-SKLS,J]R5=E#0MW[F M[,A+O+C735UY@0H9.ZR=1-*V>?J6NDFP7?S&M:^&3/.\=)`N\,M,\V.[$\2N>$J+:WU+TSGM3JOQJ M4`@:MM9FK8.RL7BT<=IO?3"E5'`7^G"ES\X%7A`Z>WHJTG"X0<6H<;B*XFTA M,8D:OG(]..^!#:3--$(%';0A3)>+?)'+CA1KX7K#[YLY[Z&=0Q6D1)?S"9R^ MA,)$6[1P7\C56R#.@Y;.>V!CI@Z)GB+JAZ="Q8])%'KXQ[WW7[BD7'Y(Y;\@ M2DA.9O%BWK9KYSVPC;/YOM\:-K3!6S[)7CWWEDP)(84NG/?`1DTMHJ2\?ZCR M`'C_:*8,DKG+U'IQ/@!;.(%4@L8&Z`VHF5JP:M9OE2':ICG`S_N8Z^Y'P`MET":5E35FFS@>I4 M0'%.49EU2JT7YP.PC;,KQ6G`!EWF4.VE[+S`31)_Y7NY<"I'A'+H)!&+O.]7 MH\Z<#\"&SZZ4I#DW=)E*3Q:0=W46W^,1'[.=_.Z`[^@E)=7U=NP[X?RC'VT0 M1N"'WL]>M"T^//?788X[3,LS'>;A0Q3X'LDD3K_K0.>;XHJ8;O;HG"'=78+/-?<_17D)5[R8Q>%G-R5KD/R,9^Q2E#XY M&4%B!Q/20FQD MS$'MCU4R^Y)*-]#;C)0F\2? M$)WLY'O0@$$%O4 MX4ADMB`&!?06PV8I?7?AP+!_,M3MF8O8#1/7*R(VSAYQ1A^'Q!01D4),%M:8 MU":00B_0DTI&"/3II0C2_BEWBV+_&7?XC.JINL^^FE>#J!4:QP?G?Z#ENKEC M78M>8;8TY>'*[7O-NX6>QRTER-I!VS'$_CF?OSEOH@#C2,I46V?6]>*K$G/X ML"'$M#QE%CFRJ\U!Z3Z@)]PIN^ES2`E03R9,F7RCGL+DW#O$CK]Y0L!=Y>>U.1]);AXKRX4^;=5!VS]+ M[UP_SJ.&/R.7P(-X=]^-8<]EF8V81P8Q^6CCD9EK7#KHJ25B,GTF"2'9/W'F MV6."_LIPKR-2@/?L>]KQ]Z4BX>DD(#?%H[%(W0Q9--"3A,=8QIV0!Z4'DV/\ M:3*^&]\,)XOASBS]EII!@-9&_%"CH\%9MMSP\W`T*D]PN M3])(J*X#LETXP"%E331!!5L_"C^,W#C$+"*9XG*SDKP>""@=X&"Q)N*7@`1= MTD'?,D"S+*JM`A(].,"9L9HN`I+0H&-%=6E#Z&%>%ME#9W[RYPT>MY^2G[@: MP*1R@'-F-9,Z%PYT\0==1[\$7[@\D@CP%A]Z@B@/4BB=^`O]YA[^A-0.<&ZM M9L<_*5C]2(&W,Z]-5V7,M!O4_#.$.B!%[P!GRFJB!=+`#,V%A7(#3$*R7P3%8T22!:D;RFSO3;MR@%-CJ4B\#4;H2@\,X=-\K2H_0XFKG7(? MS@5PWBME>2NC:UW#P8CE?H*^U5@51R'^T4.U%4W^Q*_:E7-AH2FP$X/L^G#:+;X8SBY'?WWE_'#Y]%DLQ=ATSU[TQK> MW,R^C&Y'__,PFLQ'0Z;FW0/;/KLET,9H_#/\87M^/8*:6Q0&>>V4A8VHPA4[)H">-:JBG"(O],V2^F-[\ M<_JP&$\GY?N^L@/XB&*>*G7!E.T:>?@$[DC M'WL]G.F%+XB0%>2WR3!+-U'L_PLMO^#%)Z[QAYS*'9->-G5U#>WVHEOE=/(%VF6&I5!43$." M9IW;_JY?3T*NAM_<>!>@.,W2A"34*7(1E[,J1R^G=6?Z/K1+3C>J>4;F=>C\ M`QFT`W,/Z%OH3LW*4O)V.<6J[65QC%4K]S'^$D:/"8J?";_'X5.6$I?3T,-4 MN8B5(GXT?@[ZG-\R4$@S)WIPW>>%4-RBU/6#MP@*#6YR"T8!#CX!]&S3XARW M0Z)IM@2&>#Y>OUZCT-MLW?C/X8O/*V$O(H6^>K)%)BEB"IZ^";O"=QMM73]4 M$O8A*?2E3T9XLF(_16:WV*L\P7C+1WY^`OB,MH\H%N\[)R30%R@98='%S$-D M9CG'N8OO)&5DUJ2B8H9]NDR.!@_]"*3I5D&>$!;X*X*3QT$[<)=XU=/%Z>AU20_H!"%\ M+4I8ST5[5H1+\GP^<;=(>`;IXG/.!72*C1.E8#@I=`7>;GO$:/L41*\(U=PQ MA`8))HUS`6QYZDS(=)WB,\)NQ:`8\20V&`Z5.^':)RBK=+RO2-R+H#-5:U7[T,HNG+EZ#)2S?UUZ*]\CX0>4DM]9VX@K'"H MT(=S`6S;$LB']M2@"J^?\_@!Q>07[AI=J,SD&IES`61):R9&R?E]#-!,\^ET2+PQ8&B3JR8C4>V%=8*X:;$/ M6SH#T**P>J8Y#1.TS;;)U"XA-)K/):TS`#*UG6<2UU'V(Z]E+7_;G.Q+(XPT M?HK]!-TBS$F?,#+;9OD+QFU&W(./*3B3O7WGS@#(6J=S?=#$AGZDSOR*_/4& M`QWB86!DU72[]8,,_[8(PZL%F'"T2[$G9P!DV].I2DTP]R,19^.HI3(LN<:5 M@FMM'J%4O^4,@,R.6H\YG7"E'TE"V_+F=Y2064VBZ9Z0AW]<1.17M=BZSI56 M=@C.`,BH:I(N*S'+T/RGU>9QEP7!PM^BZJ609GSE$S@#(,.K]E,_'9JA.4RK M01//(B4!GA`X`R!+JW8!TJ'U(S4I-^TVUZ^70^<,>F!H%2/4EG$47]U@8E0_ M3<>33S?3R$B:H+2H(70?)Z3G[I!:7!E M[1W4QE`QK(UERH?2X+W88S^[ MF)$ABE_K0#_%^*#!40`V$71^#UG9T27/Q]4+>=]E<>BG)`-TN+SS7\A/B4C< M3!KH!!_MI,V%!7W2T>2T5YP,2+)38@//\-%B'JW2;YB[(J&+2*&S?K23O0PZ M:/<>/2IPC]P$D>OA>/N$#_Y%])%(^&PBZ/0@[<3.Q]4/;Q\FAT1"YQ-"IP!I M)W@Q-EV>-VF$UQ6H\.N:CQ'"P_:*1([XYP#EX@J7PVV$+UK_RG_/9`I'271] M`CKK2#MUTLF%UJX['PO%"]&:C,>T58?O*LPC@\YZTM&*4R+3Y1-SLMX`E>^" MLLWTH7Y7%3=0#JL:U4&-JILLCN5,3@UZ`[?6-*GHU1!G+Z[Q)=)9].H&-9Q\ MK:!10!ML&@J1J1$LC'V2.MY:5BA)<@!W2$'X#$)H,TX7.L"!V@_3SI@$&*`D M+9DFU@$Z`;091ZOLV1#[889^"9%3VT-;<+1*G(FP'[:J*C(*[9Y?Z M73BZ)N4]NW00^<9''<]E"W7(5=03A^L+H4DLA.% M>!#$?%K\E))``8PSR].5Y"DHQDF"F<'+_:;6$=255%*T#/N3,D301;=+TS/> MC291Z#6T0Q]00[W\MU(%25RZ%G5(!1B]D'"AS$\V1,6G*S(+/N'S!XE/FR#\ MBX7[PM$`&7*H(BNM5$`6F*[7"+`XY3G)\?+X2GQ:TM=;'_/%?\QR":UCE)]> M=84MB[\DS$8KW8,66Y3X<[)9=%4[`@UY5N,RY7#5"&XOSEL/<>0AM$SN,$=) MX&4%//_%[FU+X+DKTP.HI:R1?.G+K`)<,Y/O/J#8CTBNR:\;W]O<97F^K'%2 M!>:R5@0!&6A;D%$G M4I-6@A3:/U!-LI*`H%V`67,XV:!87GJ,YM#^?(ISD0T"VF^7(:7QHT?NHHGT MUL@D@(YJ5),4%P:T7RU#5G=1%J>;SVYX'WC2\N(205=\5Y.9$`ITL0"&W&[= MT$?!?[E;E.#!NX47C+0`Y:C!"\6KB5(!5%]R[-?8/7Z:J^C0N?M'A$X!7<.=RGW1B%6'KQ.%5'QYF&]69@U=R<(>B$^HLI[9Z0OH5MD)4%+8FPF$3@"@S^7%JR2>BM!R\%JO=ZVS,K"*@=1 MPYI[E%0/!PQ9BHG`JJ4W$J(D'FT.-E!!7Y0'0J"(K[=WPK=W0FM>E=[>"?LF MT;=WPK=W0H,,,G:^$UX'&?*(;WJ9]O;.#]W00]+RDZ6WZT50!96ASX`["/>1 M&P[Q?69)[C22PJ30V/7P)T)BZ(O?!'T3O\]DZ(:^Z:FX1U#=`ZQZ MR6,A,/01;^>84<;4^>2NCP=^FZ%Q^%]NF+GQ*SE#\L6FUHM=SWSJV`Q]]^," MN4./L099GW9CV4M@$W303X)F>JV!/PUV[K96>R\TK1YUQWYK1CTA:G%8N#0YAT(] M\>GU#JT][%V89HC9(907%H?$N;#*#B-"4@G--$/,P;C+84]#%;$=$SD75EEJ MQ%@JT9EFNZ&-'!^2U46W(W(NK#+GB+%4HC/-LD,=.:9H,.]J9,Z%5<8;&325 M`$VSU]#&3GS.U>6WIW(&5EEC),!4TC/-^L(U)%WL[8:#%M:VTVZ<@556ER;H M*H&;9G*1M!.WD3>%(5898AJ`JZ1MFE&&"^6S^WKQH:6LC_IP!E:9;92A57(V MS9##`H*/[WHF-K,C9V"5X:<9OIWK@"5B+Z!D(;IXWW8M/^K$&5AE/%+'5HG: M-),2%\D-K'X_=VX11$*U?/\51]G0?>"I>1NH].9=6F;L:`JPD#V;QTA-SM#M9$%X) M"PE16CN7MEB[1"`JB;:V:FFM"51D01'/T^-VSJ55MBGJ\"N)M+8_007T8:;G M66N*S-"DUE44XK\FHE!-'IUS"6V":A:S*<0$EN5%4UV00US"V$UJ>^<2VN`D M%!-=O&PT=L?D?G5)43KQSGC0SKD$MB*QI4&7WNGH>Y$`IEV-Q$M@$Y&J$.D( MS"FYA$]=/Z^CYW=+Y!*$#N)#0N0(R++25 MVR$"0V/Z5<(LJ!$)5T"6`5GI,`=M:.2]2O`$-<[@"NB2WT`@AX,V-#2>FN^[ M0=[S"BG0]5U6/**QZPIB!S*Z>/7]>!`5)@0C-9K95S M!>R;<Z2J]\1[:&4)GZ8WW`WVW*66Y+3KMFK#>\BJ#2+YT6>G'*A>R+Y)P97WD"4G/>`QE9&DBW M+4QM=3M:O]3K6KS'(1X+2M*9FZ+1:H6\U']&F"$>$>2:-\.5^G'>`YEZM"WJ M,@`-?8_HH"C/>R!C4-,Y+T9CZ)L$.7@>5A]B">RTI?,>R/K35$H,"(:^3EQ' M<1Q]P_M'1+S9^O'QPX_3U(8O)'I(N(H(GF:X8V5"'X7*XCE%N5&8)5>8]/46[TO2NW6=R/D`9,_2MC6?H(%.+JQ' MSEB9/826N?+OCZ4/L?^,<3X$KL=:.=0Z<#X`&<1:R%\!F:')B:<>7K`P=SQ4 MW#ZFJQEZ#9CFONUCV_[25JLSL7/Q^MR\5MGG/^/:&<)-QF] MX&N@GR"\_GBT/5B.T/E@CY5,`9&I&9'O7#_^W0TRO&\\)3(FI][][=`F;?>?6OG M@STV*A$,\%S)W9B>O1CAX\'0\V*\_E0&5@63,Y7>^6"/U4L=&'C297V:4#RP M)'CTY5,+@5KQ8/\:@Y87`I60[\CYU1X36`N$VG([0[]3<7$/M\1XWTHYRBZ< M7^TT@4EC,S7W\R?7#^^C))F&-;!3DCH_&J/54L!$7A:9UV' M.\S#1[S%+4GL/`J34CHQ<6TDR*]?]TT>"EO0\)L;+W>7ER%>[K8Y=GSG?$(> M5GUR;N*M!MU]U/G5'I/;F;AA:E[J6Y1XL9^/16JA8;5W?K7,-L<%8FHZZ;U_ MQ715O=8OHIL@2HC;#L/<)DGI_&J/O4T%$GB^:$VYFK:/:+DD&>#R5QW_&=4, M5Z?_.$&\BZ-Z9\ZO]ICU6J(T-=ET;?#[02?#<#EROTS07QEFY`P]$6?; M<,UX`6_C*1L(2N`2I\ZL]!D(E3*;FHA8_#^98FC^8 MYN3.K_;8_Y1Q@>>D[L(0?(,9\(K7H\)B(6W_/21S?K/3M,?%`YZ[NA-Q[QWK M#R%/5XL-.DJI)Z\-*KTZO]EI\&L#MR?9L`_9<.=Z2''9V),XO]EC(Y3"8FAZ M[+KE(;^GWD4Q.9(>>NLF-94>AVE4V_](,,[VR0U?I:PT[3[A_&:/+:\3[-HR M>INT3M1=A&L,:^0P7:-W?K/'"J@.;!?.9+8(?7`GX<8;?ULR]$" M(:WSFSU61#50E?0MMR-6WA/DB2),6/&OG-;.;_99`EDP*IF:9NH;+I=^,1`Y M<8F)G-\L,]Z)T53"L]RQ;[C\WZQP&DX6T1[U@^LOQV&9F_4H]OJKGV[VO@YW MB.Q9O&`G79]P?K/'0M@)]DKE6EL2(1V)>`_6M_ZSOT3A@M=U.D8^4'^TG3 M.A_M,32J@:JD;YKO7QTS'FWH^4\!^_5`1.)\M,?V)X5EEP''[DD+%5KRT3Y# M8`.$E9)8;A4\-('>^:&+IT.XOHF2E#A,5?907LBA;!?.1_OLATK8*I4`,RIV M[*0P7NUF1NEK-7KQ4)+DKVUD%25(U;T4)+IU/MICQ-2&MU*G+LR<[^I\O,?# M/^8M^=T!E=UB'6^W:.EC6'?NU@]>B\H8T]6^LM,TWIU$ MIM]"%`OK@C3LT0$R'/"%R_`D:`[1S"JT$WRSV22I&U_[^'SK;<(HB-:O>:'6 M^\`[])D359Q3[4%A3WGI`7^P'15RP0AN!-1VSO`A0A15[`!W5=8A4+VN45VF7%YZ_53`+G`MCX MU40:E+6<#]#,^\L,,QPS:R,I0T9SYP+8/*5)@CQXT-<13<8HI2+-%]#%$C5; M'0^`Z;K'0)D5E:LW7T`;B@[8SQ%1;;QVVPB;502^@+;K',F`+JG3,?>B(&6S M@ML7T$8=.9&=C!FV#*6F]UO,[7RS/DI3D`BV.2Z=-EH[-Y`:VD%A"OR25OG`MAJQ)8*78IT!)HD"+E$ MESFIA"(\:.<,@&TZJN(['7T_[HQ%5H]\Z$()GK1U!L#&'54ITA%`/WKID>1# M-5:Y%976W!D`FWI4YO``[FP,LZ&]WZ(QO@@T<#W;$?J#'IF_)'!J^O) M39>1G87\R(&:;:Z5(G<&T)8A&=E0[;7R^'IAG;C-T"*JH?91+THD.6Q:!MBDK^+XK+8#7.Z-^G+&4`F!FJM%PT!0_O#B9>.1N*7 MH78N(5/^Z%L(1!!+$8/E@V+F''Y,:T5R6;(\:N9<0J;D:2DT&I92.F!)F23* M.LW0,PHSE"RB:S1#'O*?T7*8S*)7-TB9^9ZE.W`N(3/LM)2H&LI2UJ:5>!RM M5L@CM4KJ^:%X:3V9!,XE9,*P%*"0*N'>D;'AHHG7E M7$(FV.GVS,3$6VJ"Y%3PO@Z.FSJ6==C(NGDJLEB=HUUEAZ=).LY<4KDK< M5B='9U>#D19WGK4VSI7-!K-C()54+#>%UK)V/B=VR/K3T2HJ;3>1?*3BM:9[RHU*NUD4UK,60&TOQE0!VNHFXU M_(IS9:>QKBM65)IE=2#*''E9++;;[ELY5W;;\HZA5%+LPCOM7'GF;[$N/[OD MA2'PW4=2DGG MFRC.O:B)PLEGH#\E@TXTWU("C,DH`&QW$/PA)OPU46(+6GMS$LC31<00+`M* MSR0J3%?!H(!.#L^4CZ0XX9/!L_P,\V(R>)4B=@8_Q6>%XB[`3X_'IX).U,[A M/N6D*\9B;D;#M`PT$8B+TA0ZI[J:C!@`H,/?=)DZ=SZ/]3N31!X8#AUT]G5I M^4JC@0ZH@\A+:4QN+I6SS,'P+4_TK)Y\$CHA>YWY'/F<9%^W5$#-,D\"Y\LZ MD@!=3"XF,.W0"\.SG&F[FAV#`$BLS MHSQ^+4XH8+.VYFG@HHI6'UXM-<\^J73C4='7*O]?"RQI?GZ:K%;XP#]?X MQI6D-U%`'H%B0;UE/9\`2[[>1J,E9+L`RTJO0TF4 M0$*G">I>-7Z/\!J:+[(ME..P$[`4]UVK!P4F=.J@[A1DYB=_WL7H(!&$HGK0 MN@#+A-^5:8""S]OMX;"Q66H^AW3\FY;]R8XH:=`=6.$#'>M(8,'0")E;<`+$)7N/YL"2%%!#6 M^$(8NYJ9UZ_[)F6(X_";&R\KD"5V\D90>,`S8P>T?PFL,$'K]:@C7IB:\ZEF MU:FMQ"Q%H;<&*TW06M@B_D0[':UV=7L*P\).439VI/'-`:YZ=,D MQ1`O#XW=PJTC$CKIGS8&]\_G289[U#T"8;D46>E359R)J87$@%WZZ<)B"%8, MI1=>`>UJA@+[_ZL)E#+XMXK.##IPS_]6.RL+D>5^Y'JJ-D.'`XB$Q'"#8&&Q M?:]ML_P"APDP92*[`EL?.%#?@.XEG)JI[:$#"1JMM4PDIODSUTTOA<)*.C,+ M"<$#"I@RH%E3I="8Z<0\R-PH(7S=N77S7QEX1*!Q2>T$Z\84T]D5B"'#:BH8D&**/3M4G#WGNIR<4*U9^@;_D_\2_`,AW` MQB*TT08%?/UP">8"+G:W!,,B3XR[G2[/3):_5#;5%&''L.$'G6F0'.Y^^!(+ M$AGJ5BRY?F$C%CK0*P78T'[(S3*,\H%-PZ8Y187]PD8O-#[4:H'=H;_RV=Q' M%M.;?TX?%N/I9#ZZA-U&2)OD6\5CS MS$ID\DVVZA@ZY:3`6RUAN:NIY*=L]0UH_Y?VXA7ZR[1GD-WVZ`*+..GE03N# MO&C:RX^N(B=X[19SMSHA&,M:4CZ';KWVC[ M%$2O".7GLVD^=N'K)9,&VBNH*Q$S3'0\-O3"HZBQW[[,`VK[SJ%]ELZPV^EA MDN7.,HV94$S*9)JE2>J&2U(W)PJ"NR@F_]B%:G(_".Z(I467-.NID&/?]T)Z MRI[B\?<\REM\"]S-K#/=ZER7]PS4I,9/A=4^=>/44E7^E`?TC6Q<;<:@?"=#:\AHS M=X7\-",Y+=E.SPV54^&UP!TK;5E4YCK9VYOA8:'Z(UL0N;ZGF MPYY^P=-46Z;9=`[J9[JOZ/L$F'/NN;6Q$\;I\H6Q?4&M">$K(OFG$.88BMTU M.DA3=9XC`V\$8-['MBZ^*GS5E=C0`OL:\RF):J_I:D[H&P683[6Q\T(S;_N1 MR;$UURK&@$\-I8&`>89;.SO4V0N=J]*0"5(S24%/$<6A@/G$6SM)FC`8/-WF MVX5#\6#\]M+9&5^UI3*U_?Y=,Y$!30?)$8"5<[!U.JCPM9H.K=]HS;&)UB]; MZ'AWG"'B&XPE<1.%>4Q+Y@:,))<(';&#DHK,Z/0.Y/C`6[H0#+NXAJ@9RE)UAN:&9K= MW?)Z!!TZURUW6GY#P;/,$EMO:&9L3\PAZ/S+,-LO$V%$WU!SCQ`L,!1N(AG"]'X\<)V7HPL=%Y;Z5H#8BY>RM%*W!H--P]XZT4;1]=%]]* MT=JK?U]=P@!V@!FUG9D!9EV5G#V!WF-_@;;/)KAZ/NI%=NI6FE>,WF\>RL3JY:+]SRZS4U_ M:MY;N@4:+^*HKJ.$(1.A10(Y^W-LFO?RW>D$.3]W=?DQIBBV[]13//H4-86[ MK(1+^PY8I*Q-BS^3<=!>ATUOC;1+=E*?QH=8%8\O9Q\#6(CO&948AJG0WGX= M9<0ON`"<$%]I$&"QPL:IN':N]L2SCCB)%.!OLQA#+69XL775/$AVWB/<(X9R M9V!1PA#GB&;1>#,3&\UT@#8W/N:JLP:_=QIA:LUOEQYN1;)L;EFKJTTYFGK7"L[<<9 M>\J&&QA8:X'."UFJK2*L$3.AA=//6TU8VV8(`'NUE8,]\?$R(]S\\BWVY9G<8J6:NO!6#U:]@*J?/UJS\;K7YK1ALAUJE785M*P8[ ME:H?NFME9IQ^:\E03*2GN#6)KUEX!K]&8215H##Z+DO`'N#6%9#6@1!Q$ZDZ MD_MV9@:6=R?(0^2PX5(\4=Y%62PAR7VS[ZS^ZR%P7?%#'MP&NXGE>*![C[$0?2+-,==+U4,VKWUD(ZWXKW`A;O M!39[GBJ%;I=8`7B[[3W-DN"!UT+M2IATW3D%W^/,3PWW[WO`RKS0)C_[#-@B M=II6F9?V>$YB=7:OVZ)\>=(=@,4.GD&JE).U&E_>ECU3J^)"AONIZ=`YUC(* M=]Y4U]1*MY!A><:I+HT[T-5K#=3=M[JAUFBT7"U0^Y/)G7AI-N376R50XZ>& M(8R$?9"R<>J\U?;\#B>1?+U.H"=!@\]7;]4ZK3E?\2MPZ@_DL'63>*N_:=`D M@.2>KA1_<"%.A"WEJ,/EMU(FRR+"*<5]XM/B6YR3L7%.;V4U#8A>^H[*:LZQ M4'.@H[\R/WTE7(C"G(N"D",>G>G!0SJ*E8GPVZT61ZB$7D34]N!1-R(9T47+ MQ&*W2*VL;,F4A8Q/#OS;-"M7%7I*\R%.0Q+@L=A$68(/:XN-'Z<(A7QW7REB MZ"@92;FI`>K'D]?"3\G.-,87I&=_B4_C@IV6VAX\>*;['9:)VW+_WA-<7_UT MDY]HR0UUXS\MHE&8XMDCW'05>X*.TV$*5%+^8G1V;]#3U)S6`F*BLGP=;IRSZ?X\!;]-#^@QH^)W+>#' M&+_D>@&98;C+\;4HC*_"(MY2U.`A-IID1[L/R#.@Q_Z;\@D//^7LJ3+R?XJC MI).5B?TUX,IF\NJB>142<$17&>TH\5/_V5CM[&NU*-!J:)WKM'YFP28G`4ZC MFO_Q.TI2/US/"*,2S#6/J,U:J-.ZOP=B MZ3/`ASLOZ%G`Y+3`]Y?*C=5UGN_6RX,D83^#]K:`+ MG:1]![C4%9@^,GFAJX*RE3M]X4T53.FJ-^Y@K8Q8[9^F@-VPZ47A00C"CT?`4=NUP:&!7]3']@^.%X;,/CLI6ER=C&WL*PW\*PW\*PW\*PJ:)]"\-^"\,V0V1W?NCBS>.8J??8\D%UQ1`">DE$A"_R=Q4*_& MST!'B7.4@:X]NL$;%D.*3\I)%I##\G`=HV*>\:-)V13@T=R:144Q'/#!V[VG MF!Y]"ET+THK@T]_,BSWE7,TEXT_E>X`.;=K"H\*"[SL(%=17!"I&OH&6 MG,-=I!8,_^8M8K^W"%2(/[QVM^=;/W*%&?/0:\6C/F@:`K/G2Q-6?N?ALKZA\TU`*JXQUSH461L)_.XEEM?LBI0)W:"+L8)F[;`[.6[*3NA M8W<[\9JMHN(6$3D%/VXQPI7V'H MK6$S!+06.0>4KDA2V"UWZ'EQAI:SZ-4-4LR6FRPF7,7O8H*110L=E,B;R##UEL;?!RQ)Y&O+Q&',1W$7QEQ"5":FJG!:LZ:W2!VPL M>NM)KPP5.NR1*?8$#S7)W6W=QSP.GBW=DZ:P@=@:A$A'I"LL4+.L[A!*9LA# M_G-9IFOW=,L2&9L"-C2YM>0$P$P-::N\^Q_*M0,?]`@KHC"/`F!)D4\%&]3; M6I(2X+1%D8$5CML9_SXCE_AO$W[=%L$'YXXZV`UE[TTN4PV.1P814[`;S_5K M65AVOD$H_11'V1/60%&X@`PY="2`B.4,)T%)9':[^-RBE1^BY34*\0\IJ5%Y M_4K^'"8)2F_PA6P=Q7@)$KB2*O0"[>\O*U:Z4B@"M5LW*,"$GJ%,&F@'?T7) MT<7/16>8'^?HQ4-)47GR%L7^LTOR<_,=.3DDT,[]7,Y33D,"*'9/S&;A&C0(8)ZHF@_+E9D#LZ&\B2RG(;Y'9W&,#Q'7 M;N(G7\+H,4'Q,SE0C,.G+,7_'.'[7.!7%R*ABW07GX-VR6]W_NJ*(Y8O+!K9 M0][3Q*2O\VM)M_5SK7N8:SV=D+;W":+8C4C3OA2G+( MEN20B3N+M-I-QA_S2QZ3P-2@2CJT>(K M2C3#6I%6[VTL%6[0%6QPP%D4KRE7#%T\A\O_S9+BU781#9=+OQC5@^MCGMRX M3W[J!IAU@9LD_NJU>.-- M_V?1S+.R$CILA:'.G]WXST5$_D3,XV6]#:P[_%G4X@1N/Z(_]!P`:M$`-\7$ M\`EO\]FPB0+,J*0(&RA<>3'W8_PY=(N*_W=PV=8Z/E@7^J[5VSQ6ZXH$@8P+ M;\K-W?ZPRUDSS=+IZAX]H^"R@XG"_1YL(('IBB]F'72,B695'H?/J#P:C<(T M-\$L-FY:V5/0!*7YVV#>&,_O?-*?<#'G%HI7R81ZN#C#5V&#(\ZNUATQL!^Q M./UX/0"-_3!]G1:S3E<(4?%4,`J70,I]N'A'0FJ2B)=%^#['OH*GLDB MNH2)@-P/8Y0/0^(@QB(!J:9T.!9A821*<^B#&8^=]*61A<+N_?88%?Z>J"81 MG0(Z.I$E'CEAUD#T3I["R$,F#73D(4=*TF*%CS+L1+#","AJ>^A81*Y\I$2J M/1`1]@),@L,F[E:TYM:;04>,+NDNWPX[+9%-#1?*?,IMD"N^]J,4>9L\ MQ\%]X/$/>WPJL$`,*N\HASV)X9L9^K4;>'J/TK26"%-27'0RL`@)97EQQ@]V MW65%724;%//%4FL"YL4O*X+CL>HZ-(.61SO<[NYE"H(R2,"9`^J;@3 MXVO6\ID8=9DI$!IW")M47UT5-*`U-")<;@74H!02/<(FZ->K%;)P=46;-[L+ M<.JWEW4%"@3$N?(F"D/DD=&5ADG,L*IL(E,9U'MR!I`.T`V5H"%,V'AH6>'G M"YP^#9#KSAE`>B?K4@,%K-`AQ8WVAW"/BZ"><`:2W0,?X-CFAGDO96G[-&4`F%>GB;-N. M%8:6\5.ZUJE$0%O- M\'(7``"R&`$`$0`<`&)H'-D550)``-^*6U3?BEM4W5X M"P`!!"4.```$.0$``.T]77/C-I+OJC\=);F5M26= M)&>R3UL0"5F\4(`"D+:UO_X:("F"),`/21Z#HZE*I3Q"=Z,_@$8W/IJ__/UY M%3B/F'&?DH\GYV_>GCB8N-3SRG?3IR___K]=[]P=XE7R`D1>\#A M$*TP7R,7?SQ9AN'ZP]G9T]/3F[E/EQBQT"?N&Y>NSMZ]/?_Q[<7%.9`,\`J3 M\(:RU35>H"@(/Y[\%:'`7_C8.W&^_PZX(/S#?,G"AA2__\Z1.#GPIXLWE#T` MU-OSLS_N;J>2Y1-G"_PA\,F?.8SG.0M2G(LST3Q''*LH`L++N%(1?CJ+&W/@ M007]/VZA@R)QOP+!)SQ$Q,TS5!(B$?O\_?OW9[(U4\\'@A]0B#UC'^_/&`WP M60*F]N/2B(1LDY><8_?-`WT\2QJ%02Y.WYZ?"I,HJ!%C,(I,N$FK0'Y71O:P MK\>#!D-_'EXS[-;(B9@K15T@-SS%S^L`$112MKF!?ZO$\+.[U#,@6@P<^.01 M\U"/%K<9$`GR7:['DTT"[5R#1@F)5GIIO9"=A9LU&)624X#"S'=SN/6(922& M%T;=_GP&K2HP]UV]2-!@$(B':V;`@18#4L1/'Q!:;_$6B,\E4TF#0>=)ZRD* M0S,J-#)_'H68%U"%AK@63[84^Q2^$Q%"0Q2"B_WU%[1>^V1!Q<]BJGX08W(& MB([XXWXRJ/1_<@!?4S<2WK1'O#X)_7`S`'IL)>F?.#[,@4J(;<\>7OC$EUR! MPW1.G11-_1,1SXEI.`J17\Z*%%*B$B/PJ_X9)R8&&Q!">+\%*0'08&<%F M\"X*W"@P=W"64_$>.K^BA-/`]X2/N42!\,G3)<8ACQ5N;M9K^QVH>`J*P8FZ M`=_#!-AV$FPG1O^FYU218P1K1KC$H0^\U"@]#ZNWP$5#"S@_Y*C]]U%;9*LP M/EJ,UIC)[C53P`"GM\2/1DMD9!RZ<#)"S@_W!$6>#ST=MSUXJB"ZX"%U_US2 MP(-07O#N^F'9+C7P>OO\5&\?89ZI0O"_G.N8Y'%;:C2SZ>CFJC?]Q\WMZ/,T,5`MF-XN/S><-U>(+YV;@#X=][R9^@\$TDT705CD MRO0%4MPQS`S7QXD+JP;16^%_1+#D@/&)8F"0CXF14G)3,T>G]$P7Q86RZ MF)$["*K!/<3:UC7H=?RWHHXEJI/@.@GRT6EVS"@LB>%&1/E_1?Y:S/A8M=H6 MO6[?%W6;XL:1?XI]=,J%J=OBRI-T)P4[^B4"0L2 M\>8;,9K"#:@FSJRAV]X#PS@;MPW@]"H_+WGAF)(3DW)46LZ6V-'984A##-G1 M!LT#'&L\]XM>M^^*NI4X3H)T=#J_HR#" M=Q@)_60QF[9%K^)2'B=P'8GL*-A'I]QI-.?XKPBDZ3_BS%D4?]4KM93`97A. MC'A\^AQ\&@YN!E>]X:QW=36Z'\X&PT_CT>W@:M"?%K9\&H%J-?^NE.?5;/TX M/Z1_'=_NVW@R&OYTSD#XD=*MKURB]E?/I]"^>'F,KQ M:1R&\^2^?]W_8]P?3OM35=GZ)KV>2]E?<3/C>#4\',W`1_3^U;N\[:OJU?RN MUVTI^\MEUL>KV.EL=/7/T7@V&`VGX!`^]R83\,^Y(5P-HE=W*1,TQM/'JWI= M-*?JO:)=K_12EJB/^8Y7XY41R#4.D1\TB5522+T5RJED7:B2T#L^>WP:@5:O M1L.K_F1XUYO-^I.\%2K:];HO)9;:TZLCUK@N]LNIO`I`K_-2IFF*#H]6Z848 M,*=O0YM>U:7\LQP@'J^2\^>%B1YF^#F,TDMLU2!:E5_4'C!N5>XDA(Y/]?5' MB?FUM3&XWB2['4`>\=10DZ2<)70->IU7'TQ^TZVJPIS/J6C7:[HN43UZ;S/I MWXKK>^,>1"DSR$2GO2N9FN9&=AV07O>EK-5X1'S$(SX[TPVR(UU/57XEA%[S MI=15?W)\Q&I73WRQ7.B\_*)J:M8K7'_@63A1/F9UZS>]\H%,-8Q>\>5+K.:= ML6_:UVKVO(GZSPWZ+Z6K]?IWSK]9(*_<=TTL\,Y@@?(I:KT%WGVS0%ZY%TTL M<*&WP(_ET]1Z"UP/*^"%$10KBCP(DU4 MU$+2<4HB*5Q27?(%B,@3+G#Z9RGS)V<'D`<4WE:>O(VLDB9`\[;2``H.K!,$ MQG5;00I3X;#BG*5U3>"OK-H)-(`DE(4.*56,JBS6$E>;NJ6NI),O#*-%/,-! MR--?3C-2;YZY%W/8B)%R"9?=.9&TVK%250'*P$@91?SK-,4[%3^=GK_;M?^M ME5OVG^+MUW]=U:8F/`6,Y:CT,R*"N?>"N?.?=V).TMR6SFK*C(IU(`Y:J"+% MV*-G?8&I)@RHF,,8\2!\[,;#+@SHZ[\UG!LI@NCRIZ:=59560"4*G\G[+)T:C==J)#^1/G+-?G9)\ MD#Q2YOE$+(/7>!ZJ3Z<5N:K!5'E6%)8UQ#8ZB18HX%J1XC@I3)OF8J)7+[6V6Z)%$-G$TB228'G$F9)><'SK99TN$MS8#I?L$)*5`?8%=LI M3`](WK?^1GT2_@[@$<.%FE1;H[9'[X)BE$$:.YQ[XF$VCD*=&IH`=\(QUPM2 MFM?-46R:Y%6+JNJIR*/8U8>^6BS*%?B=&`1CAA>8,5&N>"OD@%0LRTT1OB+I M2].@'9I-4T%=Q@SIFF'1,T)WPM"]%86I^1_9C[*$)9;K/[M+1![P#66WOBM? MC_4(_![B((`%+D)!^G124<[A2'9AB:R6-A\)E"LL-E!8%8DN*$C=DE.YC^6# M83#%[!%&`I]@L6:*L[*M9G;`[<2LJY@4\-\<(R:ZU`59K3&[,$3BMQL#`KS( M76K#V)]X.HWL@OP5*25;7/=0CI9(%Y14BKN+DA7VPF"I29Y#BQ4'(H[*!&8' M8AU5FN)&4I=:K1@M0D>%+QAY)6U\'>$9_10)?QI2QD>+2T3^'"UZ\E8`NJ6( MM!HYS8EV5(G*@%"?LT_\AV78(&@\&,4NJ*\^3:J)`G8ET`7E5,>_YL.2EGA= M4(7T#H^8>0PM5/,7?N]$R`N*CT>FB./+UM,W=T,R93-`35(,5Q::@7=A>*J2 MJ-SWO$?1E>F40`_:-8'5:MWIN8=7JNE=$KX>K0N*T*S6ZN)CV.=HA75`-;R\ MP.95J2UB)SQ>C5"F79OF:C%3^!KTDV:+,.W'F*!`/)@HQBOF0Y>7(-X)K=8' MO8;!UA:Q$]J88#=`G,LRG0(M#2<2*6:T9D7>$;\3NM%\/$YS)[82RJ*KL!H^ MQ7O5RR!_=Z8:+'?',$Q_?\VCY[J2>AJ+M4&RR(#U;.OLV0K+-O-.1"$M\T8F^$[9M*LCJ@67;[VEAL(U9]G9HM@D] M=9?8BP(\6LA#_DL$V0T$+*+PJ.Q$KL!IKM.#@.01I)+%O;53X!#4K%.15I2> M$.)!PEUN,I!D6Z3WA-@V11Q%H;BJ[X%+$\\YXB12"FW4XQ?KTCIEHT`<#C]B M$N%/E'IBWS@]KQCBL/SVH!E\3LS7?H00\9"N,!N1\E,*39N-K,^>J)%UIP&)N95UMM8K_R8]9)-11=`-8*S:(0;!@)&XP6J6%XPKZ\1))NPF2/C=1W M5VTQ5:E]@'O`[/7\7R7WB9]K*NP6W$H);Z(@F/DKW%^M`[K!N5RW`L9*643. M72>+!L8J60SIJ-ZO-`&VR)M\INQ/P3!:^R$*KC%X1#]W24O?OO?>R1=XHUGX MXL"L>%51V_R%3>.%'Y:`R=QHC@=-);GUB03F9FD4$(L&6U'EQDE4!VB13,WV M-@PQ2'M]$#1$&0?LR6-!+5./OBXM$]3"TW`G\+=ECYG%,F#ZA* M*^M2K:F"#8).8U6 M*PAD\X>HNG6[&LZB-?HRB+`KSM"3`/[&)R+.KC)<XI4"VF[6")4;R25"FB34)7.^CQ;H]ZU<_,ZS,Z(O;/4 M71;Z#FW.?VXO<@FM"P+#4K"SH2MPNR!ZS'M$\/E/.XSO$EYG1)[B=2AY;B^U M%K4+@O<6H;P8\R^,RHM4&R2;A%7KX28F&KDA-5FV&;CE`@[IHWGL-H2W7$3A M6D1-Z";B%6%M$FT(H=^2AXA=^L"LNR0TH`\;B7P;N#5;(;L@VR1\O+FK%:W< M9!/C=^B!(`E;8KS<9!/CMS2,>')RJN??"&&3&-O]E&1SV;SA4@"P28B*B+%- M=-DET70;%0U@;1*M9B?)_@VDFGTC^[>+M$>"S0X.;11'W4,UW_&IA++HI+"R M%/<>%51K">1T\,JE,\5>GO'MK:Y19?[U+RY=4L;H$ZA>UF>8+7T6OWD=1TRH M/YQ1(0,?+0R7=T05,$V)GL.2555FZ]71D9M\M@G'@U@\XU^G95T*!;,:P#:; MYE]FC"3OH.*).J-@0W>).-87L6\"O.?\W5KS$/=NTB\<;TN/QIRK5VZ,(%T8 ME^F->>41F\%9U4*JXNYRP_Z0=OL$R_@MY7Q4JF10%JP![-Z6_!(/^Z_QMKZR M250SB$T.!;R>"_^"0&VT2#_B-*-7`>4B!F"^JXK4!#B)\2#`6\?0KR>;XBVR MQ\SB(64?NUR)\`W+U6;_&+/\^2GP5&0UC%*GK,4\J8:N)=;S`XW,=3(`DQ(7'\= MX+A.K"$3+D%U8/I?T0A6*5F/=(79U1)\V`K!OR\I8I[F0WD-H&W:SA@M%C#Y M&*Q.US[#;DC+1XEF$)L$T50`U[S=,<+8),H$`C3$LVD';IOUR-R0G3+[!IE5*64?3Z*00M*BFB#?V%(/HB_GM1LFF MC4`EVM"7W%,J>B=59O)5YG=!MV@GI;J&N5;B9@@6R2CB*V5[)!>3%EJZ$)ZK MJ752WX+/Z"6."WI@K\7]Q4(4`!5EQ>*`>0)NI1!55\!8 M)$F-GQ`S1Q8^W63Q2G,OH\>V:`+6E'_-)X#-R\86\;HP>5N)5/_)QB;8-@^$ M'D]6C'I12Z`VR87X4E.O-O]S%X:GX6S7_-UN4]7KDCT/3MFF*'*W+\8WJ#E^ M:,*=.#&!>!)S#DNZ\`%^")+$-B_EQ'6`=J7&'(=I;4IM=E]JM8G];$L_+>Q: M672O&;A%.7UZ/B'*SA<^MR80^GJ%.Y"Q:*IGF[8\=Z+ZFB&EK#)7CHA+33:%PY*[ MH:]Y7E!JL8[M&29ZKI4&ZYCN!V+7VC!*#=OM5#-B3K]&^7$>3JH7M?6VRP*:A)8J[RF]IB@WU,:ZNME9NL8UQ;3ZW48A_; MOBED5UNL8WOJ/^NY5AIL8KKV8VV:**X%CDVA65IS"ERC4F)?/+(-L2:S;0AO MDS&36^.Z1:'<9!/CZ@?NE>_:UQR.-$"P:?SMO',K_O<[YN%VJ_Q`T9"!<#.= MO6:DJ1'VHP'*II5R>S4JNPMXAQ$7]8-&9"+N5H@Q M!,[=YVG1CP%Q@\B3CXL0$QMB7+.8'IBN1>OM5K)$'M$D+OG>$SKGF,FO]@[( M.I)?\:40/@2^[#PO]-8O#0CH!@6Y*A7S,!LT/?F]IK1TET[#K\-')R[:Z(1* M!9(7L<7S1YJ[X)N[1[H#=B?TTO/^+^)QJ#NC6>V#,?)A]B5%/V&X,[<JV\S_W`E)='[( MG&0U@K;(VZN/,^-GU>*@4U-?IPXP=S+ZR@65*)M#MB)&@KFF016030%,L8IW M6K^[MMQW$=!*H<);++Y>;C93+:1-8LE/H.H_C&HCNUEQL/XCKMYSKH.TR*-5 MW;'>OEE67ZEI'D_N0:,3:UIM&=T]E-2(B$T9;^FUK\@RL@>.R7('4R`M(5;Y M5+@!LM7"RS&^EP::4O@*9@HQOX/-?;67>#W79?*665PHHO$TVJ,'FX99I4-] M02WNW4&7!VE^N9IB]@@1.Y]@L:6:>XNU(WZ7=5-8I=HKIY9`!Z9?089DDR>] M\MI:!R7\#J@@/\9;:Z`&W=(9&UL550%``-^*6U3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`!WJI1$LB M$EXW#0``6,D``!4`&````````0```*2!X`Q0````(``=ZJ41C MW1:JU#(```20`P`5`!@```````$```"D@6?7``!B:')T+3(P,30P,S,Q7V1E M9BYX;6Q55`4``WXI;5-U>`L``00E#@``!#D!``!02P$"'@,4````"``'>JE$ M&9K[(PN+```4N@@`%0`8```````!````I(&*"@$`8FAR="TR,#$T,#,S,5]L M86(N>&UL550%``-^*6U3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`!WJI M1(54[1"W3@``W*\%`!4`&````````0```*2!Y)4!`&)H`Q0````(``=Z MJ41`6\WPKD`0!B:')T+3(P,30P,S,Q M+GAS9%54!0`#?BEM4W5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``"G %_`$````` ` end XML 42 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Statements of Operations (Unaudited) (USD $)
3 Months Ended 176 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Statements of Operations [Abstract]      
Revenue $ 322,572 $ 4,192 $ 1,688,297
Cost and operating expenses:      
Cost of sales 94,446    677,181
Research and development 9,857 163,974 65,329,892
Marketing, general and administrative 838,329 370,533 39,943,996
Impairment of investment       58,695
Depreciation and amortization 863 769 900,967
Total operating expenses 943,495 535,276 106,910,731
Net loss from operations (620,923) (531,084) (105,222,434)
Other income (expenses):      
Development revenues       117,500
Gain on settlement of debt 2,093,632 1,004,224 3,117,071
Loss on change of fair value of derivative liability (489,371) (640,589) (365,423)
Interest income       762,277
Other income   939 344,821
Interest expense (305,898) (352,383) (16,257,355)
Total other income (expenses) 1,298,363 12,191 (12,281,109)
Net income (loss) before income taxes 677,440 (518,893) (117,503,543)
Income taxes (benefit)         
NET INCOME (LOSS) $ 677,440 $ (518,893) $ (117,503,543)
Net income (loss) per common share, basic $ 0.002 $ (0.003)  
Net income (loss) per common share, diluted $ 0.001 $ (0.003)  
Weighted average number of common shares outstanding, basic 401,553,577 185,421,093  
Weighted average number of common shares outstanding, diluted 498,696,292 185,421,093  
XML 43 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Notes Payable
3 Months Ended
Mar. 31, 2014
Notes Payable [Abstract]  
NOTES PAYABLE
NOTE 6 – NOTES PAYABLE
 
Notes payable were comprised of the following as of March 31, 2014 and December 31, 2013:
 
  
March 31,
2014
  
December 31,
2013
 
Seaside Bank note payable.
 $980,000  $980,000 
August 2008 Unsecured Promissory Note
  500,000   500,000 
Hunton & Williams notes payable
  384,972   384,972 
Asher notes payable
  183,000   143,000 
Daniel James Management note payable
  35,000     
Fourth Man, LLC note payable
  35,000   35,000 
Total notes payable
  2,117,972   2,042,972 
Less unamortized debt discount
  (151,027)  (112,131)
Total notes payable net of unamortized debt discount
 $1,966,946  $1,930,841 
 
Seaside Bank
 
On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2014 to extend the maturity date to December 23, 2015.
 
August 2008 Unsecured Promissory Note
 
On August 20, 2008, the Company borrowed $1.0 million from a third party pursuant to the terms of an unsecured Promissory Note and Agreement. Outstanding principal and interest on the loan, which accrues at the rate of 13.5% per annum, is payable in one balloon payment upon the Company’s repayment of the BlueCrest Loan, which is scheduled to mature in May 2010, however the Company is not obligated to make payments until BlueCrest Loan is paid off. In the event the Company completes a private placement of its common stock and/or securities exercisable for or convertible into its common stock which generates at least $19.0 million of gross proceeds, the Company may prepay, without penalty, all outstanding principal and interest due under the loan using the same type of securities issued in the subject private placement. Because repayment of the loan could occur within 12 months from the date of the balance sheet, the Company has classified this loan as short term.
 
Subject to certain conditions, at the end of each calendar quarter during the time the loan is outstanding, the Company may, but is not required to, pay all or any portion of the interest accrued but unpaid as of such date with shares of its common stock. In April 2009, as consideration for the authorization to amend certain documents related to the Note, the Company issued to the Note holder a warrant to purchase 451,053 shares of common stock at an exercise price of $0.5321 per share.
 
The warrant, which became exercisable immediately upon issuance, has a ten year term. This warrant had a fair value of $195,694, which was accounted for as additional paid in capital and reflected as a component of debt discount and has been fully amortized as interest expense ratably over the term of the loan.
 
In 2013, 1,000,000 shares of common stock were issued to the debt holder, in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note resulting in a gain of $1,078,625. A gain of $1,078,625 was included in the net gain on settlement of debt and trade payables on the statement of operations. As of March 31, 2014 the principle of this note was $500,000.
 
Hunton & Williams Notes
 
At March 31, 2014 and December 31, 2013, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822 are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.
 
Asher Notes (During this year)
 
During the three months ended March 31, 2014, the Company entered into a Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”) or affiliates, for the sale of 8% convertible notes in aggregate principal amount of $97,500 (the “Asher Notes”).
 
The Asher Notes bear interest at the rate of 8% per annum. As of the quarter ended March 31, 2014 all interest and principal must be repaid nine months from the issuance date, the last note due December 26, 2014. The Notes are convertible into common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes.
 
These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date which at March 31, 2014 was $153,564. At the inception of the Asher Notes, the Company determined the aggregate fair value of $214,346 of the embedded derivatives.
 
Daniel James Management
 
On February 19, 2014, the Company entered into a Securities Purchase Agreements with Daniel James Management (“Daniel”) for the sale of 8% convertible note in principal amount of $35,000 (the “Daniel Note”).
 
The Daniel Note bear interest at the rate of 8% per annum with all interest and principal due February 28, 2015. The Daniel Note is convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Daniel Note. These embedded derivatives included certain conversion features and reset provision.
 
The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Daniel Note and to fair value as of each subsequent reporting date which at March 31, 2014 was $63,343. At the inception of the Daniel Note, the Company determined the aggregate fair value of $63,343 of the embedded derivatives.
 
The fair value of the embedded derivatives of the Asher Notes and Daniel Note, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 158.19% to 181.73%, (3) weighted average risk-free interest rate of 0.03% to 0.15%, (4) expected lives of 0.03 to 1.00 years, and (5) estimated fair value of the Company’s common stock from $0.001 to $0.0447 per share. The initial fair value of the embedded debt derivative of $292,257 was allocated as a debt discount up to the proceeds of the note ($127,500) with the remainder ($164,757) charged to current period operations as interest expense. For the three months ended March 31, 2014 and 2013, the Company amortized an aggregate of $93,604 and $124,838 of debt discounts to current period operations as interest expense, respectively.
XML 44 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Standby Equity Distribution Agreement
3 Months Ended
Mar. 31, 2014
Standby Equity Distribution Agreement [Abstract]  
STANDBY EQUITY DISTRIBUTION AGREEMENT
NOTE 5 – STANDBY EQUITY DISTRIBUTION AGREEMENT
 
On November 2, 2011, the Company and Greystone Capital Partners (“Greystone”) had entered into a Standby Equity Distribution Agreement (the “Agreement”).  Pursuant to the Agreement, Greystone had agreed to provide the Company with up to $1.0 million of funding for the 24-month period following the date a registration statement of the Company’s common stock is declared effective by the SEC (the “Equity Line”).  The registration statement went effective on February 10, 2012. The Agreement automatically terminated on the first of April, 2014 (the first day of the month next following the second (2nd) anniversary of the Effective Date).
XML 45 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Notes Payable (Tables)
3 Months Ended
Mar. 31, 2014
Notes Payable [Abstract]  
Summary of notes payable

  
March 31,
2014
  
December 31,
2013
 
Seaside Bank note payable.
 $980,000  $980,000 
August 2008 Unsecured Promissory Note
  500,000   500,000 
Hunton & Williams notes payable
  384,972   384,972 
Asher notes payable
  183,000   143,000 
Daniel James Management note payable
  35,000     
Fourth Man, LLC note payable
  35,000   35,000 
Total notes payable
  2,117,972   2,042,972 
Less unamortized debt discount
  (151,027)  (112,131)
Total notes payable net of unamortized debt discount
 $1,966,946  $1,930,841 
 
XML 46 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Subsequent Events
3 Months Ended
Mar. 31, 2014
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS
NOTE 13 — SUBSEQUENT EVENTS
 
In April 2014, the Company issued an aggregate of 3,839,832 shares of its common stock for services rendered valued at $43,250.
 
In April 2014, the Company issued 5,263,315 shares of its common stock in settlement of related party advances of $100,000.
 
In April, 2014, the Company issued 1,002,808 shares of its common stock in settlement of common stock subscriptions of $50,000
 
In April 2014, the Company issued 274,681 shares of its common stock as settlement of six months accrued interest on the Northstar note obligation.
 
In April 2014, the Company issued 18,383,774 shares of its common stock for service rendered valued at $180,511.
 
In April 2014, the Company issued an aggregate of 4,793,268 shares of its common stock in settlement of $67,500 convertible notes payable and $2,700 accrued interest.
 
In April 2014, the Company issued 11,918,181 shares of its common stock in connection with the exercise of warrants. Proceeds received was $136,000, of which $6,000 during the three months ended March 31, 2014.
XML 47 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity
3 Months Ended
Mar. 31, 2014
Stockholders' Equity [Abstract]  
STOCKHOLDERS' EQUITY

NOTE 9 – STOCKHOLDERS’ EQUITY

Preferred stock

On August 17, 2012, the board of directors designated 5,000,000 shares of preferred stock as Series A Convertible Preferred Stock which was increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. Each share of preferred stock is convertible into equal number of common shares at the option of the holder; entitled to 20 votes on all matters presented to be voted by the holders of common stock; upon event of liquidation, entitled to amount equal to stated value plus any accrued and unpaid dividends or other fees before distribution to junior securities. In lieu of the initial two payments due to Northstar, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders (see Note 7 above).

Common stock

During the three months ended March 31, 2014, the Company issued an aggregate of 6,750,781 shares of its common stock in settlement of outstanding accounts payable. In connection with the issuance, the Company incurred a loss on settlement of debt of $65,548.

During the three months ended March 31, 2014, the Company issued an aggregate of 7,166,214 shares of its common stock for the conversion of $57,500 of convertible notes payable and related accrued interest of $2,300.

XML 48 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Related Party Transactions
3 Months Ended
Mar. 31, 2014
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS
NOTE 7 — RELATED PARTY TRANSACTIONS
 
Advances
 
As of March 31, 2014 and December 31, 2013, the Company officers and directors have provided advances in the aggregate of $403,957 and $416,198 respectively, for working capital purposes. The advances are unsecured, due on demand and non-interest bearing.
 
Notes payable-related party
 
Northstar Biotechnology Group, LLC
 
On February 29, 2012, a note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267.
 
On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. As of September 30, 2012, the Company was in default, however, subsequent to September 30, 2012, the Company renegotiated the terms of the Note, Northstar has agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.
 
On September 21, 2012, the Company issued 5,000,000 common stock purchase warrants to Northstar that was treated as Additional interest expense upon issuance.
 
On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.
 
In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
 
Effective October 1, 2012, the effective interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum.
 
In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued. In addition, the Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock. The Company is required to issue additional shares of its common stock (as amended), in lieu of cash, each six month anniversary of the effective date for any accrued and unpaid interest.
 
As of March 31, 2014 and December 31, 2013, the principle of this note was $362,000.
 
Officer and Director Notes
 
At March 31, 2014 and December 31, 2013, the Company has outstanding notes payable to officers and directors with interest at 8% per annum due at maturity. The three subordinated notes, $125,000, $100,000 and $140,000 were previously due on October 22, 2012, November 30, 2012 and June 4, 2011 respectively, and are unsecured. The Company is not obligated to make payment until Northstar loan is paid off.
 
On October 9, 2012, the Company issued an aggregate of $1,278,324 of promissory notes due October 9, 2013 to officers and directors in settlement of outstanding advances and accrued compensation (currently in default). The promissory notes bear interest of 5% per annum and due at maturity.
 
On September 30, 2013, the Company issued an aggregate of 15,350,876 shares of its common stock in settlement of $175,000 of related party notes payable.
 
On August 1, 2013, the Company issued an aggregate of $500,000 promissory notes due on demand to officers and employee in settlement of accrued compensation. The promissory notes bear interest of 5% per annum and due at various maturity dates. During the three months ended March 31, 2014, the Company paid off $63,740 of the outstanding promissory notes. The principle outstanding balance of these notes as of March 31, 2014 is $349,413.
 
Subordinated debt, related party
 
As of March 31, 2014 and December 31, 2013, the Company officers and directors have provided notes in aggregate of $1,500,000. The notes are at from 4.75% to 8% per annum and are due upon payoff of the Northstar note payable described above.
XML 49 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Derivative Liabilities
3 Months Ended
Mar. 31, 2014
Derivative Liabilities [Abstract]  
DERIVATIVE LIABILITIES
NOTE 8 — DERIVATIVE LIABILITIES
 
Reset warrants
 
On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 7 above, the Company issued an aggregate of 15,000,000 common stock purchase warrants to purchase the Company’s common stock with an exercise price of $0.014 per share for ten years with anti-dilutive (reset) provisions.
 
The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date.
 
At March 31, 2014, the fair value of the reset provision of $666,485 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 173.72%; risk free rate: 2.73%; and expected life: 8.50 years. The Company recorded a loss on change in derivative liabilities of $519,630 during the three months ended March 31, 2014.
 
Convertible notes
 
In 2013 and the three months ended March 31, 2014, the Company issued convertible notes (see Note 6 above).
 
These notes are convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these notes relating to certain anti-dilutive (reset) provisions. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Note and to fair value as of each subsequent reporting date.
 
The fair value of the embedded derivatives at March 31, 2014, in the amount of $384,711, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 173.72%, (3) weighted average risk-free interest rate of 0.03 to 0.13%, (4) expected lives of 0.03 to 0.74 years, and (5) estimated fair value of the Company’s common stock of $0.0447 per share. The Company recorded a gain on change in derivative liabilities of $30,259 during the three months ended March 31, 2014.
 
Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.
 
At March 31, 2014, the aggregate derivative liabilities was valued at $1,051,196, the Company believes an event under the contract that would create an obligation to settle in cash or other current assets is remote and has classified the obligation as a long term liability.
XML 50 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Option and Warrants
3 Months Ended
Mar. 31, 2014
Stock Options and Warrants [Abstract]  
STOCK OPTIONS AND WARRANTS

NOTE 10 — STOCK OPTIONS AND WARRANTS

Stock Options

In December 1999, the Board of Directors and shareholders adopted the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011.

In April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty million shares of common stock for issuance.

A summary of options at March 31, 2014 and activity during the three months then ended is presented below:

 

 

Shares

 

Weighted-
Average
Exercise Price

 

Weighted-
Average
Remaining
Contractual
Term (in years)

 

 

 

 

 

Options outstanding at January 1, 2013

 

 

7,853,376

 

 

$

0.67

 

 

8.2

 

Granted

 

 

17,400,000

 

 

$

0.016

 

 

9.9

 

Exercised

 

 

 

 

$

 

 

 

 

 

Forfeited/Expired

 

 

(1,340,433

)

 

$

1.08

 

 

 

 

Options outstanding at December 31, 2013

 

 

23,912,943

 

 

$

0.15

 

 

9.0

 

Granted

 

 

19,800,000 

 

 

$

0.019

 

 

9.1

 

Exercised

 

 

 

 

 

 

 

 

 

 

Forfeited/Expired

 

 

(62,087

)

 

$

1.08

 

 

 

 

Options outstanding at March 31, 2014

 

 

43,650,856

 

 

$

0.08

 

 

9.3

 

Options exercisable at March 31, 2014

 

 

16,650,856

 

 

$

0.18

 

 

8.9

 

Available for grant at March 31, 2014

 

 

12,800,000

 

 

 

 

 

 

 

 

 

The following information applies to options outstanding and exercisable at March 31, 2014:

 

 

Options Outstanding

 

Options Exercisable

 

 

 

Shares

 

Weighted-
Average
Remaining
Contractual
Term

 

Weighted-
Average
Exercise
Price

Shares

 

Weighted-
Average
Exercise
Price

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$0.00 – $0.70

 

    

43,090,000

 

 

    

9.4

 

 

$

0.03

 

 

 

16,090,000

 

 

$

0.04

 

$0.71 – $1.28

 

    

162,286

 

 

    

4.2

 

 

$

0.80

 

 

 

162,286

 

 

$

0.80

 

$5.25 – $5.67

 

    

373,858

 

 

    

2.1

 

 

$

5.55

 

 

    

373,858

 

 

$

5.55

 

$7.69

 

    

24,712

 

 

    

2.3

 

 

$

7.69

 

 

    

24,712

 

 

$

7.69

 

  

 

    

43,650,856

 

 

    

9.3

 

 

$

0.08

 

 

    

16,650,856

 

 

$

0.18

 

On February 24, 2014, the Company issued an aggregate 15,000,000 options to purchase the Company’s common stock at $0.019 per share to officers, vesting at 25% immediately and the remainder over approximately 42 months, exercisable over 10 years. The aggregate fair value of $282,597, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 163.63% and Risk free rate: 2.75%.

On February 24, 2014, the Company issued an aggregate 4,800,000 options to purchase the Company’s common stock at $0.019 per share to officers, vesting immediately and exercisable over 10 years. The aggregate fair value of $90,431, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 163.63% and Risk free rate: 2.75%.

The fair value of all options vesting during the three months ended March 31, 2014 and 2013 of $194,565 and $19,632, respectively, was charged to current period operations.

Warrants

A summary of common stock purchase warrants at March 31, 2014 and activity during the three months then ended is presented below:

 

 

Shares

 

Weighted-
Average
Exercise
Price

 

Weighted-
Average
Remaining
Contractual
Term (in
years)

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at January 1, 2013

 

    

74,073,322

 

 

$

0.37

 

 

    

4.5

 

   Issued

 

    

50,350,536

 

 

$

0.16

 

 

    

9.2

 

   Exercised

 

    

— 

 

 

$

0.00

 

 

    

 

 

   Forfeited

 

    

(6,345,002)

  

 

$

0.38

 

 

    

 

 

Outstanding at December 31, 2013

 

    

118,078,856

 

 

$

0.22

 

 

    

6.3

 

   Issued

 

    

32,292,783

 

 

$

0.017

 

 

    

8.4

 

   Exercised

 

    

 

 

$

 

 

 

 

 

   Expired

 

    

(2,314,575

)  

 

$

0.18

 

 

    

 

 

Outstanding at March 31, 2014

 

    

148,057,064

 

 

$

0.17

 

 

    

6.7

 

Exercisable at March 31, 2014

 

    

102,401,650

 

 

$

0.13

 

 

    

5.7

 

The following information applies to common stock purchase warrants outstanding and exercisable at March 31, 2014:

 

 

Warrants Outstanding

 

Warrants Exercisable

 

 

 

Shares

 

Weighted-
Average
Remaining
Contractual
Term

 

Weighted-
Average
Exercise
Price

 

Shares

Weighted-
Average
Exercise
Price

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$0.01 – $0.50

 

    

141,807,931

 

 

    

6.7

 

 

$

0.02

 

 

    

97,696,967

 

 

$

0.02

 

$0.52 – $0.68

 

    

2,699,675

 

 

    

5.1

 

 

$

0.58

 

 

    

2,699,675

 

 

$

0.58

 

$0.70 – $1.62

 

    

848,176

 

 

    

5.8

 

 

$

0.71

 

 

    

848,176

 

 

$

0.71

 

$5.67 – $7.69

 

    

2,701,282

 

 

    

8.6

 

 

$

7.55

 

 

    

1,156,832

 

 

$

7.35

 

 

 

    

148,057,064

 

 

    

6.7

 

 

$

0.17

 

 

    

102,401,650

 

 

$

0.13

 

In conjunction with the authorized issuance of common stock, the Company granted 24,292,783 common stock purchase warrants during the three months ended March 31, 2014.

During the three months ended March 31, 2014, the Company issued an aggregate of 8,000,000 warrants in connection with a joint venture agreement dated March 10, 2014. The warrants are exercisable at $0.0217 for four years vesting from June 8, 2014 through March 10, 2015. During the three months ended March 31, 2014, the Company charged $22,546 to current period operations for the vesting portion.

XML 51 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
Related Party Transaction (Details) (USD $)
0 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 0 Months Ended 3 Months Ended
Mar. 31, 2014
Dec. 31, 2013
Oct. 01, 2012
Northstar Biotechnology Group, LLC Promissory Note [Member]
Sep. 21, 2012
Northstar Biotechnology Group, LLC Promissory Note [Member]
Feb. 28, 2013
Northstar Biotechnology Group, LLC Promissory Note [Member]
Dec. 31, 2012
Northstar Biotechnology Group, LLC Promissory Note [Member]
Mar. 31, 2014
Northstar Biotechnology Group, LLC Promissory Note [Member]
Dec. 31, 2013
Northstar Biotechnology Group, LLC Promissory Note [Member]
Feb. 29, 2012
Northstar Biotechnology Group, LLC Promissory Note [Member]
Mar. 30, 2012
Promissory Note [Member]
Oct. 09, 2012
Officer and Director [Member]
Mar. 31, 2014
Officer and Director [Member]
Dec. 31, 2013
Officer and Director [Member]
Aug. 01, 2013
Officer and Director [Member]
Nov. 30, 2012
Officer and Director [Member]
Oct. 22, 2012
Officer and Director [Member]
Jun. 04, 2011
Officer and Director [Member]
Mar. 31, 2014
Officer and Director [Member]
Minimum [Member]
Mar. 31, 2014
Officer and Director [Member]
Maximum [Member]
Related Party Transactions (Textual)                                      
Advances, related party $ 403,957 $ 416,198                                  
Outstanding principal amount of debt 349,413           362,000 362,000 544,267                    
Repayment terms                   The first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012.                  
Common stock purchase warrants issued       5,000,000                              
Series A convertible preferred stock issued in exchange for payments     5,000,000     5,000,000                          
Common stock issued in exchange for payments     10,000,000                                
Value of debt outstanding     210,000                                
Percentage of revenues to be received as royalty     8.00%                                
Effective interest rate     12.85%   7.00%                            
Subordinated debt, related party 1,500,000 1,500,000                                  
Effective interest rate                     5.00% 8.00% 8.00% 5.00%       4.75% 8.00%
Subordinated notes                             100,000 125,000 140,000    
Face value of note                     1,278,324     500,000          
Debt instrument, Maturity date                     Oct. 09, 2013                
Common Stock, Voting Rights           25 votes                          
Preferred Stock, Voting Rights           20 votes                          
Common stock issued in settlement of related party notes payable,Shares                       15,350,876              
Common stock issued in settlement of related party notes payable                       175,000              
Outstanding promissory notes $ 63,740                                    
XML 52 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Property and Equipment (Tables)
3 Months Ended
Mar. 31, 2014
Property and Equipment [Abstract]  
Summary of property and equipment

  
March 31,
2014
  
December 31,
2013
 
Laboratory and medical equipment
 $352,358  $352,358 
Furniture, fixtures and equipment
  125,634   125,634 
Computer equipment
  39,525   39,525 
Leasehold improvements
  362,046   362,046 
   879,563   879,563 
Less accumulated depreciation and amortization
  (871,371)  (870,508)
  $8,192  $9,055 
 
XML 53 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
Significant Accounting Policies (Details) (USD $)
3 Months Ended 176 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended
Mar. 31, 2014
Employees
Mar. 31, 2013
Mar. 31, 2014
Dec. 31, 2013
Mar. 31, 2014
Employee Stock Option [Member]
Dec. 31, 2013
Employee Stock Option [Member]
Dec. 31, 2012
Employee Stock Option [Member]
Mar. 31, 2014
Accounts Receivable [Member]
Customer Concentration Risk [Member]
Customer
Dec. 31, 2013
Accounts Receivable [Member]
Customer Concentration Risk [Member]
Customer
Mar. 31, 2014
Accounts Receivable [Member]
Customer One [Member]
Customer Concentration Risk [Member]
Dec. 31, 2013
Accounts Receivable [Member]
Customer One [Member]
Customer Concentration Risk [Member]
Mar. 31, 2014
Accounts Receivable [Member]
Customer Two [Member]
Customer Concentration Risk [Member]
Dec. 31, 2013
Accounts Receivable [Member]
Customer Two [Member]
Customer Concentration Risk [Member]
Dec. 31, 2013
Accounts Receivable [Member]
Customer Three [Member]
Customer Concentration Risk [Member]
Mar. 31, 2014
Sales Revenue Goods and Services Net [Member]
Customer Concentration Risk [Member]
Customer
Mar. 31, 2014
Sales Revenue Goods and Services Net [Member]
Customer One [Member]
Customer Concentration Risk [Member]
Mar. 31, 2014
Sales Revenue Goods and Services Net [Member]
Customer Two [Member]
Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)                                  
Concentration Risk, Percentage               51.00% 76.00% 26.00% 20.00% 25.00% 20.00% 36.00%   17.00% 10.00%
Number of customer accounted for accounts receivable               2 3                
Revenue $ 322,572 $ 4,192 $ 1,688,297                       $ 322,572    
Number of customers accounted for revenue                             2    
Deficit accumulated during development stage 117,503,543   117,503,543 118,180,983                          
Number of fully diluted shares outstanding 498,696,292 185,421,093                              
Option outstanding to purchase common stock         43,650,856 23,912,943 7,853,376                    
Options vested         16,650,856                        
Number of full time employees 4                                
Number of part time employees 1                                
Research and development expense $ 9,857 $ 163,974 $ 65,329,892                            
XML 54 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Option and Warrants (Details Textual) (USD $)
3 Months Ended 0 Months Ended 3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Feb. 24, 2014
Officer [Member]
Feb. 24, 2014
Officer One [Member]
Mar. 31, 2014
Warrant [Member]
Stock Options and Warrants (Textual)          
Options to purchase the Company's common stock     15,000,000 4,800,000  
Exercise price     $ 0.019 $ 0.019  
Stock option vesting right percentage     25.00%    
Stock option exercisable period     10 years 10 years  
Fair value of the option vested $ 194,565 $ 19,632 $ 282,597 $ 90,431  
Dividend yield     0.00% 0.00%  
Volatility     163.63% 163.63%  
Risk free rate     2.75% 2.75%  
Share based compensation shares authorized         24,292,783
Warrants issued         8,000,000
Fair value of vested warrants         $ 22,546
Warrant vesting period description         Vesting from June 8, 2014 through March 10, 2015
Warrants exercise price         $ 0.0217
Warrant vesting period         4 years
XML 55 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Statement of Stockholders' Deficit (Unaudited) (USD $)
Total
Preferred stock
Common stock
Additional Paid in Capital
Subscription Receivable
Deficit Accumulated During Development Stage
Beginning Balance at Dec. 31, 2013 $ (13,747,076) $ 20,000 $ 379,788 $ 103,819,119 $ 215,000 $ (118,180,983)
Beginning Balance, Shares at Dec. 31, 2013   20,000,000 379,787,745      
Common stock issued in settlement of accounts payable 107,474    6,751 100,723      
Common stock issued in settlement of accounts payable, Shares     6,750,781      
Common stock issued in connection with settlement of other debt 194,044    7,166 186,878     
Common stock issued in connection with settlement of other debt, Shares     7,166,214      
Proceeds from issuance of common stock 371,000   27,215 348,785 (5,000)  
Proceeds from issuance of common stock, Shares     27,215,417      
Proceeds from exercise of warrants 6,000     6,000    
Fair value of vesting warrants issued in connection with joint venture 22,546     22,546    
Stock based compensation 194,564     194,564    
Net income 677,440         677,440
Balance at Mar. 31, 2014 $ (12,174,008) $ 20,000 $ 420,920 $ 104,678,615 $ 210,000 $ (117,503,543)
Balance, Shares at Mar. 31, 2014   20,000,000 420,920,157      
XML 56 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accrued Expenses
3 Months Ended
Mar. 31, 2014
Accrued Expenses [Abstract]  
ACCRUED EXPENSES
NOTE 4 — ACCRUED EXPENSES
 
Accrued expenses consisted of the following as of March 31, 2014 and December 31, 2013:
 
  
March 31,
2014
  
December 31,
2013
 
License and royalty fees
 $  $2,122,130 
Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest
  1,356,013   1,373,775 
Interest payable on notes payable
  757,669   714,180 
Vendor accruals and other
  127,189   120,692 
Employee commissions, compensation, etc.
  127,506   149,558 
  $2,368,377  $4,480,335 
 
In June 2000, the Company had entered into an agreement with William Beaumont Hospital, or WBH, pursuant to which WBH granted the Company a worldwide, exclusive, non-sublicenseable license to two U.S. method patents covering the inducement of human adult myocardial cell proliferation in vitro, or the WBH IP. The term of the agreement was for the life of the patents, which expire in 2015. The Company did not use this license in any of thier technologies or made any payments to WBH other than the initial payment to acquire the license. On April 2, 2014, the Company received confirmation that it has no obligation under the patent license agreement, WBH agreed to terminate the patent license agreement pursuant to a termination letter dated March 3, 2014, and WBH agreed to terminate the patent license agreement.
 
Accordingly, the Company recognized approximately $2,122,130 in settlement of debt which represents the accumulative accrual and related interest from past years under the 2000 patent license agreement.
 
During the three months ended March 31, 2014, the Company issued an aggregate of 6,750,781 shares of its common stock in settlement of outstanding accounts payable. In connection with the issuance, the Company incurred $65,548 loss in settlement of debt.
XML 57 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Going Concern Matters (Details) (USD $)
3 Months Ended 176 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Going Concern Matters (Textual)      
Net losses attributable to common shareholders $ 620,923    
Net cash used in operating activities (257,762) (546,378) (75,135,166)
Working capital deficit $ 11,100,000   $ 11,100,000
XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 159 298 1 false 47 0 false 8 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.bioheartinc.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 002 - Statement - Condensed Balance Sheets Sheet http://www.bioheartinc.com/role/ConsolidatedBalanceSheets Condensed Balance Sheets false false R3.htm 003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.bioheartinc.com/role/ConsolidatedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) false false R4.htm 004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://www.bioheartinc.com/role/ConsolidatedStatementsOfOperations Condensed Statements of Operations (Unaudited) false false R5.htm 005 - Statement - Condensed Statement of Stockholders' Deficit (Unaudited) Sheet http://www.bioheartinc.com/role/Consolidatedstatementofstockholdersdeficit Condensed Statement of Stockholders' Deficit (Unaudited) false false R6.htm 006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://www.bioheartinc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS Condensed Statements of Cash Flows (Unaudited) false false R7.htm 007 - Disclosure - Significant Accounting Policies Sheet http://www.bioheartinc.com/role/SignificantAccountingPolicies Significant Accounting Policies false false R8.htm 008 - Disclosure - Going Concern Matters Sheet http://www.bioheartinc.com/role/GoingConcernMatters Going Concern Matters false false R9.htm 009 - Disclosure - Property and Equipment Sheet http://www.bioheartinc.com/role/PropertyAndEquipment Property and Equipment false false R10.htm 010 - Disclosure - Accrued Expenses Sheet http://www.bioheartinc.com/role/AccruedExpenses Accrued Expenses false false R11.htm 011 - Disclosure - Standby Equity Distribution Agreement Sheet http://www.bioheartinc.com/role/StandbyEquityDistributionAgreement Standby Equity Distribution Agreement false false R12.htm 012 - Disclosure - Notes Payable Notes http://www.bioheartinc.com/role/NotesPayable Notes Payable false false R13.htm 013 - Disclosure - Related Party Transactions Sheet http://www.bioheartinc.com/role/RelatedPartyTransactions Related Party Transactions false false R14.htm 014 - Disclosure - Derivative Liabilities Sheet http://www.bioheartinc.com/role/DerivativeLiabilities Derivative Liabilities false false R15.htm 015 - Disclosure - Stockholders' Equity Sheet http://www.bioheartinc.com/role/StockholdersEquity Stockholders' Equity false false R16.htm 016 - Disclosure - Stock Option and Warrants Sheet http://www.bioheartinc.com/role/StockOptionsAndWarrants Stock Option and Warrants false false R17.htm 017 - Disclosure - Commiments and Contingencies Sheet http://www.bioheartinc.com/role/CommitmentsAndContingencies Commiments and Contingencies false false R18.htm 018 - Disclosure - Fair Value Measurement Sheet http://www.bioheartinc.com/role/FairValueMeasurement Fair Value Measurement false false R19.htm 019 - Disclosure - Subsequent Events Sheet http://www.bioheartinc.com/role/SubsequentEvents Subsequent Events false false R20.htm 020 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.bioheartinc.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies Significant Accounting Policies (Policies) false false R21.htm 021 - Disclosure - Property and Equipment (Tables) Sheet http://www.bioheartinc.com/role/PROPERTYANDEQUIPMENTTables Property and Equipment (Tables) false false R22.htm 022 - Disclosure - Accrued Expenses (Tables) Sheet http://www.bioheartinc.com/role/ACCRUEDEXPENSESTables Accrued Expenses (Tables) false false R23.htm 023 - Disclosure - Notes Payable (Tables) Notes http://www.bioheartinc.com/role/NOTESPAYABLETables Notes Payable (Tables) false false R24.htm 024 - Disclosure - Stock Option and Warrants (Tables) Sheet http://www.bioheartinc.com/role/STOCKOPTIONSANDWARRANTSTables Stock Option and Warrants (Tables) false false R25.htm 025 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.bioheartinc.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) false false R26.htm 026 - Disclosure - Significant Accounting Policies (Details) Sheet http://www.bioheartinc.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails Significant Accounting Policies (Details) false false R27.htm 027 - Disclosure - Going Concern Matters (Details) Sheet http://www.bioheartinc.com/role/GOINGCONCERNMATTERSDetails Going Concern Matters (Details) false false R28.htm 028 - Disclosure - Property and Equipment (Details) Sheet http://www.bioheartinc.com/role/PROPERTYANDEQUIPMENTDetails Property and Equipment (Details) false false R29.htm 029 - Disclosure - Accrued Expenses (Details) Sheet http://www.bioheartinc.com/role/ACCRUEDEXPENSESDetails Accrued Expenses (Details) false false R30.htm 030 - Disclosure - Accrued Expenses (Details Textual) Sheet http://www.bioheartinc.com/role/AccruedExpensesDetailsTextual Accrued Expenses (Details Textual) false false R31.htm 031 - Disclosure - Standby Equity Distribution Agreement (Details) Sheet http://www.bioheartinc.com/role/StandbyEquityDistributionAgreementDetails Standby Equity Distribution Agreement (Details) false false R32.htm 032 - Disclosure - Notes Payable (Details) Notes http://www.bioheartinc.com/role/NOTESPAYABLEDetails Notes Payable (Details) false false R33.htm 033 - Disclosure - Notes Payable (Details Textual) Notes http://www.bioheartinc.com/role/NOTESPAYABLEDetailsTextual Notes Payable (Details Textual) false false R34.htm 034 - Disclosure - Related Party Transaction (Details) Sheet http://www.bioheartinc.com/role/RELATEDPARTYTRANSACTIONSDetails Related Party Transaction (Details) false false R35.htm 035 - Disclosure - Derivative Liabilities (Details) Sheet http://www.bioheartinc.com/role/Derivativeliabilitiesdetails Derivative Liabilities (Details) false false R36.htm 036 - Disclosure - Stockholders' Equity (Details) Sheet http://www.bioheartinc.com/role/Stockholdersequitydetails Stockholders' Equity (Details) false false R37.htm 037 - Disclosure - Stock Option and Warrants (Details) Sheet http://www.bioheartinc.com/role/STOCKOPTIONSANDWARRANTSDetails Stock Option and Warrants (Details) false false R38.htm 038 - Disclosure - Stock Option and Warrants (Details 1) Sheet http://www.bioheartinc.com/role/STOCKOPTIONSANDWARRANTSDetails1 Stock Option and Warrants (Details 1) false false R39.htm 039 - Disclosure - Stock Option and Warrants (Details 2) Sheet http://www.bioheartinc.com/role/STOCKOPTIONSANDWARRANTSDetails2 Stock Option and Warrants (Details 2) false false R40.htm 040 - Disclosure - Stock Option and Warrants (Details 3) Sheet http://www.bioheartinc.com/role/STOCKOPTIONSANDWARRANTSDetails3 Stock Option and Warrants (Details 3) false false R41.htm 041 - Disclosure - Stock Option and Warrants (Details Textual) Sheet http://www.bioheartinc.com/role/Stockoptionandwarrantsdetailstextual Stock Option and Warrants (Details Textual) false false R42.htm 042 - Disclosure - Commiments and Contingencies (Details Textual) Sheet http://www.bioheartinc.com/role/Commitmentsandcontingenciesdetailstextual Commiments and Contingencies (Details Textual) false false R43.htm 043 - Disclosure - Fair Value Measurement (Details) Sheet http://www.bioheartinc.com/role/FairValueMeasurementDetails Fair Value Measurement (Details) false false R44.htm 044 - Disclosure - Fair Value Measurement (Details Textual) Sheet http://www.bioheartinc.com/role/Fairvaluemeasurementdetailstextual Fair Value Measurement (Details Textual) false false R45.htm 045 - Disclosure - Subsequent Events (Details) Sheet http://www.bioheartinc.com/role/Subsequenteventsdetails Subsequent Events (Details) false false All Reports Book All Reports Element bhrt_ShareBasedCompensationArrangementsByShareBasedPaymentsAwardOptionsIssuedInPeriodWeightedAverageExercisePrice had a mix of decimals attribute values: 2 3. Element us-gaap_DebtInstrumentInterestRateEffectivePercentage had a mix of decimals attribute values: 3 4. Element us-gaap_NotesPayable had a mix of decimals attribute values: -5 0. Element us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice had a mix of decimals attribute values: 2 3. Process Flow-Through: 002 - Statement - Condensed Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: Removing column 'Aug. 11, 1999' Process Flow-Through: 003 - Statement - Condensed Balance Sheets (Parenthetical) Process Flow-Through: 004 - Statement - Condensed Statements of Operations (Unaudited) Process Flow-Through: 006 - Statement - Condensed Statements of Cash Flows (Unaudited) bhrt-20140331.xml bhrt-20140331.xsd bhrt-20140331_cal.xml bhrt-20140331_def.xml bhrt-20140331_lab.xml bhrt-20140331_pre.xml true true XML 59 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Option and Warrants (Details 1) (Stock Options [Member], USD $)
3 Months Ended
Mar. 31, 2014
Options outstanding and exercisable for stock-based payment awards  
Options Outstanding, Shares 43,650,856
Options Outstanding, Weighted-Average Remaining Contractual Term 9 years 3 months 18 days
Options Outstanding, Weighted- Average Exercise Price $ 0.08
Options Exercisable, Shares 16,650,856
Options Exercisable, Weighted-Average Exercise Price $ 0.18
$0.00 - $0.70 [Member]
 
Options outstanding and exercisable for stock-based payment awards  
Range of Exercise Prices, Minimum $ 0.00
Range of Exercise Prices, Maximum $ 0.70
Options Outstanding, Shares 43,090,000
Options Outstanding, Weighted-Average Remaining Contractual Term 9 years 4 months 24 days
Options Outstanding, Weighted- Average Exercise Price $ 0.03
Options Exercisable, Shares 16,090,000
Options Exercisable, Weighted-Average Exercise Price $ 0.04
$0.71 - $1.28 [Member]
 
Options outstanding and exercisable for stock-based payment awards  
Range of Exercise Prices, Minimum $ 0.71
Range of Exercise Prices, Maximum $ 1.28
Options Outstanding, Shares 162,286
Options Outstanding, Weighted-Average Remaining Contractual Term 4 years 2 months 12 days
Options Outstanding, Weighted- Average Exercise Price $ 0.80
Options Exercisable, Shares 162,286
Options Exercisable, Weighted-Average Exercise Price $ 0.80
$5.25 - $5.67 [Member]
 
Options outstanding and exercisable for stock-based payment awards  
Range of Exercise Prices, Minimum $ 5.25
Range of Exercise Prices, Maximum $ 5.67
Options Outstanding, Shares 373,858
Options Outstanding, Weighted-Average Remaining Contractual Term 2 years 1 month 6 days
Options Outstanding, Weighted- Average Exercise Price $ 5.55
Options Exercisable, Shares 373,858
Options Exercisable, Weighted-Average Exercise Price $ 5.55
$7.69 [Member]
 
Options outstanding and exercisable for stock-based payment awards  
Range of Exercise Prices $ 7.69
Options Outstanding, Shares 24,712
Options Outstanding, Weighted-Average Remaining Contractual Term 2 years 3 months 18 days
Options Outstanding, Weighted- Average Exercise Price $ 7.69
Options Exercisable, Shares 24,712
Options Exercisable, Weighted-Average Exercise Price $ 7.69
XML 60 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2014
Significant Accounting Policies [Abstract]  
Basis and business presentation

Basis and business presentation

 

Bioheart, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through March 31, 2014, the Company has accumulated a deficit through its development stage of $117,503,543.

 

Revenue Recognition

Revenue Recognition


The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.

At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.

Revenues for test kits and equipment sold are not recorded until test kits are delivered. Revenues from trainings are not recorded until the completion of the training. Any cash received as a deposit for trainings are recorded by the company as a liability.

Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets.

Comprehensive Income

Comprehensive Income

 

The Company does not have any items of comprehensive income in any of the periods presented.

 

Net Income (loss) per Common Share, basic and diluted

Net Income (loss) per Common Share, basic and diluted

 

The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options, warrants and shares issuable upon conversion of notes payable have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation for the three months ended March 31, 2013. Fully diluted shares outstanding were 498,696,292 and 222,688,816 for the three months ended March 31, 2014 and 2013, respectively.

Stock based compensation

Stock Based Compensation

 

The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10).

 

As of March 31, 2014, there were outstanding stock options to purchase 43,650,856 shares of common stock, 16,650,856 shares of which were vested.

Concentrations of Credit Risk

Concentrations of Credit Risk

 

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. The financial stability of these institutions is periodically reviewed by senior management.

 

As of March 31, 2014, two customers represented 26% and 25% (total of 51%) of the Company’s accounts receivable.

 

As of December 31, 2013, three customers represented 20%, 20% and 36% (total 76%) of the Company’s accounts receivable.

 

For the three months ended March 31, 2014, the Company’s revenues earned from the sale of products and services were $322,572, of which two customers represented 17% and 10% of the Company’s revenues.

Research and Development

Research and Development

 

The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $9,857 and $163,974 for the three months ended March 31, 2014 and 2013, respectively; and $65,329,892 from August 12, 1999 (date of inception) to March 31, 2014.

Fair Value

Fair Value

 

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

 

The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.

Reliance on Key Personnel and Consultants

Reliance on Key Personnel and Consultants

 

The Company has 4 full-time employees and 1 part-time employee. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.

Derivative Instrument Liability

Derivative Instrument Liability

 

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2014 and December 31, 2013, the Company did not have any derivative instruments that were designated as hedges.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed financial position, results of operations or cash flows.